01193000000000433000450099100020000070000020000270600020000470100020000609100090
00081300053000174210020000701510024000902300053001140350010001674800047001770300
02000224031000300244032000200247036000600249930000600255042000200261117000600263
08500030026920000020027206500090027412200030028304800140028604800140030004800240
03140490023003380490051003610490037004120490027004490490043004760490042005190430
06500561043006500626043006800691#1#0#i#1#20080401#Brazilian Journal of Medical a
nd Biological Research#Braz J Med Biol Res#Braz. j. med. biol. res#Revista brasi
leira de pesquisas médicas e biológicas#0100-879X#Associação Brasileira de Divul
gação Científica#Braz J Med Biol Res#41#2#20082#BJMBR#1#other#nd#0#20080200#15#^
les^hSumario#^lpt^hSumário#^len^hTable of Contents#^len^cBJMBR090^tReview#^len^c
BJMBR010^tBiochemistry and Molecular Biology#^len^cBJMBR040^tExperimental Biolog
y#^len^cBJMBR050^tImmunology#^len^cBJMBR060^tNeurosciences and Behavior#^len^cBJ
MBR080^tPhysiology and Biophysics#^les^tBraz J Med Biol Res^vv.41^nn.2^cRibeirão
 Preto^mfeb.^a2008#^lpt^tBraz J Med Biol Res^vv.41^nn.2^cRibeirão Preto^mfev.^a2
008#^len^tBraz J Med Biol Res^vvol.41^nno.2^cRibeirão Preto^mFeb.^a2008##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#o#1#1#article#1#20
080402#165735#6752.htm#147##
03190000000000601000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016001201110
01700100028002810100026003090100025003350100032003600100023003920100021004150100
03100436070003500467070003300502070012600535083174600661085000802407085001902415
08500360243408500280247008500180249811700060251607200030252211200090252511100180
2534114000902552113001802561002000902579#v41n2#v:\scielo\serial\bjmbr\v41n2\mark
up\6752.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#12#BJMBR060#FAPESP#Braz
 J Med Biol Res#41#2#20080200#^f152^l158#0100-879X#Gastroesophageal reflux episo
des in asthmatic patients and their temporal relation with sleep architecture^le
n#^rND^1A01^nL.^sMello-Fujita#^rND^1A01^nS.^sRoizenblat#^rND^1A02^nC.R.^sFrison.
#^rND^1A03^nL.^sRodrigues Junior#^rND^1A01^nS.^sGarbuio#^rND^1A01^nS.^sTufik#^rN
D^1A01^nL.R.A.^sBittencourt#Departamento de Psicobiologia^iA01#Departamento de P
neumologia^iA02#Departamento de Gastroenterologia^iA03^1Escola Paulista de Medic
ina^2Universidade Federal de São Paulo^cSão Paulo^sSP^pBrazil#^len^aGastroesopha
geal reflux (GER) is common in asthma patients and can contribute to sleep disru
ption. The aim of the present study was to determine the time-related distributi
on of GER events together with their impact on sleep in asthmatic subjects with 
GER disease symptoms. The inclusion criteria were: 18-65 years, controlled moder
ate to severe asthma and GER-compatible clinical evidence. The exclusion criteri
a were: chronic obstructive lung disease, smoking, infections of the upper airwa
ys, use of oral corticosteroids, other co-morbidities, pregnancy, sleep-related 
disorders, night-time shift work, and the use of substances with impact on sleep
. Asthmatic patients with nocturnal symptoms were excluded. All-night polysomnog
raphy and esophageal pH monitoring were recorded simultaneously. Of the 147 subj
ects selected, 31 patients and 31 controls were included. Seventeen patients wer
e classified as DeMeester positive and 14 as DeMeester negative. Both groups dis
played similar outcomes when general variables were considered. Sleep stage modi
fication one minute prior to GER was observed in the DeMeester-positive group. A
wakening was the most frequent occurrence at GER onset and during the 1-min peri
od preceding 38% of the nocturnal GER. Sleep stage 2 was also prevalent and prec
eded 36% of GER events. In the DeMeester-negative group, awakening was the most 
frequent response before and during GER. Modifications in sleep stages, arousals
 or awakenings were associated with 75% of the total GER events analyzed during 
the period of one minute before and after the fall of esophageal pH below 4 in t
he DeMeester-positive group. These data provide evidence that sleep modification
s precede the GER events in asthmatic patients.#^dnd^i1#^tm^len^kAsthma^i1#^tm^l
en^kGastroesophageal reflux^i1#^tm^len^kPolysomnography^i1#^tm^len^kSleep^i1#oth
er#40#20061215#December 15, 2006#20071213#December 13, 2007#6752.htm##
03197000000000601000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016001201180
01700100028002880100026003160100025003420100032003670100023003990100021004220100
03100443070003500474070003300509070012600542083174600668085000802414085001902422
08500360244108500280247708500180250511700060252307200030252911200090253211100180
2541114000902559113001802568002000902586#v41n2#v:\scielo\serial\bjmbr\v41n2\mark
up\6752.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#12#BJMBR060#FAPESP#Braz
 J Med Biol Res#41#2#20080200#^f152^l158#0100-879X#<b>Gastroesophageal reflux ep
isodes in asthmatic patients and their temporal relation with sleep architecture
</b>^len#^rND^1A01^nL.^sMello-Fujita#^rND^1A01^nS.^sRoizenblat#^rND^1A02^nC.R.^s
Frison.#^rND^1A03^nL.^sRodrigues Junior#^rND^1A01^nS.^sGarbuio#^rND^1A01^nS.^sTu
fik#^rND^1A01^nL.R.A.^sBittencourt#Departamento de Psicobiologia^iA01#Departamen
to de Pneumologia^iA02#Departamento de Gastroenterologia^iA03^1Escola Paulista d
e Medicina^2Universidade Federal de São Paulo^cSão Paulo^sSP^pBrazil#^len^aGastr
oesophageal reflux (GER) is common in asthma patients and can contribute to slee
p disruption. The aim of the present study was to determine the time-related dis
tribution of GER events together with their impact on sleep in asthmatic subject
s with GER disease symptoms. The inclusion criteria were: 18-65 years, controlle
d moderate to severe asthma and GER-compatible clinical evidence. The exclusion 
criteria were: chronic obstructive lung disease, smoking, infections of the uppe
r airways, use of oral corticosteroids, other co-morbidities, pregnancy, sleep-r
elated disorders, night-time shift work, and the use of substances with impact o
n sleep. Asthmatic patients with nocturnal symptoms were excluded. All-night pol
ysomnography and esophageal pH monitoring were recorded simultaneously. Of the 1
47 subjects selected, 31 patients and 31 controls were included. Seventeen patie
nts were classified as DeMeester positive and 14 as DeMeester negative. Both gro
ups displayed similar outcomes when general variables were considered. Sleep sta
ge modification one minute prior to GER was observed in the DeMeester-positive g
roup. Awakening was the most frequent occurrence at GER onset and during the 1-m
in period preceding 38% of the nocturnal GER. Sleep stage 2 was also prevalent a
nd preceded 36% of GER events. In the DeMeester-negative group, awakening was th
e most frequent response before and during GER. Modifications in sleep stages, a
rousals or awakenings were associated with 75% of the total GER events analyzed 
during the period of one minute before and after the fall of esophageal pH below
 4 in the DeMeester-positive group. These data provide evidence that sleep modif
ications precede the GER events in asthmatic patients.#^dnd^i1#^tm^len^kAsthma^i
1#^tm^len^kGastroesophageal reflux^i1#^tm^len^kPolysomnography^i1#^tm^len^kSleep
^i1#other#40#20061215#December 15, 2006#20071213#December 13, 2007#6752.htm##
03343000000000625000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100038000400105121000300109049000900112
15800070012103000240012803100030015203200020015506500090015701400110016603500100
01770120111001870100027002980100025003250100025003500100031003750100022004060100
02000428010003200448070003700480070003500517070012800552083176700680085000802447
08500190245508500360247408500280251008500180253811700060255607200030256211200090
2565111001802574114000902592113001802601002000902619008008902628#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#l#4#1#article#1#^mFeb.^a2008#oa#en#bjmbr#1
#3.1#ilus#tab#12#BJMBR060#FAPESP#Braz. j. med. biol. res#41#2#20080200#^f152^l15
8#0100-879X#Gastroesophageal reflux episodes in asthmatic patients and their tem
poral relation with sleep architecture^len#^rND^1A01^nL^sMello-Fujita#^rND^1A01^
nS^sRoizenblat#^rND^1A02^nC. R^sFrison.#^rND^1A03^nL^sRodrigues Junior#^rND^1A01
^nS^sGarbuio#^rND^1A01^nS^sTufik#^rND^1A01^nL. R. A^sBittencourt#^iA01^1Departam
ento de Psicobiologia#^iA02^1Departamento de Pneumologia#^iA03^1Departamento de 
Gastroenterologia^2Escola Paulista de Medicina^3Universidade Federal de São Paul
o^cSão Paulo^sSP^pBrazil#^len^aGastroesophageal reflux (GER) is common in asthma
 patients and can contribute to sleep disruption. The aim of the present study w
as to determine the time-related distribution of GER events together with their 
impact on sleep in asthmatic subjects with GER disease symptoms. The inclusion c
riteria were: 18-65 years, controlled moderate to severe asthma and GER-compatib
le clinical evidence. The exclusion criteria were: chronic obstructive lung dise
ase, smoking, infections of the upper airways, use of oral corticosteroids, othe
r co-morbidities, pregnancy, sleep-related disorders, night-time shift work, and
 the use of substances with impact on sleep. Asthmatic patients with nocturnal s
ymptoms were excluded. All-night polysomnography and esophageal pH monitoring we
re recorded simultaneously. Of the 147 subjects selected, 31 patients and 31 con
trols were included. Seventeen patients were classified as DeMeester positive an
d 14 as DeMeester negative. Both groups displayed similar outcomes when general 
variables were considered. Sleep stage modification one minute prior to GER was 
observed in the DeMeester-positive group. Awakening was the most frequent occurr
ence at GER onset and during the 1-min period preceding 38 percent of the noctur
nal GER. Sleep stage 2 was also prevalent and preceded 36 percent of GER events.
 In the DeMeester-negative group, awakening was the most frequent response befor
e and during GER. Modifications in sleep stages, arousals or awakenings were ass
ociated with 75 percent of the total GER events analyzed during the period of on
e minute before and after the fall of esophageal pH below 4 in the DeMeester-pos
itive group. These data provide evidence that sleep modifications precede the GE
R events in asthmatic patients.#^dnd^i1#^tm^len^kAsthma^i1#^tm^len^kGastroesopha
geal reflux^i1#^tm^len^kPolysomnography^i1#^tm^len^kSleep^i1#other#40#20061215#D
ecember 15, 2006#20071213#December 13, 2007#6752.htm#Internet^ihttp://www.scielo
.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000200012##
00376000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704015000071002000900221#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#5#1#article#103#<P> <font face="Arial, H
elvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, February 2008, 
Volume 41(2) 152-158</B> </font></P>      ^cY#6752.htm##
00410000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704018400071002000900255#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#6#2#article#103#<P><B><font size="5" fac
e="Arial, Helvetica, sans-serif">Gastroesophageal reflux episodes in asthmatic p
atients and their temporal relation with sleep architecture</font></B>      ^cY#
6752.htm##
00681000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704045500071002000900526#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#7#3#article#103#<P><font face="Arial, He
lvetica, sans-serif">L. Mello-Fujita<SUP>1</SUP>, S. Roizenblat<SUP>1</SUP>, C.R
. Frison<SUP>2</SUP>, L. Rodrigues Junior<SUP>3</SUP>, S. Garbuio<SUP>1</SUP>, S
. Tufik<SUP>1</SUP> and <b><a href="#Correspondence"><img src="/img/revistas/bjm
br/v41n2/recor.gif" border="0"></a></b> <a href="mailto:lia@psicobio.epm.br"><im
g src="/img/revistas/bjmbr/v41n2/email-ca.gif" border="0"></a> L.R.A. Bittencour
t<SUP>1</SUP> </font>      ^cY#6752.htm##
00519000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704029300071002000900364#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#8#4#article#103#<P><font face="Arial, He
lvetica, sans-serif"><SUP>1</SUP>Departamento de Psicobiologia, <SUP>2</SUP>Depa
rtamento de Pneumologia, <SUP>3</SUP>Departamento de Gastroenterologia, Escola P
aulista de Medicina, Universidade Federal de S&atilde;o Paulo, S&atilde;o Paulo,
 SP, Brazil</font>       ^cY#6752.htm##
00416000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704019000071002000900261#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#9#5#article#103#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n2/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>  
  ^cY#6752.htm##
00414000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704018700072002000900259#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#10#6#article#103#<BR>   <A HREF="#Introd
uction"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPA
CE=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    
^cY#6752.htm##
00414000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704018700072002000900259#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#11#7#article#103#<BR>   <A HREF="#Materi
al"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0
 HSPACE=0></A> <A HREF="#Material"><strong>Patients and Methods</strong></A>    
^cY#6752.htm##
00399000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704017200072002000900244#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#12#8#article#103#<BR>   <A HREF="#Result
s"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#6752.htm##
00408000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704018100072002000900253#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#13#9#article#103#<BR>   <A HREF="#Discus
sion"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#67
52.htm##
00396000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704016800073002000900241#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#14#10#article#103#<BR>   <A HREF="#Refer
ences"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#6752.htm##
00462000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704023400073002000900307#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#15#11#article#103#<br>   </strong></A>  
 <A HREF="#Correspondence"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=B
OTTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspo
ndence and Footnotes</strong></A>  </font>      ^cY#6752.htm##
00276000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004800073002000900121#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#16#12#article#103#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>      ^cY#6752.htm##
00538000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031000073002000900383#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#17#13#article#103#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/ba
ck.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  <fon
t face="Arial, Helvetica, sans-serif">      ^cY#6752.htm##
01980000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704175200073002000901825#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#18#14#article#103#<P>Gastroesophageal re
flux (GER) is common in asthma patients and can contribute to sleep disruption. 
The aim of the present study was to determine the time-related distribution of G
ER events together with their impact on sleep in asthmatic subjects with GER dis
ease symptoms. The inclusion criteria were: 18-65 years, controlled moderate to 
severe asthma and GER-compatible clinical evidence. The exclusion criteria were:
 chronic obstructive lung disease, smoking, infections of the upper airways, use
 of oral corticosteroids, other co-morbidities, pregnancy, sleep-related disorde
rs, night-time shift work, and the use of substances with impact on sleep. Asthm
atic patients with nocturnal symptoms were excluded. All-night polysomnography a
nd esophageal pH monitoring were recorded simultaneously. Of the 147 subjects se
lected, 31 patients and 31 controls were included. Seventeen patients were class
ified as DeMeester positive and 14 as DeMeester negative. Both groups displayed 
similar outcomes when general variables were considered. Sleep stage modificatio
n one minute prior to GER was observed in the DeMeester-positive group. Awakenin
g was the most frequent occurrence at GER onset and during the 1-min period prec
eding 38% of the nocturnal GER. Sleep stage 2 was also prevalent and preceded 36
% of GER events. In the DeMeester-negative group, awakening was the most frequen
t response before and during GER. Modifications in sleep stages, arousals or awa
kenings were associated with 75% of the total GER events analyzed during the per
iod of one minute before and after the fall of esophageal pH below 4 in the DeMe
ester-positive group. These data provide evidence that sleep modifications prece
de the GER events in asthmatic patients.      ^cY#6752.htm##
00352000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704012400073002000900197#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#19#15#article#103#<P>Key words: Asthma; 
Gastroesophageal reflux; Polysomnography; Sleep   </font>  <HR ALIGN=LEFT WIDTH=
100% SIZE=2>      ^cY#6752.htm##
00594000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704036600073002000900439#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#20#16#article#103#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><
B>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-ser
if"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTO
M BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>    <font face="Arial, Helvetica
, sans-serif">      ^cY#6752.htm##
00981000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704075300073002000900826#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#21#17#article#103#<P>Occasional regurgit
ation and heartburn due to gastroesophageal reflux (GER) are frequent in the gen
eral population. GER disease refers to the presence of symptoms which are second
ary to the reflux of gastric content through the esophagus with or without signs
 of esophageal mucosa lesions (1). In more severe manifestations, GER seems to b
e related to recurrent and long-lasting reflux episodes which occur even during 
sleep (2). The increase in the transdiaphragmatic pressure, which occurs in the 
initial phases of sleep, may predispose patients to GER (3). The literature also
 highlights a greater frequency of GER occurring during arousals and the awakeni
ng period, but being markedly absent during rapid eye movement (REM) sleep (4,5)
.      ^cY#6752.htm##
01582000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704135400073002000901427#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#22#18#article#103#<P>Approximately 50 to
 70% of asthmatic subjects regularly display GER symptoms (6-9). Esophageal mobi
lity alterations occur in 82% of cases due to longer periods of contact between 
the esophageal mucosa and gastric acid (10). Sleep abnormalities frequently dete
cted in these subjects may not only result from asthma aggravation during the ni
ght (11,12) but may also stem from GER events (10,13) as reported by Goodall et 
al. (6) in a double-blind crossover study of 20 asthmatic patients. In that part
icular study, the investigators reported the beneficial effect of cimetidine on 
the night symptoms of asthma and GER. Additionally, reproduction of the alterati
ons in night-time breathing patterns by infusing acid solution into the distal e
sophagus of asthmatic patients with esophagitis has been reported (14,15). Howev
er, the relationship between asthma, GER and disordered sleep is not understood.
 In a controlled study of nine patients with asthma, Hughes et al. (4) failed to
 find a higher incidence of GER or any impact of the latter on respiratory and s
leep parameters, since GER episodes occurred mainly during arousals or waking pe
riods. Similarly, in a study based on simultaneous and continuous recording of p
H and lower airway resistance, Tan et al. (16) failed to identify any impact of 
GER on day- or night-time asthma attacks.       ^cY#6752.htm##
00545000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031700073002000900390#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#23#19#article#103#<P>Assuming that, befo
re their detection, GER events can contribute to sleep disruption in asthma, the
 present study was conducted with the aim of determining the time-related distri
bution of GER events together with their impact on sleep in asthmatic subjects. 
   </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6752.htm##
00596000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704036800073002000900441#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#24#20#article#103#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Pa
tients and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans
-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=B
OTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>  <font face="Arial, Helveti
ca, sans-serif">      ^cY#6752.htm##
00265000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704003700073002000900110#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#25#21#article#103#<P><b>Patients</b>  </
font>      ^cY#6752.htm##
01703000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704147500073002000901548#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#26#22#article#103#<P><font face="Arial, 
Helvetica, sans-serif">From 2000 to 2002, 147 subjects with moderate/severe asth
ma were recruited from the outpatient Pneumology Unit of S&atilde;o Paulo Federa
l University (UNIFESP). Patient selection was based on the Global Initiative for
 Asthma (17). These subjects fulfilled the inclusion criteria, i.e., age 18-65 y
ears, a diagnosis of moderate to severe bronchitic asthma controlled with regula
r inhalatory corticosteroids at doses equivalent to 1000 &#181;g/day beclomethas
one by a metered dose inhaler for at least 60 days, and the presence of GER-comp
atible clinical evidence (18), such as heartburn symptoms or regurgitation up to
 two weeks before the initial interview. The exclusion criteria were: a diagnosi
s of chronic obstructive lung disease; a history of smoking during the previous 
year (even if the individual had already stopped smoking); infectious diseases o
f the upper airways during the previous 6-month period; use of oral corticostero
ids; presence of co-morbidities, particularly gastrointestinal, neurologic or me
tabolic diseases; pregnancy; illiteracy; alcoholism; sleep-related disorders; ni
ght-time shift working, and the use of medications with an impact on sleep. The 
exclusion of asthmatic subjects who complained of night-time or morning aggravat
ion over 20 days prior to the initiation of the project was based on the decisio
n to minimize the influence of any other respiratory condition on our data. </fo
nt>      ^cY#6752.htm##
00569000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704034100073002000900414#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#27#23#article#103#<P><font face="Arial, 
Helvetica, sans-serif">The study also included anthropometric and polysomnograph
y (PSG) data from 31 healthy controls with sleep disturbances but without respir
atory or gastroesophageal complaints, matched for sex and age, taken from the da
tabase of the Sleep Medicine and Biology Discipline, UNIFESP. </font>      ^cY#6
752.htm##
00510000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704028200073002000900355#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#28#24#article#103#<P><font face="Arial, 
Helvetica, sans-serif">The study was approved by the Research Ethics Committee o
f UNIFESP. The participants were provided with all the relevant information and 
gave written informed consent to participate in the research on a voluntary basi
s. </font>      ^cY#6752.htm##
00309000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704008100073002000900154#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#29#25#article#103#<P><font face="Arial, 
Helvetica, sans-serif"><B>Sleep study</B> </font>      ^cY#6752.htm##
00516000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704028800073002000900361#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#30#26#article#103#<P><font face="Arial, 
Helvetica, sans-serif">All 31 patients included were invited to the Sleep Labora
tory of UNIFESP for an initial clinical sleep evaluation by first-night basal fu
ll PSG followed by placement of a pH catheter and a subsequent second night of f
ull PSG. </font>      ^cY#6752.htm##
01293000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704106500073002000901138#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#31#27#article#103#<P><font face="Arial, 
Helvetica, sans-serif">The computerized Oxford System&#153; (UK) and Sleep Analy
zer Computer (version 9.3) were used for sleep recordings, carried out for at le
ast 7 h. Of the 16 channels of the system, three were used for the electroenceph
alogram (C3-A2, C4-A1, O1-A2), two for the electroculogram (right and left), two
 for the electromyogram (chin and the anterior tibialis muscle), one for the ele
ctrocardiogram (V2 modified), and the remaining ones for body position sensor, n
asal thermistor, microphone, and abdominal and thoracic belts. Pulse oximetry (O
hmeda&#153;, USA) was also carried out. After the recordings, the sleep stages w
ere analyzed visually and blindly by an experienced investigator at a sampling f
requency of 256 Hz/channel, in consecutive epochs of 30 s according to standardi
zed criteria (19). The percents of sleep stages were measured as percent total s
leep time and the percents of wake after sleep onset as percent total recording 
time. Respiratory events (20) and arousals (21) were also scored. </font>      ^
cY#6752.htm##
00320000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009200073002000900165#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#32#28#article#103#<P><font face="Arial, 
Helvetica, sans-serif"><B>Gastroesophageal study</B> </font>      ^cY#6752.htm##
01314000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704108600073002000901159#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#33#29#article#103#<P><font face="Arial, 
Helvetica, sans-serif">Esophageal pH monitoring (Zinetics, Meditronic Medizinele
ktronik GmbH, Hohen, Neuendorf, Germany) was initiated immediately after the bas
al PSG, at 8:00 am with subjects in the fasting condition. The two-channel pH ca
theter was introduced nasally and placed 5 cm from the lower esophagus, tracked 
by esophageal manometry. During the study period, catheterized subjects recorded
 eating times on a daily basis (beginning and end of food ingestion period), tim
e spent lying down, the taking of regular medication, along with all symptomatic
 periods. Patients were instructed to maintain their usual level of physical act
ivity and meal characteristics, with the exception of acidic foods. Patients wer
e not allowed to lie down during the day, when pH monitoring occurred. During th
e night, pHmetry recordings were performed concomitantly with the second PSG rec
ording. All data obtained were stored in a database. The recording and analysis 
of GER events were performed by the Esophogram software (Gastrosoft, Irving, TX,
 USA). </font>      ^cY#6752.htm##
01546000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704131800073002000901391#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#34#30#article#103#<P><font face="Arial, 
Helvetica, sans-serif">Acid GER was defined as a drop of pH below 4, with a mini
mum duration of 15 s (22). Patients were classified according to the criteria pr
oposed by DeMeester et al. (22) based on the following parameters measured on th
e distal electrode: total number of reflux episodes, number of reflux episodes w
ith pH below 4 lasting 5 min or more, duration in minutes of the longest reflux 
episode, percent of total time with pH below 4, percent of time with pH below 4 
in the orthostatic position period, and percent of time with pH below 4 in the s
upine position period. Subjects were classified as DeMeester positive for scores
 of 14.72 or more and as DeMeester negative for scores below 14.72. According to
 the position during reflux, GER was classified as orthostatic or supine. GER ep
isodes during sleep were analyzed according to time of reflux, duration in secon
ds, sleep stage at the time of reflux and during the period of 1-min that preced
ed it. Sleep fragmentation was defined in terms of changes in sleep stage, arous
als and awakenings at the time of GER and during the 1-min period that preceded 
it. Asthma exacerbation related to GER episodes was clinically evaluated for eac
h episode, and again in the morning, upon completion of both sleep recordings. <
/font>      ^cY#6752.htm##
00318000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009000073002000900163#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#35#31#article#103#<P><font face="Arial, 
Helvetica, sans-serif"><B>Statistical analysis</B> </font>      ^cY#6752.htm##
00990000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704076200073002000900835#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#36#32#article#103#<P><font face="Arial, 
Helvetica, sans-serif">The normality of data distribution was submitted to the K
olmogorov-Smirnov test. Descriptive data are presented as mean &#177; SD for par
ametric data and median (interquartile range: 25th and 75th percentiles) for non
-parametric ones. Comparisons between DeMeester-positive and -negative patients 
regarding the quantitative variables were performed by the Student <I>t</I>-test
 or by the Mann-Whitney U-test when the distribution of the data was not normal.
 Qualitative variables were analyzed by the chi-square or Fisher test as appropr
iate. The level of significance adopted was 0.05. The `Statistica', Statistical 
package version 5 was used for data processing. </font>  <HR ALIGN=LEFT WIDTH=10
0% SIZE=2>      ^cY#6752.htm##
00538000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031000073002000900383#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#37#33#article#103#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Res
ults</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HRE
F="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0
 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6752.htm##
00622000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039400073002000900467#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#38#34#article#103#<P><font face="Arial, 
Helvetica, sans-serif">Of the 147 subjects selected, only 31 completed the trial
, while the others dropped out because they presented one or more of the followi
ng features during the study: infectious diseases of the upper airways (8 patien
ts), asthma aggravation (30 patients), and being absent during one or more phase
s of the study (78 patients). </font> </P>      ^cY#6752.htm##
01049000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704082100073002000900894#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#39#35#article#103#<P><font face="Arial, 
Helvetica, sans-serif">The 31 patients included in the study (age: 47 &#177; 10 
years; range: 18-65 years, 28 females, 3 males) exhibited basal forced expirator
y volume in the first second (FEV<SUB>1</SUB>) of 1.6 &#177; 0.6 L/min, and a De
Meester index of 15 &#177; 38. In comparison to the 31 healthy controls matched 
for sex and age (age: 47 &#177; 9 years; range: 18-65 years, 28 females, 3 males
), the body mass index (BMI) of the asthmatic subjects was higher (30 &#177; 8 <
I>vs</I> 21 &#177; 2 kg/m<SUP>2</SUP>, respectively, P &lt; 0.001). Of the 31 as
thmatic subjects, 9 (29%) had a BMI &gt;25 kg/m<SUP>2</SUP> and 13 (42%) a BMI &
gt;30 kg/m<SUP>2</SUP>, whereas only 1 of the control group volunteers displayed
 a BMI higher than 25 kg/m<SUP>2</SUP> (27 kg/m<SUP>2</SUP>). </font>      ^cY#6
752.htm##
00838000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704061000073002000900683#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#40#36#article#103#<P><font face="Arial, 
Helvetica, sans-serif">In comparison to the control group, asthmatic patients pr
esented significantly lower total sleep time (434.2 &#177; 44.3 <I>vs</I> 360.2 
&#177; 38.6 min, P &lt; 0.001), sleep efficiency (92.8 &#177; 4.6 <I>vs</I> 81.9
 &#177; 8.44%, P &lt; 0.001), percent REM sleep (23.1 &#177; 3.2 <I>vs</I> 19.5 
&#177; 6.2%, P = 0.006), and also higher mean values for arousals (4.8 &#177; 5.
7 <I>vs</I> 18 &#177; 13.7/h, P &lt; 0.001), and percent total sleep time with b
lood oxygen saturation below 90% (0.2 &#177; 0.2 <I>vs</I> 0.8 &#177; 2.2%, P &l
t; 0.001). </font>      ^cY#6752.htm##
00567000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033900073002000900412#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#41#37#article#103#<P><font face="Arial, 
Helvetica, sans-serif">Among the 31 asthmatic subjects, the median number of GER
 episodes, detected by esophageal pH recording, was greater during the day in th
e orthostatic position than during the night in the supine position (35, range 1
-262, <I>vs</I> 5, range 0-48, respectively, P &lt; 0.001). </font>      ^cY#675
2.htm##
00634000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704040600073002000900479#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#42#38#article#103#<P><font face="Arial, 
Helvetica, sans-serif">Seventeen of the 31 asthmatic subjects were DeMeester pos
itive while 14 were DeMeester negative, with no significant difference between g
roups in terms of sex, age, BMI, or FEV<SUB>1</SUB> values. Additionally, there 
was no significant difference between the two basal FEV<SUB>1</SUB> values obtai
ned after sleep recording for each individual. </font>      ^cY#6752.htm##
00698000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704047000073002000900543#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#43#39#article#103#<P><font face="Arial, 
Helvetica, sans-serif">Over the 24-h period encompassing GER recordings, the DeM
eester-positive group exhibited a total of 1596 GER episodes, 1262 (79%) of whic
h occurred in the orthostatic position. In the DeMeester-negative group, a signi
ficantly lower number of GER episodes was detected, i.e., 254 events (<font face
="Symbol">c</font><SUP>2</SUP> = 17.22, P &lt; 0.001), 229 (90%) of which occurr
ed in the orthostatic position.</font>      ^cY#6752.htm##
02646000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704241800073002000902491#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#44#40#article#103#<P><font face="Arial, 
Helvetica, sans-serif">No significant difference in PSG parameters was detected 
between the DeMeester-positive and -negative groups (<a href="#Tab1">Table 1</a>
). Sleep oscillations and variation in esophageal pH were detected in 10 of the 
17 DeMeester-positive subjects, and in 7 of the 14 DeMeester-negative ones, corr
esponding to a total of 167 GER episodes in the DeMeester-positive group and 12 
in the DeMeester-negative group. The data for the remaining patients were not st
udied due to artifacts in sleep recordings. Modifications in sleep pattern were 
evaluated at the time when the esophageal pH level fell below 4.0, along with re
adings during the minute preceding the onset of GER (<a href="#Tab2">Table 2</a>
). In the DeMeester-negative group, only one GER was followed by arousal. Awaken
ing was the most prevalent condition at the time of a GER event and during the m
inute that preceded it (P = 0.01 in both groups). Although awakening was also th
e most prevalent condition in the DeMeester-positive group, stage 2 was also a p
revalent sleep stage during the 1 min that preceded GER (<a href="#Tab2">Table 2
</a>). In this group, in 72 of the 103 GER that occurred during sleep, sleep sta
ge modification or arousal events were detected throughout the period from 1 min
 before to 1 min after the GER event: of 18 GER in stage 1 non-REM sleep, 94% we
re associated with changes to a superficial pattern of sleep (P &lt; 0.001, Fish
er test), and this was the case for 78.3% of 60 GER events in stage 2 non-REM sl
eep (<font face="Symbol">c</font><SUP>2</SUP> = 39.14, P &lt; 0.001) and for 85.
7% of 7 GER events during REM sleep (P = 0.04, Fisher test; <a href="#Fig1">Figu
re 1</a>). No significant influence of GER on sleep was observed in stages 3 and
 4. Arousals preceded the detection of 22 GER episodes, and followed 28 episodes
 (<a href="#Tab2">Table 2</a>). Modifications in sleep showed no significant rel
ationship with asthma exacerbation, since the subjects did not exhibit cough, ch
est wheezing or dyspnea symptoms, nor did they need to use asthma relief medicat
ion during the study period.</font>   <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table 
width="100%"  border="0">    <tr align="left" valign="top">      <td width="13%"
><a href="/img/revistas/bjmbr/v41n2/html/6752i01.htm"><img src="/img/revistas/bj
mbr/v41n2/6752i01peq.jpg" border="2"></a></td>      <td width="87%">    ^cY#6752
.htm##
00698000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704047000073002000900543#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#45#41#article#103#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. Association between gastroes
ophageal reflux (GER) and modification of sleep stages in the DeMeester-positive
 group. Dark columns = no changes; light columns = changes. SWS = slow wave slee
p; REM = rapid eye movement. *P &lt; 0.01 for percent GER during sleep stage 1, 
stage 2, REM sleep, but not SWS (<font face="Symbol">c</font><SUP>2</SUP> test).
 </font>      </td>    </tr>  </table>      ^cY#6752.htm##
00610000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038200073002000900455#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#46#42#article#103#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (56 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v
41n2/html/6752t01.htm"><img src="/img/revistas/bjmbr/v41n2/table.jpg" border="2"
></a></td>      <td width="87%">    ^cY#6752.htm##
00426000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704019800073002000900271#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#47#43#article#103#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Tab1"></a>Table 1. Sleep characteristics of asth
matic subjects according to the DeMeester index. </font>      </td>    </tr>  </
table>      ^cY#6752.htm##
00618000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039000073002000900463#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#48#44#article#103#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this table (210 K JPG file)]</fon
t></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <
tr align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/
v41n2/html/6752t02.htm"><img src="/img/revistas/bjmbr/v41n2/table.jpg" border="2
"></a></td>      <td width="87%">           ^cY#6752.htm##
00407000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704017900073002000900252#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#49#45#article#103#<p><font face="Arial, 
Helvetica, sans-serif"><a name="Tab2"></a>Table 2.          Influence of gastroe
sophageal reflux on sleep. </font></p>     </td>    </tr>  </table>      ^cY#675
2.htm##
00346000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011800073002000900191#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#50#46#article#103#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this table (121 K JPG file)]</fon
t></P>      ^cY#6752.htm##
00276000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004800073002000900121#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#51#47#article#103#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>      ^cY#6752.htm##
00500000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704027200073002000900345#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#52#48#article#103#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007
F><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n
2/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT> </font> </P>
      ^cY#6752.htm##
00787000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704055900073002000900632#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#53#49#article#103#<P><font face="Arial, 
Helvetica, sans-serif">This study was designed to evaluate the role of GER in sl
eep abnormalities in patients with asthma and GER-related symptoms, using all-ni
ght PSG recordings along with a 24-h monitoring of esophageal pH. In comparison 
to a matched control group without respiratory or gastrointestinal symptoms, mea
n BMI value was higher in the subjects with asthma and GER symptoms. These subje
cts presented evidence of sleep fragmentation, reduction in blood oxygen saturat
ion, but a normal apnea-hypopnea index. </font>      ^cY#6752.htm##
01271000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704104300073002000901116#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#54#50#article#103#<P><font face="Arial, 
Helvetica, sans-serif">Although higher BMI values were observed in the group of 
asthmatics than in controls, the findings of this study are applicable to asthma
tics in general, since the prevalence of obesity in asthma has been described (2
4,25). Considering the role of obesity as a risk factor both for GER disease (26
) and sleep-related breathing disorders (27), we propose that this aspect may ha
ve influenced some of the results of the present study, including the reduction 
in blood oxygen saturation possibly caused by a certain degree of hypoventilatio
n. Therefore, obesity, associated with the likelihood of subclinical bronchial h
yper-reactivity, could justify the increased number of arousals in the group of 
patients. The influence of upper airways resistance syndrome cannot be excluded 
in spite of the normality of the apnea-hypopnea index and the absence of daytime
 sleepiness complaints among patients, in view of the fact that a specific devic
e was not used during sleep recording (28). </font>      ^cY#6752.htm##
00580000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704035200073002000900425#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#55#51#article#103#<P><font face="Arial, 
Helvetica, sans-serif">The use of DeMeester criteria to analyze esophageal pH va
riability is justified given that this method considers the duration of events w
ith pH &lt;4 as a key factor. In our view, this corresponds to the parameter tha
t best discriminates physiological from pathological GER events (29,30). </font>
      ^cY#6752.htm##
00753000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704052500073002000900598#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#56#52#article#103#<P><font face="Arial, 
Helvetica, sans-serif">Regarding GER, 17 of the 31 (50%) asthmatic patients were
 classified as DeMeester positive. The higher prevalence of orthostatic GER in b
oth DeMeester-positive and -negative groups highlights the greater competence of
 the esophagogastric junction in the supine rather than in the orthostatic posit
ion (22,31). Furthermore, physiological GER events, which are less severe and ra
rely symptomatic, mainly occur in the orthostatic position, particularly after m
eals. </font>      ^cY#6752.htm##
00907000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704067900073002000900752#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#57#53#article#103#<P><font face="Arial, 
Helvetica, sans-serif">GER episodes occurred more frequently during wakefulness.
 During sleep, GER events are less common, and may reflect a dysfunction of the 
lower esophageal sphincter, leading to inflammation and erosion of the esophagea
l mucosa due to the continuous and prolonged contact with the gastric content (2
3) or to frequent modifications in esophageal pH (32). Even though the contact t
ime between the esophageal mucosa and acid is a more important factor than the n
umber of GER events, the total number of reflux episodes was taken into consider
ation in the present study in order to assess sleep alterations related to GER. 
</font>      ^cY#6752.htm##
01433000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704120500073002000901278#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#58#54#article#103#<P><font face="Arial, 
Helvetica, sans-serif">Despite the higher prevalence of wakefulness at the time 
of GER detection, 62% of the events were preceded by sleep, particularly stage 2
 of non-REM sleep, showing that sleep alterations occurred at least one minute p
rior to the fall in esophageal pH to values of 4 or below. A further increase in
 arousals with modifications of sleep stages preceding GER events during stages 
1 and 2 of non-REM sleep was a notable feature. As previously described, GER eve
nts were less frequent during REM sleep, a period during which secondary contrac
tions of the esophagus might act as a protecting factor for the esophageal mucos
a in contact with the acid refluxate (2,33). Sleep alterations, at least one min
ute prior to the drop in esophageal pH to values of 4 or below, were independent
 of the duration of the GER event. Modifications in sleep to a light sleep archi
tecture, characterized by arousals, lighter sleep stages or awakening after slee
p onset, can be interpreted as a protection of the esophageal mucosa by permitti
ng swallowing and heightened peristalsis, thereby avoiding prolonged local acidi
ty and lesions to the esophageal mucosa (33). </font>      ^cY#6752.htm##
00702000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704047400073002000900547#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#59#55#article#103#<P><font face="Arial, 
Helvetica, sans-serif">The reports of sleep disruption in asthmatic patients cou
ld be attributed to asthma (26,34), GER (31,33), or to aggravation of asthma by 
GER events (9,10,13,14,35). Even though the time-related association of GER and 
blood desaturation episodes was not detected in the present study, nor was exace
rbation of asthma observed after GER events, the role of asthma in sleep fragmen
tation cannot be excluded (26,34). </font>      ^cY#6752.htm##
00846000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704061800073002000900691#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#60#56#article#103#<P><font face="Arial, 
Helvetica, sans-serif">The impact of sleep (12,34,36) or GER (9,10,13,14,35) on 
day- or night-time asthma attacks remains unresolved. In a controlled study of 9
 patients with asthma, Hughes et al. (4) failed to find a relationship between G
ER episodes and modification of respiratory sleep parameters, since GER episodes
 occurred mainly during arousals or awakening periods. In a study based on simul
taneous and continuous recordings of pH and lower airway resistance, Tan et al. 
(16) was also unsuccessful in establishing any impact of GER on day- or night-ti
me asthma attacks. </font>      ^cY#6752.htm##
00931000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704070300073002000900776#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#61#57#article#103#<P><font face="Arial, 
Helvetica, sans-serif">To the best of our knowledge, this is the first study hig
hlighting sleep fragmentation preceding GER events in patients with asthma. Even
 though a cause and effect relationship between GER and sleep disruption cannot 
be fully established, it can be suggested that decreases in pH which precede GER
 detection by pHmetry (32) could have an impact on sleep architecture. The asses
sment of any swallowing activity, the analysis of a longer sleep period precedin
g GER detection, and the inclusion of a sample of non-asthmatic individuals with
 GER symptoms would also be required to clarify the relationship between acid GE
R and sleep disruption. </font>      ^cY#6752.htm##
00921000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704069300073002000900766#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#62#58#article#103#<P><font face="Arial, 
Helvetica, sans-serif">A limitation of this study is related to the detection of
 GER events by monitoring esophageal pH, since this detection can be biased by e
sophageal alkalization due to the presence of saliva, sub-mucous secretion, and 
the presence of food particles, oral infection or esophageal obstruction (33,37)
. The combination of intraluminal impedance measurement (38) and esophageal pH m
onitoring has been considered to be the most appropriate method for the detectio
n of GER (39), despite the fact that the classification of GER as acid and non-a
cid is theoretical, in view of the deleterious effects of both on the esophageal
 mucosa (40). </font>      ^cY#6752.htm##
00697000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704046900073002000900542#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#63#59#article#103#<P><font face="Arial, 
Helvetica, sans-serif">In conclusion, no difference in sleep architecture was de
tected between DeMeester-positive and -negative subgroups of asthmatic patients,
 and GER events were more frequent during the daytime and in wakefulness. When G
ER occurs during sleep, it can be related to sleep instability, preceding the de
tection of reflux. Further studies are needed to elucidate these findings. </fon
t>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6752.htm##
00544000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031600073002000900389#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#64#60#article#103#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>
References</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif">
<A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BO
RDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6752.htm##
00416000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704017400075002000900249#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#65#61#article#103#1#<P><font
 face="Arial, Helvetica, sans-serif">1. Tibbling L. Epidemiology of gastro-oesop
hageal reflux disease. <I>Scand J Gastroenterol</I> 1984; 19: 14-15. </font>    
  ^cY#6752.htm##
00493000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704025100075002000900326#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#66#62#article#103#2#<P><font
 face="Arial, Helvetica, sans-serif">2. Orr WC. Gastrointestinal physiology. In:
 Kryger MH, Roth T, Dement WC (Editors), <I>Principles and practice of sleep med
icine</I>. 3rd edn. Philadelphia: WB Saunders; 2000. p 1113-1122. </font>      ^
cY#6752.htm##
00482000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704024000075002000900315#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#67#63#article#103#3#<P><font
 face="Arial, Helvetica, sans-serif">3. Tabachnik E, Muller NL, Levison H, Bryan
 AC. Chest wall mechanics and pattern of breathing during sleep in asthmatic ado
lescents. <I>Am Rev Respir Dis</I> 1981; 124: 269-273. </font>      ^cY#6752.htm
##
00445000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704020300075002000900278#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#68#64#article#103#4#<P><font
 face="Arial, Helvetica, sans-serif">4. Hughes DM, Spier S, Rivlin J, Levison H.
 Gastroesophageal reflux during sleep in asthmatic patients. <I>J Pediatr</I> 19
83; 102: 666-672. </font>      ^cY#6752.htm##
00407000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704016500075002000900240#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#69#65#article#103#5#<P><font
 face="Arial, Helvetica, sans-serif">5. Orr WC. Reflux events and sleep: are we 
vulnerable? <I>Curr Gastroenterol Rep</I> 2006; 8: 202-207. </font>      ^cY#675
2.htm##
00456000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704021400075002000900289#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#70#66#article#103#6#<P><font
 face="Arial, Helvetica, sans-serif">6. Goodall RJ, Earis JE, Cooper DN, Bernste
in A, Temple JG. Relationship between asthma and gastro-oesophageal reflux. <I>T
horax</I> 1981; 36: 116-121. </font>      ^cY#6752.htm##
00431000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704018900075002000900264#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#71#67#article#103#7#<P><font
 face="Arial, Helvetica, sans-serif">7. Harding SM, Richter JE. The role of gast
roesophageal reflux in chronic cough and asthma. <I>Chest</I> 1997; 111: 1389-14
02. </font>      ^cY#6752.htm##
00428000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704018600075002000900261#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#72#68#article#103#8#<P><font
 face="Arial, Helvetica, sans-serif">8. Morales JEG, Hernandez LL, Spencer DG. A
sma asociada a reflujo gastroesof&aacute;gico. <I>Alerg Mex</I> 1998; 45: 16-21.
 </font>      ^cY#6752.htm##
00440000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704019800075002000900273#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#73#69#article#103#9#<P><font
 face="Arial, Helvetica, sans-serif">9. Field SK, Underwood M, Brant R, Cowie RL
. Prevalence of gastroesophageal reflux symptoms in asthma. <I>Chest</I> 1996; 1
09: 316-322. </font>      ^cY#6752.htm##
00423000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704018000076002000900256#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#74#70#article#103#10#<P><fon
t face="Arial, Helvetica, sans-serif">10. Harding SM. Nocturnal asthma: role of 
nocturnal gastroesophageal reflux. <I>Chronobiol Int</I> 1999; 16: 641-662. </fo
nt>      ^cY#6752.htm##
00394000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704015100076002000900227#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#75#71#article#103#11#<P><fon
t face="Arial, Helvetica, sans-serif">11. Shigemitsu H, Afshar K. Nocturnal asth
ma. <I>Curr Opin Pulm Med</I> 2007; 13: 49-55. </font>      ^cY#6752.htm##
00388000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704014500076002000900221#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#76#72#article#103#12#<P><fon
t face="Arial, Helvetica, sans-serif">12. Branscomb BV. The difficult asthmatic.
 <I>Clin Chest Med</I> 1984; 5: 695-713. </font>      ^cY#6752.htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024200076002000900318#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#77#73#article#103#13#<P><fon
t face="Arial, Helvetica, sans-serif">13. Valipour A, Makker HK, Hardy R, Emegbo
 S, Toma T, Spiro SG. Symptomatic gastroesophageal reflux in subjects with a bre
athing sleep disorder. <I>Chest</I> 2002; 121: 1748-1753. </font>      ^cY#6752.
htm##
00473000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023000076002000900306#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#78#74#article#103#14#<P><fon
t face="Arial, Helvetica, sans-serif">14. Martin ME, Grunstein MM, Larsen GL. Th
e relationship of gastroesophageal reflux to nocturnal wheezing in children with
 asthma. <I>Ann Allergy</I> 1982; 49: 318-322.</font>      ^cY#6752.htm##
00483000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024000076002000900316#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#79#75#article#103#15#<P><fon
t face="Arial, Helvetica, sans-serif">15. Davis RS, Larsen GL, Grunstein MM. Res
piratory response to intraesophageal acid infusion in asthmatic children during 
sleep. <I>J Allergy Clin Immunol</I> 1983; 72: 393-398. </font>      ^cY#6752.ht
m##
00482000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023900076002000900315#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#80#76#article#103#16#<P><fon
t face="Arial, Helvetica, sans-serif">16. Tan WC, Martin RJ, Pandey R, Ballard R
D. Effects of spontaneous and simulated gastroesophageal reflux on sleeping asth
matics. <I>Am Rev Respir Dis</I> 1990; 141: 1394-1399. </font>      ^cY#6752.htm
##
00401000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704015800076002000900234#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#81#77#article#103#17#<P><fon
t face="Arial, Helvetica, sans-serif">17. Asthma management and prevention. Glob
al initiative for asthma. <I>Ir Med J</I> 2000; 1-39. </font>      ^cY#6752.htm#
#
00558000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704031500076002000900391#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#82#78#article#103#18#<P><fon
t face="Arial, Helvetica, sans-serif">18. Moraes-Filho J, Cecconello I, Gama-Rod
rigues J, Castro L, Henry MA, Meneghelli UG, et al. Brazilian consensus on gastr
oesophageal reflux disease: proposals for assessment, classification, and manage
ment. <I>Am J Gastroenterol</I> 2002; 97: 241-248. </font>      ^cY#6752.htm##
00488000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024500076002000900321#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#83#79#article#103#19#<P><fon
t face="Arial, Helvetica, sans-serif">19. Rechtschaffen A, Kales A. <I>A manual 
of standardized terminology, techniques and scoring systems for sleep stages of 
human subjects</I>. Los Angeles: BIS/BRI, UCLA Press,  1968. </font>      ^cY#67
52.htm##
00539000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029600076002000900372#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#84#80#article#103#20#<P><fon
t face="Arial, Helvetica, sans-serif">20. Sleep-related breathing disorders in a
dults: recommendations for syndrome definition and measurement techniques in cli
nical research. The Report of an American Academy of Sleep Medicine Task Force. 
<I>Sleep</I> 1999; 22: 667-689. </font>      ^cY#6752.htm##
00421000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704017800076002000900254#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#85#81#article#103#21#<P><fon
t face="Arial, Helvetica, sans-serif">21. American Sleep Disorders Association. 
EEG arousals: scoring rules and examples. <I>Sleep</I> 1992; 15: 173-184. </font
>      ^cY#6752.htm##
00474000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023100076002000900307#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#86#82#article#103#22#<P><fon
t face="Arial, Helvetica, sans-serif">22. DeMeester TR, Johnson LF, Joseph GJ, T
oscano MS, Hall AW, Skinner DB. Patterns of gastroesophageal reflux in health an
d disease. <I>Ann Surg</I> 1976; 184: 459-470. </font>      ^cY#6752.htm##
00404000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704016100076002000900237#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#87#83#article#103#23#<P><fon
t face="Arial, Helvetica, sans-serif">23. Orr WC, Chen CL. Sleep and the gastroi
ntestinal tract. <I>Neurol Clin</I> 2005; 23: 1007-1024. </font>      ^cY#6752.h
tm##
00489000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024600076002000900322#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#88#84#article#103#24#<P><fon
t face="Arial, Helvetica, sans-serif">24. Chinn S, Jarvis D, Burney P. Relation 
of bronchial responsiveness to body mass index in the ECRHS. European Community 
Respiratory Health Survey. <I>Thorax</I> 2002; 57: 1028-1033. </font>      ^cY#6
752.htm##
00393000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704015000076002000900226#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#89#85#article#103#25#<P><fon
t face="Arial, Helvetica, sans-serif">25. Shore SA, Johnston RA. Obesity and ast
hma. <I>Pharmacol Ther</I> 2006; 110: 83-102. </font>      ^cY#6752.htm##
00590000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704034700076002000900423#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#90#86#article#103#26#<P><fon
t face="Arial, Helvetica, sans-serif">26. Janson C, De Backer W, Gislason T, Pla
schke P, Bjornsson E, Hetta J, et al. Increased prevalence of sleep disturbances
 and daytime sleepiness in subjects with bronchial asthma: a population study of
 young adults in three European countries. <I>Eur Respir J</I> 1996; 9: 2132-213
8. </font>      ^cY#6752.htm##
00514000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704027100076002000900347#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#91#87#article#103#27#<P><fon
t face="Arial, Helvetica, sans-serif">27. Berger KI, Ayappa I, Chatr-Amontri B, 
Marfatia A, Sorkin IB, Rapoport DM, et al. Obesity hypoventilation syndrome as a
 spectrum of respiratory disturbances during sleep. <I>Chest</I> 2001; 120: 1231
-1238. </font>      ^cY#6752.htm##
00478000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023500076002000900311#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#92#88#article#103#28#<P><fon
t face="Arial, Helvetica, sans-serif">28. Guilleminault C, Stoohs R, Clerk A, Ce
tel M, Maistros P. A cause of excessive daytime sleepiness. The upper airway res
istance syndrome. <I>Chest</I> 1993; 104: 781-787. </font>      ^cY#6752.htm##
00516000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704027300076002000900349#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#93#89#article#103#29#<P><fon
t face="Arial, Helvetica, sans-serif">29. Wiener GJ, Morgan TM, Copper JB, Wu WC
, Castell DO, Sinclair JW, et al. Ambulatory 24-hour esophageal pH monitoring. R
eproducibility and variability of pH parameters. <I>Dig Dis Sci</I> 1988; 33: 11
27-1133. </font>      ^cY#6752.htm##
00456000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021300076002000900289#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#94#90#article#103#30#<P><fon
t face="Arial, Helvetica, sans-serif">30. Galmiche JP, Scarpignato C. Esophageal
 pH monitoring. Functional evaluation in esophageal disease. <I>Front Gastrointe
st Res</I> 1994; 22: 71-108. </font>      ^cY#6752.htm##
00454000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021100076002000900287#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#95#91#article#103#31#<P><fon
t face="Arial, Helvetica, sans-serif">31. Orr WC, Robinson MG, Johnson LF. The e
ffect of esophageal acid volume on arousals from sleep and acid clearance. <I>Ch
est</I> 1991; 99: 351-354. </font>      ^cY#6752.htm##
00466000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704022300076002000900299#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#96#92#article#103#32#<P><fon
t face="Arial, Helvetica, sans-serif">32. Theodoropoulos DS, Pecoraro DL, Lockey
 RF, Boyce HW Jr, Bukantz SC. Visceral sensitivity in gastroesophageal reflux. <
I>Dig Dis Sci</I> 2002; 47: 2554-2564. </font>      ^cY#6752.htm##
00421000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704017800076002000900254#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#97#93#article#103#33#<P><fon
t face="Arial, Helvetica, sans-serif">33. Orr WC. Sleep and gastroesophageal ref
lux: what are the risks? <I>Am J Med</I> 2003; 115 (Suppl 3A): 109S-113S. </font
>      ^cY#6752.htm##
00477000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023400076002000900310#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#98#94#article#103#34#<P><fon
t face="Arial, Helvetica, sans-serif">34. Bellia V, Cuttitta G, Insalaco G, Visc
onti A, Bonsignore G. Relationship of nocturnal bronchoconstriction to sleep sta
ges. <I>Am Rev Respir Dis</I> 1989; 140: 363-367. </font>      ^cY#6752.htm##
00528000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028500076002000900361#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#99#95#article#103#35#<P><fon
t face="Arial, Helvetica, sans-serif">35. Cuttitta G, Cibella F, Visconti A, Sci
chilone N, Bellia V, Bonsignore G. Spontaneous gastroesophageal reflux and airwa
y patency during the night in adult asthmatics. <I>Am J Respir Crit Care Med</I>
 2000; 161: 177-181. </font>      ^cY#6752.htm##
00416000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704017200077002000900249#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#100#96#article#103#36#<P><fo
nt face="Arial, Helvetica, sans-serif">36. Ballard RD. Sleep, respiratory physio
logy, and nocturnal asthma. <I>Chronobiol Int</I> 1999; 16: 565-580. </font>    
  ^cY#6752.htm##
00504000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704026000077002000900337#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#101#97#article#103#37#<P><fo
nt face="Arial, Helvetica, sans-serif">37. Dent J, Dodds WJ, Friedman RH, Sekigu
chi T, Hogan WJ, Arndorfer RC, et al. Mechanism of gastroesophageal reflux in re
cumbent asymptomatic human subjects. <I>J Clin Invest</I> 1980; 65: 256-267. </f
ont>      ^cY#6752.htm##
00464000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704022000077002000900297#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#102#98#article#103#38#<P><fo
nt face="Arial, Helvetica, sans-serif">38. Orr WC, Craddock A, Goodrich S. Acidi
c and non-acidic reflux during sleep under conditions of powerful acid suppressi
on. <I>Chest</I> 2007; 131: 460-465. </font>      ^cY#6752.htm##
00532000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000300074704028800077002000900365#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#103#99#article#103#39#<P><fo
nt face="Arial, Helvetica, sans-serif">39. Mackie C, Hulks G, Cuschieri A. Enter
ogastric reflux and gastric clearance of refluxate in normal subjects and in pat
ients with and without bile vomiting following peptic ulcer surgery. <I>Ann Surg
</I> 1986; 204: 537-542. </font>      ^cY#6752.htm##
00522000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704027700078002000900355#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#p#104#100#article#103#40#<P><f
ont face="Arial, Helvetica, sans-serif">40. Schindlbeck NE, Heinrich C, Stellaar
d F, Paumgartner G, Muller-Lissner SA. Healthy controls have as much bile reflux
 as gastric ulcer patients. <I>Gut</I> 1987; 28: 1577-1583.</font>   <HR ALIGN=L
EFT WIDTH=100% SIZE=2>      ^cY#6752.htm##
00566000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704033600075002000900411#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#105#101#article#103#<P><FONT SIZE=4 face
="Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F
><B>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, H
elvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6752
.htm##
00615000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704038500075002000900460#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#106#102#article#103#<p><font face="Arial
, Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v41n2/
recor.gif" border="0"></a> Address for correspondence:</b> L.R.A. Bittencourt, R
ua Napole&atilde;o de Barros, 925, Vila Clementino, 04024-002 S&atilde;o Paulo, 
SP, Brasil. Fax: +55-11-5572-5092. E-mail: <a href="mailto:lia@psicobio.epm.br">
lia@psicobio.epm.br</a></font> </p>      ^cY#6752.htm##
00381000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704015100075002000900226#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6752.htm#S#p#107#103#article#103#<P><font face="Arial
, Helvetica, sans-serif">Publication supported by FAPESP. Received December 15, 
2006. Accepted December 13, 2007. </font>      ^cY#6752.htm##
00507000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740120054000920300
02200146065000900168064000500177031000300182014000600185865000900191002000900200
035001000209801002200219#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#
108#1#article#40#1#^rND^sTibbling^nL#Epidemiology of gastro-oesophageal reflux d
isease^len#Scand J Gastroenterol#19840000#1984#19#14-15#20080200#6752.htm#0036-5
521#Scand J Gastroenterol##
00585000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100014000740120032000880160
01700120016001400137016001700151018004600168063000200214066001300216062001200229
065000900241064000500250014001000255865000900265002000900274#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6752.htm#S#c#109#2#article#40#2#^rND^sOrr^nWC#Gastrointes
tinal physiology^len#^rND^sKryger^nMH#^rND^sRoth^nT#^rND^sDement^nWC#Principles 
and practice of sleep medicine^len#3#Philadelphia#WB Saunders#20000000#2000#1113
-1122#20080200#6752.htm##
00623000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100017000930100
01700110010001600127012008800143030001800231065000900249064000500258031000400263
014000800267865000900275002000900284035001000293801001800303#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6752.htm#S#c#110#3#article#40#3#^rND^sTabachnik^nE#^rND^s
Muller^nNL#^rND^sLevison^nH#^rND^sBryan^nAC#Chest wall mechanics and pattern of 
breathing during sleep in asthmatic adolescents^len#Am Rev Respir Dis#19810000#1
981#124#269-273#20080200#6752.htm#0003-0805#Am Rev Respir Dis##
00578000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100015000910100
01600106010001700122012006300139030001000202065000900212064000500221031000400226
014000800230865000900238002000900247035001000256801001000266#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6752.htm#S#c#111#4#article#40#4#^rND^sHughes^nDM#^rND^sSp
ier^nS#^rND^sRivlin^nJ#^rND^sLevison^nH#Gastroesophageal reflux during sleep in 
asthmatic patients^len#J Pediatr#19830000#1983#102#666-672#20080200#6752.htm#002
2-3476#J Pediatr##
00457000000000253000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100014000740120048000880300
02300136710000200159065000900161064000500170031000200175014000800177865000900185
002000900194#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#112#5#articl
e#40#5#^rND^sOrr^nWC#Reflux events and sleep: are we vulnerable?^len#Curr Gastro
enterol Rep#2#20060000#2006#8#202-207#20080200#6752.htm##
00604000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100016000920100
01700108010001900125010001700144012006200161030000700223065000900230064000500239
031000300244014000800247865000900255002000900264035001000273801000700283#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#113#6#article#40#6#^rND^sGoodall
^nRJ#^rND^sEaris^nJE#^rND^sCooper^nDN#^rND^sBernstein^nA#^rND^sTemple^nJG#Relati
onship between asthma and gastro-oesophageal reflux^len#Thorax#19810000#1981#36#
116-121#20080200#6752.htm#0040-6376#Thorax##
00524000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100018000920120
06800110030000600178065000900184064000500193031000400198014001000202865000900212
002000900221035001000230801000600240#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
752.htm#S#c#114#7#article#40#7#^rND^sHarding^nSM#^rND^sRichter^nJE#The role of g
astroesophageal reflux in chronic cough and asthma^len#Chest#19970000#1997#111#1
389-1402#20080200#6752.htm#0012-3692#Chest##
00506000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100020000930100
01800113012004400131030001000175710000200185065000900187064000500196031000300201
014000600204865000900210002000900219#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
752.htm#S#c#115#8#article#40#8#^rND^sMorales^nJEG#^rND^sHernandez^nLL#^rND^sSpen
cer^nDG#Asma asociada a reflujo gastroesofágico^les#Alerg Mex#2#19980000#1998#45
#16-21#20080200#6752.htm##
00569000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100019000900100
01500109010001600124012006100140030000600201065000900207064000500216031000400221
014000800225865000900233002000900242035001000251801000600261#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6752.htm#S#c#116#9#article#40#9#^rND^sField^nSK#^rND^sUnd
erwood^nM#^rND^sBrant^nR#^rND^sCowie^nRL#Prevalence of gastroesophageal reflux s
ymptoms in asthma^len#Chest#19960000#1996#109#316-322#20080200#6752.htm#0012-369
2#Chest##
00507000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120064000940300
01500158065000900173064000500182031000300187014000800190865000900198002000900207
035001000216801001500226#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#
117#10#article#40#10#^rND^sHarding^nSM#Nocturnal asthma: role of nocturnal gastr
oesophageal reflux^len#Chronobiol Int#19990000#1999#16#641-662#20080200#6752.htm
#0742-0528#Chronobiol Int##
00500000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100016000960120
02100112030001900133065000900152064000500161031000300166014000600169865000900175
002000900184035001000193801001900203#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
752.htm#S#c#118#11#article#40#11#^rND^sShigemitsu^nH#^rND^sAfshar^nK#Nocturnal a
sthma^len#Curr Opin Pulm Med#20070000#2007#13#49-55#20080200#6752.htm#1078-1641#
Curr Opin Pulm Med##
00472000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760120028000960300
01500124065000900139064000500148031000200153014000800155865000900163002000900172
035001000181801001500191#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#
119#12#article#40#12#^rND^sBranscomb^nBV#The difficult asthmatic^len#Clin Chest 
Med#19840000#1984#5#695-713#20080200#6752.htm#0272-5231#Clin Chest Med##
00650000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01500111010001600126010001400142010001600156012008400172030000600256065000900262
06400050027103100040027601400100028086500090029000200090029903500100030880100060
0318#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#120#13#article#40#13
#^rND^sValipour^nA#^rND^sMakker^nHK#^rND^sHardy^nR#^rND^sEmegbo^nS#^rND^sToma^nT
#^rND^sSpiro^nSG#Symptomatic gastroesophageal reflux in subjects with a breathin
g sleep disorder^len#Chest#20020000#2002#121#1748-1753#20080200#6752.htm#0012-36
92#Chest##
00591000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100020000930100
01700113012009400130030001200224065000900236064000500245031000300250014000800253
865000900261002000900270035001000279801001200289#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6752.htm#S#c#121#14#article#40#14#^rND^sMartin^nME#^rND^sGrunstein^nM
M#^rND^sLarsen^nGL#The relationship of gastroesophageal reflux to nocturnal whee
zing in children with asthma^len#Ann Allergy#19820000#1982#49#318-322#20080200#6
752.htm#0003-4738#Ann Allergy##
00611000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
02000109012009300129030002300222065000900245064000500254031000300259014000800262
865000900270002000900279035001000288801002300298#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6752.htm#S#c#122#15#article#40#15#^rND^sDavis^nRS#^rND^sLarsen^nGL#^r
ND^sGrunstein^nMM#Respiratory response to intraesophageal acid infusion in asthm
atic children during sleep^len#J Allergy Clin Immunol#19830000#1983#72#393-398#2
0080200#6752.htm#0091-6749#J Allergy Clin Immunol##
00623000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100017000900100
01600107010001800123012008800141030001800229065000900247064000500256031000400261
014001000265865000900275002000900284035001000293801001800303#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6752.htm#S#c#123#16#article#40#16#^rND^sTan^nWC#^rND^sMar
tin^nRJ#^rND^sPandey^nR#^rND^sBallard^nRD#Effects of spontaneous and simulated g
astroesophageal reflux on sleeping asthmatics^len#Am Rev Respir Dis#19900000#199
0#141#1394-1399#20080200#6752.htm#0003-0805#Am Rev Respir Dis##
00461000000000253000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730110033000760120033001090300
00900142065000900151064000500160014000500165865000900170002000900179035001000188
801000900198#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#124#17#artic
le#40#17#Asthma management and prevention#Global initiative for asthma^len#Ir Me
d J#20000000#2000#1-39#20080200#6752.htm#0332-3102#Ir Med J##
00747000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100022000760100020000980100
02400118010001600142010001600158010002100174810000600195012011700201030001900318
06500090033706400050034603100030035101400080035486500090036200200090037103500100
0380801001900390#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#125#18#a
rticle#40#18#^rND^sMoraes-Filho^nJ#^rND^sCecconello^nI#^rND^sGama-Rodrigues^nJ#^
rND^sCastro^nL#^rND^sHenry^nMA#^rND^sMeneghelli^nUG#et al#Brazilian consensus on
 gastroesophageal reflux disease: proposals for assessment, classification, and 
management^len#Am J Gastroenterol#20020000#2002#97#241-248#20080200#6752.htm#000
2-9270#Am J Gastroenterol##
00528000000000241000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730160023000760160015000990180
10800114066001200222062002000234065000900254064000500263865000900268002000900277
#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#126#19#article#40#19#^rN
D^sRechtschaffen^nA#^rND^sKales^nA#A manual of standardized terminology, techniq
ues and scoring systems for sleep stages of human subjects^len#Los Angeles#BIS/B
RI, UCLA Press#19680000#1968#20080200#6752.htm##
00596000000000253000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730120201000760300006002770650
00900283064000500292031000300297014000800300865000900308002000900317035001000326
801000600336#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#127#20#artic
le#40#20#Sleep-related breathing disorders in adults: recommendations for syndro
me definition and measurement techniques in clinical research. The Report of an 
American Academy of Sleep Medicine Task Force^len#Sleep#19990000#1999#22#667-689
#20080200#6752.htm#0161-8105#Sleep##
00489000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730110037000760120045001130300
00600158065000900164064000500173031000300178014000800181865000900189002000900198
035001000207801000600217#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#
128#21#article#40#21#American Sleep Disorders Association#EEG arousals: scoring 
rules and examples^len#Sleep#19920000#1992#15#173-184#20080200#6752.htm#0161-810
5#Sleep##
00642000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100018000960100
01700114010001800131010001500149010001800164012006200182030000900244065000900253
06400050026203100040026701400080027186500090027900200090028803500100029780100090
0307#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#129#22#article#40#22
#^rND^sDeMeester^nTR#^rND^sJohnson^nLF#^rND^sJoseph^nGJ#^rND^sToscano^nMS#^rND^s
Hall^nAW#^rND^sSkinner^nDB#Patterns of gastroesophageal reflux in health and dis
ease^len#Ann Surg#19760000#1976#184#459-470#20080200#6752.htm#0003-4932#Ann Surg
##
00503000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100015000900120
04100105030001200146065000900158064000500167031000300172014001000175865000900185
002000900194035001000203801001200213#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
752.htm#S#c#130#23#article#40#23#^rND^sOrr^nWC#^rND^sChen^nCL#Sleep and the gast
rointestinal tract^len#Neurol Clin#20050000#2005#23#1007-1024#20080200#6752.htm#
0733-8619#Neurol Clin##
00601000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910100
01600107012011900123030000700242065000900249064000500258031000300263014001000266
865000900276002000900285035001000294801000700304#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6752.htm#S#c#131#24#article#40#24#^rND^sChinn^nS#^rND^sJarvis^nD#^rND
^sBurney^nP#Relation of bronchial responsiveness to body mass index in the ECRHS
: European Community Respiratory Health Survey^len#Thorax#20020000#2002#57#1028-
1033#20080200#6752.htm#0040-6376#Thorax##
00495000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100019000920120
02300111030001500134065000900149064000500158031000400163014000700167865000900174
002000900183035001000192801001500202#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
752.htm#S#c#132#25#article#40#25#^rND^sShore^nSA#^rND^sJohnston^nRA#Obesity and 
asthma^len#Pharmacol Ther#20060000#2006#110#83-102#20080200#6752.htm#0163-7258#P
harmacol Ther##
00773000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100019000920100
01800111010001800129010001900147010001500166810000600181012016800187030001300355
06500090036806400050037703100020038201400100038486500090039400200090040303500100
0412801001300422#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#133#26#a
rticle#40#26#^rND^sJanson^nC#^rND^sDe^nBacker W#^rND^sGislason^nT#^rND^sPlaschke
^nP#^rND^sBjornsson^nE#^rND^sHetta^nJ#et al#Increased prevalence of sleep distur
bances and daytime sleepiness in subjects with bronchial asthma: a population st
udy of young adults in three European countries^len#Eur Respir J#19960000#1996#9
#2132-2138#20080200#6752.htm#0903-1936#Eur Respir J##
00690000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
02300109010001800132010001700150010001900167810000600186012009200192030000600284
06500090029006400050029903100040030401400100030886500090031800200090032703500100
0336801000600346#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#134#27#a
rticle#40#27#^rND^sBerger^nKI#^rND^sAyappa^nI#^rND^sChatr-Amontri^nB#^rND^sMarfa
tia^nA#^rND^sSorkin^nIB#^rND^sRapoport^nDM#et al#Obesity hypoventilation syndrom
e as a spectrum of respiratory disturbances during sleep^len#Chest#20010000#2001
#120#1231-1238#20080200#6752.htm#0012-3692#Chest##
00625000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100023000760100016000990100
01500115010001500130010001800145012008200163030000600245065000900251064000500260
031000400265014000800269865000900277002000900286035001000295801000600305#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#135#28#article#40#28#^rND^sGuill
eminault^nC#^rND^sStoohs^nR#^rND^sClerk^nA#^rND^sCetel^nM#^rND^sMaistros^nP#A ca
use of excessive daytime sleepiness: The upper airway resistance syndrome^len#Ch
est#19930000#1993#104#781-787#20080200#6752.htm#0012-3692#Chest##
00698000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930100
01700110010001300127010001800140010001900158810000600177012009800183030001200281
06500090029306400050030203100030030701400100031086500090032000200090032903500100
0338801001200348#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#136#29#a
rticle#40#29#^rND^sWiener^nGJ#^rND^sMorgan^nTM#^rND^sCopper^nJB#^rND^sWu^nWC#^rN
D^sCastell^nDO#^rND^sSinclair^nJW#et al#Ambulatory 24-hour esophageal pH monitor
ing: Reproducibility and variability of pH parameters^len#Dig Dis Sci#19880000#1
988#33#1127-1133#20080200#6752.htm#0163-2116#Dig Dis Sci##
00566000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100021000950120
07400116030002300190065000900213064000500222031000300227014000700230865000900237
002000900246035001000255801002300265#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
752.htm#S#c#137#30#article#40#30#^rND^sGalmiche^nJP#^rND^sScarpignato^nC#Esophag
eal pH monitoring: Functional evaluation in esophageal disease^len#Front Gastroi
ntest Res#19940000#1994#22#71-108#20080200#6752.htm#0302-0665#Front Gastrointest
 Res##
00565000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100019000900100
01800109012008300127030000600210065000900216064000500225031000300230014000800233
865000900241002000900250035001000259801000600269#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6752.htm#S#c#138#31#article#40#31#^rND^sOrr^nWC#^rND^sRobinson^nMG#^r
ND^sJohnson^nLF#The effect of esophageal acid volume on arousals from sleep and 
acid clearance^len#Chest#19910000#1991#99#351-354#20080200#6752.htm#0012-3692#Ch
est##
00619000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100025000760100019001010100
01700120010001900137010001800156012005200174030001200226065000900238064000500247
031000300252014001000255865000900265002000900274035001000283801001200293#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#139#32#article#40#32#^rND^sTheod
oropoulos^nDS#^rND^sPecoraro^nDL#^rND^sLockey^nRF#^rND^sBoyce^nHW Jr#^rND^sBukan
tz^nSC#Visceral sensitivity in gastroesophageal reflux^len#Dig Dis Sci#20020000#
2002#47#2554-2564#20080200#6752.htm#0163-2116#Dig Dis Sci##
00506000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760120059000900300
00900149065000900158064000500167031000400172032000500176014001000181865000900191
002000900200035001000209801000900219#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
752.htm#S#c#140#33#article#40#33#^rND^sOrr^nWC#Sleep and gastroesophageal reflux
: what are the risks?^len#Am J Med#20030000#2003#115#^s3A#109S-113S#20080200#675
2.htm#0002-9343#Am J Med##
00636000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01800110010001800128010002000146012006600166030001800232065000900250064000500259
031000400264014000800268865000900276002000900285035001000294801001800304#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#141#34#article#40#34#^rND^sBelli
a^nV#^rND^sCuttitta^nG#^rND^sInsalaco^nG#^rND^sVisconti^nA#^rND^sBonsignore^nG#R
elationship of nocturnal bronchoconstriction to sleep stages^len#Am Rev Respir D
is#19890000#1989#140#363-367#20080200#6752.htm#0003-0805#Am Rev Respir Dis##
00713000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01800111010002000129010001600149010002000165012009600185030002600281065000900307
06400050031603100040032101400080032586500090033300200090034203500100035180100260
0361#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#142#35#article#40#35
#^rND^sCuttitta^nG#^rND^sCibella^nF#^rND^sVisconti^nA#^rND^sScichilone^nN#^rND^s
Bellia^nV#^rND^sBonsignore^nG#Spontaneous gastroesophageal reflux and airway pat
ency during the night in adult asthmatics^len#Am J Respir Crit Care Med#20000000
#2000#161#177-181#20080200#6752.htm#1073-449X#Am J Respir Crit Care Med##
00499000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120056000940300
01500150065000900165064000500174031000300179014000800182865000900190002000900199
035001000208801001500218#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#
143#36#article#40#36#^rND^sBallard^nRD#Sleep, respiratory physiology, and noctur
nal asthma^len#Chronobiol Int#19990000#1999#16#565-580#20080200#6752.htm#0742-05
28#Chronobiol Int##
00687000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100016000900100
01900106010001900125010001600144010002000160810000600180012008200186030001400268
06500090028206400050029103100030029601400080029986500090030700200090031603500100
0325801001400335#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#144#37#a
rticle#40#37#^rND^sDent^nJ#^rND^sDodds^nWJ#^rND^sFriedman^nRH#^rND^sSekiguchi^nT
#^rND^sHogan^nWJ#^rND^sArndorfer^nRC#et al#Mechanism of gastroesophageal reflux 
in recumbent asymptomatic human subjects^len#J Clin Invest#19800000#1980#65#256-
267#20080200#6752.htm#0021-9738#J Clin Invest##
00574000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100018000900100
01800108012009200126030000600218065000900224064000500233031000400238014000800242
865000900250002000900259035001000268801000600278#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6752.htm#S#c#145#38#article#40#38#^rND^sOrr^nWC#^rND^sCraddock^nA#^rN
D^sGoodrich^nS#Acidic and non-acidic reflux during sleep under conditions of pow
erful acid suppression^len#Chest#20070000#2007#131#460-465#20080200#6752.htm#001
2-3692#Chest##
00645000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100015000920100
01900107012015700126030000900283065000900292064000500301031000400306014000800310
865000900318002000900327035001000336801000900346#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6752.htm#S#c#146#39#article#40#39#^rND^sMackie^nC#^rND^sHulks^nG#^rND
^sCuschieri^nA#Enterogastric reflux and gastric clearance of refluxate in normal
 subjects and in patients with and without bile vomiting following peptic ulcer 
surgery^len#Ann Surg#19860000#1986#204#537-542#20080200#6752.htm#0003-4932#Ann S
urg##
00630000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100022000760100018000980100
01900116010002100135010002500156012007200181030000400253065000900257064000500266
031000300271014001000274865000900284002000900293035001000302801000400312#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6752.htm#S#c#147#40#article#40#40#^rND^sSchin
dlbeck^nNE#^rND^sHeinrich^nC#^rND^sStellaard^nF#^rND^sPaumgartner^nG#^rND^sMulle
r-Lissner^nSA#Healthy controls have as much bile reflux as gastric ulcer patient
s^len#Gut#19870000#1987#28#1577-1583#20080200#6752.htm#0017-5749#Gut##
00267000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00300094#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#o#1#1#article#1#20
080402#165738#6754.htm#76##
02822000000000613000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016022300090
01700120090001790100024002690100025002930100028003180100025003460100027003710700
14400398083140700542085000801949085002001957085002201977085002201999085002402021
08500330204508500280207811700060210607200030211205800060211511200090212111100180
2130114000902148113001802157881002402175002000902199#v41n2#v:\scielo\serial\bjmb
r\v41n2\markup\6754.htm#S#h#2#1#article#1#sc#en#bjmbr#1#3.1#ILUS#TAB#08#BJMBR040
#FAPESP#Braz J Med Biol Res#41#2#20080200#^f122^l125#0100-879X#20080111#Effect o
f obesity on rat reproduction and on the development of their adult offspring^le
n#^rND^1A01^nK.E.^sCampos#^rND^1A01^nG.T.^sVolpato#^rND^1A01^nI.M.P.^sCalderon#^
rND^1A01^nM.V.C.^sRudge#^rND^1A01^nD.C.^sDamasceno#Universidade Estadual Paulist
a (UNESP)^iA01^1Faculdade de Medicina de Botucatu^2Departamento de Ginecologia e
 Obstetrícia^cBotucatu^sSP^pBrasil#^len^aThe aim of the present study was to ass
ess the reproductive parameters of obese Wistar rats and to determine the freque
ncy of their obese adult offspring. Neonatal rats were divided into two groups: 
F1 generation, induced to obesity by monosodium glutamate (MSG; F1MSG, N = 30), 
and rats given saline (F1CON, N = 13). At 90 days of age all animals were mated,
 producing the F2 offspring (F2CON, N = 28; F2MSG, N = 15). Reproductive paramet
ers (fertility, pregnancy, and delivery indexes) were evaluated in F1 rats. F2 n
ewborns were weighed, and the obesity parameter for F1 and F2 generations was de
termined from months 5 to 7 of life. At month 7, periovarian fat was weighed and
 no differences were found. Mean newborn weight also did not differ. The F1 and 
F2MSG groups presented approximately 90% of obese rats since month 5 of life, wh
ereas F1 and F2CON groups presented only 33%. There was no difference in periova
rian weight among groups. Although obesity did not affect reproductive parameter
s, obese dams (F1MSG) were responsible for the appearance of obesity in the subs
equent generation. Thus, obesity induced by neonatal MSG administration did not 
interfere with reproduction, but did provide a viable model for obesity in secon
d-generation adult Wistar rats. This model might contribute to a better understa
nding of the pathophysiological mechanisms involved in transgenerational obesity
.#^dnd^i1#^tm^len^kObesity^i1#^tm^len^kOffspring^i1#^tm^len^kFertility^i1#^tm^le
n^kWistar rats^i1#^tm^len^kMonosodium glutamate^i1#^tm^len^kTransgeneration^i1#o
ther#19#CAPES#20061215#December 15, 2006#20071130#November 30, 2007#S0100-879X20
08005000001#6754.htm##
02958000000000601000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016022300090
01700120097001790100024002760100025003000100028003250100025003530100027003780700
14400405083157200549085000802121085002002129085002202149085002202171085002402193
08500330221708500280225011700060227807200030228405800060228711200090229311100180
2302114000902320113001802329002000902347#v41n2#v:\scielo\serial\bjmbr\v41n2\mark
up\6754.htm#S#f#3#1#article#1#sc#en#bjmbr#1#3.1#ILUS#TAB#08#BJMBR040#FAPESP#Braz
 J Med Biol Res#41#2#20080200#^f122^l125#0100-879X#20080111#<b>Effect of obesity
 on rat reproduction and on the development of their adult offspring</b>^len#^rN
D^1A01^nK.E.^sCampos#^rND^1A01^nG.T.^sVolpato#^rND^1A01^nI.M.P.^sCalderon#^rND^1
A01^nM.V.C.^sRudge#^rND^1A01^nD.C.^sDamasceno#Universidade Estadual Paulista (UN
ESP)^iA01^1Faculdade de Medicina de Botucatu^2Departamento de Ginecologia e Obst
etrícia^cBotucatu^sSP^pBrasil#^len^aThe aim of the present study was to assess t
he reproductive parameters of obese Wistar rats and to determine the frequency o
f their obese adult offspring. Neonatal rats were divided into two groups: F<sub
>1</sub> generation, induced to obesity by monosodium glutamate (MSG; F<sub>1</s
ub>MSG, N = 30), and rats given saline (F<sub>1</sub>CON, N = 13). At 90 days of
 age all animals were mated, producing the F<sub>2</sub> offspring (F<sub>2</sub
>CON, N = 28; F<sub>2</sub>MSG, N = 15). Reproductive parameters (fertility, pre
gnancy, and delivery indexes) were evaluated in F<sub>1</sub> rats. F<sub>2</sub
> newborns were weighed, and the obesity parameter for F<sub>1</sub> and F<sub>2
</sub> generations was determined from months 5 to 7 of life. At month 7, periov
arian fat was weighed and no differences were found. Mean newborn weight also di
d not differ. The F<sub>1</sub> and F<sub>2</sub>MSG groups presented approximat
ely 90% of obese rats since month 5 of life, whereas F<sub>1</sub> and F<sub>2</
sub>CON groups presented only 33%. There was no difference in periovarian weight
 among groups. Although obesity did not affect reproductive parameters, obese da
ms (F<sub>1</sub>MSG) were responsible for the appearance of obesity in the subs
equent generation. Thus, obesity induced by neonatal MSG administration did not 
interfere with reproduction, but did provide a viable model for obesity in secon
d-generation adult Wistar rats. This model might contribute to a better understa
nding of the pathophysiological mechanisms involved in transgenerational obesity
.#^dnd^i1#^tm^len^kObesity^i1#^tm^len^kOffspring^i1#^tm^len^kFertility^i1#^tm^le
n^kWistar rats^i1#^tm^len^kMonosodium glutamate^i1#^tm^len^kTransgeneration^i1#o
ther#19#CAPES#20061215#December 15, 2006#20071130#November 30, 2007#6754.htm##
02934000000000625000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100038000400105121000300109049000900112
15800070012103000240012803100030015203200020015506500090015701400110016603500100
01772230009001870120090001960100024002860100025003100100029003350100026003640100
02700390070014600417083142100563085000801984085002001992085002202012085002202034
08500240205608500330208008500280211311700060214107200030214705800060215011200090
2156111001802165114000902183113001802192002000902210008008902219#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#l#4#1#article#1#^mFeb.^a2008#sc#en#bjmbr#1
#3.1#ilus#tab#08#BJMBR040#FAPESP#Braz. j. med. biol. res#41#2#20080200#^f122^l12
5#0100-879X#20080111#Effect of obesity on rat reproduction and on the developmen
t of their adult offspring^len#^rND^1A01^nK. E^sCampos#^rND^1A01^nG. T^sVolpato#
^rND^1A01^nI. M. P^sCalderon#^rND^1A01^nM. V. C^sRudge#^rND^1A01^nD. C^sDamascen
o#^iA01^1Universidade Estadual Paulista (UNESP)^2Faculdade de Medicina de Botuca
tu^3Departamento de Ginecologia e Obstetrícia^cBotucatu^sSP^pBrasil#^len^aThe ai
m of the present study was to assess the reproductive parameters of obese Wistar
 rats and to determine the frequency of their obese adult offspring. Neonatal ra
ts were divided into two groups: F1 generation, induced to obesity by monosodium
 glutamate (MSG; F1MSG, N = 30), and rats given saline (F1CON, N = 13). At 90 da
ys of age all animals were mated, producing the F2 offspring (F2CON, N = 28; F2M
SG, N = 15). Reproductive parameters (fertility, pregnancy, and delivery indexes
) were evaluated in F1 rats. F2 newborns were weighed, and the obesity parameter
 for F1 and F2 generations was determined from months 5 to 7 of life. At month 7
, periovarian fat was weighed and no differences were found. Mean newborn weight
 also did not differ. The F1 and F2MSG groups presented approximately 90 percent
 of obese rats since month 5 of life, whereas F1 and F2CON groups presented only
 33 percent. There was no difference in periovarian weight among groups. Althoug
h obesity did not affect reproductive parameters, obese dams (F1MSG) were respon
sible for the appearance of obesity in the subsequent generation. Thus, obesity 
induced by neonatal MSG administration did not interfere with reproduction, but 
did provide a viable model for obesity in second-generation adult Wistar rats. T
his model might contribute to a better understanding of the pathophysiological m
echanisms involved in transgenerational obesity.#^dnd^i1#^tm^len^kObesity^i1#^tm
^len^kOffspring^i1#^tm^len^kFertility^i1#^tm^len^kWistar rats^i1#^tm^len^kMonoso
dium glutamate^i1#^tm^len^kTransgeneration^i1#other#19#CAPES#20061215#December 1
5, 2006#20071130#November 30, 2007#6754.htm#Internet^ihttp://www.scielo.br/sciel
o.php?script=sci_arttext&pid=S0100-879X2008000200008##
00410000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704018500070002000900255#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#5#1#article#53#<P class="style4"> <A NAM
E="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif">F
ebruary 2008, Volume 41(2) 122-125</font> (Short Communication)</B></P>     ^cY#
6754.htm##
00387000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704016200070002000900232#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#6#2#article#53#<P><font size="5" face="A
rial, Helvetica, sans-serif"><B>Effect of obesity on rat reproduction and on the
 development of their adult offspring</B></font>     ^cY#6754.htm##
00633000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704040800070002000900478#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#7#3#article#53#<P><font face="Arial, Hel
vetica, sans-serif"><span class="style4"><a href="#Correspondence"><img src="/im
g/revistas/bjmbr/v41n2/recor.gif" border="0"></a> <a href="mailto:kecampos@yahoo
.com.br"><img src="/img/revistas/bjmbr/v41n2/email-ca.gif" border="0"></a></span
></font> <font face="Arial, Helvetica, sans-serif">K.E. Campos, G.T. Volpato, I.
M.P. Calderon, M.V.C. Rudge and D.C. Damasceno </font>     ^cY#6754.htm##
00432000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704020700070002000900277#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#8#4#article#53#<P><font face="Arial, Hel
vetica, sans-serif">Departamento de Ginecologia e Obstetr&iacute;cia, Faculdade 
de Medicina de Botucatu, Universidade Estadual Paulista (UNESP), Botucatu, SP, B
rasil </font>     ^cY#6754.htm##
00464000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704023900070002000900309#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#9#5#article#53#<P class="style4"> <A HRE
F="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=
0 VSPACE=0 HSPACE=0></A>    <A HREF="#Abstract"><strong><font face="Arial, Helve
tica, sans-serif">Abstract</font></strong></A>    ^cY#6754.htm##
00441000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704021500071002000900286#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#10#6#article#53#<BR>   <A HREF="#Text"><
IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0></A>    <A HREF="#Text"><strong><font face="Arial, Helvetica, sans-serif">T
ext</font></strong></A>    ^cY#6754.htm##
00446000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704022000071002000900291#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#11#7#article#53#<BR>   <A HREF="#Referen
ces"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A>    <A HREF="#References"><strong><font face="Arial, Helvetica, s
ans-serif">References</font>    ^cY#6754.htm##
00484000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704025800071002000900329#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#12#8#article#53#<br>   </strong></A><fon
t face="Arial, Helvetica, sans-serif"><A HREF="#Acknowledgments"><IMG SRC="/img/
revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A H
REF="#Acknowledgments"><strong>Acknowledgments</strong></A></font>    ^cY#6754.h
tm##
00524000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704029800071002000900369#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#13#9#article#53#<BR>   <A HREF="#Corresp
ondence"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSP
ACE=0 HSPACE=0></A>    <A HREF="#Correspondence"><strong><font face="Arial, Helv
etica, sans-serif">Correspondence    and Footnotes</font></strong></a>  <HR ALIG
N=LEFT WIDTH=100% SIZE=2>     ^cY#6754.htm##
00574000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704034700072002000900419#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#14#10#article#53#<P class="style4"> <A N
AME="Abstract"></A><span class="style3"><font color="#00007F" face="Arial, Helve
tica, sans-serif" size="4"><b>Abstract</b></font><FONT COLOR=#00007F>    </FONT>
</span><A HREF="#Home"><FONT SIZE=4><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.
gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>     
^cY#6754.htm##
01853000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704162600072002000901698#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#15#11#article#53#<P><font face="Arial, H
elvetica, sans-serif">The aim of the present study was to assess the reproductiv
e parameters of obese Wistar rats and to determine the frequency of their obese 
adult offspring. Neonatal rats were divided into two groups: F<SUB>1</SUB> gener
ation, induced to obesity by monosodium glutamate (MSG; F<SUB>1</SUB>MSG, N = 30
), and rats given saline (F<SUB>1</SUB>CON, N = 13). At 90 days of age all anima
ls were mated, producing the F<SUB>2</SUB> offspring (F<SUB>2</SUB>CON, N = 28; 
F<SUB>2</SUB>MSG, N = 15). Reproductive parameters (fertility, pregnancy, and de
livery indexes) were evaluated in F<SUB>1</SUB> rats. F<SUB>2</SUB> newborns wer
e weighed, and the obesity parameter for F<SUB>1</SUB> and F<SUB>2</SUB> generat
ions was determined from months 5 to 7 of life. At month 7, periovarian fat was 
weighed and no differences were found. Mean newborn weight also did not differ. 
The F<SUB>1</SUB> and F<SUB>2</SUB>MSG groups presented approximately 90% of obe
se rats since month 5 of life, whereas F<SUB>1</SUB> and F<SUB>2</SUB>CON groups
 presented only 33%. There was no difference in periovarian weight among groups.
 Although obesity did not affect reproductive parameters, obese dams (F<SUB>1</S
UB>MSG) were responsible for the appearance of obesity in the subsequent generat
ion. Thus, obesity induced by neonatal MSG administration did not interfere with
 reproduction, but did provide a viable model for obesity in second-generation a
dult Wistar rats. This model might contribute to a better understanding of the p
athophysiological mechanisms involved in transgenerational obesity.</font>     ^
cY#6754.htm##
00415000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704018800072002000900260#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#16#12#article#53#<P><font face="Arial, H
elvetica, sans-serif">Key words: Obesity; Offspring; Fertility; Wistar rats; Mon
osodium glutamate; Transgeneration </font> <HR ALIGN=LEFT WIDTH=100% SIZE=2>    
 ^cY#6754.htm##
00520000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704029300072002000900365#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#17#13#article#53#<P class="style4"><A NA
ME="Text"></A><FONT SIZE=4><B><span class="style3"><font color="#00007F" face="A
rial, Helvetica, sans-serif">Text</font></span>    <a href="#Home"><IMG SRC="/im
g/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0
"></a></B></FONT></P>     ^cY#6754.htm##
01010000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704078300072002000900855#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#18#14#article#53#<P><font face="Arial, H
elvetica, sans-serif">Although the negative effects of obesity on reproductive f
unction were first documented more than 2000 years ago by Hippocrates, few scien
tific investigations of women have dealt with the etiology of this unfavorable c
ondition (1). Obesity is rapidly growing among women in general and women of fer
tile age (2). Clinical investigations show that obese women have a greater preva
lence of amenorrhea and infertility. It is common to find greater risks of compl
ications during pregnancy among these women such as hypertension, gestational di
abetes and greater susceptibility to complications during delivery, which result
 in unplanned cesarean surgeries. Maternal obesity can have a negative effect on
 children's health (3). </font>     ^cY#6754.htm##
00737000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704051000072002000900582#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#19#15#article#53#<P><font face="Arial, H
elvetica, sans-serif">Since it is difficult to determine obesity-induced reprodu
ctive complications in women, experimental studies are carried out to induce obe
sity. The model of neonatally monosodium glutamate (MSG)-treated rats is of spec
ial interest regarding the development of obesity (4-6). Neonatal treatment with
 MSG has been shown to destroy hypothalamic arcuate nucleus neurons, resulting i
n several endocrine disturbances (7), stunted growth, and obesity (8). </font>  
   ^cY#6754.htm##
00669000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704044200072002000900514#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#20#16#article#53#<P><font face="Arial, H
elvetica, sans-serif">In the context of the existing relationship between obesit
y and complications of female reproduction and considering the interest in hered
itary consequences (transgenerational effect), the objective of the present stud
y aims to evaluate the reproductive parameters of Wistar rats treated with MSG d
uring the neonatal period and to determine the frequency of their obese offsprin
g. </font>     ^cY#6754.htm##
00792000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704056500072002000900637#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#21#17#article#53#<P><font face="Arial, H
elvetica, sans-serif">Wistar rats were kept in collective cages under controlled
 conditions of temperature (22 &#177; 3&#176;C), light (12-h light/dark cycle) a
nd relative humidity (60 &#177; 5%). The animals were fed laboratory chow (Purin
a<SUP>&#174;</SUP>) and had free access to tap water. The animals were cared for
 in accordance with the principles of the Guide for Care and Use of Experimental
 Animals. The local Ethics Committee of Animal Experimentation approved all the 
experimental procedures of the present study. </font>     ^cY#6754.htm##
00694000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704046700072002000900539#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#22#18#article#53#<P><font face="Arial, H
elvetica, sans-serif">Female newborns were divided into two groups: rats receivi
ng subcutaneously (<I>sc</I>) saline solution (2.0% NaCl, control) at days 2, 4,
 6, 8, and 10 of life (F<SUB>1</SUB>CON group, N = 13), and rats receiving a sol
ution of MSG (4.0 mg/g body weight, <I>sc</I>) on the same days (F<SUB>1</SUB>MS
G group, N = 30) (4,5,9). After weaning, rats were housed 4 to a cage and kept u
nder controlled conditions. </font>     ^cY#6754.htm##
01344000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704111700072002000901189#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#23#19#article#53#<P><font face="Arial, H
elvetica, sans-serif">Obesity was determined by the Lee index at months 3, 5, 6,
 and 7 of life for each rat, calculated by the cube root of body weight (g) x 10
 / naso-anal length (mm), for which a value equal to or lower than 0.300 was cla
ssified as normal at month 3 of life. For values higher than 0.300, the rats wer
e classified as obese (9). In the 3rd month, rats classified as obese were inclu
ded in the experiment and mated. Each female (F<SUB>1</SUB>CON group, N = 8; F<S
UB>1</SUB>MSG group, N = 5, total = 13 female rats) was mated with 1 normal male
 rat (total males used = 13). Several indexes were evaluated to estimate female 
reproductive performance: fertility index was calculated by the number of pregna
nt females x 100 / number of mated females; delivery index was calculated by the
 number of delivering females x 100 / number of pregnant females, and pregnancy 
index was determined by the number of dams with live newborns x 100 / number of 
pregnant females (10). At month 7 all rats were anesthetized and killed and tota
l periovarian fat was weighed (4,11). </font>     ^cY#6754.htm##
01399000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704117200072002000901244#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#24#20#article#53#<P><font face="Arial, H
elvetica, sans-serif">The female offspring of F<SUB>1</SUB> generation was kept 
with their dams until day 21 of life. After weaning all F<SUB>2</SUB> pups were 
separated from their dams and denominated according to maternal experimental gro
up: F<SUB>2</SUB>CON (N = 28, obtained from F<SUB>1</SUB>CON dams) and F<SUB>2</
SUB>MSG (N = 15, obtained from F<SUB>1</SUB>MSG rats; <strong><a href="#Fig1">Fi
gure 1</a></strong>). Food and tap water were given <I>ad libitum</I>. F<SUB>2</
SUB> rats were kept until month 7 of life. The Lee index was evaluated monthly f
rom the 5th to 7th month of life (9). In month 7, F<SUB>2</SUB> rats were anesth
etized and killed to collect and weigh periovarian fat. Data regarding the repro
ductive parameters were analyzed statistically by the z-test, with z &gt;1.96 be
ing considered significant (12). Periovarian fat weight data were analyzed by an
alysis of variance (ANOVA) followed by the multiple comparisons Tukey test (13).
 The frequency of obese animals was calculated by the <font face="Symbol">c</fon
t><SUP>2</SUP> test. The level of statistical significance was set at 5% (P &lt;
 0.05) (12). </font>     ^cY#6754.htm##
01065000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704083800072002000900910#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#25#21#article#53#<P><font face="Arial, H
elvetica, sans-serif">The negative effects of obesity on reproductive physiology
 have been studied for many years. In the present study, all 13 F<SUB>1</SUB>CON
 rats that started the experiment reached adult age and were submitted to mating
 and 84.6% of them presented a positive diagnosis of pregnancy. Twenty-one of th
e 30 F<SUB>1</SUB>MSG rats (70%) reached adult age and 9 (30%) died before this 
period. We suggest that death in the MSG group occurred due to the fact that blo
od brain barrier was not fully formed during the first 10 days of life and, ther
efore, permitted MSG passage, leading to its pharmacological action in the centr
al nervous system (6,7). This fact caused an exhaustion of energy stores and cel
l death, which impaired other vital functions, affecting neonatal development. <
/font>     ^cY#6754.htm##
00989000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704076200072002000900834#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#26#22#article#53#<P><font face="Arial, H
elvetica, sans-serif">Obesity may interfere with many ovarian and extra-ovarian 
functions, thereby reducing both ovulatory and fertility rates in otherwise heal
thy women (14). In the present study, pregnancy was confirmed in 14 of 21 obese 
rats mated (66.7%), but no difference was found compared to F<SUB>1</SUB>CON (z 
&lt;1.96). Only 5 of 14 pregnant obese rats (35.7%) delivered when compared to F
<SUB>1</SUB>CON (72.7%), but the difference was non-significant (z &lt;1.96; <st
rong><a href="#Tab1">Table 1</a></strong>). These results did not agree with lit
erature data because obesity affects female fertility, with a greater risk of ov
ulatory infertility, that is increased in women with a high body mass index (3,9
). </font>     ^cY#6754.htm##
01961000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704173400072002000901806#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#27#23#article#53#<P><font face="Arial, H
elvetica, sans-serif">In the present study, the mean weight of the F<SUB>2</SUB>
MSG group did not differ significantly from that of F<SUB>2</SUB>CON (P &gt; 0.0
5; <strong><a href="#Tab1">Table 1</a></strong>). All F<SUB>1</SUB>MSG rats were
 classified as obese (100%) according to the Lee index. The periovarian fat of o
bese F<SUB>1</SUB> and F<SUB>2</SUB> rats did not differ significantly from cont
rol (P &gt; 0.05; <strong><a href="#Tab1">Table 1</a></strong>). There was an in
creased percentage of obese rats in the F<SUB>2</SUB>MSG group compared to the F
<SUB>2</SUB>CON group (P &lt; 0.05). This result confirms that maternal obesity 
caused obesity in the subsequent generation and demonstrates that the experiment
al model employed was viable for obtaining a similar clinical diagnosis of obese
 patients based on body mass index. Children of obese parents have an increased 
risk of becoming obese compared to children of parents of normal weight (15). Th
e Lee index values of F<SUB>1</SUB> and F<SUB>2</SUB>MSG were higher, a fact pro
bably justified by lower body length because obesity disorders contribute to a r
eduction of body protein by the presence of high levels of circulating corticost
erone (16). There is considerable experimental and clinical evidence that an alt
ered body composition before and during pregnancy produces altered metabolism in
 the offspring; unbalanced maternal nutrition or overweight and gestational diab
etes are all associated with changes in metabolic control in the offspring, whic
h then have a greater propensity to develop diabetes and/or obesity (17). Howeve
r, there is little information about the pathological mechanisms of transgenerat
ional obesity. </font>     ^cY#6754.htm##
00916000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704068900072002000900761#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#28#24#article#53#<P><font face="Arial, H
elvetica, sans-serif">In the 7th month of life, there was a significant increase
 in number of obese animals (50%) in the F<SUB>1</SUB>CON group compared to othe
r months (P &lt; 0.05). The presence of obesity in F<SUB>1</SUB> and F<SUB>2</SU
B>CON rats at month 7 of life might be justified by the aging process. In rats, 
this process starts at the end of month 6 of life (18). Similarly, in month 7 of
 life, F<SUB>1</SUB> and F<SUB>2</SUB>MSG rats presented a higher rate of obesit
y compared to their respective control groups. There is evidence that obesity is
 present in the human population and its prevalence increases as the population 
ages (19).</font>     ^cY#6754.htm##
01122000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704089500072002000900967#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#29#25#article#53#<P><font face="Arial, H
elvetica, sans-serif">The most interesting result of the present study is that, 
although obesity did not influence the reproductive parameters, obese dams (F<SU
B>1</SUB>MSG) were responsible for the appearance of obesity in the subsequent g
eneration. Thus, obesity induced by neonatal MSG administration was not a worsen
ing factor for reproduction. However, we conclude that this is a viable model fo
r obtaining obesity in adult Wistar rats of the second generation. This might co
ntribute to a better understanding of the pathophysiological mechanisms involved
 in transgenerational obesity.</font> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table w
idth="100%"  border="0">   <tr align="left" valign="top">     <td width="11%"><a
 href="/img/revistas/bjmbr/v41n2/html/6754i01.htm"><img src="/img/revistas/bjmbr
/v41n2/6754i01peq.jpg" border="2"></a></td>     <td width="89%">    ^cY#6754.htm
##
00704000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704047700072002000900549#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#30#26#article#53#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig1"></a>Figure 1. Rat generation scheme (F<SUB>
1</SUB> and F<SUB>2</SUB>) of obese rats neonatally treated with monosodium glut
amate (F<SUB>1</SUB>MSG group) and of the control group (F<SUB>1</SUB>CON) and t
heir respective offspring (F<SUB>2</SUB> generation). F<SUB>2</SUB> rat distribu
tion was almost similar in both groups (approximately N = 3 F<SUB>2</SUB> female
 rat/dam). </font>     </td>   </tr> </table>     ^cY#6754.htm##
00957000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704073000072002000900802#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#31#27#article#53#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (109 K JPG file)]</font
> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <tr align
="left" valign="top">     <td width="11%"><a href="/img/revistas/bjmbr/v41n2/htm
l/6754t01.htm"><img src="/img/revistas/bjmbr/v41n2/table.jpg" border="2"></a></t
d>     <td width="89%"><font face="Arial, Helvetica, sans-serif"><a name="Tab1">
</a>Table 1. Reproductive performance, newborn mean weight, obesity month freque
ncy (%), and periovarian fat weight of controls (CON, saline-treated rats) and o
bese females (MSG, monosodium glutamate-treated rats) in both generations (F<SUB
>1</SUB> and F<SUB>2</SUB>). </font></td>   </tr> </table>     ^cY#6754.htm##
00374000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704014700072002000900219#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#32#28#article#53#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (134 K JPG file)]</font
> <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6754.htm##
00534000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704030700072002000900379#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#33#29#article#53#<P class="style4"> <A N
AME="References"></A><FONT color="#00007F" SIZE=4><B><font face="Arial, Helvetic
a, sans-serif">References</font></B></FONT>    <A HREF="#Home"><FONT SIZE=4><B><
IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0 LOOP="0"></B></FONT></A>  </P>     ^cY#6754.htm##
00417000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704017600074002000900250#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#34#30#article#53#1#<P><font 
face="Arial, Helvetica, sans-serif">1. Bray GA. Obesity: historical development 
of scientific and cultural ideas. <I>Int J Obes</I> 1990; 14: 909-926. </font>  
   ^cY#6754.htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024400074002000900318#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#35#31#article#53#2#<P><font 
face="Arial, Helvetica, sans-serif">2. World Health Organization. <I>Obesity: pr
eventing and managing the global epidemic. Report of a WHO Consultation on Obesi
ty, 3-5 June</I>. Geneva: World Health Organization; 1997. </font>     ^cY#6754.
htm##
00427000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704018600074002000900260#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#36#32#article#53#3#<P><font 
face="Arial, Helvetica, sans-serif">3. Linne Y. Effects of obesity on women's re
production and complications during pregnancy. <I>Obes Rev</I> 2004; 5: 137-143.
 </font>     ^cY#6754.htm##
00555000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704031400074002000900388#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#37#33#article#53#4#<P><font 
face="Arial, Helvetica, sans-serif">4. Mozes S, Sefcikova Z, Lenhardt L, Racek L
. Obesity and changes of alkaline phosphatase activity in the small intestine of
 40- and 80-day-old rats subjected to early postnatal overfeeding or monosodium 
glutamate. <I>Physiol Res</I> 2004; 53: 177-186. </font>     ^cY#6754.htm##
00453000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021200074002000900286#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#38#34#article#53#5#<P><font 
face="Arial, Helvetica, sans-serif">5. Ribeiro EB, Marmo MR, Andrade IS, Dolniko
ff MS. Effect of fasting on monosodium glutamate-obese rats. <I>Braz J Med Biol 
Res</I> 1989; 22: 917-921. </font>     ^cY#6754.htm##
00514000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704027300074002000900347#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#39#35#article#53#6#<P><font 
face="Arial, Helvetica, sans-serif">6. Bueno AA, Oyama LM, Estadella D, Habitant
e CA, Bernardes BS, Ribeiro EB, et al. Lipid metabolism of monosodium glutamate 
obese rats after partial removal of adipose tissue. <I>Physiol Res</I> 2005; 54:
 57-65. </font>     ^cY#6754.htm##
00440000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704019900074002000900273#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#40#36#article#53#7#<P><font 
face="Arial, Helvetica, sans-serif">7. Olney JW. Brain lesions, obesity, and oth
er disturbances in mice treated with monosodium glutamate. <I>Science</I> 1969; 
164: 719-721. </font>     ^cY#6754.htm##
00500000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704025900074002000900333#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#41#37#article#53#8#<P><font 
face="Arial, Helvetica, sans-serif">8. Ribeiro EB, do Nascimento CM, Andrade IS,
 Hirata AE, Dolnikoff MS. Hormonal and metabolic adaptations to fasting in monos
odium glutamate-obese rats. <I>J Comp Physiol [B]</I> 1997; 167: 430-437. </font
>     ^cY#6754.htm##
00489000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024800074002000900322#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#42#38#article#53#9#<P><font 
face="Arial, Helvetica, sans-serif">9. Bernardis LL, Patterson BD. Correlation b
etween `Lee index' and carcass fat content in weanling and adult female rats wit
h hypothalamic lesions. <I>J Endocrinol</I> 1968; 40: 527-528. </font>     ^cY#6
754.htm##
00512000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027000075002000900345#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#43#39#article#53#10#<P><font
 face="Arial, Helvetica, sans-serif">10. Clegg ED, Perreault SD, Klinefelter GR.
 Assessment of male reproductive toxicity. In: Hayes AW (Editor), <I>Principles 
and methods of toxicology</I>. Philadelphia: Taylor &amp; Francis; 2001. p 1263-
1299. </font>     ^cY#6754.htm##
00451000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020900075002000900284#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#44#40#article#53#11#<P><font
 face="Arial, Helvetica, sans-serif">11. Gelardi NL, Cha CJ, Oh W. Glucose metab
olism in adipocytes of obese offspring of mild hyperglycemic rats. <I>Pediatr Re
s</I> 1990; 28: 641-645. </font>     ^cY#6754.htm##
00495000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025300075002000900328#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#45#41#article#53#12#<P><font
 face="Arial, Helvetica, sans-serif">12. Soares JF, Siqueira AL. Comparando dois
 grupos. In: Soares JF (Editor), <I>Introdu&ccedil;&atilde;o &agrave; estat&iacu
te;stica m&eacute;dica</I>. Belo Horizonte: Segrac; 2001. p 174-223. </font>    
 ^cY#6754.htm##
00444000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020200075002000900277#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#46#42#article#53#13#<P><font
 face="Arial, Helvetica, sans-serif">13. Vieira S. Outros delineamentos. In: Vie
ira S (Editor), <I>Estat&iacute;stica experimental.</I> S&atilde;o Paulo: Atlas;
 1997. p 119-132. </font>     ^cY#6754.htm##
00454000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021200075002000900287#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#47#43#article#53#14#<P><font
 face="Arial, Helvetica, sans-serif">14. Pasquali R, Pelusi C, Genghini S, Cacci
ari M, Gambineri A. Obesity and reproductive disorders in women. <I>Hum Reprod U
pdate</I> 2003; 9: 359-372. </font>     ^cY#6754.htm##
00449000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020700075002000900282#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#48#44#article#53#15#<P><font
 face="Arial, Helvetica, sans-serif">15. Lyra R, Neves G, Cavalcanti N. Obesity.
 In: Bandeira F (Editor), <I>Endocrinologia e diabetes</I>. Rio de Janeiro: Medi
si; 2003. p 1023-1032. </font>     ^cY#6754.htm##
00498000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025600075002000900331#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#49#45#article#53#16#<P><font
 face="Arial, Helvetica, sans-serif">16. Dolnikoff MS, Kater CE, Egami M, de And
rade I, Marmo MR. Neonatal treatment with monosodium glutamate increases plasma 
corticosterone in the rat. <I>Neuroendocrinology</I> 1988; 48: 645-649. </font> 
    ^cY#6754.htm##
00437000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019500075002000900270#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#50#46#article#53#17#<P><font
 face="Arial, Helvetica, sans-serif">17. Gluckman PD, Hanson MA, Beedle AS. Non-
genomic transgenerational inheritance of disease risk. <I>Bioessays</I> 2007; 29
: 145-154. </font>     ^cY#6754.htm##
00550000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704030800075002000900383#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#51#47#article#53#18#<P><font
 face="Arial, Helvetica, sans-serif">18. Pivetta M. Da obesidade ao diabetes.   
 <i>Revista FAPESP</i> <a href="http://www.revistapesquisa.fapesp.br/?art=1996&b
d=1&pg=1&lg=_" target="_blank">http://www.revistapesquisa.fapesp.br/?art    = 19
96&amp;bd =1&amp;pg =1&amp;lg =_</a>; 2003.</font>      ^cY#6754.htm##
00431000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704018900075002000900264#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#p#52#48#article#53#19#<P><font
 face="Arial, Helvetica, sans-serif">19. Rosmond R. Aetiology of obesity: a stri
ving after wind? <I>Obes Rev</I> 2004; 5: 177-181. </font> <HR ALIGN=LEFT WIDTH=
100% SIZE=2>     ^cY#6754.htm##
00561000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033400072002000900406#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#53#49#article#53#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE=4
><B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, san
s-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=
BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P>     ^cY#6754.htm#
#
00460000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704023300072002000900305#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#54#50#article#53#<P><font face="Arial, H
elvetica, sans-serif">The authors are grateful to the Research Support Center (R
SC) for its valuable contribution to the study design and statistical analysis. 
</font> <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6754.htm##
00553000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704032600072002000900398#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#55#51#article#53#<P class="style4"><A NA
ME="Correspondence"></A><FONT color="#00007F" SIZE=4><B><font face="Arial, Helve
tica, sans-serif">Correspondence    and Footnotes</font></B></FONT> <A HREF="#Ho
me"><FONT SIZE=4><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM B
ORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></P>     ^cY#6754.htm##
00696000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704046900072002000900541#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#56#52#article#53#<P class="style4"><B><a
 href="#Home"><img src="/img/revistas/bjmbr/v41n2/recor.gif" border="0"></a> Add
ress for correspondence: </B><font face="Arial, Helvetica, sans-serif">D.C. Dama
sceno, Departamento de Ginecologia e Obstetr&iacute;cia, Faculdade de Medicina d
e Botucatu, UNESP, Distrito de Rubi&atilde;o J&uacute;nior, s/n, 18618-000 Botuc
atu, SP, Brasil. E-mail: <strong><a href="mailto:kecampos@yahoo.com.br">kecampos
@yahoo.com.br</a></strong></font></P>     ^cY#6754.htm##
00405000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704017800072002000900250#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6754.htm#S#p#57#53#article#53#<P><font face="Arial, H
elvetica, sans-serif">Research supported by CAPES. Publication supported by FAPE
SP. Received December 15, 2006. Accepted November 30, 2007.</font>     ^cY#6754.
htm##
00498000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100015000730120069000880300
01100157065000900168064000500177031000300182014000800185865000900193002000900202
035001000211801001100221#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#c#
58#1#article#19#1#^rND^sBray^nGA#Obesity: historical development of scientific a
nd cultural ideas^len#Int J Obes#19900000#1990#14#909-926#20080200#6754.htm#0307
-0565#Int J Obes##
00502000000000229000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710170026000730180108000990660
00700207062002600214065000900240064000500249865000900254002000900263#v41n2#v:\sc
ielo\serial\bjmbr\v41n2\markup\6754.htm#S#c#59#2#article#19#2#World Health Organ
ization#Obesity: preventing and managing the global epidemic. Report of a WHO Co
nsultation on Obesity, 3-5 June^len#Geneva#World Health Organization#19970000#19
97#20080200#6754.htm##
00477000000000253000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100015000730120082000880300
00900170710000200179065000900181064000500190031000200195014000800197865000900205
002000900214#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#c#60#3#article
#19#3#^rND^sLinne^nY#Effects of obesity on women's reproduction and complication
s during pregnancy^len#Obes Rev#2#20040000#2004#5#137-143#20080200#6754.htm##
00691000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100015000730100019000880100
01800107010001500125012017200140030001200312065000900324064000500333031000300338
014000800341865000900349002000900358035001000367801001200377#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6754.htm#S#c#61#4#article#19#4#^rND^sMozes^nS#^rND^sSefci
kova^nZ#^rND^sLenhardt^nL#^rND^sRacek^nL#Obesity and changes of alkaline phospha
tase activity in the small intestine of 40- and 80-day-old rats subjected to ear
ly postnatal overfeeding or monosodium glutamate^len#Physiol Res#20040000#2004#5
3#177-186#20080200#6754.htm#0862-8408#Physiol Res##
00597000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100016000910100
01800107010002000125012005700145030002000202065000900222064000500231031000300236
014000800239865000900247002000900256035001000265801002000275#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6754.htm#S#c#62#5#article#19#5#^rND^sRibeiro^nEB#^rND^sMa
rmo^nMR#^rND^sAndrade^nIS#^rND^sDolnikoff^nMS#Effect of fasting on monosodium gl
utamate-obese rats^len#Braz J Med Biol Res#19890000#1989#22#917-921#20080200#675
4.htm#0100-879X#Braz J Med Biol Res##
00697000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100016000890100
01900105010002000124010002000144010001800164810000600182012009600188030001200284
06500090029606400050030503100030031001400060031386500090031900200090032803500100
0337801001200347#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#c#63#6#art
icle#19#6#^rND^sBueno^nAA#^rND^sOyama^nLM#^rND^sEstadella^nD#^rND^sHabitante^nCA
#^rND^sBernardes^nBS#^rND^sRibeiro^nEB#et al#Lipid metabolism of monosodium glut
amate obese rats after partial removal of adipose tissue^len#Physiol Res#2005000
0#2005#54#57-65#20080200#6754.htm#0862-8408#Physiol Res##
00518000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730120093000890300
00800182065000900190064000500199031000400204014000800208865000900216002000900225
035001000234801000800244#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#c#
64#7#article#19#7#^rND^sOlney^nJW#Brain lesions, obesity, and other disturbances
 in mice treated with monosodium glutamate^len#Science#19690000#1969#164#719-721
#20080200#6754.htm#0036-8075#Science##
00661000000000313000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100024000910100
01800115010001700133010002000150012008500170030001900255065000900274064000500283
031000400288014000800292865000900300002000900309035001000318801001900328#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#c#65#8#article#19#8#^rND^sRibeiro^
nEB#^rND^sdo^nNascimento CM#^rND^sAndrade^nIS#^rND^sHirata^nAE#^rND^sDolnikoff^n
MS#Hormonal and metabolic adaptations to fasting in monosodium glutamate-obese r
ats^len#J Comp Physiol [B]#19970000#1997#167#430-437#20080200#6754.htm#0174-1578
#J Comp Physiol [B]##
00590000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100020000730100020000930120
12000113030001300233065000900246064000500255031000300260014000800263865000900271
002000900280035001000289801001300299#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
754.htm#S#c#66#9#article#19#9#^rND^sBernardis^nLL#^rND^sPatterson^nBD#Correlatio
n between `Lee index' and carcass fat content in weanling and adult female rats 
with hypothalamic lesions^len#J Endocrinol#19680000#1968#40#527-528#20080200#675
4.htm#0022-0795#J Endocrinol##
00597000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100020000910100
02200111012004500133016001600178018004100194066001300235062001700248065000900265
064000500274014001000279865000900289002000900298#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6754.htm#S#c#67#10#article#19#10#^rND^sClegg^nED#^rND^sPerreault^nSD#
^rND^sKlinefelter^nGR#Assessment of male reproductive toxicity^len#^rND^sHayes^n
AW#Principles and methods of toxicology^len#Philadelphia#Taylor & Francis#200100
00#2001#1263-1299#20080200#6754.htm##
00569000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750100014000930100
01200107012008300119030001200202065000900214064000500223031000300228014000800231
865000900239002000900248035001000257801001200267#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6754.htm#S#c#68#11#article#19#11#^rND^sGelardi^nNL#^rND^sCha^nCJ#^rND
^sOh^nW#Glucose metabolism in adipocytes of obese offspring of mild hyperglycemi
c rats^len#Pediatr Res#19900000#1990#28#641-645#20080200#6754.htm#0031-3998#Pedi
atr Res##
00531000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100019000920120
02700111016001700138018003600155066001500191062000700206065000900213064000500222
014000800227865000900235002000900244#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
754.htm#S#c#69#12#article#19#12#^rND^sSoares^nJF#^rND^sSiqueira^nAL#Comparando d
ois grupos^lpt#^rND^sSoares^nJF#Introdução à estatística médica^lpt#Belo Horizon
te#Segrac#20010000#2001#174-223#20080200#6754.htm##
00483000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750120025000910160
01600116018002900132066001000161062000600171065000900177064000500186014000800191
865000900199002000900208#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#c#
70#13#article#19#13#^rND^sVieira^nS#Outros delineamentos^lpt#^rND^sVieira^nS#Est
atística experimental^lpt#São Paulo#Atlas#19970000#1997#119-132#20080200#6754.ht
m##
00614000000000313000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750100016000930100
01800109010001800127010001900145012004800164030001800212065000900230064000500239
031000200244014000800246865000900254002000900263035001000272801001800282#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#c#71#14#article#19#14#^rND^sPasqua
li^nR#^rND^sPelusi^nC#^rND^sGenghini^nS#^rND^sCacciari^nM#^rND^sGambineri^nA#Obe
sity and reproductive disorders in women^lpt#Hum Reprod Update#20030000#2003#9#3
59-372#20080200#6754.htm#1355-4786#Hum Reprod Update##
00538000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100014000750100015000890100
02000104012001200124016001800136018003000154066001500184062000700199065000900206
064000500215014001000220865000900230002000900239#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6754.htm#S#c#72#15#article#19#15#^rND^sLyra^nR#^rND^sNeves^nG#^rND^sC
avalcanti^nN#Obesity^len#^rND^sBandeira^nF#Endocrinologia e diabetes^lpt#Rio de 
Janeiro#Medisi#20030000#2003#1023-1032#20080200#6754.htm##
00659000000000313000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100020000750100016000950100
01500111010002000126010001600146012009200162030001900254065000900273064000500282
031000300287014000800290865000900298002000900307035001000316801001900326#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#c#73#16#article#19#16#^rND^sDolnik
off^nMS#^rND^sKater^nCE#^rND^sEgami^nM#^rND^sde^nAndrade I#^rND^sMarmo^nMR#Neona
tal treatment with monosodium glutamate increases plasma corticosterone in the r
at^lpt#Neuroendocrinology#19880000#1988#48#645-649#20080200#6754.htm#0028-3835#N
euroendocrinology##
00553000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750100017000940100
01700111012006200128030001000190065000900200064000500209031000300214014000800217
865000900225002000900234035001000243801001000253#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6754.htm#S#c#74#17#article#19#17#^rND^sGluckman^nPD#^rND^sHanson^nMA#
^rND^sBeedle^nAS#Non-genomic transgenerational inheritance of disease risk^lpt#B
ioessays#20070000#2007#29#145-154#20080200#6754.htm#0265-9247#Bioessays##
00362000000000205000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750120029000920300
01500121710000200136865000900138002000900147#v41n2#v:\scielo\serial\bjmbr\v41n2\
markup\6754.htm#S#c#75#18#article#19#18#^rND^sPivetta^nM#Da obesidade ao diabete
s^lpt#Revista FAPESP#2#20080200#6754.htm##
00448000000000253000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750120049000920300
00900141710000200150065000900152064000500161031000200166014000800168865000900176
002000900185#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6754.htm#S#c#76#19#articl
e#19#19#^rND^sRosmond^nR#Aetiology of obesity: a striving after wind?^len#Obes R
ev#2#20040000#2004#5#177-181#20080200#6754.htm##
00267000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00300094#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#o#1#1#article#1#20
080402#165740#6761.htm#96##
03195000000000613000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000700104030002000111
03100030013103200020013406500090013601400110014503500100015601200440016601000250
02100100026002350100020002610100022002810700128003030700106004310700082005370700
15900619083155300778085000802331085003302339085002402372085002302396085002902419
08500210244808500230246911700060249207200030249805800050250106000120250611200090
2518111001802527114000902545113001802554002000902572#v41n2#v:\scielo\serial\bjmb
r\v41n2\markup\6761.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#10#BJMBR060#FAP
ESP#Braz J Med Biol Res#41#2#20080200#^f135^l140#0100-879X#Thigmotactic response
s in an open-field^len#^rND^1A01^nM.R.^sLamprea#^rND^1A02^nF.P.^sCardenas#^rND^1
A03^nJ^sSetem#^rND^1A04^nS.^sMorato#Universidad Nacional de Colombia - Sede Bogo
tá^iA01^1Facultad de Ciencias Humanas^2Departamento de Psicología^cBogotá^pColom
bia#Universidad de Los Andes^iA02^1Facultad de Ciencias Humanas^2Departamento de
 Psicología^cBogotá^pColombia#Instituto de Estudos do Comportamento (Psicolog)^i
A03^cRibeirão Preto^sSP^pBrasil#Universidade de São Paulo^iA04^1Faculdade de Fil
osofia, Ciências e Letras de Ribeirão Preto^2Departamento de Psicologia e Educaç
ão^cRibeirão Preto^sSP^pBrasil#^len^aThe goal of the present study was to invest
igate the role of thigmotaxis (the tendency to remain close to vertical surfaces
) in rat exploratory behavior in an open-field. Thigmotaxis was investigated in 
a parametric way, using 24 experimentally adult naive male Wistar rats (210-230 
g). Exploratory behavior was studied in an open-field (N = 12) in 5-min sessions
 and behavior was analyzed in terms of where it occurred: in areas surrounded by
 two, one, or no walls. Another group of rats (N = 12) was studied in an open-fi
eld with blocks placed near two of the corners so as to make these corner areas 
surrounded by three walls. The floor of the open-fields was divided into 20-cm s
quares in order to locate the exact place of occurrence of each behavior. The fo
llowing behaviors were recorded: entries into the squares, rearings, and groomin
gs. In both types of open-field the rats chose to remain longer in the squares s
urrounded by the largest possible number of walls. In one of the open-fields, th
e mean time (seconds) spent in squares surrounded by two walls was longer than t
he time spent in squares surrounded by one or no walls (37.2, 7.7, and 1.8 s, re
spectively). In the other open-field, the mean time spent in squares surrounded 
by three walls was longer than the time spent in squares surrounded by two, one 
or no walls (41.7, 20.4, 7.0, and 2.6 s, respectively). Other measures presented
 a similar profile. These results indicate that rats are sensitive to the number
 of walls in an environment and prefer to remain close to them.#^dnd^i1#^tm^len^
kExploratory behavior^i1#^tm^len^kThigmotaxis^i1#^tm^len^kOpen-field^i1#^tm^len^
kRearing behavior^i1#^tm^len^kGrooming^i1#^tm^len^kLocomotion^i1#other#17#CNPq#3
51317/96-1#20061222#December 22, 2006#20071129#November 29, 2007#6761.htm##
03202000000000613000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000700104030002000111
03100030013103200020013406500090013601400110014503500100015601200510016601000250
02170100026002420100020002680100022002880700128003100700106004380700082005440700
15900626083155300785085000802338085003302346085002402379085002302403085002902426
08500210245508500230247611700060249907200030250505800050250806000120251311200090
2525111001802534114000902552113001802561002000902579#v41n2#v:\scielo\serial\bjmb
r\v41n2\markup\6761.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#10#BJMBR060#FAP
ESP#Braz J Med Biol Res#41#2#20080200#^f135^l140#0100-879X#<b>Thigmotactic respo
nses in an open-field</b>^len#^rND^1A01^nM.R.^sLamprea#^rND^1A02^nF.P.^sCardenas
#^rND^1A03^nJ^sSetem#^rND^1A04^nS.^sMorato#Universidad Nacional de Colombia - Se
de Bogotá^iA01^1Facultad de Ciencias Humanas^2Departamento de Psicología^cBogotá
^pColombia#Universidad de Los Andes^iA02^1Facultad de Ciencias Humanas^2Departam
ento de Psicología^cBogotá^pColombia#Instituto de Estudos do Comportamento (Psic
olog)^iA03^cRibeirão Preto^sSP^pBrasil#Universidade de São Paulo^iA04^1Faculdade
 de Filosofia, Ciências e Letras de Ribeirão Preto^2Departamento de Psicologia e
 Educação^cRibeirão Preto^sSP^pBrasil#^len^aThe goal of the present study was to
 investigate the role of thigmotaxis (the tendency to remain close to vertical s
urfaces) in rat exploratory behavior in an open-field. Thigmotaxis was investiga
ted in a parametric way, using 24 experimentally adult naive male Wistar rats (2
10-230 g). Exploratory behavior was studied in an open-field (N = 12) in 5-min s
essions and behavior was analyzed in terms of where it occurred: in areas surrou
nded by two, one, or no walls. Another group of rats (N = 12) was studied in an 
open-field with blocks placed near two of the corners so as to make these corner
 areas surrounded by three walls. The floor of the open-fields was divided into 
20-cm squares in order to locate the exact place of occurrence of each behavior.
 The following behaviors were recorded: entries into the squares, rearings, and 
groomings. In both types of open-field the rats chose to remain longer in the sq
uares surrounded by the largest possible number of walls. In one of the open-fie
lds, the mean time (seconds) spent in squares surrounded by two walls was longer
 than the time spent in squares surrounded by one or no walls (37.2, 7.7, and 1.
8 s, respectively). In the other open-field, the mean time spent in squares surr
ounded by three walls was longer than the time spent in squares surrounded by tw
o, one or no walls (41.7, 20.4, 7.0, and 2.6 s, respectively). Other measures pr
esented a similar profile. These results indicate that rats are sensitive to the
 number of walls in an environment and prefer to remain close to them.#^dnd^i1#^
tm^len^kExploratory behavior^i1#^tm^len^kThigmotaxis^i1#^tm^len^kOpen-field^i1#^
tm^len^kRearing behavior^i1#^tm^len^kGrooming^i1#^tm^len^kLocomotion^i1#other#17
#CNPq#351317/96-1#20061222#December 22, 2006#20071129#November 29, 2007#6761.htm
##
03332000000000637000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000300105049000900108158000700117
03000240012403100030014803200020015106500090015301400110016203500100017301200440
01830100025002270100026002520100020002780100021002980700130003190700108004490700
08400557070016100641083155300802085000802355085003302363085002402396085002302420
08500290244308500210247208500230249311700060251607200030252205800050252506000120
2530112000902542111001802551114000902569113001802578002000902596008008902605#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#l#4#1#article#1#^mFeb.^a2008#o
a#en#bjmbr#1#3.1#ilus#10#BJMBR060#FAPESP#Braz. j. med. biol. res#41#2#20080200#^
f135^l140#0100-879X#Thigmotactic responses in an open-field^len#^rND^1A01^nM. R^
sLamprea#^rND^1A02^nF. P^sCardenas#^rND^1A03^nJ^sSetem#^rND^1A04^nS^sMorato#^iA0
1^1Universidad Nacional de Colombia - Sede Bogotá^2Facultad de Ciencias Humanas^
3Departamento de Psicología^cBogotá^pColombia#^iA02^1Universidad de Los Andes^2F
acultad de Ciencias Humanas^3Departamento de Psicología^cBogotá^pColombia#^iA03^
1Instituto de Estudos do Comportamento (Psicolog)^cRibeirão Preto^sSP^pBrasil#^i
A04^1Universidade de São Paulo^2Faculdade de Filosofia, Ciências e Letras de Rib
eirão Preto^3Departamento de Psicologia e Educação^cRibeirão Preto^sSP^pBrasil#^
len^aThe goal of the present study was to investigate the role of thigmotaxis (t
he tendency to remain close to vertical surfaces) in rat exploratory behavior in
 an open-field. Thigmotaxis was investigated in a parametric way, using 24 exper
imentally adult naive male Wistar rats (210-230 g). Exploratory behavior was stu
died in an open-field (N = 12) in 5-min sessions and behavior was analyzed in te
rms of where it occurred: in areas surrounded by two, one, or no walls. Another 
group of rats (N = 12) was studied in an open-field with blocks placed near two 
of the corners so as to make these corner areas surrounded by three walls. The f
loor of the open-fields was divided into 20-cm squares in order to locate the ex
act place of occurrence of each behavior. The following behaviors were recorded:
 entries into the squares, rearings, and groomings. In both types of open-field 
the rats chose to remain longer in the squares surrounded by the largest possibl
e number of walls. In one of the open-fields, the mean time (seconds) spent in s
quares surrounded by two walls was longer than the time spent in squares surroun
ded by one or no walls (37.2, 7.7, and 1.8 s, respectively). In the other open-f
ield, the mean time spent in squares surrounded by three walls was longer than t
he time spent in squares surrounded by two, one or no walls (41.7, 20.4, 7.0, an
d 2.6 s, respectively). Other measures presented a similar profile. These result
s indicate that rats are sensitive to the number of walls in an environment and 
prefer to remain close to them.#^dnd^i1#^tm^len^kExploratory behavior^i1#^tm^len
^kThigmotaxis^i1#^tm^len^kOpen-field^i1#^tm^len^kRearing behavior^i1#^tm^len^kGr
ooming^i1#^tm^len^kLocomotion^i1#other#17#CNPq#351317/96-1#20061222#December 22,
 2006#20071129#November 29, 2007#6761.htm#Internet^ihttp://www.scielo.br/scielo.
php?script=sci_arttext&pid=S0100-879X2008000200010##
00375000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704015000070002000900220#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#5#1#article#75#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, February 2008, V
olume 41(2) 135-140</B> </font></P>      ^cY#6761.htm##
00343000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704011800070002000900188#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#6#2#article#75#<P><font size="5" face="A
rial, Helvetica, sans-serif"><B>Thigmotactic responses in an open-field</B> </fo
nt>      ^cY#6761.htm##
00589000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704036400070002000900434#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#7#3#article#75#<P><font face="Arial, Hel
vetica, sans-serif">M.R. Lamprea<SUP>1</SUP>, F.P. Cardenas<SUP>2</SUP>, J. Sete
m<SUP>3</SUP> and <b><a href="#Correspondence"><img src="/img/revistas/bjmbr/v41
n2/recor.gif" border="0"></a></b> <a href="mailto:smorato@ffclrp.usp.br"><img sr
c="/img/revistas/bjmbr/v41n2/email-ca.gif" border="0"></a> S. Morato<SUP>4</SUP>
 </font>       ^cY#6761.htm##
00434000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704020900070002000900279#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#8#4#article#75#<P><font face="Arial, Hel
vetica, sans-serif"><SUP>1</SUP>Departamento de Psicolog&iacute;a, Facultad de C
iencias Humanas, Universidad Nacional de Colombia - Sede Bogot&aacute;, Bogot&aa
cute;, Colombia     ^cY#6761.htm##
00367000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704014200070002000900212#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#9#5#article#75#<br>   <SUP>2</SUP>Depart
amento de Psicolog&iacute;a, Facultad de Ciencias Humanas, Universidad de Los An
des, Bogot&aacute;, Colombia     ^cY#6761.htm##
00337000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704011100071002000900182#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#10#6#article#75#<br>   <SUP>3</SUP>Insti
tuto de Estudos do Comportamento (Psicolog), Ribeir&atilde;o Preto, SP, Brasil  
   ^cY#6761.htm##
00456000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704023000071002000900301#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#11#7#article#75#<br>  <SUP>4</SUP>Depart
amento de Psicologia e Educa&ccedil;&atilde;o, Faculdade de Filosofia, Ci&ecirc;
ncias e Letras de Ribeir&atilde;o Preto, Universidade de S&atilde;o Paulo, Ribei
r&atilde;o Preto, SP, Brasil</font>       ^cY#6761.htm##
00416000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704019000071002000900261#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#12#8#article#75#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n2/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>  
  ^cY#6761.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#13#9#article#75#<BR>   <A HREF="#Introdu
ction"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#6761.htm##
00414000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704018700072002000900259#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#14#10#article#75#<BR>   <A HREF="#Materi
al"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0
 HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    
^cY#6761.htm##
00399000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704017200072002000900244#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#15#11#article#75#<BR>   <A HREF="#Result
s"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#6761.htm##
00408000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704018100072002000900253#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#16#12#article#75#<BR>   <A HREF="#Discus
sion"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#67
61.htm##
00395000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704016800072002000900240#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#17#13#article#75#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#6761.htm##
00461000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704023400072002000900306#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#18#14#article#75#<br>   </strong></A>   
<A HREF="#Correspondence"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspon
dence and Footnotes</strong></A>  </font>      ^cY#6761.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004800072002000900120#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#19#15#article#75#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>      ^cY#6761.htm##
00537000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031000072002000900382#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#20#16#article#75#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  <font
 face="Arial, Helvetica, sans-serif">      ^cY#6761.htm##
01786000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704155900072002000901631#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#21#17#article#75#<P>The goal of the pres
ent study was to investigate the role of thigmotaxis (the tendency to remain clo
se to vertical surfaces) in rat exploratory behavior in an open-field. Thigmotax
is was investigated in a parametric way, using 24 experimentally adult naive mal
e Wistar rats (210-230 g). Exploratory behavior was studied in an open-field (N 
= 12) in 5-min sessions and behavior was analyzed in terms of where it occurred:
 in areas surrounded by two, one, or no walls. Another group of rats (N = 12) wa
s studied in an open-field with blocks placed near two of the corners so as to m
ake these corner areas surrounded by three walls. The floor of the open-fields w
as divided into 20-cm squares in order to locate the exact place of occurrence o
f each behavior. The following behaviors were recorded: entries into the squares
, rearings, and groomings. In both types of open-field the rats chose to remain 
longer in the squares surrounded by the largest possible number of walls. In one
 of the open-fields, the mean time (seconds) spent in squares surrounded by two 
walls was longer than the time spent in squares surrounded by one or no walls (3
7.2, 7.7, and 1.8 s, respectively). In the other open-field, the mean time spent
 in squares surrounded by three walls was longer than the time spent in squares 
surrounded by two, one or no walls (41.7, 20.4, 7.0, and 2.6 s, respectively). O
ther measures presented a similar profile. These results indicate that rats are 
sensitive to the number of walls in an environment and prefer to remain close to
 them.      ^cY#6761.htm##
00380000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704015300072002000900225#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#22#18#article#75#<P>Key words: Explorato
ry behavior; Thigmotaxis; Open-field; Rearing behavior; Grooming; Locomotion  </
font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6761.htm##
00593000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036600072002000900438#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#23#19#article#75#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>    <font face="Arial, Helvetica,
 sans-serif">      ^cY#6761.htm##
00726000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704049900072002000900571#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#24#20#article#75#<P>The role played by d
ifferent aversive stimuli in behavioral tasks that take advantage of the rat's n
atural tendency to explore, like the open-field or the elevated plus-maze, is no
t fully understood. For long it has been assumed that the innate fear of open sp
aces was the most important anxiety-triggering stimulus (1), an assumption that 
later received experimental support (e.g., 2). However, the mechanisms by which 
rodents perceive the openness of an environment are still unclear.      ^cY#6761
.htm##
00648000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704042100072002000900493#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#25#21#article#75#<P>Barnett (1) states t
hat &quot;rats, like other small mammals, tend to move in contact with a vertica
l surface; they also eat in a corner rather than in an open space&quot; (p. 49).
 In the same paragraph, he speculates that &quot;Functionally, thigmotactic beha
vior is presumably an aspect of taking cover from predators&quot;. Grossen and K
elley (3) specifically narrowed this assumption to aerial predators.      ^cY#67
61.htm##
00969000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704074200072002000900814#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#26#22#article#75#<P>In the elevated plus
-maze, several aspects have been proposed as explanations for the aversion rats 
exhibit to the open arms. It has been suggested that rats are afraid of the nove
lty of the open arms (4). It has also been proposed that the height perceived fr
om the open arms is the dimension causing fear and, consequently, aversion to th
em (5). Similarly, File (6) stated that rats previously exposed to an elevated p
lus-maze present fear of heights when tested again in the same apparatus. They a
dditionally suggest that the animals acquire such a fear of heights during the i
nitial 5-min exposure to the maze and that, given this rapid acquisition, &quot;
there may be a genetic predisposition for such a fear&quot; (p. 494).      ^cY#6
761.htm##
00624000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704039700072002000900469#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#27#23#article#75#<P>However, Treit et al
. (2) clearly demonstrated that &quot;open spaces, rather than height or novelty
, is the anxiogenic stimulus in the elevated plus-maze&quot; (p. 463). They also
 concluded that &quot;rat's fear of the open arms is driven by thigmotaxis, a na
tural defensive response in which rats remain close to vertical surfaces, thereb
y shielding themselves from predators&quot;.      ^cY#6761.htm##
00603000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704037600072002000900448#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#28#24#article#75#<P>The open-field is an
other test that takes advantage of the rat's tendency to explore new environment
s, as measured by ambulation (7,8). Typically, rats are more active and remain l
onger in the periphery of the apparatus in comparison to the central areas, main
ly in the first session, a preference that has been interpreted as being determi
ned by thigmotaxis (9).      ^cY#6761.htm##
00676000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704044900072002000900521#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#29#25#article#75#<P>Since, to our knowle
dge, there are no experiments investigating the role of thigmotaxis <I>per se</I
> (i.e., thigmotaxis is usually a given characteristic of the apparatus), the go
al of the present study was to investigate the role of vertical surfaces in a mo
re parametric way. This was carried out by testing rats in a modified open-field
 that had divisions with different numbers of walls.  </font>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>      ^cY#6761.htm##
00595000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036800072002000900440#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#30#26#article#75#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Mat
erial and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>  <font face="Arial, Helvetic
a, sans-serif">      ^cY#6761.htm##
00264000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704003700072002000900109#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#31#27#article#75#<P><b>Subjects</b>  </f
ont>      ^cY#6761.htm##
00639000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704041200072002000900484#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#32#28#article#75#<P><font face="Arial, H
elvetica, sans-serif">Adult male Wistar-derived rats weighing 213-227 g obtained
 from the vivarium of the University of S&atilde;o Paulo at Ribeir&atilde;o Pret
o, with free access to food and water were housed 6 to a cage (40 x 33 x 16 cm),
 on a 12-h dark-light cycle (lights on at 7:00 am). All behavioral tests occurre
d in the light phase of the cycle, before 11:30 am. </font>      ^cY#6761.htm##
00307000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704008000072002000900152#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#33#29#article#75#<P><font face="Arial, H
elvetica, sans-serif"><B>Apparatus</B> </font>       ^cY#6761.htm##
01531000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704130400072002000901376#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#34#30#article#75#<P><font face="Arial, H
elvetica, sans-serif">A 1.2-m square open-field with a    dark brown Formica flo
or surrounded by 50-cm high wooden walls was used. The    tests were carried out
 in a room lit by a 60-W light bulb 1.75 m above the center    of the open-field
 (150 lux at the center of the apparatus). The experimental    sessions were rec
orded with a video camera interfaced with a television set    and a video casset
te recorder in an adjacent room. One group of rats (N = 12)    was tested in a s
tandard way, with the open-field divided into three areas according    to the nu
mber of adjacent walls: a) two walls (corners, luminosity: 147 lux),    b) one w
all (the laterals, 147 lux), and c) no walls (center, 150 lux). The    maximum n
umber of walls possible in a square of the apparatus was two and the    apparatu
s was designated 2W open-field. Another group of animals (N = 12) was    tested 
in the open-field with two 20 x 20 x 30 cm blocks placed inside and near    two 
of the corners so as to form, in addition to the areas described in (a),    (b),
 and (c), two 20 x 20 cm areas with three walls each (luminosity: 146 lux;    se
e <a href="#Fig1">Figure 1</a>). Thus, the maximum possible number of walls    i
n this apparatus was three and the apparatus was designated 3W. </font>      ^cY
#6761.htm##
00306000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704007900072002000900151#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#35#31#article#75#<P><font face="Arial, H
elvetica, sans-serif"><B>Procedure</B> </font>      ^cY#6761.htm##
01225000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704099800072002000901070#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#36#32#article#75#<P><font face="Arial, H
elvetica, sans-serif">Each rat was placed in the center of the open-field and al
lowed to freely explore for 5 min. After each test, the open-field was cleaned w
ith 10% ethanol, and then dried with a dry cloth. In order to record locomotor a
ctivity on-line, the image of the open-field on the television screen was divide
d into thirty-six 20 x 20 cm squares. Every time both hind paws entered one of t
hese squares, a crossing was recorded. The total distance run by the animals was
 estimated from the number of crossings. Rearing and grooming frequencies and th
e time spent rearing and grooming were also recorded and analyzed in terms of th
e area of occurrence. A rearing episode was recorded whenever the rat stood on i
ts hind paws with the body at an angle with the floor greater than 45&#176;. A g
rooming episode was defined by repetitive movements of front paws or mouth on th
e fur. We were also prepared to record stretching behavior but none occurred. </
font>      ^cY#6761.htm##
00317000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704009000072002000900162#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#37#33#article#75#<P><font face="Arial, H
elvetica, sans-serif"><B>Statistical analysis</B> </font>      ^cY#6761.htm##
00989000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704076200072002000900834#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#38#34#article#75#<P><font face="Arial, H
elvetica, sans-serif">When absolute measures were not used, a mean transformatio
n was employed, obtained by adding the measures recorded for single squares of o
ne type (e.g., 3W) and dividing them by the total number of squares of that type
. One-way analysis of variance (ANOVA) for repeated measures was used to detect 
differences between data referring to areas with different numbers of surroundin
g walls. When ANOVA was significant, the Tukey test for multiple comparisons bet
ween means was performed. Differences between the two arrangements of the open-f
ield were determined by the Student <I>t</I>-test. In all cases, the level of st
atistical significance was set to P &lt; 0.05. </font>  <HR ALIGN=LEFT WIDTH=100
% SIZE=2>      ^cY#6761.htm##
00538000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031100072002000900383#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#39#35#article#75#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF
="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0 
VSPACE=0 HSPACE=0></B></A></font></P>       ^cY#6761.htm##
01260000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704103300072002000901105#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#40#36#article#75#<P><font face="Arial, H
elvetica, sans-serif">Animals tested in the 2W and 3W open-fields    exhibited a
 very similar level of locomotor activity during the 5-min session    when the t
otal number of crossings was analyzed. The <I>t</I>-test (<I>t</I>(22)    = -0.1
55, P = 0.878) showed no differences in the distance run by 2W (24.4 &#177;    1
.91 m) and 3W rats (24.8 &#177; 1.40 m). Considering the different areas of    t
he 2W and 3W open-fields, the animals avoided entering in the central area    an
d spent little time there but they did run along the walls, i.e., squares    wit
h one wall, without remaining much time in them (<a href="#Fig2">Figure 2</a>). 
   The rats in the 3W open-field entered the non-walled squares significantly mo
re    but did not differ in terms of time spent in these squares. The animals in
 the    2W open-field remained longer in the two-walled squares than the ones in
 the    3W open-field, but these seemed to distribute their time in both two- an
d three-walled    squares. </font> </P>       ^cY#6761.htm##
00964000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704073700072002000900809#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#41#37#article#75#<P><font face="Arial, H
elvetica, sans-serif">The <I>t</I>-test showed no differences    between 2W and 
3W rats in the total number of rearings (24.58 &#177; 2.06 and    28.33 &#177; 2
.19, respectively; <I>t</I>(22) = -1.247, P = 0.225), total rearing    time (29.
47 &#177; 3.29 and 39.75 &#177; 3.97 s; <I>t</I>(22) = -1.998, P =    0.058) and
 mean rearing time (1.2 &#177; 0.10 and 1.40 &#177; 0.07 s; <I>t</I>(22)    = -1
.662, P = 0.111). When comparing the frequency and rearing time in the squares, 
   again there were no differences between subjects tested in the 2W and 3W open
-fields.    Both groups, however, exhibited more of this behavior in squares sur
rounded    by more walls (<a href="#Fig3">Figure 3</a>). </font>      ^cY#6761.h
tm##
01551000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704132400072002000901396#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#42#38#article#75#<P><font face="Arial, H
elvetica, sans-serif">The <I>t</I>-test (<I>t</I>(22) =    -2.358, P = 0.028) sh
owed that the rats in the 3W open-field groomed more often    (13.08 &#177; 2.12
) than those in the 2W open-field (7.75 &#177; 0.79) but did    not differ in th
e time they spent grooming (3W: 29.44 &#177; 4.68 s; 2W: 29.52    &#177; 4.40 s;
 <I>t</I>(22) = 0.013, P = 0.990), which, in turn, altered the    grooming patte
rn in the sense that the mean grooming episode lasted less in    3W than in 2W s
ubjects (3W: 2.51 &#177; 0.41 s; 2W: 4.23 &#177; 0.64 s; <I>t</I>(22)    = 2.261
, P = 0.034). <a href="#Fig4">Figure 4</a> shows grooming in the different    sq
uares. There were no differences between the animals in the two open-fields    b
ut the animals groomed more in squares surrounded by more walls. The animals    
in the 2W open-field groomed more in the two-walled squares than the animals    
in the 3W open-field but, as happened with the entries, these seemed to distribu
te    their time in both two- and three-walled squares</font>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>  <table width="100%"  border="0">    <tr align="left" valign="t
op">      <td width="17%"><a href="/img/revistas/bjmbr/v41n2/html/6761i01.htm"><
img src="/img/revistas/bjmbr/v41n2/6761i01peq.jpg" border="2"></a></td>      <td
 width="83%">    ^cY#6761.htm##
00560000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033300072002000900405#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#43#39#article#75#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig1"></a>Figure 1. Diagram of the open-field. Ea
ch line is 20 cm long and the digit inside the divisions indicates the number of
 walls surrounding it. <I>B</I> indicates the location where the blocks were pla
ced. For details, see text.</font>  </td>    </tr>  </table>      ^cY#6761.htm##
00614000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038700072002000900459#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#44#40#article#75#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (57 K JPG file)]</font>
</P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr
 align="left" valign="top">      <td width="17%"><a href="/img/revistas/bjmbr/v4
1n2/html/6761i02.htm"><img src="/img/revistas/bjmbr/v41n2/6761i02peq.jpg" border
="2"></a></td>      <td width="83%">    ^cY#6761.htm##
01117000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704089000072002000900962#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#45#41#article#75#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig2"></a>Figure 2. Mean frequency of entries and
 mean time spent per square. These values were obtained by dividing the totals o
ccurring in squares with a certain number of walls surrounding them and dividing
 by the number of walls. 2W = open-field in which the maximum number of walls pe
r square was two or 3W = open-field with the block that allowed a maximum number
 of three walls in certain squares. d.f. = degrees of freedom; F = statistical F
 value; <I>t</I> = statistical <I>t</I> value for the specified number of d.f.; 
P = probability. *P &lt; 0.05 compared to squares with a larger number of walls;
 &#176;P &lt; 0.05 compared to squares with a smaller number of walls (ANOVA fol
lowed by the Tukey test). <SUP>+</SUP>P &lt; 0.05 compared to different 3W (Stud
ent <I>t</I>-test). </font>      </td>    </tr>  </table>      ^cY#6761.htm##
00615000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038800072002000900460#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#46#42#article#75#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (166 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="17%"><a href="/img/revistas/bjmbr/v
41n2/html/6761i03.htm"><img src="/img/revistas/bjmbr/v41n2/6761i03peq.jpg" borde
r="2"></a></td>      <td width="83%">    ^cY#6761.htm##
00977000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704075000072002000900822#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#47#43#article#75#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig3"></a>Figure 3. Mean frequency of rearings an
d mean time rearing per square. These values were obtained by dividing the total
s occurring in squares with a certain number of walls surrounding them and divid
ing by the number of walls. 2W = open-field in which the maximum number of walls
 per square was two or 3W = open-field with the block that allowed a maximum num
ber of three walls in certain squares. d.f. = degrees of freedom; F = statistica
l F value; <I>t</I> = statistical <I>t</I> value for the specified number of d.f
.; P = probability. *P &lt; 0.05 compared to squares with a smaller number of wa
lls (ANOVA followed by the Tukey test). </font>      </td>    </tr>  </table>   
   ^cY#6761.htm##
00622000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704039500072002000900467#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#48#44#article#75#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (165 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="17%"><a href="/img/revistas/bjmbr/v
41n2/html/6761i04.htm"><img src="/img/revistas/bjmbr/v41n2/6761i04peq.jpg" borde
r="2"></a></td>      <td width="83%">           ^cY#6761.htm##
01148000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704092100072002000900993#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#49#45#article#75#<p><font face="Arial, H
elvetica, sans-serif"><a name="Fig4" id="Fig4"></a>Figure          4. Mean frequ
ency of groomings and mean time grooming per square. These          values were 
obtained dividing the totals occurring in squares with a certain          number
 of walls surrounding them and dividing by the number of walls.          2W = op
en-field in which the maximum amount of walls per square is two          or 3W =
 open-field with the block that allowed a maximum number of three          walls
 in certain squares. d.f. = degrees of freedom; F = statistical F          value
; <I>t</I> = statistical <I>t</I> value for the specified number          of d.f
.; P = probability. *P &lt;0.05 compared to squares with a smaller          numb
er of walls; <SUP>o</SUP>P &lt; 0.05 compared to squares with no walls          
and one wall (ANOVA followed by the Tukey test).</font></p>     </td>    </tr>  
</table>      ^cY#6761.htm##
00345000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704011800072002000900190#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#50#46#article#75#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (174 K JPG file)]</font
></P>      ^cY#6761.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004800072002000900120#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#51#47#article#75#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>      ^cY#6761.htm##
00497000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704027000072002000900342#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#52#48#article#75#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#6761.htm##
01671000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704144400072002000901516#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#53#49#article#75#<P><font face="Arial, H
elvetica, sans-serif">The rats in both open-fields exhibited no differences in l
ocomotor activity, as shown by the almost identical distances run in both appara
tuses during the sessions. The number of squares entered shows that the rats pre
ferred to enter squares with at least one adjacent wall, indicated by the lower 
number of entries into squares with no walls and a similar number of entries int
o squares with one, two or three adjacent walls. However, the time the rats rema
ined in each square was a function of the number of walls. When squares with thr
ee adjacent walls were available to the animals they preferred to remain in them
 at the expense of the time allocated to squares with two adjacent walls, but no
t at the expense of squares with no or just one adjacent wall. In addition, the 
rats spent an amount of time in the squares with two adjacent walls in the 2W op
en-field similar to the amount of time spent in the squares with three adjacent 
walls in the 3W open-field. This indicates that, at least for this kind of explo
ratory behavior, the rats use thigmotaxis in order to choose where and how long 
to remain in the different areas of the apparatus. It also indicates that the ra
ts preferred to remain in the most secure area of the open-field, since the occu
pation of the two-walled squares in the 2W open-field was similar to that of the
 three-walled squares in the 3W open-field. </font>      ^cY#6761.htm##
01745000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704151800072002000901590#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#54#50#article#75#<P><font face="Arial, H
elvetica, sans-serif">As far as thigmotaxis is concerned, it is interesting to n
otice that in both apparatuses the rats avoided the central area, composed of sq
uares with no adjacent walls. As incursions in the central area are correlated w
ith a decrease in anxiety (10), the presence of three-walled squares did not aff
ect whatever anxiety the apparatuses may have caused. In this respect, it may be
 argued that the rats preferred squares with the largest possible number of adja
cent walls because, by allowing more thigmotaxis, these squares elicited less an
xiety. Also, this is similar to what happens in a widely used anxiety model, the
 elevated plus-maze: rats usually prefer to remain in the arms surrounded by wal
ls and avoid the open arm, probably for the same motivational reasons as the cen
tral area of an open-field (10,11). Additionally, Horev et al. (12) showed a sim
ilar effect in the trajectory of the mouse in an open-field. They suggested a do
uble-influence of the wall on the mouse's exploratory behavior: one of guidance 
and the other of attraction. The first function is suggested because the animals
 progress in parallel to the wall guiding the heading direction and increasing t
he speed of locomotion when they are more parallel to the wall. The attraction i
nfluence is reflected by the fact that mice tend to perform a large component of
 their activity near the wall, including most of their progression, considering 
this to be one aspect of thigmotaxis. </font>      ^cY#6761.htm##
00942000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704071500072002000900787#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#55#51#article#75#<P><font face="Arial, H
elvetica, sans-serif">Another behavior considered to be of an exploratory nature
 is rearing (13-15). Like the exploratory behavior already discussed, the freque
ncy of rearing did not differ in any important way between the 2W and 3W open-fi
elds. Also similar was the time allocated to rearing according to the number of 
adjacent walls, except that the more the adjacent walls, the more time the rats 
reared in a square. No or almost no rearings occurred in the central area of the
 two open-fields, perhaps because the walls offered more stimuli to be explored 
by rearing. It remains to be determined what relationship, if any, exists betwee
n rearing behavior and thigmotaxis.</font>      ^cY#6761.htm##
01607000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704138000072002000901452#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#56#52#article#75#<P><font face="Arial, H
elvetica, sans-serif">Unlike the measures discussed so far, grooming was sensiti
ve to the differences between the 2W and 3W open-fields: the rats groomed more o
ften in the 3W open-field but the total time used in this activity was the same 
in both apparatuses. This shows that there was a difference in the temporal patt
ern of grooming between groups, i.e., rats in the 3W open-field groomed more fre
quently but each episode lasted less time than in the 2W open-field. In addition
, the rats spent similar total amounts of time in both apparatuses, but allocate
d more time to the squares with the higher number of adjacent walls, either two 
or three, according to the open-field they were tested in. A similar time alloca
tion pattern was observed for exploratory behavior. It is difficult to attribute
 motivational properties to this behavior since in factor analysis studies groom
ing loads similarly on the different (and perhaps incompatible) factors of explo
ration and anxiety (13,15). Our data, however, do support an exploratory nature 
of grooming rather than an eventual connection with anxiety, since the mean groo
ming frequency exhibited a similar profile as the mean rearing frequency while t
he mean time grooming exhibited a similar profile as the mean time spent in each
 square and both measures correlated well with exploration. </font>      ^cY#676
1.htm##
01077000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704085000072002000900922#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#57#53#article#75#<P><font face="Arial, H
elvetica, sans-serif">Our results do not allow us to identify the factor guiding
 the rats choice of squares with as many walls as possible. One explanation coul
d be that the rats just see the walls and choose to remain in squares with more 
walls surrounding them. This is supported by the data reported by Mart&iacute;ne
z et al. (16) suggesting that the exploratory behavior of rats in the elevated p
lus-maze is dependent on vision. An alternative explanation could be that rats a
re using their vibrissae to recognize the squares with more walls. However, Mila
ni et al. (17) showed that rats with the vibrissae of one side of the head remov
ed do not increase the total time they are in contact with the wall of a circula
r open-field, thus indicating that the animals are not using the vibrissae for t
his task. </font>      ^cY#6761.htm##
01161000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704093400072002000901006#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#58#54#article#75#<P><font face="Arial, H
elvetica, sans-serif">In general, the data reported in the present experiment sh
ow that exploratory and other behaviors tend to occur more in squares surrounded
 by walls. We do not think this behavioral pattern was influenced by the amount 
of light reaching each square since, on the one hand, one- and two-walled square
s were used differently by the rats in spite of receiving the same amount of lig
ht, and on the other hand, the difference between the amount of light in two- an
d three-walled squares was too little to matter, indicating that the animals wer
e sensitive to the number of walls. The larger the number of walls, the more beh
avior occurs in a particular square. This indicates that thigmotaxis is a determ
inant factor of rat behavior in unfamiliar places and that the rats are sensitiv
e to the number of walls near which they can choose to be. </font>  <HR ALIGN=LE
FT WIDTH=100% SIZE=2>      ^cY#6761.htm##
00543000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031600072002000900388#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#59#55#article#75#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6761.htm##
00403000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704016200074002000900236#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#p#60#56#article#75#1#<P><font 
face="Arial, Helvetica, sans-serif">1. Barnett SA. <I>The rat: A study in behavi
or</I>. Chicago: The University of Chicago Press; 1975. </font>      ^cY#6761.ht
m##
00430000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704018900074002000900263#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#p#61#57#article#75#2#<P><font 
face="Arial, Helvetica, sans-serif">2. Treit D, Menard J, Royan C. Anxiogenic st
imuli in the elevated plus-maze. <I>Pharmacol Biochem Behav</I> 1993; 44: 463-46
9. </font>      ^cY#6761.htm##
00451000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021000074002000900284#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#p#62#58#article#75#3#<P><font 
face="Arial, Helvetica, sans-serif">3. Grossen NE, Kelley MJ. Species-specific b
ehavior and acquisition of avoidance behavior in rats. <I>J Comp Physiol Psychol
</I> 1972; 81: 307-310. </font>      ^cY#6761.htm##
00451000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021000074002000900284#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#p#63#59#article#75#4#<P><font 
face="Arial, Helvetica, sans-serif">4. Montgomery KC. The relation between fear 
induced by novel stimulation and exploratory behavior. <I>J Comp Physiol Psychol
</I> 1955; 48: 254-260. </font>      ^cY#6761.htm##
00500000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704025900074002000900333#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#p#64#60#article#75#5#<P><font 
face="Arial, Helvetica, sans-serif">5. Pellow S, File SE. Anxiolytic and anxioge
nic drug effects on exploratory activity in an elevated plus-maze: a novel test 
of anxiety in the rat. <I>Pharmacol Biochem Behav</I> 1986; 24: 525-529. </font>
      ^cY#6761.htm##
00422000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704018100074002000900255#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#p#65#61#article#75#6#<P><font 
face="Arial, Helvetica, sans-serif">6. File SE. The interplay of learning and an
xiety in the elevated plus-maze. <I>Behav Brain Res</I> 1993; 58: 199-202. </fon
t>      ^cY#6761.htm##
00407000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704016600074002000900240#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#p#66#62#article#75#7#<P><font 
face="Arial, Helvetica, sans-serif">7. Walsh RN, Cummins RA. The Open-Field Test
: a critical review. <I>Psychol Bull</I> 1976; 83: 482-504. </font>      ^cY#676
1.htm##
00469000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704022800074002000900302#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#p#67#63#article#75#8#<P><font 
face="Arial, Helvetica, sans-serif">8. Nahas TR. O teste do campo aberto. In: Xa
vier GF (Editor), <I>T&eacute;cnicas para o estudo do sistema nervoso</I>. S&ati
lde;o Paulo: Editora Pl&ecirc;iade; 1999. </font>      ^cY#6761.htm##
00428000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704018700074002000900261#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#p#68#64#article#75#9#<P><font 
face="Arial, Helvetica, sans-serif">9. Valle FP. Effects of strain, sex, and ill
umination on open-field behavior of rats. <I>Am J Psychol</I> 1970; 83: 103-111.
 </font>      ^cY#6761.htm##
00415000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017300075002000900248#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#p#69#65#article#75#10#<P><font
 face="Arial, Helvetica, sans-serif">10. Lister RG. Ethologically-based animal m
odels of anxiety disorders. <I>Pharmacol Ther</I> 1990; 46: 321-340.</font>     
 ^cY#6761.htm##
00487000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024500075002000900320#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#p#70#66#article#75#11#<P><font
 face="Arial, Helvetica, sans-serif">11. Carobrez AP, Bertoglio LJ. Ethological 
and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 
years on. <I>Neurosci Biobehav Rev</I> 2005; 29: 1193-1205. </font>      ^cY#676
1.htm##
00464000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022200075002000900297#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#p#71#67#article#75#12#<P><font
 face="Arial, Helvetica, sans-serif">12. Horev G, Benjamini Y, Sakov A, Golani I
. Estimating wall guidance and attraction in mouse free locomotor behavior. <I>G
enes Brain Behav</I> 2007; 6: 30-41. </font>      ^cY#6761.htm##
00458000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021600075002000900291#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#p#72#68#article#75#13#<P><font
 face="Arial, Helvetica, sans-serif">13. Cruz AP, Frei F, Graeff FG. Ethopharmac
ological analysis of rat behavior on the elevated plus-maze. <I>Pharmacol Bioche
m Behav</I> 1994; 49: 171-176. </font>      ^cY#6761.htm##
00462000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022000075002000900295#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#p#73#69#article#75#14#<P><font
 face="Arial, Helvetica, sans-serif">14. Hogg S. A review of the validity and va
riability of the elevated plus-maze as an animal model of anxiety. <I>Pharmacol 
Biochem Behav</I> 1996; 54: 21-30. </font>      ^cY#6761.htm##
00475000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023300075002000900308#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#p#74#70#article#75#15#<P><font
 face="Arial, Helvetica, sans-serif">15. Anseloni VZ, Brand&atilde;o ML. Ethopha
rmacological analysis of behaviour of rats using variations of the elevated plus
-maze. <I>Behav Pharmacol</I> 1997; 8: 533-540. </font>      ^cY#6761.htm##
00506000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026400075002000900339#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#p#75#71#article#75#16#<P><font
 face="Arial, Helvetica, sans-serif">16. Mart&iacute;nez JC, Cardenas F, Lamprea
 M, Morato S. The role of vision and proprioception in the aversion of rats to t
he open arms of an elevated plus-maze. <I>Behav Processes</I> 2002; 60: 15-26. <
/font>      ^cY#6761.htm##
00522000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028000075002000900355#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#p#76#72#article#75#17#<P><font
 face="Arial, Helvetica, sans-serif">17. Milani H, Steiner H, Huston JP. Analysi
s of recovery from behavioral asymmetries induced by unilateral removal of vibri
ssae in the rat. <I>Behav Neurosci</I> 1989; 103: 1067-1074.</font>  <HR ALIGN=L
EFT WIDTH=100% SIZE=2>      ^cY#6761.htm##
00563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033600072002000900408#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#77#73#article#75#<P><FONT SIZE=4 face="A
rial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F><B
>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, Helv
etica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.g
if" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6761.ht
m##
00654000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704042700072002000900499#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#78#74#article#75#<p><font face="Arial, H
elvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v41n2/rec
or.gif" border="0"></a> Address for correspondence:</b>  S. Morato, Departamento
 de Psicologia e Educa&ccedil;&atilde;o, FFCLRP, USP, Avenida Bandeirantes, 3900
, 14040-901 Ribeir&atilde;o Preto, SP, Brasil. Fax: +55-16-3602-4835. E-mail: <a
 href="mailto:smorato@ffclrp.usp.br">smorato@ffclrp.usp.br</a></font> </p>      
^cY#6761.htm##
00460000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704023300072002000900305#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6761.htm#S#p#79#75#article#75#<P><font face="Arial, H
elvetica, sans-serif">S. Morato was the recipient of a research fellowship from 
CNPq (No. 351317/96-1). Publication supported by FAPESP. Received December 22, 2
006. Accepted November 29, 2007. </font>      ^cY#6761.htm##
00426000000000229000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710160018000730180033000910660
00800124062003200132065000900164064000500173865000900178002000900187#v41n2#v:\sc
ielo\serial\bjmbr\v41n2\markup\6761.htm#S#c#80#1#article#17#1#^rND^sBarnett^nSA#
The rat: A study in behavior^len#Chicago#The University of Chicago Press#1975000
0#1975#20080200#6761.htm##
00559000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100015000730100016000880100
01500104012004900119030002400168065000900192064000500201031000300206014000800209
865000900217002000900226035001000235801002400245#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6761.htm#S#c#81#2#article#17#2#^rND^sTreit^nD#^rND^sMenard^nJ#^rND^sR
oyan^nC#Anxiogenic stimuli in the elevated plus-maze^len#Pharmacol Biochem Behav
#19930000#1993#44#463-469#20080200#6761.htm#0091-3057#Pharmacol Biochem Behav##
00561000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100017000910120
07600108030002300184065000900207064000500216031000300221014000800224865000900232
002000900241035001000250801002300260#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
761.htm#S#c#82#3#article#17#3#^rND^sGrossen^nNE#^rND^sKelley^nMJ#Species-specifi
c behavior and acquisition of avoidance behavior in rats^len#J Comp Physiol Psyc
hol#19720000#1972#81#307-310#20080200#6761.htm#0021-9940#J Comp Physiol Psychol#
#
00543000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100021000730120084000940300
02300178065000900201064000500210031000300215014000800218865000900226002000900235
035001000244801002300254#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#c#
83#4#article#17#4#^rND^sMontgomery^nKC#The relation between fear induced by nove
l stimulation and exploratory behavior^len#J Comp Physiol Psychol#19550000#1955#
48#254-260#20080200#6761.htm#0021-9940#J Comp Physiol Psychol##
00611000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100015000890120
12800104030002400232065000900256064000500265031000300270014000800273865000900281
002000900290035001000299801002400309#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
761.htm#S#c#84#5#article#17#5#^rND^sPellow^nS#^rND^sFile^nSE#Anxiolytic and anxi
ogenic drug effects on exploratory activity in an elevated plus-maze: a novel te
st of anxiety in the rat^len#Pharmacol Biochem Behav#19860000#1986#24#525-529#20
080200#6761.htm#0091-3057#Pharmacol Biochem Behav##
00507000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100015000730120068000880300
01600156065000900172064000500181031000300186014000800189865000900197002000900206
035001000215801001600225#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#c#
85#6#article#17#6#^rND^sFile^nSE#The interplay of learning and anxiety in the el
evated plus-maze^len#Behav Brain Res#19930000#1993#58#199-202#20080200#6761.htm#
0166-4328#Behav Brain Res##
00507000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100018000890120
04300107030001300150065000900163064000500172031000300177014000800180865000900188
002000900197035001000206801001300216#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
761.htm#S#c#86#7#article#17#7#^rND^sWalsh^nRN#^rND^sCummins^nRA#The Open-Field T
est: a critical review^len#Psychol Bull#19760000#1976#83#482-504#20080200#6761.h
tm#0033-2909#Psychol Bull##
00492000000000253000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730120028000890160
01700117018004600134066001000180062001600190065000900206064000500215865000900220
002000900229#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#c#87#8#article
#17#8#^rND^sNahas^nTR#O teste do campo aberto^lpt#^rND^sXavier^nGF#Técnicas para
 o estudo do sistema nervoso^lpt#São Paulo#Editora Plêiade#19990000#1999#2008020
0#6761.htm##
00510000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730120076000890300
01300165065000900178064000500187031000300192014000800195865000900203002000900212
035001000221801001300231#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#c#
88#9#article#17#9#^rND^sValle^nFP#Effects of strain, sex, and illumination on op
en-field behavior of rats^len#Am J Psychol#19700000#1970#83#103-111#20080200#676
1.htm#0002-9556#Am J Psychol##
00500000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750120059000920300
01500151065000900166064000500175031000300180014000800183865000900191002000900200
035001000209801001500219#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#c#
89#10#article#17#10#^rND^sLister^nRG#Ethologically-based animal models of anxiet
y disorders^len#Pharmacol Ther#19900000#1990#46#321-340#20080200#6761.htm#0163-7
258#Pharmacol Ther##
00596000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750100020000940120
10500114030002200219065000900241064000500250031000300255014001000258865000900268
002000900277035001000286801002200296#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
761.htm#S#c#90#11#article#17#11#^rND^sCarobrez^nAP#^rND^sBertoglio^nLJ#Ethologic
al and temporal analyses of anxiety-like behavior: the elevated plus-maze model 
20 years on^lpt#Neurosci Biobehav Rev#20050000#2005#29#1193-1205#20080200#6761.h
tm#0149-7634#Neurosci Biobehav Rev##
00567000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100015000750100019000900100
01500109010001600124012007700140030001800217710000200235065000900237064000500246
031000200251014000600253865000900259002000900268#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6761.htm#S#c#91#12#article#17#12#^rND^sHorev^nG#^rND^sBenjamini^nY#^r
ND^sSakov^nA#^rND^sGolani^nI#Estimating wall guidance and attraction in mouse fr
ee locomotor behavior^len#Genes Brain Behav#2#20070000#2007#6#30-41#20080200#676
1.htm##
00587000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100015000750100014000900100
01700104012007500121030002400196065000900220064000500229031000300234014000800237
865000900245002000900254035001000263801002400273#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6761.htm#S#c#92#13#article#17#13#^rND^sCruz^nAP#^rND^sFrei^nF#^rND^sG
raeff^nFG#Ethopharmacological analysis of rat behavior on the elevated plus-maze
^len#Pharmacol Biochem Behav#19940000#1994#49#171-176#20080200#6761.htm#0091-305
7#Pharmacol Biochem Behav##
00555000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100014000750120101000890300
02400190065000900214064000500223031000300228014000600231865000900237002000900246
035001000255801002400265#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6761.htm#S#c#
93#14#article#17#14#^rND^sHogg^nS#A review of the validity and variability of th
e elevated plus-maze as an animal model of anxiety^len#Pharmacol Biochem Behav#1
9960000#1996#54#21-30#20080200#6761.htm#0091-3057#Pharmacol Biochem Behav##
00571000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750100018000940120
09700112030001600209065000900225064000500234031000200239014000800241865000900249
002000900258035001000267801001600277#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
761.htm#S#c#94#15#article#17#15#^rND^sAnseloni^nVZ#^rND^sBrandão^nML#Ethopharmac
ological analysis of behaviour of rats using variations of the elevated plus-maz
e^len#Behav Pharmacol#19970000#1997#8#533-540#20080200#6761.htm#0955-8810#Behav 
Pharmacol##
00638000000000301000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750100018000940100
01700112010001600129012010800145030001600253065000900269064000500278031000300283
014000600286865000900292002000900301035001000310801001600320#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6761.htm#S#c#95#16#article#17#16#^rND^sMartínez^nJC#^rND^
sCardenas^nF#^rND^sLamprea^nM#^rND^sMorato^nS#The role of vision and propriocept
ion in the aversion of rats to the open arms of an elevated plus-maze^len#Behav 
Processes#20020000#2002#60#15-26#20080200#6761.htm#0376-6357#Behav Processes##
00608000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100017000910100
01700108012010700125030001500232065000900247064000500256031000400261014001000265
865000900275002000900284035001000293801001500303#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6761.htm#S#c#96#17#article#17#17#^rND^sMilani^nH#^rND^sSteiner^nH#^rN
D^sHuston^nJP#Analysis of recovery from behavioral asymmetries induced by unilat
eral removal of vibrissae in the rat^len#Behav Neurosci#19890000#1989#103#1067-1
074#20080200#6761.htm#0735-7044#Behav Neurosci##
00267000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00300094#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#o#1#1#article#1#20
080402#165742#6764.htm#71##
02940000000000721000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000300108
03000200011103100030013103200020013406500090013601400090014503500100015422300090
01640120101001730100028002740100028003020100020003300100023003500100030003730100
02800403010002200431010003100453070011700484070013100601070008200732083103000814
08500080184408500290185208500310188108500380191208500330195008500300198311700060
20130720003020190580005020220600014020270580032020410600013020730580033020860600
01402119112000902133111001602142114000902158113001802167881002402185002000902209
#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#h#2#1#article#1#sc#en#bjmb
r#1#3.1#ILUS#TAB#03#BJMBR010#nd#Braz J Med Biol Res#41#2#20080200#^f95^l98#0100-
879X#20080111#Sequence change in the HS2-LCR and Gg-globin gene promoter region 
of sickle cell anemia patients^len#^rND^1A01 A02^nE.V.^sAdorno#^rND^1A02^nJ.P.^s
Moura-Neto#^rND^1A03^nI.^sLyra#^rND^1A03^nA.^sZanette#^rND^1A01 A02^nL.F.O.^sSan
tos#^rND^1A01 A02^nM.O.^sSeixas#^rND^1A01^nM.G.^sReis#^rND^1A01 A02^nM.S.^sGonca
lves#FIOCRUZ^iA01^1Centro de Pesquisas Gonçalo Moniz^2Laboratório de Patologia e
 Biologia Molecular^cSalvador^sBA^pBrasil#Universidade Federal da Bahia^iA02^1Fa
culdade de Farmácia^2Departamento de Análises Clínicas e Toxicológicas^cSalvador
^sBA^pBrasil#Fundação de Hematologia e Hemoterapia da Bahia^iA03^1HEMOBA^cSalvad
or^sBA^pBrasil#^len^aThe fetal hemoglobin (HbF) levels and ßS-globin gene haplot
ypes of 125 sickle cell anemia patients from Brazil were investigated. We sequen
ced the Gg- and Ag-globin gene promoters and the DNase I-2 hypersensitive sites 
in the locus control regions (HS2-LCR) of patients with HbF level disparities as
 compared to their ßS haplotypes. Sixty-four (51.2%) patients had CAR/Ben genoty
pe; 36 (28.8%) Ben/Ben; 18 (14.4%) CAR/CAR; 2 (1.6%) CAR/Atypical; 2 (1.6%) Ben/
Cam; 1 (0.8%) CAR/Cam; 1 (0.8%) CAR/Arab-Indian, and 1 (0.8%) Sen/Atypical. The 
HS2-LCR sequence analyses demonstrated a c.-10.677G>A change in patients with th
e Ben haplotype and high HbF levels. The Gg gene promoter sequence analyses show
ed a c.-157T>C substitution shared by all patients, and a c.-222_-225del related
 to the Cam haplotype. These results identify new polymorphisms in the HS2-LCR a
nd Gg-globin gene promoter. Further studies are required to determine the correl
ation between HbF synthesis and the clinical profile of sickle cell anemia patie
nts.#^dnd^i1#^tm^len^kFetal hemoglobin^i1#^tm^len^kSickle cell anemia^i1#^tm^len
^kßS-globin gene haplotypes^i1#^tm^len^kLocus control region^i1#^tm^len^kg-globi
n promoter^i1#other#16#CNPq#306524/2004-0#FAPESB/SECTI/SESAB/Gestão Saúde#143104
005306#FIOCRUZ, MCT/CNPq/MS-SCTIE-DECIT#409800/2006-6#20070105#January 5, 2007#2
0071119#November 19, 2007#S0100-879X2008005000002#6764.htm##
02950000000000709000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000300108
03000200011103100030013103200020013406500090013601400090014503500100015422300090
01640120108001730100028002810100028003090100020003370100023003570100030003800100
02800410010002200438010003100460070011700491070013100608070008200739083105800821
08500080187908500290188708500310191608500490194708500330199608500300202911700060
20590720003020650580005020680600014020730580032020870600013021190580033021320600
01402165112000902179111001602188114000902204113001802213002000902231#v41n2#v:\sc
ielo\serial\bjmbr\v41n2\markup\6764.htm#S#f#3#1#article#1#sc#en#bjmbr#1#3.1#ILUS
#TAB#03#BJMBR010#nd#Braz J Med Biol Res#41#2#20080200#^f95^l98#0100-879X#2008011
1#<b>Sequence change in the HS2-LCR and Gg-globin gene promoter region of sickle
 cell anemia patients</b>^len#^rND^1A01 A02^nE.V.^sAdorno#^rND^1A02^nJ.P.^sMoura
-Neto#^rND^1A03^nI.^sLyra#^rND^1A03^nA.^sZanette#^rND^1A01 A02^nL.F.O.^sSantos#^
rND^1A01 A02^nM.O.^sSeixas#^rND^1A01^nM.G.^sReis#^rND^1A01 A02^nM.S.^sGoncalves#
FIOCRUZ^iA01^1Centro de Pesquisas Gonçalo Moniz^2Laboratório de Patologia e Biol
ogia Molecular^cSalvador^sBA^pBrasil#Universidade Federal da Bahia^iA02^1Faculda
de de Farmácia^2Departamento de Análises Clínicas e Toxicológicas^cSalvador^sBA^
pBrasil#Fundação de Hematologia e Hemoterapia da Bahia^iA03^1HEMOBA^cSalvador^sB
A^pBrasil#^len^aThe fetal hemoglobin (HbF) levels and ß<sup>S</sup>-globin gene 
haplotypes of 125 sickle cell anemia patients from Brazil were investigated. We 
sequenced the Gg- and Ag-globin gene promoters and the DNase I-2 hypersensitive 
sites in the locus control regions (HS2-LCR) of patients with HbF level disparit
ies as compared to their ß<sup>S</sup> haplotypes. Sixty-four (51.2%) patients h
ad CAR/Ben genotype; 36 (28.8%) Ben/Ben; 18 (14.4%) CAR/CAR; 2 (1.6%) CAR/Atypic
al; 2 (1.6%) Ben/Cam; 1 (0.8%) CAR/Cam; 1 (0.8%) CAR/Arab-Indian, and 1 (0.8%) S
en/Atypical. The HS2-LCR sequence analyses demonstrated a c.-10.677G&gt;A change
 in patients with the Ben haplotype and high HbF levels. The Gg gene promoter se
quence analyses showed a c.-157T&gt;C substitution shared by all patients, and a
 c.-222_-225del related to the Cam haplotype. These results identify new polymor
phisms in the HS2-LCR and Gg-globin gene promoter. Further studies are required 
to determine the correlation between HbF synthesis and the clinical profile of s
ickle cell anemia patients.#^dnd^i1#^tm^len^kFetal hemoglobin^i1#^tm^len^kSickle
 cell anemia^i1#^tm^len^kß<sup>S</sup>-globin gene haplotypes^i1#^tm^len^kLocus 
control region^i1#^tm^len^kg-globin promoter^i1#other#16#CNPq#306524/2004-0#FAPE
SB/SECTI/SESAB/Gestão Saúde#143104005306#FIOCRUZ, MCT/CNPq/MS-SCTIE-DECIT#409800
/2006-6#20070105#January 5, 2007#20071119#November 19, 2007#6764.htm##
03095000000000733000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100038000400105121000300109049000900112
15800030012103000240012403100030014803200020015106500090015301400090016203500100
01712230009001810120101001900100028002910100028003190100019003470100022003660100
03100388010002800419010002200447010003100469070011900500070013300619070008400752
08310860083608500080192208500290193008500310195908500380199008500330202808500300
20611170006020910720003020970580005021000600014021050580032021190600013021510580
03302164060001402197112000902211111001602220114000902236113001802245002000902263
008008902272#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#l#4#1#article#
1#^mFeb.^a2008#sc#en#bjmbr#1#3.1#ilus#tab#03#BJMBR010#nd#Braz. j. med. biol. res
#41#2#20080200#^f95^l98#0100-879X#20080111#Sequence change in the HS2-LCR and Gg
-globin gene promoter region of sickle cell anemia patients^len#^rND^1A01 A02^nE
. V^sAdorno#^rND^1A02^nJ. P^sMoura-Neto#^rND^1A03^nI^sLyra#^rND^1A03^nA^sZanette
#^rND^1A01 A02^nL. F. O^sSantos#^rND^1A01 A02^nM. O^sSeixas#^rND^1A01^nM. G^sRei
s#^rND^1A01 A02^nM. S^sGoncalves#^iA01^1FIOCRUZ^2Centro de Pesquisas Gonçalo Mon
iz^3Laboratório de Patologia e Biologia Molecular^cSalvador^sBA^pBrasil#^iA02^1U
niversidade Federal da Bahia^2Faculdade de Farmácia^3Departamento de Análises Cl
ínicas e Toxicológicas^cSalvador^sBA^pBrasil#^iA03^1Fundação de Hematologia e He
moterapia da Bahia^2HEMOBA^cSalvador^sBA^pBrasil#^len^aThe fetal hemoglobin (HbF
) levels and ßS-globin gene haplotypes of 125 sickle cell anemia patients from B
razil were investigated. We sequenced the Gg- and Ag-globin gene promoters and t
he DNase I-2 hypersensitive sites in the locus control regions (HS2-LCR) of pati
ents with HbF level disparities as compared to their ßS haplotypes. Sixty-four (
51.2 percent) patients had CAR/Ben genotype; 36 (28.8 percent) Ben/Ben; 18 (14.4
 percent) CAR/CAR; 2 (1.6 percent) CAR/Atypical; 2 (1.6 percent) Ben/Cam; 1 (0.8
 percent) CAR/Cam; 1 (0.8 percent) CAR/Arab-Indian, and 1 (0.8 percent) Sen/Atyp
ical. The HS2-LCR sequence analyses demonstrated a c.-10.677G>A change in patien
ts with the Ben haplotype and high HbF levels. The Gg gene promoter sequence ana
lyses showed a c.-157T>C substitution shared by all patients, and a c.-222_-225d
el related to the Cam haplotype. These results identify new polymorphisms in the
 HS2-LCR and Gg-globin gene promoter. Further studies are required to determine 
the correlation between HbF synthesis and the clinical profile of sickle cell an
emia patients.#^dnd^i1#^tm^len^kFetal hemoglobin^i1#^tm^len^kSickle cell anemia^
i1#^tm^len^kßS-globin gene haplotypes^i1#^tm^len^kLocus control region^i1#^tm^le
n^kg-globin promoter^i1#other#16#CNPq#306524/2004-0#FAPESB/SECTI/SESAB/Gestão Sa
úde#143104005306#FIOCRUZ, MCT/CNPq/MS-SCTIE-DECIT#409800/2006-6#20070105#January
 5, 2007#20071119#November 19, 2007#6764.htm#Internet^ihttp://www.scielo.br/scie
lo.php?script=sci_arttext&pid=S0100-879X2008000200003##
00408000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704018300070002000900253#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#5#1#article#51#<P class="style4"> <A NAM
E="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif">F
ebruary 2008, Volume 41(2) 95-98</font> (Short Communication)</B></P>     ^cY#67
64.htm##
00445000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704022000070002000900290#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#6#2#article#51#<P class="style2"><B><fon
t size="5" face="Arial, Helvetica, sans-serif">Sequence change in the HS2-LCR an
d G<font face="Symbol">g</font>-globin gene promoter region of sickle cell anemi
a patients</font></B> </P>     ^cY#6764.htm##
00769000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704054400070002000900614#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#7#3#article#51#<P><font face="Arial, Hel
vetica, sans-serif">E.V. Adorno<SUP>1,2</SUP>, J.P. Moura-Neto<SUP>2</SUP>, I. L
yra<SUP>3</SUP>, A. Zanette<SUP>3</SUP>, L.F.O. Santos<SUP>1,2</SUP>, M.O. Seixa
s<SUP>1,2</SUP>, M.G. Reis<SUP>1</SUP> and <span class="style4"><a href="#Corres
pondence"><img src="/img/revistas/bjmbr/v41n2/recor.gif" border="0"></a> <a href
="mailto:mari@bahia.fiocruz.br"><img src="/img/revistas/bjmbr/v41n2/email-ca.gif
" border="0"></a></span></font> <font face="Arial, Helvetica, sans-serif">M.S. G
oncalves<SUP>1,2</SUP> </font>     ^cY#6764.htm##
00416000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704019100070002000900261#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#8#4#article#51#<P><font face="Arial, Hel
vetica, sans-serif"><SUP>1</SUP>Laborat&oacute;rio de Patologia e Biologia Molec
ular, Centro de Pesquisas Gon&ccedil;alo Moniz, FIOCRUZ, Salvador, BA, Brasil   
  ^cY#6764.htm##
00408000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704018300070002000900253#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#9#5#article#51#<br>     <SUP>2</SUP>Depa
rtamento de An&aacute;lises Cl&iacute;nicas e Toxicol&oacute;gicas, Faculdade de
 Farm&aacute;cia, Universidade Federal da Bahia, Salvador, BA, Brasil     ^cY#67
64.htm##
00354000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704012800071002000900199#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#10#6#article#51#<br>     <SUP>3</SUP>HEM
OBA, Funda&ccedil;&atilde;o de Hematologia e Hemoterapia da Bahia, Salvador, BA,
 Brasil </font>     ^cY#6764.htm##
00465000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704023900071002000900310#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#11#7#article#51#<P class="style4"> <A HR
EF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER
=0 VSPACE=0 HSPACE=0></A>    <A HREF="#Abstract"><strong><font face="Arial, Helv
etica, sans-serif">Abstract</font></strong></A>    ^cY#6764.htm##
00441000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704021500071002000900286#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#12#8#article#51#<BR>   <A HREF="#Text"><
IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0></A>    <A HREF="#Text"><strong><font face="Arial, Helvetica, sans-serif">T
ext</font></strong></A>    ^cY#6764.htm##
00446000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704022000071002000900291#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#13#9#article#51#<BR>   <A HREF="#Referen
ces"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A>    <A HREF="#References"><strong><font face="Arial, Helvetica, s
ans-serif">References</font>    ^cY#6764.htm##
00485000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704025800072002000900330#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#14#10#article#51#<br>   </strong></A><fo
nt face="Arial, Helvetica, sans-serif"><A HREF="#Acknowledgments"><IMG SRC="/img
/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A 
HREF="#Acknowledgments"><strong>Acknowledgments</strong></A></font>    ^cY#6764.
htm##
00525000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704029800072002000900370#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#15#11#article#51#<BR>   <A HREF="#Corres
pondence"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A>    <A HREF="#Correspondence"><strong><font face="Arial, Hel
vetica, sans-serif">Correspondence    and Footnotes</font></strong></a>  <HR ALI
GN=LEFT WIDTH=100% SIZE=2>     ^cY#6764.htm##
00575000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704034800072002000900420#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#16#12#article#51#<P class="style4"> <A N
AME="Abstract"></A><span class="style3"><font color="#00007F" face="Arial, Helve
tica, sans-serif" size="4"><b>Abstract</b></font><FONT COLOR=#00007F>    </FONT>
</span><A HREF="#Home"><FONT SIZE=4><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.
gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>     
 ^cY#6764.htm##
01503000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704127600072002000901348#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#17#13#article#51#<P><font face="Arial, H
elvetica, sans-serif">The fetal hemoglobin (HbF) levels and &szlig;<SUP>S</SUP>-
globin gene haplotypes of 125 sickle cell anemia patients from Brazil were inves
tigated. We sequenced the G<font face="Symbol">g</font>- and A<font face="Symbol
">g</font>-globin gene promoters and the DNase I-2 hypersensitive sites in the l
ocus control regions (HS2-LCR) of patients with HbF level disparities as compare
d to their &szlig;<SUP>S</SUP> haplotypes. Sixty-four (51.2%) patients had CAR/B
en genotype; 36 (28.8%) Ben/Ben; 18 (14.4%) CAR/CAR; 2 (1.6%) CAR/Atypical; 2 (1
.6%) Ben/Cam; 1 (0.8%) CAR/Cam; 1 (0.8%) CAR/Arab-Indian, and 1 (0.8%) Sen/Atypi
cal. The HS2-LCR sequence analyses demonstrated a c.-10.677G&gt;A change in pati
ents with the Ben haplotype and high HbF levels. The G<font face="Symbol">g</fon
t> gene promoter sequence analyses showed a c.-157T&gt;C substitution shared by 
all patients, and a c.-222_-225del related to the Cam haplotype. These results i
dentify new polymorphisms in the HS2-LCR and G<font face="Symbol">g</font>-globi
n gene promoter. Further studies are required to determine the correlation betwe
en HbF synthesis and the clinical profile of sickle cell anemia patients. </font
> <font face="Arial, Helvetica, sans-serif">     ^cY#6764.htm##
00440000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704021300072002000900285#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#18#14#article#51#<P>Key words: Fetal hem
oglobin; Sickle cell anemia; &szlig;<SUP>S</SUP>-globin gene haplotypes; Locus c
ontrol region; <font face="Symbol">g</font>-globin promoter </font> <HR ALIGN=LE
FT WIDTH=100% SIZE=2>     ^cY#6764.htm##
00565000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033800072002000900410#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#19#15#article#51#<P class="style4"><A NA
ME="Text"></A><FONT SIZE=4><B><span class="style3"><font color="#00007F" face="A
rial, Helvetica, sans-serif">Text</font></span>    <a href="#Home"><IMG SRC="/im
g/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0
"></a></B></FONT>  </P> <font face="Arial, Helvetica, sans-serif">     ^cY#6764.
htm##
00997000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704077000072002000900842#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#20#16#article#51#<P>Patients with sickle
 cell anemia (SCA) have a wide spectrum of clinical manifestations, characterize
d by heterogeneous severity, that are frequently associated with the levels of f
etal hemoglobin (HbF) (1). The &szlig;<SUP>S</SUP>-globin gene haplotypes are re
lated to polymorphic restriction enzyme sites distributed throughout the &szlig;
<SUP>S</SUP>-globin gene cluster region, and have been associated with specific 
HbF levels and the phenotypic diversity presented by SCA patients (1,2). The maj
or &szlig;<SUP>S</SUP>-globin gene haplotypes have been named Benin (Ben), Centr
al African Republic (CAR), Senegal (Sen), Arab-Indian, and Cameroon (Cam), accor
ding to their geographical origin and the ethnic groups in which they are freque
ntly found (2,3).      ^cY#6764.htm##
00760000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704053300072002000900605#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#21#17#article#51#<P>Previous reports hav
e investigated the roles of &szlig;<SUP>S </SUP>haplotypes and HbF levels as mar
kers of clinical heterogeneity in SCA (2-4). For example, there is a T&gt;A vari
ation in the A<font face="Symbol">g</font>-globin gene promoter region (-499) th
at is associated with the Ben haplotype among Sicilian and North American indivi
duals (5). Most patients with the CAR haplotype have very low HbF levels, often 
below 5% of total HbF, while Ben haplotype carriers have intermediate HbF levels
, from 5 to 15% (4).      ^cY#6764.htm##
01167000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704094000072002000901012#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#22#18#article#51#<P>Hemoglobin gene swit
ching depends on complex interactions of stage-specific transcription factors, c
hromosomal gene order, proximity to the globin locus control region (LCR), and e
rythroid-specific and ubiquitous trans-acting factors that interact with the pro
moter regions (3,6). Some mutations in the <font face="Symbol">g</font>-globin g
ene promoter region are associated with increased HbF synthesis, such as the c.-
158 C&gt;T polymorphism has been described in the Sen haplotype (2,3). The LCR i
s characterized by a series of five DNase I-hypersensitive sites (5'-HS1-HS5). O
f particular importance is the 5'-HS2-LCR enhancer, which contains a 46-base pai
r (bp) binding sequence for the NF-E2 and AP-1 trans-acting factors. The 5'-HS2-
LCR is flanked by multiple <I>cis</I>-acting sequences that modulate enhancer ac
tivity, that contain different number of AT-rich sequences and some single-nucle
otide polymorphisms (7,8).       ^cY#6764.htm##
00593000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036600072002000900438#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#23#19#article#51#<P>Here, we suggest tha
t sequence variations in both the promoter regions for the G<font face="Symbol">
g</font>- and A<font face="Symbol">g</font>-globin genes and the HS2-LCR regions
 may be important in establishing the HbF level diversity found among specific &
szlig;<SUP>S</SUP>-globin gene haplotypes in SCA patients from Northeastern Braz
ilian (9,10).      ^cY#6764.htm##
01075000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704084800072002000900920#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#24#20#article#51#<P>The &szlig;<SUP>S </
SUP>haplotypes and HbF levels of a group of 125 SCA patients from the Blood Cent
er of Bahia, Salvador, BA, Brazil (HEMOBA) were investigated. The study was appr
oved by the Oswaldo Cruz Research Foundation's human research Ethics Committee. 
The &szlig;<SUP>S</SUP> haplotypes were identified using polymerase chain reacti
on and restriction fragment length polymorphism techniques (11). The HbF levels 
were estimated using high-performance liquid chromatography (VARIANT I, BIO-RAD,
 Hercules, CA, USA). The G<font face="Symbol">g</font>- and A<font face="Symbol"
>g</font>-globin gene promoters and HS2-LCR regions (6,7,12) were sequenced in a
n ABI Prism 3100 DNA Sequencer using Kit BigDye 03 Terminator&#153; Sequencing S
tandards (Applied Biosystems, Foster City, CA, USA) and specific sequencing prim
ers (13).</font>     ^cY#6764.htm##
01752000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704152500072002000901597#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#25#21#article#51#<P><font face="Arial, H
elvetica, sans-serif">The frequencies of various &szlig;<SUP>S</SUP>    haplotyp
es in the 125 patients were 64 (51.2%) with genotype CAR/Ben; 36 (28.8%)    Ben/
Ben; 18 (14.4%) CAR/CAR; 2 (1.6%) CAR/Atypical; 2 (1.6%) Ben/Cam; 1 (0.8%)    CA
R/Cam; 1 (0.8%) CAR/Arab-Indian, and 1 (0.8%) Sen/Atypical. Among these, 4    CA
R/CAR patients had HbF levels <font face="Symbol">&#179;</font>10.0%, 3 Ben/Ben 
   patients had HbF <font face="Symbol">&#163;</font>5.0%, 11 CAR/Ben patients  
  had HbF <font face="Symbol">&#179;</font>15.0%, 18 CAR/Ben patients had HbF   
 <font face="Symbol">&#163;</font>5.0%, and 2 Cam/Ben patients had HbF <font fac
e="Symbol">&#179;</font>15.0%.    From this sample group, ten patients presentin
g a disparity between the level    of HbF and the &szlig;<SUP>S </SUP>haplotype 
were selected for sequencing of    the G<font face="Symbol">g</font>- and A<font
 face="Symbol">g</font>-globin    gene promoter and HS2-LCR regions. Two Cam/Ben
 patients were selected, with    HbF levels of 17.1 and 27.4%. Two Ben/Ben patie
nts were selected, with HbF levels    of 11.5 and 1.3%. Three CAR/Ben patients w
ere selected, with HbF levels of 1.2,    10.1, and 17.6%. Two CAR/CAR patients w
ere selected, with HbF levels of 8.7    and 14.9%. The CAR/Atypical patient was 
also studied and had an HbF level of    9.6%. The HbF levels and clinical charac
teristics of the ten patients are shown    in <a href="#Tab1"><b>Table 1</b></a>
. </font>  <font face="Arial, Helvetica, sans-serif">     ^cY#6764.htm##
01144000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704091700072002000900989#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#26#22#article#51#<P>Sequencing of the G<
font face="Symbol">g</font>- and A<font face="Symbol">g</font>-globin    gene pr
omoter regions confirmed the presence of specific polymorphisms (14),    includi
ng c.-533_-532<I>inv</I> (AGA to AAG) and c.-400_ -395del in the 5' region    of
 the G<font face="Symbol">g</font>gene, and c.-225_-222del in the 5' region    o
f the Ag gene. We also found a nucleotide substitution at c.-157T&gt;C detected 
   in the G<font face="Symbol">g</font>-globin gene promoter (GenBank accession 
   No. bankit 818161, DQ873521; <strong><a href="#Fig1"><b>Figure 1</b></a></str
ong>),    suggesting that this polymorphism, located in the vicinity of another 
polymorphism    (c.-158C&gt;T), is associated with high <font face="Symbol">g</f
ont>-globin    gene expression (2,3). To confirm this finding, it is necessary t
o know its    distribution in other Afro-descendant populations from Bahia, howe
ver.      ^cY#6764.htm##
00999000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704077200072002000900844#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#27#23#article#51#<P>The Ben/Cam patients
 presented the c.-222_-225del of the A<font face="Symbol">g</font>-globin gene p
romoter region, which may be part of a <I>cis</I>-acting element that increases 
the expression of <font face="Symbol">g</font>-globin gene when bound to a speci
fic <I>trans</I>-acting factor (15). Furthermore, the two patients with the Cam 
haplotype had high HbF levels, and polymerase chain reaction amplification with 
primers that were specific and distinct for the promoter regions of either the G
<font face="Symbol">g</font>- or A<font face="Symbol">g</font>-globin genes demo
nstrated a similar c.-222_-225del of the G<font face="Symbol">g</font>-globin ge
ne (GenBank accession No. bankit 825906, DQ873519; <strong><a href="#Fig1">Figur
e 1</a></strong>).       ^cY#6764.htm##
01369000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704114200072002000901214#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#28#24#article#51#<P>We detected a G&gt;A
 substitution outside the core sequences of HS2-LCR (-10.677    position; GenBan
k accession No. bankit 825964, DQ873522) in 5 SCA patients with    the Ben haplo
type and high HbF levels (<strong><a href="#Fig1">Figure 1</a></strong>).    The
 CAR/Ben and Ben/Ben patients with low HbF levels did not have this sequence    
variation. In the small patient group investigated, there were two CAR/CAR patie
nts    with high HbF levels without this G&gt;A substitution (<b><a href="#Tab1"
>Table    1</a></b>), suggesting that this substitution plays an important role 
in the    regulation of <font face="Symbol">g</font>-globin gene expression when
 associated    with the Ben haplotype, probably by affecting interaction with a 
binding site    for a specific <I>trans</I>-acting factor. This HS2-LCR sequence
 change is located    close to a binding site for GATA-1 and a ubiquitous <I>tra
ns</I>-acting factor,    and can constitute a motif associated with the Ben chro
mosome (2-4). The other    HS2-LCR polymorphisms described here have been relate
d to specific haplotypes    in agreement with previous studies (7,8).      ^cY#6
764.htm##
01349000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704112200072002000901194#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#29#25#article#51#<P>This study confirms 
the relationship between genotypic heterogeneity and HbF levels in Brazilian SCA
 patients, emphasizing the high racial admixture of the Bahian Africans populati
on that came from the slave trade from Western Africa, mainly from the Bay of Be
nin (16). Further studies need to be conducted in the same population in order t
o clarify the role of new biological markers in the clinical progress of SCA pat
ients, however. The sequence analyses presented herein have identified a new pol
ymorphic site on the promoter region for the G<font face="Symbol">g</font>-globi
n gene, suggestive of a common sequence characteristic among Brazilian SCA patie
nts. The new sequence variation in the HS2-LCR region may be associated with <fo
nt face="Symbol">g</font>-globin gene expression. </font> <HR ALIGN=LEFT WIDTH=1
00% SIZE=2> <table width="100%"  border="0">   <tr align="left" valign="top">   
  <td width="13%"><a href="/img/revistas/bjmbr/v41n2/html/6764i01.htm"><img src=
"/img/revistas/bjmbr/v41n2/6764i01peq.jpg" border="2"></a></td>     <td width="8
7%"><font face="Arial, Helvetica, sans-serif">         ^cY#6764.htm##
00700000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704047300072002000900545#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#30#26#article#51#<P><a name="Fig1"></a>F
igure 1. Sequence analysis. <I>A</I>, c.-222_-225del of the G<font face="Symbol"
>g</font>-globin gene promoter region described in the Cam haplotype. <I>B</I>, 
Nucleotide substitution (c.-157T&gt;C) at the G<font face="Symbol">g</font>-glob
in gene promoter found in all patients. <I>C</I>, Nucleotide substitution (c.-10
.677G&gt;A) outside the core sequences of HS2-LCR found in the Ben haplotype.   
          </font> </td>   </tr> </table>      ^cY#6764.htm##
00611000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038400072002000900456#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#31#27#article#51#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (247 K JPG file)]</font
>   <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">   <tr al
ign="left" valign="top">     <td width="13%"><a href="/img/revistas/bjmbr/v41n2/
html/6764t01.htm"><img src="/img/revistas/bjmbr/v41n2/table.jpg" border="2"></a>
</td>     <td width="87%">           ^cY#6764.htm##
00571000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704034400072002000900416#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#32#28#article#51#<p><font face="Arial, H
elvetica, sans-serif"><a name="Tab1"></a>Table 1.          Summary of fetal hemo
globin levels (HbF), age, &szlig;<SUP>S</SUP>-globin          gene haplotype and
 polymorphic <I>cis</I>-acting sequences found among          sickle cell anemia
 patients from Northeast Brazil. </font></p>     </td>   </tr> </table>      ^cY
#6764.htm##
00375000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704014800072002000900220#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#33#29#article#51#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (193 K JPG file)]</font
>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6764.htm##
00577000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704035000072002000900422#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#34#30#article#51#<P class="style4"> <A N
AME="References"></A><FONT color="#00007F" SIZE=4><B><font face="Arial, Helvetic
a, sans-serif">References</font></B></FONT>    <A HREF="#Home"><FONT SIZE=4><B><
IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0 LOOP="0"></B></FONT></A>  </P> <font face="Arial, Helvetica, sans-serif">  
   ^cY#6764.htm##
00355000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704011400074002000900188#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#p#35#31#article#51#1#<P>1. Cha
rache S. Fetal hemoglobin, sickling, and sickle cell disease. <I>Adv Pediatr</I>
 1990; 37: 1-31.     ^cY#6764.htm##
00569000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704032800074002000900402#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#p#36#32#article#51#2#<P>2. Nag
el RL, Steinberg MH. Genetics of the S gene: origins, genetic epidemiology, and 
epistasis in sickle cell anemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL
 (Editors), <I>Disorders of hemoglobin: genetics, pathophysiology, and clinical 
management</I>. New York. Cambridge University Press; 2001. p 711-755.     ^cY#6
764.htm##
00363000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704012200074002000900196#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#p#37#33#article#51#3#<P>3. Ste
inberg MH. Predicting clinical severity in sickle cell anaemia. <I>Br J Haematol
</I> 2005; 129: 465-481.     ^cY#6764.htm##
00418000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704017700074002000900251#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#p#38#34#article#51#4#<P>4. Pow
ars D, Hiti A. Sickle cell anemia. Beta s gene cluster haplotypes as genetic mar
kers for severe disease expression. <I>Am J Dis Child</I> 1993; 147: 1197-1202. 
    ^cY#6764.htm##
00474000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704023300074002000900307#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#p#39#35#article#51#5#<P>5. Pat
rinos GP, Samperi P, Lo Nigro L, Kollia P, Schiliro G, Papadakis MN. Evidence fo
r the molecular heterogeneity of sickle cell anemia chromosomes bearing the beta
S/Benin haplotype. <I>Am J Hematol</I> 2005; 80: 79-80.     ^cY#6764.htm##
00406000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704016500074002000900239#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#p#40#36#article#51#6#<P>6. Tua
n D, Kong S, Hu K. Transcription of the hypersensitive site HS2 enhancer in eryt
hroid cells. <I>Proc Natl Acad Sci U S A</I> 1992; 89: 11219-11223.     ^cY#6764
.htm##
00537000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704029600074002000900370#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#p#41#37#article#51#7#<P>7. One
r C, Dimovski AJ, Altay C, Gurgey A, Gu YC, Huisman TH, et al. Sequence variatio
ns in the 5' hypersensitive site-2 of the locus control region of beta S chromos
omes are associated with different levels of fetal globin in hemoglobin S homozy
gotes. <I>Blood</I> 1992; 79: 813-819.     ^cY#6764.htm##
00509000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704026800074002000900342#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#p#42#38#article#51#8#<P>8. Fig
ueiredo MS, Steinberg MH. Fetal hemoglobin in sickle cell anemia: examination of
 phylogenetically conserved sequences within the locus control region but outsid
e the cores of hypersensitive sites 2 and 3. <I>Blood Cells Mol Dis</I> 1997; 23
: 188-200.     ^cY#6764.htm##
00487000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024600074002000900320#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#p#43#39#article#51#9#<P>9. Ado
rno EV, Zanette A, Lyra I, Souza CC, Santos LF, Menezes JF, et al. The beta-glob
in gene cluster haplotypes in sickle cell anemia patients from Northeast Brazil:
 a clinical and molecular view. <I>Hemoglobin</I> 2004; 28: 267-271.     ^cY#676
4.htm##
00470000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022800075002000900303#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#p#44#40#article#51#10#<P>10. G
oncalves MS, Bomfim GC, Maciel E, Cerqueira I, Lyra I, Zanette A, et al. BetaS-h
aplotypes in sickle cell anemia patients from Salvador, Bahia, Northeastern Braz
il. <I>Braz J Med Biol Res</I> 2003; 36: 1283-1288.     ^cY#6764.htm##
00443000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020100075002000900276#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#p#45#41#article#51#11#<P>11. S
utton M, Bouhassira EE, Nagel RL. Polymerase chain reaction amplification applie
d to the determination of beta-like globin gene cluster haplotypes. <I>Am J Hema
tol</I> 1989; 32: 66-69.     ^cY#6764.htm##
00478000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023600075002000900311#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#p#46#42#article#51#12#<P>12. G
oncalves MS, Nechtman JF, Figueiredo MS, Kerbauy J, Arruda VR, Sonati MF, et al.
 Sickle cell disease in a Brazilian population from S&atilde;o Paulo: a study of
 the beta s haplotypes. <I>Hum Hered</I> 1994; 44: 322-327.     ^cY#6764.htm##
00393000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704015100075002000900226#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#p#47#43#article#51#13#<P>13. S
anger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors
. <I>Proc Natl Acad Sci U S A</I> 1977; 74: 5463-5467.     ^cY#6764.htm##
00496000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025400075002000900329#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#p#48#44#article#51#14#<P>14. L
anclos KD, Oner C, Dimovski AJ, Gu YC, Huisman TH. Sequence variations in the 5'
 flanking and IVS-II regions of the G gamma- and A gamma-globin genes of beta S 
chromosomes with five different haplotypes. <I>Blood</I> 1991; 77: 2488-2496.   
  ^cY#6764.htm##
00448000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020600075002000900281#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#p#49#45#article#51#15#<P>15. L
u ZH, Steinberg MH. Fetal hemoglobin in sickle cell anemia: relation to regulato
ry sequences cis to the beta-globin gene. Multicenter Study of Hydroxyurea. <I>B
lood</I> 1996; 87: 1604-1611.     ^cY#6764.htm##
00442000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020000075002000900275#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#p#50#46#article#51#16#<P>16. V
erger P. <I>Flux et reflux de la traite des N&egrave;gres entre le Golfe de Beni
n et Bahia de Todos os Santos</I>. Paris: Mouton Press; 1968. </font> <HR ALIGN=
LEFT WIDTH=100% SIZE=2>     ^cY#6764.htm##
00604000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704037700072002000900449#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#51#47#article#51#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE=4
><B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, san
s-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=
BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P> <font face="Arial
, Helvetica, sans-serif">     ^cY#6764.htm##
00421000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704019400072002000900266#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#52#48#article#51#<P>We are grateful to F
abiola Nascimento Concei&ccedil;&atilde;o from the Oswaldo Cruz Foundation, Salv
ador, BA, Brazil, for the English review.</font> <HR ALIGN=LEFT WIDTH=100% SIZE=
2>     ^cY#6764.htm##
00553000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704032600072002000900398#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#53#49#article#51#<P class="style4"><A NA
ME="Correspondence"></A><FONT color="#00007F" SIZE=4><B><font face="Arial, Helve
tica, sans-serif">Correspondence    and Footnotes</font></B></FONT> <A HREF="#Ho
me"><FONT SIZE=4><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM B
ORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></P>     ^cY#6764.htm##
00703000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704047600072002000900548#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#54#50#article#51#<P class="style4"><B><a
 href="#Home"><img src="/img/revistas/bjmbr/v41n2/recor.gif" border="0"></a> Add
ress for correspondence: </B><font face="Arial, Helvetica, sans-serif">M.S. Gon&
ccedil;alves, Laborat&oacute;rio de Patologia e Biologia Molecular, Centro de Pe
squisas Gon&ccedil;alo Moniz, FIOCRUZ, Rua Waldemar Falc&atilde;o, 121, 40295-00
1 Salvador, BA, Brasil. E-mail: <a href="mailto:mari@bahia.fiocruz.br"><strong>m
ari@bahia.fiocruz.br</strong></a></font></P>     ^cY#6764.htm##
00509000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704028200072002000900354#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6764.htm#S#p#55#51#article#51#<P><font face="Arial, H
elvetica, sans-serif">Research supported by CNPq (No. 306524/2004-0), FAPESB/SEC
TI/SESAB/Gest&atilde;o Sa&uacute;de (No. 143104005306), FIOCRUZ, MCT/CNPq/MS-SCT
IE-DECIT (No. 409800/2006-6). Received January 5, 2007. Accepted November 19, 20
07.</font>     ^cY#6764.htm##
00487000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730120056000910300
01200147065000900159064000500168031000300173014000500176865000900181002000900190
035001000199801001200209#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#c#
56#1#article#16#1#^rND^sCharache^nS#Fetal hemoglobin, sickling, and sickle cell 
disease^len#Adv Pediatr#19900000#1990#37#1-31#20080200#6764.htm#0065-3101#Adv Pe
diatr##
00743000000000313000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100020000890120
09500109016002000204016001700224016001600241016001600257018008000273066000900353
062002700362065000900389064000500398014000800403865000900411002000900420#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#c#57#2#article#16#2#^rND^sNagel^nR
L#^rND^sSteinberg^nMH#Genetics of the S gene: origins, genetic epidemiology, and
 epistasis in sickle cell anemia^len#^rND^sSteinberg^nMH#^rND^sForget^nBG#^rND^s
Higgs^nDR#^rND^sNagel^nRL#Disorders of hemoglobin: genetics, pathophysiology, an
d clinical management^len#New York#Cambridge University Press#20010000#2001#711-
755#20080200#6764.htm##
00497000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100020000730120056000930300
01400149065000900163064000500172031000400177014000800181865000900189002000900198
035001000207801001400217#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#c#
58#3#article#16#3#^rND^sSteinberg^nMH#Predicting clinical severity in sickle cel
l anaemia^len#Br J Haematol#20050000#2005#129#465-481#20080200#6764.htm#0007-104
8#Br J Haematol##
00571000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100014000890120
10400103030001500207065000900222064000500231031000400236014001000240865000900250
002000900259035001000268801001500278#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
764.htm#S#c#59#4#article#16#4#^rND^sPowars^nD#^rND^sHiti^nA#Sickle cell anemia: 
Beta s gene cluster haplotypes as genetic markers for severe disease expression^
len#Am J Dis Child#19930000#1993#147#1197-1202#20080200#6764.htm#0002-922X#Am J 
Dis Child##
00697000000000325000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100019000730100017000920100
01800109010001600127010001800143010002000161012011300181030001300294065000900307
06400050031603100030032101400060032486500090033000200090033903500100034880100130
0358#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#c#60#5#article#16#5#^r
ND^sPatrinos^nGP#^rND^sSamperi^nP#^rND^sLo^nNigro L#^rND^sKollia^nP#^rND^sSchili
ro^nG#^rND^sPapadakis^nMN#Evidence for the molecular heterogeneity of sickle cel
l anemia chromosomes bearing the betaS/Benin haplotype^len#Am J Hematol#20050000
#2005#80#79-80#20080200#6764.htm#0361-8609#Am J Hematol##
00587000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100014000730100014000870100
01200101012007700113030002500190065000900215064000500224031000300229014001200232
865000900244002000900253035001000262801002500272#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6764.htm#S#c#61#6#article#16#6#^rND^sTuan^nD#^rND^sKong^nS#^rND^sHu^n
K#Transcription of the hypersensitive site HS2 enhancer in erythroid cells^len#P
roc Natl Acad Sci U S A#19920000#1992#89#11219-11223#20080200#6764.htm#0027-8424
#Proc Natl Acad Sci U S A##
00764000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100014000730100019000870100
01500106010001600121010001300137010001800150810000600168012018700174030000600361
06500090036706400050037603100030038101400080038486500090039200200090040103500100
0410801000600420#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#c#62#7#art
icle#16#7#^rND^sOner^nC#^rND^sDimovski^nAJ#^rND^sAltay^nC#^rND^sGurgey^nA#^rND^s
Gu^nYC#^rND^sHuisman^nTH#et al#Sequence variations in the 5' hypersensitive site
-2 of the locus control region of beta S chromosomes are associated with differe
nt levels of fetal globin in hemoglobin S homozygotes^len#Blood#19920000#1992#79
#813-819#20080200#6764.htm#0006-4971#Blood##
00667000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100021000730100020000940120
18200114030002000296065000900316064000500325031000300330014000800333865000900341
002000900350035001000359801002000369#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
764.htm#S#c#63#8#article#16#8#^rND^sFigueiredo^nMS#^rND^sSteinberg^nMH#Fetal hem
oglobin in sickle cell anemia: examination of phylogenetically conserved sequenc
es within the locus control region but outside the cores of hypersensitive sites
 2 and 3^len#Blood Cells Mol Dis#19970000#1997#23#188-200#20080200#6764.htm#1079
-9796#Blood Cells Mol Dis##
00719000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100017000900100
01400107010001600121010001700137010001800154810000600172012012800178030001100306
06500090031706400050032603100030033101400080033486500090034200200090035103500100
0360801001100370#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#c#64#9#art
icle#16#9#^rND^sAdorno^nEV#^rND^sZanette^nA#^rND^sLyra^nI#^rND^sSouza^nCC#^rND^s
Santos^nLF#^rND^sMenezes^nJF#et al#The beta-globin gene cluster haplotypes in si
ckle cell anemia patients from Northeast Brazil: a clinical and molecular view^l
en#Hemoglobin#20040000#2004#28#267-271#20080200#6764.htm#0363-0269#Hemoglobin##
00711000000000337000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100020000750100017000950100
01600112010001900128010001400147010001700161810000600178012009400184030002000278
06500090029806400050030703100030031201400100031586500090032500200090033403500100
0343801002000353#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#c#65#10#ar
ticle#16#10#^rND^sGoncalves^nMS#^rND^sBomfim^nGC#^rND^sMaciel^nE#^rND^sCerqueira
^nI#^rND^sLyra^nI#^rND^sZanette^nA#et al#BetaS-haplotypes in sickle cell anemia 
patients from Salvador, Bahia, Northeastern Brazil^len#Braz J Med Biol Res#20030
000#2003#36#1283-1288#20080200#6764.htm#0100-879X#Braz J Med Biol Res##
00612000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100021000910100
01600112012011700128030001300245065000900258064000500267031000300272014000600275
865000900281002000900290035001000299801001300309#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6764.htm#S#c#66#11#article#16#11#^rND^sSutton^nM#^rND^sBouhassira^nEE
#^rND^sNagel^nRL#Polymerase chain reaction amplification applied to the determin
ation of beta-like globin gene cluster haplotypes^len#Am J Hematol#19890000#1989
#32#66-69#20080200#6764.htm#0361-8609#Am J Hematol##
00702000000000337000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100020000750100019000950100
02100114010001700135010001700152010001700169810000600186012009900192030001000291
06500090030106400050031003100030031501400080031886500090032600200090033503500100
0344801001000354#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#c#67#12#ar
ticle#16#12#^rND^sGoncalves^nMS#^rND^sNechtman^nJF#^rND^sFigueiredo^nMS#^rND^sKe
rbauy^nJ#^rND^sArruda^nVR#^rND^sSonati^nMF#et al#Sickle cell disease in a Brazil
ian population from São Paulo: a study of the beta s haplotypes^len#Hum Hered#19
940000#1994#44#322-327#20080200#6764.htm#0001-5652#Hum Hered##
00574000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100017000910100
01800108012005300126030002500179065000900204064000500213031000300218014001000221
865000900231002000900240035001000249801002500259#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6764.htm#S#c#68#13#article#16#13#^rND^sSanger^nF#^rND^sNicklen^nS#^rN
D^sCoulson^nAR#DNA sequencing with chain-terminating inhibitors^len#Proc Natl Ac
ad Sci U S A#19770000#1977#74#5463-5467#20080200#6764.htm#0027-8424#Proc Natl Ac
ad Sci U S A##
00694000000000313000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750100014000930100
01900107010001300126010001800139012015600157030000600313065000900319064000500328
031000300333014001000336865000900346002000900355035001000364801000600374#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#c#69#14#article#16#14#^rND^sLanclo
s^nKD#^rND^sOner^nC#^rND^sDimovski^nAJ#^rND^sGu^nYC#^rND^sHuisman^nTH#Sequence v
ariations in the 5' flanking and IVS-II regions of the G gamma- and A gamma-glob
in genes of beta S chromosomes with five different haplotypes^len#Blood#19910000
#1991#77#2488-2496#20080200#6764.htm#0006-4971#Blood##
00566000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100013000750100020000880120
10500108030004000213710000200253065000900255064000500264031000300269014001000272
865000900282002000900291#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6764.htm#S#c#
70#15#article#16#15#^rND^sLu^nZH#^rND^sSteinberg^nMH#Fetal hemoglobin in sickle 
cell anemia: relation to regulatory sequences cis to the beta-globin gene^len#Mu
lticenter Study of Hydroxyurea. Blood#2#19960000#1996#87#1604-1611#20080200#6764
.htm##
00467000000000229000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720160016000750180095000910660
00600186062001300192065000900205064000500214865000900219002000900228#v41n2#v:\sc
ielo\serial\bjmbr\v41n2\markup\6764.htm#S#c#71#16#article#16#16#^rND^sVerger^nP#
Flux et reflux de la traite des Nègres entre le Golfe de Benin et Bahia de Todos
 os Santos^lfr#Paris#Mouton Press#19680000#1968#20080200#6764.htm##
00267000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00300094#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#o#1#1#article#1#20
080402#165744#6829.htm#82##
02979000000000649000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400110014103500100015222300090016201200950
01710100025002660100025002910100027003160700194003430831466005370850008020030850
01802011085002902029085003002058085002902088085003202117085003102149117000602180
07200030218605800060218906000140219505800050220906000120221405800090222605800060
22350580005022411120009022461110015022551140009022701130017022798810024022960020
00902320#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#h#2#1#article#1#sc
#en#bjmbr#1#3.1#ILUS#07#BJMBR040#nd#Braz J Med Biol Res#41#2#20080200#^f117^l121
#0100-879X#20071220#Antioxidant responses of Laeonereis acuta (Polychaeta) after
 exposure to hydrogen peroxide^len#^rND^1A01^nC.E. da^sRosa#^rND^1A01^nA.^sBianc
hini#^rND^1A01^nJ.M.^sMonserrat#Fundação Universidade Federal do Rio Grande^iA01
^1Programa de Pós-Graduação em Ciências Fisiológicas - Fisiologia Animal Compara
da^2Departamento de Ciências Fisiológicas^cRio Grande^sRS^pBrasil#^len^aThe effe
cts of H2O2 were evaluated in the estuarine worm Laeonereis acuta (Polychaeta, N
ereididae) collected at the Patos Lagoon estuary (Southern Brazil) and maintaine
d in the laboratory under controlled salinity (10 psu diluted seawater) and temp
erature (20°C). The worms were exposed to H2O2 (10 and 50 µM) for 4, 7, and 10 d
ays and the following variables were determined: oxygen consumption, catalase (C
AT) and glutathione peroxidase activity in both the supernatant and pellet fract
ions of whole body homogenates. The concentrations of non-protein sulfhydryl and
 lipid peroxides (LPO) were also measured. The oxygen consumption response was b
iphasic, decreasing after 4 days and increasing after 7 and 10 days of exposure 
to 50 µM H2O2 (P < 0.05). At the same H2O2 concentration, CAT activity was lower
 (P < 0.05) in the pellet fraction of worms exposed for 10 days compared to cont
rol. Non-protein sulfhydryl concentration and glutathione peroxidase activity we
re not affected by H2O2 exposure. After 10 days, LPO levels were higher (P < 0.0
5) in worms exposed to 50 µM H2O2 compared to control. The reduction in the anti
oxidant defense was paralleled by oxidative stress as indicated by higher LPO va
lues (441% compared to control). The reduction of CAT activity in the pellet fra
ction may be related to protein oxidation. These results, taken together with pr
evious findings, suggest that the worms were not able to cope with this H2O2 con
centration.#^dnd^i1#^tm^len^kWorms^i1#^tm^len^kLaeonereis acuta^i1#^tm^len^kHydr
ogen peroxide^i1#^tm^len^kOxidative stress^i1#^tm^len^kAntioxidant enzymes^i1#^t
m^len^kOxygen consumption^i1#other#19#FINEP#23.01.0719.00#CNPq#300536/90-9#PGCF-
FAC#CAPES#CNPq#20070316#March 16, 2007#20071018#October 18, 2007#S0100-879X20060
05000201#6829.htm##
03155000000000637000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400110014103500100015222300090016201201160
01710100025002870100025003120100027003370700194003640831643005580850008022010850
01802209085004302227085003002270085002902300085003202329085003102361117000602392
07200030239805800060240106000140240705800050242106000120242605800090243805800060
2447058000502453112000902458111001502467114000902482113001702491002000902508#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#f#3#1#article#1#sc#en#bjmbr#1#
3.1#ILUS#07#BJMBR040#nd#Braz J Med Biol Res#41#2#20080200#^f117^l121#0100-879X#2
0071220#<b>Antioxidant responses of <i>Laeonereis</i><i> acuta</i> (Polychaeta) 
after exposure to hydrogen peroxide</b>^len#^rND^1A01^nC.E. da^sRosa#^rND^1A01^n
A.^sBianchini#^rND^1A01^nJ.M.^sMonserrat#Fundação Universidade Federal do Rio Gr
ande^iA01^1Programa de Pós-Graduação em Ciências Fisiológicas - Fisiologia Anima
l Comparada^2Departamento de Ciências Fisiológicas^cRio Grande^sRS^pBrasil#^len^
aThe effects of H<sub>2</sub>O<sub>2 </sub>were evaluated in the estuarine worm 
<i>Laeonereis</i><i> acuta</i> (Polychaeta, Nereididae) collected at the Patos L
agoon estuary (Southern Brazil) and maintained in the laboratory under controlle
d salinity (10 psu diluted seawater) and temperature (20°C). The worms were expo
sed to H<sub>2</sub>O<sub>2</sub> (10 and 50 µM) for 4, 7, and 10 days and the f
ollowing variables were determined: oxygen consumption, catalase (CAT) and gluta
thione peroxidase activity in both the supernatant and pellet fractions of whole
 body homogenates. The concentrations of non-protein sulfhydryl and lipid peroxi
des (LPO) were also measured. The oxygen consumption response was biphasic, decr
easing after 4 days and increasing after 7 and 10 days of exposure to 50 µM H<su
b>2</sub>O<sub>2</sub> (P &lt; 0.05). At the same H<sub>2</sub>O<sub>2</sub> con
centration, CAT activity was lower (P &lt; 0.05) in the pellet fraction of worms
 exposed for 10 days compared to control. Non-protein sulfhydryl concentration a
nd glutathione peroxidase activity were not affected by H<sub>2</sub>O<sub>2</su
b> exposure. After 10 days, LPO levels were higher (P &lt; 0.05) in worms expose
d to 50 µM H<sub>2</sub>O<sub>2</sub> compared to control. The reduction in the 
antioxidant defense was paralleled by oxidative stress as indicated by higher LP
O values (441% compared to control). The reduction of CAT activity in the pellet
 fraction may be related to protein oxidation. These results, taken together wit
h previous findings, suggest that the worms were not able to cope with this H<su
b>2</sub>O<sub>2</sub> concentration.#^dnd^i1#^tm^len^kWorms^i1#^tm^len^k<i>Laeo
nereis</i><i> acuta</i>^i1#^tm^len^kHydrogen peroxide^i1#^tm^len^kOxidative stre
ss^i1#^tm^len^kAntioxidant enzymes^i1#^tm^len^kOxygen consumption^i1#other#19#FI
NEP#23.01.0719.00#CNPq#300536/90-9#PGCF-FAC#CAPES#CNPq#20070316#March 16, 2007#2
0071018#October 18, 2007#6829.htm##
03082000000000661000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000300105049000900108158000300117
03000240012003100030014403200020014706500090014901400110015803500100016922300090
01790120095001880100026002830100024003090100027003330700196003600831473005560850
00802029085001802037085002902055085003002084085002902114085003202143085003102175
11700060220607200030221205800060221506000140222105800050223506000120224005800090
22520580006022610580005022671120009022721110015022811140009022961130017023050020
00902322008008902331#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#l#4#1#
article#1#^mFeb.^a2008#sc#en#bjmbr#1#3.1#ilus#07#BJMBR040#nd#Braz. j. med. biol.
 res#41#2#20080200#^f117^l121#0100-879X#20071220#Antioxidant responses of Laeone
reis acuta (Polychaeta) after exposure to hydrogen peroxide^len#^rND^1A01^nC. E.
 da^sRosa#^rND^1A01^nA^sBianchini#^rND^1A01^nJ. M^sMonserrat#^iA01^1Fundação Uni
versidade Federal do Rio Grande^2Programa de Pós-Graduação em Ciências Fisiológi
cas - Fisiologia Animal Comparada^3Departamento de Ciências Fisiológicas^cRio Gr
ande^sRS^pBrasil#^len^aThe effects of H2O2 were evaluated in the estuarine worm 
Laeonereis acuta (Polychaeta, Nereididae) collected at the Patos Lagoon estuary 
(Southern Brazil) and maintained in the laboratory under controlled salinity (10
 psu diluted seawater) and temperature (20°C). The worms were exposed to H2O2 (1
0 and 50 µM) for 4, 7, and 10 days and the following variables were determined: 
oxygen consumption, catalase (CAT) and glutathione peroxidase activity in both t
he supernatant and pellet fractions of whole body homogenates. The concentration
s of non-protein sulfhydryl and lipid peroxides (LPO) were also measured. The ox
ygen consumption response was biphasic, decreasing after 4 days and increasing a
fter 7 and 10 days of exposure to 50 µM H2O2 (P < 0.05). At the same H2O2 concen
tration, CAT activity was lower (P < 0.05) in the pellet fraction of worms expos
ed for 10 days compared to control. Non-protein sulfhydryl concentration and glu
tathione peroxidase activity were not affected by H2O2 exposure. After 10 days, 
LPO levels were higher (P < 0.05) in worms exposed to 50 µM H2O2 compared to con
trol. The reduction in the antioxidant defense was paralleled by oxidative stres
s as indicated by higher LPO values (441 percent compared to control). The reduc
tion of CAT activity in the pellet fraction may be related to protein oxidation.
 These results, taken together with previous findings, suggest that the worms we
re not able to cope with this H2O2 concentration.#^dnd^i1#^tm^len^kWorms^i1#^tm^
len^kLaeonereis acuta^i1#^tm^len^kHydrogen peroxide^i1#^tm^len^kOxidative stress
^i1#^tm^len^kAntioxidant enzymes^i1#^tm^len^kOxygen consumption^i1#other#19#FINE
P#23.01.0719.00#CNPq#300536/90-9#PGCF-FAC#CAPES#CNPq#20070316#March 16, 2007#200
71018#October 18, 2007#6829.htm#Internet^ihttp://www.scielo.br/scielo.php?script
=sci_arttext&pid=S0100-879X2008000200007##
00410000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704018500070002000900255#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#5#1#article#59#<P class="style4"> <A NAM
E="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif">F
ebruary 2008, Volume 41(2) 117-121</font> (Short Communication)</B></P>     ^cY#
6829.htm##
00401000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704017600070002000900246#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#6#2#article#59#<P><font size="5" face="A
rial, Helvetica, sans-serif"><B>Antioxidant responses of <I>Laeonereis acuta</I>
 (Polychaeta) after exposure to hydrogen peroxide </B> </font>     ^cY#6829.htm#
#
00616000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704039100070002000900461#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#7#3#article#59#<P><font face="Arial, Hel
vetica, sans-serif">C.E. da Rosa, A. Bianchini and <span class="style4"><a href=
"#Correspondence"><img src="/img/revistas/bjmbr/v41n2/recor.gif" border="0"></a>
 <a href="mailto:josemmonserrat@pesquisador.cnpq.br"><img src="/img/revistas/bjm
br/v41n2/email-ca.gif" border="0"></a></span></font> <font face="Arial, Helvetic
a, sans-serif">J.M. Monserrat </font>     ^cY#6829.htm##
00536000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704031100070002000900381#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#8#4#article#59#<P><font face="Arial, Hel
vetica, sans-serif">Departamento de Ci&ecirc;ncias Fisiol&oacute;gicas, Programa
 de P&oacute;s-Gradua&ccedil;&atilde;o em Ci&ecirc;ncias Fisiol&oacute;gicas - F
isiologia Animal Comparada, Funda&ccedil;&atilde;o Universidade Federal do Rio G
rande, Rio Grande, RS, Brasil </font>     ^cY#6829.htm##
00464000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704023900070002000900309#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#9#5#article#59#<P class="style4"> <A HRE
F="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=
0 VSPACE=0 HSPACE=0></A>    <A HREF="#Abstract"><strong><font face="Arial, Helve
tica, sans-serif">Abstract</font></strong></A>    ^cY#6829.htm##
00441000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704021500071002000900286#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#10#6#article#59#<BR>   <A HREF="#Text"><
IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0></A>    <A HREF="#Text"><strong><font face="Arial, Helvetica, sans-serif">T
ext</font></strong></A>    ^cY#6829.htm##
00446000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704022000071002000900291#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#11#7#article#59#<BR>   <A HREF="#Referen
ces"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A>    <A HREF="#References"><strong><font face="Arial, Helvetica, s
ans-serif">References</font>    ^cY#6829.htm##
00538000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704031200071002000900383#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#12#8#article#59#<br>   </strong></A> <A 
HREF="#Correspondence"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTO
M BORDER=0 VSPACE=0 HSPACE=0></A>    <A HREF="#Correspondence"><strong><font fac
e="Arial, Helvetica, sans-serif">Correspondence    and Footnotes</font></strong>
</a>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6829.htm##
00616000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704039000071002000900461#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#13#9#article#59#<P class="style4"> <A NA
ME="Abstract"></A><span class="style3"><font color="#00007F" face="Arial, Helvet
ica, sans-serif" size="4"><b>Abstract</b></font><FONT COLOR=#00007F>    </FONT><
/span><A HREF="#Home"><FONT SIZE=4><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.g
if" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P> <font
 face="Arial, Helvetica, sans-serif">     ^cY#6829.htm##
01888000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704166100072002000901733#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#14#10#article#59#<P>The effects of H<SUB
>2</SUB>O<SUB>2 </SUB>were evaluated in the estuarine worm <I>Laeonereis acuta</
I> (Polychaeta, Nereididae) collected at the Patos Lagoon estuary (Southern Braz
il) and maintained in the laboratory under controlled salinity (10 psu diluted s
eawater) and temperature (20&#176;C). The worms were exposed to H<SUB>2</SUB>O<S
UB>2</SUB> (10 and 50 &#181;M) for 4, 7, and 10 days and the following variables
 were determined: oxygen consumption, catalase (CAT) and glutathione peroxidase 
activity in both the supernatant and pellet fractions of whole body homogenates.
 The concentrations of non-protein sulfhydryl and lipid peroxides (LPO) were als
o measured. The oxygen consumption response was biphasic, decreasing after 4 day
s and increasing after 7 and 10 days of exposure to 50 &#181;M H<SUB>2</SUB>O<SU
B>2</SUB> (P &lt; 0.05). At the same H<SUB>2</SUB>O<SUB>2</SUB> concentration, C
AT activity was lower (P &lt; 0.05) in the pellet fraction of worms exposed for 
10 days compared to control. Non-protein sulfhydryl concentration and glutathion
e peroxidase activity were not affected by H<SUB>2</SUB>O<SUB>2</SUB> exposure. 
After 10 days, LPO levels were higher (P &lt; 0.05) in worms exposed to 50 &#181
;M H<SUB>2</SUB>O<SUB>2</SUB> compared to control. The reduction in the antioxid
ant defense was paralleled by oxidative stress as indicated by higher LPO values
 (441% compared to control). The reduction of CAT activity in the pellet fractio
n may be related to protein oxidation. These results, taken together with previo
us findings, suggest that the worms were not able to cope with this H<SUB>2</SUB
>O<SUB>2</SUB> concentration.     ^cY#6829.htm##
00399000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704017200072002000900244#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#15#11#article#59#<P>Key words: Worms; <I
>Laeonereis acuta</I>; Hydrogen peroxide; Oxidative stress; Antioxidant enzymes;
 Oxygen consumption</font> <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6829.htm##
00565000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033800072002000900410#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#16#12#article#59#<P class="style4"><A NA
ME="Text"></A><FONT SIZE=4><B><span class="style3"><font color="#00007F" face="A
rial, Helvetica, sans-serif">Text</font></span>    <a href="#Home"><IMG SRC="/im
g/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0
"></a></B></FONT>  </P> <font face="Arial, Helvetica, sans-serif">     ^cY#6829.
htm##
00899000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704067200072002000900744#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#17#13#article#59#<P>Hydrogen peroxide (H
<SUB>2</SUB>O<SUB>2</SUB>) is a non-radical reactive oxygen species and the most
 stable intermediate in the four-electron reduction of O<SUB>2</SUB> to water. I
n the aquatic environment, H<SUB>2</SUB>O<SUB>2</SUB> predominantly derives from
 UV-driven photoactivation of dissolved organic matter (1). Since H<SUB>2</SUB>O
<SUB>2</SUB> is uncharged, it easily passes through cell membranes by diffusion,
 and when inside the cells it can react with transition metals liberating hydrox
yl radicals (HO<SUP>&#183;</SUP>) (2). At high concentrations, these radicals in
duce peroxidation of lipids and proteins, affecting cell integrity (2,3).</font>
     ^cY#6829.htm##
01139000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704091200072002000900984#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#18#14#article#59#<P><font face="Arial, H
elvetica, sans-serif">Aquatic organisms have to cope with a wide variety of envi
ronmental pro-oxidants, as well as with those produced by normal aerobic metabol
ism, leading to the requirement of efficient antioxidant mechanisms. Aerobic cel
ls have acquired a variety of antioxidant mechanisms, including enzymatic (super
oxide dismutase, catalase (CAT), glutathione peroxidase (GPx)) and non-enzymatic
 (glutathione, carotenoids, <font face="Symbol">a</font>-tocopherol, etc.) defen
ses (4). The existence of antioxidant defenses and oxidative stress generation u
nder exposure to pro-oxidants such as H<SUB>2</SUB>O<SUB>2 </SUB>have been repor
ted in marine organism, with an increase in lipid peroxide (LPO) content (1), in
duction of antioxidant enzymes (CAT, superoxide dismutase) (2) and a reduction i
n oxygen consumption (2,4,5). </font> <font face="Arial, Helvetica, sans-serif">
     ^cY#6829.htm##
00913000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704068600072002000900758#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#19#15#article#59#<P>Since H<SUB>2</SUB>O
<SUB>2 </SUB>is a conspicuous environmental pro-oxidant, the aim of the present 
study was to evaluate the effects of H<SUB>2</SUB>O<SUB>2</SUB> exposure on oxyg
en consumption, on H<SUB>2</SUB>O<SUB>2</SUB> detoxification enzymes in the pell
et and supernatant fractions, non-protein sulfhydryl groups and oxidative damage
 (LPO) of the estuarine worm <I>Laeonereis acuta </I>(Polychaeta, Nereididae). T
he estuarine worm <I>L. acuta </I>has been widely employed in toxicological and 
environmental studies for analysis of their antioxidant and oxidative damage res
ponses to copper, cadmium and cyanobacterium bloom events and in biomonitoring p
rograms (6-9).     ^cY#6829.htm##
00450000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704022300072002000900295#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#20#16#article#59#<P>Specimens of <I>L. a
cuta</I> (60-120 mg) were collected in a salt marsh (&quot;Saco do Justino&quot;
) near Rio Grande city (Southern Brazil, 32&#176; S, 52&#176; W). This site was 
reported to be unpolluted (6).      ^cY#6829.htm##
00697000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704047000072002000900542#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#21#17#article#59#<P>The organisms were m
aintained under laboratory conditions as previously described (10). Briefly, the
 worms were kept individually in glass dishes (6.0 cm in diameter) containing a 
thin sand layer and approximately 100 mL of 10 psu diluted seawater at pH 8.0, 2
0&#176;C. The fixed photoperiod was a 12-h light:12-h dark cycle. During the acc
limation period (5 days) the animals were fed frozen <I>Artemia</I> sp and 100% 
of the water was renewed every 2 days.     ^cY#6829.htm##
00752000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704052500072002000900597#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#22#18#article#59#<P>After the acclimatio
n period the animals were divided into three groups: a control group exposed to 
diluted seawater (salinity = 10 psu; N = 60), and a second (N = 60) and a third 
group (N = 60) receiving diluted seawater (salinity = 10 psu) containing 10 and 
50 &#181;M hydrogen peroxide, respectively. The condition was the same as employ
ed in the acclimation period except for the absence of sand in dishes and for wa
ter renewal, which was done daily. No mortality was recorded during the experime
ntal period.      ^cY#6829.htm##
00459000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704023200072002000900304#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#23#19#article#59#<P>At the end of the ex
posure period of 4, 7, and 10 days, some of the animals (N = 10 per experimental
 group) were used for the oxygen consumption assay and the remaining ones were f
rozen at -70&#176;C for later analyses.      ^cY#6829.htm##
00571000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704034400072002000900416#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#24#20#article#59#<P>For the determinatio
n of oxygen consumption (11) the animals were transferred to 10-mL chambers cont
aining 10 psu diluted seawater, pH 8.0, at 20&#176;C. Oxygen consumption was rec
orded with a manual oximeter (DIGIMED, S&atilde;o Paulo, SP, Brazil). Values are
 reported as mg O<SUB>2</SUB> h<SUP>-1</SUP> g wet weight<SUP>-1</SUP>.      ^cY
#6829.htm##
00971000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704074400072002000900816#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#25#21#article#59#<P>For the enzymatic de
terminations (12), whole animals were homogenized with cold buffer (1:3, v/v) co
ntaining 0.5 M sucrose and 0.15 M NaCl in 20 mM Tris-HCl, pH 7.6. The homogenate
 was centrifuged at 500 <I>g</I> for 15 min at 4&#176;C and the resulting supern
atant was centrifuged at 12,000 <I>g</I> for 30 min at 4&#176;C. The 12,000-<I>g
</I> pellet (peroxisomal and mitochondrial fraction) was resuspended with the ho
mogenization buffer in the same volume as employed for homogenization. Both extr
acts (supernatant of 12,000 <I>g</I> and the resuspended pellet) were used for t
he determination of CAT and GPx activity since CAT activity is expected to occur
 only in the pellet fraction and GPx activity in the cytosolic fraction.     ^cY
#6829.htm##
00989000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704076200072002000900834#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#26#22#article#59#<P>CAT activity was mea
sured as the rate of enzymatic decomposition of H<SUB>2</SUB>O<SUB>2</SUB> monit
ored as a decrease of absorbance at 240 nm (13). Enzyme activity is reported as 
CAT units, with one unit being the amount of enzyme needed to hydrolyze 1 &#181;
mol H<SUB>2</SUB>O<SUB>2</SUB> min<SUP>-1</SUP> mg protein<SUP>-1</SUP> at 30&#1
76;C and pH 8.0. GPx-Se activity (14) was measured as NADPH oxidation measured a
t 340 nm in the presence of excess glutathione reductase, reduced glutathione, H
<SUB>2</SUB>O<SUB>2</SUB>, and aliquots of the homogenate. The results are repor
ted as GPx units, with one unit being the amount of enzyme necessary to oxidize 
1 &#181;mol NADPH min<SUP>-1</SUP> mg protein<SUP>-1</SUP> at 30&#176;C and pH 7
.2.</font>     ^cY#6829.htm##
00838000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704061100072002000900683#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#27#23#article#59#<P><font face="Arial, H
elvetica, sans-serif">For the measurement of non-protein sulfhydryl groups (NP-S
H) (15), tissues were homogenized (1:20) in 20 mM EDTA. NP-SH content was measur
ed after deproteinization with 50% trichloroacetic acid. NP-SH were detected usi
ng 5,5-dithiobis(2-nitrobenzoic acid) and absorbance at 405 nm was determined in
 a microplate reader. The result was divided by the protein concentration of eac
h sample prior to deproteinization and is reported as specific activity, <font f
ace="Symbol">h</font>mol glutathione/mg protein. </font> <font face="Arial, Helv
etica, sans-serif">     ^cY#6829.htm##
00795000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704056800072002000900640#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#28#24#article#59#<P>LPO was measured by 
the Fox method (16) based on Fe<SUP>2+</SUP> oxidation by lipid hydroperoxides (
FOX reactive substances) at acid pH in the presence of the Fe<SUP>3+</SUP>-compl
exing dye xylenol orange. Samples were homogenized (1:9) in 100% cold (4&#176;C)
 methanol. The homogenate was centrifuged at 1000 <I>g</I> for 10 min at 4&#176;
C and the supernatant was collected and used for LPO determination (580 nm). Cum
ene hydroperoxide was employed as standard. The results are reported as <font fa
ce="Symbol">h</font>mol cumene hydroperoxide/g tissue.       ^cY#6829.htm##
00409000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704018200072002000900254#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#29#25#article#59#<P>Significant differen
ces between treatments were assessed by ANOVA in combination with the Newman-Keu
ls <I>a posteriori </I>test, with the level of significance set at 5%.     ^cY#6
829.htm##
02001000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704177400072002000901846#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#30#26#article#59#<P>Several studies have
 demonstrated that when marine invertebrates are exposed    to H<SUB>2</SUB>O<SU
B>2</SUB> the main response observed is an increased activity    of the enzymes 
responsible for the detoxification of H<SUB>2</SUB>O<SUB>2</SUB>,    i.e., CAT a
nd/or GPx. This result was observed in shrimp (2), worms (4) and    mussels (12)
. In contrast, <I>L. acuta</I> did not present antioxidant responses    to H<SUB
>2</SUB>O<SUB>2</SUB> exposure (5). However, the objective of the present    stu
dy was to observe the activity patterns of both enzymes in the pellet and    sup
ernatant fractions, since CAT is a well-known peroxisomal enzyme (3). The    pre
sence of CAT activity in the supernatant fraction would be related to peroxisome
    damage during homogenization (12). Concerning CAT activity, no statistical d
ifference    (P &gt; 0.05) was observed in the supernatant fraction (<a href="#F
ig1"><b>Figure    1</b></a><b><a href="#Fig1">A</a></b>), whereas a lower CAT ac
tivity (P &lt;    0.05) was observed in the pellet fraction of worms exposed to 
50 &#181;M H<SUB>2</SUB>O<SUB>2</SUB>    for 10 days (<b><a href="#Fig1">Figure 
1B</a></b>). The other enzyme that degrades    H<SUB>2</SUB>O<SUB>2</SUB>, GPx, 
was not affected by exposure to this oxidant    either in the supernatant or in 
the pellet fraction (P &gt; 0.05; <a href="#Fig1"><b>Figure    1C</b></a> and <b
><a href="#Fig1">D</a></b>). The other antioxidant mechanism    analyzed, NP-SH 
content, was not affected by H<SUB>2</SUB>O<SUB>2</SUB> exposure    (P &gt; 0.05
). The mean values (&#177; SEM) after 7 days of exposure were 2.5    &#177; 0.5,
 2.1 &#177; 0.7, and 2.5 &#177; 0.3 nmol/mg protein for the control    and 10 an
d 50 &#181;M H<SUB>2</SUB>O<SUB>2</SUB> groups, respectively.      ^cY#6829.htm#
#
00876000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704064900072002000900721#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#31#27#article#59#<P>The absence of the i
nduction of CAT and GPx activity induction does not mean that the animal is vuln
erable to daily variations in H<SUB>2</SUB>O<SUB>2</SUB> concentration in the na
tural environment. It has been demonstrated that this species possesses an alter
native mechanism to deal with environmental H<SUB>2</SUB>O<SUB>2</SUB> since it 
presents a conspicuous mucus secretion that protects its body against environmen
tal H<SUB>2</SUB>O<SUB>2 </SUB>because of high CAT and GPx activities (17). Howe
ver, during the experimental period the dishes containing the animals were clean
ed daily, with the consequent removal of this protection.     ^cY#6829.htm##
00734000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704050700072002000900579#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#32#28#article#59#<P>The absence of the i
nduction of activity of the antioxidant enzymes involved    in H<SUB>2</SUB>O<SU
B>2</SUB> degradation was paralleled by an increase of almost    441% in LPO lev
els after 10 days of exposure to the higher H<SUB>2</SUB>O<SUB>2</SUB>    concen
tration (50 &#181;M; P &lt; 0.05; <a href="#Fig2"><b>Figure 2A</b></a>).    This
 result agrees with the reduction of CAT activity in the pellet fraction    duri
ng the same period, suggesting oxidative damage at the protein level (18).      
^cY#6829.htm##
01010000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704078300072002000900855#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#33#29#article#59#<P>The oxygen consumpti
on response was biphasic, decreasing after 4 days and increasing    after 7 and 
10 days of exposure to 50 &#181;M H<SUB>2</SUB>O<SUB>2</SUB> (P    &lt; 0.05; <a
 href="#Fig2"><b>Figure 2</b></a><b><a href="#Fig2">B</a></b>).    The hehavior 
of the first phase corroborates reports about <I>Nereis diversicolor</I>    expo
sed for 6 h to 5 &#181;M H<SUB>2</SUB>O<SUB>2</SUB> (4), about the isolated    b
ody wall of <I>Arenicola maritma</I> (Polychaeta) exposed to 300 &#181;M H<SUB>2
</SUB>O<SUB>2</SUB>    (1) and about the shrimp <I>Crangon crangon</I> exposed f
or 5 h to 20 &#181;M    H<SUB>2</SUB>O<SUB>2</SUB> (2). This decrease was relate
d to damage to the membrane    transporter mechanisms and to the consequent redu
ction in intracellular pH (2).      ^cY#6829.htm##
00553000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704032600072002000900398#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#34#30#article#59#<P>The second phase res
ponse, to our knowledge, has not been reported in literature and we consider it 
to be a stress response that should increase the generation of reactive oxygen s
pecies (3). This fact plus exposure to H<SUB>2</SUB>O<SUB>2 </SUB>would lead to 
the oxidative damage situation observed at this time.      ^cY#6829.htm##
00808000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704058100072002000900653#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#35#31#article#59#<P>After the period of 
exposure to both concentrations of H<SUB>2</SUB>O<SUB>2</SUB>, morphological alt
erations were observed, similar to these described in the aquatic oligochaeta <I
>Tubifex tubifex</I> after 96-h exposure to copper and lead (19) and in <I>L. ac
uta</I> chronically exposed to copper (6). Worms exposed to H<SUB>2</SUB>O<SUB>2
</SUB> showed coiling and necrosis, particularly in the posterior region of thei
r body, where the cuticle is thinner than the other parts (5), with this region 
being more susceptible to the effects of H<SUB>2</SUB>O<SUB>2</SUB>.      ^cY#68
29.htm##
00970000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704074300072002000900815#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#36#32#article#59#<P>The present study de
monstrates that exposure to higher concentrations of H<SUB>2</SUB>O<SUB>2</SUB> 
causes a significant alteration in the metabolism of <I>L. acuta</I>, as shown b
y the oxygen consumption measurements. It was also demonstrated that its antioxi
dant defense system was not sufficient to deal with H<SUB>2</SUB>O<SUB>2 </SUB>e
xposure, as evidenced by the oxidative damage and necrosis observed. </font> <HR
 ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <tr align="lef
t" valign="top">     <td width="15%"><a href="/img/revistas/bjmbr/v41n2/html/682
9i01.htm"><img src="/img/revistas/bjmbr/v41n2/6829i01peq.jpg" border="2"></a></t
d>     <td width="85%"><font face="Arial, Helvetica, sans-serif">           ^cY#
6829.htm##
00801000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704057400072002000900646#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#37#33#article#59#<P><a name="Fig1"></a>F
igure 1. Catalase (CAT) activity (in units, U) in the supernatant (A) and pellet
 (B) fraction of <I>Laeonereis acuta</I> homogenates after exposure to 0 (contro
l), 10, or 50 &#181;M hydrogen peroxide. Glutathione peroxidase (GPx) activity (
in units, U) in the supernatant (C) and pellet (D) fraction of <I>L. acuta</I> h
omogenates after exposure to 0 (control), 10, or 50 &#181;M hydrogen peroxide. D
ata are reported as means &#177; SD for N = 5-9. *P &lt; 0.05 compared to contro
l (ANOVA and Newman-Keuls test).</font></td>   </tr> </table>      ^cY#6829.htm#
#
00615000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038800072002000900460#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#38#34#article#59#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (48 K JPG file)]</font>
   <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">   <tr ali
gn="left" valign="top">     <td width="15%"><a href="/img/revistas/bjmbr/v41n2/h
tml/6829i02.htm"><img src="/img/revistas/bjmbr/v41n2/6829i02peq.jpg" border="2">
</a></td>     <td width="85%">           ^cY#6829.htm##
00990000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704076300072002000900835#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#39#35#article#59#<p><font face="Arial, H
elvetica, sans-serif"><a name="Fig2"></a>Figure 2.          <I>A</I>, Lipid pero
xide (LPO) content of <I>Laeonereis acuta</I> after          exposure to 0 (cont
rol), 10, or 50 &#181;M hydrogen peroxide. Units of          LPO are in terms of
 cumene hydroperoxide (CHP) equivalents per gram wet          weight (w/w). <I>B
</I>, Oxygen consumption of <I>L. acuta</I> after exposure          to 0 (contro
l), 10, or 50 &#181;M hydrogen peroxide. Units of oxygen consumption          ar
e reported as mg O<SUB>2</SUB> h<SUP>-1</SUP> g wet weight<SUP>-1</SUP>         
 (w/w). Data are reported as means &#177; SEM for N = 4-8. *P &lt; 0.05         
 compared to control (ANOVA and Newman-Keuls test). </font></p>     </td>   </tr
> </table>      ^cY#6829.htm##
00374000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704014700072002000900219#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#40#36#article#59#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (31 K JPG file)]</font>
  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6829.htm##
00577000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704035000072002000900422#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#41#37#article#59#<P class="style4"> <A N
AME="References"></A><FONT color="#00007F" SIZE=4><B><font face="Arial, Helvetic
a, sans-serif">References</font></B></FONT>    <A HREF="#Home"><FONT SIZE=4><B><
IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0 LOOP="0"></B></FONT></A>  </P> <font face="Arial, Helvetica, sans-serif">  
   ^cY#6829.htm##
00490000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024900074002000900323#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#42#38#article#59#1#<P>1. Sto
rch D, Abele D, Portner HO. The effect of hydrogen peroxide on isolated body wal
l of the lugworm <I>Arenicola marina</I> (L.) at different extracellular pH leve
ls. <I>Comp Biochem Physiol C Toxicol Pharmacol</I> 2001; 128: 391-399.     ^cY#
6829.htm##
00475000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704023400074002000900308#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#43#39#article#59#2#<P>2. Abe
le-Oeschger D, Sartoris FJ, P&ouml;rtner HO. Hydrogen peroxide causes a decrease
 in aerobic metabolic rate and in intracellular pH in the shrimp <I>Crangon cran
gon</I>. <I>Comp Biochem Physiol</I> 1997; 117: 123-129.     ^cY#6829.htm##
00369000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704012800074002000900202#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#44#40#article#59#3#<P>3. Hal
liwel B, Gutteridge JM. <I>Free radicals in biology and medicine</I>. New York: 
Oxford University Press; 1998.     ^cY#6829.htm##
00481000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024000074002000900314#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#45#41#article#59#4#<P>4. Buc
hner T, Abele-Oeschger D, Theede H. Biochemical adaptations of <I>Nereis diversi
color</I> (Polychaeta) to temporarily increased hydrogen peroxide levels in inte
rtidal sandflats. <I>Mar Ecol Prog Ser</I> 1994; 106: 101-110.     ^cY#6829.htm#
#
00495000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704025400074002000900328#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#46#42#article#59#5#<P>5. da 
Rosa CE, Iurman MG, Abreu PC, Geracitano LA, Monserrat JM. Antioxidant mechanism
s of the Nereidid <I>Laeonereis acuta</I> (Anelida: Polychaeta) to cope with env
ironmental hydrogen peroxide. <I>Physiol Biochem Zool</I> 2005; 78: 641-649.    
 ^cY#6829.htm##
00501000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704026000074002000900334#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#47#43#article#59#6#<P>6. Ger
acitano LA, Bocchetti R, Monserrat JM, Regoli F, Bianchini A. Oxidative stress r
esponses in two populations of <I>Laeonereis acuta</I> (Polychaeta, Nereididae) 
after acute and chronic exposure to copper. <I>Mar Environ Res</I> 2004; 58: 1-1
7.     ^cY#6829.htm##
00495000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704025400074002000900328#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#48#44#article#59#7#<P>7. da 
Rosa CE, de Souza MS, Yunes JS, Proenca LA, Nery LE, Monserrat JM. Cyanobacteria
l blooms in estuarine ecosystems: characteristics and effects on <I>Laeonereis a
cuta</I> (Polychaeta, Nereididae). <I>Mar Pollut Bull</I> 2005; 50: 956-964.    
 ^cY#6829.htm##
00564000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704032300074002000900397#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#49#45#article#59#8#<P>8. San
drini JZ, Laurino J, Hatanaka T, Monserrat JM. cDNA cloning and expression analy
sis of the catalytic subunit of glutamate cysteine ligase gene in an annelid pol
ychaete after cadmium exposure: a potential tool for pollution biomonitoring. <I
>Comp Biochem Physiol C Toxicol Pharmacol</I> 2006; 143: 410-415.     ^cY#6829.h
tm##
00536000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704029500074002000900369#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#50#46#article#59#9#<P>9. Fer
reira-Cravo M, Piedras FR, Moraes TB, Ferreira JL, de Freitas DP, Machado MD, et
 al. Antioxidant responses and reactive oxygen species generation in different b
ody regions of the estuarine polychaeta <I>Laeonereis acuta</I> (Nereididae). <I
>Chemosphere</I> 2007; 66: 1367-1374.     ^cY#6829.htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024300075002000900318#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#51#47#article#59#10#<P>10. G
eracitano L, Monserrat JM, Bianchini A. Physiological and antioxidant enzyme res
ponses to acute and chronic exposure of <I>Laeonereis acuta</I> (Polychaeta, Ner
eididae) to copper. <I>J Exp Mar Biol Ecol</I> 2002; 277: 145-156.     ^cY#6829.
htm##
00443000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020100075002000900276#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#52#48#article#59#11#<P>11. N
ithart M, Alliot E, Salen-Picard C. Production, respiration and ammonia excretio
n of two polychaete species in a north Norfolk saltmarsh. <I>J Mar Biol Ass U K<
/I> 1999; 79: 1029-1037.     ^cY#6829.htm##
00555000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704031300075002000900388#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#53#49#article#59#12#<P>12. C
avaletto M, Ghezzi A, Burlando B, Evangelisti V, Ceratto N, Viarengo A. Effect o
f hydrogen peroxide on antioxidant enzymes and metallothionein level in the dige
stive gland of <I>Mytilus galloprovincialis</I>. cavalett@unipmn.it. <I>Comp Bio
chem Physiol C Toxicol Pharmacol</I> 2002; 131: 447-455.     ^cY#6829.htm##
00445000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020300075002000900278#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#54#50#article#59#13#<P>13. B
eutler E. The preparation of red cells for assay. In: Beutler E (Editor), <I>Red
 cell metabolism: a manual of biochemical methods</I>. New York: Grune &amp; Str
aton Editor; 1975. p 8-18.     ^cY#6829.htm##
00432000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019000075002000900265#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#55#51#article#59#14#<P>14. A
run S, Subramanian P. Antioxidant enzymes in freshwater prawn <I>Macrobrachium m
alcolmsonni</I> during embryonic development. <I>Comp Biochem Physiol</I> 1998; 
121: 273-277.     ^cY#6829.htm##
00420000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017800075002000900253#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#56#52#article#59#15#<P>15. S
edlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydr
yl groups in tissue with Ellman's reagent. <I>Anal Biochem</I> 1968; 25: 192-205
.     ^cY#6829.htm##
00448000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020600075002000900281#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#57#53#article#59#16#<P>16. H
ermes-Lima M, Willmore WG, Storey KB. Quantification of lipid peroxidation in ti
ssue extracts based on Fe(III)xylenol orange complex formation. <I>Free Radic Bi
ol Med</I> 1995; 19: 271-280.     ^cY#6829.htm##
00548000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704030600075002000900381#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#58#54#article#59#17#<P>17. M
oraes TB, Ferreira JL, da Rosa CE, Sandrini JZ, Votto AP, Trindade GS, et al. An
tioxidant properties of the mucus secreted by <I>Laeonereis acuta</I> (Polychaet
a, Nereididae): a defense against environmental pro-oxidants? <I>Comp Biochem Ph
ysiol C Toxicol Pharmacol</I> 2006; 142: 293-300.     ^cY#6829.htm##
00357000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704011500075002000900190#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#59#55#article#59#18#<P>18. K
ono Y, Fridovich I. Superoxide radical inhibits catalase. <I>J Biol Chem</I> 198
2; 257: 5751-5754.     ^cY#6829.htm##
00524000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028200075002000900357#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#p#60#56#article#59#19#<P>19. L
ucan-Bouch&eacute; ML, Biagianti-Risbourg S, Arsac F, Vernet G. An original deco
ntamination process developed by the aquatic oligochaete <I>Tubifex tubifex</I> 
exposed to copper and lead. <I>Aquat Toxicol</I> 1999; 45: 9-17.</font> <HR ALIG
N=LEFT WIDTH=100% SIZE=2>     ^cY#6829.htm##
00553000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704032600072002000900398#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#61#57#article#59#<P class="style4"><A NA
ME="Correspondence"></A><FONT color="#00007F" SIZE=4><B><font face="Arial, Helve
tica, sans-serif">Correspondence    and Footnotes</font></B></FONT> <A HREF="#Ho
me"><FONT SIZE=4><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM B
ORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></P>     ^cY#6829.htm##
00878000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704065100072002000900723#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#62#58#article#59#<P class="style4"><B><a
 href="#Home"><img src="/img/revistas/bjmbr/v41n2/recor.gif" border="0"></a> Add
ress for correspondence: </B><font face="Arial, Helvetica, sans-serif">J.M. Mons
errat, Departamento de Ci&ecirc;ncias Fisiol&oacute;gicas, Programa de P&oacute;
s-gradua&ccedil;&atilde;o em Ci&ecirc;ncias Fisiol&oacute;gicas - Fisiologia Ani
mal Comparada, Funda&ccedil;&atilde;o Universidade Federal do Rio Grande, A. It&
aacute;lia, km 8, Campus Carreiros, 96201-900 Rio Grande, RS, Brasil. Fax: +55-5
3-3233-8680. E-mail: <a href="mailto:josemmonserrat@pesquisador.cnpq.br"><strong
>josemmonserrat@pesquisador.cnpq.br</strong></a></font></P>     ^cY#6829.htm##
00557000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033000072002000900402#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6829.htm#S#p#63#59#article#59#<P><font face="Arial, H
elvetica, sans-serif">Research supported by FINEP (No. 23.01.0719.00), CNPq (No.
 300536/90-9), and PGCF-FAC. C.E. da Rosa was the recipient of a CAPES fellowshi
p. J.M. Monserrat and A. Bianchini are recipients of CNPq research fellowships. 
Received March 16, 2007. Accepted October 18, 2007.</font>     ^cY#6829.htm##
00619000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100015000890100
01800104012013200122030004100254710000200295065000900297064000500306031000400311
014000800315865000900323002000900332#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
829.htm#S#c#64#1#article#19#1#^rND^sStorch^nD#^rND^sAbele^nD#^rND^sPortner^nHO#T
he effect of hydrogen peroxide on isolated body wall of the lugworm Arenicola ma
rina (L.) at different extracellular pH levels^len#Comp Biochem Physiol C Toxico
l Pharmacol#2#20010000#2001#128#391-399#20080200#6829.htm##
00640000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100024000730100019000970100
01800116012012000134030002100254065000900275064000500284031000400289014000800293
865000900301002000900310035001000319801002100329#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6829.htm#S#c#65#2#article#19#2#^rND^sAbele-Oeschger^nD#^rND^sSartoris
^nFJ#^rND^sPörtner^nHO#Hydrogen peroxide causes a decrease in aerobic metabolic 
rate and in intracellular pH in the shrimp Crangon crangon^len#Comp Biochem Phys
iol#19970000#1997#117#123-129#20080200#6829.htm#0010-406X#Comp Biochem Physiol##
00461000000000241000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710160018000730160021000910180
04200112066000900154062002400163065000900187064000500196865000900201002000900210
#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#c#66#3#article#19#3#^rND^s
Halliwel^nB#^rND^sGutteridge^nJM#Free radicals in biology and medicine^len#New Y
ork#Oxford University Press#19980000#1998#20080200#6829.htm##
00610000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100024000900100
01600114012013800130030001800268710000200286065000900288064000500297031000400302
014000800306865000900314002000900323#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
829.htm#S#c#67#4#article#19#4#^rND^sBuchner^nT#^rND^sAbele-Oeschger^nD#^rND^sThe
ede^nH#Biochemical adaptations of Nereis diversicolor (Polychaeta) to temporaril
y increased hydrogen peroxide levels in intertidal sandflats^len#Mar Ecol Prog S
er#2#19940000#1994#106#101-110#20080200#6829.htm##
00660000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100017000910100
01600108010002100124010002000145012012700165030002100292710000200313065000900315
064000500324031000300329014000800332865000900340002000900349#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6829.htm#S#c#68#5#article#19#5#^rND^sda^nRosa CE#^rND^sIu
rman^nMG#^rND^sAbreu^nPC#^rND^sGeracitano^nLA#^rND^sMonserrat^nJM#Antioxidant me
chanisms of the Nereidid Laeonereis acuta (Anelida: Polychaeta) to cope with env
ironmental hydrogen peroxide^len#Physiol Biochem Zool#2#20050000#2005#78#641-649
#20080200#6829.htm##
00666000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100021000730100019000940100
02000113010001600133010001900149012013800168030001600306710000200322065000900324
064000500333031000300338014000500341865000900346002000900355#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6829.htm#S#c#69#6#article#19#6#^rND^sGeracitano^nLA#^rND^
sBocchetti^nR#^rND^sMonserrat^nJM#^rND^sRegoli^nF#^rND^sBianchini^nA#Oxidative s
tress responses in two populations of Laeonereis acuta (Polychaeta, Nereididae) 
after acute and chronic exposure to copper^len#Mar Environ Res#2#20040000#2004#5
8#1-17#20080200#6829.htm##
00714000000000325000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100019000910100
01600110010001800126010001500144010002000159012012400179030001600303065000900319
06400050032803100030033301400080033686500090034400200090035303500100036280100160
0372#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#c#70#7#article#19#7#^r
ND^sda^nRosa CE#^rND^sde^nSouza MS#^rND^sYunes^nJS#^rND^sProenca^nLA#^rND^sNery^
nLE#^rND^sMonserrat^nJM#Cyanobacterial blooms in estuarine ecosystems: character
istics and effects on Laeonereis acuta (Polychaeta, Nereididae)^len#Mar Pollut B
ull#20050000#2005#50#956-964#20080200#6829.htm#0025-326X#Mar Pollut Bull##
00718000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100019000730100017000920100
01800109010002000127012019400147030004100341710000200382065000900384064000500393
031000400398014000800402865000900410002000900419#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6829.htm#S#c#71#8#article#19#8#^rND^sSandrini^nJZ#^rND^sLaurino^nJ#^r
ND^sHatanaka^nT#^rND^sMonserrat^nJM#cDNA cloning and expression analysis of the 
catalytic subunit of glutamate cysteine ligase gene in an annelid polychaete aft
er cadmium exposure: a potential tool for pollution biomonitoring^len#Comp Bioch
em Physiol C Toxicol Pharmacol#2#20060000#2006#143#410-415#20080200#6829.htm##
00762000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100024000730100018000970100
01700115010001900132010002100151010001800172810000600190012014900196030001200345
06500090035706400050036603100030037101400100037486500090038400200090039303500100
0402801001200412#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#c#72#9#art
icle#19#9#^rND^sFerreira-Cravo^nM#^rND^sPiedras^nFR#^rND^sMoraes^nTB#^rND^sFerre
ira^nJL#^rND^sde^nFreitas DP#^rND^sMachado^nMD#et al#Antioxidant responses and r
eactive oxygen species generation in different body regions of the estuarine pol
ychaeta Laeonereis acuta (Nereididae)^len#Chemosphere#20070000#2007#66#1367-1374
#20080200#6829.htm#0045-6535#CHEMOSPHERE##
00614000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100020000750100020000950100
01900115012013600134030002000270710000200290065000900292064000500301031000400306
014000800310865000900318002000900327#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
829.htm#S#c#73#10#article#19#10#^rND^sGeracitano^nL#^rND^sMonserrat^nJM#^rND^sBi
anchini^nA#Physiological and antioxidant enzyme responses to acute and chronic e
xposure of Laeonereis acuta (Polychaeta, Nereididae) to copper^len#J Exp Mar Bio
l Ecol#2#20020000#2002#277#145-156#20080200#6829.htm##
00579000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100016000920100
02200108012010500130030001900235710000200254065000900256064000500265031000300270
014001000273865000900283002000900292#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
829.htm#S#c#74#11#article#19#11#^rND^sNithart^nM#^rND^sAlliot^nE#^rND^sSalen-Pic
ard^nC#Production, respiration and ammonia excretion of two polychaete species i
n a north Norfolk saltmarsh^len#J Mar Biol Ass U K#2#19990000#1999#79#1029-1037#
20080200#6829.htm##
00739000000000313000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750100016000940100
01800110010002100128010001700149010001800166012015000184030004500334710000200379
065000900381064000500390031000400395014000800399865000900407002000900416#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#c#75#12#article#19#12#^rND^sCavale
tto^nM#^rND^sGhezzi^nA#^rND^sBurlando^nB#^rND^sEvangelisti^nV#^rND^sCeratto^nN#^
rND^sViarengo^nA#Effect of hydrogen peroxide on antioxidant enzymes and metallot
hionein level in the digestive gland of Mytilus galloprovincialis: cavalett@unip
mn^len#it. Comp Biochem Physiol C Toxicol Pharmacol#2#20020000#2002#131#447-455#
20080200#6829.htm##
00544000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750120043000920160
01700135018005700152066000900209062002300218065000900241064000500250014000500255
865000900260002000900269#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#c#
76#13#article#19#13#^rND^sBeutler^nE#The preparation of red cells for assay^len#
^rND^sBeutler^nE#Red cell metabolism: a manual of biochemical methods^len#New Yo
rk#Grune & Straton Editor#19750000#1975#8-18#20080200#6829.htm##
00584000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100014000750100021000890120
10000110030002100210065000900231064000500240031000400245014000800249865000900257
002000900266035001000275801002100285#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
829.htm#S#c#77#14#article#19#14#^rND^sArun^nS#^rND^sSubramanian^nP#Antioxidant e
nzymes in freshwater prawn Macrobrachium malcolmsonni during embryonic developme
nt^len#Comp Biochem Physiol#19980000#1998#121#273-277#20080200#6829.htm#0010-406
X#Comp Biochem Physiol##
00571000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100018000910120
10500109030001300214065000900227064000500236031000300241014000800244865000900252
002000900261035001000270801001300280#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
829.htm#S#c#78#15#article#19#15#^rND^sSedlak^nJ#^rND^sLindsay^nRH#Estimation of 
total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's r
eagent^len#Anal Biochem#19680000#1968#25#192-205#20080200#6829.htm#0003-2697#Ana
l Biochem##
00624000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100021000750100019000960100
01700115012010900132030002000241065000900261064000500270031000300275014000800278
865000900286002000900295035001000304801002000314#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6829.htm#S#c#79#16#article#19#16#^rND^sHermes-Lima^nM#^rND^sWillmore^
nWG#^rND^sStorey^nKB#Quantification of lipid peroxidation in tissue extracts bas
ed on Fe(III)xylenol orange complex formation^len#Free Radic Biol Med#19950000#1
995#19#271-280#20080200#6829.htm#0891-5849#Free Radic Biol Med##
00743000000000325000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100019000920100
01800111010001900129010001600148010001900164810000600183012014100189030004100330
71000020037106500090037306400050038203100040038701400080039186500090039900200090
0408#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6829.htm#S#c#80#17#article#19#17#
^rND^sMoraes^nTB#^rND^sFerreira^nJL#^rND^sda^nRosa CE#^rND^sSandrini^nJZ#^rND^sV
otto^nAP#^rND^sTrindade^nGS#et al#Antioxidant properties of the mucus secreted b
y Laeonereis acuta (Polychaeta, Nereididae): a defense against environmental pro
-oxidants?^len#Comp Biochem Physiol C Toxicol Pharmacol#2#20060000#2006#142#293-
300#20080200#6829.htm##
00507000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100014000750100019000890120
04100108030001200149065000900161064000500170031000400175014001000179865000900189
002000900198035001000207801001200217#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
829.htm#S#c#81#18#article#19#18#^rND^sKono^nY#^rND^sFridovich^nI#Superoxide radi
cal inhibits catalase^len#J Biol Chem#19820000#1982#257#5751-5754#20080200#6829.
htm#0021-9258#J Biol Chem##
00623000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100023000750100028000980100
01500126010001600141012012000157030001400277710000200291065000900293064000500302
031000300307014000500310865000900315002000900324#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6829.htm#S#c#82#19#article#19#19#^rND^sLucan-Bouché^nML#^rND^sBiagian
ti-Risbourg^nS#^rND^sArsac^nF#^rND^sVernet^nG#An original decontamination proces
s developed by the aquatic oligochaete Tubifex tubifex exposed to copper and lea
d^len#Aquat Toxicol#2#19990000#1999#45#9-17#20080200#6829.htm##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#o#1#1#article#1#20
080402#165746#6849.htm#104##
02634000000000517000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400110014103500100015201201050016201000220
02670100024002890100024003130700110003370831474004470850008019210850019019290850
04501948085002601993085003002019117000602049072000302055112000902058111001402067
114000902081113001702090002000902107#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
849.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#14#BJMBR080#nd#Braz J Med Biol 
Res#41#2#20080200#^f170^l175#0100-879X#Role of nitric oxide and prostaglandin in
 the maintenance of cortical and renal medullary blood flow^len#^rND^1A01^nS.I^s
Gomez#^rND^1A01^nD.M.^sStrick#^rND^1A01^nJ.C.^sRomero#Mayo Clinic College of Med
icine^iA01^1Department of Physiology and Biomedical Engineering^cRochester^sMN^p
USA#^len^aThis study was undertaken in anesthetized dogs to evaluate the relativ
e participation of prostaglandins (PGs) and nitric oxide (NO) in the maintenance
 of total renal blood flow (TRBF), and renal medullary blood flow (RMBF). It was
 hypothesized that the inhibition of NO should impair cortical and medullary cir
culation because of the synthesis of this compound in the endothelial cells of t
hese two territories. In contrast, under normal conditions of perfusion pressure
 PG synthesis is confined to the renal medulla. Hence PG inhibition should predo
minantly impair the medullary circulation. The initial administration of 25 µM k
g-1 min-1 NG-nitro-L-arginine methyl ester produced a significant 26% decrease i
n TRBF and a concomitant 34% fall in RMBF, while the subsequent inhibition of PG
s with 5 mg/kg meclofenamate further reduced TRBF by 33% and RMBF by 89%. In con
trast, the initial administration of meclofenamate failed to change TRBF, while 
decreasing RMBF by 49%. The subsequent blockade of NO decreased TRBF by 35% with
out further altering RMBF. These results indicate that initial PG synthesis inhi
bition predominantly alters the medullary circulation, whereas NO inhibition dec
reases both cortical and medullary flow. This latter change induced by NO render
s cortical and RMBF susceptible to a further decrease by PG inhibition. However,
 the decrease in medullary circulation produced by NO inhibition is not further 
enhanced by subsequent PG inhibition.#^dnd^i1#^tm^len^kKidney^i1#^tm^len^kNG-nit
ro-L-arginine methyl ester^i1#^tm^len^kMeclofenamate^i1#^tm^len^kRenal circulati
on^i1#other#25#20070402#April 2, 2007#20071030#October 30, 2007#6849.htm##
02663000000000517000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400110014103500100015201201120016201000220
02740100024002960100024003200700110003440831496004540850008019500850019019580850
04501977085002602022085003002048117000602078072000302084112000902087111001402096
114000902110113001702119002000902136#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
849.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#14#BJMBR080#nd#Braz J Med Biol 
Res#41#2#20080200#^f170^l175#0100-879X#<b>Role of nitric oxide and prostaglandin
 in the maintenance of cortical and renal medullary blood flow</b>^len#^rND^1A01
^nS.I^sGomez#^rND^1A01^nD.M.^sStrick#^rND^1A01^nJ.C.^sRomero#Mayo Clinic College
 of Medicine^iA01^1Department of Physiology and Biomedical Engineering^cRocheste
r^sMN^pUSA#^len^aThis study was undertaken in anesthetized dogs to evaluate the 
relative participation of prostaglandins (PGs) and nitric oxide (NO) in the main
tenance of total renal blood flow (TRBF), and renal medullary blood flow (RMBF).
 It was hypothesized that the inhibition of NO should impair cortical and medull
ary circulation because of the synthesis of this compound in the endothelial cel
ls of these two territories. In contrast, under normal conditions of perfusion p
ressure PG synthesis is confined to the renal medulla. Hence PG inhibition shoul
d predominantly impair the medullary circulation. The initial administration of 
25 µM kg<sup>-1</sup> min<sup>-1</sup> NG-nitro-L-arginine methyl ester produced
 a significant 26% decrease in TRBF and a concomitant 34% fall in RMBF, while th
e subsequent inhibition of PGs with 5 mg/kg meclofenamate further reduced TRBF b
y 33% and RMBF by 89%. In contrast, the initial administration of meclofenamate 
failed to change TRBF, while decreasing RMBF by 49%. The subsequent blockade of 
NO decreased TRBF by 35% without further altering RMBF. These results indicate t
hat initial PG synthesis inhibition predominantly alters the medullary circulati
on, whereas NO inhibition decreases both cortical and medullary flow. This latte
r change induced by NO renders cortical and RMBF susceptible to a further decrea
se by PG inhibition. However, the decrease in medullary circulation produced by 
NO inhibition is not further enhanced by subsequent PG inhibition.#^dnd^i1#^tm^l
en^kKidney^i1#^tm^len^kNG-nitro-L-arginine methyl ester^i1#^tm^len^kMeclofenamat
e^i1#^tm^len^kRenal circulation^i1#other#25#20070402#April 2, 2007#20071030#Octo
ber 30, 2007#6849.htm##
02809000000000541000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000300105049000900108158000300117
03000240012003100030014403200020014706500090014901400110015803500100016901201050
01790100023002840100024003070100024003310700112003550831516004670850008019830850
01901991085004502010085002602055085003002081117000602111072000302117112000902120
111001402129114000902143113001702152002000902169008008902178#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6849.htm#S#l#4#1#article#1#^mFeb.^a2008#oa#en#bjmbr#1#3.1
#ilus#14#BJMBR080#nd#Braz. j. med. biol. res#41#2#20080200#^f170^l175#0100-879X#
Role of nitric oxide and prostaglandin in the maintenance of cortical and renal 
medullary blood flow^len#^rND^1A01^nS. I^sGomez#^rND^1A01^nD. M^sStrick#^rND^1A0
1^nJ. C^sRomero#^iA01^1Mayo Clinic College of Medicine^2Department of Physiology
 and Biomedical Engineering^cRochester^sMN^pUSA#^len^aThis study was undertaken 
in anesthetized dogs to evaluate the relative participation of prostaglandins (P
Gs) and nitric oxide (NO) in the maintenance of total renal blood flow (TRBF), a
nd renal medullary blood flow (RMBF). It was hypothesized that the inhibition of
 NO should impair cortical and medullary circulation because of the synthesis of
 this compound in the endothelial cells of these two territories. In contrast, u
nder normal conditions of perfusion pressure PG synthesis is confined to the ren
al medulla. Hence PG inhibition should predominantly impair the medullary circul
ation. The initial administration of 25 µM kg-1 min-1 NG-nitro-L-arginine methyl
 ester produced a significant 26 percent decrease in TRBF and a concomitant 34 p
ercent fall in RMBF, while the subsequent inhibition of PGs with 5 mg/kg meclofe
namate further reduced TRBF by 33 percent and RMBF by 89 percent. In contrast, t
he initial administration of meclofenamate failed to change TRBF, while decreasi
ng RMBF by 49 percent. The subsequent blockade of NO decreased TRBF by 35 percen
t without further altering RMBF. These results indicate that initial PG synthesi
s inhibition predominantly alters the medullary circulation, whereas NO inhibiti
on decreases both cortical and medullary flow. This latter change induced by NO 
renders cortical and RMBF susceptible to a further decrease by PG inhibition. Ho
wever, the decrease in medullary circulation produced by NO inhibition is not fu
rther enhanced by subsequent PG inhibition.#^dnd^i1#^tm^len^kKidney^i1#^tm^len^k
NG-nitro-L-arginine methyl ester^i1#^tm^len^kMeclofenamate^i1#^tm^len^kRenal cir
culation^i1#other#25#20070402#April 2, 2007#20071030#October 30, 2007#6849.htm#I
nternet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X200800
0200014##
00375000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704015000070002000900220#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#5#1#article#75#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, February 2008, V
olume 41(2) 170-175</B> </font></P>      ^cY#6849.htm##
00406000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704018100070002000900251#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#6#2#article#75#<P><font size="5" face="A
rial, Helvetica, sans-serif"><B>Role of nitric oxide and prostaglandin in the ma
intenance of cortical and renal medullary blood flow </B> </font>       ^cY#6849
.htm##
00527000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704030200070002000900372#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#7#3#article#75#<P><font face="Arial, Hel
vetica, sans-serif">S.I. Gomez, D.M. Strick and <b><a href="#Correspondence"><im
g src="/img/revistas/bjmbr/v41n2/recor.gif" border="0"></a></b> <a href="mailto:
romero.juan@mayo.edu"><img src="/img/revistas/bjmbr/v41n2/email-ca.gif" border="
0"></a> J.C. Romero </font>      ^cY#6849.htm##
00392000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704016700070002000900237#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#8#4#article#75#<P><font face="Arial, Hel
vetica, sans-serif">Department of Physiology and Biomedical Engineering, Mayo Cl
inic College of Medicine, Rochester, MN, USA</font>       ^cY#6849.htm##
00415000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704019000070002000900260#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#9#5#article#75#<P> <font face="Arial, He
lvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n2/dow
n.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>   
 ^cY#6849.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#10#6#article#75#<BR>   <A HREF="#Introdu
ction"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#6849.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#11#7#article#75#<BR>   <A HREF="#Materia
l"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    ^
cY#6849.htm##
00398000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704017200071002000900243#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#12#8#article#75#<BR>   <A HREF="#Results
"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 H
SPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#6849.htm##
00407000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018100071002000900252#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#13#9#article#75#<BR>   <A HREF="#Discuss
ion"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#684
9.htm##
00395000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704016800072002000900240#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#14#10#article#75#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#6849.htm##
00461000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704023400072002000900306#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#15#11#article#75#<br>   </strong></A>   
<A HREF="#Correspondence"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspon
dence and Footnotes</strong></A>  </font>      ^cY#6849.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004800072002000900120#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#16#12#article#75#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>      ^cY#6849.htm##
00537000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031000072002000900382#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#17#13#article#75#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  <font
 face="Arial, Helvetica, sans-serif">      ^cY#6849.htm##
01735000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704150800072002000901580#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#18#14#article#75#<P>This study was under
taken in anesthetized dogs to evaluate the relative participation of prostagland
ins (PGs) and nitric oxide (NO) in the maintenance of total renal blood flow (TR
BF), and renal medullary blood flow (RMBF). It was hypothesized that the inhibit
ion of NO should impair cortical and medullary circulation because of the synthe
sis of this compound in the endothelial cells of these two territories. In contr
ast, under normal conditions of perfusion pressure PG synthesis is confined to t
he renal medulla. Hence PG inhibition should predominantly impair the medullary 
circulation. The initial administration of 25 &#181;M kg<SUP>-1</SUP> min<SUP>-1
</SUP> NG-nitro-L-arginine methyl ester produced a significant 26% decrease in T
RBF and a concomitant 34% fall in RMBF, while the subsequent inhibition of PGs w
ith 5 mg/kg meclofenamate further reduced TRBF by 33% and RMBF by 89%. In contra
st, the initial administration of meclofenamate failed to change TRBF, while dec
reasing RMBF by 49%. The subsequent blockade of NO decreased TRBF by 35% without
 further altering RMBF. These results indicate that initial PG synthesis inhibit
ion predominantly alters the medullary circulation, whereas NO inhibition decrea
ses both cortical and medullary flow. This latter change induced by NO renders c
ortical and RMBF susceptible to a further decrease by PG inhibition. However, th
e decrease in medullary circulation produced by NO inhibition is not further enh
anced by subsequent PG inhibition.       ^cY#6849.htm##
00369000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704014200072002000900214#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#19#15#article#75#<P>Key words: Kidney; N
G-nitro-L-arginine methyl ester; Meclofenamate; Renal circulation  </font>  <HR 
ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6849.htm##
00593000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036600072002000900438#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#20#16#article#75#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>    <font face="Arial, Helvetica,
 sans-serif">      ^cY#6849.htm##
01530000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704130300072002000901375#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#21#17#article#75#<P>The relative role of
 naturally occurring vasodilators in the renal circulation has remained largely 
ill defined. However, identification of their mechanism of action is of critical
 importance to understand how the kidney influences the equilibrium of body flui
ds and blood pressure (1-4). Of particular interest are the effects of prostagla
ndins (PGs) and nitric oxide (NO), both of which exhibit a high rate of synthesi
s in the renal medulla (5-7) and in the renal vascular endothelium (8). In fact 
there are observations showing that the blockade of NO produces, in the rat, a d
ecrease in medullary circulation which leads with time to excessive sodium reten
tion and a sustained increase in blood pressure (9,10). Similarly, an increase i
n diastolic blood pressure has been observed in humans after prolonged blockade 
of PG synthesis with indomethacin (11). In spite of this, no study has been cond
ucted to determine the specific changes occurring in cortical and medullary bloo
d flow when NO and PGs (or vice versa) are inhibited in succession. This approac
h implies the definition not only of the initial effect produced by the inhibiti
on of the synthesis of each of these substances, but also the determination of h
ow the inhibition of one substance affects the response to the other.       ^cY#
6849.htm##
01015000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704078800072002000900860#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#22#18#article#75#<P>The present study wa
s undertaken to answer these questions. Total renal blood flow (TRBF) was measur
ed with an electromagnetic flow meter (12) while renal medullary blood flow (RMB
F) was continuously measured using a laser Doppler flow probe (12). Two basic ex
perimental protocols were used. In the first, flow determinations were made unde
r basal control conditions, as well as after the blockade of NO and PG synthesis
 with NG-nitro-L-arginine methyl ester (L-NAME) and meclofenamate (MECLO), respe
ctively. In the second, the order of PG and NO inhibition was reversed. The rela
tive effectiveness of L-NAME and MECLO in blocking the production of NO and PGs 
was evaluated by measuring the vasodilator response to bradykinin (BK).  </font>
  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6849.htm##
00595000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036800072002000900440#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#23#19#article#75#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Mat
erial and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>  <font face="Arial, Helvetic
a, sans-serif">      ^cY#6849.htm##
01438000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704121100072002000901283#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#24#20#article#75#<P>Experiments were per
formed on 14 male mongrel dogs (body weight 16-23 kg) maintained on a standard l
aboratory diet with free access to water. The animals were fasted the evening be
fore the surgery. On the morning of the experiments, the dogs were anesthetized 
with sodium pentobarbital (30 mg/kg) and ventilated mechanically with a Harvard 
respirator (South Natick, MA, USA) at a tidal volume appropriate for body weight
 based on the nomogram of Kleinman and Radford Jr. (13). A catheter was inserted
 into a femoral artery and advanced into the aorta to a position just below the 
renal arteries for measurement of renal perfusion pressure (RPP) using a Statham
 P23ID pressure transducer (Viggo-Spectramed, Oxnard, CA, USA), and for collecti
on of peripheral arterial blood samples. A femoral vein was cannulated for conti
nuous infusions of 0.9% saline. The volume of saline infused into the animals by
 the time the experiments were started (~60 mL) was sufficient to replace any bl
ood lost during surgery and to render the animals euvolemic. In addition, sodium
 pentobarbital (~4 mg kg<SUP>-1</SUP> h<SUP>-1</SUP>) was infused to maintain a 
constant plane of anesthesia throughout the experiments.        ^cY#6849.htm##
01892000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704166500072002000901737#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#25#21#article#75#<P>The left kidney was 
exposed through a flank incision and the dogs were then suspended in a metal fra
me that mimicked their usual standing position. A non-cannulating electromagneti
c flow probe (Carolina Medical Electronics, King, NC, USA) of suitable diameter 
was placed on the renal artery at its origin from the aorta for the measurement 
of total renal blood flow. A zero flow baseline signal for the probe was establi
shed at the beginning of each experiment and was checked at the conclusion of ea
ch protocol by occluding the renal artery distal to the probe with a snare made 
of a silk ligature enclosed in polyethylene tubing. A curved 23-gauge needle att
ached to polyethylene tubing and connected to a syringe pump (Harvard model 944)
 was inserted into the renal artery for continuous infusion of 0.9% saline, BK, 
or L-NAME at a rate of 1 mL/min. The kidney was then further prepared for measur
ement of RMBF by creating a cortical window in an alcohol-injected region of the
 kidney using an He-Ne-CO<SUB>2</SUB> beam surgical laser and placing a multiple
 optical fiber flow probe (model PF 315:72; Perimed, Inc., Stockholm, Sweden) co
nnected to a Perimed PF laser Doppler flowmeter directly on the medulla near the
 renal crest. This procedure has been published in detail elsewhere (12). Zero f
low baseline laser Doppler signals were determined at the beginning of each expe
riment by occluding the renal artery for several seconds. After completion of th
e surgical procedure, a 1-h stabilization period was allowed to elapse before st
arting the experiments. The Doppler flowmeter signal was conventionally normaliz
ed to 100% for every experiment.      ^cY#6849.htm##
00257000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704003000072002000900102#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#26#22#article#75#<P><B>Protocol 1</B>   
   ^cY#6849.htm##
02001000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704177400072002000901846#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#27#23#article#75#<P>Baseline RPP, TRBF, 
and RMBF values were recorded. The intrarenal infusion of saline was then replac
ed with an infusion of BK (4 pM kg<SUP>-1</SUP> min<SUP>-1</SUP>; 1 mL/min) whic
h was continued for 10 min. Results of preliminary studies from our laboratory h
ave shown that the administration of BK in this manner consistently produced pea
k increases in TRBF and associated increases in RMBF within 1-2 min after the be
ginning of infusion. Both parameters then declined toward a steady-state level o
ver the remainder of the infusion. The responses to BK were recorded during the 
peak (1-2 min) and during the steady-state condition (10 min). After 10 min, BK 
infusion was stopped and a 30-min recovery period was allowed. Following the rec
overy period, an intrarenal infusion of L-NAME (25 &#181;M kg<SUP>-1</SUP> min<S
UP>-1</SUP>), an inhibitor of NO synthesis, was started and 20 min were allowed 
for renal parameters to stabilize. The administration of L-NAME was continued an
d a simultaneous intrarenal infusion of BK was started. Both infusions were cont
inued for 10 min before being stopped and replaced with saline. Another 30-min r
ecovery period was allowed before an intravenous bolus injection of 5 mg/kg MECL
O, an inhibitor of PG synthesis, was administered. Forty minutes were allowed fo
r the intrarenal effects of the drug to become manifest before a final intrarena
l BK infusion was begun. RPP, TRBF, and RMBF were recorded immediately before, a
nd 20 and 40 min after the administration of L-NAME and MECLO, respectively. The
 latter values were recorded immediately before the BK infusions and thus were a
lso the baseline values for the subsequent BK responses. The peak and 10-min res
ponses of these parameters to BK infusion were also recorded.      ^cY#6849.htm#
#
00258000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704003100072002000900103#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#28#24#article#75#<P><B>Protocol 2 </B>  
    ^cY#6849.htm##
01009000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704078200072002000900854#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#29#25#article#75#<P>This protocol was id
entical to the first, except that the order of L-NAME and MECLO administration w
as reversed. BK was initially infused intrarenally for 10 min to determine TRBF 
and RMBF responses. Thirty minutes after the end of the BK infusion, an intraven
ous bolus of MECLO (5 mg/kg) was administered and 40 min were allowed for parame
ters to stabilize. Another identical BK infusion was administered a second time 
for 10 min. After the end of BK infusion, a 30-min recovery period was allowed b
efore an intrarenal infusion of L-NAME was started. Twenty minutes after initiat
ing the administration of L-NAME, a simultaneous infusion of BK was started and 
both infusions were continued for an additional 10 min. RPP, TRBF, and RMBF were
 recorded as described above.      ^cY#6849.htm##
00515000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704028800072002000900360#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#30#26#article#75#<P>At the end of each e
xperiment, the left kidney was removed, sectioned along the lines of tissue infa
rction caused by alcohol injection, and weighed to determine the weights of perf
used and non-perfused tissue (12). TRBF was then normalized per gram of perfused
 kidney weight.      ^cY#6849.htm##
00267000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004000072002000900112#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#31#27#article#75#<P><B>Statistical analy
ses</B>      ^cY#6849.htm##
00575000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704034800072002000900420#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#32#28#article#75#<P>Data are reported as
 means &#177; SEM. RPP, TRBF, and RMBF data were compared by repeated-measures a
nalysis of variance, followed by Newman-Keuls tests when a significant <I>F</I> 
value was calculated (14,15). All statistical analyses were considered to be sig
nificant if P<I> &lt; </I>0.05.  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     
 ^cY#6849.htm##
00537000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031000072002000900382#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#33#29#article#75#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF
="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0 
VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6849.htm##
00626000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704039900072002000900471#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#34#30#article#75#<P><font face="Arial, H
elvetica, sans-serif">It should first be observed that in <a href="#Fig1">Figure
s 1</a> and <a href="#Fig2">2</a> the baseline values of RPP, TRBF, and RMBF wer
e conventionally adjusted to 100%. This allows one to depict the alterations ind
uced by any of the inhibitors of PGs or NO or by the rapid infusion of BK as the
 percent change of control values. </font></P>      ^cY#6849.htm##
01945000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704171800072002000901790#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#35#31#article#75#<P><font face="Arial, H
elvetica, sans-serif">It can be seen in <a href="#Fig1">Figure 1</a> that the co
ntrol levels of TRBF were significantly increased (P &lt; 0.05) by the intrarena
l infusion of BK from 3.6 &#177; 0.5 to 4.7 &#177; 0.7 mL g<SUP>-1</SUP> min<SUP
>-1</SUP>. BK failed to produce any significant change in either RMBF (from 411.
4 &#177; 69 to 431.4 &#177; 80 conventional units) or in RPP (from 128 &#177; 3.
5 to 124 &#177; 3.2 mmHg). Thirty minutes later, the inhibition of NO with L-NAM
E resulted in a significant fall in TRBF from 3.28 &#177; 0.4 to 2.40 &#177; 0.3
 mL g<SUP>-1</SUP> min<SUP>-1</SUP>. Similarly, L-NAME induced a significant dec
rease in RMBF from 327 &#177; 68 to 215 &#177; 46 conventional units. However, L
-NAME produced a mild but significant increase (P &lt; 0.05) in RPP from 126 &#1
77; 5 to 133 &#177; 4 mmHg. None of these changes produced by L-NAME in TRBF or 
RMBF did affect the vasodilator response to BK, which significantly increased TR
BF (P &lt; 0.05) from 2.4 &#177; 0.3 to 3.4 &#177; 5 mL g<SUP>-1</SUP> min<SUP>-
1</SUP>. Similarly, RMBF increased from 215 &#177; 46 to 351 &#177; 65 mL g<SUP>
-1</SUP> min<SUP>-1</SUP>. These changes in TRBF and RMBF represent an increase 
of 41 and 63%, respectively, over preinfusion values. Under these conditions, th
e inhibition of PGs by the intrarenal infusion of MECLO produced a further decre
ase in both TRBF (from 2.3 &#177; 0.3 to 1.56 &#177; 3 mL g<SUP>-1</SUP> min<SUP
>-1</SUP>) and RMBF (from 185 &#177; 42 to 20 &#177; 6 conventional units). Furt
hermore, <a href="#Fig1">Figure 1</a> shows that, after MECLO, the administratio
n of BK failed to induce any significant increase in either TRBF or RMBF. </font
></P>      ^cY#6849.htm##
02052000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704182500072002000901897#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#36#32#article#75#<P><font face="Arial, H
elvetica, sans-serif"><a href="#Fig2">Figure 2</a> shows the same parameters as 
those illustrated in <a href="#Fig1">Figure 1</a>, except that the order of the 
inhibitors administered was reversed (i.e., MECLO was given before L-NAME). Dose
s and routes of administration were the same used in <a href="#Fig1">Figure 1</a
>. Infusion of BK alone in this group of dogs significantly increased (P &lt; 0.
001) RMBF from 211.1 &#177; 27 to 261 &#177; 39 conventional units and TRBF from
 3.6 &#177; 0.6 to 5.6 &#177; 7.1 above baseline. However, BK failed to alter RP
P (from 126 &#177; 3 to 125 &#177; 3 mmHg). Administration of MECLO had no signi
ficant effect on TRBF (from 4.3 &#177; 1 to 4.6 &#177; 0.5 mL g<SUP>-1</SUP> min
<SUP>-1</SUP>) but significantly decreased RMBF from 169 &#177; 26 to 81 &#177; 
26 conventional units. Intrarenal infusion of BK during inhibition of PG synthes
is did not alter significantly TRBF but it did change RMBF from 81 &#177; 26 to 
201 &#177; 34 conventional units (P &lt; 0.01). Inhibition of intrarenal NO synt
hesis by L-NAME during continued PG synthesis blockade had no further effect on 
RMBF (69.3 &#177; 26 to 35 &#177; 10 conventional units) but decreased TRBF sign
ificantly by 35% (4.5 &#177; 0.6 to 2.9 &#177; 0.8 mL g<SUP>-1</SUP> min<SUP>-1<
/SUP>). BK infusion after L-NAME administration did not significantly alter TRBF
 (3.7 &#177; 0.8 to 3.2 &#177; 0.7 mL g<SUP>-1</SUP> min<SUP>-1</SUP>) or RMBF (
69 &#177; 26 to 35.5 &#177; 10 conventional units). RPP was increased slightly b
y the administration of L-NAME after MECLO (126 &#177; 4 to 141 &#177; 5 mmHg). 
Plasma hematocrit averaged 50 &#177; 2%. Total kidney weight averaged 31 &#177; 
2 g and the average weight of the perfused kidney sections after alcohol infusio
n was 18 &#177; 1 g. </font></P>      ^cY#6849.htm##
00512000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704028500072002000900357#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#37#33#article#75#<P>    <HR ALIGN=LEFT W
IDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr align="left" valign="
top">      <td width="13%"><a href="/img/revistas/bjmbr/v41n2/html/6849i01.htm">
<img src="/img/revistas/bjmbr/v41n2/6849i01peq.jpg" border="2"></a></td>      <t
d width="87%">    ^cY#6849.htm##
00866000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704063900072002000900711#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#38#34#article#75#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig1"></a>Figure 1. The response of renal perfusi
on pressure (RPP), total renal blood flow (TRBF), and renal medullary blood flow
 (RMBF) to intrarenal infusion of bradykinin (BK; 4 pM kg<SUP>-1</SUP> min<SUP>-
1</SUP>; 1 mL/min) followed by the sequential intrarenal infusion of 25 &#181;M 
kg<SUP>-1</SUP> min<SUP>-1</SUP> NG-nitro-L-arginine methyl ester (L-NAME) and t
hen an intravenous bolus injection of meclofenamate (MECLO; 5 mg/kg). *P &lt; 0.
05 compared to pre-inhibitor baseline recorded immediately before the injection 
(ANOVA). </font>      </td>    </tr>  </table>      ^cY#6849.htm##
00621000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704039400072002000900466#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#39#35#article#75#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (51 K JPG file)]</font>
</P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr
 align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v4
1n2/html/6849i02.htm"><img src="/img/revistas/bjmbr/v41n2/6849i02peq.jpg" border
="2"></a></td>      <td width="87%">           ^cY#6849.htm##
00929000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704070200072002000900774#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#40#36#article#75#<p><font face="Arial, H
elvetica, sans-serif"><a name="Fig2"></a>Figure 2.          The response of rena
l perfusion pressure (RPP), total renal blood flow          (TRBF), and renal me
dullary blood flow (RMBF) to intrarenal infusion of          bradykinin (BK; 4 p
M kg<SUP>-1</SUP> min<SUP>-1</SUP>; 1 mL/min) followed          by the sequentia
l intravenous bolus injection of meclofenamate (MECLO;          5 mg/kg) and the
n intrarenal infusion of 25 &#181;M kg<SUP>-1</SUP> min<SUP>-1</SUP>          NG
-nitro-L-arginine methyl ester (L-NAME). *P &lt; 0.05 compared to pre-inhibitor 
         baseline recorded immediately before the injection (ANOVA). </font></p>
     </td>    </tr>  </table>      ^cY#6849.htm##
00344000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704011700072002000900189#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#41#37#article#75#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (47 K JPG file)]</font>
</P>      ^cY#6849.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004800072002000900120#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#42#38#article#75#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>      ^cY#6849.htm##
00541000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031400072002000900386#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#43#39#article#75#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  <
font face="Arial, Helvetica, sans-serif">      ^cY#6849.htm##
01684000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704145700072002000901529#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#44#40#article#75#<P>There is, at present
, a well accepted notion that PGs (9,10) and NO (5,16,17) play an important role
 in the regulation of TRBF. In fact, previous studies have shown that the blocka
de of either NO or PG is followed by a decrease in TRBF and impairment in urine 
sodium excretion both under basal conditions (5,6) and during pressure- induced 
natriuresis (6,7,18). However, the specific effect of the inhibition of each of 
these substances when compared under similar conditions or under conditions wher
e one of them had been previously abolished has never been tested. This prompted
 us to perform the present study in which we assessed the relative significance 
of NO and PG in the maintenance of both RMBF and TRBF under resting conditions a
nd after the consecutive inhibition of PGs and/or NO. The results confirmed our 
assumption that the inhibition of NO synthesis with the administration of L-NAME
 produced a significant decrease of both TRBF by 26%, and RMBF by 34%. In contra
st, the initial inhibition of PG synthesis with indomethacin induced a significa
nt 49% fall in RMBF without altering TRBF. It was also observed that the initial
 effects of each of these inhibitors were altered when given after the response 
of the other had been produced. The results also showed that the initial effect 
of each of these inhibitors, L-NAME or MECLO, was altered when one inhibitor was
 administered after the response to the other had been obtained.      ^cY#6849.h
tm##
02240000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704201300072002000902085#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#45#41#article#75#<P>To a large extent, t
he primary and secondary effects of PG and NO inhibition can be understood on th
e basis of previous experimental findings showing that the efficacy of renal vas
odilators in modulating renal, and particularly medullary, circulation is mainly
 determined by the level of RPP (5,19,20). Fenoy et al. (21), in agreement with 
our observation, observed that the administration of L-NAME to rats failed to pr
oduce significant changes in RMBF in kidneys perfused at normal levels of RPP. H
owever, the inhibition of NO synthesis in kidneys perfused at higher RPP (140 mm
Hg) was followed by significant decreases in medullary blood flow. The authors i
nterpreted these results as indicating that renal NO synthesis at high levels of
 perfusion pressure is largely responsible for maintaining medullary vasodilatat
ion. Since in anesthetized normal dogs basal blood pressure (125 &#177; 5 mmHg) 
is slightly elevated when compared to non-anesthetized normotensive dogs (110 &#
177; 5), we thought that this might predispose the kidney to be more responsive 
to inhibition of NO synthesis. In fact, the initial NO synthesis inhibition at a
 perfusion pressure of 125 &#177; 5 mmHg was followed by a significant decrease 
in TRBF as well as RMBF. In contrast to the effects observed after the blockade 
of NO synthesis, the inhibition of PG synthesis is followed by a marked reductio
n of renal blood flow when perfused at low, but not at high RPP levels (5,7,16,1
9). This is in agreement with our results showing that PG inhibition did not alt
er TRBF. However, it produced a significant decrease of RMBF even under normal p
erfusion pressure. This suggests that PG synthesis is important to maintain RMBF
 under normal conditions. It should be emphasized that the specific effect of PG
 inhibition at different levels of pressure on RMBF has not been studied, althou
gh it has been well established that PGs have a protective effect on the renal c
irculation during a decrease in perfusion pressure (5,7,11).      ^cY#6849.htm##
01187000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704096000072002000901032#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#46#42#article#75#<P>In the present study
, the efficacy of L-NAME and MECLO in inhibiting NO and PGs was assessed by the 
decrease caused by this inhibitor in the endothelium-dependent vasodilator effec
ts of BK. In this respect, BK was used according to the characteristics shown by
 previous studies, i.e., that the simultaneous stimulation of PG and NO synthesi
s produced by any endothelium-dependent vasodilator is not altered when only one
 of these substances (i.e., NO or PG) is inhibited (22). In the present study, w
e confirmed this characteristic, since the vasodilator response to BK was increa
sed after the blockade of either PG or NO, but these responses were abolished af
ter both NO and PG synthesis was inhibited. Mean arterial pressure (MAP) was not
 altered by any of the surgical procedures performed on the kidney or by the int
rarenal infusion of BK. This latter observation indicates that the actions of BK
 were mainly limited to the renal vasculature.       ^cY#6849.htm##
00468000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704024100072002000900313#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#47#43#article#75#<P>The reason why the b
lockade of one vasodilator compensates for the actions of the other is not known
, nor is it known why there are circumstances in which the inhibition of NO or P
Gs enhances the vasodilator effect of the other.      ^cY#6849.htm##
01148000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704092100072002000900993#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#48#44#article#75#<P>The findings of this
 study conducted on anesthetized dogs with the systematic inhibition of PGs or N
O can be summarized as follows: 1) NO inhibition produced a systematic decrease 
of cortical circulation when performed before or after PG inhibition; 2) convers
ely, PG inhibition produced a systematic decrease in medullary circulation when 
performed before or after NO inhibition; 3) NO inhibition decreased medullary ci
rculation only when NO was given before MECLO, and 4) PG inhibition affected cor
tical blood flow only when given after NO inhibition. All of these observations 
indicate that NO has a consistent influence on the cortical circulation, whereas
 PG exhibits a predominant effect on the medullary circulation. Conversely, it w
ould appear that the effects of PG on the cortical circulation and of NO on the 
medullary circulation became noticeable after the other vasodilator had been inh
ibited.       ^cY#6849.htm##
01948000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704172100072002000901793#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#49#45#article#75#<P>It should be mention
ed that preservation of renal medullary circulation appears to be important, not
 only to maintain the ability of the kidney to concentrate urine, but also to pr
eserve sodium balance and thereby to maintain blood pressure (9,10,22). Furtherm
ore, in some animal species such as the rat, significant elevations of systemic 
blood pressure have been obtained after selective NO inhibition in the renal med
ulla (10). These effects are not as evident when PG synthesis is inhibited. Our 
study does not allow us to draw further conclusions on these issues because a) t
he changes induced by PG or NO synthesis inhibitors were acutely limited to a sh
ort period of time (40 min), and b) the homeostasis of the renal medullary circu
lation in the dog may differ significantly from that of the rat (18). In the rat
, changes in RPP above 75-80 mmHg are accompanied by good cortical autoregulatio
n, while autoregulatory responses in the medulla are conspicuously absent (23). 
However, in the dog, Majid et al. (18) observed that the medullary circulation e
xhibits an autoregulatory response that does not differ from that observed in th
e cortical vasculature. Similarly, Strick et al. (12) reported a similar finding
 in the dog, except that the autoregulatory response of the renal medulla was no
t as efficient as in the cortex in the lower range of autoregulation. Furthermor
e, investigations on intrarenal blood flow redistribution with electron beam com
puterized tomography have shown in the dog that increments of RPP within the ran
ge of autoregulation are accompanied by some redistribution of blood perfusion b
etween the outer and inner medullary zone without altering overall medullary flo
w (24).       ^cY#6849.htm##
00877000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704065000072002000900722#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#50#46#article#75#<P>The significance of 
PGs in the maintenance of the medullary circulation should be further explored. 
In normotensive humans, chronic inhibition of PGs leads to decrements in plasma 
renin activity, hypoaldosteronism, and a sustained increase in diastolic pressur
e (11). There is also evidence showing that, in the rat, inhibition of NO produc
es a sustained decrease in medullary blood flow and hypertension. Bergstr&ouml;m
 and Evans (25) have suggested that differences in medullary function and their 
importance for the maintenance of blood pressure may vary widely in different an
imal species.  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6849.htm##
00543000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031600072002000900388#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#51#47#article#75#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6849.htm##
00502000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704026100074002000900335#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#52#48#article#75#1#<P><font 
face="Arial, Helvetica, sans-serif">1. Stein JH, Ferris TF, Huprich JE, Smith TC
, Osgood RW. Effect of renal vasodilatation on the distribution of cortical bloo
d flow in the kidney of the dog. <I>J Clin Invest</I> 1971; 50: 1429-1438. </fon
t>      ^cY#6849.htm##
00453000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021200074002000900286#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#53#49#article#75#2#<P><font 
face="Arial, Helvetica, sans-serif">2. Hardaker WT Jr, Wechsler AS. Redistributi
on of renal intracortical blood flow during dopamine infusion in dogs. <I>Circ R
es</I> 1973; 33: 437-444. </font>      ^cY#6849.htm##
00562000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704032100074002000900395#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#54#50#article#75#3#<P><font 
face="Arial, Helvetica, sans-serif">3. Riley RJ. Effects of acute changes in ren
al cortical blood flow distribution on renal function in dogs. In: Wesson CG, Fi
nelli GM Jr (Editors), <I>Recent advances in renal physiology and pharmacology</
I>. Baltimore: University Park Press; 1974. p 149-163. </font>      ^cY#6849.htm
##
00448000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704020700074002000900281#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#55#51#article#75#4#<P><font 
face="Arial, Helvetica, sans-serif">4. Zou AP, Cowley AW Jr. Nitric oxide in ren
al cortex and medulla. An <I>in vivo</I> microdialysis study. <I>Hypertension</I
> 1997; 29: 194-198. </font>      ^cY#6849.htm##
00427000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704018600074002000900260#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#56#52#article#75#5#<P><font 
face="Arial, Helvetica, sans-serif">5. Dunn MJ, Zambraski EJ. Renal effects of d
rugs that inhibit prostaglandin synthesis. <I>Kidney Int</I> 1980; 18: 609-622. 
</font>      ^cY#6849.htm##
00504000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704026300074002000900337#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#57#53#article#75#6#<P><font 
face="Arial, Helvetica, sans-serif">6. Romero JC, Knox FG. Mechanisms underlying
 pressure-related natriuresis: the role of the renin-angiotensin and prostagland
in systems. State of the art lecture. <I>Hypertension</I> 1988; 11: 724-738. </f
ont>      ^cY#6849.htm##
00494000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704025300074002000900327#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#58#54#article#75#7#<P><font 
face="Arial, Helvetica, sans-serif">7. Romero JC, Bentley MD, Vanhoutte PM, Knox
 FG. Intrarenal mechanisms that regulate sodium excretion in relationship to cha
nges in blood pressure. <I>Mayo Clin Proc</I> 1989; 64: 1406-1424. </font>      
^cY#6849.htm##
00474000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704023300074002000900307#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#59#55#article#75#8#<P><font 
face="Arial, Helvetica, sans-serif">8. Romero JC, Lahera V, Salom MG, Biondi ML.
 Role of the endothelium-dependent relaxing factor nitric oxide on renal functio
n. <I>J Am Soc Nephrol</I> 1992; 2: 1371-1387. </font>      ^cY#6849.htm##
00455000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021400074002000900288#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#60#56#article#75#9#<P><font 
face="Arial, Helvetica, sans-serif">9. Cowley AW, Roman RJ, Fenoy FJ, Mattson DL
. Effect of renal medullary circulation on arterial pressure. <I>J Hypertens Sup
pl</I> 1992; 10: S187-S193. </font>      ^cY#6849.htm##
00456000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021400075002000900289#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#61#57#article#75#10#<P><font
 face="Arial, Helvetica, sans-serif">10. Mattson DL, Roman RJ, Cowley AW Jr. Rol
e of nitric oxide in renal papillary blood flow and sodium excretion. <I>Hyperte
nsion</I> 1992; 19: 766-769. </font>      ^cY#6849.htm##
00492000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025000075002000900325#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#62#58#article#75#11#<P><font
 face="Arial, Helvetica, sans-serif">11. Ruilope LM, Garcia RR, Paya C, Alcazar 
JM, Miravalles E, Sancho-Rof J, et al. Effects of long-term treatment with indom
ethacin on renal function. <I>Hypertension</I> 1986; 8: 677-684. </font>      ^c
Y#6849.htm##
00473000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023100075002000900306#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#63#59#article#75#12#<P><font
 face="Arial, Helvetica, sans-serif">12. Strick DM, Fiksen-Olsen MJ, Lockhart JC
, Roman RJ, Romero JC. Direct measurement of renal medullary blood flow in the d
og. <I>Am J Physiol</I> 1994; 267: R253-R259. </font>      ^cY#6849.htm##
00418000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017600075002000900251#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#64#60#article#75#13#<P><font
 face="Arial, Helvetica, sans-serif">13. Kleinman LI, Radford EP Jr. Ventilation
 standards for small mammals. <I>J Appl Physiol</I> 1964; 19: 360-362. </font>  
    ^cY#6849.htm##
00406000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704016400075002000900239#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#65#61#article#75#14#<P><font
 face="Arial, Helvetica, sans-serif">14. Bruning JL, Kinz BL. <I>Computational h
andbook of statistics</I>. Glenview: Scott-Foresman; 1977. </font>      ^cY#6849
.htm##
00387000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704014500075002000900220#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#66#62#article#75#15#<P><font
 face="Arial, Helvetica, sans-serif">15. Zar JH. <I>Biostatistical analysis</I>.
 Englewood Cliffs: Prentice Hall; 1974. </font>      ^cY#6849.htm##
00486000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024400075002000900319#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#67#63#article#75#16#<P><font
 face="Arial, Helvetica, sans-serif">16. Donker AJ, Arisz L, Brentjens JR, van d
er Hem GK, Hollemans HJ. The effect of indomethacin on kidney function and plasm
a renin activity in man. <I>Nephron</I> 1976; 17: 288-296. </font>      ^cY#6849
.htm##
00477000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023500075002000900310#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#68#64#article#75#17#<P><font
 face="Arial, Helvetica, sans-serif">17. Blasingham MC, Nasjletti A. Differentia
l renal effects of cyclooxygenase inhibition in sodium-replete and sodium-depriv
ed dog. <I>Am J Physiol</I> 1980; 239: F360-F365. </font>      ^cY#6849.htm##
00441000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019900075002000900274#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#69#65#article#75#18#<P><font
 face="Arial, Helvetica, sans-serif">18. Majid DS, Godfrey M, Navar LG. Pressure
 natriuresis and renal medullary blood flow in dogs. <I>Hypertension</I> 1997; 2
9: 1051-1057. </font>      ^cY#6849.htm##
00437000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019500075002000900270#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#70#66#article#75#19#<P><font
 face="Arial, Helvetica, sans-serif">19. Clive DM, Stoff JS. Renal syndromes ass
ociated with nonsteroidal antiinflammatory drugs. <I>N Engl J Med</I> 1984; 310:
 563-572. </font>      ^cY#6849.htm##
00466000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022400075002000900299#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#71#67#article#75#20#<P><font
 face="Arial, Helvetica, sans-serif">20. Schnermann J, Briggs JP. Participation 
of renal cortical prostaglandins in the regulation of glomerular filtration rate
. <I>Kidney Int</I> 1981; 19: 802-815. </font>      ^cY#6849.htm##
00467000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022500075002000900300#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#72#68#article#75#21#<P><font
 face="Arial, Helvetica, sans-serif">21. Fenoy FJ, Ferrer P, Carbonell L, Garcia
-Salom M. Role of nitric oxide on papillary blood flow and pressure natriuresis.
 <I>Hypertension</I> 1995; 25: 408-414. </font>      ^cY#6849.htm##
00484000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024200075002000900317#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#73#69#article#75#22#<P><font
 face="Arial, Helvetica, sans-serif">22. Salom MG, Lahera V, Romero JC. Role of 
prostaglandins and endothelium-derived relaxing factor on the renal response to 
acetylcholine. <I>Am J Physiol</I> 1991; 260: F145-F149. </font>      ^cY#6849.h
tm##
00455000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021300075002000900288#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#74#70#article#75#23#<P><font
 face="Arial, Helvetica, sans-serif">23. Roman RJ. Pressure-diuresis in volume-e
xpanded rats. Tubular reabsorption in superficial and deep nephrons. <I>Hyperten
sion</I> 1988; 12: 177-183. </font>      ^cY#6849.htm##
00511000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026900075002000900344#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#75#71#article#75#24#<P><font
 face="Arial, Helvetica, sans-serif">24. Lerman LO, Bentley MD, Fiksen-Olsen MJ,
 Strick DM, Ritman EL, Romero JC. Pressure dependency of canine intrarenal blood
 flow within the range of autoregulation. <I>Am J Physiol</I> 1995; 268: F404-F4
09. </font>      ^cY#6849.htm##
00487000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024500075002000900320#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#p#76#72#article#75#25#<P><font
 face="Arial, Helvetica, sans-serif">25. Bergstrom G, Evans RG. Mechanisms under
lying the antihypertensive functions of the renal medulla. <I>Acta Physiol Scand
</I> 2004; 181: 475-486. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#684
9.htm##
00563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033600072002000900408#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#77#73#article#75#<P><FONT SIZE=4 face="A
rial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F><B
>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, Helv
etica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.g
if" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6849.ht
m##
00585000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704035800072002000900430#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#78#74#article#75#<p><font face="Arial, H
elvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v41n2/rec
or.gif" border="0"></a> Address for correspondence:</b>  J.C. Romero, Mayo Clini
c, Stabile 7, 200 First Street SW, Rochester, MN 55905, USA. Fax: +1-507-266-931
6. E-mail: <a href="mailto:romero.juan@mayo.edu">romero.juan@mayo.edu</a></font>
 </p>      ^cY#6849.htm##
00436000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704020900072002000900281#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6849.htm#S#p#79#75#article#75#<P><font face="Arial, H
elvetica, sans-serif">Research supported by National Institutes of Health, grant
 HL16496, and by the Mayo Foundation. Received April 2, 2007. Accepted October 3
0, 2007. </font>      ^cY#6849.htm##
00657000000000313000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100017000890100
01800106010001600124010001700140012010300157030001400260065000900274064000500283
031000300288014001000291865000900301002000900310035001000319801001400329#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#c#80#1#article#25#1#^rND^sStein^nJ
H#^rND^sFerris^nTF#^rND^sHuprich^nJE#^rND^sSmith^nTC#^rND^sOsgood^nRW#Effect of 
renal vasodilatation on the distribution of cortical blood flow in the kidney of
 the dog^len#J Clin Invest#19710000#1971#50#1429-1438#20080200#6849.htm#0021-973
8#J Clin Invest##
00549000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100022000730100019000950120
08600114030000900200065000900209064000500218031000300223014000800226865000900234
002000900243035001000252801000900262#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
849.htm#S#c#81#2#article#25#2#^rND^sHardaker^nWT Jr#^rND^sWechsler^nAS#Redistrib
ution of renal intracortical blood flow during dopamine infusion in dogs^len#Cir
c Res#19730000#1973#33#437-444#20080200#6849.htm#0009-7330#Circ Res##
00631000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730120097000890160
01700186016002100203018005700224066001000281062002200291065000900313064000500322
014000800327865000900335002000900344#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
849.htm#S#c#82#3#article#25#3#^rND^sRiley^nRJ#Effects of acute changes in renal 
cortical blood flow distribution on renal function in dogs^len#^rND^sWesson^nCG#
^rND^sFinelli^nGM Jr#Recent advances in renal physiology and pharmacology^len#Ba
ltimore#University Park Press#19740000#1974#149-163#20080200#6849.htm##
00541000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100014000730100020000870120
07700107030001300184065000900197064000500206031000300211014000800214865000900222
002000900231035001000240801001300250#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
849.htm#S#c#83#4#article#25#4#^rND^sZou^nAP#^rND^sCowley^nAW Jr#Nitric oxide in 
renal cortex and medulla: An in vivo microdialysis study^len#Hypertension#199700
00#1997#29#194-198#20080200#6849.htm#0194-911X#Hypertension##
00525000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100015000730100020000880120
06400108030001100172065000900183064000500192031000300197014000800200865000900208
002000900217035001000226801001100236#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
849.htm#S#c#84#5#article#25#5#^rND^sDunn^nMJ#^rND^sZambraski^nEJ#Renal effects o
f drugs that inhibit prostaglandin synthesis^len#Kidney Int#19800000#1980#18#609
-622#20080200#6849.htm#0085-2538#Kidney int##
00571000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100015000900120
11600105030003900221710000200260065000900262064000500271031000300276014000800279
865000900287002000900296#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#c#
85#6#article#25#6#^rND^sRomero^nJC#^rND^sKnox^nFG#Mechanisms underlying pressure
-related natriuresis: the role of the renin-angiotensin and prostaglandin system
s^len#State of the art lecture. Hypertension#2#19880000#1988#11#724-738#20080200
#6849.htm##
00632000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100018000900100
02000108010001500128012010200143030001500245065000900260064000500269031000300274
014001000277865000900287002000900296035001000305801001500315#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6849.htm#S#c#86#7#article#25#7#^rND^sRomero^nJC#^rND^sBen
tley^nMD#^rND^sVanhoutte^nPM#^rND^sKnox^nFG#Intrarenal mechanisms that regulate 
sodium excretion in relationship to changes in blood pressure^len#Mayo Clin Proc
#19890000#1989#64#1406-1424#20080200#6849.htm#0025-6196#Mayo Clin Proc##
00614000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100016000900100
01600106010001700122012008500139030001700224065000900241064000500250031000200255
014001000257865000900267002000900276035001000285801001700295#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6849.htm#S#c#87#8#article#25#8#^rND^sRomero^nJC#^rND^sLah
era^nV#^rND^sSalom^nMG#^rND^sBiondi^nML#Role of the endothelium-dependent relaxi
ng factor nitric oxide on renal function^len#J Am Soc Nephrol#19920000#1992#2#13
71-1387#20080200#6849.htm#1046-6673#J Am Soc Nephrol##
00596000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100016000900100
01600106010001800122012006300140030001800203065000900221064000500230031000300235
014001000238865000900248002000900257035001000266801001800276#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6849.htm#S#c#88#9#article#25#9#^rND^sCowley^nAW#^rND^sRom
an^nRJ#^rND^sFenoy^nFJ#^rND^sMattson^nDL#Effect of renal medullary circulation o
n arterial pressure^len#J Hypertens Suppl#19920000#1992#10#S187-S193#20080200#68
49.htm#0952-1178#J Hypertens Suppl##
00574000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750100016000930100
02000109012007600129030001300205065000900218064000500227031000300232014000800235
865000900243002000900252035001000261801001300271#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6849.htm#S#c#89#10#article#25#10#^rND^sMattson^nDL#^rND^sRoman^nRJ#^r
ND^sCowley^nAW Jr#Role of nitric oxide in renal papillary blood flow and sodium 
excretion^len#Hypertension#19920000#1992#19#766-769#20080200#6849.htm#0194-911X#
Hypertension##
00675000000000337000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750100017000930100
01400110010001800124010002000142010002000162810000600182012007100188030001300259
06500090027206400050028103100020028601400080028886500090029600200090030503500100
0314801001300324#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#c#90#11#ar
ticle#25#11#^rND^sRuilope^nLM#^rND^sGarcia^nRR#^rND^sPaya^nC#^rND^sAlcazar^nJM#^
rND^sMiravalles^nE#^rND^sSancho-Rof^nJ#et al#Effects of long-term treatment with
 indomethacin on renal function^len#Hypertension#19860000#1986#8#677-684#2008020
0#6849.htm#0194-911X#Hypertension##
00627000000000313000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100023000920100
01900115010001600134010001700150012006400167030001300231065000900244064000500253
031000400258014001000262865000900272002000900281035001000290801001300300#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#c#91#12#article#25#12#^rND^sStrick
^nDM#^rND^sFiksen-Olsen^nMJ#^rND^sLockhart^nJC#^rND^sRoman^nRJ#^rND^sRomero^nJC#
Direct measurement of renal medullary blood flow in the dog^len#Am J Physiol#199
40000#1994#267#R253-R259#20080200#6849.htm#0002-9513#Am J Physiol##
00520000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750100021000940120
04400115030001500159065000900174064000500183031000300188014000800191865000900199
002000900208035001000217801001500227#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
849.htm#S#c#92#13#article#25#13#^rND^sKleinman^nLI#^rND^sRadford^nEP Jr#Ventilat
ion standards for small mammals^len#J Appl Physiol#19640000#1964#19#360-362#2008
0200#6849.htm#0021-8987#J Appl Physiol##
00447000000000241000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720160018000750160015000930180
04100108066000900149062001500158065000900173064000500182865000900187002000900196
#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#c#93#14#article#25#14#^rND
^sBruning^nJL#^rND^sKinz^nBL#Computational handbook of statistics^len#Glenview#S
cott-Foresman#19770000#1977#20080200#6849.htm##
00410000000000229000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720160014000750180028000890660
01700117062001400134065000900148064000500157865000900162002000900171#v41n2#v:\sc
ielo\serial\bjmbr\v41n2\markup\6849.htm#S#c#94#15#article#25#15#^rND^sZar^nJH#Bi
ostatistical analysis^len#Englewood Cliffs#Prentice Hall#19740000#1974#20080200#
6849.htm##
00635000000000313000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100015000920100
02000107010002200127010002000149012008300169030000800252065000900260064000500269
031000300274014000800277865000900285002000900294035001000303801000800313#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#c#95#16#article#25#16#^rND^sDonker
^nAJ#^rND^sArisz^nL#^rND^sBrentjens^nJR#^rND^svan^nder Hem GK#^rND^sHollemans^nH
J#The effect of indomethacin on kidney function and plasma renin activity in man
^len#Nephron#19760000#1976#17#288-296#20080200#6849.htm#0028-2766#Nephron##
00577000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100021000750100019000960120
10200115030001300217065000900230064000500239031000400244014001000248865000900258
002000900267035001000276801001300286#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
849.htm#S#c#96#17#article#25#17#^rND^sBlasingham^nMC#^rND^sNasjletti^nA#Differen
tial renal effects of cyclooxygenase inhibition in sodium-replete and sodium-dep
rived dog^len#Am J Physiol#19800000#1980#239#F360-F365#20080200#6849.htm#0002-95
13#Am J Physiol##
00559000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100017000910100
01600108012006400124030001300188065000900201064000500210031000300215014001000218
865000900228002000900237035001000246801001300256#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6849.htm#S#c#97#18#article#25#18#^rND^sMajid^nDS#^rND^sGodfrey^nM#^rN
D^sNavar^nLG#Pressure natriuresis and renal medullary blood flow in dogs^len#Hyp
ertension#19970000#1997#29#1051-1057#20080200#6849.htm#0194-911X#Hypertension##
00537000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100016000910120
07200107030001300179065000900192064000500201031000400206014000800210865000900218
002000900227035001000236801001300246#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
849.htm#S#c#98#19#article#25#19#^rND^sClive^nDM#^rND^sStoff^nJS#Renal syndromes 
associated with nonsteroidal antiinflammatory drugs^len#N Engl J Med#19840000#19
84#310#563-572#20080200#6849.htm#0028-4793#N Engl J Med##
00564000000000277000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100020000750100017000950120
09900112030001100211065000900222064000500231031000300236014000800239865000900247
002000900256035001000265801001100275#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
849.htm#S#c#99#20#article#25#20#^rND^sSchnermann^nJ#^rND^sBriggs^nJP#Participati
on of renal cortical prostaglandins in the regulation of glomerular filtration r
ate^len#Kidney Int#19810000#1981#19#802-815#20080200#6849.htm#0085-2538#Kidney i
nt##
00604000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920100
01900108010002200127012007400149030001300223065000900236064000500245031000300250
014000800253865000900261002000900270035001000279801001300289#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6849.htm#S#c#100#21#article#25#21#^rND^sFenoy^nFJ#^rND^sF
errer^nP#^rND^sCarbonell^nL#^rND^sGarcia-Salom^nM#Role of nitric oxide on papill
ary blood flow and pressure natriuresis^len#Hypertension#19950000#1995#25#408-41
4#20080200#6849.htm#0194-911X#Hypertension##
00603000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920100
01700108012010600125030001300231065000900244064000500253031000400258014001000262
865000900272002000900281035001000290801001300300#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6849.htm#S#c#101#22#article#25#22#^rND^sSalom^nMG#^rND^sLahera^nV#^rN
D^sRomero^nJC#Role of prostaglandins and endothelium-derived relaxing factor on 
the renal response to acetylcholine^len#Am J Physiol#19910000#1991#260#F145-F149
#20080200#6849.htm#0002-9513#Am J Physiol##
00538000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760120101000920300
01300193065000900206064000500215031000300220014000800223865000900231002000900240
035001000249801001300259#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#c#
102#23#article#25#23#^rND^sRoman^nRJ#Pressure-diuresis in volume-expanded rats: 
Tubular reabsorption in superficial and deep nephrons^len#Hypertension#19880000#
1988#12#177-183#20080200#6849.htm#0194-911X#Hypertension##
00684000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930100
02300111010001700134010001700151010001700168012009100185030001300276065000900289
06400050029803100040030301400100030786500090031700200090032603500100033580100130
0345#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6849.htm#S#c#103#24#article#25#24
#^rND^sLerman^nLO#^rND^sBentley^nMD#^rND^sFiksen-Olsen^nMJ#^rND^sStrick^nDM#^rND
^sRitman^nEL#^rND^sRomero^nJC#Pressure dependency of canine intrarenal blood flo
w within the range of autoregulation^len#Am J Physiol#19950000#1995#268#F404-F40
9#20080200#6849.htm#0002-9513#Am J Physiol##
00559000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100016000950120
07800111030001900189065000900208064000500217031000400222014000800226865000900234
002000900243035001000252801001900262#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
849.htm#S#c#104#25#article#25#25#^rND^sBergstrom^nG#^rND^sEvans^nRG#Mechanisms u
nderlying the antihypertensive functions of the renal medulla^len#Acta Physiol S
cand#20040000#2004#181#475-486#20080200#6849.htm#0001-6772#Acta Physiol Scand##
00267000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00300094#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#o#1#1#article#1#20
080402#165749#6858.htm#73##
03920000000000757000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400110014103500100015201201010016201000220
02630100030002850100025003150100029003400100026003690100027003950100028004220100
03700450010002500487010002500512010002400537010002600561010002000587010002400607
01000280063107001120065907000600077107000790083107000890091007000680099907000720
10670700098011390700136012370831563013730850008029360850045029440850025029890850
02503014085002903039085002503068117000603093072000303099112000903102111001503111
114000903126113001803135002000903153#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
858.htm#S#h#2#1#article#1#sc#en#bjmbr#1#3.1#ILUS#15#BJMBR080#nd#Braz J Med Biol 
Res#41#2#20080200#^f176^l179#0100-879X#Comparison of serum hormone levels of cap
tive and free-living maned wolves Chrysocyon brachyurus^len#^rND^1A01^nO.B.^sMai
a#^rND^1A05 A07^nA.T.A.^sJácomo#^rND^1A04^nB.A.^sBringel#^rND^1A07^nC.K.^sKashiv
akura#^rND^1A08^nC.A.^sOliveira#^rND^1A04^nL.O.F.^sTeodoro#^rND^1A05 A07^nL.^sSi
lveira#^rND^1A06^nM.E.L.^sTeixeira da Costa#^rND^1A06^nM.C.C.^sMalta#^rND^1A07^n
M.M.^sFurtado#^rND^1A07^nN.M.^sTorres#^rND^1A03^nP.S.R.^sMattos#^rND^1A08^n.P^sV
iau#^rND^1A04^nT.F.G.^sLima#^rND^1A01 A07^nR.G.^sMorato#Centro Nacional de Pesqu
isa para a Conservação dos Predadores Naturais (Cenap/ICMBio)^iA01^cAtibaia^sSP^
pBrasil#Bet Laboratories do Brasil^iA02^cRio de Janeiro^sRJ^pBrasil#Centro de Pe
squisa Agroflorestal (Embrapa Roraima)^iA03^cBoa Vista^sRR^pBrasil#Parque Natura
l da Companhia Brasileira de Mineração e Metalurgia^iA04^cAraxá^sMG^pBrasil#Fund
o para a Conservação da Onça-Pintada^iA05^cMineiros^sGO^pBrasil#Fundação Zoobotâ
nica de Belo Horizonte^iA06^cBelo Horizonte^sMG^pBrasil#Instituto para Conservaç
ão dos Carnívoros Neotropicais (Pró-Carnívoros)^iA07^cAtibaia^sSP^pBrasil#Univer
sidade de São Paulo^iA08^1Faculdade de Medicina Veterinária e Zootecnia^2Laborat
ório de Dosagens Hormonais^cSão Paulo^sSP^pBrasil#^len^aSerum hormone levels wer
e compared between captive and free-living maned wolves and seasonal variations 
of sex hormones were studied. Blood samples were collected from 16 male and 26 f
emale adult animals from Brazilian zoos, and from 30 male and 24 female free-liv
ing adults to determine serum progesterone and testosterone by radioimmunoassay.
 Serum testosterone concentrations varied (P < 0.05) across seasons for 16 capti
ve males, being higher in autumn (2184.7 ± 355.1 pg/mL) than in summer (1080.7 ±
 205.4 pg/mL), winter (1270.1 ± 276.6 pg/mL) and spring (963.9 ± 248.1 pg/mL), a
lthough they did not differ between summer, winter and spring. Testosterone conc
entration of 30 free-living males differed (P < 0.05) between autumn (824.1 ± 51
2.2 pg/mL), winter (14.4 ± 8.0 pg/mL) and spring (151.9 ± 90.5 pg/mL). Compariso
n between captive and free-living animals showed no difference in autumn (P > 0.
05). Sixteen captive males showed higher testosterone concentration during winte
r and spring compared with 30 free-living animals (P < 0.05). Progesterone conce
ntration varied among seasons in 26 captive females (P < 0.05), being higher in 
autumn (15.3 ± 3.1 ng/mL) than in summer (6.6 ± 1.5 ng/mL), winter (5.3 ± 3.1 ng
/mL) and spring (4.3 ± 0.7 ng/mL). Progesterone concentration of 24 free-living 
females varied between autumn (17.1 ± 6.0 ng/mL) and winter (1.7 ± 0.3 ng/mL) (P
 < 0.05), but we could not obtain data for spring or summer. No difference in pr
ogesterone levels was observed between captive and free-living females in autumn
 and winter.#^dnd^i1#^tm^len^kManed wolf Chrysocyon brachyurus^i1#^tm^len^kProge
sterone^i1#^tm^len^kTestosterone^i1#^tm^len^kRadioimmunoassay^i1#^tm^len^kReprod
uction^i1#other#15#20070413#April 13, 2007#20071113#November 13, 2007#6858.htm##
03973000000000757000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400110014103500100015201201220016201000220
02840100030003060100025003360100029003610100026003900100027004160100028004430100
03700471010002500508010002500533010002400558010002600582010002000608010002400628
01000280065207001120068007000600079207000790085207000890093107000680102007000720
10880700098011600700136012580831581013940850008029750850059029830850025030420850
02503067085002903092085002503121117000603146072000303152112000903155111001503164
114000903179113001803188002000903206#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
858.htm#S#f#3#1#article#1#sc#en#bjmbr#1#3.1#ILUS#15#BJMBR080#nd#Braz J Med Biol 
Res#41#2#20080200#^f176^l179#0100-879X#<b>Comparison of serum hormone levels of 
captive and free-living maned wolves <i>Chrysocyon</i><i> brachyurus</i></b>^len
#^rND^1A01^nO.B.^sMaia#^rND^1A05 A07^nA.T.A.^sJácomo#^rND^1A04^nB.A.^sBringel#^r
ND^1A07^nC.K.^sKashivakura#^rND^1A08^nC.A.^sOliveira#^rND^1A04^nL.O.F.^sTeodoro#
^rND^1A05 A07^nL.^sSilveira#^rND^1A06^nM.E.L.^sTeixeira da Costa#^rND^1A06^nM.C.
C.^sMalta#^rND^1A07^nM.M.^sFurtado#^rND^1A07^nN.M.^sTorres#^rND^1A03^nP.S.R.^sMa
ttos#^rND^1A08^n.P^sViau#^rND^1A04^nT.F.G.^sLima#^rND^1A01 A07^nR.G.^sMorato#Cen
tro Nacional de Pesquisa para a Conservação dos Predadores Naturais (Cenap/ICMBi
o)^iA01^cAtibaia^sSP^pBrasil#Bet Laboratories do Brasil^iA02^cRio de Janeiro^sRJ
^pBrasil#Centro de Pesquisa Agroflorestal (Embrapa Roraima)^iA03^cBoa Vista^sRR^
pBrasil#Parque Natural da Companhia Brasileira de Mineração e Metalurgia^iA04^cA
raxá^sMG^pBrasil#Fundo para a Conservação da Onça-Pintada^iA05^cMineiros^sGO^pBr
asil#Fundação Zoobotânica de Belo Horizonte^iA06^cBelo Horizonte^sMG^pBrasil#Ins
tituto para Conservação dos Carnívoros Neotropicais (Pró-Carnívoros)^iA07^cAtiba
ia^sSP^pBrasil#Universidade de São Paulo^iA08^1Faculdade de Medicina Veterinária
 e Zootecnia^2Laboratório de Dosagens Hormonais^cSão Paulo^sSP^pBrasil#^len^aSer
um hormone levels were compared between captive and free-living maned wolves and
 seasonal variations of sex hormones were studied. Blood samples were collected 
from 16 male and 26 female adult animals from Brazilian zoos, and from 30 male a
nd 24 female free-living adults to determine serum progesterone and testosterone
 by radioimmunoassay. Serum testosterone concentrations varied (P &lt; 0.05) acr
oss seasons for 16 captive males, being higher in autumn (2184.7 ± 355.1 pg/mL) 
than in summer (1080.7 ± 205.4 pg/mL), winter (1270.1 ± 276.6 pg/mL) and spring 
(963.9 ± 248.1 pg/mL), although they did not differ between summer, winter and s
pring. Testosterone concentration of 30 free-living males differed (P &lt; 0.05)
 between autumn (824.1 ± 512.2 pg/mL), winter (14.4 ± 8.0 pg/mL) and spring (151
.9 ± 90.5 pg/mL). Comparison between captive and free-living animals showed no d
ifference in autumn (P &gt; 0.05). Sixteen captive males showed higher testoster
one concentration during winter and spring compared with 30 free-living animals 
(P &lt; 0.05). Progesterone concentration varied among seasons in 26 captive fem
ales (P &lt; 0.05), being higher in autumn (15.3 ± 3.1 ng/mL) than in summer (6.
6 ± 1.5 ng/mL), winter (5.3 ± 3.1 ng/mL) and spring (4.3 ± 0.7 ng/mL). Progester
one concentration of 24 free-living females varied between autumn (17.1 ± 6.0 ng
/mL) and winter (1.7 ± 0.3 ng/mL) (P &lt; 0.05), but we could not obtain data fo
r spring or summer. No difference in progesterone levels was observed between ca
ptive and free-living females in autumn and winter.#^dnd^i1#^tm^len^kManed wolf 
<i>Chrysocyon</i><i> brachyurus</i>^i1#^tm^len^kProgesterone^i1#^tm^len^kTestost
erone^i1#^tm^len^kRadioimmunoassay^i1#^tm^len^kReproduction^i1#other#15#20070413
#April 13, 2007#20071113#November 13, 2007#6858.htm##
04072000000000781000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000300105049000900108158000300117
03000240012003100030014403200020014706500090014901400110015803500100016901201010
01790100022002800100031003020100025003330100029003580100026003870100028004130100
02700441010003800468010002600506010002500532010002400557010002700581010002100608
01000250062901000280065407001140068207000620079607000810085807000910093907000700
10300700074011000700100011740700138012740831563014120850008029750850045029830850
02503028085002503053085002903078085002503107117000603132072000303138112000903141
111001503150114000903165113001803174002000903192008008903201#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6858.htm#S#l#4#1#article#1#^mFeb.^a2008#sc#en#bjmbr#1#3.1
#ilus#15#BJMBR080#nd#Braz. j. med. biol. res#41#2#20080200#^f176^l179#0100-879X#
Comparison of serum hormone levels of captive and free-living maned wolves Chrys
ocyon brachyurus^len#^rND^1A01^nO. B^sMaia#^rND^1A05 A07^nA. T. A^sJácomo#^rND^1
A04^nB. A^sBringel#^rND^1A07^nC. K^sKashivakura#^rND^1A08^nC. A^sOliveira#^rND^1
A04^nL. O. F^sTeodoro#^rND^1A05 A07^nL^sSilveira#^rND^1A06^nM. E. L^sTeixeira da
 Costa#^rND^1A06^nM. C. C^sMalta#^rND^1A07^nM. M^sFurtado#^rND^1A07^nN. M^sTorre
s#^rND^1A03^nP. S. R^sMattos#^rND^1A08^n. P^sViau#^rND^1A04^nT. F. G^sLima#^rND^
1A01 A07^nR. G^sMorato#^iA01^1Centro Nacional de Pesquisa para a Conservação dos
 Predadores Naturais (Cenap/ICMBio)^cAtibaia^sSP^pBrasil#^iA02^1Bet Laboratories
 do Brasil^cRio de Janeiro^sRJ^pBrasil#^iA03^1Centro de Pesquisa Agroflorestal (
Embrapa Roraima)^cBoa Vista^sRR^pBrasil#^iA04^1Parque Natural da Companhia Brasi
leira de Mineração e Metalurgia^cAraxá^sMG^pBrasil#^iA05^1Fundo para a Conservaç
ão da Onça-Pintada^cMineiros^sGO^pBrasil#^iA06^1Fundação Zoobotânica de Belo Hor
izonte^cBelo Horizonte^sMG^pBrasil#^iA07^1Instituto para Conservação dos Carnívo
ros Neotropicais (Pró-Carnívoros)^cAtibaia^sSP^pBrasil#^iA08^1Universidade de Sã
o Paulo^2Faculdade de Medicina Veterinária e Zootecnia^3Laboratório de Dosagens 
Hormonais^cSão Paulo^sSP^pBrasil#^len^aSerum hormone levels were compared betwee
n captive and free-living maned wolves and seasonal variations of sex hormones w
ere studied. Blood samples were collected from 16 male and 26 female adult anima
ls from Brazilian zoos, and from 30 male and 24 female free-living adults to det
ermine serum progesterone and testosterone by radioimmunoassay. Serum testostero
ne concentrations varied (P < 0.05) across seasons for 16 captive males, being h
igher in autumn (2184.7 ± 355.1 pg/mL) than in summer (1080.7 ± 205.4 pg/mL), wi
nter (1270.1 ± 276.6 pg/mL) and spring (963.9 ± 248.1 pg/mL), although they did 
not differ between summer, winter and spring. Testosterone concentration of 30 f
ree-living males differed (P < 0.05) between autumn (824.1 ± 512.2 pg/mL), winte
r (14.4 ± 8.0 pg/mL) and spring (151.9 ± 90.5 pg/mL). Comparison between captive
 and free-living animals showed no difference in autumn (P > 0.05). Sixteen capt
ive males showed higher testosterone concentration during winter and spring comp
ared with 30 free-living animals (P < 0.05). Progesterone concentration varied a
mong seasons in 26 captive females (P < 0.05), being higher in autumn (15.3 ± 3.
1 ng/mL) than in summer (6.6 ± 1.5 ng/mL), winter (5.3 ± 3.1 ng/mL) and spring (
4.3 ± 0.7 ng/mL). Progesterone concentration of 24 free-living females varied be
tween autumn (17.1 ± 6.0 ng/mL) and winter (1.7 ± 0.3 ng/mL) (P < 0.05), but we 
could not obtain data for spring or summer. No difference in progesterone levels
 was observed between captive and free-living females in autumn and winter.#^dnd
^i1#^tm^len^kManed wolf Chrysocyon brachyurus^i1#^tm^len^kProgesterone^i1#^tm^le
n^kTestosterone^i1#^tm^len^kRadioimmunoassay^i1#^tm^len^kReproduction^i1#other#1
5#20070413#April 13, 2007#20071113#November 13, 2007#6858.htm#Internet^ihttp://w
ww.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000200015##
00410000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704018500070002000900255#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#5#1#article#54#<P class="style4"> <A NAM
E="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif">F
ebruary 2008, Volume 41(2) 176-179</font> (Short Communication)</B></P>     ^cY#
6858.htm##
00405000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704018000070002000900250#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#6#2#article#54#<P><font size="5" face="A
rial, Helvetica, sans-serif"><B>Comparison of serum hormone levels of captive an
d free-living maned wolves <I>Chrysocyon brachyurus</I></B></font>     ^cY#6858.
htm##
00999000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704077400070002000900844#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#7#3#article#54#<P><font face="Arial, Hel
vetica, sans-serif">O.B. Maia<SUP>1</SUP>, A.T.A. J&aacute;como<SUP>5,7</SUP>,  
  B.A. Bringel<SUP>2</SUP>, C.K. Kashivakura<SUP>5</SUP>, C.A. Oliveira<SUP>8</S
UP>,    L.O.F. Teodoro<SUP>4</SUP>, L. Silveira<SUP>5,7</SUP>, M.E.L.Teixeira da
 Costa<SUP>6</SUP>,    M.C.C. Malta<SUP>6</SUP>, M.M. Furtado<SUP>5</SUP>, N.M. 
Torres<SUP>5</SUP>,    P.S.R. Mattos<SUP>3</SUP>, P. Viau<SUP>8</SUP>, T.F.G. Li
ma<SUP>2</SUP> and    <span class="style4"><a href="#Correspondence"><img src="/
img/revistas/bjmbr/v41n2/recor.gif" border="0"></a>    <a href="mailto:ronaldo.m
orato@icmbio.gov.br"><img src="/img/revistas/bjmbr/v41n2/email-ca.gif" border="0
"></a></span></font>    <font face="Arial, Helvetica, sans-serif">R.G. Morato<SU
P>1,7</SUP> </font>      ^cY#6858.htm##
00411000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704018600070002000900256#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#8#4#article#54#<P><font face="Arial, Hel
vetica, sans-serif"><SUP>1</SUP>Centro Nacional de Pesquisa para a Conserva&cced
il;&atilde;o dos Predadores Naturais (Cenap/ICMBio), Atibaia, SP, Brasil     ^cY
#6858.htm##
00311000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704008600070002000900156#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#9#5#article#54#<br>       <SUP>2</SUP>Be
t Laboratories do Brasil, Rio de Janeiro, RJ, Brasil     ^cY#6858.htm##
00331000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704010500071002000900176#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#10#6#article#54#<br>       <SUP>3</SUP>C
entro de Pesquisa Agroflorestal (Embrapa Roraima), Boa Vista, RR, Brasil     ^cY
#6858.htm##
00362000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704013600071002000900207#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#11#7#article#54#<br>       <SUP>4</SUP>P
arque Natural da Companhia Brasileira de Minera&ccedil;&atilde;o e Metalurgia, A
rax&aacute;, MG, Brasil     ^cY#6858.htm##
00341000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704011500071002000900186#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#12#8#article#54#<br>       <SUP>5</SUP>F
undo para a Conserva&ccedil;&atilde;o da On&ccedil;a-Pintada, Mineiros, GO, Bras
il     ^cY#6858.htm##
00344000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704011800071002000900189#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#13#9#article#54#<br>       <SUP>6</SUP>F
unda&ccedil;&atilde;o Zoobot&acirc;nica de Belo Horizonte, Belo Horizonte, MG, B
rasil     ^cY#6858.htm##
00386000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704015900072002000900231#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#14#10#article#54#<br>       <SUP>7</SUP>
Instituto para Conserva&ccedil;&atilde;o dos Carn&iacute;voros Neotropicais (Pr&
oacute;-Carn&iacute;voros), Atibaia, SP, Brasil     ^cY#6858.htm##
00424000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704019700072002000900269#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#15#11#article#54#<br>       <SUP>8</SUP>
Laborat&oacute;rio de Dosagens Hormonais, Faculdade de Medicina Veterin&aacute;r
ia e Zootecnia, Universidade de S&atilde;o Paulo, S&atilde;o Paulo, SP, Brasil</
font>     ^cY#6858.htm##
00466000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704023900072002000900311#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#16#12#article#54#<P class="style4"> <A H
REF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDE
R=0 VSPACE=0 HSPACE=0></A>    <A HREF="#Abstract"><strong><font face="Arial, Hel
vetica, sans-serif">Abstract</font></strong></A>    ^cY#6858.htm##
00442000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704021500072002000900287#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#17#13#article#54#<BR>   <A HREF="#Text">
<IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSP
ACE=0></A>    <A HREF="#Text"><strong><font face="Arial, Helvetica, sans-serif">
Text</font></strong></A>    ^cY#6858.htm##
00447000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704022000072002000900292#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#18#14#article#54#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A>    <A HREF="#References"><strong><font face="Arial, Helvetica, 
sans-serif">References</font>    ^cY#6858.htm##
00485000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704025800072002000900330#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#19#15#article#54#<br>   </strong></A><fo
nt face="Arial, Helvetica, sans-serif"><A HREF="#Acknowledgments"><IMG SRC="/img
/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A 
HREF="#Acknowledgments"><strong>Acknowledgments</strong></A></font>    ^cY#6858.
htm##
00525000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704029800072002000900370#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#20#16#article#54#<BR>   <A HREF="#Corres
pondence"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A>    <A HREF="#Correspondence"><strong><font face="Arial, Hel
vetica, sans-serif">Correspondence    and Footnotes</font></strong></a>  <HR ALI
GN=LEFT WIDTH=100% SIZE=2>     ^cY#6858.htm##
00574000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704034700072002000900419#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#21#17#article#54#<P class="style4"> <A N
AME="Abstract"></A><span class="style3"><font color="#00007F" face="Arial, Helve
tica, sans-serif" size="4"><b>Abstract</b></font><FONT COLOR=#00007F>    </FONT>
</span><A HREF="#Home"><FONT SIZE=4><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.
gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P>     
^cY#6858.htm##
01927000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704170000072002000901772#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#22#18#article#54#<P><font face="Arial, H
elvetica, sans-serif">Serum hormone levels were compared between captive and fre
e-living maned wolves and seasonal variations of sex hormones were studied. Bloo
d samples were collected from 16 male and 26 female adult animals from Brazilian
 zoos, and from 30 male and 24 female free-living adults to determine serum prog
esterone and testosterone by radioimmunoassay. Serum testosterone concentrations
 varied (P &lt; 0.05) across seasons for 16 captive males, being higher in autum
n (2184.7 &#177; 355.1 pg/mL) than in summer (1080.7 &#177; 205.4 pg/mL), winter
 (1270.1 &#177; 276.6 pg/mL) and spring (963.9 &#177; 248.1 pg/mL), although the
y did not differ between summer, winter and spring. Testosterone concentration o
f 30 free-living males differed (P &lt; 0.05) between autumn (824.1 &#177; 512.2
 pg/mL), winter (14.4 &#177; 8.0 pg/mL) and spring (151.9 &#177; 90.5 pg/mL). Co
mparison between captive and free-living animals showed no difference in autumn 
(P &gt; 0.05). Sixteen captive males showed higher testosterone concentration du
ring winter and spring compared with 30 free-living animals (P &lt; 0.05). Proge
sterone concentration varied among seasons in 26 captive females (P &lt; 0.05), 
being higher in autumn (15.3 &#177; 3.1 ng/mL) than in summer (6.6 &#177; 1.5 ng
/mL), winter (5.3 &#177; 3.1 ng/mL) and spring (4.3 &#177; 0.7 ng/mL). Progester
one concentration of 24 free-living females varied between autumn (17.1 &#177; 6
.0 ng/mL) and winter (1.7 &#177; 0.3 ng/mL) (P &lt; 0.05), but we could not obta
in data for spring or summer. No difference in progesterone levels was observed 
between captive and free-living females in autumn and winter.</font>     ^cY#685
8.htm##
00440000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704021300072002000900285#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#23#19#article#54#<P><font face="Arial, H
elvetica, sans-serif">Key words: Maned wolf <I>Chrysocyon brachyurus</I><B>; </B
>Progesterone; Testosterone; Radioimmunoassay; Reproduction </font> <HR ALIGN=LE
FT WIDTH=100% SIZE=2>     ^cY#6858.htm##
00522000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704029500072002000900367#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#24#20#article#54#<P class="style4"><A NA
ME="Text"></A><FONT SIZE=4><B><span class="style3"><font color="#00007F" face="A
rial, Helvetica, sans-serif">Text</font></span>    <a href="#Home"><IMG SRC="/im
g/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0
"></a></B></FONT>  </P>     ^cY#6858.htm##
02296000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704206900072002000902141#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#25#21#article#54#<P><font face="Arial, H
elvetica, sans-serif">The maned wolf <I>Chrysocyon brachyurus</I> is the largest
 canid (20-25 kg) and one of the most typical species present in the grassland a
reas of the Brazilian Central Highlands (1). The most significant threat to mane
d wolf populations is the drastic reduction of their habitat, especially due to 
conversion to agricultural land (2). Efforts for conservation of maned wolves ha
ve resulted in the establishment of an international management plan for the dev
elopment of policies to optimize captivity management (3). Captive-breeding prog
rams may be useful for maintaining a population insuring against extinction. It 
is possible to increase the reproductive potential of the species through assist
ed reproductive techniques such as artificial insemination, <I>in vitro</I> fert
ilization, intracytoplasmic sperm injection, and embryo transfer, as demonstrate
d for other carnivore species (4). These techniques can also contribute to prese
rving wild species by the construction of a biological bank-containing gametes, 
tissues and DNA (5). Finally, assisted reproductive techniques can contribute to
 the establishment of gene flow between free-living and captive populations, con
tributing to the maintenance of adequate genetic heterozygosity (6). Fundamental
 knowledge of basic reproductive physiology is essential to plan and implement g
enome resource banking strategies that should be used in conjunction with studie
s on assisted reproductive techniques (7). Basic information on the reproductive
-endocrine function of captive maned wolves in the Northern Hemisphere has been 
reported (8). However, the reproductive-endocrine characteristics of South Ameri
can captive populations are unknown and there is no information on the reproduct
ive endocrine function of free-living maned wolf populations. Thus, our objectiv
e was to study the influence of seasonality on gonadal functions of captive mane
d wolves in Brazil and to compare their levels of reproductive hormones to those
 of free-living maned wolves. </font>     ^cY#6858.htm##
03736000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704350900072002000903581#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#26#22#article#54#<P><font face="Arial, H
elvetica, sans-serif">Blood samples were collected from 42 captive adult maned w
olves (16 males and 26 females) from Brazilian zoos (Parque Natural da Companhia
 Brasileira de Metalurgia de Minera&ccedil;&atilde;o, Arax&aacute;, MG, N = 8; F
unda&ccedil;&atilde;o Zoobot&acirc;nica de Belo Horizonte, Belo Horizonte, MG, N
 = 9; Zool&oacute;gico Municipal de Curitiba, Curitiba, PR, N = 5; Parque Zool&o
acute;gico Quinzinho de Barros, Sorocaba, SP, N = 6; Zool&oacute;gico de Bras&ia
cute;lia, Bras&iacute;lia, DF, N = 4; Funda&ccedil;&atilde;o Rio-Z&ocirc;o, Rio 
de Janeiro, RJ, N = 4; Zool&oacute;gico Municipal de Guarulhos, Guarulhos, SP, N
 = 2; Zool&oacute;gico Municipal de Americana, Americana, SP, N = 4). Animals we
re housed in pairs and fed a fruit-meat-based diet and dog food. Water was provi
ded <I>ad libitum</I>. Samples were collected between June 1995 and January 1998
. Samples were collected every 30 days from 16 adults between March 1996 and Mar
ch 1997. Additional samples were collected opportunistically. The other 26 adult
s were bled on the day of vaccination against infectious diseases and 30 days po
st-vaccination, with additional samples being collected opportunistically every 
30, 60, or 90 days. In general, for captive animals, the time elapsed from chemi
cal restraint to blood sample collection was 3-7 min. Blood samples were also co
llected from 54 free-ranging adult maned wolves (30 males and 24 females) from E
sta&ccedil;&atilde;o Ecol&oacute;gica de Jata&iacute; (21&#176;33'S and 47&#176;
45'W) and Parque Nacional das Emas (18&#176;19'S and 52&#176;45'W). The wolves w
ere captured using a box-trap baited with live chickens. All free-living animals
 were captured in accordance with legal requirements. We were not able to determ
ine the time elapsed between capture and blood collection for free-living animal
s. Samples were collected via a cephalic or saphenous vein using physical or che
mical restraint (tiletamine-zolazepam, 5-10 mg/kg, Zoletil 50<SUP>&#174;</SUP>, 
Virbac do Brazil, S&atilde;o Paulo, SP, Brazil). Clotted blood samples were cent
rifuged and the sera separated and frozen within 2 h of collection. Sera were he
ated at 56&#176;C for 30 min and stored frozen (-20&#176;C) until the time for d
etection of serum progesterone and testosterone by radioimmunoassay. Assays were
 performed in duplicate using a solid-phase <SUP>125</SUP>I kit (Diagnostic Prod
ucts Corporation, Los Angeles, CA, USA) specific for each hormone and routinely 
used for domestic dogs. The sensitivity of the assay was 0.004 ng/mL for progest
erone and 8.0 pg/mL for testosterone. The intra- and inter-assay coefficients of
 variation were &lt;10%. Data are reported as means &#177; SEM. To assess season
ality, data were averaged by season (summer: December-February, autumn: March-Ma
y, winter: June-August, and spring: September-November) and differences determin
ed by ANOVA followed by Dunn's multiple comparison test. Samples from free-livin
g animals were averaged by season as described above and comparisons between sea
sons were performed by Kruskal-Wallis one-way ANOVA on ranks. It is important to
 point out that summer was not represented for free-living males and summer and 
spring were represented in only one sample for females and therefore were not av
ailable for this analysis. When appropriate, comparisons of samples from captive
 and free-living populations obtained during the same season were performed usin
g the Mann-Whitney rank test. </font>     ^cY#6858.htm##
02493000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704226600072002000902338#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#27#23#article#54#<P><font face="Arial, H
elvetica, sans-serif">Mean &#177; SEM serum testosterone concentration varied ac
ross seasons (P &lt; 0.05) for captive males. Testosterone concentrations were h
igher in autumn (2184.7 &#177; 355.1 pg/mL; range: 104.1-4166.6 pg/mL; N = 19) t
han in summer (1080.7 &#177; 205.4 pg/mL; range: 129.9-3136.8 pg/mL; N = 27), wi
nter (1270.1 &#177; 276.6 pg/mL; range: 21.4-4078.3 pg/mL; N = 28) and spring (9
63.9 &#177; 248.1 pg/mL; range: 18.7-3856.0 pg/mL; N = 29). Comparisons between 
summer, winter and spring did not reveal any difference (P &gt; 0.05). Similarly
, we observed a difference (P &lt; 0.05) between autumn (824.1 &#177; 512.2 pg/m
L; range: 8.4-3515.9 pg/mL; N = 7), winter (14.4 &#177; 8.0 pg/mL; range: 0.8-10
2.9 pg/mL; N = 13) and spring (151.9 &#177; 90.5 pg/mL; range: 1.4-889.1 pg/mL; 
N = 10) for testosterone concentration in free-living male maned wolves (<strong
><a href="#Fig1">Figure 1</a></strong>). Unfortunately, we could not capture and
 collect samples from free-living male maned wolves during summer. There was no 
difference in autumn values between captive and free-living maned wolves (P &gt;
 0.05), but captive males showed higher (P &lt; 0.05) testosterone concentration
s during winter and spring compared with free-living animals. Progesterone level
s varied among seasons in captive female maned wolves. Levels were higher in aut
umn (15.3 &#177; 3.1 ng/mL; range: 0.83-51.5 ng/mL; N = 29) than in summer (6.6 
&#177; 1.5 ng/mL; range: 0.4-40.0 ng/mL; N = 31), winter (5.3 &#177; 1.0 ng/mL; 
range: 0.49-19.6 ng/mL; N = 26) and spring (4.3 &#177; 0.7 ng/mL; range: 1.0-16.
4 ng/mL; N = 34), but did not differ between summer, winter and spring (P &gt; 0
.05). For free-living female maned wolves, we obtained only one sample for summe
r and one for spring and therefore we could not compare these seasons with autum
n and winter. However, levels were higher (P &lt; 0.05) in autumn (17.1 &#177; 6
.0 ng/mL; range: 0.3-40.0 ng/mL; N = 8) than in winter (1.7 &#177; 0.3 ng/mL; ra
nge: 0.5-4.6 ng/mL; N = 13). Comparisons between captive and free-living female 
maned wolves did not show significant differences (P &gt; 0.05) considering only
 autumn and winter (<strong><a href="#Fig2">Figure 2</a></strong>).</font>     ^
cY#6858.htm##
01887000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704166000072002000901732#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#28#24#article#54#<P><font face="Arial, H
elvetica, sans-serif">These are the first hormonal data from free-living maned w
olves. Previous behavioral and ecological studies have indicated that the free-l
iving maned wolf is a seasonal breeder with an autumn breeding season (1), as ha
s been described for the endocrine behavior of captive animals in both the South
ern and Northern Hemispheres (8). Unfortunately, because we were unable to obtai
n samples from free-living females during summer and spring, we cannot draw a co
nclusion about the ovarian endocrine function of wild-maned wolves. Probably the
 failure or the low rate of capture in the summer and spring is influenced by th
e availability of food and maternal care, respectively. Maned wolves are omnivor
ous and 60% of their diet is composed of fruits, with <I>Solanum lypocarpun </I>
representing the main fruit consumed by them (9). This fruit reaches peak produc
tion during the summer, probably affecting our capture rate. The peak of births 
among maned wolves occurs during the winter (1). Radiotelemetry studies have sho
wn that during this season the mother reduces her movement area, probably spendi
ng more time with the newborn (1), a behavior that may have influenced our rate 
of capture during the winter. Regarding the limitations of the present study, fr
ee-living maned wolves appear to mate in autumn and births probably occur during
 the winter. However, it is clear that a longitudinal analysis is needed and fec
al hormone analysis can help to better address this question. The gonadal activi
ty of free-living maned wolves could be determined by closely monitoring radio-c
ollared individuals. </font>     ^cY#6858.htm##
00567000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704034000072002000900412#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#29#25#article#54#<P><font face="Arial, H
elvetica, sans-serif">Regarding the testicular endocrine function, the difficult
y in capturing wild wolves did not allow us to obtain samples from the same anim
al year-round, thus hampering a better understanding of the influence of season 
on the reproductive status of free-living male maned wolves. </font>     ^cY#685
8.htm##
00630000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704040300072002000900475#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#30#26#article#54#<P><font face="Arial, H
elvetica, sans-serif">Captive females showed an autumn breeding season as descri
bed previously (8). Similarly, male captive maned wolves showed a peak of testos
terone production during autumn, in agreement with data on testis size and sperm
 count (Wildt DE, Bush M, Howard J, unpublished results) previously collected fr
om zoo animals kept in North American Zoos. </font>     ^cY#6858.htm##
01497000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704127000072002000901342#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#31#27#article#54#<P><font face="Arial, H
elvetica, sans-serif">Captive maned wolves presented higher hormone levels than 
free-living animals during the non-breeding period. We may suggest that visual a
nd/or olfactory contact between captive males and females can stimulate testoste
rone production in the male even during the non-breeding season. Exposure to fem
ales has been shown to increase circulating testosterone in rhesus monkey (10). 
In addition, captive maned wolves received a balanced diet throughout the year, 
which probably affected serum testosterone levels (11). The testosterone variati
on in captive males followed the pattern described here for progesterone in capt
ive females. Similarly, within season, progesterone levels were higher in captiv
e females (P &lt; 0.05) when comparison was possible. Captive females presented 
a wide range of progesterone concentration even during the non-breeding seasons.
 In domestic dogs, levels above 2 ng/mL can represent the occurrence of ovulatio
n (12), with progesterone concentration reaching values above 32 ng/mL in diestr
ous (13). Previous studies have reported some births in March, September, Novemb
er, and December in the Southern Hemisphere (3), a fact that can explain the ran
ge found in the present study. </font>     ^cY#6858.htm##
00856000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704062900072002000900701#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#32#28#article#54#<P><font face="Arial, H
elvetica, sans-serif">Differences between captive and free-living males may be r
elated to the time elapsed between capture/restraint and sample collection. In c
aptive animals, blood samples were obtained immediately after restraint while fo
r free-living animals blood samples were obtained at least 5 h after capture. St
ress hormones are capable of suppressing testosterone concentration in males by 
acting along the hypothalamic-pituitary-gonadal axis (14), and the latency for a
 significant change in cortisol or testosterone concentration after the onset of
 stress is about 10 min (15). </font>     ^cY#6858.htm##
00880000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704065300072002000900725#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#33#29#article#54#<P><font face="Arial, H
elvetica, sans-serif"> Although samples were collected irregularly from each ani
mal, combined data demonstrated a seasonal pattern and permitted a comparison be
tween captive and free-living animals. Thus, opportunistic blood sample collecti
on provided valuable information related to the reproductive status of captive a
nd free-living maned wolves.</font> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table wid
th="100%"  border="0">   <tr align="left" valign="top">     <td width="14%"><a h
ref="/img/revistas/bjmbr/v41n2/html/6858i01.htm"><img src="/img/revistas/bjmbr/v
41n2/6858i01peq.jpg" border="2"></a></td>     <td width="86%">    ^cY#6858.htm##
00765000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704053800072002000900610#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#34#30#article#54#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig1"></a>Figure 1. Seasonal variation of testost
erone levels in captive and free-living male maned wolves. *P &lt; 0.05 for comp
arison among seasons (ANOVA followed by Dunn&rsquo;s multiple comparison test fo
r captive wolves and Kruskal-Wallis one-way ANOVA test for free-living wolves). 
+P &lt; 0.05 for comparison of captive and free-living animals (Mann-Whitney ran
k test). We could not obtain samples from free-living animals in summer.</font> 
    </td>   </tr> </table>     ^cY#6858.htm##
00616000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038900072002000900461#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#35#31#article#54#<p><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (56 K JPG file)]</font>
</p> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <tr al
ign="left" valign="top">     <td width="14%"><a href="/img/revistas/bjmbr/v41n2/
html/6858i02.htm"><img src="/img/revistas/bjmbr/v41n2/6858i02peq.jpg" border="2"
></a></td>     <td width="86%">           ^cY#6858.htm##
00743000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704051600072002000900588#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#36#32#article#54#<p><font face="Arial, H
elvetica, sans-serif"><a name="Fig2"></a>Figure 2.          Seasonal variations 
of progesterone levels in the captive and free-living          female maned wolf
. *P &lt; 0.05 for comparison among seasons (ANOVA followed          by Dunn&rsq
uo;s multiple comparison test for captive wolves and Kruskal-Wallis          one
-way ANOVA test for free-living wolves). We did not include summer          and 
spring in the analysis of free-living animals.</font></p>     </td>   </tr> </ta
ble>     ^cY#6858.htm##
00377000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704015000072002000900222#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#37#33#article#54#<p><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (54 K JPG file)]</font>
</p> <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6858.htm##
00534000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704030700072002000900379#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#38#34#article#54#<P class="style4"> <A N
AME="References"></A><FONT color="#00007F" SIZE=4><B><font face="Arial, Helvetic
a, sans-serif">References</font></B></FONT>    <A HREF="#Home"><FONT SIZE=4><B><
IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0 LOOP="0"></B></FONT></A>  </P>     ^cY#6858.htm##
00448000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704020700074002000900281#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#p#39#35#article#54#1#<P><font 
face="Arial, Helvetica, sans-serif">1. Dietz JM. <I>Ecology and social organizat
ion of maned wolf Chrysocyon brachyurus</I>. Washington: Smithosonian Contribuit
ion to Zoology; 1984. </font>     ^cY#6858.htm##
00479000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704023800074002000900312#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#p#40#36#article#54#2#<P><font 
face="Arial, Helvetica, sans-serif">2. Machado ABM, Martins CS, Drummond GM. <I>
Lista da fauna brasileira amea&ccedil;ada de extin&ccedil;&atilde;o</I>. Belo Ho
rizonte: Funda&ccedil;&atilde;o Biodiversitas; 2005. </font>     ^cY#6858.htm##
00457000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021600074002000900290#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#p#41#37#article#54#3#<P><font 
face="Arial, Helvetica, sans-serif">3. Maia OB, Gouveia AM. Birth and mortality 
of maned wolves <I>Chrysocyon brachyurus</I> (Illiger, 1811) in captivity. <I>Br
az J Biol</I> 2002; 62: 25-32. </font>     ^cY#6858.htm##
00436000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704019500074002000900269#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#p#42#38#article#54#4#<P><font 
face="Arial, Helvetica, sans-serif">4. Wildt DE, Roth TL. Assisted reproduction 
for managing and conserving threatened felids. <I>Int Zoo Yearbook</I> 1997; 35:
 164-172. </font>     ^cY#6858.htm##
00497000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704025600074002000900330#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#p#43#39#article#54#5#<P><font 
face="Arial, Helvetica, sans-serif">5. Wildt DE. Endangered species spermatozoa:
 diversity, research and conservation. In: Bartke A (Editor), <I>Function of som
atic cells in the testis</I>. New York: Springer Verlag; 1994. p 1-24. </font>  
   ^cY#6858.htm##
00541000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704030000074002000900374#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#p#44#40#article#54#6#<P><font 
face="Arial, Helvetica, sans-serif">6. Morato RG, Conforti VA, Azevedo FC, Jacom
o AT, Silveira L, Sana D, et al. Comparative analyses of semen and endocrine cha
racteristics of free-living versus captive jaguars (<I>Panthera onca</I>). <I>Re
production</I> 2001; 122: 745-751. </font>     ^cY#6858.htm##
00482000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024100074002000900315#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#p#45#41#article#54#7#<P><font 
face="Arial, Helvetica, sans-serif">7. Brown JL, Terio KA, Graham LH. Fecal andr
ogen metabolite analysis for non invasive monitoring of testicular steroidogenic
 activity in felids. <I>Zoo Biol</I> 1996; 15: 425-434. </font>     ^cY#6858.htm
##
00481000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024000074002000900314#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#p#46#42#article#54#8#<P><font 
face="Arial, Helvetica, sans-serif">8. Velloso AL, Wasser SK, Monfort SL, Dietz 
JM. Longitudinal fecal steroid excretion in maned wolves (<I>Chrysocyon brachyur
us</I>). <I>Gen Comp Endocrinol</I> 1998; 112: 96-107. </font>     ^cY#6858.htm#
#
00552000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704031100074002000900385#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#p#47#43#article#54#9#<P><font 
face="Arial, Helvetica, sans-serif">9. Jacomo ATA, Silveira L, Diniz-Filho JAF. 
Niche separation between the maned-wolf <I>Chrysocyon brachyurus</I>, the crab-e
ating fox <I>Dusicyon thous</I> and the hoary fox <I>Dusicyon vetulus</I> in cen
tral Brazil. <I>J Zool</I> 2004; 262: 99-106. </font>     ^cY#6858.htm##
00464000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022200075002000900297#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#p#48#44#article#54#10#<P><font
 face="Arial, Helvetica, sans-serif">10. Rose RM, Gordon TP, Bernstein IS. Plasm
a testosterone levels in the male rhesus: influences of sexual and social stimul
i. <I>Science</I> 1972; 178: 643-645. </font>     ^cY#6858.htm##
00462000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022000075002000900295#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#p#49#45#article#54#11#<P><font
 face="Arial, Helvetica, sans-serif">11. Grewall T, Mickelsen O, Hafs HD. Androg
en secretion and spermatogenesis in rats following semistarvation. <I>Proc Soc E
xp Biol Med</I> 1971; 138: 723-727. </font>     ^cY#6858.htm##
00525000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028300075002000900358#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#p#50#46#article#54#12#<P><font
 face="Arial, Helvetica, sans-serif">12. Bouchard GF, Solorzano N, Concannon PW,
 Youngquist RS, Bierschwal CJ. Determination of ovulation time in bitches based 
on teasing, vaginal cytology, and ELISA for progesterone. <I>Theriogenology</I> 
1991; 35: 603-611. </font>     ^cY#6858.htm##
00540000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704029800075002000900373#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#p#51#47#article#54#13#<P><font
 face="Arial, Helvetica, sans-serif">13. Badinand F, Fontbonne A, Maurel MC, Sil
iart B. Fertilization time in the bitch in relation to plasma concentration of o
estradiol, progesterone and luteinizing hormone and vaginal smears. <I>J Reprod 
Fertil Suppl</I> 1993; 47: 63-67. </font>     ^cY#6858.htm##
00462000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022000075002000900295#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#p#52#48#article#54#14#<P><font
 face="Arial, Helvetica, sans-serif">14. Cumming DC, Quigley ME, Yen SS. Acute s
uppression of circulating testosterone levels by cortisol in men. <I>J Clin Endo
crinol Metab</I> 1983; 57: 671-673. </font>     ^cY#6858.htm##
00492000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025000075002000900325#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#p#53#49#article#54#15#<P><font
 face="Arial, Helvetica, sans-serif">15. Sapolsky RM. Stress-induced suppression
 of testicular function in the wild baboon: role of glucocorticoids. <I>Endocrin
ology</I> 1985; 116: 2273-2278. </font> <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^c
Y#6858.htm##
00561000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033400072002000900406#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#54#50#article#54#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE=4
><B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, san
s-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=
BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P>     ^cY#6858.htm#
#
00795000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704056800072002000900640#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#55#51#article#54#<P><font face="Arial, H
elvetica, sans-serif">We appreciate the collaboration of colleagues from Z&ocirc
;o de Bras&iacute;lia, Z&ocirc;o de Curitiba, Z&ocirc;o de Americana, Z&ocirc;o 
de Guarulhos, Parque Zool&oacute;gico Quinzinho de Barros, Funda&ccedil;&atilde;
o Rio-Z&ocirc;o, Earthwatch Institute and Memphis Zoo. We are also grateful to I
nstituto Brasileiro do Meio Ambiente e dos Recursos Naturais Renov&aacute;veis (
Ibama) and Instituto Florestal de S&atilde;o Paulo for permitting the capture of
 maned wolves. </font> <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#6858.htm##
00553000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704032600072002000900398#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#56#52#article#54#<P class="style4"><A NA
ME="Correspondence"></A><FONT color="#00007F" SIZE=4><B><font face="Arial, Helve
tica, sans-serif">Correspondence    and Footnotes</font></B></FONT> <A HREF="#Ho
me"><FONT SIZE=4><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM B
ORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></P>     ^cY#6858.htm##
00660000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704043300072002000900505#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#57#53#article#54#<P class="style4"><B><a
 href="#Home"><img src="/img/revistas/bjmbr/v41n2/recor.gif" border="0"></a> Add
ress for correspondence: </B><font face="Arial, Helvetica, sans-serif">R.G. Mora
to, Cenap/ICMBio, Av. dos Bandeirantes, s/n, Balne&aacute;rio Municipal, 12941-6
80 Atibaia, SP, Brasil. Fax: +55-11-4411-6633. E-mail: <strong><a href="mailto:r
onaldo.morato@icmbio.gov.br">ronaldo.morato@icmbio.gov.br</a></strong></font></P
>     ^cY#6858.htm##
00340000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704011300072002000900185#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6858.htm#S#p#58#54#article#54#<P><font face="Arial, H
elvetica, sans-serif">Received April 13, 2007. Accepted November 13, 2007.</font
>     ^cY#6858.htm##
00472000000000229000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710160016000730180072000890660
01100161062003800172065000900210064000500219865000900224002000900233#v41n2#v:\sc
ielo\serial\bjmbr\v41n2\markup\6858.htm#S#c#59#1#article#15#1#^rND^sDietz^nJM#Ec
ology and social organization of maned wolf Chrysocyon brachyurus^len#Washington
#Smithosonian Contribuition to Zoology#19840000#1984#20080200#6858.htm##
00504000000000253000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710160019000730160018000920160
01900110018005100129066001500180062002300195065000900218064000500227865000900232
002000900241#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#c#60#2#article
#15#2#^rND^sMachado^nABM#^rND^sMartins^nCS#^rND^sDrummond^nGM#Lista da fauna bra
sileira ameaçada de extinção^lpt#Belo Horizonte#Fundação Biodiversitas#20050000#
2005#20080200#6858.htm##
00518000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100015000730100018000880120
09100106030001200197710000200209065000900211064000500220031000300225014000600228
865000900234002000900243#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#c#
61#3#article#15#3#^rND^sMaia^nOB#^rND^sGouveia^nAM#Birth and mortality of maned 
wolves Chrysocyon brachyurus (Illiger, 1811) in captivity^lpt#Braz J Biol#2#2002
0000#2002#62#25-32#20080200#6858.htm##
00504000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100015000890120
07200104030001700176710000200193065000900195064000500204031000300209014000800212
865000900220002000900229#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#c#
62#4#article#15#4#^rND^sWildt^nDE#^rND^sRoth^nTL#Assisted reproduction for manag
ing and conserving threatened felids^lpt#Int Zoo Yearbook#2#19970000#1997#35#164
-172#20080200#6858.htm##
00550000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730120073000890160
01600162018004400178066000900222062001600231065000900247064000500256014000500261
865000900266002000900275#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#c#
63#5#article#15#5#^rND^sWildt^nDE#Endangered species spermatozoa: diversity, res
earch and conservation^len#^rND^sBartke^nA#Function of somatic cells in the test
is^len#New York#Springer Verlag#19940000#1994#1-24#20080200#6858.htm##
00685000000000325000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100019000900100
01800109010001700127010001800144010001400162810000600176012011800182030001300300
71000020031306500090031506400050032403100040032901400080033386500090034100200090
0350#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#c#64#6#article#15#6#^r
ND^sMorato^nRG#^rND^sConforti^nVA#^rND^sAzevedo^nFC#^rND^sJacomo^nAT#^rND^sSilve
ira^nL#^rND^sSana^nD#et al#Comparative analyses of semen and endocrine character
istics of free-living versus captive jaguars (Panthera onca)^len#Reproduction#2#
20010000#2001#122#745-751#20080200#6858.htm##
00568000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100016000890100
01700105012011400122030000900236710000200245065000900247064000500256031000300261
014000800264865000900272002000900281#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
858.htm#S#c#65#7#article#15#7#^rND^sBrown^nJL#^rND^sTerio^nKA#^rND^sGraham^nLH#F
ecal androgen metabolite analysis for non invasive monitoring of testicular ster
oidogenic activity in felids^len#Zoo Biol#2#19960000#1996#15#425-434#20080200#68
58.htm##
00618000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100017000910100
01800108010001600126012008100142030002000223065000900243064000500252031000400257
014000700261865000900268002000900277035001000286801002000296#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6858.htm#S#c#66#8#article#15#8#^rND^sVelloso^nAL#^rND^sWa
sser^nSK#^rND^sMonfort^nSL#^rND^sDietz^nJM#Longitudinal fecal steroid excretion 
in maned wolves (Chrysocyon brachyurus)^len#Gen Comp Endocrinol#19980000#1998#11
2#96-107#20080200#6858.htm#0016-6480#Gen Comp Endocrinol##
00644000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100018000910100
02300109012015500132030000700287065000900294064000500303031000400308014000700312
865000900319002000900328035001000337801000700347#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6858.htm#S#c#67#9#article#15#9#^rND^sJacomo^nATA#^rND^sSilveira^nL#^r
ND^sDiniz-Filho^nJAF#Niche separation between the maned-wolf Chrysocyon brachyur
us, the crab-eating fox Dusicyon thous and the hoary fox Dusicyon vetulus in cen
tral Brazil^len#J Zool#20040000#2004#262#99-106#20080200#6858.htm#0022-5460#J Zo
ol##
00578000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100015000750100017000900100
02000107012009100127030000800218065000900226064000500235031000400240014000800244
865000900252002000900261035001000270801000800280#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6858.htm#S#c#68#10#article#15#10#^rND^sRose^nRM#^rND^sGordon^nTP#^rND
^sBernstein^nIS#Plasma testosterone levels in the male rhesus: influences of sex
ual and social stimuli^len#Science#19720000#1972#178#643-645#20080200#6858.htm#0
036-8075#Science##
00590000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100019000920100
01500111012007600126030002200202065000900224064000500233031000400238014000800242
865000900250002000900259035001000268801002200278#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6858.htm#S#c#69#11#article#15#11#^rND^sGrewall^nT#^rND^sMickelsen^nO#
^rND^sHafs^nHD#Androgen secretion and spermatogenesis in rats following semistar
vation^len#Proc Soc Exp Biol Med#19710000#1971#138#723-727#20080200#6858.htm#003
7-9727#Proc Soc Exp Biol Med##
00682000000000313000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750100019000940100
02000113010002100133010002100154012011000175030001500285065000900300064000500309
031000300314014000800317865000900325002000900334035001000343801001500353#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#c#70#12#article#15#12#^rND^sBoucha
rd^nGF#^rND^sSolorzano^nN#^rND^sConcannon^nPW#^rND^sYoungquist^nRS#^rND^sBiersch
wal^nCJ#Determination of ovulation time in bitches based on teasing, vaginal cyt
ology, and ELISA for progesterone^len#Theriogenology#19910000#1991#35#603-611#20
080200#6858.htm#0093-691X#THERIOGENOLOGY##
00686000000000301000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750100019000930100
01700112010001700129012014300146030002200289065000900311064000500320031000300325
014000600328865000900334002000900343035001000352801002200362#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6858.htm#S#c#71#13#article#15#13#^rND^sBadinand^nF#^rND^s
Fontbonne^nA#^rND^sMaurel^nMC#^rND^sSiliart^nB#Fertilization time in the bitch i
n relation to plasma concentration of oestradiol, progesterone and luteinizing h
ormone and vaginal smears^len#J Reprod Fertil Suppl#19930000#1993#47#63-67#20080
200#6858.htm#0449-3087#J Reprod Fertil Suppl##
00592000000000289000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100018000750100018000930100
01400111012007600125030002400201065000900225064000500234031000300239014000800242
865000900250002000900259035001000268801002400278#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6858.htm#S#c#72#14#article#15#14#^rND^sCumming^nDC#^rND^sQuigley^nME#
^rND^sYen^nSS#Acute suppression of circulating testosterone levels by cortisol i
n men^len#J Clin Endocrinol Metab#19830000#1983#57#671-673#20080200#6858.htm#002
1-972X#J Clin Endocrinol Metab##
00542000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750120098000940300
01400192065000900206064000500215031000400220014001000224865000900234002000900243
035001000252801001400262#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6858.htm#S#c#
73#15#article#15#15#^rND^sSapolsky^nRM#Stress-induced suppression of testicular 
function in the wild baboon: role of glucocorticoids^len#Endocrinology#19850000#
1985#116#2273-2278#20080200#6858.htm#0013-7227#Endocrinology##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#o#1#1#article#1#20
080402#165751#6877.htm#141##
02858000000000625000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400100014103500100015122300090016101200560
01700100029002260100027002550100022002820100029003040100026003330700133003590700
12700492083132900619085000801948085002501956085002701981085002602008117000602034
07200030204005800050204305800070204805800380205505800220209305800360211511200090
2151111001202160114000902172113001802181881002402199002000902223#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#04#
BJMBR010#nd#Braz J Med Biol Res#41#2#20080200#^f99^l105#0100-879X#20080111#Proco
agulant properties of human MV3 melanoma cells^len#^rND^1A01^nD.L.A.^sGeaquinto#
^rND^1A01^nR.S.^sFernandes#^rND^1A01^nL.G.^sLima#^rND^1A02^nC.^sBarja-Fidalgo#^r
ND^1A01^nR.Q.^sMonteiro#Universidade Federal do Rio de Janeiro^iA01^1Centro de C
iências da Saúde^2Instituto de Bioquímica Médica^cRio de Janeiro^sRJ^pBrasil#Uni
versidade do Estado do Rio de Janeiro^iA02^1Instituto de Biologia^2Departamento 
de Farmacologia^cRio de Janeiro^sRJ^pBrasil#^len^aA correlation between cancer a
nd prothrombotic states has long been described. More recently, a number of stud
ies have focused on the procoagulant mechanisms exhibited by tumor cells. In the
 present study, we dissected the molecular mechanisms responsible for the procoa
gulant activity of MV3, a highly aggressive human melanoma cell line. It was obs
erved that tumor cells strongly accelerate plasma coagulation as a result of: i)
 expression of the blood clotting initiator protein, a tissue factor, as shown b
y flow cytometry and functional assays (factor Xa formation in the presence of c
ells and factor VIIa), and ii) direct activation of prothrombin to thrombin by c
ells, as evidenced by hydrolysis of the synthetic substrate, S-2238, and the nat
ural substrate, fibrinogen. This ability was highly potentiated by the addition 
of exogenous factor Va, which functions as a co-factor for the enzyme factor Xa.
 In contrast, prothrombin activation was not observed when cells were previously
 incubated with DEGR-factor Xa, an inactive derivative of the enzyme. Moreover, 
a monoclonal antibody against bovine factor Xa reduced the prothrombin-convertin
g activity of tumor cells. In conclusion, the data strongly suggest that MV3 cel
ls recruit factor Xa from the culture medium, triggering an uncommon procoagulan
t mechanism.#^dnd^i1#^tm^len^kMV3 melanoma^i1#^tm^len^kBlood clotting^i1#^tm^len
^kTissue factor^i1#other#37#CNPq#FAPERJ#Fundação Universitária José Bonifácio#Fu
ndação Ary Frauzino#Fundação Educacional Charles Darwin#20070503#May 3, 2007#200
71122#November 22, 2007#S0100-879X2008005000003#6877.htm##
02829000000000613000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400100014103500100015122300090016101200630
01700100029002330100027002620100022002890100029003110100026003400700133003660700
12700499083132900626085000801955085002501963085002701988085002602015117000602041
07200030204705800050205005800070205505800380206205800220210005800360212211200090
2158111001202167114000902179113001802188002000902206#v41n2#v:\scielo\serial\bjmb
r\v41n2\markup\6877.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#04#BJMBR010#nd#
Braz J Med Biol Res#41#2#20080200#^f99^l105#0100-879X#20080111#<b>Procoagulant p
roperties of human MV3 melanoma cells</b>^len#^rND^1A01^nD.L.A.^sGeaquinto#^rND^
1A01^nR.S.^sFernandes#^rND^1A01^nL.G.^sLima#^rND^1A02^nC.^sBarja-Fidalgo#^rND^1A
01^nR.Q.^sMonteiro#Universidade Federal do Rio de Janeiro^iA01^1Centro de Ciênci
as da Saúde^2Instituto de Bioquímica Médica^cRio de Janeiro^sRJ^pBrasil#Universi
dade do Estado do Rio de Janeiro^iA02^1Instituto de Biologia^2Departamento de Fa
rmacologia^cRio de Janeiro^sRJ^pBrasil#^len^aA correlation between cancer and pr
othrombotic states has long been described. More recently, a number of studies h
ave focused on the procoagulant mechanisms exhibited by tumor cells. In the pres
ent study, we dissected the molecular mechanisms responsible for the procoagulan
t activity of MV3, a highly aggressive human melanoma cell line. It was observed
 that tumor cells strongly accelerate plasma coagulation as a result of: i) expr
ession of the blood clotting initiator protein, a tissue factor, as shown by flo
w cytometry and functional assays (factor Xa formation in the presence of cells 
and factor VIIa), and ii) direct activation of prothrombin to thrombin by cells,
 as evidenced by hydrolysis of the synthetic substrate, S-2238, and the natural 
substrate, fibrinogen. This ability was highly potentiated by the addition of ex
ogenous factor Va, which functions as a co-factor for the enzyme factor Xa. In c
ontrast, prothrombin activation was not observed when cells were previously incu
bated with DEGR-factor Xa, an inactive derivative of the enzyme. Moreover, a mon
oclonal antibody against bovine factor Xa reduced the prothrombin-converting act
ivity of tumor cells. In conclusion, the data strongly suggest that MV3 cells re
cruit factor Xa from the culture medium, triggering an uncommon procoagulant mec
hanism.#^dnd^i1#^tm^len^kMV3 melanoma^i1#^tm^len^kBlood clotting^i1#^tm^len^kTis
sue factor^i1#other#37#CNPq#FAPERJ#Fundação Universitária José Bonifácio#Fundaçã
o Ary Frauzino#Fundação Educacional Charles Darwin#20070503#May 3, 2007#20071122
#November 22, 2007#6877.htm##
02956000000000637000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000300105049000900108158000300117
03000240012003100030014403200020014706500090014901400100015803500100016822300090
01780120056001870100030002430100027002730100022003000100028003220100026003500700
13500376070012900511083132900640085000801969085002501977085002702002085002602029
11700060205507200030206105800050206405800070206905800380207605800220211405800360
2136112000902172111001202181114000902193113001802202002000902220008008902229#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#l#4#1#article#1#^mFeb.^a2008#o
a#en#bjmbr#1#3.1#ilus#04#BJMBR010#nd#Braz. j. med. biol. res#41#2#20080200#^f99^
l105#0100-879X#20080111#Procoagulant properties of human MV3 melanoma cells^len#
^rND^1A01^nD. L. A^sGeaquinto#^rND^1A01^nR. S^sFernandes#^rND^1A01^nL. G^sLima#^
rND^1A02^nC^sBarja-Fidalgo#^rND^1A01^nR. Q^sMonteiro#^iA01^1Universidade Federal
 do Rio de Janeiro^2Centro de Ciências da Saúde^3Instituto de Bioquímica Médica^
cRio de Janeiro^sRJ^pBrasil#^iA02^1Universidade do Estado do Rio de Janeiro^2Ins
tituto de Biologia^3Departamento de Farmacologia^cRio de Janeiro^sRJ^pBrasil#^le
n^aA correlation between cancer and prothrombotic states has long been described
. More recently, a number of studies have focused on the procoagulant mechanisms
 exhibited by tumor cells. In the present study, we dissected the molecular mech
anisms responsible for the procoagulant activity of MV3, a highly aggressive hum
an melanoma cell line. It was observed that tumor cells strongly accelerate plas
ma coagulation as a result of: i) expression of the blood clotting initiator pro
tein, a tissue factor, as shown by flow cytometry and functional assays (factor 
Xa formation in the presence of cells and factor VIIa), and ii) direct activatio
n of prothrombin to thrombin by cells, as evidenced by hydrolysis of the synthet
ic substrate, S-2238, and the natural substrate, fibrinogen. This ability was hi
ghly potentiated by the addition of exogenous factor Va, which functions as a co
-factor for the enzyme factor Xa. In contrast, prothrombin activation was not ob
served when cells were previously incubated with DEGR-factor Xa, an inactive der
ivative of the enzyme. Moreover, a monoclonal antibody against bovine factor Xa 
reduced the prothrombin-converting activity of tumor cells. In conclusion, the d
ata strongly suggest that MV3 cells recruit factor Xa from the culture medium, t
riggering an uncommon procoagulant mechanism.#^dnd^i1#^tm^len^kMV3 melanoma^i1#^
tm^len^kBlood clotting^i1#^tm^len^kTissue factor^i1#other#37#CNPq#FAPERJ#Fundaçã
o Universitária José Bonifácio#Fundação Ary Frauzino#Fundação Educacional Charle
s Darwin#20070503#May 3, 2007#20071122#November 22, 2007#6877.htm#Internet^ihttp
://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000200004##
00375000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704014900071002000900220#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#5#1#article#100#<P> <font face="Arial, H
elvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, February 2008, 
Volume 41(2) 99-105</B> </font></P>      ^cY#6877.htm##
00357000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704013100071002000900202#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#6#2#article#100#<P><font size="5" face="
Arial, Helvetica, sans-serif"><B>Procoagulant properties of human MV3 melanoma c
ells</B> </font>       ^cY#6877.htm##
00632000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704040600071002000900477#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#7#3#article#100#<P><font face="Arial, He
lvetica, sans-serif">D.L.A. Geaquinto<SUP>1</SUP>, R.S. Fernandes<SUP>1</SUP>, L
.G. Lima<SUP>1</SUP>, C. Barja-Fidalgo<SUP>2</SUP> and <b><a href="#Corresponden
ce"><img src="/img/revistas/bjmbr/v41n2/recor.gif" border="0"></a></b> <a href="
mailto:robsonqm@bioqmed.ufrj.br"><img src="/img/revistas/bjmbr/v41n2/email-ca.gi
f" border="0"></a> R.Q. Monteiro<SUP>1</SUP> </font>      ^cY#6877.htm##
00446000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704022000071002000900291#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#8#4#article#100#<P><font face="Arial, He
lvetica, sans-serif"><SUP>1</SUP>Instituto de Bioqu&iacute;mica M&eacute;dica, C
entro de Ci&ecirc;ncias da Sa&uacute;de, Universidade Federal do Rio de Janeiro,
 Rio de Janeiro, RJ, Brasil     ^cY#6877.htm##
00389000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704016300071002000900234#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#9#5#article#100#<br>        <SUP>2</SUP>
Departamento de Farmacologia, Instituto de Biologia, Universidade do Estado do R
io de Janeiro, Rio de Janeiro, RJ, Brasil</font>       ^cY#6877.htm##
00417000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704019000072002000900262#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#10#6#article#100#<P> <font face="Arial, 
Helvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n2/d
own.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A> 
   ^cY#6877.htm##
00414000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704018700072002000900259#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#11#7#article#100#<BR>   <A HREF="#Introd
uction"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPA
CE=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    
^cY#6877.htm##
00414000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704018700072002000900259#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#12#8#article#100#<BR>   <A HREF="#Materi
al"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0
 HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    
^cY#6877.htm##
00399000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704017200072002000900244#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#13#9#article#100#<BR>   <A HREF="#Result
s"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#6877.htm##
00409000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704018100073002000900254#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#14#10#article#100#<BR>   <A HREF="#Discu
ssion"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#6
877.htm##
00396000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704016800073002000900241#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#15#11#article#100#<BR>   <A HREF="#Refer
ences"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#6877.htm##
00437000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704020900073002000900282#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#16#12#article#100#<br>   </strong></A><A
 HREF="#Acknowledgments"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOT
TOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Acknowledgments"><strong>Acknowled
gments</strong></A>    ^cY#6877.htm##
00446000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704021800073002000900291#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#17#13#article#100#<BR>   <A HREF="#Corre
spondence"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 V
SPACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspondence and Footn
otes</strong></A>  </font>      ^cY#6877.htm##
00276000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004800073002000900121#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#18#14#article#100#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>      ^cY#6877.htm##
00538000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031000073002000900383#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#19#15#article#100#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/ba
ck.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  <fon
t face="Arial, Helvetica, sans-serif">      ^cY#6877.htm##
01563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704133500073002000901408#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#20#16#article#100#<P>A correlation betwe
en cancer and prothrombotic states has long been described. More recently, a num
ber of studies have focused on the procoagulant mechanisms exhibited by tumor ce
lls. In the present study, we dissected the molecular mechanisms responsible for
 the procoagulant activity of MV3, a highly aggressive human melanoma cell line.
 It was observed that tumor cells strongly accelerate plasma coagulation as a re
sult of: i) expression of the blood clotting initiator protein, a tissue factor,
 as shown by flow cytometry and functional assays (factor Xa formation in the pr
esence of cells and factor VIIa), and ii) direct activation of prothrombin to th
rombin by cells, as evidenced by hydrolysis of the synthetic substrate, S-2238, 
and the natural substrate, fibrinogen. This ability was highly potentiated by th
e addition of exogenous factor Va, which functions as a co-factor for the enzyme
 factor Xa. In contrast, prothrombin activation was not observed when cells were
 previously incubated with DEGR-factor Xa, an inactive derivative of the enzyme.
 Moreover, a monoclonal antibody against bovine factor Xa reduced the prothrombi
n-converting activity of tumor cells. In conclusion, the data strongly suggest t
hat MV3 cells recruit factor Xa from the culture medium, triggering an uncommon 
procoagulant mechanism.      ^cY#6877.htm##
00348000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704012000073002000900193#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#21#17#article#100#<P>Key words: MV3 mela
noma; Blood clotting; Tissue factor; Thrombin </font>  <HR ALIGN=LEFT WIDTH=100%
 SIZE=2>      ^cY#6877.htm##
00592000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704036400073002000900437#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#22#18#article#100#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><
B>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-ser
if"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTO
M BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>  <font face="Arial, Helvetica, 
sans-serif">      ^cY#6877.htm##
00988000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704076000073002000900833#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#23#19#article#100#<P>Blood coagulation i
nvolves a series of zymogen acti-vation reactions that are mainly performed by e
nzyma- tic complexes consisting of a serine protease, a protein co-factor and me
mbranes containing anionic phospholipids (1). Tissue factor (TF) is a 47-kDa mem
brane-bound protein that serves as a receptor and co-factor for the enzyme facto
r VIIa (FVIIa), with subsequent formation of the extrinsic tenase complex that c
onverts factor X (FX) to FXa (2). Further recruitment of activated platelets, wh
ich expose phosphatidylserine on their membranes, allows the assembly of the int
rinsic tenase (FIXa/FVIIIa) and prothrombinase (FXa/FVa) complexes, resulting in
 additional FX activation and conversion of prothrombin to thrombin, respectivel
y (3).        ^cY#6877.htm##
00975000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704074700073002000900820#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#24#20#article#100#<P>A correlation betwe
en cancer and procoagulant states has been described for more than a century (4,
5) and a number of mechanisms have been proposed to explain such observations, i
ncluding (6): i) increased expression of procoagulant proteins by tumor cells; i
i) production of inflammatory cytokines by tumor cells and/or the host with subs
equent activation of vascular cells, including platelets, endothelial cells and 
monocytes; iii) direct tumor-cell interactions also resulting in activation of v
ascular cells; iv) exposure of procoagulant lipids, in particular phosphatidylse
rine, by tumor cells (7,8). Therefore, tumor cells may activate blood clotting b
y promoting the assembly of procoagulant complexes on their surface (9-11).     
 ^cY#6877.htm##
00910000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704068200073002000900755#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#25#21#article#100#<P>Several studies hav
e indicated that coagulation proteins play significant roles in cancer biology. 
Studies employing cultured cells as well as patient samples have demonstrated a 
strong correlation between TF expression and an aggressive pattern (12,13). Also
, the presence of TF correlates with production of vascular endothelial growth f
actor and/or increased microvessel density (13,14). Aberrant expression and acti
vation of the coagulation enzyme receptors (proteinase-activated receptors) on t
umor cells have also been associated with many aspects of tumor biology includin
g migration, survival and production of angiogenic factors, enzymes and cytokine
s (15-17).      ^cY#6877.htm##
01167000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704093900073002000901012#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#26#22#article#100#<P>Melanoma is a highl
y metastatic cancer, and there is strong evidence that a procoagulant behavior c
ontributes to this aggressive pattern (18,19). MV3 is a human melanoma cell line
 that has been established after subcutaneous implantation of fragments of a fre
sh human melanoma metastasis sample in nude mice (20). This cell line is highly 
tumorigenic and metastatic in nude mice and represents a useful tool for studyin
g the expression and regulation of molecules in human melanoma cells involved in
 the process of metastasis. In the present study, we demonstrate that MV3 cells 
display potent procoagulant activity, an ability partially due to the presence o
f functional TF on MV3 cells. In addition, tumor cells directly activated prothr
ombin to thrombin, this effect being strongly potentiated by FVa and significant
ly inhibited by DEGR-FXa or a monoclonal antibody against FXa.   </font>  <HR AL
IGN=LEFT WIDTH=100% SIZE=2>      ^cY#6877.htm##
00596000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704036800073002000900441#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#27#23#article#100#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Ma
terial and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans
-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=B
OTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>  <font face="Arial, Helveti
ca, sans-serif">      ^cY#6877.htm##
00265000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704003700073002000900110#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#28#24#article#100#<P><b>Material</b>  </
font>      ^cY#6877.htm##
01147000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704091900073002000900992#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#29#25#article#100#<P><font face="Arial, 
Helvetica, sans-serif">Human prothrombin was purified according to a previously 
reported procedure (21). FXa and human fibrinogen were purchased from Calbiochem
 (USA). Human FVa, FX and monoclonal anti-bovine (ABX-5051) and anti-human (AHX-
5050) FX were purchased from Haematological Technologies (USA). According to the
 manufacturer, an antibody raised against the human protein does not recognize b
ovine FX. Human FVIIa was purchased from American Diagnostica (USA). Chromogenic
 substrates for FXa (S2765, n<font face="Symbol">a</font>benzyloxycarbonylDArgGl
yArgpnitroanilide) and thrombin (S-2238, H-D-phenylalanyl-L-pipecolyl-L-arginine
-p-nitroaniline dihydrochloride) were purchased from Diapharma. MV3 cells were k
indly provided by Dr. C. Marcinkiewicz (Temple University, USA). Ethylenediamine
tetraacetic acid (EDTA) and polyethyleneglycol were purchased from Sigma (USA). 
</font>      ^cY#6877.htm##
00310000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704008200073002000900155#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#30#26#article#100#<P><font face="Arial, 
Helvetica, sans-serif"><B>Cell culture</B> </font>      ^cY#6877.htm##
00953000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704072500073002000900798#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#31#27#article#100#<P><font face="Arial, 
Helvetica, sans-serif">The human melanoma cell line, MV3, was grown at 37&#176;C
 in a humidified 5% CO<SUB>2</SUB> atmosphere in culture flasks by subconfluent 
passages in Dulbecco's modified Eagle's medium (DMEM, Gibco-BRL, USA) supplement
ed with 2 g/L HEPES, 60 mg/L penicillin, 100 mg/L streptomycin, 2 g/L sodium bic
arbonate. Subconfluent tumor cells were detached with Hank's EDTA buffer (0.4 g/
L potassium chloride, 0.06 g/L potassium phosphate monobasic, 8 g/L NaCl, 0.048 
g/L sodium phosphate dibasic, 1 g/L D-glucose, 350 mg/L sodium bicarbonate, 1.86
 g/L EDTA, pH 7.2), resuspended in DMEM and transferred to another culture flask
 with DMEM containing 10% fetal bovine serum. </font>      ^cY#6877.htm##
00352000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704012400073002000900197#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#32#28#article#100#<P><font face="Arial, 
Helvetica, sans-serif"><B>Procoagulant activity measured by recalcification time
</B> </font>      ^cY#6877.htm##
00846000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704061800073002000900691#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#33#29#article#100#<P><font face="Arial, 
Helvetica, sans-serif">The ability of MV3 melanoma cells to potentiate plasma co
agulation was assessed by measuring the recalcification time on an Amelung KC4A 
coagulometer (Labcon, Germany), using plastic tubes. Fifty microliters of citrat
ed human platelet-poor plasma (3.8% sodium citrate, 1:9, v/v) was incubated with
 50 &#181;L MV3 cells at 5 x 10<SUP>3</SUP>, 5 x 10<SUP>4</SUP>, or 5 x 10<SUP>5
 </SUP>cells and suspended in PBS for 1 min at 37&#176;C. Plasma clotting was in
itiated by the addition of 100 &#181;L 12.5 mM CaCl<SUB>2</SUB> and coagulation 
time was recorded. </font>      ^cY#6877.htm##
00322000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704009400073002000900167#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#34#30#article#100#<P><font face="Arial, 
Helvetica, sans-serif"><B>Flow cytometric analyses</B> </font>      ^cY#6877.htm
##
00843000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704061500073002000900688#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#35#31#article#100#<P><font face="Arial, 
Helvetica, sans-serif">Cells grown in culture were resuspended in phosphate buff
er containing 1% BSA and incubated for 30 min, at 4&#176;C, with a murine monocl
onal antibody against TF (4509, American Diagnostica), that had been directly la
beled with the green-fluorescent Alexa Fluor 488 dye using the Alexa Fluor<SUP>&
#174;</SUP> 488 Monoclonal Antibody Labeling Kit (A-20181, Molecular Probes/Invi
trogen, USA). After washing to remove unbound antibody, cells were analyzed usin
g a FACScalibur (Becton-Dickinson, USA). Data were analyzed with the BD CellQues
t 3.3 software. </font>      ^cY#6877.htm##
00362000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704013400073002000900207#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#36#32#article#100#<P><font face="Arial, 
Helvetica, sans-serif"><B>FX activation as followed by hydrolysis of chromogenic
 substrate</B> </font>      ^cY#6877.htm##
01416000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704118800073002000901261#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#37#33#article#100#<P><font face="Arial, 
Helvetica, sans-serif">Activation of FX to FXa catalyzed by FVIIa was performed 
in 50&#160;mM HEPES, 100&#160;mM NaCl, 5&#160;mM CaCl<SUB>2</SUB>, 1 mg/mL BSA, 
pH 7.5 (HEPES-BSA buffer), as follows: FVIIa (1 nM) was incubated for different 
times at 37&#176;C with MV3 cells (0 to 5 x 10<SUP>4</SUP> cells/mL) in the pres
ence of 100 nM FX. After the addition of 50 &#181;L 300 &#181;M S-2765 prepared 
in 50&#160;mM Tris-HCl, 150&#160;mM NaCl, 20&#160;mM EDTA, 1 mg/mL polyethyleneg
lycol 6000, pH 7.5 (Tris-EDTA buffer), absorbance at 405 nm was recorded at 37&#
176;C for 30 min at 6-s intervals using a Thermomax Microplate Reader (Molecular
 Devices, USA) equipped with a microplate mixer and heating system as described 
(22). Velocities (mOD/min) obtained in the first minutes of reaction were used t
o calculate the amount of FXa formed, as compared to a standard curve using know
n enzyme concentrations. In some experiments, cells were previously incubated wi
th anti-TF antibody (4509, American Diagnostica), before starting the FX activat
ion reaction. Appropriate controls performed in the absence of FVIIa showed no s
ignificant formation of FXa. </font>      ^cY#6877.htm##
00385000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704015700073002000900230#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#38#34#article#100#<P><font face="Arial, 
Helvetica, sans-serif"><B>Prothrombin activation as followed by hydrolysis of ch
romogenic substrate or fibrinogen</B> </font>      ^cY#6877.htm##
01345000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704111700073002000901190#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#39#35#article#100#<P><font face="Arial, 
Helvetica, sans-serif">Activation of prothrombin to thrombin was performed in 50
&#160;mM HEPES, 100&#160;mM NaCl, 5&#160;mM CaCl<SUB>2</SUB>, 1 mg/mL BSA, pH 7.
5 (HEPES-BSA buffer), as follows: 500 nM prothrombin was incubated for different
 times at 37&#176;C with 0 to 5 x 10<SUP>4</SUP> cells/mL MV3 cells in the prese
nce or absence of 1 nM FVa. After the addition of 50 &#181;L 300 &#181;M S-2765 
(prepared in Tris-EDTA buffer) or 2 mg/mL fibrinogen (prepared in HEPES-BSA buff
er), absorbance at 405 nm was recorded at 37&#176;C for 60 min at 6-s intervals 
using a Thermomax Microplate Reader (Molecular Devices) as described above. Velo
cities (mOD/min) obtained in the first minutes of reaction were used to calculat
e the amount of thrombin formed, as compared to a standard curve using known enz
yme concentrations. In some experiments, MV3 cells were pre-incubated with DEGR-
FXa (130 nM) overnight or with monoclonal anti-bovine or anti-human FX antibodie
s (10 &#181;g/mL) for 10 min, before starting the prothrombin activation reactio
n. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6877.htm##
00539000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031100073002000900384#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#40#36#article#100#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Res
ults</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HRE
F="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0
 VSPACE=0 HSPACE=0></B></A></font></P>       ^cY#6877.htm##
01692000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704146400073002000901537#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#41#37#article#100#<P><font face="Arial, 
Helvetica, sans-serif">In order to determine whether MV3    melanoma cells displ
ay procoagulant properties, we first tested the effect of    these cells on the 
recalcification time of human plasma. As shown in <a href="#Fig1">Figure    1</a
>, increasing cell concentrations strongly decreased the coagulation time,    de
monstrating that these cells display potent procoagulant activity. Previous    s
tudies employing other human melanoma cell lines have demonstrated this ability 
   as a result of TF expression (18,23). Accordingly, by means of flow-cytometri
c    analysis using a monoclonal antibody, we demonstrated positive staining for
    TF on MV3 cells (<a href="#Fig2">Figure 2A</a>). Further enzymatic assays sh
owed    that TF expressed on MV3 cells is functional. <a href="#Fig2">Figure 2</
a> shows    that FXa formation was both FVIIa- (<a href="#Fig2">Figure 2B</a>) a
nd time-dependent    (<a href="#Fig2">Figure 2C</a>), indicating the formation o
f the extrinsic tenase    complex. Negligible zymogen activation was observed in
 the absence of FVIIa    (<a href="#Fig2">Figure 2C</a>), possibly indicating th
at MV3 cells are not    able to directly activate FX. In addition, <a href="#Fig
2">Figure 2D</a> shows    that increasing concentrations of a monoclonal anti-TF
 antibody progressively    decreased FX activation, confirming that this effect 
is dependent on the presence    of the FVIIa co-factor, TF. </font> </P>      ^c
Y#6877.htm##
00820000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704059200073002000900665#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#42#38#article#100#<P><font face="Arial, 
Helvetica, sans-serif">In addition to TF expression, other mechanisms have been 
proposed to explain the procoagulant activity of tumor cells (6). In this contex
t, MV3 cells were able to directly convert prothrombin to thrombin, i.e., in the
 absence of additional blood clotting proteins in the assay medium (<a href="#Fi
g3">Figure 3</a>, open squares). Remarkably, this ability was strongly potentiat
ed by the addition of the FXa co-factor, FVa (<a href="#Fig3">Figure 3</a>, fill
ed squares), suggesting that MV3 cells display previously bound enzyme. </font> 
      ^cY#6877.htm##
00956000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704072800073002000900801#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#43#39#article#100#<P><font face="Arial, 
Helvetica, sans-serif">The ability of MV3-generated thrombin    to cleave fibrin
ogen was further evaluated. <a href="#Fig4">Figure 4A</a> shows    that incubati
on of prothrombin with MV3 cells results in fibrinogen clotting,    as detected 
by increased absorbance at 405 nm. No significant clotting was detected    when 
fibrinogen was incubated only with MV3 cells or prothrombin. As observed    with
 the chromogenic substrate, addition of FVa to the assay medium efficiently    p
otentiated thrombin formation which resulted in a significant decrease of the   
 time for fibrinogen clotting, as compared to curves in the absence of the prote
in    co-factor (<a href="#Fig4">Figure 4B</a>). </font>      ^cY#6877.htm##
01066000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704083800073002000900911#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#44#40#article#100#<P><font face="Arial, 
Helvetica, sans-serif">Finally, to better understand the    mechanism of prothro
mbin activation by MV3, cells were pre-incubated with DEGR-FXa,    an inactive F
Xa derivative, prior to zymogen activation assay. As seen in <a href="#Fig5">Fig
ure    5A</a>, treatment with the inactivated enzyme rendered MV3 cells unable t
o activate    prothrombin. In addition, assays were performed in the presence of
 specific    anti-FX monoclonal antibodies. As seen in <a href="#Fig5">Figure 5B
</a>, anti-bovine    but not anti-human FX significantly decreased zymogen activ
ation. Overall, these    data strongly suggest that MV3 cells recruit FXa from t
he fetal calf serum-enriched    culture medium, with this mechanism being, at le
ast in part, responsible for    the procoagulant ability of these tumor cells. <
/font>      ^cY#6877.htm##
00511000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704028300073002000900356#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#45#41#article#100#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>  <table width="100%"  border="0">    <tr align="left" valign="t
op">      <td width="12%"><a href="/img/revistas/bjmbr/v41n2/html/6877i01.htm"><
img src="/img/revistas/bjmbr/v41n2/6877i01peq.jpg" border="2"></a></td>      <td
 width="88%">    ^cY#6877.htm##
00669000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704044100073002000900514#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#46#42#article#100#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. Procoagulant activity of MV3
 melanoma cells. MV3 cells (in PBS) at the indicated concentrations were incubat
ed with human plasma followed by recalcification with 12.5 mM CaCl<SUB>2</SUB>. 
Each point represents the mean &#177; SD of three assays. The open square repres
ents controls performed in the absence of cells. </font>         </td>    </tr> 
 </table>      ^cY#6877.htm##
00615000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038700073002000900460#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#47#43#article#100#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (69 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v
41n2/html/6877i02.htm"><img src="/img/revistas/bjmbr/v41n2/6877i02peq.jpg" borde
r="2"></a></td>      <td width="88%">    ^cY#6877.htm##
01251000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704102300073002000901096#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#48#44#article#100#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig2"></a>Figure 2. MV3 cells express functional
 tissue factor (TF) and assemble the extrinsic tenase complex. <I>A</I>, Flow-cy
tometric analysis of TF expression in MV3 melanoma cells. The solid line represe
nts staining with monoclonal anti-TF antibody labeled with green-fluorescent Ale
xa Fluor 488 dye. The grey region represents control cells with no staining. <I>
B</I>, FVIIa-dependence for activation of FX (100 nM) in the presence of 5 x 10<
SUP>4</SUP> cells, after 8 min of reaction. <I>C</I>, Kinetics of the activation
 of FX (100 nM) in the presence of FVIIa (1 nM) and MV3 cells (5 x 10<SUP>4</SUP
> cells/mL; squares), or MV3 cells (5 x 10<SUP>4</SUP> cells/mL) in the absence 
of FVIIa (asterisk). <I>D</I>, Effect of increasing concentrations of monoclonal
 antibody against human TF on the activation of FX. Each point represents the me
an &#177; SD of three determinations. FVIIa = factor VIIa; FX = factor X. </font
>      </td>    </tr>  </table>      ^cY#6877.htm##
00616000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038800073002000900461#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#49#45#article#100#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (102 K JPG file)]</fon
t></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <
tr align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/
v41n2/html/6877i03.htm"><img src="/img/revistas/bjmbr/v41n2/6877i03peq.jpg" bord
er="2"></a></td>      <td width="88%">    ^cY#6877.htm##
00668000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704044000073002000900513#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#50#46#article#100#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig3"></a>Figure 3. Prothrombin activation by MV
3 cells, as detected by S-2238 hydrolysis. MV3 cells (5 x 10<SUP>4</SUP> cells/m
L) were incubated with 0.5 &#181;M prothrombin in the absence (open squares) or 
in the presence (filled squares) of FVa (1 nM). Each point represents the mean &
#177; SD of three determinations. FVa = factor Va. </font>      </td>    </tr>  
</table>      ^cY#6877.htm##
00615000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038700073002000900460#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#51#47#article#100#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (81 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v
41n2/html/6877i04.htm"><img src="/img/revistas/bjmbr/v41n2/6877i04peq.jpg" borde
r="2"></a></td>      <td width="88%">    ^cY#6877.htm##
01037000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704080900073002000900882#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#52#48#article#100#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig4"></a>Figure 4. Fibrinogen clotting by MV3-g
enerated thrombin. <I>A</I>, MV3 cells at the indicated concentrations were incu
bated with human fibrinogen (2 mg/mL) and 0.5 &#181;M prothrombin. Fibrinogen cl
otting was monitored by the increase in absorbance at 405 nm. The filled circles
 indicate controls performed in the presence of MV3 cells (5 x 10<SUP>4</SUP> ce
lls/mL) and in the absence of prothrombin (No PT). <I>B</I>, MV3 cells (5 x 10<S
UP>4</SUP> cells/mL) were incubated with human fibrinogen (2 mg/mL) and 0.5 &#18
1;M prothrombin in the presence (filled squares) or in the absence (open squares
) of FVa (1 nM). Each point represents the mean &#177; SD of three determination
s. FVa = factor Va. </font>      </td>    </tr>  </table>      ^cY#6877.htm##
00622000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039400073002000900467#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#53#49#article#100#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (92 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/v
41n2/html/6877i05.htm"><img src="/img/revistas/bjmbr/v41n2/6877i05peq.jpg" borde
r="2"></a></td>      <td width="88%">           ^cY#6877.htm##
01074000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704084600073002000900919#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#54#50#article#100#<p><font face="Arial, 
Helvetica, sans-serif"><a name="Fig5"></a>Figure 5.          DEGR-FXa and bovine
 anti-FX (factor X) decrease prothrombin activation          by MV3 cells. <I>A<
/I>, Kinetics of the activation of prothrombin (0.5          &#181;M) in the pre
sence of 5 x 10<SUP>4</SUP> MV3 cells/mL cultured overnight          in the pres
ence (open squares) or in the absence (filled squares) of 130          nM DEGR-F
Xa. <I>B</I>, Effect of the indicated monoclonal anti-FX antibodies          (10
 &#181;g/mL) on prothrombin (0.5 &#181;M) activation by 5 x 10<SUP>4</SUP>      
    MV3 cells/mL after 90 min of incubation, as determined by S-2238 hydrolysis.
          Each point represents the mean &#177; SD of three determinations. DEGR
-FXa          = an inactive derivative of the enzyme. </font></p>     </td>    <
/tr>  </table>      ^cY#6877.htm##
00345000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011700073002000900190#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#55#51#article#100#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (84 K JPG file)]</font
></P>      ^cY#6877.htm##
00276000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004800073002000900121#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#56#52#article#100#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>      ^cY#6877.htm##
00498000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704027000073002000900343#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#57#53#article#100#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007
F><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n
2/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  
    ^cY#6877.htm##
01279000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704105100073002000901124#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#58#54#article#100#<P><font face="Arial, 
Helvetica, sans-serif">Several lines of evidence indicate that the procoagulant 
properties of cancer cells play a significant role in tumor biology, with this o
bservation being particularly evident in melanoma. In the present study, we iden
tified two major procoagulant mechanisms in the highly aggressive human melanoma
 cell line, MV3. These cells express functional TF on their surface as demonstra
ted by flow cytometric and functional assays. In fact, the presence of TF in mel
anoma cell lines has been well documented and the levels of protein expression s
eem to be correlated with the aggressiveness (23). TF levels seem to be also inv
olved in the metastatic potential of melanoma cells, although procoagulant activ
ity is not required for this ability (19). In addition, the production of vascul
ar endothelial growth factor was directly correlated with TF expression in melan
oma cell lines, with this property being dependent on the cytoplasmic tail but n
ot on the extracellular domain of the protein (24). </font>      ^cY#6877.htm##
00976000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704074800073002000900821#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#59#55#article#100#<P><font face="Arial, 
Helvetica, sans-serif">Our data strongly suggest that MV3 cells recruit small am
ounts of active FXa, resulting in an unusual mechanism of procoagulant activity 
in which cells directly activate prothrombin to thrombin in the absence of addit
ional exogenous blood clotting factors. In fact the ability of tumor cells to re
cruit FXa and promote prothrombin activation has been previously reported for B1
6-F10 melanoma (10), colon adenocarcinoma (25), human pleural mesothelial cells 
(26), and others. In the last case, it was reported that a number of monoclonal 
antibodies raised against FXa impaired the function of tumor cell-bound enzyme, 
offering a potential means to prevent local thrombin formation (27). </font>    
  ^cY#6877.htm##
00720000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704049200073002000900565#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#60#56#article#100#<P><font face="Arial, 
Helvetica, sans-serif">In addition to TF, thrombin seems to play a key role in m
elanoma progression. Thrombin increases the metastatic potential of B16 melanoma
 cells in mice (28,29) while the inhibition of the enzyme by hirudin decreases t
umor growth, metastasis and seeding into blood (30-32). In fact, a number of thr
ombin actions in melanoma cells are mediated by the protease-activated receptor 
(33-35), which requires catalytically active enzyme. </font>      ^cY#6877.htm##
00900000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704067200073002000900745#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#61#57#article#100#<P><font face="Arial, 
Helvetica, sans-serif">The presence of fibrin in the tumor stroma has been well 
documented (36) and in fact the cross-linked fibrin provides a provisional matri
x that facilitates tumor angiogenesis (37). In this context, TF-induced generati
on of thrombin with subsequent fibrin deposition is usually referred to as the m
ain clotting-dependent mechanism in tumor progression. Herein we demonstrate tha
t incubation of prothrombin with MV3 cells results in fibrinogen cleavage. As a 
consequence, tumor cells displaying this ability could support fibrin deposition
 despite presenting low levels of TF. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>
      ^cY#6877.htm##
00544000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031600073002000900389#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#62#58#article#100#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>
References</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif">
<A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BO
RDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6877.htm##
00407000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704016500075002000900240#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#63#59#article#100#1#<P><font
 face="Arial, Helvetica, sans-serif">1. Mann KG. Biochemistry and physiology of 
blood coagulation. <I>Thromb Haemost</I> 1999; 82: 165-174. </font>      ^cY#687
7.htm##
00451000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704020900075002000900284#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#64#60#article#100#2#<P><font
 face="Arial, Helvetica, sans-serif">2. Mackman N. Role of tissue factor in hemo
stasis, thrombosis, and vascular development. <I>Arterioscler Thromb Vasc Biol</
I> 2004; 24: 1015-1022. </font>      ^cY#6877.htm##
00434000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704019200075002000900267#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#65#61#article#100#3#<P><font
 face="Arial, Helvetica, sans-serif">3. Monroe DM, Hoffman M, Roberts HR. Platel
ets and thrombin generation. <I>Arterioscler Thromb Vasc Biol</I> 2002; 22: 1381
-1389. </font>      ^cY#6877.htm##
00490000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704024800075002000900323#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#66#62#article#100#4#<P><font
 face="Arial, Helvetica, sans-serif">4. Mandala M, Ferretti G, Cremonesi M, Cazz
aniga M, Curigliano G, Barni S. Venous thromboembolism and cancer: new issues fo
r an old topic. <I>Crit Rev Oncol Hematol</I> 2003; 48: 65-80. </font>      ^cY#
6877.htm##
00413000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704017100075002000900246#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#67#63#article#100#5#<P><font
 face="Arial, Helvetica, sans-serif">5. Otten HM, Prins MH. Venous thromboemboli
sm and occult malignancy. <I>Thromb Res</I> 2001; 102: V187-V194. </font>      ^
cY#6877.htm##
00438000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704019600075002000900271#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#68#64#article#100#6#<P><font
 face="Arial, Helvetica, sans-serif">6. Rickles FR, Falanga A. Molecular basis f
or the relationship between thrombosis and cancer. <I>Thromb Res</I> 2001; 102: 
V215-V224. </font>      ^cY#6877.htm##
00577000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704033500075002000900410#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#69#65#article#100#7#<P><font
 face="Arial, Helvetica, sans-serif">7. Connor J, Bucana C, Fidler IJ, Schroit A
J. Differentiation-dependent expression of phosphatidylserine in mammalian plasm
a membranes: quantitative assessment of outer-leaflet lipid by prothrombinase co
mplex formation. <I>Proc Natl Acad Sci U S A </I>1989; 86: 3184-3188. </font>   
   ^cY#6877.htm##
00519000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704027700075002000900352#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#70#66#article#100#8#<P><font
 face="Arial, Helvetica, sans-serif">8. Barrowcliffe TW, Fabregas P, Jardi M, Ca
ncelas J, Rabaneda M, Felez J. Procoagulant activity of T lymphoblastoid cells d
ue to exposure of negatively charged phospholipid. <I>Thromb Haemost</I> 2002; 8
7: 442-449. </font>      ^cY#6877.htm##
00475000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704023300075002000900308#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#71#67#article#100#9#<P><font
 face="Arial, Helvetica, sans-serif">9. VanDeWater L, Tracy PB, Aronson D, Mann 
KG, Dvorak HF. Tumor cell generation of thrombin via functional prothrombinase a
ssembly. <I>Cancer Res</I> 1985; 45: 5521-5525. </font>      ^cY#6877.htm##
00461000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021800076002000900294#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#72#68#article#100#10#<P><fon
t face="Arial, Helvetica, sans-serif">10. Kirszberg C, Rumjanek VM, Monteiro RQ.
 Assembly and regulation of prothrombinase complex on B16F10 melanoma cells. <I>
Thromb Res</I> 2005; 115: 123-129.</font>      ^cY#6877.htm##
00490000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024700076002000900323#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#73#69#article#100#11#<P><fon
t face="Arial, Helvetica, sans-serif">11. Fernandes RS, Kirszberg C, Rumjanek VM
, Monteiro RQ. On the molecular mechanisms for the highly procoagulant pattern o
f C6 glioma cells. <I>J Thromb Haemost</I> 2006; 4: 1546-1552. </font>      ^cY#
6877.htm##
00424000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704018100076002000900257#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#74#70#article#100#12#<P><fon
t face="Arial, Helvetica, sans-serif">12. Ruf W, Mueller BM. Tissue factor in ca
ncer angiogenesis and metastasis. <I>Curr Opin Hematol</I> 1996; 3: 379-384. </f
ont>      ^cY#6877.htm##
00442000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704019900076002000900275#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#75#71#article#100#13#<P><fon
t face="Arial, Helvetica, sans-serif">13. Guan M, Jin J, Su B, Liu WW, Lu Y. Tis
sue factor expression and angiogenesis in human glioma. <I>Clin Biochem</I> 2002
; 35: 321-325. </font>      ^cY#6877.htm##
00539000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029600076002000900372#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#76#72#article#100#14#<P><fon
t face="Arial, Helvetica, sans-serif">14. Nakasaki T, Wada H, Shigemori C, Miki 
C, Gabazza EC, Nobori T, et al. Expression of tissue factor and vascular endothe
lial growth factor is associated with angiogenesis in colorectal cancer. <I>Am J
 Hematol</I> 2002; 69: 247-254. </font>      ^cY#6877.htm##
00505000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026200076002000900338#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#77#73#article#100#15#<P><fon
t face="Arial, Helvetica, sans-serif">15. Even-Ram S, Uziely B, Cohen P, Grisaru
-Granovsky S, Maoz M, Ginzburg Y, et al. Thrombin receptor overexpression in mal
ignant and physiological invasion processes. <I>Nat Med</I> 1998; 4: 909-914. </
font>      ^cY#6877.htm##
00474000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023100076002000900307#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#78#74#article#100#16#<P><fon
t face="Arial, Helvetica, sans-serif">16. Belting M, Ahamed J, Ruf W. Signaling 
of the tissue factor coagulation pathway in angiogenesis and cancer. <I>Arterios
cler Thromb Vasc Biol</I> 2005; 25: 1545-1550. </font>      ^cY#6877.htm##
00422000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704017900076002000900255#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#79#75#article#100#17#<P><fon
t face="Arial, Helvetica, sans-serif">17. Rao LV, Pendurthi UR. Tissue factor-fa
ctor VIIa signaling. <I>Arterioscler Thromb Vasc Biol</I> 2005; 25: 47-56. </fon
t>      ^cY#6877.htm##
00500000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704025700076002000900333#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#80#76#article#100#18#<P><fon
t face="Arial, Helvetica, sans-serif">18. Mueller BM, Reisfeld RA, Edgington TS,
 Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematog
enous metastasis. <I>Proc Natl Acad Sci U S A</I> 1992; 89: 11832-11836. </font>
      ^cY#6877.htm##
00512000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026900076002000900345#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#81#77#article#100#19#<P><fon
t face="Arial, Helvetica, sans-serif">19. Bromberg ME, Konigsberg WH, Madison JF
, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway in
dependent of blood coagulation. <I>Proc Natl Acad Sci U S A</I> 1995; 92: 8205-8
209. </font>      ^cY#6877.htm##
00531000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028800076002000900364#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#82#78#article#100#20#<P><fon
t face="Arial, Helvetica, sans-serif">20. van Muijen GN, Jansen KF, Cornelissen 
IM, Smeets DF, Beck JL, Ruiter DJ. Establishment and characterization of a human
 melanoma cell line (MV3) which is highly metastatic in nude mice. <I>Int J Canc
er</I> 1991; 48: 85-91. </font>      ^cY#6877.htm##
00495000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704025200076002000900328#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#83#79#article#100#21#<P><fon
t face="Arial, Helvetica, sans-serif">21. Bezeaud A, Denninger MH, Guillin MC. I
nteraction of human alpha-thrombin and gamma-thrombin with antithrombin III, pro
tein C and thrombomodulin. <I>Eur J Biochem</I> 1985; 153: 491-496. </font>     
 ^cY#6877.htm##
00455000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021200076002000900288#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#84#80#article#100#22#<P><fon
t face="Arial, Helvetica, sans-serif">22. Francischetti IM, Valenzuela JG, Ribei
ro JM. Anophelin: kinetics and mechanism of thrombin inhibition. <I>Biochemistry
</I> 1999; 38: 16678-16685. </font>      ^cY#6877.htm##
00499000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704025600076002000900332#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#85#81#article#100#23#<P><fon
t face="Arial, Helvetica, sans-serif">23. Amirkhosravi A, Biggerstaff JP, Warnes
 G, Francis DA, Francis JL. Determination of tumor cell procoagulant activity by
 Sonoclot analysis in whole blood. <I>Thromb Res</I> 1996; 84: 323-332. </font> 
     ^cY#6877.htm##
00543000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704030000076002000900376#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#86#82#article#100#24#<P><fon
t face="Arial, Helvetica, sans-serif">24. Abe K, Shoji M, Chen J, Bierhaus A, Da
nave I, Micko C, et al. Regulation of vascular endothelial growth factor product
ion and angiogenesis by the cytoplasmic tail of tissue factor. <I>Proc Natl Acad
 Sci U S A</I> 1999; 96: 8663-8668. </font>      ^cY#6877.htm##
00460000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704021700076002000900293#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#87#83#article#100#25#<P><fon
t face="Arial, Helvetica, sans-serif">25. Sakai T, Noguchi M, Kisiel W. Tumor ce
lls augment the factor Xa-catalyzed conversion of prothrombin to thrombin. <I>Ha
emostasis</I> 1990; 20: 125-135. </font>      ^cY#6877.htm##
00477000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023400076002000900310#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#88#84#article#100#26#<P><fon
t face="Arial, Helvetica, sans-serif">26. Kumar A, Koenig KB, Johnson AR, Idell 
S. Expression and assembly of procoagulant complexes by human pleural mesothelia
l cells. <I>Thromb Haemost</I> 1994; 71: 587-592. </font>      ^cY#6877.htm##
00511000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704026800076002000900344#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#89#85#article#100#27#<P><fon
t face="Arial, Helvetica, sans-serif">27. Kumar A, Koenig KB, Johnson AR, Fair D
S, Idell S. Inhibition of factor Xa-mediated procoagulant activity of human lung
 fibroblasts and pleural mesothelial cells. <I>Eur Respir J</I> 1995; 8: 2038-20
45. </font>      ^cY#6877.htm##
00488000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024500076002000900321#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#90#86#article#100#28#<P><fon
t face="Arial, Helvetica, sans-serif">28. Nierodzik ML, Plotkin A, Kajumo F, Kar
patkin S. Thrombin stimulates tumor-platelet adhesion <I>in vitro</I> and metast
asis <I>in vivo</I>. <I>J Clin Invest</I> 1991; 87: 229-236. </font>      ^cY#68
77.htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024200076002000900318#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#91#87#article#100#29#<P><fon
t face="Arial, Helvetica, sans-serif">29. Wojtukiewicz MZ, Tang DG, Ciarelli JJ,
 Nelson KK, Walz DA, Diglio CA, et al. Thrombin increases the metastatic potenti
al of tumor cells. <I>Int J Cancer</I> 1993; 54: 793-806. </font>      ^cY#6877.
htm##
00500000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704025700076002000900333#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#92#88#article#100#30#<P><fon
t face="Arial, Helvetica, sans-serif">30. Esumi N, Fan D, Fidler IJ. Inhibition 
of murine melanoma experimental metastasis by recombinant desulfatohirudin, a hi
ghly specific thrombin inhibitor. <I>Cancer Res</I> 1991; 51: 4549-4556. </font>
      ^cY#6877.htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704024200076002000900318#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#93#89#article#100#31#<P><fon
t face="Arial, Helvetica, sans-serif">31. Hu L, Lee M, Campbell W, Perez-Soler R
, Karpatkin S. Role of endogenous thrombin in tumor implantation, seeding, and s
pontaneous metastasis. <I>Blood</I> 2004; 104: 2746-2751. </font>      ^cY#6877.
htm##
00527000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704028400076002000900360#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#94#90#article#100#32#<P><fon
t face="Arial, Helvetica, sans-serif">32. Im JH, Fu W, Wang H, Bhatia SK, Hammer
 DA, Kowalska MA, et al. Coagulation facilitates tumor cell spreading in the pul
monary vasculature during early metastatic colony formation. <I>Cancer Res</I> 2
004; 64: 8613-8619. </font>      ^cY#6877.htm##
00536000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029300076002000900369#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#95#91#article#100#33#<P><fon
t face="Arial, Helvetica, sans-serif">33. Nierodzik ML, Chen K, Takeshita K, Li 
JJ, Huang YQ, Feng XS, et al. Protease-activated receptor 1 (PAR-1) is required 
and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. <I>Bl
ood</I> 1998; 92: 3694-3700. </font>      ^cY#6877.htm##
00439000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704019600076002000900272#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#96#92#article#100#34#<P><fon
t face="Arial, Helvetica, sans-serif">34. Tellez C, Bar-Eli M. Role and regulati
on of the thrombin receptor (PAR-1) in human melanoma. <I>Oncogene</I> 2003; 22:
 3130-3137. </font>      ^cY#6877.htm##
00495000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704025200076002000900328#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#97#93#article#100#35#<P><fon
t face="Arial, Helvetica, sans-serif">35. Shi X, Gangadharan B, Brass LF, Ruf W,
 Mueller BM. Protease-activated receptors (PAR1 and PAR2) contribute to tumor ce
ll motility and metastasis. <I>Mol Cancer Res</I> 2004; 2: 395-402. </font>     
 ^cY#6877.htm##
00534000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704029100076002000900367#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#98#94#article#100#36#<P><fon
t face="Arial, Helvetica, sans-serif">36. Nagy JA, Brown LF, Senger DR, Lanir N,
 Van de Water L, Dvorak AM, et al. Pathogenesis of tumor stroma generation: a cr
itical role for leaky blood vessels and fibrin deposition. <I>Biochim Biophys Ac
ta</I> 1989; 948: 305-326. </font>      ^cY#6877.htm##
00475000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000300073704023200076002000900308#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#p#99#95#article#100#37#<P><fon
t face="Arial, Helvetica, sans-serif">37. Fernandez PM, Patierno SR, Rickles FR.
 Tissue factor and fibrin in tumor angiogenesis. <I>Semin Thromb Hemost</I> 2004
; 30: 31-44. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6877.htm##
00564000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704033500074002000900409#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#100#96#article#100#<P><font face="Arial,
 Helvetica, sans-serif"><A NAME="Acknowledgments"></A><FONT color="#00007F" SIZE
=4><B>Acknowledgments</B></FONT></font> <font size="4" face="Arial, Helvetica, s
ans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIG
N=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></A></font></P>      ^cY#6877.h
tm##
00546000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704031700074002000900391#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#101#97#article#100#<P><font face="Arial,
 Helvetica, sans-serif">We thank Dr. C.R. Carlini (UFRGS) for a careful revision
 of the manuscript, Dr. Carmen Nogueira (HUCFF/UFRJ, RJ, Brazil) for providing t
he human plasma samples, and Ana L&uacute;cia O. Carvalho for technical assistan
ce. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6877.htm##
00565000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704033600074002000900410#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#102#98#article#100#<P><FONT SIZE=4 face=
"Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F>
<B>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, He
lvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back
.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6877.
htm##
00673000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704044400074002000900518#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#103#99#article#100#<p><font face="Arial,
 Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v41n2/r
ecor.gif" border="0"></a> Address for correspondence:</b> R.Q. Monteiro, Institu
to de Bioqu&iacute;mica M&eacute;dica, CCS, UFRJ, Avenida Bauh&iacute;nia, 400, 
Ilha do Fund&atilde;o, 21941590 Rio de Janeiro, RJ, Brasil. Fax: +55-21-2270-864
7. E-mail: <a href="mailto:robsonqm@bioqmed.ufrj.br">robsonqm@bioqmed.ufrj.br</a
></font> </p>      ^cY#6877.htm##
00718000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704048800075002000900563#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6877.htm#S#p#104#100#article#100#<P><font face="Arial
, Helvetica, sans-serif">Research supported by CNPq, FAPERJ, Funda&ccedil;&atild
e;o Universit&aacute;ria Jos&eacute; Bonif&aacute;cio (FUJB), and &quot;Programa
 Interinstitucional de Ensino, Pesquisa e Extens&atilde;o em Biologia do C&acirc
;ncer&quot; of Funda&ccedil;&atilde;o Ary Frauzino para Pesquisa e Controle do C
&acirc;ncer (FAF), and Funda&ccedil;&atilde;o Educacional Charles Darwin (FECD).
 Received May 3, 2007. Accepted November 22, 2007. </font>      ^cY#6877.htm##
00491000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100015000740120053000890300
01500142065000900157064000500166031000300171014000800174865000900182002000900191
035001000200801001500210#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#c#
105#1#article#37#1#^rND^sMann^nKG#Biochemistry and physiology of blood coagulati
on^len#Thromb Haemost#19990000#1999#82#165-174#20080200#6877.htm#0340-6245#Throm
b Haemost##
00550000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740120078000910300
03000169065000900199064000500208031000300213014001000216865000900226002000900235
035001000244801003000254#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#c#
106#2#article#37#2#^rND^sMackman^nN#Role of tissue factor in hemostasis, thrombo
sis, and vascular development^len#Arterioscler Thromb Vasc Biol#20040000#2004#24
#1015-1022#20080200#6877.htm#1079-5642#Arterioscler Thromb Vasc Biol##
00569000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100017000910100
01800108012003800126030003000164065000900194064000500203031000300208014001000211
865000900221002000900230035001000239801003000249#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6877.htm#S#c#107#3#article#37#3#^rND^sMonroe^nDM#^rND^sHoffman^nM#^rN
D^sRoberts^nHR#Platelets and thrombin generation^len#Arterioscler Thromb Vasc Bi
ol#20020000#2002#22#1381-1389#20080200#6877.htm#1079-5642#Arterioscler Thromb Va
sc Biol##
00672000000000325000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100018000910100
01900109010001900128010002000147010001500167012006700182030002300249065000900272
06400050028103100030028601400060028986500090029500200090030403500100031380100230
0323#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#c#108#4#article#37#4#^
rND^sMandala^nM#^rND^sFerretti^nG#^rND^sCremonesi^nM#^rND^sCazzaniga^nM#^rND^sCu
rigliano^nG#^rND^sBarni^nS#Venous thromboembolism and cancer: new issues for an 
old topic^len#Crit Rev Oncol Hematol#20030000#2003#48#65-80#20080200#6877.htm#10
40-8428#Crit Rev Oncol Hematol##
00511000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100016000900120
04900106030001100155065000900166064000500175031000400180014001000184865000900194
002000900203035001000212801001100222#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
877.htm#S#c#109#5#article#37#5#^rND^sOtten^nHM#^rND^sPrins^nMH#Venous thromboemb
olism and occult malignancy^len#Thromb Res#20010000#2001#102#V187-V194#20080200#
6877.htm#0049-3848#Thromb Res##
00536000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100017000920120
07100109030001100180065000900191064000500200031000400205014001000209865000900219
002000900228035001000237801001100247#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
877.htm#S#c#110#6#article#37#6#^rND^sRickles^nFR#^rND^sFalanga^nA#Molecular basi
s for the relationship between thrombosis and cancer^len#Thromb Res#20010000#200
1#102#V215-V224#20080200#6877.htm#0049-3848#Thromb Res##
00725000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100016000900100
01700106010001800123012017700141030002500318065000900343064000500352031000300357
014001000360865000900370002000900379035001000388801002500398#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6877.htm#S#c#111#7#article#37#7#^rND^sConnor^nJ#^rND^sBuc
ana^nC#^rND^sFidler^nIJ#^rND^sSchroit^nAJ#Differentiation-dependent expression o
f phosphatidylserine in mammalian plasma membranes: quantitative assessment of o
uter-leaflet lipid by prothrombinase complex formation^len#Proc Natl Acad Sci U 
S A#19890000#1989#86#3184-3188#20080200#6877.htm#0027-8424#Proc Natl Acad Sci U 
S A##
00693000000000325000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100023000740100018000970100
01500115010001800130010001800148010001500166012010300181030001500284065000900299
06400050030803100030031301400080031686500090032400200090033303500100034280100150
0352#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#c#112#8#article#37#8#^
rND^sBarrowcliffe^nTW#^rND^sFabregas^nP#^rND^sJardi^nM#^rND^sCancelas^nJ#^rND^sR
abaneda^nM#^rND^sFelez^nJ#Procoagulant activity of T lymphoblastoid cells due to
 exposure of negatively charged phospholipid^len#Thromb Haemost#20020000#2002#87
#442-449#20080200#6877.htm#0340-6245#Thromb Haemost##
00627000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100020000740100016000940100
01700110010001500127010001700142012007700159030001100236065000900247064000500256
031000300261014001000264865000900274002000900283035001000292801001100302#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#c#113#9#article#37#9#^rND^sVanDeWa
ter^nL#^rND^sTracy^nPB#^rND^sAronson^nD#^rND^sMann^nKG#^rND^sDvorak^nHF#Tumor ce
ll generation of thrombin via functional prothrombinase assembly^len#Cancer Res#
19850000#1985#45#5521-5525#20080200#6877.htm#0008-5472#Cancer res##
00578000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100019000950100
01900114012007900133030001100212065000900223064000500232031000400237014000800241
865000900249002000900258035001000267801001100277#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6877.htm#S#c#114#10#article#37#10#^rND^sKirszberg^nC#^rND^sRumjanek^n
VM#^rND^sMonteiro^nRQ#Assembly and regulation of prothrombinase complex on B16F1
0 melanoma cells^len#Thromb Res#20050000#2005#115#123-129#20080200#6877.htm#0049
-3848#Thromb Res##
00593000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100019000960100
01900115010001900134012008700153030001700240710000200257065000900259064000500268
031000200273014001000275865000900285002000900294#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6877.htm#S#c#115#11#article#37#11#^rND^sFernandes^nRS#^rND^sKirszberg
^nC#^rND^sRumjanek^nVM#^rND^sMonteiro^nRQ#On the molecular mechanisms for the hi
ghly procoagulant pattern of C6 glioma cells^len#J Thromb Haemost#2#20060000#200
6#4#1546-1552#20080200#6877.htm##
00529000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100018000890120
05600107030001800163065000900181064000500190031000200195014000800197865000900205
002000900214035001000223801001800233#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
877.htm#S#c#116#12#article#37#12#^rND^sRuf^nW#^rND^sMueller^nBM#Tissue factor in
 cancer angiogenesis and metastasis^len#Curr Opin Hematol#19960000#1996#3#379-38
4#20080200#6877.htm#1065-6251#Curr Opin Hematol##
00596000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100013000900100
01200103010001400115010001200129012006200141030001300203065000900216064000500225
031000300230014000800233865000900241002000900250035001000259801001300269#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#c#117#13#article#37#13#^rND^sGuan^
nM#^rND^sJin^nJ#^rND^sSu^nB#^rND^sLiu^nWW#^rND^sLu^nY#Tissue factor expression a
nd angiogenesis in human glioma^len#Clin Biochem#20020000#2002#35#321-325#200802
00#6877.htm#0009-9120#Clin Biochem##
00722000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100014000940100
01900108010001400127010001800141010001600159810000600175012012400181030001300305
06500090031806400050032703100030033201400080033586500090034300200090035203500100
0361801001300371#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#c#118#14#a
rticle#37#14#^rND^sNakasaki^nT#^rND^sWada^nH#^rND^sShigemori^nC#^rND^sMiki^nC#^r
ND^sGabazza^nEC#^rND^sNobori^nT#et al#Expression of tissue factor and vascular e
ndothelial growth factor is associated with angiogenesis in colorectal cancer^le
n#Am J Hematol#20020000#2002#69#247-254#20080200#6877.htm#0361-8609#Am J Hematol
##
00683000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940100
01500110010002700125010001400152010001800166810000600184012008700190030000800277
06500090028506400050029403100020029901400080030186500090030900200090031803500100
0327801000800337#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#c#119#15#a
rticle#37#15#^rND^sEven-Ram^nS#^rND^sUziely^nB#^rND^sCohen^nP#^rND^sGrisaru-Gran
ovsky^nS#^rND^sMaoz^nM#^rND^sGinzburg^nY#et al#Thrombin receptor overexpression 
in malignant and physiological invasion processes^len#Nat Med#19980000#1998#4#90
9-914#20080200#6877.htm#1078-8956#Nat Med##
00609000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01300109012008200122030003000204065000900234064000500243031000300248014001000251
865000900261002000900270035001000279801003000289#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6877.htm#S#c#120#16#article#37#16#^rND^sBelting^nM#^rND^sAhamed^nJ#^r
ND^sRuf^nW#Signaling of the tissue factor coagulation pathway in angiogenesis an
d cancer^len#Arterioscler Thromb Vasc Biol#20050000#2005#25#1545-1550#20080200#6
877.htm#1079-5642#Arterioscler Thromb Vasc Biol##
00539000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100020000900120
04000110030003000150065000900180064000500189031000300194014000600197865000900203
002000900212035001000221801003000231#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
877.htm#S#c#121#17#article#37#17#^rND^sRao^nLV#^rND^sPendurthi^nUR#Tissue factor
-factor VIIa signaling^len#Arterioscler Thromb Vasc Biol#20050000#2005#25#47-56#
20080200#6877.htm#1079-5642#Arterioscler Thromb Vasc Biol##
00648000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100019000940100
02000113010001300133012009300146030002500239065000900264064000500273031000300278
014001200281865000900293002000900302035001000311801002500321#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6877.htm#S#c#122#18#article#37#18#^rND^sMueller^nBM#^rND^
sReisfeld^nRA#^rND^sEdgington^nTS#^rND^sRuf^nW#Expression of tissue factor by me
lanoma cells promotes efficient hematogenous metastasis^len#Proc Natl Acad Sci U
 S A#19920000#1992#89#11832-11836#20080200#6877.htm#0027-8424#Proc Natl Acad Sci
 U S A##
00678000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100021000950100
01800116010001700134010001500151012009300166030002500259065000900284064000500293
031000300298014001000301865000900311002000900320035001000329801002500339#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#c#123#19#article#37#19#^rND^sBromb
erg^nME#^rND^sKonigsberg^nWH#^rND^sMadison^nJF#^rND^sPawashe^nA#^rND^sGaren^nA#T
issue factor promotes melanoma metastasis by a pathway independent of blood coag
ulation^len#Proc Natl Acad Sci U S A#19950000#1995#92#8205-8209#20080200#6877.ht
m#0027-8424#Proc Natl Acad Sci U S A##
00703000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100017000970100
02200114010001700136010001500153010001700168012011500185030001300300065000900313
06400050032203100030032701400060033086500090033600200090034503500100035480100130
0364#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#c#124#20#article#37#20
#^rND^svan^nMuijen GN#^rND^sJansen^nKF#^rND^sCornelissen^nIM#^rND^sSmeets^nDF#^r
ND^sBeck^nJL#^rND^sRuiter^nDJ#Establishment and characterization of a human mela
noma cell line (MV3) which is highly metastatic in nude mice^len#Int J Cancer#19
910000#1991#48#85-91#20080200#6877.htm#0020-7136#Int J Cancer##
00614000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100020000930100
01800113012011100131030001400242065000900256064000500265031000400270014000800274
865000900282002000900291035001000300801001400310#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6877.htm#S#c#125#21#article#37#21#^rND^sBezeaud^nA#^rND^sDenninger^nM
H#^rND^sGuillin^nMC#Interaction of human alpha-thrombin and gamma-thrombin with 
antithrombin III, protein C and thrombomodulin^len#Eur J Biochem#19850000#1985#1
53#491-496#20080200#6877.htm#0014-2956#Eur J Biochem##
00573000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100024000760100021001000100
01800121012006100139030001300200065000900213064000500222031000300227014001200230
865000900242002000900251035001000260801001300270#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6877.htm#S#c#126#22#article#37#22#^rND^sFrancischetti^nIM#^rND^sValen
zuela^nJG#^rND^sRibeiro^nJM#Anophelin: kinetics and mechanism of thrombin inhibi
tion^len#Biochemistry#19990000#1999#38#16678-16685#20080200#6877.htm#0006-2960#B
iochemistry##
00651000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100022000760100022000980100
01600120010001800136010001800154012009000172030001100262065000900273064000500282
031000300287014000800290865000900298002000900307035001000316801001100326#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#c#127#23#article#37#23#^rND^sAmirk
hosravi^nA#^rND^sBiggerstaff^nJP#^rND^sWarnes^nG#^rND^sFrancis^nDA#^rND^sFrancis
^nJL#Determination of tumor cell procoagulant activity by Sonoclot analysis in w
hole blood^len#Thromb Res#19960000#1996#84#323-332#20080200#6877.htm#0049-3848#T
hromb Res##
00738000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100015000890100
01400104010001800118010001600136010001500152810000600167012012200173030002500295
06500090032006400050032903100030033401400100033786500090034700200090035603500100
0365801002500375#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#c#128#24#a
rticle#37#24#^rND^sAbe^nK#^rND^sShoji^nM#^rND^sChen^nJ#^rND^sBierhaus^nA#^rND^sD
anave^nI#^rND^sMicko^nC#et al#Regulation of vascular endothelial growth factor p
roduction and angiogenesis by the cytoplasmic tail of tissue factor^len#Proc Nat
l Acad Sci U S A#19990000#1999#96#8663-8668#20080200#6877.htm#0027-8424#Proc Nat
l Acad Sci U S A##
00577000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100017000910100
01600108012008600124030001200210065000900222064000500231031000300236014000800239
865000900247002000900256035001000265801001200275#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6877.htm#S#c#129#25#article#37#25#^rND^sSakai^nT#^rND^sNoguchi^nM#^rN
D^sKisiel^nW#Tumor cells augment the factor Xa-catalyzed conversion of prothromb
in to thrombin^len#Haemostasis#19900000#1990#20#125-135#20080200#6877.htm#0301-0
147#Haemostasis##
00615000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100017000910100
01800108010001500126012008900141030001500230065000900245064000500254031000300259
014000800262865000900270002000900279035001000288801001500298#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6877.htm#S#c#130#26#article#37#26#^rND^sKumar^nA#^rND^sKo
enig^nKB#^rND^sJohnson^nAR#^rND^sIdell^nS#Expression and assembly of procoagulan
t complexes by human pleural mesothelial cells^len#Thromb Haemost#19940000#1994#
71#587-592#20080200#6877.htm#0340-6245#Thromb Haemost##
00665000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100017000910100
01800108010001500126010001500141012011500156030001300271065000900284064000500293
031000200298014001000300865000900310002000900319035001000328801001300338#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#c#131#27#article#37#27#^rND^sKumar
^nA#^rND^sKoenig^nKB#^rND^sJohnson^nAR#^rND^sFair^nDS#^rND^sIdell^nS#Inhibition 
of factor Xa-mediated procoagulant activity of human lung fibroblasts and pleura
l mesothelial cells^len#Eur Respir J#19950000#1995#8#2038-2045#20080200#6877.htm
#0903-1936#Eur Respir J##
00611000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100017000960100
01600113010001900129012008000148030001400228065000900242064000500251031000300256
014000800259865000900267002000900276035001000285801001400295#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6877.htm#S#c#132#28#article#37#28#^rND^sNierodzik^nML#^rN
D^sPlotkin^nA#^rND^sKajumo^nF#^rND^sKarpatkin^nS#Thrombin stimulates tumor-plate
let adhesion in vitro and metastasis in vivo^len#J Clin Invest#19910000#1991#87#
229-236#20080200#6877.htm#0021-9738#J Clin Invest##
00668000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100023000760100015000990100
01900114010001700133010001500150010001700165810000600182012006300188030001300251
06500090026406400050027303100030027801400080028186500090028900200090029803500100
0307801001300317#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#c#133#29#a
rticle#37#29#^rND^sWojtukiewicz^nMZ#^rND^sTang^nDG#^rND^sCiarelli^nJJ#^rND^sNels
on^nKK#^rND^sWalz^nDA#^rND^sDiglio^nCA#et al#Thrombin increases the metastatic p
otential of tumor cells^len#Int J Cancer#19930000#1993#54#793-806#20080200#6877.
htm#0020-7136#Int J Cancer##
00616000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100013000910100
01700104012012800121030001100249065000900260064000500269031000300274014001000277
865000900287002000900296035001000305801001100315#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6877.htm#S#c#134#30#article#37#30#^rND^sEsumi^nN#^rND^sFan^nD#^rND^sF
idler^nIJ#Inhibition of murine melanoma experimental metastasis by recombinant d
esulfatohirudin, a highly specific thrombin inhibitor^len#Cancer Res#19910000#19
91#51#4549-4556#20080200#6877.htm#0008-5472#Cancer res##
00632000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100012000760100013000880100
01800101010002100119010001900140012009100159030000600250065000900256064000500265
031000400270014001000274865000900284002000900293035001000302801000600312#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#c#135#31#article#37#31#^rND^sHu^nL
#^rND^sLee^nM#^rND^sCampbell^nW#^rND^sPerez-Soler^nR#^rND^sKarpatkin^nS#Role of 
endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis^l
en#Blood#20040000#2004#104#2746-2751#20080200#6877.htm#0006-4971#Blood##
00708000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100012000890100
01400101010001700115010001700132010001900149810000600168012011900174030001100293
06500090030406400050031303100030031801400100032186500090033100200090034003500100
0349801001100359#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#c#136#32#a
rticle#37#32#^rND^sIm^nJH#^rND^sFu^nW#^rND^sWang^nH#^rND^sBhatia^nSK#^rND^sHamme
r^nDA#^rND^sKowalska^nMA#et al#Coagulation facilitates tumor cell spreading in t
he pulmonary vasculature during early metastatic colony formation^len#Cancer Res
#20040000#2004#64#8613-8619#20080200#6877.htm#0008-5472#Cancer res##
00712000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100014000960100
01900110010001300129010001600142010001500158810000600173012012800179030000600307
06500090031306400050032203100030032701400100033086500090034000200090034903500100
0358801000600368#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#c#137#33#a
rticle#37#33#^rND^sNierodzik^nML#^rND^sChen^nK#^rND^sTakeshita^nK#^rND^sLi^nJJ#^
rND^sHuang^nYQ#^rND^sFeng^nXS#et al#Protease-activated receptor 1 (PAR-1) is req
uired and rate-limiting for thrombin-enhanced experimental pulmonary metastasis^
len#Blood#19980000#1998#92#3694-3700#20080200#6877.htm#0006-4971#Blood##
00535000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920120
07500109030000900184065000900193064000500202031000300207014001000210865000900220
002000900229035001000238801000900248#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
877.htm#S#c#138#34#article#37#34#^rND^sTellez^nC#^rND^sBar-Eli^nM#Role and regul
ation of the thrombin receptor (PAR-1) in human melanoma^len#Oncogene#20030000#2
003#22#3130-3137#20080200#6877.htm#0950-9232#Oncogene##
00616000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100021000890100
01600110010001300126010001800139012009800157030001500255710000200270065000900272
064000500281031000200286014000800288865000900296002000900305#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6877.htm#S#c#139#35#article#37#35#^rND^sShi^nX#^rND^sGang
adharan^nB#^rND^sBrass^nLF#^rND^sRuf^nW#^rND^sMueller^nBM#Protease-activated rec
eptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis^len#Mol 
Cancer Res#2#20040000#2004#2#395-402#20080200#6877.htm##
00725000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910100
01700107010001500124010002200139010001700161810000600178012010700184030002100291
06500090031206400050032103100040032601400080033086500090033800200090034703500100
0356801002100366#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6877.htm#S#c#140#36#a
rticle#37#36#^rND^sNagy^nJA#^rND^sBrown^nLF#^rND^sSenger^nDR#^rND^sLanir^nN#^rND
^sVan^nde Water L#^rND^sDvorak^nAM#et al#Pathogenesis of tumor stroma generation
: a critical role for leaky blood vessels and fibrin deposition^len#Biochim Biop
hys Acta#19890000#1989#948#305-326#20080200#6877.htm#0006-3002#Biochim Biophys A
cta##
00565000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100019000960100
01800115012005100133030002000184065000900204064000500213031000300218014000600221
865000900227002000900236035001000245801002000255#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6877.htm#S#c#141#37#article#37#37#^rND^sFernandez^nPM#^rND^sPatierno^
nSR#^rND^sRickles^nFR#Tissue factor and fibrin in tumor angiogenesis^len#Semin T
hromb Hemost#20040000#2004#30#31-44#20080200#6877.htm#0094-6176#Semin Thromb Hem
ost##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#o#1#1#article#1#20
080402#165754#6887.htm#155##
03246000000000649000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016022300090
01700120101001790100033002800100021003130100024003340100027003580100024003850100
02500409010002500434010002500459070014200484070007200626083164600698085000802344
08500300235208500230238208500180240508500380242308500220246108500220248311700060
25050720003025111120009025141110013025231140009025361130018025458810024025630020
00902587#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#h#2#1#article#1#oa
#en#bjmbr#1#3.1#ILUS#TAB#09#BJMBR050#FAPESP#Braz J Med Biol Res#41#2#20080200#^f
126^l134#0100-879X#20080111#Cost-effective analysis of different algorithms for 
the diagnosis of hepatitis C virus infection^len#^rND^1A01 A02^nA.M.E.C.^sBarret
o#^rND^1A01^nK.^sTakei#^rND^1A02^sE.C.^nSabino#^rND^1A02^nM.A.O.^sBellesa#^rND^1
A02^nN.A.^sSalles#^rND^1A02^nC.C.^sBarreto#^rND^1A02^nA.S.^sNishiya#^rND^1A02^nD
.F.^sChamone#Universidade de São Paulo^iA01^1Faculdade de Ciências Farmacêuticas
^2Departamento de Análises Clínicas e Toxicológicas^cSão Paulo^sSP^pBrasil#Funda
ção Pró-Sangue Hemocentro de São Paulo^iA02^cSão Paulo^sSP^pBrasil#^len^aWe comp
ared the cost-benefit of two algorithms, recently proposed by the Centers for Di
sease Control and Prevention, USA, with the conventional one, the most appropria
te for the diagnosis of hepatitis C virus (HCV) infection in the Brazilian popul
ation. Serum samples were obtained from 517 ELISA-positive or -inconclusive bloo
d donors who had returned to Fundação Pró-Sangue/Hemocentro de São Paulo to conf
irm previous results. Algorithm A was based on signal-to-cut-off (s/co) ratio of
 ELISA anti-HCV samples that show s/co ratio &sup3;95% concordance with immunobl
ot (IB) positivity. For algorithm B, reflex nucleic acid amplification testing b
y PCR was required for ELISA-positive or -inconclusive samples and IB for PCR-ne
gative samples. For algorithm C, all positive or inconclusive ELISA samples were
 submitted to IB. We observed a similar rate of positive results with the three 
algorithms: 287, 287, and 285 for A, B, and C, respectively, and 283 were concor
dant with one another. Indeterminate results from algorithms A and C were elucid
ated by PCR (expanded algorithm) which detected two more positive samples. The e
stimated cost of algorithms A and B was US$21,299.39 and US$32,397.40, respectiv
ely, which were 43.5 and 14.0% more economic than C (US$37,673.79). The cost can
 vary according to the technique used. We conclude that both algorithms A and B 
are suitable for diagnosing HCV infection in the Brazilian population. Furthermo
re, algorithm A is the more practical and economical one since it requires suppl
emental tests for only 54% of the samples. Algorithm B provides early informatio
n about the presence of viremia.#^dnd^i1#^tm^len^kHepatitis C virus^i1#^tm^len^k
Immunoblot^i1#^tm^len^kELISA^i1#^tm^len^kPolymerase chain reaction^i1#^tm^len^kA
lgorithm^i1#^tm^len^kDiagnosis^i1#other#28#20070511#May 11, 2007#20071126#Novemb
er 26, 2007#S0100-879X2008005000004#6887.htm##
03322000000000637000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016022300090
01700120108001790100033002870100021003200100024003410100027003650100024003920100
02500416010002500441010002500466070014200491070007200633083175100705085000802456
08500300246408500230249408500180251708500380253508500220257308500220259511700060
2617072000302623112000902626111001302635114000902648113001802657002000902675#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#f#3#1#article#1#oa#en#bjmbr#1#
3.1#ILUS#TAB#09#BJMBR050#FAPESP#Braz J Med Biol Res#41#2#20080200#^f126^l134#010
0-879X#20080111#<B>Cost-effective analysis of different algorithms for the diagn
osis of hepatitis C virus infection</B>^len#^rND^1A01 A02^nA.M.E.C.^sBarreto#^rN
D^1A01^nK.^sTakei#^rND^1A02^sE.C.^nSabino#^rND^1A02^nM.A.O.^sBellesa#^rND^1A02^n
N.A.^sSalles#^rND^1A02^nC.C.^sBarreto#^rND^1A02^nA.S.^sNishiya#^rND^1A02^nD.F.^s
Chamone#Universidade de São Paulo^iA01^1Faculdade de Ciências Farmacêuticas^2Dep
artamento de Análises Clínicas e Toxicológicas^cSão Paulo^sSP^pBrasil#Fundação P
ró-Sangue Hemocentro de São Paulo^iA02^cSão Paulo^sSP^pBrasil#^len^aWe compared 
the cost-benefit of two algorithms, recently proposed by the Centers for Disease
 Control and Prevention, USA, with the conventional one, the most appropriate fo
r the diagnosis of hepatitis C virus (HCV) infection in the Brazilian population
. Serum samples were obtained from 517 ELISA-positive or -inconclusive blood don
ors who had returned to Fundação Pró-Sangue/Hemocentro de São Paulo to confirm p
revious results. Algorithm <I>A</I> was based on signal-to-cut-off (s/co) ratio 
of ELISA anti-HCV samples that show s/co ratio &sup3;95% concordance with immuno
blot (IB) positivity. For algorithm <I>B</I>, reflex nucleic acid amplification 
testing by PCR was required for ELISA-positive or -inconclusive samples and IB f
or PCR-negative samples. For algorithm <I>C</I>, all positive or inconclusive EL
ISA samples were submitted to IB. We observed a similar rate of positive results
 with the three algorithms: 287, 287, and 285 for <I>A</I>, <I>B</I>, and <I>C</
I>, respectively, and 283 were concordant with one another. Indeterminate result
s from algorithms <I>A</I> and <I>C </I>were elucidated by PCR (expanded algorit
hm) which detected two more positive samples. The estimated cost of algorithms <
I>A</I> and <I>B</I> was US$21,299.39 and US$32,397.40, respectively, which were
 43.5 and 14.0% more economic than <I>C </I>(US$37,673.79). The cost can vary ac
cording to the technique used. We conclude that both algorithms <I>A</I> and <I>
B </I>are suitable for diagnosing HCV infection in the Brazilian population. Fur
thermore, algorithm <I>A</I> is the more practical and economical one since it r
equires supplemental tests for only 54% of the samples. Algorithm <I>B </I>provi
des early information about the presence of viremia.#^dnd^i1#^tm^len^kHepatitis 
C virus^i1#^tm^len^kImmunoblot^i1#^tm^len^kELISA^i1#^tm^len^kPolymerase chain re
action^i1#^tm^len^kAlgorithm^i1#^tm^len^kDiagnosis^i1#other#28#20070511#May 11, 
2007#20071126#November 26, 2007#6887.htm##
03367000000000661000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100038000400105121000300109049000900112
15800070012103000240012803100030015203200020015506500090015701400110016603500100
01772230009001870120101001960100035002970100020003320100024003520100028003760100
02400404010002500428010002500453010002500478070014400503070007400647083166700721
08500080238808500300239608500230242608500180244908500380246708500220250508500220
25271170006025490720003025551120009025581110013025671140009025801130018025890020
00902607008008902616#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#l#4#1#
article#1#^mFeb.^a2008#oa#en#bjmbr#1#3.1#ilus#tab#09#BJMBR050#FAPESP#Braz. j. me
d. biol. res#41#2#20080200#^f126^l134#0100-879X#20080111#Cost-effective analysis
 of different algorithms for the diagnosis of hepatitis C virus infection^len#^r
ND^1A01 A02^nA. M. E. C^sBarreto#^rND^1A01^nK^sTakei#^rND^1A02^sE.C.^nSabino#^rN
D^1A02^nM. A. O^sBellesa#^rND^1A02^nN. A^sSalles#^rND^1A02^nC. C^sBarreto#^rND^1
A02^nA. S^sNishiya#^rND^1A02^nD. F^sChamone#^iA01^1Universidade de São Paulo^2Fa
culdade de Ciências Farmacêuticas^3Departamento de Análises Clínicas e Toxicológ
icas^cSão Paulo^sSP^pBrasil#^iA02^1Fundação Pró-Sangue Hemocentro de São Paulo^c
São Paulo^sSP^pBrasil#^len^aWe compared the cost-benefit of two algorithms, rece
ntly proposed by the Centers for Disease Control and Prevention, USA, with the c
onventional one, the most appropriate for the diagnosis of hepatitis C virus (HC
V) infection in the Brazilian population. Serum samples were obtained from 517 E
LISA-positive or -inconclusive blood donors who had returned to Fundação Pró-San
gue/Hemocentro de São Paulo to confirm previous results. Algorithm A was based o
n signal-to-cut-off (s/co) ratio of ELISA anti-HCV samples that show s/co ratio 
&sup3;95 percent concordance with immunoblot (IB) positivity. For algorithm B, r
eflex nucleic acid amplification testing by PCR was required for ELISA-positive 
or -inconclusive samples and IB for PCR-negative samples. For algorithm C, all p
ositive or inconclusive ELISA samples were submitted to IB. We observed a simila
r rate of positive results with the three algorithms: 287, 287, and 285 for A, B
, and C, respectively, and 283 were concordant with one another. Indeterminate r
esults from algorithms A and C were elucidated by PCR (expanded algorithm) which
 detected two more positive samples. The estimated cost of algorithms A and B wa
s US$21,299.39 and US$32,397.40, respectively, which were 43.5 and 14.0 percent 
more economic than C (US$37,673.79). The cost can vary according to the techniqu
e used. We conclude that both algorithms A and B are suitable for diagnosing HCV
 infection in the Brazilian population. Furthermore, algorithm A is the more pra
ctical and economical one since it requires supplemental tests for only 54 perce
nt of the samples. Algorithm B provides early information about the presence of 
viremia.#^dnd^i1#^tm^len^kHepatitis C virus^i1#^tm^len^kImmunoblot^i1#^tm^len^kE
LISA^i1#^tm^len^kPolymerase chain reaction^i1#^tm^len^kAlgorithm^i1#^tm^len^kDia
gnosis^i1#other#28#20070511#May 11, 2007#20071126#November 26, 2007#6887.htm#Int
ernet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X20080002
00009##
00376000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704015000071002000900221#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#5#1#article#123#<P> <font face="Arial, H
elvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, February 2008, 
Volume 41(2) 126-134</B> </font></P>      ^cY#6887.htm##
00400000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704017400071002000900245#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#6#2#article#123#<P><B><font size="5" fac
e="Arial, Helvetica, sans-serif">Cost-effective analysis of different algorithms
 for the diagnosis of hepatitis C virus infection</font></B>      ^cY#6887.htm##
00699000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704047300071002000900544#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#7#3#article#123#<P><font face="Arial, He
lvetica, sans-serif"><b><a href="#Correspondence"><img src="/img/revistas/bjmbr/
v41n2/recor.gif" border="0"></a></b> <a href="mailto:amegydio@uol.com.br"><img s
rc="/img/revistas/bjmbr/v41n2/email-ca.gif" border="0"></a> A.M.E.C. Barreto<SUP
>1,2</SUP>, K. Takei<SUP>1</SUP>, E.C. Sabino<SUP>2</SUP>, M.A.O. Bellesa<SUP>2<
/SUP>, N.A. Salles<SUP>2</SUP>, C.C. Barreto<SUP>2</SUP>, A.S. Nishiya<SUP>2</SU
P> and D.F. Chamone<SUP>2</SUP> </font>      ^cY#6887.htm##
00475000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704024900071002000900320#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#8#4#article#123#<P><font face="Arial, He
lvetica, sans-serif"><SUP>1</SUP>Departamento de An&aacute;lises Cl&iacute;nicas
 e Toxicol&oacute;gicas, Faculdade de Ci&ecirc;ncias Farmac&ecirc;uticas, Univer
sidade de S&atilde;o Paulo, S&atilde;o Paulo, SP, Brasil     ^cY#6887.htm##
00366000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704014000071002000900211#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#9#5#article#123#<br>     <SUP>2</SUP>Fun
da&ccedil;&atilde;o Pr&oacute;-Sangue Hemocentro de S&atilde;o Paulo, S&atilde;o
 Paulo, SP, Brasil </font>      ^cY#6887.htm##
00416000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704018900072002000900261#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#10#6#article#123#<P><font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n2/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>  
  ^cY#6887.htm##
00417000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704019000072002000900262#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#11#7#article#123#<BR>      <A HREF="#Int
roduction"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 V
SPACE=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A> 
   ^cY#6887.htm##
00417000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704019000072002000900262#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#12#8#article#123#<BR>      <A HREF="#Mat
erial"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A> 
   ^cY#6887.htm##
00402000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704017500072002000900247#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#13#9#article#123#<BR>      <A HREF="#Res
ults"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#6887.htm
##
00412000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704018400073002000900257#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#14#10#article#123#<BR>      <A HREF="#Di
scussion"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^c
Y#6887.htm##
00399000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704017100073002000900244#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#15#11#article#123#<BR>      <A HREF="#Re
ferences"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#6887.htm##
00468000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704024000073002000900313#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#16#12#article#123#<br>      </strong></A
>      <A HREF="#Correspondence"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" A
LIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Co
rrespondence and Footnotes</strong></A>  </font>      ^cY#6887.htm##
00276000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004800073002000900121#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#17#13#article#123#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>      ^cY#6887.htm##
00547000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031900073002000900392#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#18#14#article#123#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/ba
ck.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  <fon
t face="Arial, Helvetica, sans-serif">  </font>      ^cY#6887.htm##
02137000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704190900073002000901982#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#19#15#article#123#<P><font face="Arial, 
Helvetica, sans-serif">We compared the cost-benefit of two algorithms, recently 
proposed by the Centers for Disease Control and Prevention, USA, with the conven
tional one, the most appropriate for the diagnosis of hepatitis C virus (HCV) in
fection in the Brazilian population. Serum samples were obtained from 517 ELISA-
positive or -inconclusive blood donors who had returned to Funda&ccedil;&atilde;
o Pr&oacute;-Sangue/Hemocentro de S&atilde;o Paulo to confirm previous results. 
Algorithm <I>A</I> was based on signal-to-cut-off (s/co) ratio of ELISA anti-HCV
 samples that show s/co ratio <font face="Symbol">&#179;</font>95% concordance w
ith immunoblot (IB) positivity. For algorithm <I>B</I>, reflex nucleic acid ampl
ification testing by PCR was required for ELISA-positive or -inconclusive sample
s and IB for PCR-negative samples. For algorithm <I>C</I>, all positive or incon
clusive ELISA samples were submitted to IB. We observed a similar rate of positi
ve results with the three algorithms: 287, 287, and 285 for <I>A</I>, <I>B</I>, 
and <I>C</I>, respectively, and 283 were concordant with one another. Indetermin
ate results from algorithms <I>A</I> and <I>C </I>were elucidated by PCR (expand
ed algorithm) which detected two more positive samples. The estimated cost of al
gorithms <I>A</I> and <I>B</I> was US$21,299.39 and US$32,397.40, respectively, 
which were 43.5 and 14.0% more economic than <I>C </I>(US$37,673.79). The cost c
an vary according to the technique used. We conclude that both algorithms <I>A</
I> and <I>B </I>are suitable for diagnosing HCV infection in the Brazilian popul
ation. Furthermore, algorithm <I>A</I> is the more practical and economical one 
since it requires supplemental tests for only 54% of the samples. Algorithm <I>B
 </I>provides early information about the presence of viremia.   </font>   <font
 face="Arial, Helvetica, sans-serif">      ^cY#6887.htm##
00381000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704015300073002000900226#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#20#16#article#123#<P>Key words: Hepatiti
s C virus; Immunoblot; ELISA; Polymerase chain reaction; Algorithm; Diagnosis  <
/font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6887.htm##
00594000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704036600073002000900439#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#21#17#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><
B>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-ser
if"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTO
M BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>    <font face="Arial, Helvetica
, sans-serif">      ^cY#6887.htm##
01473000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704124500073002000901318#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#22#18#article#123#<P>In 1989 the Food an
d Drug Administration (FDA, USA) licensed the first antibody detection test for 
hepatitis C virus (HCV) using the c100-3 protein as antigen (1,2). Since then ne
w generations of anti-HCV tests have been introduced for laboratory diagnosis an
d these have been widely used in the serological screening of infected symptomat
ic or asymptomatic individuals. Currently, second- or third-generation enzyme-li
nked immunosorbent assays (ELISA) are commercially available. These tests detect
 antibodies against one or more of the several recombinant or synthetic peptides
 produced by genes from different regions of the HCV genome. The first-generatio
n tests detect antibodies with a sensitivity of 70 to 80% when applied to popula
tions with a high prevalence of HCV infection, presenting an immunological windo
w of 4 to 6 months (3). The second- and third-generation tests have a high sensi
tivity of ~99.8% and an immunological window reduced to approximately 10 weeks w
hen compared to the first-generation tests (4). However, these tests yield a hig
h frequency of false-positive results, mainly in low-risk populations such as bl
ood donors (5-7). Therefore, supplemental tests are required to ensure a reliabl
e diagnosis.       ^cY#6887.htm##
00935000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704070700073002000900780#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#23#19#article#123#<P>The Centers for Dis
ease Control and Prevention (CDC, Atlanta, GA, USA) have recommended that no ind
ividual be considered an HCV carrier until all positive results obtained by scre
ening tests are confirmed by more specific tests, such as immunoblot (IB) (8). H
owever, since the IB test uses the same antigens as the screening test it has li
mited value as a confirmatory test and is therefore regarded as a supplemental t
est. Another limitation is that both screening and supplemental tests fail to de
tect infection during the immunologic window, in which antibodies are either abs
ent or present at very low concentrations. In this case, only molecular tests ar
e able to detect HCV infection (9).      ^cY#6887.htm##
00750000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704052200073002000900595#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#24#20#article#123#<P>Thus, the laborator
y diagnosis of HCV infection requires more than one test (screening and suppleme
ntal) to confirm a result, since a gold standard test is still unavailable. Anot
her problem is the lack of standardization in interpreting the results of supple
mental tests. Furthermore, the high cost involved reduces the accessibility of t
hese procedures in low budget laboratories. In this respect, there is a need for
 more available and less expensive alternative methods for the diagnosis of HCV 
infection.      ^cY#6887.htm##
00975000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704074700073002000900820#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#25#21#article#123#<P>In 2003, the CDC re
commended two new algorithms (termed here <I>A</I> and <I>B</I>) as an alternati
ve approach to the conventional algorithm <I>C</I> (8). Algorithm <I>A</I> is an
 option that uses signal-to-cut-off (s/co) ratios for screening-test-positive re
sults to minimize the number of samples that require supplemental testing. For e
ach population the proportion of IB-positive among screening-test-positive resul
ts increases with increasing s/co ratio. Algorithm <I>B </I>requires polymerase 
chain reaction (PCR) tests for all ELISA-positive or -inconclusive samples, as w
ell as IB tests for samples with negative PCR results. Conventional algorithm <I
>C </I>requires an IB test for all ELISA-positive or -inconclusive samples.     
 ^cY#6887.htm##
00766000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704053800073002000900611#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#26#22#article#123#<P>The use of these ne
w algorithms in the US population has been helpful for simplifying HCV diagnosis
 and lowering its cost (8). In Brazil, few data concerning diagnostic performanc
e (10) and cost (11) are available. With this in mind, we compared the diagnosti
c performance and the cost-benefit of the two new algorithms (<I>A</I> and <I>B<
/I>) with the conventional (<I>C</I>) one in Brazilian blood donors who showed p
ositive or inconclusive anti-HCV results in screening tests.    </font>  <HR ALI
GN=LEFT WIDTH=100% SIZE=2>      ^cY#6887.htm##
00596000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704036800073002000900441#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#27#23#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Ma
terial and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans
-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=B
OTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>  <font face="Arial, Helveti
ca, sans-serif">      ^cY#6887.htm##
00264000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704003600073002000900109#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#28#24#article#123#<P><b>Samples</b>  </f
ont>      ^cY#6887.htm##
00851000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704062300073002000900696#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#29#25#article#123#<P><font face="Arial, 
Helvetica, sans-serif">From September 1997 to December 1998, 197,637 blood donor
s at Funda&ccedil;&atilde;o Pr&oacute;-Sangue Hemocentro de S&atilde;o Paulo wer
e screened with anti-HCV tests. Positive or inconclusive results were obtained f
or 1796 (0.91%) of the samples. A total of 692 blood donors who were positive at
 the time of donation returned to the Institution to repeat the screening test (
ELISA). Of these, 175 (25.3%) were ELISA-negative and the 517 who remained posit
ive (437) or inconclusive (80) formed our series and were submitted to supplemen
tal tests for anti-HCV. </font>      ^cY#6887.htm##
00697000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704046900073002000900542#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#30#26#article#123#<P><font face="Arial, 
Helvetica, sans-serif">The donors were informed that their blood samples would b
e used for research purposes and they all signed the corresponding informed cons
ent term. The study was approved by the Faculdade de Ci&ecirc;ncias Farmac&ecirc
;uticas, Universidade de S&atilde;o Paulo (Protocol No. 204/2003) and the Ethics
 Committee of Funda&ccedil;&atilde;o Pr&oacute;-Sangue Hemocentro de S&atilde;o 
Paulo (Protocol No. 08/2003). </font>      ^cY#6887.htm##
00364000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704013600073002000900209#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#31#27#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><B>Algorithms evaluated for the laboratory diagnosis of H
CV infection</B> </font>      ^cY#6887.htm##
00511000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704028300073002000900356#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#32#28#article#123#<P><font face="Arial, 
Helvetica, sans-serif">The basic strategy of this study was to compare the resul
ts obtained for our sample by a conventional algorithm, designated here algorith
m (<I>C</I>), with the new algorithms <I>A </I>and <I>B</I> recommended by the C
DC. </font>      ^cY#6887.htm##
01159000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704093100073002000901004#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#33#29#article#123#<P><font face="Arial, 
Helvetica, sans-serif">Algorithm <I>A</I> requires the establishment of a specif
ic level of s/co ratio to determine the need for reflex supplemental testing. Fo
r this purpose, the s/co ratios of each sample tested by ELISA were stratified i
nto 6 groups: <font face="Symbol">&#179;</font>1 &lt;2, <font face="Symbol">&#17
9;</font>2 &lt;3, <font face="Symbol">&#179;</font>3 &lt;4, <font face="Symbol">
&#179;</font>4 &lt;5, <font face="Symbol">&#179;</font>5 &lt;6, <font face="Symb
ol">&#179;</font>6. The s/co ratio chosen for cut-off (cut-off ratio) correspond
ed to the ratio which had the highest &#179;95% concordance with positive result
s in the IB test. The sample was positive when the result had an s/co ratio high
er than the cut-off ratio. When the ratio was lower than the cut-off ratio, refl
ex testing (IB) was required. The sample was considered true positive when IB wa
s positive. </font>      ^cY#6887.htm##
00589000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704036100073002000900434#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#34#30#article#123#<P><font face="Arial, 
Helvetica, sans-serif">For algorithm <I>B</I>, reflex testing by the supplementa
l nucleic acid amplification test (NAT) was required for samples that were posit
ive or inconclusive in the screening test. A sample was considered true positive
 when both ELISA and PCR were positive. When PCR was negative IB was carried out
. </font>      ^cY#6887.htm##
00458000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704023000073002000900303#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#35#31#article#123#<P><font face="Arial, 
Helvetica, sans-serif">The most commonly used algorithm is <I>C</I>, which is ba
sed on the use of supplemental serologic reflex testing such as IB to confirm sc
reening-test-positive results. </font>      ^cY#6887.htm##
00478000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704025000073002000900323#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#36#32#article#123#<P><font face="Arial, 
Helvetica, sans-serif">We evaluated the concordance of the results obtained by e
ach algorithm. Samples with indeterminate IB results were further analyzed by PC
R using an algorithm termed here as expanded form. </font>      ^cY#6887.htm##
00346000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011800073002000900191#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#37#33#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><B>Number of tests required to apply each algorithm</B> <
/font>      ^cY#6887.htm##
00594000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704036600073002000900439#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#38#34#article#123#<P><font face="Arial, 
Helvetica, sans-serif">The first assessment estimated the number of tests requir
ed to implement each of the three algorithms in all samples. To predict the cost
 estimate of each algorithm, we multiplied the resulting figures by the cost of 
each test. The same estimate can be performed for each algorithm in its expanded
 form. </font>      ^cY#6887.htm##
00673000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704044500073002000900518#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#39#35#article#123#<P><font face="Arial, 
Helvetica, sans-serif">Costs were estimated as follows and do not include person
al time or additional equipment: US$4.07/sample for ELISA; US$68.80/sample for I
B, US$22.93/sample for in-house PCR, or US$91.74/sample for commercially availab
le PCR. These values were obtained from 7 Brazilian commercial kit suppliers and
 the mean value was used as a base for cost estimation and converted into US dol
lars. </font>      ^cY#6887.htm##
00314000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704008600073002000900159#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#40#36#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><B>Laboratory tests</B> </font>      ^cY#6887.htm##
01237000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704100900073002000901082#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#41#37#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><I>Screening test</I>. The HCV antibody test was performe
d according to manufacturer instructions using third-generation ELISA kits from 
EMBRABIO (Hemobio<SUP>&#174;</SUP> ELISA HCV third generation, S&atilde;o Paulo,
 SP, Brazil), which detects antibodies against recombinant antigenic proteins NS
3 and NS5 and against synthetic peptides corresponding to core and NS4 genes. Th
e cut-off recommended by the manufacturer was calculated by the average absorban
ce of the positive controls plus the average absorbance of the negative controls
, dividing the total by 5. Samples with absorbance above this cut-off were consi
dered to be positive, samples with absorbance below it were considered negative,
 and &#177;10% ranges around the cut-off were considered to be inconclusive. The
 s/co ratio referred to absorbance of the sample signal (s) divided by co. Sampl
es with s/co ratio higher than 1.0 were considered to be reactive by this screen
ing test. </font>      ^cY#6887.htm##
00704000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704047600073002000900549#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#42#38#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><I>Immunoblot</I>. The confirmation of positive and incon
clusive ELISA anti-HCV test results was obtained using a supplemental third-gene
ration immunoblot kit (Immunoblot LiaTeK<SUP>&#174;</SUP> HCVIII from Organon Te
knika, Boxtel, Netherlands) according to manufacturer instructions. The kit cont
ained protein fractions corresponding to the genomic regions of core 1, core 2, 
E2NS1, NS3, NS4 (A and B), and NS5A. </font>      ^cY#6887.htm##
00600000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704037200073002000900445#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#43#39#article#123#<P><font face="Arial, 
Helvetica, sans-serif">The reactive bands were read as scores, specifically 1+, 
2+, 3+, and 4+, which were compared to the internal control bands of the kit. Re
sults were interpreted according to literature references (12): positive when at
 least two bands were &#179;1+; negative when bands were absent and indeterminat
e otherwise. </font>      ^cY#6887.htm##
00384000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704015600073002000900229#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#44#40#article#123#<P><font face="Arial, 
Helvetica, sans-serif">Samples were classified as serologically positive when bo
th ELISA and IB tests were positive. </font>      ^cY#6887.htm##
00313000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704008500073002000900158#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#45#41#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><B>Molecular tests</B> </font>      ^cY#6887.htm##
00418000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704019000073002000900263#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#46#42#article#123#<P><font face="Arial, 
Helvetica, sans-serif">HCV RNA detection was performed in all serum samples, whi
ch were stored at -20&#176;C, using the nested PCR in-house technique. </font>  
    ^cY#6887.htm##
01239000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704101100073002000901084#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#47#43#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><I>Extraction of RNA HCV and cDNA synthesis</I>. RNA isol
ation: 100 &#181;L serum was mixed with 300 &#181;L Trizol (Gibco-BRL, Gaithersb
urg, MD, USA), and incubated for 5 min at room temperature. Eighty microliters c
hloroform (Sigma, St. Louis, MO, USA) was then added. The mixture was vigorously
 shaken, incubated at room temperature for 2 to 15 min, and centrifuged at 12,00
0 <I>g</I> for 15 min at 4&#176;C. The supernatant was transferred to a tube and
 RNA was precipitated from the colorless aqueous phase with 40 &#181;L 1 &#181;g
/&#181;L dextran T500 (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA) and
 200 &#181;L isopropanol (Sigma). The mixture was agitated briefly and incubated
 at room temperature for 10 min, and centrifuged at 12,000 <I>g</I> for 10 min a
t 4&#176;C. The pellet was washed in ice cold 70% ethanol and centrifuged at 750
0 <I>g</I> for 5 min. The supernatant was removed and the RNA pellet was briefly
 air dried. </font>      ^cY#6887.htm##
00985000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704075700073002000900830#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#48#44#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><I>cDNA synthesis</I>. The pellet was dissolved in 12 &#1
81;L of a solution containing diethyl pyrocarbonate-treated water and 300 ng ran
dom primers (Pharmacia Biotech). After the denaturation step at 70&#176;C for 10
 min, cDNA was synthesized from RNA by the addition of a solution containing 100
 U reverse transcriptase (SuperScript&#153; II Rnase H-Reverse Transcriptase Gib
co-BRL), 50 mM Tris-HCl, 75 mM KCl, 3 mM MgCl<SUB>2</SUB>, 10 &#181;M DTT, 5 U R
nase inhibitor (Gibco-BRL), and 0.5 mM 2'-deoxynucleoside 5'-triphosphate mix (d
NTP; Pharmacia Biotech), in a final reaction volume of 20 &#181;L. The mixture w
as incubated at 42&#176;C for 90 min and then heated at 70&#176;C for 15 min. </
font>      ^cY#6887.htm##
00337000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704010900073002000900182#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#49#45#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><B>Polymerase chain reaction amplification</B> </font>   
   ^cY#6887.htm##
01406000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704117800073002000901251#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#50#46#article#123#<P><font face="Arial, 
Helvetica, sans-serif">A two-round PCR was run in a thermal cycle as follows: in
itial cycle at 94&#176;C for 1 min and 40 cycles at 94&#176;C for 30 s, 55&#176;
C for 30 s, and 72&#176;C for 30 s, followed by a final extension-cycle at 72&#1
76;C for 5 min. NCR1 (5'-GTATCTCGA GGCGACACTCCACCATAG-3') and NCR2 (5'-ATACTCGA 
GGTGCACGGTCTACGAGAC-3') were used as outer primers, and NCR3 (5'-CCACCATAGATCTCT
CCCCTGT-3') and NCR4 (5'-CACTCTCGAGCACCCTATCAGGCAGT-3') as inner primers. For th
e first amplification round, 5 &#181;L cDNA was mixed with 45 &#181;L of a react
ion mixture containing 20 mM Tris-HCl, 50 mM KCl, 2 mM MgCl<SUB>2</SUB>, 0.15 mM
 dNTP (Pharmacia Biotech) mix, 1 U Taq DNA polymerase (Gibco-BRL), and 12.5 pmol
 of each outer primer. The second amplification was performed using 3 &#181;L of
 the first amplification product and a mixture of the same composition as descri
bed above, but using inner primers, 0.2 mM dNTP (Pharmacia Biotech) mix and 1.5 
mM MgCl<SUB>2</SUB>. The second PCR amplification product was separated by 1.5% 
agarose gel electrophoresis, stained with ethidium bromide and visualized under 
ultraviolet light. </font>      ^cY#6887.htm##
00518000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704029000073002000900363#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#51#47#article#123#<P><font face="Arial, 
Helvetica, sans-serif">The first PCR round amplified a fragment of the 5'-untran
slated region of the HCV genome with about 300 bp, and the second round amplifie
d an internal fragment of the first amplification product of approximately 235 b
p (13,14). </font>      ^cY#6887.htm##
00493000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704026500073002000900338#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#52#48#article#123#<P><font face="Arial, 
Helvetica, sans-serif">The test sensitivity was about 1000 copies/mL, as determi
ned by the control VQC serum panel (Viral Quality Control Laboratory, Alkmaar, N
etherlands) of the proficiency program for viral NAT assays (15). </font>      ^
cY#6887.htm##
00351000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704012300073002000900196#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#53#49#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><B>Commercially available polymerase chain reaction kits<
/B> </font>      ^cY#6887.htm##
01008000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704078000073002000900853#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#54#50#article#123#<P><font face="Arial, 
Helvetica, sans-serif">A total of 38 samples reactive for both ELISA and IB but 
negative for nested PCR were submitted to a commercially available PCR test (Amp
licor HCV version 2.0, Roche Molecular Systems, Branchburg, NJ, USA). This PCR w
as performed according to manufacturer instructions and comprised three major st
eps: RNA extraction, cDNA amplification with biotinylated primers, and amplicon 
detection. The internal control of known concentration was amplified simultaneou
sly with the HCV RNA to ensure the validity of the test reaction. The biotinylat
ed amplicon product was detected by hybridization with specific probes adsorbed 
on the microplate surface. The test detection limit was 50 IU/mL. </font>  <HR A
LIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6887.htm##
00538000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031000073002000900383#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#55#51#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Res
ults</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HRE
F="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0
 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6887.htm##
00677000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704044900073002000900522#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#56#52#article#123#<P><font face="Arial, 
Helvetica, sans-serif">A global comparison of algorithms<I> A,</I> <I>B</I> and 
the conventional algorithm (<I>C</I>) for the diagnosis of HCV infection is give
n in <a href="#Fig1">Figure 1</a>. The conventional algorithm (<I>C</I>) was abl
e to define the serological diagnosis in 72.7% of the samples (285/517 as positi
ve and 91/517 as negative results); however, 27.3% (141/517) remained indetermin
ate. </font> </P>      ^cY#6887.htm##
00466000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704023800073002000900311#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#57#53#article#123#<P><font face="Arial, 
Helvetica, sans-serif">For algorithm <I>A</I> the stratification of s/co ratio p
erformed in all 517 ELISA-positive samples resulted in the IB confirmation rates
 shown in <a href="#Tab1">Table 1</a>. </font>      ^cY#6887.htm##
00837000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704060900073002000900682#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#58#54#article#123#<P><font face="Arial, 
Helvetica, sans-serif">The use of algorithm <I>A</I> provided 287 positive resul
ts, in which 238 samples had s/co ratio <font face="Symbol">&#179;</font>6, whil
e 49 had s/co ratio&lt;6 but positive by IB. Negative results were obtained in 9
1 samples and indeterminate in 139. Therefore, algorithm <I>A</I> was able to de
fine serologic diagnosis in 73.1% (378/517) of the samples, and 26.9% (139/517) 
remained undefined (IB indeterminate). The concordance of positive results obtai
ned by algorithm <I>A </I>and by the conventional algorithm <I>C</I> was 99.3% (
285/287). </font>      ^cY#6887.htm##
00846000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704061800073002000900691#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#59#55#article#123#<P><font face="Arial, 
Helvetica, sans-serif">For algorithm <I>B</I>, 287 results were considered posit
ive, comprising 249 PCR-positive and 38 PCR-negative (in-house and commercial PC
R) but IB-positive tests. Negative results were obtained for 91 samples by both 
PCR and IB tests, and 139 samples were PCR negative and IB indeterminate. Thus, 
algorithm <I>B</I> defined a serological or molecular diagnosis in 73.1% (378/51
7) of the samples. Despite the indeterminate IB results, 26.9% (139/157) of the 
samples were defined because PCR-negative results allowed us to exclude possible
 active infection. </font>      ^cY#6887.htm##
00390000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704016200073002000900235#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#60#56#article#123#<P><font face="Arial, 
Helvetica, sans-serif">The concordance between algorithm <I>B</I> and convention
al algorithm <I>C</I> was 99.3% (285/287). </font>      ^cY#6887.htm##
00545000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031700073002000900390#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#61#57#article#123#<P><font face="Arial, 
Helvetica, sans-serif">The positive results obtained using the three algorithms 
were: 287 for algorithm <I>A</I>, 287 for <I>B</I>, and 285 for conventional alg
orithm <I>C</I>. However, some of the samples did not receive a definite diagnos
is owing to indeterminate IB results. </font>      ^cY#6887.htm##
00738000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704051000073002000900583#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#62#58#article#123#<P><font face="Arial, 
Helvetica, sans-serif">A total of 283 samples were positive for all three algori
thms. Discrepant results were observed in four samples. Two of them were only po
sitive for algorithm <I>A</I> (samples 2268 and 86, with s/co ratio <font face="
Symbol">&#179;</font>6) and the other two were only positive for algorithm <I>B<
/I> (samples 1992 and 2699, PCR-positive). All four samples were indeterminate f
or the conventional algorithm (<I>C</I>; <a href="#Tab2">Table 2</a>). </font>  
    ^cY#6887.htm##
00775000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704054700073002000900620#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#63#59#article#123#<P><font face="Arial, 
Helvetica, sans-serif">The cost of each algorithm depends on the method used and
 on the number of tests performed. The number and the cost of ELISA, IB and PCR 
tests performed for algorithms <I>A</I>, <I>B</I> and conventional <I>C</I> are 
shown in <a href="#Tab3">Table 3</a>. The cost of algorithms <I>A</I> and <I>B <
/I>(in-house PCR) were 43.5 and 14.0%, respectively, lower than the cost of <I>C
</I>; the cost of algorithm <I>B</I> using a commercial PCR kit was 80.4% higher
 than the cost of <I>C</I>. </font>      ^cY#6887.htm##
01038000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704081000073002000900883#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#64#60#article#123#<P><font face="Arial, 
Helvetica, sans-serif">In order to clarify indeterminate results (139 by algorit
hm <I>A</I> and 141 by algorithm <I>C</I>), these algorithms were expanded by pe
rforming PCR, with two samples becoming positive by this procedure. The total nu
mber of tests performed for each method, the cost involved in expanding the algo
rithms and the comparison among their cost can be seen in <a href="#Tab4">Table 
4</a>. The cost of algorithms <I>A</I> and <I>C</I> increased by 15.0 and 8.6%, 
respectively, when the algorithms were expanded using in-house PCR and by 59.1 a
nd 34.3% if a commercial PCR was used. When using in-house PCR, the expanded alg
orithm <I>A</I> was 40.1% cheaper than the expanded algorithm <I>C</I> and 32.7%
 less expensive than when commercial PCR was used. </font>      ^cY#6887.htm##
00511000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704028300073002000900356#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#65#61#article#123#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>  <table width="100%"  border="0">    <tr align="left" valign="t
op">      <td width="12%"><a href="/img/revistas/bjmbr/v41n2/html/6887i01.htm"><
img src="/img/revistas/bjmbr/v41n2/6887i01peq.jpg" border="2"></a></td>      <td
 width="88%">    ^cY#6887.htm##
00954000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704072600073002000900799#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#66#62#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. Algorithms <I>A</I>, <I>B</I
> or <I>C</I> required for the diagnosis of HCV infection in a Brazilian populat
ion. The present study compared the conventional algorithm (<I>C</I>) used in mo
st laboratories with the two new algorithms (<I>A</I> and <I>B</I>) recommended 
by the Centers for Disease Control and Prevention, USA. The three algorithms wer
e applied to 517 ELISA-positive and -inconclusive serum samples of blood donors 
from Funda&ccedil;&atilde;o Pr&oacute;-Sangue - Hemocentro de S&atilde;o Paulo, 
who had returned to the institution to confirm their previous results. s/co = si
gnal-to-cut-off. </font>      </td>    </tr>  </table>      ^cY#6887.htm##
00611000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038300073002000900456#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#67#63#article#123#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (163 K JPG file)]</fon
t></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <
tr align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/
v41n2/html/6887t01.htm"><img src="/img/revistas/bjmbr/v41n2/table.jpg" border="2
"></a></td>      <td width="88%">    ^cY#6887.htm##
00588000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704036000073002000900433#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#68#64#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Tab1"></a>Table 1. Association of the signal-to-
cut-off (s/co) ratio obtained in all of the 495 ELISA-positive results, stratifi
ed into six groups, with the frequency of positive results obtained by anti-HCV 
immunoblot (IB) or by in-house nested PCR, or both.</font>      </td>    </tr>  
</table>      ^cY#6887.htm##
00611000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038300073002000900456#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#69#65#article#123#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this table (104 K JPG file)]</fon
t></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <
tr align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/
v41n2/html/6887t02.htm"><img src="/img/revistas/bjmbr/v41n2/table.jpg" border="2
"></a></td>      <td width="88%">    ^cY#6887.htm##
00487000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704025900073002000900332#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#70#66#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Tab2"></a>Table 2. Serological and molecular res
ults of the four samples whose results were in disagreement with algorithms <I>A
</I>, <I>B</I>, and <I>C</I>. </font>      </td>    </tr>  </table>      ^cY#688
7.htm##
00611000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038300073002000900456#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#71#67#article#123#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this table (116 K JPG file)]</fon
t></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <
tr align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/
v41n2/html/6887t03.htm"><img src="/img/revistas/bjmbr/v41n2/table.jpg" border="2
"></a></td>      <td width="88%">    ^cY#6887.htm##
00494000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704026600073002000900339#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#72#68#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Tab3"></a>Table 3. Number of ELISA, immunoblot, 
or PCR tests required for 517 samples and the estimated cost to implement algori
thms <I>A</I>, <I>B</I> or <I>C</I>. </font>      </td>    </tr>  </table>      
^cY#6887.htm##
00618000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039000073002000900463#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#73#69#article#123#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this table (116 K JPG file)]</fon
t></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <
tr align="left" valign="top">      <td width="12%"><a href="/img/revistas/bjmbr/
v41n2/html/6887t04.htm"><img src="/img/revistas/bjmbr/v41n2/table.jpg" border="2
"></a></td>      <td width="88%">           ^cY#6887.htm##
00500000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704027200073002000900345#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#74#70#article#123#<p><font face="Arial, 
Helvetica, sans-serif"><a name="Tab4"></a>Table 4.          Number of ELISA, imm
unoblot, or in-house PCR tests required for 517 samples          to implement ex
panded algorithms <I>A</I> or <I>C</I>. </font></p>     </td>    </tr>  </table>
      ^cY#6887.htm##
00346000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011800073002000900191#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#75#71#article#123#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this table (111 K JPG file)]</fon
t></P>      ^cY#6887.htm##
00276000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004800073002000900121#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#76#72#article#123#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>      ^cY#6887.htm##
00498000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704027000073002000900343#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#77#73#article#123#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007
F><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n
2/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  
    ^cY#6887.htm##
00765000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704053700073002000900610#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#78#74#article#123#<P><font face="Arial, 
Helvetica, sans-serif">Some laboratories report a result as positive for HCV inf
ection considering only the screening antibody test, without any further confirm
ation by supplemental tests such as IB or PCR (8). Since there is no established
 gold standard test, and given the high cost of supplemental tests for diagnosin
g HCV infection, the CDC published guidelines that proposed the two new algorith
ms (termed <I>A</I> and <I>B</I> in the present study) as an alternative to the 
conventional one. </font>      ^cY#6887.htm##
00550000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704032200073002000900395#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#79#75#article#123#<P><font face="Arial, 
Helvetica, sans-serif">In the present study, for algorithm <I>A</I>, the cut-off
 ratio <font face="Symbol">&#179;</font>6 for ELISA-positive samples agreed with
 IB-positive results in 99.2% of the cases, underscoring its ability to accurate
ly predict true antibody-positive results. </font>      ^cY#6887.htm##
01616000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704138800073002000901461#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#80#76#article#123#<P><font face="Arial, 
Helvetica, sans-serif">Some investigators have also considered s/co ratio as an 
effective viremia predictor. In samples with strong ELISA-positive results (s/co
 ratio &gt;50) HCV RNA was detected in 93.6% of the cases. These investigators s
uggested a threshold set at s/co ratio = 10 to separate viremic and non-viremic 
populations (12). The cut-off ratio may vary according to the kit manufacturer a
nd to the population tested, so it must be carefully established for each labora
tory. Reports from the US CDC show that average s/co ratio &gt;3.8 is highly pre
dictive of the true anti-HCV status for kits manufactured by Ortho-Clinical Diag
nostics (Ortho HCV version 3.0 ELISA, Raritan, NJ, USA) and by Abbott EIA (Abbot
t EIA 2.0, Chicago, IL, USA) and ratios &gt;8.0 for kits manufactured by VITROS 
anti-HCV (Ortho-Clinical Diagnostics) (16,17), with sensitivity higher than 95%.
 A wide range of variation has been reported by Ren et al. (18) for domestic EIA
 kits, such as 6.0 to 14.0, with <font face="Symbol">&#179;</font>95% sensitivit
y. Reflex supplemental testing could be limited to screening test-positive sampl
es with ratios below the cut-off value. In studies conducted in October 2000 usi
ng the second-generation HCV ELISA assay, the authors obtained s/co ratio &gt;3.
0 as cut-off and high concordance (96%) with IB-positive tests (10). </font>    
  ^cY#6887.htm##
00783000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704055500073002000900628#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#81#77#article#123#<P><font face="Arial, 
Helvetica, sans-serif">In our samples, algorithm <I>A</I> was able to diagnose 4
6% (238/517) of the samples as true positive only by ELISA (s/co ratio <font fac
e="Symbol">&#179;</font>6). In 54% (279/517) of the cases with s/co ratio &lt;6 
the IB tests were performed, producing definite positive (N = 49) or negative (N
 = 91) results in almost half the samples (140/279). For the remaining 139 (26.9
%) samples, algorithm <I>A</I> was unable to define a laboratory diagnosis becau
se of the indeterminate IB results. </font>      ^cY#6887.htm##
00589000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704036100073002000900434#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#82#78#article#123#<P><font face="Arial, 
Helvetica, sans-serif">Algorithm <I>A</I> was considered to be the best in terms
 of cost and feasibility, and for minimizing the number of samples requiring sup
plemental testing, being particularly suitable for limited resource laboratories
. However, supplemental PCR tests were still required to detect active infection
. </font>      ^cY#6887.htm##
00781000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704055300073002000900626#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#83#79#article#123#<P><font face="Arial, 
Helvetica, sans-serif">For algorithm <I>B</I>, all 517 ELISA-positive samples we
re submitted to reflex PCR testing, which produced positive results in 48.2% (24
9/517) of the cases. IB tests were carried out for the remaining 51.8% (268/517)
 of PCR-negative samples. No conclusive diagnosis was obtained for 139 (26.9%) s
amples (indeterminate IB). Nevertheless, the PCR-negative results for these samp
les were sufficient to define diagnosis, showing the absence of viremia, which i
s important in clinical practice. </font>      ^cY#6887.htm##
00687000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704045900073002000900532#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#84#80#article#123#<P><font face="Arial, 
Helvetica, sans-serif">The conventional algorithm (<I>C</I>) is particularly imp
ortant in low prevalence populations, especially prone to false-positive HCV inf
ection results. However, infection activity cannot be confirmed using only IB te
sting. The IB test used for this algorithm resulted in 141 (27.3%) indeterminate
 results, similar to the rate obtained using algorithm <I>A</I>, providing no co
nclusive diagnosis. </font>      ^cY#6887.htm##
00577000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704034900073002000900422#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#85#81#article#123#<P><font face="Arial, 
Helvetica, sans-serif">All three algorithms had similar diagnostic performance f
or the samples studied. Positive results were obtained in 287, 287 and 285 cases
 for algorithms <I>A</I>, <I>B</I>, and <I>C</I>, respectively. These data revea
led a remarkable agreement in the results obtained by the algorithms. </font>   
   ^cY#6887.htm##
00594000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704036600073002000900439#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#86#82#article#123#<P><font face="Arial, 
Helvetica, sans-serif">PCR was performed to clarify indeterminate results (139 s
amples from algorithm <I>A</I> and 141 samples from conventional algorithm <I>C<
/I>) and was also applied to samples from the three algorithms that did not agre
e. This supplemental diagnosis entailed increased cost and is not mandated by th
e CDC. </font>      ^cY#6887.htm##
01261000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704103300073002000901106#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#87#83#article#123#<P><font face="Arial, 
Helvetica, sans-serif">The main problem related to IB testing concerns the indet
erminate results. Some plausible causes are: 1) seroconversion phase, during whi
ch ELISA is already positive due to its higher sensitivity when compared to the 
IB test, which can still fail to meet the positivity criteria (19,20); 2) serore
version in patients who spontaneously eliminate HCV. In these individuals, antib
odies against some antigenic fractions have already turned negative for the IB t
est, but they are sufficient to yield ELISA-positive results (19,21); 3) individ
uals infected with genotype 3 or other uncommon genotypes that could have low re
activity to antigen fractions from genotype 1a used in most commercially availab
le kits for anti-HCV. In this case, IB may be indeterminate but ELISA could be p
ositive due to the reaction with better-preserved antigens such as core (22). 4)
 Other factors related to the kit performance (23) or to patient immunoresponse 
variability (24) may be involved. </font>      ^cY#6887.htm##
01621000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704139300073002000901466#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#88#84#article#123#<P><font face="Arial, 
Helvetica, sans-serif">Two samples (2699 and 1992) were PCR positive for algorit
hm <I>B</I>, but were indeterminate for both algorithm <I>A </I>and <I>C</I>. Sa
mple 2699 had an s/co ratio three times higher in the sample collected at the do
nor's return visit when compared to that collected at the time of donation. This
 suggests that the sample belonged to an individual who was under seroconversion
. IB was indeterminate in the presence of an NS3 band. This band was supposedly 
the one that most favors early seroconversion detection. It also shows concordan
ce with viremia (25), which is consistent with the hypothesis we proposed. Sampl
e 1992 had an s/co ratio of 1.0 and was IB indeterminate, with bands NS3 (&#177;
), NS5(&#177;) and NS4 (2+). A sample collected 31 days before the patient's ret
urn visit also had an s/co ratio of 1.0, indicating the low probability of its c
orresponding to a seroconversion phase, because the antibody level detected by E
LISA did not increase during the period between the two sample collections. Howe
ver, this same sample was ELISA positive upon further testing using a kit from a
 different manufacturer (Murex, Abbott Laboratories), showing s/co ratio &gt;4.0
, suggesting low reactivity of the ELISA kit initially used. The positive PCR re
sult ensured that the sample belonged to a patient truly infected by HCV. </font
>      ^cY#6887.htm##
00683000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704045500073002000900528#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#89#85#article#123#<P><font face="Arial, 
Helvetica, sans-serif">Samples 2268 and 86 were positive only for algorithm <I>A
</I> owing to their s/co ratios of 7.0 and 8.6, respectively. Both were IB indet
erminate and PCR negative. These results could correspond to individuals who had
 spontaneously eliminated the virus and who were in the early seroreversion phas
e (19,26-28). However, the possibility of false-positive ELISA results must also
 be considered. </font>      ^cY#6887.htm##
01443000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704121500073002000901288#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#90#86#article#123#<P><font face="Arial, 
Helvetica, sans-serif">The cost of each algorithm depends on the number of suppl
emental tests required and varies according to the frequency of positive results
 in the population studied. It can be estimated by multiplying each test by its 
unitary cost (11) that was estimated taking into account the selling price used 
in Brazil; however, it must be only considered as an example. The following supp
lemental tests were carried out for the 517 ELISA-positive samples: 279 IB tests
 for algorithm <I>A</I>; 517 PCR and 268 IB tests for algorithm <I>B</I>, and 51
7 IB tests for conventional algorithm <I>C</I>. The total cost of the algorithms
 in American dollars on August 2007 based on the mean cost of 7 commercial tests
 (ELISA, and IB) and in-house PCR showed that algorithms <I>A</I> and <I>B</I> w
ere respectively 43.5 and 16.0% cheaper than <I>C</I>. However, if the commercia
l PCR is used, the total cost of algorithm <I>B</I> will be 80.4% higher than th
e cost of algorithm <I>C.</I> Algorithm <I>A</I> was certainly the most economic
al option while the cost of algorithms <I>B</I> and <I>C </I>depends on the use 
of either in-house PCR or a commercially available kit. </font>      ^cY#6887.ht
m##
01070000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704084200073002000900915#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#91#87#article#123#<P><font face="Arial, 
Helvetica, sans-serif">In order to solve the problem of indeterminate IB results
, algorithms <I>A</I> and <I>C</I> were expanded by performing in-house PCR test
ing which detected two additional positive samples. Algorithms <I>A</I> and <I>C
</I> became 15.0 and 8.6% more expensive when they were expanded. Therefore, the
 cost of expanded algorithm <I>A</I> was 40.1% lower than that of expanded algor
ithm <I>C</I> that required lower number. In laboratories using the commercially
 available PCR kit, the cost of algorithms <I>A</I> and <I>C</I> increased signi
ficantly for a total of 517 samples (US$34,051.25 and US$50,609.13, respectively
) but is lower than algorithm <I>B</I> (US$67,972.17). The expanded algorithm <I
>A</I> involved the lowest number of supplemental tests, which are very expensiv
e. </font>      ^cY#6887.htm##
01455000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704122700073002000901300#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#92#88#article#123#<P><font face="Arial, 
Helvetica, sans-serif">Algorithm <I>A</I> is also recommended for populations wi
th a high prevalence of HCV infection owing to its consistently positive results
 in screening tests and high concordance with true-positive results, in that IB 
testing was required only for weakly reactive samples (3). With respect to algor
ithm <I>B,</I> PCR performance may speed up the clinical decision and lead to ea
rly treatment of HCV infection. This algorithm is the most suitable for immunosu
ppressed patients for whom the IB test could represent a problem because of its 
low antibody level, leading to occasional false-negative results. Conventional a
lgorithm <I>C</I> was useful for determining the immune status of the patients a
gainst HCV infection and also for confirming the specificity of positive ELISA r
esults. It is recommended for low prevalence populations for which false-positiv
e antibody results are usually high. However, in the present study, this algorit
hm yielded a high frequency of IB-indeterminate results, producing no conclusive
 diagnosis. Furthermore, this algorithm did not differentiate between active and
 past infections, a fact that may be crucial for clinical purposes. </font>     
 ^cY#6887.htm##
00627000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039900073002000900472#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#93#89#article#123#<P><font face="Arial, 
Helvetica, sans-serif">Since screening tests are currently performed using only 
serological tests, of the three alternatives, algorithm <I>B</I> provided the mo
st complete information. However, it was unable to screen pre-seroconversion pha
se individuals because ELISA-negative samples (a condition observed during the w
indow phase) were not submitted to PCR. </font>      ^cY#6887.htm##
00534000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704030600073002000900379#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#94#90#article#123#<P><font face="Arial, 
Helvetica, sans-serif">The mandatory application of the NAT would render the IB 
test unnecessary except for ELISA-positive and NAT-negative samples. In this cas
e, the IB test would screen patients with past HCV infections who have spontaneo
usly eliminated the virus. </font>      ^cY#6887.htm##
00649000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704042100073002000900494#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#95#91#article#123#<P><font face="Arial, 
Helvetica, sans-serif">The new algorithms <I>A</I> and <I>B </I>are highly sensi
tive and could be validated to diagnose HCV infection in Brazil. The choice of a
n algorithm must take into account its purpose, the population and the prevalenc
e of HCV infection. It would also depend on the financial and infrastructure con
ditions of the laboratory. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6
887.htm##
00544000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031600073002000900389#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#96#92#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>
References</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif">
<A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BO
RDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6887.htm##
00494000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704025200075002000900327#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#97#93#article#123#1#<P><font
 face="Arial, Helvetica, sans-serif">1. Choo QL, Kuo G, Weiner AJ, Overby LR, Br
adley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A
, non-B viral hepatitis genome. <I>Science</I> 1989; 244: 359-362. </font>      
^cY#6887.htm##
00507000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704026500075002000900340#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#98#94#article#123#2#<P><font
 face="Arial, Helvetica, sans-serif">2. Kuo G, Choo QL, Alter HJ, Gitnick GL, Re
deker AG, Purcell RH, et al. An assay for circulating antibodies to a major etio
logic virus of human non-A, non-B hepatitis. <I>Science</I> 1989; 244: 362-364. 
</font>      ^cY#6887.htm##
00389000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069888000200073704014700075002000900222#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#99#95#article#123#3#<P><font
 face="Arial, Helvetica, sans-serif">3. Gretch DR. Diagnostic tests for hepatiti
s C. <I>Hepatology</I> 1997; 26: 43S-47S. </font>      ^cY#6887.htm##
00519000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000200074704027600076002000900352#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#100#96#article#123#4#<P><fon
t face="Arial, Helvetica, sans-serif">4. Neville JA, Prescott LE, Bhattacherjee 
V, Adams N, Pike I, Rodgers B, et al. Antigenic variation of core, NS3, and NS5 
proteins among genotypes of hepatitis C virus. <I>J Clin Microbiol</I> 1997; 35:
 3062-3070. </font>      ^cY#6887.htm##
00511000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000200074704026800076002000900344#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#101#97#article#123#5#<P><fon
t face="Arial, Helvetica, sans-serif">5. Alter MJ, Kruszon-Moran D, Nainan OV, M
cQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infecti
on in the United States, 1988 through 1994. <I>N Engl J Med</I> 1999; 341: 556-5
62. </font>      ^cY#6887.htm##
00542000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000200074704029900076002000900375#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#102#98#article#123#6#<P><fon
t face="Arial, Helvetica, sans-serif">6. Conry-Cantilena C, VanRaden M, Gibble J
, Melpolder J, Shakil AO, Viladomiu L, et al. Routes of infection, viremia, and 
liver disease in blood donors found to have hepatitis C virus infection. <I>N En
gl J Med</I> 1996; 334: 1691-1696. </font>      ^cY#6887.htm##
00547000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070888000200074704030400076002000900380#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#103#99#article#123#7#<P><fon
t face="Arial, Helvetica, sans-serif">7. Centers for Disease Control and Prevent
ion (CDC). Hepatitis C virus infection among firefighters, emergency medical tec
hnicians, and paramedics - selected locations, United States, 1991-2000. <I>Morb
 Mortal Wkly Rep</I> 2000; 49: 660-665. </font>      ^cY#6887.htm##
00492000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704024800077002000900325#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#104#100#article#123#8#<P><fo
nt face="Arial, Helvetica, sans-serif">8. Centers for Disease Control and Preven
tion (CDC). Guidelines for laboratory testing and result reporting of antibody t
o hepatitis C virus. <I>Morb Mortal Wkly Rep</I> 2003; 52: 1-15. </font>      ^c
Y#6887.htm##
00395000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704015100077002000900228#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#105#101#article#123#9#<P><fo
nt face="Arial, Helvetica, sans-serif">9. Hoofnagle JH. Course and outcome of he
patitis C. <I>Hepatology</I> 2002; 36: S21-S29. </font>      ^cY#6887.htm##
00635000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704039000078002000900468#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#106#102#article#123#10#<P><f
ont face="Arial, Helvetica, sans-serif">10. Gon&ccedil;ales NS, Costa FF, Vassal
lo J, Gon&ccedil;ales FL Jr. Diagnosis of hepatitis C virus in Brazilian blood d
onors using a reverse transcriptase nested polymerase chain reaction: comparison
 with enzyme immunoassay and recombinant protein immunoblot assay. <I>Rev Inst M
ed Trop S&atilde;o Paulo</I> 2000; 42: 263-267. </font>      ^cY#6887.htm##
00628000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704038300078002000900461#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#107#103#article#123#11#<P><f
ont face="Arial, Helvetica, sans-serif">11. Barreto AMEC, Takei K, Sabino EC, Sa
lles NA, Barreto CC, Nishiya AS, et al. An&aacute;lise do custo benef&iacute;cio
 dos diferentes algoritmos para o diagn&oacute;stico da infec&ccedil;&atilde;o p
elo HCV. <I>Annals of Congresso Brasileiro de Patologia Cl&iacute;nica/Medicina 
Laboratorial</I>. 2004. p 38 (Abstract). </font>      ^cY#6887.htm##
00504000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704025900078002000900337#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#108#104#article#123#12#<P><f
ont face="Arial, Helvetica, sans-serif">12. Bossi V, Galli C. Quantitative signa
l of anti-HCV by an automated assay predicts viremia in a population at high pre
valence of hepatitis C virus infection. <I>J Clin Virol</I> 2004; 30: 45-49. </f
ont>      ^cY#6887.htm##
00543000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704029800078002000900376#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#109#105#article#123#13#<P><f
ont face="Arial, Helvetica, sans-serif">13. Stuyver L, Rossau R, Wyseur A, Duham
el M, Vanderborght B, Van Heuverswyn H, et al. Typing of hepatitis C virus isola
tes and characterization of new subtypes using a line probe assay. <I>J Gen Viro
l</I> 1993; 74 (Part 6): 1093-1102. </font>      ^cY#6887.htm##
00486000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024100078002000900319#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#110#106#article#123#14#<P><f
ont face="Arial, Helvetica, sans-serif">14. Stuyver L, Wyseur A, van Arnhem W, H
ernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus
 genotyping. <I>J Clin Microbiol</I> 1996; 34: 2259-2266. </font>       ^cY#6887
.htm##
00713000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704046800078002000900546#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#111#107#article#123#15#<P><f
ont face="Arial, Helvetica, sans-serif">15. VQC proficiency programme for    vir
al NAT assays in 2000. The Viral Quality Control (VQC) laboratory, The National 
   Serology Reference Laboratory, The Delft Diagnostic Laboratory, organized [Ci
ted    Aug 27, 2007]. <I>Viral Quality Control (VQC) laboratory</I> <a href="htt
p://www.inmunochem.com/descargar/VQC_2000.pdf" target="_blank">http://www.inmuno
chem.com/descargar/VQC_2000.pdf</a>;    2007. </font>      ^cY#6887.htm##
00473000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704022800078002000900306#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#112#108#article#123#16#<P><f
ont face="Arial, Helvetica, sans-serif">16. National Institutes of Health Consen
sus Development Conference Statement: Management of hepatitis C: 2002 - June 10-
12, 2002. <I>Hepatology</I> 2002; 36: S3-S20. </font>      ^cY#6887.htm##
00604000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704035900078002000900437#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#113#109#article#123#17#<P><f
ont face="Arial, Helvetica, sans-serif">17. Oethinger M, Mayo DR, Falcone J, Bar
ua PK, Griffith BP. Efficiency of the ortho VITROS assay for detection of hepati
tis C virus-specific antibodies increased by elimination of supplemental testing
 of samples with very low sample-to-cut-off ratios. <I>J Clin Microbiol</I> 2005
; 43: 2477-2480. </font>      ^cY#6887.htm##
00536000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704029100078002000900369#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#114#110#article#123#18#<P><f
ont face="Arial, Helvetica, sans-serif">18. Ren FR, Lv QS, Zhuang H, Li JJ, Gong
 XY, Gao GJ, et al. Significance of the signal-to-cut-off ratios of anti-hepatit
is C virus enzyme immunoassays in screening of Chinese blood donors. <I>Transfus
ion</I> 2005; 45: 1816-1822. </font>      ^cY#6887.htm##
00553000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704030800078002000900386#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#115#111#article#123#19#<P><f
ont face="Arial, Helvetica, sans-serif">19. Kiely P, Kay D, Parker S, Piscitelli
 L. The significance of third-generation HCV RIBA-indeterminate, RNA-negative re
sults in voluntary blood donors screened with sequential third-generation immuno
assays. <I>Transfusion</I> 2004; 44: 349-358. </font>      ^cY#6887.htm##
00600000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704035500078002000900433#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#116#112#article#123#20#<P><f
ont face="Arial, Helvetica, sans-serif">20. Kleinman SH, Stramer SL, Brodsky JP,
 Caglioti S, Busch MP. Integration of nucleic acid amplification test results in
to hepatitis C virus supplemental serologic testing algorithms: implications for
 donor counseling and revision of existing algorithms. <I>Transfusion</I> 2006; 
46: 695-702. </font>      ^cY#6887.htm##
00574000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704032900078002000900407#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#117#113#article#123#21#<P><f
ont face="Arial, Helvetica, sans-serif">21. Kondili LA, Chionne P, Costantino A,
 Villano U, Lo Noce C, Pannozzo F, et al. Infection rate and spontaneous serorev
ersion of anti-hepatitis C virus during the natural course of hepatitis C virus 
infection in the general population. <I>Gut</I> 2002; 50: 693-696. </font>      
^cY#6887.htm##
00621000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704037600078002000900454#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#118#114#article#123#22#<P><f
ont face="Arial, Helvetica, sans-serif">22. Bassit L, Da Silva LC, Ribeiro-Dos-S
antos G, Maertens G, Carrilho FJ, Fonseca LE, et al. Chronic hepatitis C virus i
nfections in Brazilian patients: association with genotypes, clinical parameters
 and response to long-term alpha interferon therapy. <I>Rev Inst Med Trop S&atil
de;o Paulo</I> 1999; 41: 183-189. </font>      ^cY#6887.htm##
00567000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704032200078002000900400#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#119#115#article#123#23#<P><f
ont face="Arial, Helvetica, sans-serif">23. Zachary P, Ullmann M, Djeddi S, Meye
r N, Wendling MJ, Schvoerer E, et al. Evaluation of three commercially available
 hepatitis C virus antibody detection assays under the conditions of a clinical 
virology laboratory. <I>J Clin Virol</I> 2005; 34: 207-210. </font>      ^cY#688
7.htm##
00523000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704027800078002000900356#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#120#116#article#123#24#<P><f
ont face="Arial, Helvetica, sans-serif">24. Busch MP. Insights into the epidemio
logy, natural history and pathogenesis of hepatitis C virus infection from studi
es of infected donors and blood product recipients. <I>Transfus Clin Biol</I> 20
01; 8: 200-206. </font>      ^cY#6887.htm##
00477000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023200078002000900310#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#121#117#article#123#25#<P><f
ont face="Arial, Helvetica, sans-serif">25. Feucht HH, Zollner B, Polywka S, Lau
fs R. Study on reliability of commercially available hepatitis C virus antibody 
tests. <I>J Clin Microbiol</I> 1995; 33: 620-624. </font>      ^cY#6887.htm##
00488000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704024300078002000900321#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#122#118#article#123#26#<P><f
ont face="Arial, Helvetica, sans-serif">26. Simon N, Courouce AM, Lemarrec N, Tr
epo C, Ducamp S. A twelve year natural history of hepatitis C virus infection in
 hemodialyzed patients. <I>Kidney Int</I> 1994; 46: 504-511. </font>      ^cY#68
87.htm##
00500000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704025500078002000900333#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#123#119#article#123#27#<P><f
ont face="Arial, Helvetica, sans-serif">27. Lefrere JJ, Guiramand S, Lefrere F, 
Mariotti M, Aumont P, Lerable J, et al. Full or partial seroreversion in patient
s infected by hepatitis C virus. <I>J Infect Dis</I> 1997; 175: 316-322. </font>
      ^cY#6887.htm##
00553000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704030800078002000900386#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#p#124#120#article#123#28#<P><f
ont face="Arial, Helvetica, sans-serif">28. Poignet JL, Degos F, Bouchardeau F, 
Chauveau P, Courouce AM. Complete response to interferon-alpha for acute hepatit
is C after needlestick injury in a hemodialysis nurse. <I>J Hepatol</I> 1995; 23
: 740-741.</font>   <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6887.htm##
00566000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704033600075002000900411#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#125#121#article#123#<P><FONT SIZE=4 face
="Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F
><B>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, H
elvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6887
.htm##
00676000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704044600075002000900521#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#126#122#article#123#<p><font face="Arial
, Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v41n2/
recor.gif" border="0"></a> Address for correspondence:</b>  A.M.E.C. Barreto, Fu
nda&ccedil;&atilde;o Pr&oacute;-Sangue Hemocentro de S&atilde;o Paulo, Rua En&ea
cute;as de Carvalho Aguiar, 155, 05403-900 S&atilde;o Paulo, SP, Brasil. Fax: +5
5-11-3088-8317. E-mail: <a href="mailto:amegydio@uol.com.br">amegydio@uol.com.br
</a></font> </p>      ^cY#6887.htm##
00376000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704014600075002000900221#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6887.htm#S#p#127#123#article#123#<P><font face="Arial
, Helvetica, sans-serif">Publication supported by FAPESP. Received May 11, 2007.
 Accepted November 26, 2007. </font>      ^cY#6887.htm##
00661000000000325000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100015000740100013000890100
01700102010001700119010001800136010001800154012009300172030000800265065000900273
06400050028203100040028701400080029186500090029900200090030803500100031780100080
0327#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#128#1#article#28#1#^
rND^sChoo^nQL#^rND^sKuo^nG#^rND^sWeiner^nAJ#^rND^sOverby^nLR#^rND^sBradley^nDW#^
rND^sHoughton^nM#Isolation of a cDNA clone derived from a blood-borne non-A, non
-B viral hepatitis genome^len#Science#19890000#1989#244#359-362#20080200#6887.ht
m#0036-8075#Science##
00685000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100013000740100015000870100
01600102010001800118010001800136010001800154810000600172012009900178030000800277
06500090028506400050029403100040029901400080030386500090031100200090032003500100
0329801000800339#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#129#2#ar
ticle#28#2#^rND^sKuo^nG#^rND^sChoo^nQL#^rND^sAlter^nHJ#^rND^sGitnick^nGL#^rND^sR
edeker^nAG#^rND^sPurcell^nRH#et al#An assay for circulating antibodies to a majo
r etiologic virus of human non-A, non-B hepatitis^len#Science#19890000#1989#244#
362-364#20080200#6887.htm#0036-8075#Science##
00469000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740120037000910300
01100128065000900139064000500148031000300153014000800156865000900164002000900173
035001000182801001100192#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#
130#3#article#28#3#^rND^sGretch^nDR#Diagnostic tests for hepatitis C^len#Hepatol
ogy#19970000#1997#26#43S-47S#20080200#6887.htm#0161-0538#HEPATOLOGY##
00705000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100019000920100
02300111010001500134010001400149010001700163810000600180012009200186030001700278
06500090029506400050030403100030030901400100031286500090032200200090033103500100
0340801001700350#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#131#4#ar
ticle#28#4#^rND^sNeville^nJA#^rND^sPrescott^nLE#^rND^sBhattacherjee^nV#^rND^sAda
ms^nN#^rND^sPike^nI#^rND^sRodgers^nB#et al#Antigenic variation of core, NS3, and
 NS5 proteins among genotypes of hepatitis C virus^len#J Clin Microbiol#19970000
#1997#35#3062-3070#20080200#6887.htm#0095-1137#J Clin Microbiol##
00693000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100023000900100
01700113010002000130010001300150010001600163810000600179012009000185030001300275
06500090028806400050029703100040030201400080030686500090031400200090032303500100
0332801001300342#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#132#5#ar
ticle#28#5#^rND^sAlter^nMJ#^rND^sKruszon-Moran^nD#^rND^sNainan^nOV#^rND^sMcQuill
an^nGM#^rND^sGao^nF#^rND^sMoyer^nLA#et al#The prevalence of hepatitis C virus in
fection in the United States, 1988 through 1994^len#N Engl J Med#19990000#1999#3
41#556-562#20080200#6887.htm#0028-4793#N Engl J Med##
00724000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100025000740100018000990100
01600117010001900133010001700152010001900169810000600188012011000194030001300304
06500090031706400050032603100040033101400100033586500090034500200090035403500100
0363801001300373#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#133#6#ar
ticle#28#6#^rND^sConry-Cantilena^nC#^rND^sVanRaden^nM#^rND^sGibble^nJ#^rND^sMelp
older^nJ#^rND^sShakil^nAO#^rND^sViladomiu^nL#et al#Routes of infection, viremia,
 and liver disease in blood donors found to have hepatitis C virus infection^len
#N Engl J Med#19960000#1996#334#1691-1696#20080200#6887.htm#0028-4793#N Engl J M
ed##
00623000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720110043000740120145001170300
02100262065000900283064000500292031000300297014000800300865000900308002000900317
035001000326801002100336#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#
134#7#article#28#7#Centers for Disease Control and Prevention#Hepatitis C virus 
infection among firefighters, emergency medical technicians, and paramedics - se
lected locations, United States, 1991-2000^len#Morb Mortal Wkly Rep#20000000#200
0#49#660-665#20080200#6887.htm#0091-0031#Morb Mortal Wkly Rep##
00567000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720110043000740120092001170300
02100209065000900230064000500239031000300244014000500247865000900252002000900261
035001000270801002100280#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#
135#8#article#28#8#Centers for Disease Control and Prevention#Guidelines for lab
oratory testing and result reporting of antibody to hepatitis C virus^len#Morb M
ortal Wkly Rep#20030000#2003#52#1-15#20080200#6887.htm#0091-0031#Morb Mortal Wkl
y Rep##
00473000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100020000740120038000940300
01100132065000900143064000500152031000300157014000800160865000900168002000900177
035001000186801001100196#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#
136#9#article#28#9#^rND^sHoofnagle^nJH#Course and outcome of hepatitis C^len#Hep
atology#20020000#2002#36#S21-S29#20080200#6887.htm#0161-0538#HEPATOLOGY##
00763000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100016000950100
01800111010002200129012020100151030002800352065000900380064000500389031000300394
014000800397865000900405002000900414035001000423801002800433#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6887.htm#S#c#137#10#article#28#10#^rND^sGonçales^nNS#^rND
^sCosta^nFF#^rND^sVassallo^nJ#^rND^sGonçales^nFL Jr#Diagnosis of hepatitis C vir
us in Brazilian blood donors using a reverse transcriptase nested polymerase cha
in reaction: comparison with enzyme immunoassay and recombinant protein immunobl
ot assay^len#Rev Inst Med Trop São Paulo#20000000#2000#42#263-267#20080200#6887.
htm#0036-4665#Rev Inst Med Trop São Paulo##
00730000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100015000960100
01700111010001700128010001800145010001800163810000600181012009700187030007400284
71000020035806500090036006400050036901400030037406100090037786500090038600200090
0395#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#138#11#article#28#11
#^rND^sBarreto^nAMEC#^rND^sTakei^nK#^rND^sSabino^nEC#^rND^sSalles^nNA#^rND^sBarr
eto^nCC#^rND^sNishiya^nAS#et al#Análise do custo benefício dos diferentes algori
tmos para o diagnóstico da infecção pelo HCV^lpt#Annals of Congresso Brasileiro 
de Patologia Clínica/Medicina Laboratorial#2#20040000#2004#38#Abstract#20080200#
6887.htm##
00602000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100015000910120
14100106030001300247065000900260064000500269031000300274014000600277865000900283
002000900292035001000301801001300311#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
887.htm#S#c#139#12#article#28#12#^rND^sBossi^nV#^rND^sGalli^nC#Quantitative sign
al of anti-HCV by an automated assay predicts viremia in a population at high pr
evalence of hepatitis C virus infection^len#J Clin Virol#20040000#2004#30#45-49#
20080200#6887.htm#0928-0197#J Clin Virol##
00733000000000349000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01600109010001700125010002200142010002400164810000600188012010300194030001200297
06500090030906400050031803100030032306100070032601400100033386500090034300200090
0352035001000361801001200371#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#
S#c#140#13#article#28#13#^rND^sStuyver^nL#^rND^sRossau^nR#^rND^sWyseur^nA#^rND^s
Duhamel^nM#^rND^sVanderborght^nB#^rND^sVan Heuverswyn^nH#et al#Typing of hepatit
is C virus isolates and characterization of new subtypes using a line probe assa
y^len#J Gen Virol#19930000#1993#74#Part 6#1093-1102#20080200#6887.htm#0022-1317#
J Gen Virol##
00641000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
02000109010001900129010001800148012007200166030001700238065000900255064000500264
031000300269014001000272865000900282002000900291035001000300801001700310#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#141#14#article#28#14#^rND^sStuyv
er^nL#^rND^sWyseur^nA#^rND^svan^nArnhem W#^rND^sHernandez^nF#^rND^sMaertens^nG#S
econd-generation line probe assay for hepatitis C virus genotyping^len#J Clin Mi
crobiol#19960000#1996#34#2259-2266#20080200#6887.htm#0095-1137#J Clin Microbiol#
#
00640000000000229000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730120212000760300039002887100
00200327062004900329065000900378064000500387865000900392002000900401#v41n2#v:\sc
ielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#142#15#article#28#15#VQC proficiency
 programme for viral NAT assays in 2000. The Viral Quality Control (VQC) laborat
ory, The National Serology Reference Laboratory, The Delft Diagnostic Laboratory
, organized [Cited Aug 27, 2007]^len#Viral Quality Control (VQC) laboratory#2#ht
tp://www.inmunochem.com/descargar/VQC_2000.pdf#20070000#2007#20080200#6887.htm##
00533000000000253000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730120129000760300011002050650
00900216064000500225031000300230014000700233865000900240002000900249035001000258
801001100268#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#143#16#artic
le#28#16#National Institutes of Health Consensus Development Conference Statemen
t: Management of hepatitis C: 2002 - June 10-12, 2002^len#Hepatology#20020000#20
02#36#S3-S20#20080200#6887.htm#0161-0538#HEPATOLOGY##
00760000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100015000950100
01700110010001600127010001900143012019500162030001700357065000900374064000500383
031000300388014001000391865000900401002000900410035001000419801001700429#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#144#17#article#28#17#^rND^sOethi
nger^nM#^rND^sMayo^nDR#^rND^sFalcone^nJ#^rND^sBarua^nPK#^rND^sGriffith^nBP#Effic
iency of the ortho VITROS assay for detection of hepatitis C virus-specific anti
bodies increased by elimination of supplemental testing of samples with very low
 sample-to-cut-off ratios^len#J Clin Microbiol#20050000#2005#43#2477-2480#200802
00#6887.htm#0095-1137#J Clin Microbiol##
00716000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100013000900100
01600103010001300119010001500132010001400147810000600161012013200167030001200299
06500090031106400050032003100030032501400100032886500090033800200090034703500100
0356801001200366#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#145#18#a
rticle#28#18#^rND^sRen^nFR#^rND^sLv^nQS#^rND^sZhuang^nH#^rND^sLi^nJJ#^rND^sGong^
nXY#^rND^sGao^nGJ#et al#Significance of the signal-to-cut-off ratios of anti-hep
atitis C virus enzyme immunoassays in screening of Chinese blood donors^len#Tran
sfusion#20050000#2005#45#1816-1822#20080200#6887.htm#0041-1132#Transfusion##
00686000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100013000910100
01600104010002000120012016700140030001200307065000900319064000500328031000300333
014000800336865000900344002000900353035001000362801001200372#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6887.htm#S#c#146#19#article#28#19#^rND^sKiely^nP#^rND^sKa
y^nD#^rND^sParker^nS#^rND^sPiscitelli^nL#The significance of third-generation HC
V RIBA-indeterminate, RNA-negative results in voluntary blood donors screened wi
th sequential third-generation immunoassays^len#Transfusion#20040000#2004#44#349
-358#20080200#6887.htm#0041-1132#Transfusion##
00751000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100018000950100
01800113010001800131010001600149012019500165030001200360065000900372064000500381
031000300386014000800389865000900397002000900406035001000415801001200425#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#147#20#article#28#20#^rND^sKlein
man^nSH#^rND^sStramer^nSL#^rND^sBrodsky^nJP#^rND^sCaglioti^nS#^rND^sBusch^nMP#In
tegration of nucleic acid amplification test results into hepatitis C virus supp
lemental serologic testing algorithms: implications for donor counseling and rev
ision of existing algorithms^len#Transfusion#20060000#2006#46#695-702#20080200#6
887.htm#0041-1132#Transfusion##
00746000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
02000111010001700131010001700148010001800165810000600183012015800189030000400347
06500090035106400050036003100030036501400080036886500090037600200090038503500100
0394801000400404#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#148#21#a
rticle#28#21#^rND^sKondili^nLA#^rND^sChionne^nP#^rND^sCostantino^nA#^rND^sVillan
o^nU#^rND^sLo^nNoce C#^rND^sPannozzo^nF#et al#Infection rate and spontaneous ser
oreversion of anti-hepatitis C virus during the natural course of hepatitis C vi
rus infection in the general population^len#Gut#20020000#2002#50#693-696#2008020
0#6887.htm#0017-5749#Gut##
00810000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100019000920100
02800111010001800139010001900157010001800176810000600194012016300200030002800363
06500090039106400050040003100030040501400080040886500090041600200090042503500100
0434801002800444#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#149#22#a
rticle#28#22#^rND^sBassit^nL#^rND^sDa^nSilva LC#^rND^sRibeiro-Dos-Santos^nG#^rND
^sMaertens^nG#^rND^sCarrilho^nFJ#^rND^sFonseca^nLE#et al#Chronic hepatitis C vir
us infections in Brazilian patients: association with genotypes, clinical parame
ters and response to long-term alpha interferon therapy^len#Rev Inst Med Trop Sã
o Paulo#19990000#1999#41#183-189#20080200#6887.htm#0036-4665#Rev Inst Med Trop S
ão Paulo##
00748000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930100
01600110010001500126010001900141010001900160810000600179012014600185030001300331
06500090034406400050035303100030035801400080036186500090036900200090037803500100
0387801001300397#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#150#23#a
rticle#28#23#^rND^sZachary^nP#^rND^sUllmann^nM#^rND^sDjeddi^nS#^rND^sMeyer^nN#^r
ND^sWendling^nMJ#^rND^sSchvoerer^nE#et al#Evaluation of three commercially avail
able hepatitis C virus antibody detection assays under the conditions of a clini
cal virology laboratory^len#J Clin Virol#20050000#2005#34#207-210#20080200#6887.
htm#0928-0197#J Clin Virol##
00609000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760120161000920300
01900253065000900272064000500281031000200286014000800288865000900296002000900305
035001000314801001900324#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#
151#24#article#28#24#^rND^sBusch^nMP#Insights into the epidemiology, natural his
tory and pathogenesis of hepatitis C virus infection from studies of infected do
nors and blood product recipients^len#Transfus Clin Biol#20010000#2001#8#200-206
#20080200#6887.htm#1246-7820#Transfus Clin Biol##
00615000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930100
01700110010001500127012008400142030001700226065000900243064000500252031000300257
014000800260865000900268002000900277035001000286801001700296#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6887.htm#S#c#152#25#article#28#25#^rND^sFeucht^nHH#^rND^s
Zollner^nB#^rND^sPolywka^nS#^rND^sLaufs^nR#Study on reliability of commercially 
available hepatitis C virus antibody tests^len#J Clin Microbiol#19950000#1995#33
#620-624#20080200#6887.htm#0095-1137#J Clin Microbiol##
00638000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100019000910100
01800110010001500128010001600143012009000159030001100249065000900260064000500269
031000300274014000800277865000900285002000900294035001000303801001100313#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#153#26#article#28#26#^rND^sSimon
^nN#^rND^sCourouce^nAM#^rND^sLemarrec^nN#^rND^sTrepo^nC#^rND^sDucamp^nS#A twelve
 year natural history of hepatitis C virus infection in hemodialyzed patients^le
n#Kidney Int#19940000#1994#46#504-511#20080200#6887.htm#0085-2538#Kidney int##
00681000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100019000940100
01700113010001800130010001600148010001700164810000600181012007600187030001300263
06500090027606400050028503100040029001400080029486500090030200200090031103500100
0320801001300330#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#154#27#a
rticle#28#27#^rND^sLefrere^nJJ#^rND^sGuiramand^nS#^rND^sLefrere^nF#^rND^sMariott
i^nM#^rND^sAumont^nP#^rND^sLerable^nJ#et al#Full or partial seroreversion in pat
ients infected by hepatitis C virus^len#J Infect Dis#19970000#1997#175#316-322#2
0080200#6887.htm#0022-1899#J Infect Dis##
00667000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100015000940100
02100109010001800130010001900148012011300167030001000280065000900290064000500299
031000300304014000800307865000900315002000900324035001000333801001000343#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6887.htm#S#c#155#28#article#28#28#^rND^sPoign
et^nJL#^rND^sDegos^nF#^rND^sBouchardeau^nF#^rND^sChauveau^nP#^rND^sCourouce^nAM#
Complete response to interferon-alpha for acute hepatitis C after needlestick in
jury in a hemodialysis nurse^len#J Hepatol#19950000#1995#23#740-741#20080200#688
7.htm#0168-8278#J Hepatol##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#o#1#1#article#1#20
080402#165757#6911.htm#144##
02508000000000529000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000700104030002000111
03100030013103200020013406500090013601400110014503500100015601200450016601000230
02110100034002340700128002680831374003960850008017700850032017780850030018100850
02701840085003501867117000601902072000301908058000501911058000601916112000901922
111001301931114000901944113001601953002000901969#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6911.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#13#BJMBR060#FAPESP#
Braz J Med Biol Res#41#2#20080200#^f159^l169#0100-879X#Evidence for divided auto
matic attention^len#^rND^1A01^nP.S.^sSilva#^rND^1A01^nL.E.^sRibeiro-do-Valle#Uni
versidade de São Paulo^iA01^1Instituto de Ciências Biomédicas^2Departamento de F
isiologia e Biofísica^cSão Paulo^sSP^pBrasil#^len^aA long-standing debate in the
 literature is whether attention can form two or more independent spatial foci i
n addition to the well-known unique spatial focus. There is evidence that volunt
ary visual attention divides in space. The possibility that this also occurs for
 automatic visual attention was investigated here. Thirty-six female volunteers 
were tested. In each trial, a prime stimulus was presented in the left or right 
visual hemifield. This stimulus was characterized by the blinking of a superior,
 middle or inferior ring, the blinking of all these rings, or the blinking of th
e superior and inferior rings. A target stimulus to which the volunteer should r
espond with the same side hand or a target stimulus to which she should not resp
ond was presented 100 ms later in a primed location, a location between two prim
ed locations or a location in the contralateral hemifield. Reaction time to the 
positive target stimulus in a primed location was consistently shorter than reac
tion time in the horizontally corresponding contralateral location. This attenti
onal effect was significantly smaller or absent when the positive target stimulu
s appeared in the middle location after the double prime stimulus. These results
 suggest that automatic visual attention can focus on two separate locations sim
ultaneously, to some extent sparing the region in between.#^dnd^i1#^tm^len^kAuto
matic attention^i1#^tm^len^kDivided attention^i1#^tm^len^kVisual priming^i1#^tm^
len^kGo/no-go reaction time^i1#other#17#CNPq#FINEP#20070528#May 28, 2007#2008010
3#January 3, 2008#6911.htm##
02515000000000529000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000700104030002000111
03100030013103200020013406500090013601400110014503500100015601200520016601000230
02180100034002410700128002750831374004030850008017770850032017850850030018170850
02701847085003501874117000601909072000301915058000501918058000601923112000901929
111001301938114000901951113001601960002000901976#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6911.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#13#BJMBR060#FAPESP#
Braz J Med Biol Res#41#2#20080200#^f159^l169#0100-879X#<b>Evidence for divided a
utomatic attention</b>^len#^rND^1A01^nP.S.^sSilva#^rND^1A01^nL.E.^sRibeiro-do-Va
lle#Universidade de São Paulo^iA01^1Instituto de Ciências Biomédicas^2Departamen
to de Fisiologia e Biofísica^cSão Paulo^sSP^pBrasil#^len^aA long-standing debate
 in the literature is whether attention can form two or more independent spatial
 foci in addition to the well-known unique spatial focus. There is evidence that
 voluntary visual attention divides in space. The possibility that this also occ
urs for automatic visual attention was investigated here. Thirty-six female volu
nteers were tested. In each trial, a prime stimulus was presented in the left or
 right visual hemifield. This stimulus was characterized by the blinking of a su
perior, middle or inferior ring, the blinking of all these rings, or the blinkin
g of the superior and inferior rings. A target stimulus to which the volunteer s
hould respond with the same side hand or a target stimulus to which she should n
ot respond was presented 100 ms later in a primed location, a location between t
wo primed locations or a location in the contralateral hemifield. Reaction time 
to the positive target stimulus in a primed location was consistently shorter th
an reaction time in the horizontally corresponding contralateral location. This 
attentional effect was significantly smaller or absent when the positive target 
stimulus appeared in the middle location after the double prime stimulus. These 
results suggest that automatic visual attention can focus on two separate locati
ons simultaneously, to some extent sparing the region in between.#^dnd^i1#^tm^le
n^kAutomatic attention^i1#^tm^len^kDivided attention^i1#^tm^len^kVisual priming^
i1#^tm^len^kGo/no-go reaction time^i1#other#17#CNPq#FINEP#20070528#May 28, 2007#
20080103#January 3, 2008#6911.htm##
02640000000000553000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000300105049000900108158000700117
03000240012403100030014803200020015106500090015301400110016203500100017301200450
01830100023002280100034002510700130002850831374004150850008017890850032017970850
03001829085002701859085003501886117000601921072000301927058000501930058000601935
112000901941111001301950114000901963113001601972002000901988008008901997#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#l#4#1#article#1#^mFeb.^a2008#oa#en
#bjmbr#1#3.1#ilus#13#BJMBR060#FAPESP#Braz. j. med. biol. res#41#2#20080200#^f159
^l169#0100-879X#Evidence for divided automatic attention^len#^rND^1A01^nP. S^sSi
lva#^rND^1A01^nL. E^sRibeiro-do-Valle#^iA01^1Universidade de São Paulo^2Institut
o de Ciências Biomédicas^3Departamento de Fisiologia e Biofísica^cSão Paulo^sSP^
pBrasil#^len^aA long-standing debate in the literature is whether attention can 
form two or more independent spatial foci in addition to the well-known unique s
patial focus. There is evidence that voluntary visual attention divides in space
. The possibility that this also occurs for automatic visual attention was inves
tigated here. Thirty-six female volunteers were tested. In each trial, a prime s
timulus was presented in the left or right visual hemifield. This stimulus was c
haracterized by the blinking of a superior, middle or inferior ring, the blinkin
g of all these rings, or the blinking of the superior and inferior rings. A targ
et stimulus to which the volunteer should respond with the same side hand or a t
arget stimulus to which she should not respond was presented 100 ms later in a p
rimed location, a location between two primed locations or a location in the con
tralateral hemifield. Reaction time to the positive target stimulus in a primed 
location was consistently shorter than reaction time in the horizontally corresp
onding contralateral location. This attentional effect was significantly smaller
 or absent when the positive target stimulus appeared in the middle location aft
er the double prime stimulus. These results suggest that automatic visual attent
ion can focus on two separate locations simultaneously, to some extent sparing t
he region in between.#^dnd^i1#^tm^len^kAutomatic attention^i1#^tm^len^kDivided a
ttention^i1#^tm^len^kVisual priming^i1#^tm^len^kGo/no-go reaction time^i1#other#
17#CNPq#FINEP#20070528#May 28, 2007#20080103#January 3, 2008#6911.htm#Internet^i
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000200013##
00376000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704015000071002000900221#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#5#1#article#123#<P> <font face="Arial, H
elvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, February 2008, 
Volume 41(2) 159-169</B> </font></P>      ^cY#6911.htm##
00346000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704012000071002000900191#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#6#2#article#123#<P><font size="5" face="
Arial, Helvetica, sans-serif"><B>Evidence for divided automatic attention</B> </
font>       ^cY#6911.htm##
00523000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704029700071002000900368#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#7#3#article#123#<P><font face="Arial, He
lvetica, sans-serif">P.S. Silva and <b><a href="#Correspondence"><img src="/img/
revistas/bjmbr/v41n2/recor.gif" border="0"></a></b> <a href="mailto:ribeiro@icb.
usp.br"><img src="/img/revistas/bjmbr/v41n2/email-ca.gif" border="0"></a> L.E. R
ibeiro-do-Valle </font>      ^cY#6911.htm##
00445000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704021900071002000900290#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#8#4#article#123#<P><font face="Arial, He
lvetica, sans-serif">Departamento de Fisiologia e Biof&iacute;sica, Instituto de
 Ci&ecirc;ncias Biom&eacute;dicas, Universidade de S&atilde;o Paulo, S&atilde;o 
Paulo, SP, Brasil </font>      ^cY#6911.htm##
00415000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704018900071002000900260#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#9#5#article#123#<P><font face="Arial, He
lvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n2/dow
n.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>   
 ^cY#6911.htm##
00417000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704019000072002000900262#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#10#6#article#123#<BR>      <A HREF="#Int
roduction"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 V
SPACE=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A> 
   ^cY#6911.htm##
00416000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704018900072002000900261#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#11#7#article#123#<BR>      <A HREF="#Exp
eriment1"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Experiment1"><strong>Experiment 1 </strong></A>  
  ^cY#6911.htm##
00439000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704021200072002000900284#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#12#8#article#123#<BR>      <A HREF="#Exp
eriment2"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Experiment2"><strong>Experiment 2 </strong></A><A
 HREF="#Experiment3">    ^cY#6911.htm##
00393000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704016600072002000900238#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#13#9#article#123#<br>      <IMG SRC="/im
g/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A
 HREF="#Experiment3"><strong>Experiment 3 </strong></A>    ^cY#6911.htm##
00420000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704019200073002000900265#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#14#10#article#123#<BR>      <A HREF="#Di
scussion"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#Discussion"><strong>General Discussion</strong></
A>    ^cY#6911.htm##
00399000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704017100073002000900244#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#15#11#article#123#<BR>      <A HREF="#Re
ferences"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VS
PACE=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#6911.htm##
00468000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704024000073002000900313#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#16#12#article#123#<br>      </strong></A
>      <A HREF="#Correspondence"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" A
LIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Co
rrespondence and Footnotes</strong></A>  </font>      ^cY#6911.htm##
00276000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004800073002000900121#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#17#13#article#123#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>      ^cY#6911.htm##
00538000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031000073002000900383#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#18#14#article#123#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/ba
ck.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  <fon
t face="Arial, Helvetica, sans-serif">      ^cY#6911.htm##
01608000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704138000073002000901453#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#19#15#article#123#<P>A long-standing deb
ate in the literature is whether attention can form two or more independent spat
ial foci in addition to the well-known unique spatial focus. There is evidence t
hat voluntary visual attention divides in space. The possibility that this also 
occurs for automatic visual attention was investigated here. Thirty-six female v
olunteers were tested. In each trial, a prime stimulus was presented in the left
 or right visual hemifield. This stimulus was characterized by the blinking of a
 superior, middle or inferior ring, the blinking of all these rings, or the blin
king of the superior and inferior rings. A target stimulus to which the voluntee
r should respond with the same side hand or a target stimulus to which she shoul
d not respond was presented 100 ms later in a primed location, a location betwee
n two primed locations or a location in the contralateral hemifield. Reaction ti
me to the positive target stimulus in a primed location was consistently shorter
 than reaction time in the horizontally corresponding contralateral location. Th
is attentional effect was significantly smaller or absent when the positive targ
et stimulus appeared in the middle location after the double prime stimulus. The
se results suggest that automatic visual attention can focus on two separate loc
ations simultaneously, to some extent sparing the region in between.      ^cY#69
11.htm##
00374000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704014600073002000900219#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#20#16#article#123#<P>Key words: Automati
c attention; Divided attention; Visual priming; Go/no-go reaction time  </font> 
 <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6911.htm##
00592000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704036400073002000900437#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#21#17#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><
B>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-ser
if"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTO
M BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>  <font face="Arial, Helvetica, 
sans-serif">      ^cY#6911.htm##
00580000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704035200073002000900425#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#22#18#article#123#<P>People usually expl
ore their environment by focusing their attention on only one stimulus at a time
. The strategy of spreading one's attention to encompass several stimuli is more
 rarely used, because it results in poor perception of these stimuli, presumably
 due to the mutual interference of their neural representations (see Ref. 1).   
      ^cY#6911.htm##
01062000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704083400073002000900907#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#23#19#article#123#<P>There are circumsta
nces, however, in which it is important to follow two (or more) stimuli at the s
ame time; for example, when playing soccer, a game in which a player has to foll
ow the movements of two or more opposition and/or home team players. If these st
imuli are very close together in space, attention could spread to cover the area
 they occupy. However, if they are separated by some distance, this strategy wou
ld not be the best option, since intervening stimuli would also be processed tog
ether with the relevant stimuli and compete with them. This gives rise to the qu
estion whether attention would be divided between the separate locations in such
 a case. The intuitive notion is that this would not be possible. It is difficul
t to imagine ourselves trying to scan two or more locations using such a strateg
y.      ^cY#6911.htm##
04067000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704383900073002000903912#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#24#20#article#123#<P>Supporting this imp
ression, several studies have presented evidence that voluntary attention cannot
 be split. One of the initial studies was performed by Posner et al. (2) who ask
ed their volunteers to simultaneously attend to two of four locations aligned wi
th the horizontal meridian, two in the left visual hemifield and two in the righ
t visual hemifield, and to respond to the blinking of a light-emitting diode in 
one of these locations. One of the locations that should be attended was indicat
ed by a central symbolic cue on a trial-by-trial basis; the target stimulus appe
ared there in 65% of the trials. The other location that should be attended was 
fixed along each block of trials; the target stimulus appeared in this location 
in 25% of the trials. The remaining two locations could contain the target stimu
lus with a probability of 5% each. When the two most frequent locations were adj
acent, reaction time for the second most likely location was similar to that for
 the most likely location and shorter than those for the two less likely locatio
ns. When the two most frequent locations were separated by a less frequent locat
ion, reaction time for the second most likely location was longer than for the m
ost likely one and similar to those for the less likely locations. These finding
s were taken as evidence that as far as target stimulus detection is concerned, 
attention splitting is not possible. McCormick and Klein (3) instructed their vo
lunteers by means of a symbolic central cue to pay attention to one location or 
two non-adjacent same hemifield locations, of six equidistant locations aligned 
with the horizontal meridian, three on each side of fixation. In 80% of the tria
ls a target stimulus appeared some time later, at an indicated location (56% of 
the trials) or at a non-indicated location (24% of the trials). Reaction time to
 the target stimulus at the middle location on one side did not differ between t
he condition in which this same location was cued and the condition in which the
 external and the inner locations on the same side were cued, suggesting that th
e participants adopted the strategy of attending to the mid-location when cued t
o two non-adjacent locations. In another study, McCormick et al. (4) obtained ad
ditional evidence supporting this idea. In a first experiment there were two mar
ked locations, one on each side of fixation. One or both locations were cued. Fi
ve hundred and fifteen milliseconds later, a target stimulus was presented at on
e of these locations or at one of two probe locations between the marked locatio
ns and fixation. Reaction time to the target stimulus in the probe location did 
not differ between the one-cued location condition and the two-cued location con
dition. In a second experiment, there were four marked locations, two in each he
mifield, one near and one far from fixation. One of the far locations, the two f
ar locations or all four locations were cued. The target stimulus was presented 
at one of the four locations. Reaction time to the target stimulus in a near fix
ation location did not differ between the two-cued location condition and the fo
ur-cued location condition. Recording event-related brain potentials, Heinze et 
al. (5) verified that probe stimuli presented at a non-cued location between two
 cued locations evoked responses similar to those evoked by probe stimuli presen
ted at cued locations and greater than those evoked by probe stimuli presented a
t a non-cued location outside the zone delimited by the two-cued locations. The 
fact that irrelevant information arising from the intervening non-cued location 
was treated as that coming from a cued location provides additional support for 
the idea that when attention must be directed to two non-adjacent locations it s
preads to also encompass the area between them.      ^cY#6911.htm##
02403000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704217500073002000902248#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#25#21#article#123#<P>Some investigators,
 however, claimed to have observed a spatial division of attention. M&uuml;ller 
and Findlay (6) tested the capacity of their volunteers to simultaneously attend
 to two of four equally excentric locations. One of the relevant locations was c
ued by a long central line as more likely to contain the impending target stimul
us and the other relevant location was cued by a short central line as less like
ly to contain the impending target stimulus. The two non-cued locations were lea
st likely to contain the impending target stimulus. The authors found that sensi
tivity was lower for the location cued as less likely than for the location cued
 as more likely, and was even lower for the uncued locations. These findings wer
e interpreted as indicating that attention can be independently controlled at tw
o separate locations. A subsequent study by Castiello and Umilt&agrave; (7) obta
ined results that could be considered to point in the same direction. A target s
timulus was presented inside one of two square boxes of different sizes located 
to the left and to the right of fixation. In 45% of the trials, a central arrow 
correctly indicated the box where the target stimulus would appear. In 22.5% of 
the trials, the central arrow incorrectly indicated the other box, and in 22.5% 
of the trials, a nondirectional cross indicated that the target stimulus could a
ppear in either box. As expected, reaction times were shorter in the valid condi
tion than in the neutral condition and longer in the invalid condition than in t
he neutral condition. More importantly, both in the valid condition and in the n
eutral condition reaction times increased with the size of the box where the tar
get stimulus appeared, suggesting that the efficiency of attention decreases wit
h covered area and can be different at two separate locations. In fact, the resu
lts of M&uuml;ller and Findlay (6) and Castiello and Umilt&agrave; (7) do not re
present direct proof of a division of attention in space, although the apparentl
y independent control of attention in two locations that they observed could be 
taken as an indication that such a division might be possible.       ^cY#6911.ht
m##
02486000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704225800073002000902331#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#26#22#article#123#<P>There are two studi
es whose results support the idea that attention can divide in space, at least u
nder certain conditions. Egly and Homa (8) asked their subjects to identify a ce
ntral letter and at the same time to locate another letter that could appear in 
24 peripheral positions (eight equidistant positions 1&#176; far from fixation, 
eight equidistant positions 2&#176; far from fixation and eight equidistant posi
tions 3&#176; far from fixation). In valid trials, the ring where the peripheral
 target letter would appear was correctly indicated. In invalid trials, another 
ring than that where the peripheral target letter would appear was incorrectly i
ndicated. In neutral trials, no indication was given about the ring where the pe
ripheral target letter would appear. Independent of the ring that was cued, the 
mean error percentage in locating the peripheral target letter was lower in the 
valid condition as compared to the neutral condition, and lower in this conditio
n than in the invalid condition. These results suggest that the observers were s
electively attending to the regions located in the cued ring. In other words, at
tention would be able to be directed to spatially separate regions without inclu
ding intervening regions. More recently, Awh and Pashler (9) conducted a series 
of experiments in which they specifically tested the hypothesis that attention c
ould be spatially divided. Two horizontally or vertically oriented locations wer
e cued. In 80% of the trials two target numbers were presented at the cued locat
ions. In 20% of the trials one target number was presented directly in between t
he cued locations and another target number at a far location. Twenty-three dist
ractor letters surrounded these target numbers. Accuracy was lower for the targe
t number in between the cued locations than for the target numbers in these loca
tions. Accuracy was even lower for the target number in the far location. When t
he distractor letters were eliminated, the accuracy at the middle location (and 
at the far location) increased substantially. The most parsimonious explanation 
for these findings is that attention was split between the two cued locations, i
nhibiting sensory processing at the intermediary and far regions.       ^cY#6911
.htm##
02946000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704271800073002000902791#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#27#23#article#123#<P>Physiological evide
nce supporting the idea that attention can be divided in space was presented by 
M&uuml;ller et al. (10) and McMains and Somers (11). M&uuml;ller et al. (10) rec
orded frequency-coded steady-state visual evoked potentials to stimuli presented
 concurrently at four locations along the horizontal meridian. The observers wer
e instructed to orient their attention to two adjacent locations, either in the 
left or right visual field, or two nonadjacent locations, a far location in one 
visual field and a near location in the other visual field. The amplitude of the
 evoked potential elicited by the stimulus presented at the location in between 
the two indicated nonadjacent locations was smaller than that of the evoked pote
ntials elicited by the stimuli presented at these nonadjacent locations or that 
of the evoked potentials elicited by the stimuli presented at the indicated adja
cent locations. It did not differ from the amplitude of the evoked potential eli
cited by the stimulus presented in the location in the hemifield opposite to the
 indicated adjacent locations. McMains and Somers (11) measured blood oxygenatio
n level-dependent (BOLD) signal increase in visual areas (V1, V2, V3, V3A, and h
V4) during the performance of a modified rapid, serial, visual presentation task
. Volunteers were presented with five simultaneous streams of letters, one centr
ally (in the fixation point) and the others peripherally (one in each visual fie
ld quadrant). They were instructed to pay attention to the superior left stream,
 the superior left and central streams, the superior left, central and inferior 
right streams, or the superior left and inferior right streams. BOLD signal acti
vation in the visual regions corresponding to the attended locations declined pr
ogressively from the first condition to the third. As expected, BOLD signal acti
vation in the visual regions corresponding to the attended locations in the four
th critical condition was smaller than that corresponding to the attended locati
on in the first condition. More important, it was not different from that obtain
ed for the visual regions corresponding to the attended locations in the second 
condition and was greater than that obtained for the visual regions correspondin
g to the attended locations in the third condition. Equally important, BOLD sign
al activation in the visual region corresponding to the central location in the 
fourth critical condition was not different from that obtained for the visual re
gion corresponding to a non-attended location. Accuracy in identifying the occur
rence of the target letter in the attended streams of letters followed the same 
general pattern as the BOLD signal activation.      ^cY#6911.htm##
00950000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704072200073002000900795#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#28#24#article#123#<P>In the investigatio
ns just discussed, voluntary attention was tested. It is not known whether autom
atic attention, which is mobilized at short time intervals by peripheral prime s
timuli, behaves in the same way as voluntary attention. The objective of the pre
sent study was to examine the possibility of a spatial division of this other ki
nd of attention. The attentional effect obtained for the middle location of a do
uble peripheral prime stimulus was compared with that produced by a single perip
heral prime stimulus. A smaller effect elicited by the double prime stimulus, as
 compared to the single prime stimulus, would indicate that automatic attention 
can be divided in space, like voluntary attention.      ^cY#6911.htm##
00479000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704025100073002000900324#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#29#25#article#123#<P>The Ethics Committe
e of the Instituto de Ci&ecirc;ncias Biom&eacute;dicas of Universidade de S&atil
de;o Paulo approved this study and written informed consent was obtained from al
l participants.  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6911.htm##
00611000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038300073002000900456#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#30#26#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Experiment1" id="Experiment1"></A><FONT color="#
00007F" SIZE=4><B>Experiment 1 </B></FONT></font> <font size="4" face="Arial, He
lvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back
.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>    <font face=
"Arial, Helvetica, sans-serif">      ^cY#6911.htm##
01659000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704143100073002000901504#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#31#27#article#123#<P>A robust attentiona
l effect occurs when a single peripheral prime stimulus is presented on the hori
zontal meridian and a target stimulus is presented 100 ms later at the same loca
tion or at a symmetric location in the opposite hemifield (12). If the single pr
ime stimulus is replaced by a double prime stimulus, whose components are locate
d some degrees above and below the horizontal meridian, and the target stimulus 
is still presented on the horizontal meridian, two distinct alternative results 
could be obtained: either the attentional effect is similar to that occurring wh
en a single prime is presented or it presents a marked decrease, perhaps even di
sappearing. The first result would indicate that automatic attention continues t
o form a unique focus, although with a greater spread. The second result would s
uggest that automatic attention can divide spatially, forming two independent fo
cuses. To distinguish more clearly between the possibilities of a division of at
tention and a spread of attention, in case of a reduction in the attentional eff
ect, a triple prime stimulus, with its components above, below and on the horizo
ntal meridian, could also be used. With such a stimulus, automatic attention sho
uld form a unique spread focus or three independent foci. Finding a stronger att
entional effect than that obtained with the double prime stimulus would support 
the division of attention hypothesis.        ^cY#6911.htm##
00535000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704030700073002000900380#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#32#28#article#123#<P>In the current expe
riment, the attentional effect produced by a double prime stimulus was compared 
to those produced by a single and a triple prime stimulus. A choice go/no-go rea
ction time task was employed to test the volunteers. The target stimuli were alw
ays presented in a middle location.      ^cY#6911.htm##
00255000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704002700073002000900100#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#33#29#article#123#<P><B>Methods</B>     
 ^cY#6911.htm##
00581000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704035300073002000900426#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#34#30#article#123#<P><I>Participants</I>
. Twelve young adult females voluntarily participated in the experiment. All wer
e right handed (as evaluated by the Edinburgh Inventory; 13), presented normal o
r corrected-to-normal vision and normal color vision. None of them had had previ
ous experience with reaction time tasks or was aware of the purpose of the study
.      ^cY#6911.htm##
01135000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704090700073002000900980#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#35#31#article#123#<P><I>Apparatus</I>. T
he volunteers were tested in a dimly illuminated (&lt;0.1 cd/m<SUP>2</SUP>) and 
sound-attenuated room. Their head was spatially positioned by a chin-and-front r
est so that their eyes stayed 57 cm away from the screen of a 15-inch video moni
tor. The background color of this screen was white and its luminance was 27 cd/m
<SUP>2</SUP>. A central black square 0.05 degree wide and having a luminance of 
less than 0.01 cd/m<SUP>2</SUP> (fixation point, FP) and peripheral visual stimu
li were presented on this screen. The volunteers were instructed to keep their e
yes on the FP and to respond to some of these peripheral stimuli by pressing two
 keys, one on each side, with their index fingers. An IBM-compatible computer, c
ontrolled by programs developed with the MEL2 software (Psychology Software Tool
s Inc., Pittsburgh, USA), generated the stimuli and recorded the responses.     
 ^cY#6911.htm##
00609000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038100073002000900454#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#36#32#article#123#<P><I>Procedure</I>. E
ach volunteer participated in two testing sessions on separate days, not more th
an 7 days apart. Before each session she received a brief written explanation ab
out the task to be performed. A more detailed explanation was given in the testi
ng room while she was doing some example trials. The volunteer was then asked to
 do about 20 practice trials.      ^cY#6911.htm##
02664000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704243600073002000902509#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#37#33#article#123#<P>The main purpose of
 the first testing session was familiarizing the volunteers with the experimenta
l conditions. It consisted of one block of 72 trials. Each trial began with the 
appearance of the FP and three light gray rings (1.5 degree in diameter and a 0.
04-degree wide margin, with a luminance of 9 cd/m<SUP>2</SUP>) on each side, at 
an excentricity of 9 degrees. The middle rings were located on the horizontal me
ridian. The center-to-center distance of the rings on each side was 3.5 degrees 
(see <a href="#Fig1">Figure 1</a>). After 1850 to 2350 ms, either the middle rin
g (single condition), the superior, middle and inferior rings (triple condition)
, or the superior and inferior rings (double condition) on one side got darker (
luminance of 1 cd/m<SUP>2</SUP>) for 50 ms. Each one of these stimuli (the S1) o
ccurred in one third of the trials, 50% of the trials on the left side and 50% o
f the trials on the right side. Fifty milliseconds after the offset of the S1 (a
nd thus, 100 ms after its onset), a target stimulus appeared inside the middle r
ing on one side. This target stimulus could be either a vertical line (0.45 degr
ee long and 0.04 degree wide) or a small ring (0.25 degree in diameter and a 0.0
5-degree wide margin). Both target stimuli were black, with a luminance of less 
than 0.01 cd/m<SUP>2</SUP>, and lasted 34 ms. Each of them appeared randomly on 
the same side as the S1 in 25% of the trials and on the opposite side in 25% of 
the trials. The volunteer was instructed to respond as fast as possible to the &
quot;vertical line&quot; (the S2+), with the finger on the corresponding side, a
nd not to respond to the &quot;ring&quot; (the S2-). The trial ended with a mess
age lasting 400 ms at the site of fixation. Reaction time in milliseconds appear
ed when the volunteer responded between 150 and 600 ms after the onset of the S2
+. The message &quot;CORRECT&quot; appeared when the volunteer did not respond a
fter the S2-. The messages &quot;ANTICIPATED&quot; and &quot;SLOW&quot; were dis
played when the volunteer emitted a response before 150 ms after the onset of th
e S2+/S2- or did not respond until 600 ms after the onset of the S2+, respective
ly. The message &quot;INCORRECT&quot; was displayed when the volunteer responded
 between 150 and 600 ms after the onset of the S2- or responded with the wrong i
ndex finger. Trials in which the volunteer erred were discarded and repeated lat
er.       ^cY#6911.htm##
00517000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704028900073002000900362#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#38#34#article#123#<P>The second testing 
session was similar to the first, with four blocks of 72 trials separated by a r
esting interval controlled by the volunteer. The messages at the end of the tria
ls were replaced by a green asterisk for correct trials, and a red asterisk for 
incorrect trials.      ^cY#6911.htm##
00579000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704035100073002000900424#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#39#35#article#123#<P>Eye movement was no
t controlled, as previous experiments realized by this laboratory had indicated 
that the volunteers usually maintain fixation during the trials. It should be no
ted that the 100-ms stimulus onset asynchrony used did not allow enough time to 
perform a saccade to the primed location so as to facilitate S2 identification. 
     ^cY#6911.htm##
00261000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704003300073002000900106#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#40#36#article#123#<P><B>Data analysis</B
>      ^cY#6911.htm##
00604000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704037600073002000900449#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#41#37#article#123#<P>For each volunteer,
 the block median reaction time and then the mean of the medians of the four blo
cks were calculated for each condition of the second testing session. The total 
number of anticipated responses, slow responses, commissioned responses (false a
larms) and inverted hand responses for each condition of the second testing sess
ion were also evaluated.      ^cY#6911.htm##
00544000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031600073002000900389#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#42#38#article#123#<P>Reaction time data 
were analyzed by repeated measures analysis of variance (ANOVA) and the <I>post 
hoc</I> Newman-Keuls test. Factors in the ANOVA were the type of S1 (single, tri
ple and double) and the relative side of the S1 and the S2+ (same and opposite).
 The level of significance was set at 0.05.       ^cY#6911.htm##
00270000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004200073002000900115#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#43#39#article#123#<P><B>Results and Disc
ussion</B>      ^cY#6911.htm##
00366000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704013800073002000900211#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#44#40#article#123#<P>Three volunteers we
re excluded due to an excess of errors (more than 10% of the trials) and were re
placed with three others.       ^cY#6911.htm##
00719000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704049100073002000900564#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#45#41#article#123#<P>A main effect was o
btained for the type of S1 (F(2,22) = 7.186, P = 0.004) and the relative side of
 S1 and S2+ (F(1,11) = 32.165, P &lt; 0.001) factors; an interaction between the
se factors also appeared (F(2,22) = 14.349, P &lt; 0.001). Reaction time was not
 significantly different between the single S1 and the triple S1 (P = 0.487; see
 <a href="#Fig2">Figure 2</a>). Reaction time was longer when the S1 was double 
than when it was single (P = 0.009) or triple (P = 0.005).       ^cY#6911.htm##
00950000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704072200073002000900795#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#46#42#article#123#<P>Reaction time was s
horter when the S2+ appeared on the same side as the S1 than when it appeared on
 the opposite side to the S1, for the single S1 (P &lt; 0.001), the triple S1 (P
 &lt; 0.001) and the double S1 (P = 0.018). When the S2+ appeared on the same si
de, reaction time was not significantly different between the single and the tri
ple S1 (P = 0.691); it was, however, longer for the double S1 than for the singl
e S1 (P &lt; 0.001) and the triple S1 (P &lt; 0.001). When the S2+ appeared on t
he opposite side, reaction time was not significantly different between the sing
le and the triple S1 (P = 0.193), nor the single and the double S1 (P = 0.221), 
nor even the triple and the double S1 (P = 0.711).      ^cY#6911.htm##
00640000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041200073002000900485#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#47#43#article#123#<P>To alleviate concer
n that the replacement of three volunteers might have biased the results, extra 
analyses were performed considering these volunteers. The main results remained 
unaltered, except for the appearance of a reduction of reaction time to the targ
et stimulus in the middle opposite side location in the double prime stimulus co
ndition, as compared to the single prime stimulus condition.      ^cY#6911.htm##
00532000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704030400073002000900377#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#48#44#article#123#<P>The percentages of 
anticipation, omission, commission, and inversion errors were 0.8, 4.3, 0.9, and
 1.5%, respectively. The relatively small percentages of anticipation, commissio
n and inversion errors do not suggest that the volunteers presented any importan
t tendency to respond to the S1.      ^cY#6911.htm##
00627000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039900073002000900472#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#49#45#article#123#<P>As expected, an att
entional effect of 44 ms and 36 ms occurred in the single S1 and the triple S1 c
onditions, respectively. An attentional effect also occurred in the double S1 co
ndition but was much smaller than the others (only 11 ms). This finding could be
 taken as evidence that attention extends to the area between two separate prime
d locations, but is less intense in this area.       ^cY#6911.htm##
00601000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704037300073002000900446#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#50#46#article#123#<P>It should be noted 
that the attentional effect reduction in the double S1 condition was mainly caus
ed by a longer reaction time to the target stimulus in the same side location. T
his is exactly what would be expected in the case of a partial division of the f
acilitatory action of attention on stimulus processing.    </font>  <HR ALIGN=LE
FT WIDTH=100% SIZE=2>      ^cY#6911.htm##
00609000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038100073002000900454#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#51#47#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Experiment2" id="Experiment2"></A><FONT color="#
00007F" SIZE=4><B>Experiment 2 </B></FONT></font> <font size="4" face="Arial, He
lvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back
.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>  <font face="A
rial, Helvetica, sans-serif">      ^cY#6911.htm##
01450000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704122200073002000901295#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#52#48#article#123#<P>Although it is reas
onable to assume that automatic attention was focused on the superior and the in
ferior locations in the double prime stimulus condition (and the triple prime st
imulus condition) of the previous experiment, this was not unequivocally demonst
rated. This is a critical point for the conclusion that automatic attention was 
spatially divided in that condition, since the very small effect observed with t
he double prime stimulus could simply have been due to a weak capture of attenti
on by the superior and inferior components of this stimulus (and those of the tr
iple prime stimulus), possibly caused by the fact that the target stimuli never 
appeared at their locations. Experiment 2 attempted to confirm that attention wa
s focused on both the superior and inferior locations in a double prime stimulus
 condition. Only the double prime stimulus was used. The target stimuli could ap
pear in the superior or the inferior location, in addition to the middle locatio
n. It was expected that a large attentional effect would appear for the superior
 and inferior locations of the target stimulus and a small or absent attentional
 effect would appear for the middle location of the target stimulus.        ^cY#
6911.htm##
00255000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704002700073002000900100#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#53#49#article#123#<P><B>Methods</B>     
 ^cY#6911.htm##
00358000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704013000073002000900203#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#54#50#article#123#<P><I>Participants</I>
. Twelve different female volunteers with the characteristics described in Exper
iment 1 were used.      ^cY#6911.htm##
00552000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704032400073002000900397#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#55#51#article#123#<P><I>Procedure</I>. T
he volunteers were tested mostly as described in Experiment 1. The S1 was now of
 only one type, represented by the darkening of the superior and the inferior ri
ngs on one side. The target stimuli appeared equally and randomly in any of the 
marked locations (see <a href="#Fig1">Figure 1</a>).      ^cY#6911.htm##
00261000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704003300073002000900106#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#56#52#article#123#<P><B>Data analysis</B
>      ^cY#6911.htm##
00470000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704024200073002000900315#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#57#53#article#123#<P>The data of the sec
ond testing sessions were treated as described in Experiment 1. Factors in the A
NOVA were the location of the S2+ (superior, middle and inferior) and the relati
ve side of the S1 and the S2+ (same and opposite).      ^cY#6911.htm##
00270000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004200073002000900115#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#58#54#article#123#<P><B>Results and Disc
ussion</B>      ^cY#6911.htm##
00333000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704010500073002000900178#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#59#55#article#123#<P>Five volunteers wer
e excluded due to an excess of errors and were replaced with five others.      ^
cY#6911.htm##
00793000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704056500073002000900638#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#60#56#article#123#<P>A main effect was o
btained for the location of S2+ (F(2,22) = 8.920, P = 0.001) and the relative si
de of S1 and S2+ (F(1,11) = 19.571, P = 0.001) factors; an interaction between t
hese factors also appeared (F(2,22) = 4.026, P = 0.032). Reaction time was not s
ignificantly different between the superior location and the inferior location (
P = 0.713; see <a href="#Fig3">Figure 3</a>). Reaction time was shorter when the
 S2+ appeared in the middle location than when it appeared in the superior locat
ion (P = 0.003) or the inferior location (P = 0.002).      ^cY#6911.htm##
01176000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704094800073002000901021#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#61#57#article#123#<P>Reaction time was s
horter when the S2+ appeared on the same side as the S1 than when it appeared on
 the opposite side as the S1, for both the superior location (P = 0.003) and the
 inferior location (P = 0.001). There was no significant difference between reac
tion time to the S2+ on the same side and reaction time to the S2+ on the opposi
te side for the middle location (P = 0.887). When the S2+ appeared on the same s
ide as the S1, reaction time was not significantly different between the superio
r and the inferior locations (P = 0.693), or the superior and the middle locatio
ns (P = 0.842), or even the inferior and the middle locations (P = 0.874). When 
the S2+ appeared on the opposite side, reaction time was not significantly diffe
rent between the superior and the inferior locations (P = 0.978); it was, howeve
r, shorter for the middle location than for the superior location (P = 0.003) an
d the inferior location (P = 0.001).      ^cY#6911.htm##
00429000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704020100073002000900274#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#62#58#article#123#<P>To alleviate concer
n that the replacement of five volunteers might have biased the results, extra a
nalyses were performed considering these volunteers. The main results remained u
naltered.      ^cY#6911.htm##
00360000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704013200073002000900205#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#63#59#article#123#<P>The percentages of 
anticipation, omission, commission, and inversion errors were 0.5, 5.8, 2.6, and
 1.6%, respectively.      ^cY#6911.htm##
00688000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704046000073002000900533#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#64#60#article#123#<P>An attentional effe
ct occurred for the superior and inferior location conditions, amounting to 23 a
nd 26 ms, respectively. Absolutely no effect occurred for the middle location co
ndition. These results indicate that the two components of the prime stimulus mo
bilized attention. In addition, they suggest that no attention was mobilized for
 the middle zone along the horizontal meridian. This reinforces the idea that at
tention can divide in space.      ^cY#6911.htm##
01237000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704100900073002000901082#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#65#61#article#123#<P>It must be noted, h
owever, that, in contrast to Experiment 1, reaction time to the S2+ in the middl
e location on the same side as the S1 was as short as those measured for the S2+
 in the primed locations. On the other hand, reaction time to the S2+ in the mid
dle location on the opposite side of the S1 was shorter than those measured for 
the S2+ in the superior and the inferior locations. These results might be thoug
ht to indicate that the facilitatory action of attention was evenly distributed 
among the three same side locations, but its inhibitory action was restricted to
 the two locations diametrically opposed to the primed locations. This is quite 
different from what was considered to have occurred in Experiment 1. In addition
, the possibility that the inhibitory action of attention is split does not exac
tly fit the conventional notion that the entire area surrounding an attended reg
ion suffers inhibition (see, for example, Ref. 14).    </font>  <HR ALIGN=LEFT W
IDTH=100% SIZE=2>      ^cY#6911.htm##
00609000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038100073002000900454#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#66#62#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Experiment3" id="Experiment3"></A><FONT color="#
00007F" SIZE=4><B>Experiment 3 </B></FONT></font> <font size="4" face="Arial, He
lvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back
.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>  <font face="A
rial, Helvetica, sans-serif">      ^cY#6911.htm##
01042000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704081400073002000900887#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#67#63#article#123#<P>In Experiment 1, a 
smaller attentional effect was observed in the middle location condition when th
e S1 was double. The reduction of the attentional effect in this condition was a
lmost exclusively related to an increase in the reaction time in the same side l
ocation. In Experiment 2, no attentional effect was found in the middle location
 condition. The disappearance of the attentional effect was basically due to a d
ecrease in the reaction time in the opposite side location. Thus, although the r
esults of both experiments suggest that attention is faulty in the horizontal zo
ne in between a superior primed location and a corresponding location in the opp
osite hemifield and an inferior primed location and a corresponding location in 
the opposite hemifield, they show some important differences.       ^cY#6911.htm
##
00862000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704063400073002000900707#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#68#64#article#123#<P>Experiment 3 aimed 
at confirming, and eventually extending, the findings of the two previous experi
ments. The prime stimulus could occur singly, in any of the three locations, or 
doubly, in the superior and inferior locations, as in Experiment 1. The target s
timuli could occur in any of the three locations, as in Experiment 2. Thus, reac
tion times for the superior, the middle and the inferior locations could be dire
ctly compared between the single and the double prime stimulus conditions. It wa
s expected that this might help to explain the above mentioned differences in th
e results obtained in Experiments 1 and 2.      ^cY#6911.htm##
00255000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704002700073002000900100#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#69#65#article#123#<P><B>Methods</B>     
 ^cY#6911.htm##
00358000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704013000073002000900203#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#70#66#article#123#<P><I>Participants</I>
. Twelve different female volunteers with the characteristics described in Exper
iment 1 were used.      ^cY#6911.htm##
01088000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704086000073002000900933#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#71#67#article#123#<P><I>Procedure.</I> T
he volunteers were tested mostly as described in Experiment 1. There were three 
testing sessions; the third session was added to provide the appropriate number 
of trials per condition. The first session consisted of one block of 72 trials. 
The second and the third consisted of four blocks of 72 trials. These sessions w
ere performed on different days, with a maximum separating interval of 7 days. T
he S1 was of four types, represented by the darkening of the superior, middle or
 inferior ring or both the superior and inferior rings on one side. The target s
timuli appeared equally and randomly in any one of the marked locations, with th
e constraint of always appearing on the same horizontal level as the single S1 (
see <a href="#Fig1">Figure 1</a>). The S2+ occurred in 2/3 of the trials and the
 S2- in the remaining 1/3.        ^cY#6911.htm##
00261000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704003300073002000900106#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#72#68#article#123#<P><B>Data analysis</B
>      ^cY#6911.htm##
00545000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031700073002000900390#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#73#69#article#123#<P>Data of the second 
and third testing sessions were grouped and treated as described in Experiment 1
. Factors in the ANOVA were the type of S1 (superior, middle, inferior, and supe
rior-inferior), the location of S2+ (superior, middle, and inferior) and the rel
ative side of S1 and S2+ (same and opposite).      ^cY#6911.htm##
00270000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004200073002000900115#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#74#70#article#123#<P><B>Results and Disc
ussion</B>      ^cY#6911.htm##
00333000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704010500073002000900178#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#75#71#article#123#<P>Five volunteers wer
e excluded due to an excess of errors and were replaced with five others.      ^
cY#6911.htm##
00910000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704068200073002000900755#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#76#72#article#123#<P>A main effect was o
btained for the location of S2+ (F(2,22) = 4.637, P = 0.021) and the relative si
de of S1 and S2+ (F(1,11) = 40.838, P &lt; 0.001) factors, but not for the type 
of S1 (F(1,11) = 1.075, P = 0.322) factor. An interaction occurred between the t
ype of S1 and the location of the S2+ (F(2,22) = 3.718, P = 0.041) factors, the 
type of S1 and the relative side of S1 and S2+ (F(1,11) = 24.322, P &lt; 0.001) 
factors, and the type of S1, the location of S2+ and the relative side of S1 and
 S2+ (F(2,22) = 5.260, P = 0.014) factors. There was no interaction between the 
location of S2+ and the relative side of S1 and S2+ (F(2,22) = 1.969, P = 0.164)
 factors.       ^cY#6911.htm##
00558000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704033000073002000900403#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#77#73#article#123#<P>Reaction time was n
ot significantly different between the superior location and the inferior locati
on (P = 0.614) (see <a href="#Fig4">Figure 4</a>). Reaction time was shorter whe
n the S2+ appeared in the middle location than when it appeared in the superior 
location (P = 0.024) or the inferior location (P = 0.029).      ^cY#6911.htm##
00533000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704030500073002000900378#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#78#74#article#123#<P>Reaction time to th
e S2+ in either the superior or the inferior location did not differ significant
ly between the single and the double S1 (respectively, P = 0.762 and P = 0.697).
 Reaction time to the S2+ in the middle location was longer for the double S1 th
an for the single S1 (P = 0.002).      ^cY#6911.htm##
00439000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704021100073002000900284#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#79#75#article#123#<P>Reaction time for t
he same side was longer for the double S1 than for the single S1 (P = 0.002). Re
action time for the opposite side was shorter for the double S1 than for the sin
gle S1 (P = 0.015).      ^cY#6911.htm##
01035000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704080700073002000900880#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#80#76#article#123#<P>Reaction time to th
e S2+ in all three locations was shorter for the same side than for the opposite
 side, for both the single and double S1. For the same side, reaction time to th
e S2+ in the superior location and the inferior location did not differ signific
antly between the single S1 and the double S1 (P = 0.457 and P = 0.402, respecti
vely); reaction time to the S2+ in the middle location was longer for the double
 S1 than that for the single S1 (P &lt; 0.001). For the opposite side, reaction 
time to the S2+ in the superior location and the inferior location also did not 
differ significantly between the single S1 and the double S1 (P = 0.422 and P = 
0.208, respectively); reaction time to the S2+ in the middle location was shorte
r for the double S1 than for the single S1 (P = 0.042).      ^cY#6911.htm##
00429000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704020100073002000900274#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#81#77#article#123#<P>To alleviate concer
n that the replacement of five volunteers might have biased the results, extra a
nalyses were performed considering these volunteers. The main results remained u
naltered.      ^cY#6911.htm##
00360000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704013200073002000900205#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#82#78#article#123#<P>The percentages of 
anticipation, omission, commission, and inversion errors were 0.5, 3.9, 1.2, and
 0.7%, respectively.      ^cY#6911.htm##
00749000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704052100073002000900594#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#83#79#article#123#<P>There was an attent
ional effect for the superior, middle and inferior location of the S2+ of 39, 48
, and 43 ms, respectively, when the S1 was single. There was also an attentional
 effect for the superior, middle and inferior location of the S2+ of 28, 13, and
 31 ms, respectively, when the S1 was double. The 13-ms attentional effect obtai
ned for the middle location of the S2+ when the S1 was double was smaller than a
ll the other attentional effects, which did not differ significantly between the
mselves.       ^cY#6911.htm##
00923000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704069500073002000900768#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#84#80#article#123#<P>The decrease in the
 attentional effect for the critical condition in the current experiment was pro
duced by both a marked reaction time increase in the middle same side location a
nd a small reaction time reduction in the middle opposite side location, when co
mparing the double S1 condition with the single S1 condition. Considering only t
he double S1 conditions, the decrease in the attentional effect was associated w
ith a reaction time reduction in the middle opposite side location, as compared 
to the superior and inferior opposite side locations; no reaction time increase 
in the middle same side location compared to the superior or inferior same side 
location was apparent.       ^cY#6911.htm##
00674000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704044600073002000900519#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#85#81#article#123#<P>In general, these r
esults confirm those of Experiments 1 and 2. They provide strong support for the
 idea that both the facilitatory and the diametrically opposed inhibitory action
 of attention on sensory processing are reduced for a horizontal zone in between
 a superior primed location and the corresponding location on the opposite hemif
ield and an inferior primed location and the corresponding location on the oppos
ite hemifield.      ^cY#6911.htm##
01339000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704111100073002000901184#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#86#82#article#123#<P>The absence of any 
difference between reaction time in the middle location and reaction time in the
 superior or the inferior location for the same side double S1 condition, seen h
ere and also in Experiment 2, might be seen as disturbing for our conclusion of 
a division of the facilitatory action of attention. Concerns raised by these res
ults are alleviated by taking into account that reaction times in the superior a
nd the inferior locations tend to be higher than reaction time in the middle loc
ation. As seen, for the single S1 same side condition of the current experiment,
 reaction times were longer in the superior and the inferior locations than in t
he middle location. This might be due to spatial nonuniformities in the visual s
ystem (see, for example, Ref. 15). Thus, the simple fact that reaction time in t
he middle location was similar to those in the superior and inferior locations f
or the same side condition, here and in Experiment 2, indicates that reaction ti
me increased, presumably as a consequence of partial attention splitting.    </f
ont>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6911.htm##
00550000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704032200073002000900395#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#87#83#article#123#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007
F><B>General Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bj
mbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></fon
t></P>  <font face="Arial, Helvetica, sans-serif">      ^cY#6911.htm##
00923000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704069500073002000900768#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#88#84#article#123#<P>In all three experi
ments of this study, evidence was obtained that automatic attention, like volunt
ary attention, may divide in space. Thus, in Experiment 2, no attentional effect
 occurred for the middle location when a double prime stimulus was presented. In
 Experiments 1 and 3, the attentional effect produced by this stimulus for the m
iddle location was smaller than that produced by the single or triple prime stim
ulus for the same location. It is possible that if the distance from the superio
r and the inferior locations to the middle location had been greater than that u
sed, no attentional effect would have appeared for the middle location also in t
hese two experiments.        ^cY#6911.htm##
00506000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704027800073002000900351#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#89#85#article#123#<P>The hypothesis of a
 division of automatic attention in space is reinforced by the consistent increa
se in reaction time in the same side middle location for the double prime stimul
us condition compared to the single prime stimulus condition, in Experiments 1 a
nd 3.       ^cY#6911.htm##
01085000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704085700073002000900930#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#90#86#article#123#<P>The three locations
 on each side in all experiments of this study were equidistant from the fixatio
n point. This means that the middle location was somewhat displaced with respect
 to the axis formed by the superior and the inferior locations. It could be argu
ed that the small or absent effects that were observed for that location in the 
double priming condition might have been due to the fact that the location was o
utside a single focus of attention generated by the two superior and inferior co
mponents of the prime stimulus. It should be noted, however, that the middle loc
ation misalignment was only 0.6&#176;, presumably too small to place it outside 
this single attentional focus (the target stimuli appeared exactly on a virtual 
line joining the most peripheral point of the superior ring marker to that of th
e inferior ring marker).       ^cY#6911.htm##
01413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704118500073002000901258#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#91#87#article#123#<P>The possibility tha
t the smaller attentional effect observed for the middle location in the double 
prime stimulus condition was not associated with a true division of attention, b
ut with the allocation of attention to one of the primed locations in part of th
e trials and to the other in the other part of the trials should also be conside
red. The similar reaction times to the target stimulus in the superior or inferi
or location after presentation of a single prime stimulus and a double prime sti
mulus in Experiment 3 provide an argument against this alternative. To test the 
hypothesis in a more specific way, reaction time variance for each of these loca
tions was calculated and compared between the single and the double prime stimul
us conditions. No difference was found. A variable allocation of attention to ea
ch of the primed locations in the double prime stimulus condition would have nec
essarily increased reaction time variance, since in the trials in which the loca
tion would have been attended, reaction time would have been relatively short, a
nd in the trials in which the location would have been unattended, reaction time
 would have been relatively long.      ^cY#6911.htm##
00785000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704055700073002000900630#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#92#88#article#123#<P>Another possible wa
y to explain the smaller attentional effect observed for the middle location in 
the double prime stimulus condition without assuming any spatial division of att
ention is to suppose that attention oscillates between the two primed locations 
during the period of target stimulus presentation. The 34-ms duration of the tar
get stimulus, however, is too short to allow the successful use of this attentio
nal strategy. Castro-Barros et al. (12) demonstrated that it takes between 34 an
d 50 ms for automatic attention mobilization.      ^cY#6911.htm##
03378000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704315000073002000903223#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#93#89#article#123#<P>Current accepted kn
owledge regarding the action of attention on visual processing is that it consis
ts of the facilitation of the attended location and the general inhibition of th
e remaining locations, even those far away (see, for example, Ref. 14). Based on
 these assumptions, it could be predicted that attention division in space would
 be expressed by a reduction or the elimination of its facilitatory effect at a 
location in between two separated primed locations, accompanied by hardly any ch
ange in its inhibitory effect at relatively far locations. The longer reaction t
ime to the target stimulus in a location between the two primed locations, as co
mpared to reaction time to the target stimulus in the same location when this wa
s individually primed, observed in Experiments 1 and 3, is clearly in accordance
 with this prediction. The shorter reaction time to the target stimulus in the m
iddle location opposed to the double prime stimulus, as compared to the reaction
 time to the target stimulus in the middle location opposed to the single prime 
stimulus in Experiment 3, on the other hand, does not conform to this prediction
. This unexpected result might be related to the existence of some inverse relat
ionship between the attentional influences (i.e., facilitation and inhibition) i
n diametrically opposite locations in the visual field or to the existence of a 
diametrically opposed inhibitory sensory influence, in addition to the inhibitor
y attentional influence. The well-known inhibitory interactions of the two super
ior colliculi (16) and of homologous secondary sensory areas in the two cerebral
 hemispheres (see Ref. 17) could be the basis of this putative sensory influence
. The result might also be related to the somewhat larger distance between the p
rimed superior and inferior locations and the opposite middle location than betw
een the primed middle location and the opposite middle location. According to St
einman et al. (14), the inhibitory effect of attention first increases and then 
decreases as distance from the attended location increases. In counter-argument 
to these possibilities is the fact that reaction time to the target stimulus in 
the opposite location in the double stimulus condition did not differ from that 
in the single stimulus condition in Experiment 1. A critical difference between 
Experiment 3 and Experiment 1 is the occurrence of the target stimulus in the su
perior, middle and inferior locations in the former and its occurrence only in t
he middle location in the latter. Perhaps the contralateral middle location inhi
bition by a double prime stimulus is adjusted according to the probability of oc
currence of the target stimulus in the three opposite side locations. When the t
arget stimulus occurred only in the middle location (Experiment 1) this inhibiti
on would be focused and thus stronger. When the target stimulus could occur in t
he superior, middle and inferior locations (Experiment 3) it would be more diffu
se and thus weaker. This is not the first time that a variation in the inhibitor
y attentional strategy used by the observer has been suggested (e.g., Ref. 9).  
    ^cY#6911.htm##
01221000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704099300073002000901066#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#94#90#article#123#<P>Awh and Pashler (9)
 demonstrated a division of voluntary attention in the presence of distractor st
imuli. When these stimuli were not presented, the location intermediary between 
two relevant locations was fully attended. The authors suggested that the divisi
on of the attentional focus probably resulted from the inhibition of non-relevan
t regions so as to suppress nearby noise (they allowed, however, for an alternat
ive explanation, namely, that the strategy of selectively facilitating the relev
ant regions could have been adopted so as to increase the signal to noise ratio)
. In the present series of experiments, there were no distractor stimuli between
 the superior and the inferior locations, and yet there was an important reducti
on in the effect produced by the double prime stimulus for the middle location o
n the same side. This suggests that the influence of automatic attention is repr
esented in an important way by a selective facilitation of the primed locations.
       ^cY#6911.htm##
01408000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704118000073002000901253#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#95#91#article#123#<P>To explain the divi
sion of attention observed in their experiments and the absence of any division 
of attention in the experiments of McCormick and Klein (3), Awh and Pashler (9) 
considered the cue validity of 80% that they employed compared to that of 35% em
ployed by those investigators. They suggested that maintaining more than one att
entional focus would be difficult and, because of that, this strategy would be a
dopted only when it provides a clear advantage to the observer. As the probabili
ty of the target stimulus appearing in the primed region in the experiments of t
he present study was never more than 50% (in Experiment 1 it was 50% and in Expe
riments 2 and 3 it was 33 and 42%, respectively), it would appear that this fact
or has no importance in the case of automatic attention. It is more likely that 
the formation of independent foci is the default strategy, as far as this kind o
f attention is concerned. An interesting question is whether more than two indep
endent foci can be formed. It is possible that when there are more than a certai
n number of regions to be attended, attention spreads to the whole area instead 
of forming independent foci.      ^cY#6911.htm##
00638000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041000073002000900483#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#96#92#article#123#<P>It is interesting t
o note that the putative division of automatic attention in the current study oc
curred in one hemifield. A similar result was described by Awh and Pashler (9) f
or voluntary attention. These findings might be interpreted as indicating that a
ttentional mechanisms in each hemisphere can control at least two independent fo
ci of facilitation in the contralateral visual hemifield.       ^cY#6911.htm##
00732000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704050400073002000900577#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#97#93#article#123#<P>Awh and Pashler (9)
 observed a smaller attentional effect for the inferior than for the superior co
mponent of a double vertically oriented cue. They offered no explanation for thi
s difference. In the present study, the attentional effects of the superior and 
inferior components of the double cue were very similar. If the results of Awh a
nd Pashler (9) are confirmed, this would represent an important distinction betw
een division of voluntary attention and division of automatic attention.      ^c
Y#6911.htm##
00915000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704068700073002000900760#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#98#94#article#123#<P>In conclusion, the 
three experiments of the current study provided evidence that automatic attentio
n, like voluntary attention, may divide in space. Further experiments are requir
ed to confirm this possibility and investigate other conditions in which a divis
ion of automatic attention might occur. It would also be interesting to determin
e how many independent attentional foci could be formed.  </font>  <HR ALIGN=LEF
T WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr align="left" valig
n="top">      <td width="13%"><a href="/img/revistas/bjmbr/v41n2/html/6911i01.ht
m"><img src="/img/revistas/bjmbr/v41n2/6911i01peq.jpg" border="2"></a></td>     
 <td width="87%">    ^cY#6911.htm##
00862000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704063400073002000900707#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#99#95#article#123#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. Illustration of the sequence
 of events in a single prime stimulus trial (upper panel) and a double prime sti
mulus trial (lower panel). The left side sequence of frames shows the positive t
arget stimulus appearing on the primed hemifield and the right side sequence of 
frames shows it appearing in the opposite hemifield. Numbers on the right side o
f each panel refer to the duration (in milliseconds) of each frame. The message 
frame, that appeared immediately after the response and lasted 200 ms, is not sh
own. </font>      </td>    </tr>  </table>      ^cY#6911.htm##
00617000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704038800074002000900462#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#100#96#article#123#<p><font face="Arial,
 Helvetica, sans-serif">[View larger version of this image (87 K JPG file)]</fon
t> </p>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    
<tr align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr
/v41n2/html/6911i02.htm"><img src="/img/revistas/bjmbr/v41n2/6911i02peq.jpg" bor
der="2"></a></td>      <td width="87%">    ^cY#6911.htm##
00740000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704051100074002000900585#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#101#97#article#123#<P><font face="Arial,
 Helvetica, sans-serif"><a name="Fig2"></a>Figure 2. Mean reaction time (&#177; 
SEM) to the positive target stimulus in the same hemifield and in the opposite h
emifield as the prime stimulus in Experiment 1. The prime stimulus could occur i
n the middle location (single), the superior, middle and inferior locations (tri
ple), or the superior and inferior locations (double). The target stimulus alway
s occurred in the middle location. N = 12. </font>      </td>    </tr>  </table>
      ^cY#6911.htm##
00617000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704038800074002000900462#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#102#98#article#123#<p><font face="Arial,
 Helvetica, sans-serif">[View larger version of this image (84 K JPG file)]</fon
t> </p>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    
<tr align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr
/v41n2/html/6911i03.htm"><img src="/img/revistas/bjmbr/v41n2/6911i03peq.jpg" bor
der="2"></a></td>      <td width="87%">    ^cY#6911.htm##
00693000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704046400074002000900538#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#103#99#article#123#<P><font face="Arial,
 Helvetica, sans-serif"><a name="Fig3" id="Fig3"></a>Figure 3. Mean reaction tim
e (&#177; SEM) to the positive target stimulus in the same hemifield and in the 
opposite hemifield as the prime stimulus in Experiment 2. The prime stimulus alw
ays occurred in the superior and inferior locations (double). The target stimulu
s could occur in the superior, the middle or the inferior location. N = 12. </fo
nt>      </td>    </tr>  </table>      ^cY#6911.htm##
00625000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704039500075002000900470#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#104#100#article#123#<p><font face="Arial
, Helvetica, sans-serif">[View larger version of this image (87 K JPG file)]</fo
nt> </p>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">   
 <tr align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmb
r/v41n2/html/6911i04.htm"><img src="/img/revistas/bjmbr/v41n2/6911i04peq.jpg" bo
rder="2"></a></td>      <td width="87%">           ^cY#6911.htm##
00795000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704056500075002000900640#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#105#101#article#123#<p><font face="Arial
, Helvetica, sans-serif"><a name="Fig4"></a>Figure 4.          Mean reaction tim
e (&#177; SEM) to the positive target stimulus in the          same hemifield an
d in the opposite hemifield as the prime stimulus in          Experiment 3. The 
prime stimulus could occur in the superior (single),          middle (single), i
nferior (single), or superior and inferior (double)          locations. The targ
et stimulus could occur in the superior, the middle          or the inferior loc
ation. N = 12.</font> </p>     </td>    </tr>  </table>      ^cY#6911.htm##
00384000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704015400075002000900229#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#106#102#article#123#<p><font face="Arial
, Helvetica, sans-serif">[View larger version of this image (104 K JPG file)]</f
ont> </p>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6911.htm##
00590000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704036000075002000900435#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#107#103#article#123#<P><font face="Arial
, Helvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><
B>References</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif
"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM 
BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>  <font face="Arial, Helvetica, sa
ns-serif">      ^cY#6911.htm##
00374000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704013000077002000900207#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#p#108#104#article#123#1#<P>1. 
Desimone R, Duncan J. Neural mechanisms of selective visual attention. <I>Annu R
ev Neurosci</I> 1995; 18: 193-222.      ^cY#6911.htm##
00375000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704013100077002000900208#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#p#109#105#article#123#2#<P>2. 
Posner MI, Snyder CR, Davidson BJ. Attention and the detection of signals. <I>J 
Exp Psychol</I> 1980; 109: 160-174.      ^cY#6911.htm##
00391000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704014700077002000900224#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#p#110#106#article#123#3#<P>3. 
McCormick PA, Klein R. The spatial distribution of attention during covert visua
l orienting. <I>Acta Psychol</I> 1990; 75: 225-242.      ^cY#6911.htm##
00437000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704019300077002000900270#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#p#111#107#article#123#4#<P>4. 
McCormick PA, Klein RM, Johnston S. Splitting versus sharing focal attention: co
mment on Castiello and Umilta (1992). <I>J Exp Psychol Hum Percept Perform</I> 1
998; 24: 350-357.      ^cY#6911.htm##
00452000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704020800077002000900285#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#p#112#108#article#123#5#<P>5. 
Heinze HJ, Luck SJ, Munte TF, Gos A, Mangun GR, Hillyard SA. Attention to adjace
nt and separate positions in space: an electrophysiological analysis. <I>Percept
 Psychophys</I> 1994; 56: 42-52.      ^cY#6911.htm##
00408000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704016400077002000900241#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#p#113#109#article#123#6#<P>6. 
M&uuml;ller HJ, Findlay JM. Sensitivity and criterion effects in the spatial cui
ng of visual attention. <I>Percept Psychophys</I> 1987; 42: 383-399.      ^cY#69
11.htm##
00376000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704013200077002000900209#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#p#114#110#article#123#7#<P>7. 
Castiello U, Umilt&agrave; C. Splitting focal attention. <I>J Exp Psychol Hum Pe
rcept Perform</I> 1992; 18: 837-848.      ^cY#6911.htm##
00370000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704012600077002000900203#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#p#115#111#article#123#8#<P>8. 
Egly R, Homa D. Sensitization of the visual field. <I>J Exp Psychol Hum Percept 
Perform</I> 1984; 10: 778-793.      ^cY#6911.htm##
00374000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704013000077002000900207#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#p#116#112#article#123#9#<P>9. 
Awh E, Pashler H. Evidence for split attentional foci. <I>J Exp Psychol Hum Perc
ept Perform</I> 2000; 26: 834-846.      ^cY#6911.htm##
00397000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704015200078002000900230#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#p#117#113#article#123#10#<P>10
. M&uuml;ller MM, Malinowski P, Gruber T, Hillyard SA. Sustained division of the
 attentional spotlight. <I>Nature</I> 2003; 424: 309-312.      ^cY#6911.htm##
00409000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704016400078002000900242#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#p#118#114#article#123#11#<P>11
. McMains SA, Somers DC. Processing efficiency of divided spatial attention mech
anisms in human visual cortex. <I>J Neurosci</I> 2005; 25: 9444-9448.      ^cY#6
911.htm##
00443000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704019800078002000900276#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#p#119#115#article#123#12#<P>12
. Castro-Barros BA, Righi LL, Grechi G, Ribeiro-do-Valle LE. Interlateral asymme
try in the time course of the effect of a peripheral prime stimulus. <I>Brain Co
gn</I> 2007 (in press).      ^cY#6911.htm##
00383000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704013800078002000900216#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#p#120#116#article#123#13#<P>13
. Oldfield RC. The assessment and analysis of handedness: the Edinburgh Inventor
y. <I>Neuropsychologia</I> 1971; 9: 97-113.      ^cY#6911.htm##
00404000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704015900078002000900237#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#p#121#117#article#123#14#<P>14
. Steinman BA, Steinman SB, Lehmkuhle S. Visual attention mechanisms show a cent
er-surround organization. <I>Vision Res</I> 1995; 35: 1859-1869.      ^cY#6911.h
tm##
00358000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704011300078002000900191#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#p#122#118#article#123#15#<P>15
. Efron R, Yund EW. Spatial nonuniformities in visual search. <I>Brain Cogn</I> 
1996; 31: 331-368.      ^cY#6911.htm##
00409000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704016400078002000900242#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#p#123#119#article#123#16#<P>16
. Sprague JM. Interaction of cortex and superior colliculus in mediation of visu
ally guided behavior in the cat. <I>Science</I> 1966; 153: 1544-1547.      ^cY#6
911.htm##
00506000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704026100078002000900339#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#p#124#120#article#123#17#<P>17
. Fink GR, Driver J, Rorden C, Baldeweg T, Dolan RJ. Neural consequences of comp
eting stimuli in both visual hemifields: a physiological basis for visual extinc
tion. <I>Ann Neurol</I> 2000; 47: 440-446.  </font>  <HR ALIGN=LEFT WIDTH=100% S
IZE=2>      ^cY#6911.htm##
00566000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704033600075002000900411#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#125#121#article#123#<P><FONT SIZE=4 face
="Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F
><B>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, H
elvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6911
.htm##
00596000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704036600075002000900441#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#126#122#article#123#<p><font face="Arial
, Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v41n2/
recor.gif" border="0"></a> Address for correspondence:</b> L.E. Ribeiro-do-Valle
, Departamento de Fisiologia e Biof&iacute;sica, ICB, USP, 05508-000 S&atilde;o 
Paulo, SP, Brasil. E-mail: <a href="mailto:ribeiro@icb.usp.br">ribeiro@icb.usp.b
r</a></font></p>      ^cY#6911.htm##
00412000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704018200075002000900257#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6911.htm#S#p#127#123#article#123#<P><font face="Arial
, Helvetica, sans-serif">Research supported by CNPq and FINEP. Publication suppo
rted by FAPESP. Received May 28, 2007. Accepted January 3, 2008. </font>      ^c
Y#6911.htm##
00527000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100016000920120
05200108030001800160065000900178064000500187031000300192014000800195865000900203
002000900212035001000221801001800231#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
911.htm#S#c#128#1#article#17#1#^rND^sDesimone^nR#^rND^sDuncan^nJ#Neural mechanis
ms of selective visual attention^len#Annu Rev Neurosci#19950000#1995#18#193-222#
20080200#6911.htm#0147-006X#Annu Rev Neurosci##
00542000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100017000910100
01900108012004300127030001400170065000900184064000500193031000400198014000800202
865000900210002000900219035001000228801001400238#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6911.htm#S#c#129#2#article#17#2#^rND^sPosner^nMI#^rND^sSnyder^nCR#^rN
D^sDavidson^nBJ#Attention and the detection of signals^len#J Exp Psychol#1980000
0#1980#109#160-174#20080200#6911.htm#0022-1015#J Exp Psychol##
00506000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100020000740100015000940120
07300109030001300182710000200195065000900197064000500206031000300211014000800214
865000900222002000900231#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#c#
130#3#article#17#3#^rND^sMcCormick^nPA#^rND^sKlein^nR#The spatial distribution o
f attention during covert visual orienting^len#Acta Psychol#2#19900000#1990#75#2
25-242#20080200#6911.htm##
00624000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100020000740100016000940100
01800110012008500128030003400213065000900247064000500256031000300261014000800264
865000900272002000900281035001000290801003400300#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6911.htm#S#c#131#4#article#17#4#^rND^sMcCormick^nPA#^rND^sKlein^nRM#^
rND^sJohnston^nS#Splitting versus sharing focal attention: comment on Castiello 
and Umilta (1992)^len#J Exp Psychol Hum Percept Perform#19980000#1998#24#350-357
#20080200#6911.htm#0096-1523#J Exp Psychol Hum Percept Perform##
00678000000000325000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100015000910100
01600106010001300122010001700135010001900152012009200171030001900263065000900282
06400050029103100030029601400060029986500090030500200090031403500100032380100190
0333#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#c#132#5#article#17#5#^
rND^sHeinze^nHJ#^rND^sLuck^nSJ#^rND^sMunte^nTF#^rND^sGos^nA#^rND^sMangun^nGR#^rN
D^sHillyard^nSA#Attention to adjacent and separate positions in space: an electr
ophysiological analysis^len#Percept Psychophys#19940000#1994#56#42-52#20080200#6
911.htm#0031-5117#Percept Psychophys##
00557000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100018000910120
07900109030001900188065000900207064000500216031000300221014000800224865000900232
002000900241035001000250801001900260#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
911.htm#S#c#133#6#article#17#6#^rND^sMüller^nHJ#^rND^sFindlay^nJM#Sensitivity an
d criterion effects in the spatial cuing of visual attention^len#Percept Psychop
hys#19870000#1987#42#383-399#20080200#6911.htm#0031-5117#Percept Psychophys##
00538000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100016000930120
03000109030003400139065000900173064000500182031000300187014000800190865000900198
002000900207035001000216801003400226#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
911.htm#S#c#134#7#article#17#7#^rND^sCastiello^nU#^rND^sUmiltà^nC#Splitting foca
l attention^len#J Exp Psychol Hum Percept Perform#19920000#1992#18#837-848#20080
200#6911.htm#0096-1523#J Exp Psychol Hum Percept Perform##
00539000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100014000740100014000880120
03800102030003400140065000900174064000500183031000300188014000800191865000900199
002000900208035001000217801003400227#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
911.htm#S#c#135#8#article#17#8#^rND^sEgly^nR#^rND^sHoma^nD#Sensitization of the 
visual field^len#J Exp Psychol Hum Percept Perform#19840000#1984#10#778-793#2008
0200#6911.htm#0096-1523#J Exp Psychol Hum Percept Perform##
00543000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100013000740100017000870120
04000104030003400144065000900178064000500187031000300192014000800195865000900203
002000900212035001000221801003400231#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
911.htm#S#c#136#9#article#17#9#^rND^sAwh^nE#^rND^sPashler^nH#Evidence for split 
attentional foci^len#J Exp Psychol Hum Percept Perform#20000000#2000#26#834-846#
20080200#6911.htm#0096-1523#J Exp Psychol Hum Percept Perform##
00570000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100020000930100
01600113010001900129012005200148030000700200065000900207064000500216031000400221
014000800225865000900233002000900242035001000251801000700261#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6911.htm#S#c#137#10#article#17#10#^rND^sMüller^nMM#^rND^s
Malinowski^nP#^rND^sGruber^nT#^rND^sHillyard^nSA#Sustained division of the atten
tional spotlight^len#Nature#20030000#2003#424#309-312#20080200#6911.htm#0028-083
6#Nature##
00555000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940120
08900111030001100200065000900211064000500220031000300225014001000228865000900238
002000900247035001000256801001100266#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
911.htm#S#c#138#11#article#17#11#^rND^sMcMains^nSA#^rND^sSomers^nDC#Processing e
fficiency of divided spatial attention mechanisms in human visual cortex^len#J N
eurosci#20050000#2005#25#9444-9448#20080200#6911.htm#0270-6474#J Neurosci##
00613000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100024000760100016001000100
01600116010002700132012009100159030001100250065000900261064000500270061000900275
865000900284002000900293035001000302801001100312#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6911.htm#S#c#139#12#article#17#12#^rND^sCastro-Barros^nBA#^rND^sRighi
^nLL#^rND^sGrechi^nG#^rND^sRibeiro-do-Valle^nLE#Interlateral asymmetry in the ti
me course of the effect of a peripheral prime stimulus^len#Brain Cogn#20070000#2
007#in press#20080200#6911.htm#0278-2626#Brain Cogn##
00517000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760120071000950300
01700166065000900183064000500192031000200197014000700199865000900206002000900215
035001000224801001700234#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#c#
140#13#article#17#13#^rND^sOldfield^nRC#The assessment and analysis of handednes
s: the Edinburgh Inventory^len#Neuropsychologia#19710000#1971#9#97-113#20080200#
6911.htm#0028-3932#Neuropsychologia##
00568000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100019000950100
01900114012006800133030001100201065000900212064000500221031000300226014001000229
865000900239002000900248035001000257801001100267#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6911.htm#S#c#141#14#article#17#14#^rND^sSteinman^nBA#^rND^sSteinman^n
SB#^rND^sLehmkuhle^nS#Visual attention mechanisms show a center-surround organiz
ation^len#Vision Res#19950000#1995#35#1859-1869#20080200#6911.htm#0042-6989#Visi
on Res##
00504000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100015000910120
04500106030001100151065000900162064000500171031000300176014000800179865000900187
002000900196035001000205801001100215#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
911.htm#S#c#142#15#article#17#15#^rND^sEfron^nR#^rND^sYund^nEW#Spatial nonunifor
mities in visual search^len#Brain Cogn#19960000#1996#31#331-368#20080200#6911.ht
m#0278-2626#Brain Cogn##
00534000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120102000940300
00800196065000900204064000500213031000400218014001000222865000900232002000900241
035001000250801000800260#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#c#
143#16#article#17#16#^rND^sSprague^nJM#Interaction of cortex and superior collic
ulus in mediation of visually guided behavior in the cat^len#Science#19660000#19
66#153#1544-1547#20080200#6911.htm#0036-8075#Science##
00662000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910100
01600107010001800123010001600141012011600157030001100273065000900284064000500293
031000300298014000800301865000900309002000900318035001000327801001100337#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6911.htm#S#c#144#17#article#17#17#^rND^sFink^
nGR#^rND^sDriver^nJ#^rND^sRorden^nC#^rND^sBaldeweg^nT#^rND^sDolan^nRJ#Neural con
sequences of competing stimuli in both visual hemifields: a physiological basis 
for visual extinction^len#Ann Neurol#20000000#2000#47#440-446#20080200#6911.htm#
0364-5134#Ann Neurol##
00267000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00300094#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#o#1#1#article#1#20
080402#165800#6934.htm#96##
02815000000000649000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016001200560
01700100029002260100026002550100023002810100023003040100030003270100025003570700
03500382070013900417083133600556085000801892085003501900085003501935085002101970
08500180199111700060200907200030201505800500201805800070206806000110207506000100
20860580005020960580005021011120009021061110014021151140009021291130018021380020
00902156#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#h#2#1#article#1#oa
#en#bjmbr#1#3.1#ILUS#TAB#05#BJMBR010#FAPESP#Braz J Med Biol Res#41#2#20080200#^f
106^l109#0100-879X#Two pedigrees with restless legs syndrome in Brazil^len#^rND^
1A01 A02^nA.M.^sEsteves#^rND^1A01^nM.^sPedrazzoli#^rND^1A01^nM.^sBagnato#^rND^1A
01^nF.^sMoreira#^rND^1A01 A02^nM.T. de^sMello#^rND^1A01 A02^nS.^sTufik#Departame
nto de Psicobiologia^iA01#Universidade Federal de São Paulo^iA02^1Escola Paulist
a de Medicina^2Centro de Estudos em Psicobiologia e Exercício^cSão Paulo^sSP^pBr
asil#^len^aNumerous studies have suggested a substantial genetic contribution in
 the etiology of the primary form of restless legs syndrome (RLS) and periodic l
eg movements (PLM). We describe the symptoms, the sleep profiles and physiologic
al parameters of two families in which several members present RLS/PLM. The prob
and of family 1 is a 70-year-old woman and the proband of family 2 is a 57-year-
old woman; both have exhibited the symptoms since the age of 20 years. All patie
nts in both families were diagnosed with RLS according to the criteria of the In
ternational RLS Study Group. Polysomnographic recordings were performed to quant
ify and to describe PLM during sleep. Sleep parameters showed decreased sleep ef
ficiency, increased sleep latency in the arousal index and the presence of PLM i
n all subjects. One of the families showed an exact profile of dominant inherita
nce with anticipation of age at onset. In the other family, the founders were bl
ood relatives and there was no affected member in the third generation suggestin
g a recessive mode of inheritance. RLS/PLM is a prevalent sleep disorder affecti
ng about 5 to 15% of the population and one that substantially impairs healthy s
leep patterns. Efforts to understand the underlying pathophysiology will contrib
ute to improve the sleep and life quality of these patients.#^dnd^i1#^tm^len^kRe
stless legs syndrome^i1#^tm^len^kPeriodic leg movements^i1#^tm^len^kGenetics^i1#
^tm^len^kSleep^i1#other#17#Associação Fundo de Incentivo à Psicofarmacologia#FAP
ESP#03/06297-3#98/143033#FADA#CNPq#20070615#June 15, 2007#20071210#December 10, 
2007#6934.htm##
02822000000000649000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016001200630
01700100029002330100026002620100023002880100023003110100030003340100025003640700
03500389070013900424083133600563085000801899085003501907085003501942085002101977
08500180199811700060201607200030202205800500202505800070207506000110208206000100
20930580005021030580005021081120009021131110014021221140009021361130018021450020
00902163#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#f#3#1#article#1#oa
#en#bjmbr#1#3.1#ILUS#TAB#05#BJMBR010#FAPESP#Braz J Med Biol Res#41#2#20080200#^f
106^l109#0100-879X#<b>Two pedigrees with restless legs syndrome in Brazil</b>^le
n#^rND^1A01 A02^nA.M.^sEsteves#^rND^1A01^nM.^sPedrazzoli#^rND^1A01^nM.^sBagnato#
^rND^1A01^nF.^sMoreira#^rND^1A01 A02^nM.T. de^sMello#^rND^1A01 A02^nS.^sTufik#De
partamento de Psicobiologia^iA01#Universidade Federal de São Paulo^iA02^1Escola 
Paulista de Medicina^2Centro de Estudos em Psicobiologia e Exercício^cSão Paulo^
sSP^pBrasil#^len^aNumerous studies have suggested a substantial genetic contribu
tion in the etiology of the primary form of restless legs syndrome (RLS) and per
iodic leg movements (PLM). We describe the symptoms, the sleep profiles and phys
iological parameters of two families in which several members present RLS/PLM. T
he proband of family 1 is a 70-year-old woman and the proband of family 2 is a 5
7-year-old woman; both have exhibited the symptoms since the age of 20 years. Al
l patients in both families were diagnosed with RLS according to the criteria of
 the International RLS Study Group. Polysomnographic recordings were performed t
o quantify and to describe PLM during sleep. Sleep parameters showed decreased s
leep efficiency, increased sleep latency in the arousal index and the presence o
f PLM in all subjects. One of the families showed an exact profile of dominant i
nheritance with anticipation of age at onset. In the other family, the founders 
were blood relatives and there was no affected member in the third generation su
ggesting a recessive mode of inheritance. RLS/PLM is a prevalent sleep disorder 
affecting about 5 to 15% of the population and one that substantially impairs he
althy sleep patterns. Efforts to understand the underlying pathophysiology will 
contribute to improve the sleep and life quality of these patients.#^dnd^i1#^tm^
len^kRestless legs syndrome^i1#^tm^len^kPeriodic leg movements^i1#^tm^len^kGenet
ics^i1#^tm^len^kSleep^i1#other#17#Associação Fundo de Incentivo à Psicofarmacolo
gia#FAPESP#03/06297-3#98/143033#FADA#CNPq#20070615#June 15, 2007#20071210#Decemb
er 10, 2007#6934.htm##
02953000000000673000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100038000400105121000300109049000900112
15800070012103000240012803100030015203200020015506500090015701400110016603500100
01770120056001870100029002430100025002720100022002970100022003190100031003410100
02400372070003700396070014100433083134300574085000801917085003501925085003501960
08500210199508500180201611700060203407200030204005800500204305800070209306000110
21000600010021110580005021210580005021261120009021311110014021401140009021541130
01802163002000902181008008902190#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.
htm#S#l#4#1#article#1#^mFeb.^a2008#oa#en#bjmbr#1#3.1#ilus#tab#05#BJMBR010#FAPESP
#Braz. j. med. biol. res#41#2#20080200#^f106^l109#0100-879X#Two pedigrees with r
estless legs syndrome in Brazil^len#^rND^1A01 A02^nA. M^sEsteves#^rND^1A01^nM^sP
edrazzoli#^rND^1A01^nM^sBagnato#^rND^1A01^nF^sMoreira#^rND^1A01 A02^nM. T. de^sM
ello#^rND^1A01 A02^nS^sTufik#^iA01^1Departamento de Psicobiologia#^iA02^1Univers
idade Federal de São Paulo^2Escola Paulista de Medicina^3Centro de Estudos em Ps
icobiologia e Exercício^cSão Paulo^sSP^pBrasil#^len^aNumerous studies have sugge
sted a substantial genetic contribution in the etiology of the primary form of r
estless legs syndrome (RLS) and periodic leg movements (PLM). We describe the sy
mptoms, the sleep profiles and physiological parameters of two families in which
 several members present RLS/PLM. The proband of family 1 is a 70-year-old woman
 and the proband of family 2 is a 57-year-old woman; both have exhibited the sym
ptoms since the age of 20 years. All patients in both families were diagnosed wi
th RLS according to the criteria of the International RLS Study Group. Polysomno
graphic recordings were performed to quantify and to describe PLM during sleep. 
Sleep parameters showed decreased sleep efficiency, increased sleep latency in t
he arousal index and the presence of PLM in all subjects. One of the families sh
owed an exact profile of dominant inheritance with anticipation of age at onset.
 In the other family, the founders were blood relatives and there was no affecte
d member in the third generation suggesting a recessive mode of inheritance. RLS
/PLM is a prevalent sleep disorder affecting about 5 to 15 percent of the popula
tion and one that substantially impairs healthy sleep patterns. Efforts to under
stand the underlying pathophysiology will contribute to improve the sleep and li
fe quality of these patients.#^dnd^i1#^tm^len^kRestless legs syndrome^i1#^tm^len
^kPeriodic leg movements^i1#^tm^len^kGenetics^i1#^tm^len^kSleep^i1#other#17#Asso
ciação Fundo de Incentivo à Psicofarmacologia#FAPESP#03/06297-3#98/143033#FADA#C
NPq#20070615#June 15, 2007#20071210#December 10, 2007#6934.htm#Internet^ihttp://
www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000200005##
00375000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704015000070002000900220#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#5#1#article#75#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, February 2008, V
olume 41(2) 106-109</B> </font></P>      ^cY#6934.htm##
00356000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704013100070002000900201#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#6#2#article#75#<P><font size="5" face="A
rial, Helvetica, sans-serif"><B>Two pedigrees with restless legs syndrome in Bra
zil</B> </font>       ^cY#6934.htm##
00649000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704042400070002000900494#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#7#3#article#75#<P><font face="Arial, Hel
vetica, sans-serif">A.M. Esteves<SUP>1,2</SUP>, <b><a href="#Correspondence"><im
g src="/img/revistas/bjmbr/v41n2/recor.gif" border="0"></a></b> <a href="mailto:
pedrazzo@psicobio.epm.br"><img src="/img/revistas/bjmbr/v41n2/email-ca.gif" bord
er="0"></a> M. Pedrazzoli<SUP>1</SUP>, M. Bagnato<SUP>1</SUP>, F. Moreira<SUP>1<
/SUP>, M.T. de Mello<SUP>1,2</SUP> and S. Tufik<SUP>1,2</SUP> </font>      ^cY#6
934.htm##
00497000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704027200070002000900342#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#8#4#article#75#<P><font face="Arial, Hel
vetica, sans-serif"><SUP>1</SUP>Departamento de Psicobiologia, <SUP>2</SUP>Centr
o de Estudos em Psicobiologia e Exerc&iacute;cio, Escola Paulista de Medicina, U
niversidade Federal de S&atilde;o Paulo, S&atilde;o Paulo, SP, Brasil</font>    
   ^cY#6934.htm##
00415000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704019000070002000900260#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#9#5#article#75#<P> <font face="Arial, He
lvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n2/dow
n.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>   
 ^cY#6934.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#10#6#article#75#<BR>   <A HREF="#Introdu
ction"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#6934.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#11#7#article#75#<BR>   <A HREF="#Materia
l"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Material"><strong>Subjects and Methods</strong></A>    ^
cY#6934.htm##
00398000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704017200071002000900243#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#12#8#article#75#<BR>   <A HREF="#Results
"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 H
SPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#6934.htm##
00407000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018100071002000900252#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#13#9#article#75#<BR>   <A HREF="#Discuss
ion"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#693
4.htm##
00395000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704016800072002000900240#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#14#10#article#75#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#6934.htm##
00461000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704023400072002000900306#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#15#11#article#75#<br>   </strong></A>   
<A HREF="#Correspondence"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspon
dence and Footnotes</strong></A>  </font>      ^cY#6934.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004800072002000900120#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#16#12#article#75#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>      ^cY#6934.htm##
00537000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031000072002000900382#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#17#13#article#75#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  <font
 face="Arial, Helvetica, sans-serif">      ^cY#6934.htm##
01569000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704134200072002000901414#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#18#14#article#75#<P>Numerous studies hav
e suggested a substantial genetic contribution in the etiology of the primary fo
rm of restless legs syndrome (RLS) and periodic leg movements (PLM). We describe
 the symptoms, the sleep profiles and physiological parameters of two families i
n which several members present RLS/PLM. The proband of family 1 is a 70-year-ol
d woman and the proband of family 2 is a 57-year-old woman; both have exhibited 
the symptoms since the age of 20 years. All patients in both families were diagn
osed with RLS according to the criteria of the International RLS Study Group. Po
lysomnographic recordings were performed to quantify and to describe PLM during 
sleep. Sleep parameters showed decreased sleep efficiency, increased sleep laten
cy in the arousal index and the presence of PLM in all subjects. One of the fami
lies showed an exact profile of dominant inheritance with anticipation of age at
 onset. In the other family, the founders were blood relatives and there was no 
affected member in the third generation suggesting a recessive mode of inheritan
ce. RLS/PLM is a prevalent sleep disorder affecting about 5 to 15% of the popula
tion and one that substantially impairs healthy sleep patterns. Efforts to under
stand the underlying pathophysiology will contribute to improve the sleep and li
fe quality of these patients.      ^cY#6934.htm##
00358000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704013100072002000900203#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#19#15#article#75#<P>Key words: Restless 
legs syndrome; Periodic leg movements; Genetics; Sleep  </font>  <HR ALIGN=LEFT 
WIDTH=100% SIZE=2>      ^cY#6934.htm##
00593000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036600072002000900438#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#20#16#article#75#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>    <font face="Arial, Helvetica,
 sans-serif">      ^cY#6934.htm##
00653000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704042600072002000900498#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#21#17#article#75#<P>Restless legs syndro
me (RLS) is a common disorder affecting 2 to 5% of the general population. The f
our cardinal diagnostic features of RLS include: 1) an urge to move the limbs th
at is usually associated with paresthesias or dysesthesias, 2) symptoms that sta
rt or become worse with rest, 3) at least partial relief of symptoms with physic
al activity, and 4) worsening of symptoms in the evening or at night (1).      ^
cY#6934.htm##
00610000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038300072002000900455#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#22#18#article#75#<P>In 85% of patients, 
RLS is associated with periodic leg movements (PLM) during sleep, which occur mo
stly during stage II sleep. PLM occur every 20_40 s, and sleep disruption result
s in daytime fatigue. The pathophysiology of the syndrome has not been elucidate
d fully but may involve dopaminergic dysfunction and abnormalities in metabolism
 of iron within the brain (2).      ^cY#6934.htm##
00498000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704027100072002000900343#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#23#19#article#75#<P>Numerous studies hav
e suggested a substantial genetic contribution to the etiology of the primary fo
rm of RLS. Familial aggregation has been reported since its original clinical de
scription, and up to 40% of sporadic cases show a positive family history (3).  
    ^cY#6934.htm##
00890000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704066300072002000900735#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#24#20#article#75#<P>RLS usually begins i
n the second decade of life and often follows an intermittent, fluctuating cours
e. At the onset of the disorder, the diagnosis is sometimes not obvious because 
symptoms are generally mild, and symptom-free periods can occur. Treatment is us
ually initiated in the fifth decade of life, although some patients with familia
l RLS seek treatment early in their youth. The genetic basis of RLS is still unk
nown, and there is no specific test to diagnose RLS or to specify and limit the 
clinical picture (4). A genetic marker on chromosome 6p21.2 that is associated w
ith susceptibility to PLM during sleep has been reported recently (5).      ^cY#
6934.htm##
00515000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704028800072002000900360#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#25#21#article#75#<P>Several studies have
 investigated the occurrence of familial RLS in different patient populations (6
). However, only a limited number of studies have focused on relatives through p
ersonal interviews of the index cases to verify the diagnosis and occurrence of 
familial cases.      ^cY#6934.htm##
00418000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704019100072002000900263#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#26#22#article#75#<P>We herein describe t
he symptoms and sleep and physiological parameters of two Brazilian families in 
which several members present RLS.  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  
    ^cY#6934.htm##
00595000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036800072002000900440#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#27#23#article#75#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Sub
jects and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>  <font face="Arial, Helvetic
a, sans-serif">      ^cY#6934.htm##
00265000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704003800072002000900110#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#28#24#article#75#<P><b>Casuistic</b>  </
font>      ^cY#6934.htm##
00787000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704056000072002000900632#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#29#25#article#75#<P><font face="Arial, H
elvetica, sans-serif">We investigated two Brazilian families showing a familial 
history of RLS. The proband of family 1 is a 70-year-old woman with no clear asc
endancy although she reported all-Brazilian ancestors. All members of her family
 present clear brown skin color as seen in mulattos. The proband of family 2 is 
a 57-year-old Caucasian woman with German ascendancy. Both women were treated in
 the Sleep Institute of S&atilde;o Paulo. Pedigrees of family 1 and family 2 are
 shown in <a href="#Fig1">Figure 1</a>. </font>      ^cY#6934.htm##
00493000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704026600072002000900338#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#30#26#article#75#<P><font face="Arial, H
elvetica, sans-serif">The research design was approved by the Institutional Ethi
cs Committee (Ref. No. 481/01) of the Universidade Federal de S&atilde;o Paulo. 
Participants signed consent forms authorizing collection of data. </font>      ^
cY#6934.htm##
00306000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704007900072002000900151#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#31#27#article#75#<P><font face="Arial, H
elvetica, sans-serif"><B>Diagnosis</B> </font>      ^cY#6934.htm##
00700000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704047300072002000900545#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#32#28#article#75#<P><font face="Arial, H
elvetica, sans-serif">The primary analyses were based on identification of subje
cts, probands and family members, and self-reports of RLS and PLM. Subsequently,
 all patients truly diagnosed with RLS according to the criteria of the Internat
ional RLS Study Group were examined using a standard questionnaire that included
 demographic data, family history, clinical symptoms, subjective sleep disturban
ces, and course of the disorder. </font>      ^cY#6934.htm##
00553000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704032600072002000900398#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#33#29#article#75#<P><font face="Arial, H
elvetica, sans-serif">Nocturnal polysomnographic recordings were performed to qu
antify and describe PLM during sleep in both probands and in some members of eac
h proband's family. Clinical chemistry analysis included measurement of blood ir
on, ferritin, and transferrin concentrations. </font>      ^cY#6934.htm##
00309000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704008200072002000900154#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#34#30#article#75#<P><font face="Arial, H
elvetica, sans-serif"><B>Examinations</B> </font>      ^cY#6934.htm##
00747000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704052000072002000900592#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#35#31#article#75#<P><font face="Arial, H
elvetica, sans-serif"><I>Polysomnography</I>. The polysomnographic exam was perf
ormed in accordance with the standardized rules for sleep stages of Rechtschaffe
n and Kales (7) and the rules for placing electrodes of Jasper (8). Data were ac
quired from four electroencephalograms, two electrooculograms, and three electro
myogram channels (one submandibular and two for the legs). Electrodes for PLM an
alysis were placed on the surface of the tibialis anterior muscle of both legs. 
</font>      ^cY#6934.htm##
00722000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704049500072002000900567#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#36#32#article#75#<P><font face="Arial, H
elvetica, sans-serif">Polysomnographic measures of sleep continuity and sleep ar
chitecture included: total sleep time, sleep onset latency, wake after sleep ons
et, and sleep efficiency. Sleep architecture measures were: 1) percentages of st
ages 1, 2, 3, and 4, and rapid eye movement sleep. The PLM definition criterion 
was as indicated by the American Sleep Disorders Academy (1). Only PLM that occu
rred during non-rapid eye movement sleep was recorded. </font>      ^cY#6934.htm
##
00321000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704009400072002000900166#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#37#33#article#75#<P><font face="Arial, H
elvetica, sans-serif"><B>Clinical chemistry tests</B> </font>      ^cY#6934.htm#
#
01151000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704092400072002000900996#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#38#34#article#75#<P><font face="Arial, H
elvetica, sans-serif"><I>Iron, ferritin, and transferrin concentrations</I>. The
 blood samples were collected into dry tubes (Vacutainer), from the forearm by v
ein puncture. The tubes were subsequently centrifuged (3400 rpm/10 min) at ambie
nt temperature (22&#186;C) to serum separation. Iron concentration was measured 
using the VITROS Fe slide method (VITROS 750, Johnson &amp; Johnson, Rochester, 
USA) and the VITROS Chemistry Products Calibrator 4 Kit (VITROS Chemical Systems
, Rochester, USA). Ferritin concentration was measured using an immunoassay-type
 two-stage sandwich method using direct chemiluminometric detection technology a
nd constant amounts of two anti-ferritin antibodies (Advia Centaur, Bayer, Tarry
town, USA). Transferrin concentration was measured by an antigen-antibody reacti
on through endpoint methods (Advia 1650, Bayer). </font>  <HR ALIGN=LEFT WIDTH=1
00% SIZE=2>      ^cY#6934.htm##
00537000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031000072002000900382#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#39#35#article#75#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF
="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0 
VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6934.htm##
00902000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704067500072002000900747#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#40#36#article#75#<P><font face="Arial, H
elvetica, sans-serif">Sleep parameters showed decreased sleep efficiency and inc
reased sleep latency, arousal index, and the presence of PLM in all subjects eva
luated in the sleep laboratory. We observed no other sleep disorders except for 
patient 4 (family 1), who presented a mild apnea. The family 2 proband had a sle
ep efficiency of only 5.5% (13 min) and no REM sleep at all, and her PLM index w
as very high (<a href="#Tab1">Table 1</a>). The concentrations of iron, ferritin
, and transferrin are shown in <a href="#Tab2">Table 2</a>. Only one subject (su
bject 5) from family 1 had abnormal iron and ferritin concentrations. </font> </
P>      ^cY#6934.htm##
00510000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704028300072002000900355#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#41#37#article#75#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>  <table width="100%"  border="0">    <tr align="left" valign="to
p">      <td width="13%"><a href="/img/revistas/bjmbr/v41n2/html/6934i01.htm"><i
mg src="/img/revistas/bjmbr/v41n2/6934i01peq.jpg" border="2"></a></td>      <td 
width="87%">    ^cY#6934.htm##
00614000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038700072002000900459#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#42#38#article#75#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig1"></a>Figure 1. <I>A</I>, Family 1 pedigree, 
black color figures represent the affected members. The arrow indicates the prob
and, who is blood relative of her husband. <I>B</I>, Family 2 pedigree, black co
lor figures represent the affected members. The arrow indicates the proband. </f
ont>      </td>    </tr>  </table>      ^cY#6934.htm##
00609000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038200072002000900454#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#43#39#article#75#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (85 K JPG file)]</font>
</P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr
 align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v4
1n2/html/6934t01.htm"><img src="/img/revistas/bjmbr/v41n2/table.jpg" border="2">
</a></td>      <td width="87%">    ^cY#6934.htm##
00449000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704022200072002000900294#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#44#40#article#75#<P><font face="Arial, H
elvetica, sans-serif"><a name="Tab1"></a>Table 1. Sleep parameters of six subjec
ts from the two restless legs syndrome families including the probands. </font> 
     </td>    </tr>  </table>      ^cY#6934.htm##
00617000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704039000072002000900462#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#45#41#article#75#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (113 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v
41n2/html/6934t02.htm"><img src="/img/revistas/bjmbr/v41n2/table.jpg" border="2"
></a></td>      <td width="87%">           ^cY#6934.htm##
00486000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704025900072002000900331#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#46#42#article#75#<p><font face="Arial, H
elvetica, sans-serif"><a name="Tab2"></a>Table 2.          Plasma concentrations
 of iron, ferritin, and transferrin of seven subjects          in families 1 and
 2 including the probands.</font></p>     </td>    </tr>  </table>      ^cY#6934
.htm##
00344000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704011700072002000900189#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#47#43#article#75#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (82 K JPG file)]</font>
</P>      ^cY#6934.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004800072002000900120#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#48#44#article#75#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>      ^cY#6934.htm##
00497000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704027000072002000900342#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#49#45#article#75#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#6934.htm##
00519000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704029200072002000900364#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#50#46#article#75#<P><font face="Arial, H
elvetica, sans-serif">Herein, we report for the first time on the RLS/PLM pedigr
ees in Brazil. Clinical and polysomnographic evaluations in the probands and in 
some of the affected family members were performed to confirm the presence of th
e disorder. </font>      ^cY#6934.htm##
00565000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033800072002000900410#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#51#47#article#75#<P><font face="Arial, H
elvetica, sans-serif">The polysomnographic recordings show increased sleep onset
 latency, caused by a crawling sensation in the legs (RLS), and increased arousa
l and poor sleep efficiency, caused by leg movements during the night, compared 
with normal values described by Carskadon and Dement (9). </font>      ^cY#6934.
htm##
00638000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704041100072002000900483#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#52#48#article#75#<P><font face="Arial, H
elvetica, sans-serif">One possible cause of RLS is abnormalities in the metaboli
sm of iron (2). The concentrations of iron, ferritin, and transferrin were norma
l in these subjects except for one subject in family 1, who had low concentratio
ns of iron and ferritin. Thus, it is unlikely that abnormalities in iron metabol
ism contributed to the disorder in these families. </font>      ^cY#6934.htm##
00627000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704040000072002000900472#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#53#49#article#75#<P><font face="Arial, H
elvetica, sans-serif">The phenotype of RLS, including the symptoms and clinical 
signs, is similar in hereditary and nonhereditary cases. It is difficult to diff
erentiate genetic and sporadic cases. The main difference between these two form
s of the disorder is the early onset and frequent worsening of the symptoms duri
ng pregnancy in the genetic cases (10). </font>      ^cY#6934.htm##
00752000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704052500072002000900597#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#54#50#article#75#<P><font face="Arial, H
elvetica, sans-serif">Investigations of single families with RLS have suggested 
that an autosomal dominant mode of inheritance is associated with early onset of
 the disorder (11,12). Walters et al. (3) subdivided 105 patients according to t
he age at onset (<font face="Symbol">&#163;</font>20 years and <font face="Symbo
l">&#179;</font>20 years). In the younger group, 81% reported a positive family 
history, whereas in the older group, only 58% were aware of affected family memb
ers. </font>      ^cY#6934.htm##
00964000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704073700072002000900809#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#55#51#article#75#<P><font face="Arial, H
elvetica, sans-serif">Allen and Early (13) compared the effects of current age a
nd serum ferritin concentration on RLS severity in individuals with early- and l
ate-onset RLS. They assigned patients according to age at onset (<font face="Sym
bol">&#163;</font>45 years and &gt;45 years). They found an age effect in the ea
rly-onset form of RLS, which worsened gradually with age and had a limited nonsi
gnificant relationship with serum iron concentration. In contrast, late-onset RL
S occurred less commonly in families, worsened rapidly with age, and had a stron
ger significant relationship with iron status. These results suggest that the RL
S phenotype may depend on age at onset of symptoms (13). </font>      ^cY#6934.h
tm##
00697000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704047000072002000900542#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#56#52#article#75#<P><font face="Arial, H
elvetica, sans-serif">In our study, family 2 had the exact profile of dominant i
nheritance with anticipation of age at onset, as described elsewhere (12). Altho
ugh it is a small pedigree, we observed RLS symptoms in each generation with ant
icipatory onset from the proband, who informed us that her symptoms had begun at
 around the age of 20 years, whereas the symptoms had started at age 5 years or 
younger in her grandchildren. </font>      ^cY#6934.htm##
00947000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704072000072002000900792#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#57#53#article#75#<P><font face="Arial, H
elvetica, sans-serif">The pattern of inheritance seemed to be different in famil
y 1 because there was no onset anticipation from generation to generation. The p
roband was married to her cousin, and we observed no anticipatory onset in the f
ollowing generations or even symptoms in the third generation, which strengthens
 the argument of the recessive mode of inheritance. The lack of symptoms in the 
third generation may be explained either by a recessive mode of inheritance or t
heir young age (under 20 years) because family members with the disorder reporte
d symptom onset at more than 20 years of age. Whether the third generation will 
present RLS/PLM remains to be verified. </font>      ^cY#6934.htm##
00700000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704047300072002000900545#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#58#54#article#75#<P><font face="Arial, H
elvetica, sans-serif">Genetic linkage studies have localized five different loci
 on chromosomes 12q, 14q, 9p, 2q, and 20p (6,14_17), and a recent study localize
d a marker on chromosome 6p21.2 (5). The discovery of RLS genes may have a signi
ficant therapeutic impact by helping us understand the molecular mechanisms rela
ted to the different endophenotypes of RLS, which may lead to new treatments. </
font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6934.htm##
00543000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031600072002000900388#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#59#55#article#75#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6934.htm##
00408000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704016700074002000900241#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#p#60#56#article#75#1#<P><font 
face="Arial, Helvetica, sans-serif">1. Anonymous. Recording and scoring leg move
ments. The Atlas Task Force. <I>Sleep</I> 1993; 16: 748_759. </font>      ^cY#69
34.htm##
00449000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704020800074002000900282#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#p#61#57#article#75#2#<P><font 
face="Arial, Helvetica, sans-serif">2. Allen RP, Earley CJ. Restless legs syndro
me: a review of clinical and pathophysiologic features. <I>J Clin Neurophysiol</
I> 2001; 18: 128_147. </font>      ^cY#6934.htm##
00517000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704027600074002000900350#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#p#62#58#article#75#3#<P><font 
face="Arial, Helvetica, sans-serif">3. Walters AS, Hickey K, Maltzman J, Verrico
 T, Joseph D, Hening W, et al. A questionnaire study of 138 patients with restle
ss legs syndrome: the &quot;Night-Walkers&quot; survey. <I>Neurology</I> 1996; 4
6: 92_95. </font>      ^cY#6934.htm##
00560000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704031900074002000900393#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#p#63#59#article#75#4#<P><font 
face="Arial, Helvetica, sans-serif">4. Montplaisir J, Boucher S, Poirier G, Lavi
gne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic charact
eristics of restless legs syndrome: a study of 133 patients diagnosed with new s
tandard criteria. <I>Mov Disord</I> 1997; 12: 61_65. </font>      ^cY#6934.htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024400074002000900318#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#p#64#60#article#75#5#<P><font 
face="Arial, Helvetica, sans-serif">5. Stefansson H, Rye DB, Hicks A, Petursson 
H, Ingason A, Thorgeirsson TE, et al. A genetic risk factor for periodic limb mo
vements in sleep. <I>N Engl J Med</I> 2007; 357: 639_647. </font>      ^cY#6934.
htm##
00515000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704027400074002000900348#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#p#65#61#article#75#6#<P><font 
face="Arial, Helvetica, sans-serif">6. Desautels A, Turecki G, Montplaisir J, Se
queira A, Verner A, Rouleau GA. Identification of a major susceptibility locus f
or restless legs syndrome on chromosome 12q. <I>Am J Hum Genet</I> 2001; 69: 126
6_1270. </font>      ^cY#6934.htm##
00519000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704027800074002000900352#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#p#66#62#article#75#7#<P><font 
face="Arial, Helvetica, sans-serif">7. Rechtschaffen A, Kales A. <I>Manual of st
andardized terminology, techniques, and scoring system for sleep stages of human
 subjects</I>. Los Angeles: Brain Information Service/Brain Research Institute, 
UCLA; 1968. </font>      ^cY#6934.htm##
00445000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704020400074002000900278#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#p#67#63#article#75#8#<P><font 
face="Arial, Helvetica, sans-serif">8. Jasper HH. The ten_twenty electrode syste
m of the International Federation. <I>Electroencephalogr Clin Neurophysiol</I> 1
958; 10: 371_375. </font>      ^cY#6934.htm##
00517000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704027600074002000900350#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#p#68#64#article#75#9#<P><font 
face="Arial, Helvetica, sans-serif">9. Carskadon MA, Dement WC. Normal human sle
ep: an overview. In: Kriger MH, Roth T, Dement WC (Editors), <I>Principles and p
ractice of sleep medicine</I>. 2nd edn. Philadelphia: WB Saunders Company; 1994.
 p 16_25. </font>      ^cY#6934.htm##
00540000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704029800075002000900373#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#p#69#65#article#75#10#<P><font
 face="Arial, Helvetica, sans-serif">10. Winkelmann J, Wetter TC, Collado-Seidel
 V, Gasser T, Dichgans M, Yassouridis A, et al. Clinical characteristics and fre
quency of the hereditary restless legs syndrome in a population of 300 patients.
 <I>Sleep</I> 2000; 23: 597_602. </font>      ^cY#6934.htm##
00525000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028300075002000900358#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#p#70#66#article#75#11#<P><font
 face="Arial, Helvetica, sans-serif">11. Lazzarini A, Walters AS, Hickey K, Cocc
agna G, Lugaresi E, Ehrenberg BL, et al. Studies of penetrance and anticipation 
in five autosomal-dominant restless legs syndrome pedigrees. <I>Mov Disord</I> 1
999; 14: 111_116. </font>      ^cY#6934.htm##
00576000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704033400075002000900409#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#p#71#67#article#75#12#<P><font
 face="Arial, Helvetica, sans-serif">12. Winkelmann J, Muller-Myhsok B, Wittchen
 HU, Hock B, Prager M, Pfister H, et al. Complex segregation analysis of restles
s legs syndrome provides evidence for an autosomal dominant mode of inheritance 
in early age at onset families. <I>Ann Neurol</I> 2002; 52: 297_302. </font>    
  ^cY#6934.htm##
00449000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020700075002000900282#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#p#72#68#article#75#13#<P><font
 face="Arial, Helvetica, sans-serif">13. Allen RP, Earley CJ. Defining the pheno
type of the restless legs syndrome (RLS) using age-of-symptom-onset. <I>Sleep Me
d</I> 2000; 1: 11_19. </font>      ^cY#6934.htm##
00479000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023700075002000900312#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#p#73#69#article#75#14#<P><font
 face="Arial, Helvetica, sans-serif">14. Bonati MT, Ferini-Strambi L, Aridon P, 
Oldani A, Zucconi M, Casari G. Autosomal dominant restless legs syndrome maps on
 chromosome 14q. <I>Brain</I> 2003; 126: 1485_1492. </font>      ^cY#6934.htm##
00504000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026200075002000900337#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#p#74#70#article#75#15#<P><font
 face="Arial, Helvetica, sans-serif">15. Chen S, Ondo WG, Rao S, Li L, Chen Q, W
ang Q. Genomewide linkage scan identifies a novel susceptibility locus for restl
ess legs syndrome on chromosome 9p. <I>Am J Hum Genet</I> 2004; 74: 876_885. </f
ont>      ^cY#6934.htm##
00547000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704030500075002000900380#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#p#75#71#article#75#16#<P><font
 face="Arial, Helvetica, sans-serif">16. Pichler I, Marroni F, Volpato CB, Gusel
la JF, Klein C, Casari G, et al. Linkage analysis identifies a novel locus for r
estless legs syndrome on chromosome 2q in a South Tyrolean population isolate. <
I>Am J Hum Genet</I> 2006; 79: 716_723. </font>      ^cY#6934.htm##
00541000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704029900075002000900374#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#p#76#72#article#75#17#<P><font
 face="Arial, Helvetica, sans-serif">17. Levchenko A, Provost S, Montplaisir JY,
 Xiong L, St-Onge J, Thibodeau P, et al. A novel autosomal dominant restless leg
s syndrome locus maps to chromosome 20p13. <I>Neurology</I> 2006; 67: 900_901. <
/font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6934.htm##
00563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033600072002000900408#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#77#73#article#75#<P><FONT SIZE=4 face="A
rial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F><B
>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, Helv
etica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.g
if" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6934.ht
m##
00660000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704043300072002000900505#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#78#74#article#75#<p><font face="Arial, H
elvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v41n2/rec
or.gif" border="0"></a> Address for correspondence:</b>  M. Pedrazzoli, Departam
ento de Psicobiologia, EPM, UNIFESP, Rua Napole&atilde;o de Barros 925, 3&#176; 
andar, 04024_002 S&atilde;o Paulo, SP, Brasil. Fax: +55_11_5572_0177. E-mail: <a
 href="mailto:pedrazzo@psicobio.epm.br">pedrazzo@psicobio.epm.br</a></font> </p>
      ^cY#6934.htm##
00513000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704028600072002000900358#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6934.htm#S#p#79#75#article#75#<P><font face="Arial, H
elvetica, sans-serif">Research supported by grants from Associa&ccedil;&atilde;o
 Fundo de Incentivo &agrave; Psicofarmacologia (AFIP), FAPESP (No. 03/06297_3 an
d CEPID 98/143033), FADA and CNPq. Received June 15, 2007. Accepted December 10,
 2007.</font>      ^cY#6934.htm##
00493000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100005000730100010000780120
06200088030000600150065000900156064000500165031000300170014000800173865000900181
002000900190035001000199801000600209#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
934.htm#S#c#80#1#article#17#1#^rND#Anonymous#Recording and scoring leg movements
: The Atlas Task Force^len#Sleep#19930000#1993#16#748-759#20080200#6934.htm#0161
-8105#Sleep##
00556000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100016000730100017000890120
07900106030002000185065000900205064000500214031000300219014000800222865000900230
002000900239035001000248801002000258#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
934.htm#S#c#81#2#article#17#2#^rND^sAllen^nRP#^rND^sEarley^nCJ#Restless legs syn
drome: a review of clinical and pathophysiologic features^len#J Clin Neurophysio
l#20010000#2001#18#128-147#20080200#6934.htm#0736-0258#J Clin Neurophysiol##
00687000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100016000910100
01800107010001700125010001600142010001600158810000600174012009800180030001000278
06500090028806400050029703100030030201400060030586500090031100200090032003500100
0329801001000339#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#c#82#3#art
icle#17#3#^rND^sWalters^nAS#^rND^sHickey^nK#^rND^sMaltzman^nJ#^rND^sVerrico^nT#^
rND^sJoseph^nD#^rND^sHening^nW#et al#A questionnaire study of 138 patients with 
restless legs syndrome: the "Night-Walkers" survey^len#Neurology#19960000#1996#4
6#92-95#20080200#6934.htm#0028-3878#Neurology##
00730000000000325000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100021000730100017000940100
01700111010001700128010001800145010002000163012014800183030001100331065000900342
06400050035103100030035601400060035986500090036500200090037403500100038380100110
0393#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#c#83#4#article#17#4#^r
ND^sMontplaisir^nJ#^rND^sBoucher^nS#^rND^sPoirier^nG#^rND^sLavigne^nG#^rND^sLapi
erre^nO#^rND^sLesperance^nP#Clinical, polysomnographic, and genetic characterist
ics of restless legs syndrome: a study of 133 patients diagnosed with new standa
rd criteria^len#Mov Disord#19970000#1997#12#61-65#20080200#6934.htm#0855-3185#Mo
v Disord##
00668000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100020000730100014000930100
01500107010001900122010001700141010002300158810000600181012006300187030001300250
06500090026306400050027203100040027701400080028186500090028900200090029803500100
0307801001300317#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#c#84#5#art
icle#17#5#^rND^sStefansson^nH#^rND^sRye^nDB#^rND^sHicks^nA#^rND^sPetursson^nH#^r
ND^sIngason^nA#^rND^sThorgeirsson^nTE#et al#A genetic risk factor for periodic l
imb movements in sleep^len#N Engl J Med#20070000#2007#357#639-647#20080200#6934.
htm#0028-4793#N Engl J Med##
00689000000000325000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100019000730100017000920100
02100109010001800130010001600148010001800164012009600182030001500278065000900293
06400050030203100030030701400100031086500090032000200090032903500100033880100150
0348#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#c#85#6#article#17#6#^r
ND^sDesautels^nA#^rND^sTurecki^nG#^rND^sMontplaisir^nJ#^rND^sSequeira^nA#^rND^sV
erner^nA#^rND^sRouleau^nGA#Identification of a major susceptibility locus for re
stless legs syndrome on chromosome 12q^len#Am J Hum Genet#20010000#2001#69#1266-
1270#20080200#6934.htm#0002-9297#Am J Hum Genet##
00560000000000241000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710160023000730160015000960180
10600111066001200217062005700229065000900286064000500295865000900300002000900309
#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#c#86#7#article#17#7#^rND^s
Rechtschaffen^nA#^rND^sKales^nA#Manual of standardized terminology, techniques, 
and scoring system for sleep stages of human subjects^len#Los Angeles#Brain Info
rmation Service/Brain Research Institute, UCLA#19680000#1968#20080200#6934.htm##
00551000000000265000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730120068000900300
03700158065000900195064000500204031000300209014000800212865000900220002000900229
035001000238801003700248#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#c#
87#8#article#17#8#^rND^sJasper^nHH#The ten_twenty electrode system of the Intern
ational Federation^len#Electroencephalogr Clin Neurophysiol#19580000#1958#10#371
-375#20080200#6934.htm#0013-4694#Electroencephalogr Clin Neurophysiol##
00627000000000313000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100020000730100017000930120
03600110016001700146016001400163016001700177018004600194063000200240066001300242
062002000255065000900275064000500284014000600289865000900295002000900304#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#c#88#9#article#17#9#^rND^sCarskado
n^nMA#^rND^sDement^nWC#Normal human sleep: an overview^len#^rND^sKriger^nMH#^rND
^sRoth^nT#^rND^sDement^nWC#Principles and practice of sleep medicine^len#2#Phila
delphia#WB Saunders Company#19940000#1994#16-25#20080200#6934.htm##
00716000000000337000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100020000750100017000950100
02400112010001600136010001800152010002100170810000600191012011600197030000600313
06500090031906400050032803100030033301400080033686500090034400200090035303500100
0362801000600372#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#c#89#10#ar
ticle#17#10#^rND^sWinkelmann^nJ#^rND^sWetter^nTC#^rND^sCollado-Seidel^nV#^rND^sG
asser^nT#^rND^sDichgans^nM#^rND^sYassouridis^nA#et al#Clinical characteristics a
nd frequency of the hereditary restless legs syndrome in a population of 300 pat
ients^len#Sleep#20000000#2000#23#597-602#20080200#6934.htm#0161-8105#Sleep##
00706000000000337000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750100018000940100
01600112010001800128010001800146010002000164810000600184012010300190030001100293
06500090030406400050031303100030031801400080032186500090032900200090033803500100
0347801001100357#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#c#90#11#ar
ticle#17#11#^rND^sLazzarini^nA#^rND^sWalters^nAS#^rND^sHickey^nK#^rND^sCoccagna^
nG#^rND^sLugaresi^nE#^rND^sEhrenberg^nBL#et al#Studies of penetrance and anticip
ation in five autosomal-dominant restless legs syndrome pedigrees^len#Mov Disord
#19990000#1999#14#111-116#20080200#6934.htm#0855-3185#Mov Disord##
00757000000000337000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100020000750100023000950100
01900118010001400137010001600151010001700167810000600184012015400190030001100344
06500090035506400050036403100030036901400080037286500090038000200090038903500100
0398801001100408#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#c#91#12#ar
ticle#17#12#^rND^sWinkelmann^nJ#^rND^sMuller-Myhsok^nB#^rND^sWittchen^nHU#^rND^s
Hock^nB#^rND^sPrager^nM#^rND^sPfister^nH#et al#Complex segregation analysis of r
estless legs syndrome provides evidence for an autosomal dominant mode of inheri
tance in early age at onset families^len#Ann Neurol#20020000#2002#52#297-302#200
80200#6934.htm#0364-5134#Ann Neurol##
00516000000000265000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100016000750100017000910120
09000108030001000198710000200208065000900210064000500219031000200224014000600226
865000900232002000900241#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#c#
92#13#article#17#13#^rND^sAllen^nRP#^rND^sEarley^nCJ#Defining the phenotype of t
he restless legs syndrome (RLS) using age-of-symptom-onset^len#Sleep Med#2#20000
000#2000#1#11-19#20080200#6934.htm##
00644000000000325000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100024000920100
01600116010001600132010001700148010001600165012006900181030000600250065000900256
06400050026503100040027001400100027486500090028400200090029303500100030280100060
0312#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#c#93#14#article#17#14#
^rND^sBonati^nMT#^rND^sFerini-Strambi^nL#^rND^sAridon^nP#^rND^sOldani^nA#^rND^sZ
ucconi^nM#^rND^sCasari^nG#Autosomal dominant restless legs syndrome maps on chro
mosome 14q^len#Brain#20030000#2003#126#1485-1492#20080200#6934.htm#0006-8950#Bra
in##
00678000000000325000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100014000750100015000890100
01300104010001200117010001400129010001400143012011200157030001500269065000900284
06400050029303100030029801400080030186500090030900200090031803500100032780100150
0337#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#c#94#15#article#17#15#
^rND^sChen^nS#^rND^sOndo^nWG#^rND^sRao^nS#^rND^sLi^nL#^rND^sChen^nQ#^rND^sWang^n
Q#Genomewide linkage scan identifies a novel susceptibility locus for restless l
egs syndrome on chromosome 9p^len#Am J Hum Genet#20040000#2004#74#876-885#200802
00#6934.htm#0002-9297#Am J Hum Genet##
00732000000000337000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100017000750100017000920100
01800109010001800127010001500145010001600160810000600176012012900182030001500311
06500090032606400050033503100030034001400080034386500090035100200090036003500100
0369801001500379#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#c#95#16#ar
ticle#17#16#^rND^sPichler^nI#^rND^sMarroni^nF#^rND^sVolpato^nCB#^rND^sGusella^nJ
F#^rND^sKlein^nC#^rND^sCasari^nG#et al#Linkage analysis identifies a novel locus
 for restless legs syndrome on chromosome 2q in a South Tyrolean population isol
ate^len#Am J Hum Genet#20060000#2006#79#716-723#20080200#6934.htm#0002-9297#Am J
 Hum Genet##
00686000000000337000450000400060000070200450000670500020005170600020005370000030
00557010003000587090008000617080003000691180003000720100019000750100017000940100
02200111010001500133010001700148010001900165810000600184012008500190030001000275
06500090028506400050029403100030029901400080030286500090031000200090031903500100
0328801001000338#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6934.htm#S#c#96#17#ar
ticle#17#17#^rND^sLevchenko^nA#^rND^sProvost^nS#^rND^sMontplaisir^nJY#^rND^sXion
g^nL#^rND^sSt-Onge^nJ#^rND^sThibodeau^nP#et al#A novel autosomal dominant restle
ss legs syndrome locus maps to chromosome 20p13^len#Neurology#20060000#2006#67#9
00-901#20080200#6934.htm#0028-3878#Neurology##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#o#1#1#article#1#20
080402#165802#6947.htm#143##
02919000000000553000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016001201220
01700100025002920100025003170700183003420831587005250850008021120850039021200850
02902159085005402188085002002242085001702262117000602279072000302285058000502288
060001402293112000902307111001402316114000902330113001702339002000902356#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#
ILUS#TAB#11#BJMBR060#FAPESP#Braz J Med Biol Res#41#2#20080200#^f141^l151#0100-87
9X#Operant serial feature-positive conditional discrimination with composite fea
tures and different topography responses^len#^rND^1A01^nJ.L.O.^sBueno#^rND^1A01^
nA.A.^sScaduto#Universidade de São Paulo^iA01^1Faculdade de Filosofia, Ciências 
e Letras de Ribeirão Preto^2Departamento de Psicologia e Educação^3Setor de Psic
obiologia^cRibeirão Preto^sSP^pBrasil#^len^aIn a serial feature-positive conditi
onal discrimination procedure the properties of a target stimulus A are defined 
by the presence or not of a feature stimulus X preceding it. In the present expe
riment, composite features preceded targets associated with two different topogr
aphy operant responses (right and left bar pressing); matching and non-matching-
to-sample arrangements were also used. Five water-deprived Wistar rats were trai
ned in 6 different trials: X-R®Ar and X-L®Al, in which X and A were same modalit
y visual stimuli and the reinforcement was contingent to pressing either the rig
ht (r) or left (l) bar that had the light on during the feature (matching-to-sam
ple); Y-R®Bl and Y-L®Br, in which Y and B were same modality auditory stimuli an
d the reinforcement was contingent to pressing the bar that had the light off du
ring the feature (non-matching-to-sample); A- and B- alone. After 100 training s
essions, the animals were submitted to transfer tests with the targets used plus
 a new one (auditory click). Average percentages of stimuli with a response were
 measured. Acquisition occurred completely only for Y-L®Br+; however, complex as
sociations were established along training. Transfer was not complete during the
 tests since concurrent effects of extinction and response generalization also o
ccurred. Results suggest the use of both simple conditioning and configurational
 strategies, favoring the most recent theories of conditional discrimination lea
rning. The implications of the use of complex arrangements for discussing these 
theories are considered.#^dnd^i1#^tm^len^kConditional discrimination^i1#^tm^len^
kOccasion setting^i1#^tm^len^kNon-matching-to-sample/matching-to-sample^i1#^tm^l
en^kOperant^i1#^tm^len^kRats^i1#other#18#CNPq#(#xxxxxxxxxxx#20070621#June 21, 20
07#20070412#December 4, 2007#6947.htm##
02947000000000553000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000700108
03000200011503100030013503200020013806500090014001400110014903500100016001201290
01700100025002990100025003240700183003490831587005320850008021190850039021270850
02902166085005402195085002002249085001702269117000602286072000302292058000502295
060002102300112000902321111002102330114000902351113002402360002000902384#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#
ILUS#TAB#11#BJMBR060#FAPESP#Braz J Med Biol Res#41#2#20080200#^f141^l151#0100-87
9X#<b>Operant serial feature-positive conditional discrimination with composite 
features and different topography responses</b>^len#^rND^1A01^nJ.L.O.^sBueno#^rN
D^1A01^nA.A.^sScaduto#Universidade de São Paulo^iA01^1Faculdade de Filosofia, Ci
ências e Letras de Ribeirão Preto^2Departamento de Psicologia e Educação^3Setor 
de Psicobiologia^cRibeirão Preto^sSP^pBrasil#^len^aIn a serial feature-positive 
conditional discrimination procedure the properties of a target stimulus A are d
efined by the presence or not of a feature stimulus X preceding it. In the prese
nt experiment, composite features preceded targets associated with two different
 topography operant responses (right and left bar pressing); matching and non-ma
tching-to-sample arrangements were also used. Five water-deprived Wistar rats we
re trained in 6 different trials: X-R®Ar and X-L®Al, in which X and A were same 
modality visual stimuli and the reinforcement was contingent to pressing either 
the right (r) or left (l) bar that had the light on during the feature (matching
-to-sample); Y-R®Bl and Y-L®Br, in which Y and B were same modality auditory sti
muli and the reinforcement was contingent to pressing the bar that had the light
 off during the feature (non-matching-to-sample); A- and B- alone. After 100 tra
ining sessions, the animals were submitted to transfer tests with the targets us
ed plus a new one (auditory click). Average percentages of stimuli with a respon
se were measured. Acquisition occurred completely only for Y-L®Br+; however, com
plex associations were established along training. Transfer was not complete dur
ing the tests since concurrent effects of extinction and response generalization
 also occurred. Results suggest the use of both simple conditioning and configur
ational strategies, favoring the most recent theories of conditional discriminat
ion learning. The implications of the use of complex arrangements for discussing
 these theories are considered.#^dnd^i1#^tm^len^kConditional discrimination^i1#^
tm^len^kOccasion setting^i1#^tm^len^kNon-matching-to-sample/matching-to-sample^i
1#^tm^len^kOperant^i1#^tm^len^kRats^i1#other#18#CNPq#(<b>#xxxxxxxxxxx</b>#200706
21#<i>June 21, 2007</i>#20070412#<i>December 4, 2007</i>#6947.htm##
03052000000000577000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100038000400105121000300109049000900112
15800070012103000240012803100030015203200020015506500090015701400110016603500100
01770120122001870100026003090100025003350700185003600831587005450850008021320850
03902140085002902179085005402208085002002262085001702282117000602299072000302305
05800050230806000140231311200090232711100140233611400090235011300170235900200090
2376008008902385#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#l#4#1#arti
cle#1#^mFeb.^a2008#oa#en#bjmbr#1#3.1#ilus#tab#11#BJMBR060#FAPESP#Braz. j. med. b
iol. res#41#2#20080200#^f141^l151#0100-879X#Operant serial feature-positive cond
itional discrimination with composite features and different topography response
s^len#^rND^1A01^nJ. L. O^sBueno#^rND^1A01^nA. A^sScaduto#^iA01^1Universidade de 
São Paulo^2Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto^3Departam
ento de Psicologia e Educação. Setor de Psicobiologia^cRibeirão Preto^sSP^pBrasi
l#^len^aIn a serial feature-positive conditional discrimination procedure the pr
operties of a target stimulus A are defined by the presence or not of a feature 
stimulus X preceding it. In the present experiment, composite features preceded 
targets associated with two different topography operant responses (right and le
ft bar pressing); matching and non-matching-to-sample arrangements were also use
d. Five water-deprived Wistar rats were trained in 6 different trials: X-R®Ar an
d X-L®Al, in which X and A were same modality visual stimuli and the reinforceme
nt was contingent to pressing either the right (r) or left (l) bar that had the 
light on during the feature (matching-to-sample); Y-R®Bl and Y-L®Br, in which Y 
and B were same modality auditory stimuli and the reinforcement was contingent t
o pressing the bar that had the light off during the feature (non-matching-to-sa
mple); A- and B- alone. After 100 training sessions, the animals were submitted 
to transfer tests with the targets used plus a new one (auditory click). Average
 percentages of stimuli with a response were measured. Acquisition occurred comp
letely only for Y-L®Br+; however, complex associations were established along tr
aining. Transfer was not complete during the tests since concurrent effects of e
xtinction and response generalization also occurred. Results suggest the use of 
both simple conditioning and configurational strategies, favoring the most recen
t theories of conditional discrimination learning. The implications of the use o
f complex arrangements for discussing these theories are considered.#^dnd^i1#^tm
^len^kConditional discrimination^i1#^tm^len^kOccasion setting^i1#^tm^len^kNon-ma
tching-to-sample/matching-to-sample^i1#^tm^len^kOperant^i1#^tm^len^kRats^i1#othe
r#18#CNPq#(#xxxxxxxxxxx#20070621#June 21, 2007#20070412#December 4, 2007#6947.ht
m#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X200
8000200011##
00376000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704015000071002000900221#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#5#1#article#121#<P> <font face="Arial, H
elvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, February 2008, 
Volume 41(2) 141-151</B> </font></P>      ^cY#6947.htm##
00423000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704019700071002000900268#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#6#2#article#121#<P><font size="5" face="
Arial, Helvetica, sans-serif"><B>Operant serial feature-positive conditional dis
crimination with composite features and different topography responses</B> </fon
t>       ^cY#6947.htm##
00520000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704029400071002000900365#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#7#3#article#121#<P><font face="Arial, He
lvetica, sans-serif"><b><a href="#Correspondence"><img src="/img/revistas/bjmbr/
v41n2/recor.gif" border="0"></a></b> <a href="mailto:jldobuen@ffclrp.usp.br"><im
g src="/img/revistas/bjmbr/v41n2/email-ca.gif" border="0"></a> J.L.O. Bueno and 
A.A. Scaduto </font>      ^cY#6947.htm##
00507000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704028100071002000900352#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#8#4#article#121#<P><font face="Arial, He
lvetica, sans-serif">Setor de Psicobiologia, Departamento de Psicologia e Educa&
ccedil;&atilde;o, Faculdade de Filosofia, Ci&ecirc;ncias e Letras de Ribeir&atil
de;o Preto, Universidade de S&atilde;o Paulo, Ribeir&atilde;o Preto, SP, Brasil<
/font>       ^cY#6947.htm##
00416000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000400067704019000071002000900261#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#9#5#article#121#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n2/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>  
  ^cY#6947.htm##
00414000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704018700072002000900259#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#10#6#article#121#<BR>   <A HREF="#Introd
uction"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPA
CE=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    
^cY#6947.htm##
00414000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704018700072002000900259#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#11#7#article#121#<BR>   <A HREF="#Materi
al"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0
 HSPACE=0></A> <A HREF="#Material"><strong>Subjects and Methods</strong></A>    
^cY#6947.htm##
00399000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704017200072002000900244#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#12#8#article#121#<BR>   <A HREF="#Result
s"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#6947.htm##
00408000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000400068704018100072002000900253#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#13#9#article#121#<BR>   <A HREF="#Discus
sion"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#69
47.htm##
00396000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704016800073002000900241#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#14#10#article#121#<BR>   <A HREF="#Refer
ences"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#6947.htm##
00462000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704023400073002000900307#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#15#11#article#121#<br>   </strong></A>  
 <A HREF="#Correspondence"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=B
OTTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspo
ndence and Footnotes</strong></A>  </font>      ^cY#6947.htm##
00276000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004800073002000900121#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#16#12#article#121#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>      ^cY#6947.htm##
00547000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031900073002000900392#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#17#13#article#121#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F>
<B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/ba
ck.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  <fon
t face="Arial, Helvetica, sans-serif">  </font>      ^cY#6947.htm##
02076000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704184800073002000901921#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#18#14#article#121#<P><font face="Arial, 
Helvetica, sans-serif">In a serial feature-positive conditional discrimination p
rocedure the properties of a target stimulus A are defined by the presence or no
t of a feature stimulus X preceding it. In the present experiment, composite fea
tures preceded targets associated with two different topography operant response
s (right and left bar pressing); matching and non-matching-to-sample arrangement
s were also used. Five water-deprived Wistar rats were trained in 6 different tr
ials: X-R<font face="Symbol">&#174;</font>Ar and X-L<font face="Symbol">&#174;</
font>Al, in which X and A were same modality visual stimuli and the reinforcemen
t was contingent to pressing either the right (r) or left (l) bar that had the l
ight on during the feature (matching-to-sample); Y-R<font face="Symbol">&#174;</
font>Bl and Y-L<font face="Symbol">&#174;</font>Br, in which Y and B were same m
odality auditory stimuli and the reinforcement was contingent to pressing the ba
r that had the light off during the feature (non-matching-to-sample); A- and B- 
alone. After 100 training sessions, the animals were submitted to transfer tests
 with the targets used plus a new one (auditory click). Average percentages of s
timuli with a response were measured. Acquisition occurred completely only for Y
-L<font face="Symbol">&#174;</font>Br+; however, complex associations were estab
lished along training. Transfer was not complete during the tests since concurre
nt effects of extinction and response generalization also occurred. Results sugg
est the use of both simple conditioning and configurational strategies, favoring
 the most recent theories of conditional discrimination learning. The implicatio
ns of the use of complex arrangements for discussing these theories are consider
ed. </font>   <font face="Arial, Helvetica, sans-serif">      ^cY#6947.htm##
00398000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704017000073002000900243#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#19#15#article#121#<P>Key words: Conditio
nal discrimination; Occasion setting; Non-matching-to-sample/matching-to-sample;
 Operant; Rats  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6947.htm##
00594000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704036600073002000900439#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#20#16#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><
B>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-ser
if"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTO
M BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>    <font face="Arial, Helvetica
, sans-serif">      ^cY#6947.htm##
00548000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704032000073002000900393#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#21#17#article#121#<P>In a Pavlovian feat
ure-positive (FP) conditional discrimination procedure (XA+; A-), a conditioned 
stimulus A, called target, is followed by reinforcement if preceded by an X stim
ulus, called feature, and not reinforced if presented alone; this procedure was 
first described by Jenkins and Sainsbury (1).         ^cY#6947.htm##
01260000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704103200073002000901105#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#22#18#article#121#<P>Different models ha
ve been proposed to elucidate the processes occurring in conditional discriminat
ion learning. According to Rescorla (2), such learning would be established thro
ugh a simple feature-reinforcement association; X acquires the ability to elicit
 conditioned responses (CRs) during the presentation of A, which in turn has inh
ibitory properties when presented alone. Holland (3) proposed an occasion-settin
g hypothesis; a CR is generated by X's activation of A-unconditioned stimulus re
presentation. It was observed that, in a Pavlovian serial FP conditional discrim
ination (X<font face="Symbol">&#174;</font>A; A+), the feature sets the occasion
 for a target-reinforcement relation (4). Another hypothesis (5-7) suggests that
 animals solve conditional discriminations by a configurational association of t
he feature-target compound with the reinforcement, that is, although feature and
 target have different information related to reinforcement separately, both wou
ld be considered as a single stimulus.        ^cY#6947.htm##
01505000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704127700073002000901350#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#23#19#article#121#<P>In order to evaluat
e which types of associations are established along conditional discrimination p
rocedures, transfer tests can be used. Considering the arrangement of feature an
d target, conditional discriminations can be either serial (in which composite f
eature-target trials are presented serially, with a gap between them, i.e., X<fo
nt face="Symbol">&#174;</font>A, or without a gap, i.e., X-A) or simultaneous on
es, where composite trials are presented at the same time, XA. Ross and Holland 
(4) proposed that simultaneous conditional discriminations are more likely to el
icit primary associations between feature and reinforcement stimuli, while seria
l ones can elicit occasion-setting associations. Transfer tests consist of the p
resentation of trials in which the feature precedes either different targets, wh
ich the subjects were not trained with, or other stimuli, which had not particip
ated in the discrimination training. The transfer of feature properties to anoth
er target stimulus is observed in simultaneous conditional discriminations, but 
not in serial ones. The properties of the feature can also be tested by observin
g the topography of the response in Pavlovian procedures (4) and by countercondi
tioning of the feature stimulus trials (3).        ^cY#6947.htm##
01216000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704098800073002000901061#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#24#20#article#121#<P>The mechanisms invo
lved in conditional discrimination learning have also been studied in operant co
nditioning procedures, in which there is an operant response between target and 
reinforcement. Holland (8) examined transfer of stimulus control after discrete-
trial operant serial FP discrimination (X - A+/A-) training in rats. The results
 showed the ability of X features to facilitate responding to a subsequent targe
t cue when the transfer target had been presented during training as the target 
in another serial FP discrimination, even if that target controlled a different 
operant than controlled by the original A target. Transfer to a separately train
ed and extinguished target was smaller and occurred only if the original and tra
nsfer target controlled the same operant. The occasion-setting interpretation su
pposes that the features have the ability to act on both target-reinforcer and r
esponse-reinforcer associations subsumed by the four-term contingencies (9).    
  ^cY#6947.htm##
00735000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704050700073002000900580#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#25#21#article#121#<P>Holland (8) and God
dard and Holland (10) have suggested that the feature acted on the operant respo
nse-reinforcement relation; the stimulus modality could have been one of the pos
sible determinants of the performance observed during transfer tests. The effect
s of stimulus modality were also observed in serial Pavlovian FPs; Ross and Holl
and (4) observed different CRs to targets of different modalities (that is, rear
ing CRs during panel light (P) and head-jerk CRs during tone (T)).  </font>     
 ^cY#6947.htm##
01007000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704077900073002000900852#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#26#22#article#121#<P><font face="Arial, 
Helvetica, sans-serif">Although similarities have been observed in both Pavlovia
n and operant procedures, the relations among the events differ between these ex
perimental designs. Relations among feature, target and reinforcement are involv
ed in Pavlovian conditioning procedures. In operant conditioning procedures, the
 presence of the operant response between target and reinforcement can set a dif
ferent feature control compared to Pavlovian conditioning procedures (11). The p
resence of an operant CR can add more complex properties to the target, as it ca
n indicate not only reinforcement, but also a response-reinforcement relation; t
hus, a target can also acquire the same properties of a feature, that is, as an 
occasion setter (3).</font>      ^cY#6947.htm##
02328000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704210000073002000902173#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#27#23#article#121#<P><font face="Arial, 
Helvetica, sans-serif">In order to study the learning mechanisms involved in con
ditional discrimination procedures with operant responses, Caserta-Gon (11) used
 two topographies of the same response in rats: complete left or right rotation 
around their own axis. The use of similar operant responses would provide an ana
lysis of the processes underlying different types of conditional discriminations
 by observing the effects of their representations in acquisition and transfer. 
Same-modality features and targets were used in a serial FP conditional discrimi
nation for the right-topography response (P<font face="Symbol">&#174;</font>Tr+;
 T-), and in a serial feature-negative conditional discrimination for the left-t
opography response (H<font face="Symbol">&#174;</font>R-; Rl+), with P and H bei
ng visual stimuli (panel and house lights, respectively) and T and R being audit
ory stimuli (tone and white noise, respectively). The results showed acquisition
 of the task, but did not indicate transfer of the properties of both features (
positive and negative) to targets that were part of the training. However, FP tr
ansfer to a new stimulus (click) was observed. These results may be explained as
 a generalization of same-modality stimuli (visual features and auditory targets
). However, Caserta-Gon (11) also suggested that the lack of transfer indicates 
that the animals used an occasion-setting strategy, which explains the data patt
ern obtained in transfer tests - a specific association of the feature with the 
target-reinforcement relation. When there was no previous association between ta
rget and reinforcement, as in the case of the transfer test to a new stimulus, t
he primary association between feature and reinforcement prevailed and the FP pr
operties were transferred to this new target stimulus. Animals can be controlled
 by different types of associations, primary and conditional, in the same proced
ure, pointing out the interaction of respondent processes (primary associations)
 and S-(R-reinforcement) conditional operant relations (10). </font>      ^cY#69
47.htm##
01377000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704114900073002000901222#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#28#24#article#121#<P><font face="Arial, 
Helvetica, sans-serif">Bueno and Croisfelts (12) also used serial FP and feature
-negative conditional discriminations, with different topographies of the same r
esponse, right- or left-lever pressing (as indicated below, r and l, respectivel
y). In order to analyze how stimulus modality would affect acquisition, differen
t modality features and targets were used. Auditory T and W (white noise) were u
sed in FP trials (W<font face="Symbol">&#174;</font>Tr+, T-) and visual P and H 
were used in the feature-negative conditional discrimination pattern (P<font fac
e="Symbol">&#174;</font>H-, Hl+). The data showed acquisition of the task; durin
g transfer tests, feature-negative P transfer was observed to T, preceded during
 training by FP W. Transfer of FP W properties was also observed to target H. Ho
wever, <font face="Arial, Helvetica, sans-serif">as right- and left-responding r
ates had similar distributions,</font> the responding topography suggests both f
eature and target control. This result did not allow a definition of which strat
egy was used by the animals (simple or occasion-setting associations).</font>   
   ^cY#6947.htm##
01137000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704090900073002000900982#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#29#25#article#121#<P><font face="Arial, 
Helvetica, sans-serif">Considering that more complex processes than the use of o
nly one strategy may be related to conditional discrimination acquisition (11) a
nd that the stimulus modality acts on acquisition and transfer (8,12), the objec
tive of the present study was to analyze the hierarchical structure of learning 
in an operant serial FP conditional discrimination. In order to do so, we used c
omposite features that could acquire different properties depending on their fir
st element, in two serial FP conditional discrimination procedure arrangements (
non-matching-to-sample, NMTS, and matching-to-sample, MTS), using an operant res
ponse with two topographies. With this procedure, an evaluation of variables suc
h as stimulus modality and topography of the response can be studied in terms of
 their relevance for stimulus representation processing and learning. </font>   
   ^cY#6947.htm##
00903000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704067500073002000900748#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#30#26#article#121#<P><font face="Arial, 
Helvetica, sans-serif">This study allows an evaluation of the ability of animals
 to discriminate events at the moment when reinforcement probability is the high
est (targets preceded by features), besides discriminating which response is rei
nforced (right- or left-lever pressing), according to the schedule signaled by t
he bar lights. The use of transfer tests can allow an evaluation of which associ
ations were established among composite features, targets, responses, and reinfo
rcement, elucidating which learning mechanisms were relevant to acquisition for 
this type of conditional discrimination. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE
=2>      ^cY#6947.htm##
00552000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704032400073002000900397#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#31#27#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Su
bjects and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans
-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=B
OTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6947.htm##
00305000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704007700073002000900150#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#32#28#article#121#<P><b><font face="Aria
l, Helvetica, sans-serif">Subjects</font></b>      ^cY#6947.htm##
00970000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704074200073002000900815#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#33#29#article#121#<P><font face="Arial, 
Helvetica, sans-serif">The subjects were 9 experimentally naive male Wistar rats
 bred in the central colony room of the University of S&atilde;o Paulo. The rats
 were about 120 days old at the beginning of the experiment and were housed indi
vidually in cages in the laboratory colony room with lights on from 6:00 am to 8
:00 pm. When the animals reached a stable weight, they were water-deprived until
 they reached 80% of their pre-deprivation weights. The animals were maintained 
at 80% of their <I>ad libitum</I> body weight throughout the experiment by restr
icting their access to water, which was available for about 10 min a day in thei
r individual cages. Food, however, was available at all times. </font>      ^cY#
6947.htm##
00685000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704045700073002000900530#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#34#30#article#121#<P><font face="Arial, 
Helvetica, sans-serif">Along the experiment, 4 animals were excluded after an in
dividual analysis. One of them died before the end of the experiment, and the ot
her 3 showed no acquisition of stimulus-responding training events (see details 
in Procedure below). For this study, only animals that emitted responses at both
 topographies were considered. Thus, 5 animals were used as subjects for the dat
a presented here. </font>      ^cY#6947.htm##
00307000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704007900073002000900152#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#35#31#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><B>Apparatus</B> </font>      ^cY#6947.htm##
01887000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704165900073002000901732#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#36#32#article#121#<P><font face="Arial, 
Helvetica, sans-serif">The apparatus used consisted of four identical two-bar Sk
inner boxes (Lafayette model), measuring 20 x 20 x 23 cm, with stainless steel l
ateral walls and acrylic roof, front and back walls. The boxes were adapted to w
ooden isolation chambers, with a glass window in the center of each door. All bo
xes had a 2-cm diameter water holder on the left lateral wall 1.5 cm from the fl
oor, halfway to the door and the back wall of the box. A red-colored, 120-V and 
5-W lamp, installed 1 cm from the roof of all isolation chambers, dimly illumina
ted the boxes during the sessions. A white-colored, 5-W lamp (house light, H), i
nstalled 1 cm from the roof of the chamber, was programmed to light in flashes. 
Two white-colored 40-mA lamps (bar lights, RB for the right-bar light, and LB fo
r the left-bar light) were placed above the center of each of the two bars, 14 c
m above the water holder. Another white-colored 40-mA lamp (panel light, P) was 
placed 23 cm from the floor, in the middle of the space between the two bars. Al
l house, bar and panel lights were turned off, being turned on  by an interface 
only during training trials. The auditory cues were a 100-Hz, 30-dB tone (T), pr
oduced by an RFM audio generator (Departamento de Fisiologia, Faculdade de Medic
ina de Ribeir&atilde;o Preto), a 68-dB white noise (W) produced by a noise gener
ator model 901B (Grasson-Stadler, USA) and the reproduction of the voice number 
#1 (tambourine) of a Roland electronic drum, model TR-626 (USA), named Click (C)
. All the auditory cues were presented through four 20-W speakers installed in t
he isolation boxes. </font>      ^cY#6947.htm##
00520000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704029200073002000900365#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#37#33#article#121#<P><font face="Arial, 
Helvetica, sans-serif">The events presented in each session were controlled by a
n interface developed in our laboratory (13) linked to a Pentium 166 MHz compute
r. The Contrexp software for experimental control of animal learning research (1
4) was used. </font>      ^cY#6947.htm##
00307000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704007900073002000900152#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#38#34#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><B>Procedure</B> </font>      ^cY#6947.htm##
00819000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704059100073002000900664#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#39#35#article#121#<P><font face="Arial, 
Helvetica, sans-serif">All rats were submitted to operant response training sess
ions and then stimulus-related conditioning. First, they were submitted to a wat
er holder training session with 10 trials that consisted of water delivery at th
e times the subjects got closer to the holder. Next, three shaping sessions were
 run in which the subjects had to press either a right or a left bar in order to
 obtain water reinforcement. Two hundred water-drop reinforcements were liberate
d in a response- alternating schedule from three same-bar responses on. </font> 
     ^cY#6947.htm##
00807000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704057900073002000900652#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#40#36#article#121#<P><font face="Arial, 
Helvetica, sans-serif">After this training the rats were submitted to four stimu
lus-responding training sessions where T and H were presented. In these training
 sessions, 20 trials were reinforced after either right (Tr+; Hr+) or left (Tl+;
 Hl+) bar pressing in a 1-min variable interval reinforcement schedule. In the f
irst and second sessions, the stimuli were presented for 10 s and in the remaini
ng sessions, they were presented for 5 s. After this training, the animals were 
submitted to serial FP conditional discrimination training. </font>      ^cY#694
7.htm##
00568000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704034000073002000900413#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#41#37#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><I>Serial feature-positive conditional discrimination tra
ining</I>. The animals were submitted to 100 training sessions in which each of 
the 6 different trials described below were presented twice. Three types of tria
ls were presented according to their reinforcement schedule. </font>      ^cY#69
47.htm##
01033000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704080500073002000900878#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#42#38#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><I>Non-matching-to-sample trials.</I> In W-LB<font face="
Symbol">&#174;</font>Tr+ trials, 5-s W, followed by 5-s LB was presented to the 
subjects; after this composite feature, there was a 10-s time gap with no stimul
us presentation (<font face="Symbol">&#174;</font>). After this time gap, 5-s T 
was presented; a right bar-pressing response was reinforced once if emitted duri
ng the presentation of the target. In W-RB<font face="Symbol">&#174;</font>Tl+ t
rials, 5-s W was presented to the subjects, followed by 5-s RB; after this compo
site feature, there was a 10-s time gap with no stimulus presentation. After the
 gap, 5-s T was presented; a left bar-pressing response was reinforced once if e
mitted during the presentation of the target. </font>      ^cY#6947.htm##
00928000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704070000073002000900773#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#43#39#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><I>Matching-to-sample trials</I>. In P-RB<font face="Symb
ol">&#174;</font>Hr+ trials, 5-s P followed by 5-s RB was presented to the subje
cts; after this composite feature, there was a 10-s temporal gap. After this gap
, 5-H was presented; a right bar-pressing response was reinforced once if emitte
d during the presentation of the target. In PLB<font face="Symbol">&#174;</font>
Hl+ trials, 5-s P followed by 5-s LB was presented to the subjects; after this c
omposite feature, there was a 10-s time gap. After this gap, 5-s H was presented
; a left bar-pressing response was reinforced once if emitted during the present
ation of the target. </font>      ^cY#6947.htm##
00440000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704021200073002000900285#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#44#40#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><I>Non-reinforced trials.</I> During T- and H- trials, 5-
s T or 5-s H was presented to the subjects, with no water delivery regardless of
 responding. </font>      ^cY#6947.htm##
00721000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704049300073002000900566#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#45#41#article#121#<P><font face="Arial, 
Helvetica, sans-serif">In reinforced trials, only the first responses emitted du
ring target presentation were reinforced; neither other bar-pressing responses a
fter the first one during target presentation, nor responding after the target p
resentation were reinforced. Each session lasted 76 min, with two presentations 
of each of the trials described above, randomized with an inter-trial interval (
ITI) ranging from 4 to 9 min (average ITI = 6.5 min). </font>      ^cY#6947.htm#
#
01212000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704098400073002000901057#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#46#42#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><I>Transfer tests</I>. After the serial FP conditional di
scrimination training, subjects were submitted to sessions with the same duratio
n, number of presented trials, duration of stimulus presentation, and ITI. Seria
l FP conditional discrimination training trials and new ones were presented to t
he subjects in order to test the properties acquired by the features. In transfe
r tests 1-4, the composite features preceded targets; the subjects had not been 
trained with in the last training. In transfer test 5, the trials consisted of t
he composite features preceding a new stimulus (auditory click) in order to eval
uate transfer of the properties to a stimulus that did not take part in the cond
itional discrimination. None of the trials were reinforced. Between transfer tes
t sessions, the subjects were submitted to one serial FP conditional discriminat
ion refresher session in order to avoid conditioning extinction. </font>      ^c
Y#6947.htm##
00583000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704035500073002000900428#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#47#43#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><I>Transfer test 1</I>. Two W-LB<font face="Symbol">&#174
;</font>T- trials, two W-RB<font face="Symbol">&#174;</font>T- trials, two W-LB<
font face="Symbol">&#174;</font>H- trials, two W-RB<font face="Symbol">&#174;</f
ont>H- trials and also two T- and H- trials were presented to the subjects. </fo
nt>      ^cY#6947.htm##
00583000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704035500073002000900428#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#48#44#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><I>Transfer test 2</I>. Two P-RB<font face="Symbol">&#174
;</font>H- trials, two P-LB<font face="Symbol">&#174;</font>H- trials, two P-RB<
font face="Symbol">&#174;</font>T- trials, two P-LB<font face="Symbol">&#174;</f
ont>T- trials and also two T- and H- trials were presented to the subjects. </fo
nt>      ^cY#6947.htm##
00583000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704035500073002000900428#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#49#45#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><I>Transfer test 3</I>. Two W-LB<font face="Symbol">&#174
;</font>T- trials, two W-RB<font face="Symbol">&#174;</font>T- trials, two P-RB<
font face="Symbol">&#174;</font>T- trials, two P-LB<font face="Symbol">&#174;</f
ont>T- trials and also two T- and H- trials were presented to the subjects. </fo
nt>      ^cY#6947.htm##
00583000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704035500073002000900428#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#50#46#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><I>Transfer test 4</I>. Two P-RB<font face="Symbol">&#174
;</font>H- trials, two P-LB<font face="Symbol">&#174;</font>H- trials, two W-LB<
font face="Symbol">&#174;</font>H- trials, two W-RB<font face="Symbol">&#174;</f
ont>H- trials and also two T- and H- trials were presented to the subjects. </fo
nt>      ^cY#6947.htm##
00583000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704035500073002000900428#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#51#47#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><I>Transfer test 5</I>. Two W-LB<font face="Symbol">&#174
;</font>C- trials, two W-RB<font face="Symbol">&#174;</font>C- trials, two P-RB<
font face="Symbol">&#174;</font>C- trials, two P-LB<font face="Symbol">&#174;</f
ont>C- trials and also two T- and H- trials were presented to the subjects. </fo
nt>      ^cY#6947.htm##
00369000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704014100073002000900214#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#52#48#article#121#<P><font face="Arial, 
Helvetica, sans-serif">The complete experimental design is summarized in <a href
="#Tab1">Table 1</a>. </font>      ^cY#6947.htm##
01402000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704117400073002000901247#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#53#49#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><I>Data recoding and treatment</I>. All responding emitte
d during the experiment was recorded by the CONTREXP software (14). Preference m
easures (S) during the stimulus-responding training sessions were calculated dur
ing ITIs, T and H using the equation S = R / (R + L), where S is the right-bar p
reference measure, R is the right responding to the events, and L, the left resp
onding. During serial FP conditional discrimination training, the average percen
tages of trials with responses were calculated for each 10-session block. Percen
tages were measured during presentation of composite features, time gaps and tar
gets. Responding during W in W-LB<font face="Symbol">&#174;</font>Tr+ and W-RB<f
ont face="Symbol">&#174;</font>Tl+ trials and during P in P-RB<font face="Symbol
">&#174;</font>Hr+ and P-LB<font face="Symbol">&#174;</font>Hl+ trials was calcu
lated and is presented in the figures as a single measure in order to simplify d
ata presentation. During transfer tests, average percentages of trials with resp
onses were also calculated for composite feature elements, time gaps and target 
presentations. </font>      ^cY#6947.htm##
00579000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704035100073002000900424#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#54#50#article#121#<P><font face="Arial, 
Helvetica, sans-serif">Data were analyzed statistically by ANOVA and the <I>post
 hoc</I> Newman-Keuls test. The significance level adopted was P = 0.05. Ethical
 standards regarding subjects' care were followed according to FFCLRP's Animal E
thics Committee (Resolution 196/96). </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2> 
     ^cY#6947.htm##
00538000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031000073002000900383#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#55#51#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Res
ults</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HRE
F="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0
 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6947.htm##
00763000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704053500073002000900608#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#56#52#article#121#<P><font face="Arial, 
Helvetica, sans-serif">The average group responding indicated no preference for 
any of the bars during the stimulus-responding training, in which reinforced tar
getalone trials (T and H) for right or left responding were presented to the sub
jects. The subjects emitted responses in about 50% of the trials presented on th
e right bar in the last training session: the preference measures (S) were 0.45 
for ITI responding, (S) = 0.55 during T presentations, and (S) = 0.40 for H pres
entations. </font> </P>      ^cY#6947.htm##
00333000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704010500073002000900178#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#57#53#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><B>Conditional discrimination training</B> </font>      ^
cY#6947.htm##
00538000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704031000073002000900383#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#58#54#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><a href="#Fig1">Figures 1</a> and <a href="#Fig2">2</a> s
how the average percentages of events with responding during the last 10-session
 block of the serial FP conditional discrimination training. Only the first resp
onses emitted were considered. </font>      ^cY#6947.htm##
00944000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704071600073002000900789#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#59#55#article#121#<P><font face="Arial, 
Helvetica, sans-serif">The results show that training produced different control
 of the reinforcement schedule under NMTS and MTS. During this training, the sta
tistical effects of the reinforcement schedule (NMTS versus MTS, ANOVA F(1,4) = 
22.64007, P &lt; 0.01) and stimulus (F(7,28) = 37.55464, P &lt; 0.0025) were sig
nificant. Also, statistically significant interaction effects of topography of r
esponse versus reinforcement schedule (F(1,4) = 12.07807, P &lt; 0.01), reinforc
ement schedule versus stimulus (F(7,28) = 5.98532, P &lt; 0.01) and an interacti
on among topography of response, reinforcement schedule and stimulus (F(7,28) = 
2.43187, P &lt; 0.05) were obtained. </font>      ^cY#6947.htm##
00831000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704060300073002000900676#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#60#56#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><I>Non-matching-to-sample trials</I>. <a href="#Fig1">Fig
ure 1</a> shows the performance of the subjects during NMTS trials. ANOVA showed
 statistically significant effects of topography of response (F(1,4) = 9.90431, 
P &lt; 0.03) and stimulus (F(7,28) = 32.52515, P &lt; 0.01). <I>Post hoc</I> com
parisons showed that right-bar responding during T in W-LB<font face="Symbol">&#
174;</font>Tr+ and left-bar responding during T in W-RB<font face="Symbol">&#174
;</font>Tl+ were higher than responding during T-, suggesting T+/T- discriminati
on. </font>      ^cY#6947.htm##
01064000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704083600073002000900909#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#61#57#article#121#<P><font face="Arial, 
Helvetica, sans-serif">Analysis of topography of response effects confirmed the 
acquisition of T+/T- discrimination and right-bar responding discrimination in N
MTS trials: right-bar responding was higher during gaps and reinforced targets t
han in target-alone trials (topography of response and stimulus effects (ANOVA):
 F(1,4) = 8.2997369, P &lt; 0.04 and F(4,16) = 71.46719, P &lt; 0.01, respective
ly). A <I>post hoc</I> comparison showed that there was higher responding on the
 right than the left bar during T in W-LB&#174;Tr+ trials, but no differential t
opography responding during T in W-RB<font face="Symbol">&#174;</font>Tl+ trials
. Thus, an excitatory component for right-bar responding during targets preceded
 by composite features seems to have had an important effect on NMTS trials. </f
ont>      ^cY#6947.htm##
00819000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704059100073002000900664#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#62#58#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><I>Matching-to-sample trials</I>. <a href="#Fig2">Figure 
2</a> shows the performance of the subjects during MTS trials. A statistically s
ignificant effect of stimulus (F(7,28) = 26.625, P &lt; 0.01) was obtained. The 
<I>post hoc</I> test revealed acquisition of H+/H- discrimination, with a statis
tically significant higher right-bar responding during H+ than during H- in P-RB
<font face="Symbol">&#174;</font>Hr+ trials and higher left-bar responding durin
g H+ than during H- in P-LB<font face="Symbol">&#174;</font>Hl+ trials. </font> 
     ^cY#6947.htm##
00817000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704058900073002000900662#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#63#59#article#121#<P><font face="Arial, 
Helvetica, sans-serif">Analysis of the topography of the response effect confirm
ed the acquisition of H+/H- discrimination and right-bar responding discriminati
on in MTS trials: right-bar responding was higher during gaps and reinforced tar
gets than in target-alone trials (stimulus effect (ANOVA): F(4,16) = 36.19047, P
 &lt; 0.01) in both P-RB<font face="Symbol">&#174;</font>Hr+ and P-LB<font face=
"Symbol">&#174;</font>Hl+ trials. As also observed in NMTS trials, there seemed 
to be the effect of an excitatory component for right-bar responding. </font>   
   ^cY#6947.htm##
00312000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704008400073002000900157#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#64#60#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><B>Transfer tests</B> </font>      ^cY#6947.htm##
00621000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704039300073002000900466#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#65#61#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><I>Transfer tests 1 and 4</I>. <a href="#Fig3">Figure 3</
a> shows the data for both transfer tests 1 and 4, in which features used in NMT
S training (W-LB and W-RB) preceded H, used in MTS training. A statistically sig
nificant effect of stimulus (ANOVA) was observed for responding during trials (F
(11,44) = 9.768233, P &lt; 0.01). </font>      ^cY#6947.htm##
00758000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704053000073002000900603#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#66#62#article#121#<P><font face="Arial, 
Helvetica, sans-serif">Although stimulus effects were obtained for W-LB<font fac
e="Symbol">&#174;</font>H- (F(6,24) = 21.01873, P &lt; 0.01, ANOVA), and W-RB<fo
nt face="Symbol">&#174;</font>H- (F(6,24) = 5.791271, P &lt; 0.01, ANOVA) trials
, and a response topography effect was obtained for W-RB&#174;H- (F(1,6) = 13.38
562, P &lt; 0.02), <I>post hoc</I> comparisons did not show transfer effects, si
nce responding did not differ statistically during targets preceded by composite
 features. </font>      ^cY#6947.htm##
00628000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704040000073002000900473#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#67#63#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><I>Transfer tests 2 and 3</I>. <a href="#Fig4">Figure 4</
a> shows the data for transfer tests 2 and 3, in which the features used in MTS 
training (P-RB and P-LB) preceded T, used in NMTS training. The stimulus effect 
was significant for responding during trials (F(11,44) = 6.943789, P &lt; 0.01, 
ANOVA), but not for response topography. </font>      ^cY#6947.htm##
00588000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704036000073002000900433#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#68#64#article#121#<P><font face="Arial, 
Helvetica, sans-serif">Although stimulus effects were obtained for responding du
ring both P-RB&#174;T- and P-LB&#174;T- trials (F(6,24) = 6.995025, P &lt; 0.01 
and F(6,24) = 9.942094, P &lt; 0.01, respectively, ANOVA), no other statisticall
y significant differential responding was observed that could indicate transfer.
 </font>      ^cY#6947.htm##
00770000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704054200073002000900615#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#69#65#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><I>Transfer test 5</I>. <a href="#Fig5">Figure 5</a> show
s the data for transfer test 5, in which features used in both NMTS and MTS trai
ning preceded C, a new stimulus which had not been applied in prior training. St
atistical significance was obtained for response topography (F(1,4) = 11.57789, 
P &lt; 0.03) and stimulus (F(8,32) = 14.40376, P &lt; 0.01). A significant inter
action effect of response topography and stimulus was also obtained (F(8,32) = 3
.443478, P &lt; 0.01). </font>      ^cY#6947.htm##
00950000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704072200073002000900795#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#70#66#article#121#<P><font face="Arial, 
Helvetica, sans-serif">Although a statistically significant stimulus effect was 
obtained for W-LB<font face="Symbol">&#174;</font>C- (F(4,16) = 8.647058, P &lt;
 0.01), and effects of response topography (F(1,4) = 10.90566, P &lt; 0.03) and 
stimulus (F(4,16) = 4.78049, P &lt; 0.01) were obtained for W-RB<font face="Symb
ol">&#174;</font>C-, <I>post hoc</I> comparisons did not show transfer effects. 
In fact, responding during these trials only suggested the effect of a strong, e
xcitatory association of right-bar responding during targets preceded by NMTS fe
atures since <I>post hoc</I> comparisons showed higher right- than left-bar resp
onding during C preceded by W-LB and W-RB. </font>      ^cY#6947.htm##
01190000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704096200073002000901035#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#71#67#article#121#<P><font face="Arial, 
Helvetica, sans-serif">Similar accounts can be made for responding during trials
 that used MTS features. During P-RB<font face="Symbol">&#174;</font>C- trials, 
although the figure suggests high right-bar responding during C, no statistical 
effects were obtained. During P-LB<font face="Symbol">&#174;</font>C-, ANOVA sho
wed significant effects for response topography (F(1,4) = 10.59459, P &lt; 0.03)
, stimulus (F(4,16) = 12.88889, P &lt; 0.01) and response topography and stimulu
s interaction (F(4,16) = 13.67442, P &lt; 0.01). However, <I>post hoc</I> compar
isons showed only higher right- than left-bar responding during C preceded by P-
RB and P-LB.</font>   <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  bo
rder="0">    <tr align="left" valign="top">      <td width="14%"><a href="/img/r
evistas/bjmbr/v41n2/html/6947i01.htm"><img src="/img/revistas/bjmbr/v41n2/6947i0
1peq.jpg" border="2"></a></td>      <td width="86%">    ^cY#6947.htm##
00913000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704068500073002000900758#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#72#68#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig1"></a>Figure 1. Percentage of events with re
sponding during non-matching-to-sample (NMTS) stimulus conditional discriminatio
n trials in the last 10 training sessions (N = 5). <I>A</I>, Responding during W
-LB<font face="Symbol">&#174;</font>Tr+ and T- trials. <I>B</I>, Responding duri
ng W-RB<font face="Symbol">&#174;</font>Tl+ and T- trials. W = 5-s white noise p
resentation; RB/LB = 5-s right/left bar light presentation; <font face="Symbol">
&#174;</font> = 10-s temporal gap; T = 5-s tone presentation; r/l = right-left b
ar-pressing response; +/- = reinforcement/non-reinforcement.</font>  </td>    </
tr>  </table>      ^cY#6947.htm##
00615000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038700073002000900460#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#73#69#article#121#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (58 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/v
41n2/html/6947i02.htm"><img src="/img/revistas/bjmbr/v41n2/6947i02peq.jpg" borde
r="2"></a></td>      <td width="86%">    ^cY#6947.htm##
00920000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704069200073002000900765#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#74#70#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig2"></a>Figure 2. Percentage of events with re
sponding during matching-to-sample (MTS) stimulus conditional discrimination tri
als in the last 10 training sessions (N = 5). <I>A</I>, Responding during P-RB<f
ont face="Symbol">&#174;</font>Hr+ and H- trials. <I>B</I>, Responding during P-
LB<font face="Symbol">&#174;</font>Hl+ and H- trials. P = 5-s panel light presen
tation; RB/LB = 5-s right/left bar light presentation; <font face="Symbol">&#174
;</font> = 10-s temporal gap; H = 5-s house light presentation; r/l = right-left
 bar-pressing response; +/- = reinforcement/non-reinforcement. </font>      </td
>    </tr>  </table>      ^cY#6947.htm##
00615000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038700073002000900460#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#75#71#article#121#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (59 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/v
41n2/html/6947i03.htm"><img src="/img/revistas/bjmbr/v41n2/6947i03peq.jpg" borde
r="2"></a></td>      <td width="86%">    ^cY#6947.htm##
01094000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704086600073002000900939#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#76#72#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig3"></a>Figure 3. Percentage of events with re
sponding during conditional discrimination trials in transfer tests 1 and 4 (N =
 5). <I>A</I>, Responding during W-LB<font face="Symbol">&#174;</font>H-, T (pre
ceded by W-LB<font face="Symbol">&#174;</font>), and T-/H- target-alone trials. 
<I>B</I>, Responding during W-RB<font face="Symbol">&#174;</font>H-,T (preceded 
by W-RB<font face="Symbol">&#174;</font>), and T-/H- target-alone trials. W = 5-
s white noise presentation; RB/LB = 5-s right/left bar light presentation; <font
 face="Symbol">&#174;</font> = 10-s temporal gap; H = 5-s house light presentati
on; (W-LB/W-LR)T = 5-s tone presentation, preceded by W-LB<font face="Symbol">&#
174;</font> or W-RB<font face="Symbol">&#174;</font>; - = non-reinforcement. </f
ont>      </td>    </tr>  </table>      ^cY#6947.htm##
00615000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038700073002000900460#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#77#73#article#121#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (62 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/v
41n2/html/6947i04.htm"><img src="/img/revistas/bjmbr/v41n2/6947i04peq.jpg" borde
r="2"></a></td>      <td width="86%">    ^cY#6947.htm##
01094000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704086600073002000900939#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#78#74#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig4"></a>Figure 4. Percentage of events with re
sponding during conditional discrimination trials in transfer tests 2 and 3 (N =
 5). <I>A</I>, Responding during P-RB<font face="Symbol">&#174;</font>T-, H (pre
ceded by P-RB<font face="Symbol">&#174;</font>), and H-/T- target-alone trials. 
<I>B</I>, Responding during P-LB<font face="Symbol">&#174;</font>T-,H (preceded 
by P-LB<font face="Symbol">&#174;</font>), and H-/T- target-alone trials. P = 5-
s panel light presentation; RB/LB = 5-s right/left bar light presentation; <font
 face="Symbol">&#174;</font> = 10-s temporal gap; T = 5-s tone presentation; (P-
RB/P-LB)H = 5-s house light presentation, preceded by P-RB<font face="Symbol">&#
174;</font> or P-LB<font face="Symbol">&#174;</font>; - = non-reinforcement. </f
ont>      </td>    </tr>  </table>      ^cY#6947.htm##
00615000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704038700073002000900460#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#79#75#article#121#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (63 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/v
41n2/html/6947i05.htm"><img src="/img/revistas/bjmbr/v41n2/6947i05peq.jpg" borde
r="2"></a></td>      <td width="86%">    ^cY#6947.htm##
01074000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704084600073002000900919#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#80#76#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><a name="Fig5"></a>Figure 5. Percentage of events with re
sponding during conditional discrimination trials in transfer test 5 (N = 5). <I
>Top</I>, Responding during W-LB<font face="Symbol">&#174;</font>C- (left panel)
, W-RB<font face="Symbol">&#174;</font>C- (right panel) and T- target-alone tria
ls. <I>Bottom</I>, Responding during P-RB<font face="Symbol">&#174;</font>C- (le
ft panel), P-LB<font face="Symbol">&#174;</font>C- (right panel) and H- target-a
lone trials. W = 5-s white noise presentation; RB/LB = 5-s right/left bar light 
presentation; <font face="Symbol">&#174;</font> = 10-s temporal gap; P = 5-s pan
el light presentation; C = 5-s clicker presentation; T = 5-s tone presentation; 
H = 5-s house light presentation; - = non-reinforcement. </font>      </td>    <
/tr>  </table>      ^cY#6947.htm##
00734000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704050600073002000900579#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#81#77#article#121#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (77 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/v
41n2/html/6947t01.htm"><img src="/img/revistas/bjmbr/v41n2/table.jpg" border="2"
></a></td>      <td width="86%"><font face="Arial, Helvetica, sans-serif"><a nam
e="Tab1"></a>Table 1. Experimental design. </font></td>    </tr>  </table>      
^cY#6947.htm##
00346000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704011800073002000900191#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#82#78#article#121#<P><font face="Arial, 
Helvetica, sans-serif">[View larger version of this image (200 K JPG file)]</fon
t></P>      ^cY#6947.htm##
00276000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704004800073002000900121#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#83#79#article#121#<P>  <HR ALIGN=LEFT WI
DTH=100% SIZE=2>      ^cY#6947.htm##
00498000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704027000073002000900343#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#84#80#article#121#<P> <font face="Arial,
 Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007
F><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n
2/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  
    ^cY#6947.htm##
00332000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704010400073002000900177#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#85#81#article#121#<P><b><font face="Aria
l, Helvetica, sans-serif">Conditional discrimination training</font></b>      ^c
Y#6947.htm##
00650000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704042200073002000900495#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#86#82#article#121#<P><font face="Arial, 
Helvetica, sans-serif">The present results suggest acquisition of conditional di
scrimination. Although there was responding in all cases, the data show differen
tial responding during trials, that is, higher responding during target presenta
tion in composite trials. Also, there was more responding during target presenta
tion in composite than in single trials for both NMTS and MTS. </font>      ^cY#
6947.htm##
01406000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704117800073002000901251#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#87#83#article#121#<P><font face="Arial, 
Helvetica, sans-serif">Discrimination of topography, that is, higher responding 
during reinforced topography in composite trials, would indicate acquisition of 
NMTS or MTS. The data show that such discrimination occurred only for reinforced
 right-bar responding in NMTS trials in which significant right-bar responding w
as observed during target presentation in W-LB<font face="Symbol">&#174;</font>T
r+ composite trials. As the composite features had both conditional discriminati
on properties (related to the excitatory associations) and reinforced response t
opography ambiguity, it may have been harder to obtain full acquisition. Holland
 and Reeve (15) did not observe difficulties in acquisition, although trials wit
h ambiguous features were presented to the subjects. Bueno and Moreira (16), how
ever, did report such difficulty. Although there are differences between the stu
dy by Bueno and Moreira (16) and the present study, both can be considered proce
dures in which ambiguous targets were used, which made the procedure more comple
x, resulting in the incomplete acquisition observed, even with a high number of 
training sessions. </font>      ^cY#6947.htm##
01324000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704109600073002000901169#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#88#84#article#121#<P><font face="Arial, 
Helvetica, sans-serif">Besides the complexity of the procedure itself, propertie
s of the stimuli can also account for the results observed. Both NMTS and MTS tr
ials used features and targets of the same modality (in NMTS trials, W and T wer
e auditory stimuli, and in MTS trials, all stimuli were visual). Schmajuk et al.
 (6) pointed out that such arrangement can make acquisition harder due to a gene
ralization of stimulus properties that makes it more difficult to change the ini
tial feature-unconditional stimulus excitatory associations to inhibitory ones. 
Also, auditory events are known to be more salient than visual ones for rats, ma
king it easier to elicit more complex associations than simple conditioning ones
 (also discussed in Ref. 17). Nevertheless, the arrangement, although complex, p
roduced learning, facilitating the acquisition of complex associations by the ch
aracteristics of the procedure itself, such as the temporal arrangement (3,5,6,1
8), and the salience of stimuli, which may have facilitated acquisition of NMTS 
compared to MTS. </font>      ^cY#6947.htm##
01005000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704077700073002000900850#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#89#85#article#121#<P><font face="Arial, 
Helvetica, sans-serif">Besides the intrinsic properties of the stimuli or the ar
rangement, training itself produced representation of the stimuli and, especiall
y, the relations among them. During the temporal gap, an increase of responding 
was found, as previously reported (11,12), suggesting a prospective, occasion-se
tting strategy. This performance can also be discussed as the result of a config
urational strategy (5), in terms of an association of the temporal gap and targe
t as a configurational stimulus. In terms of the configurational hypothesis, an 
inhibitory output related to target units would have been masked by the excitato
ry properties of a temporal-gap/target unit activated by the presentation of a c
omposite feature. </font>      ^cY#6947.htm##
00993000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704076500073002000900838#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#90#86#article#121#<P><font face="Arial, 
Helvetica, sans-serif">This discussion was also proposed by Caserta-Gon (11), su
pporting a configurational hypothesis to account for the data observed in her st
udy as well as in the present experiment. However, Pearce (5) postulated in his 
model that a configuration is set between feature and target, which is different
 from what seems to have occurred in the present study. It should also be noted 
that most of the data supporting the configurational hypothesis resulted from si
multaneous and not serial conditional discrimination procedures, as previously p
ointed out by Caserta-Gon (11). A configuration of the temporal gap and the targ
et would imply considering more complex relations among the events in this proce
dure. </font>      ^cY#6947.htm##
01243000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704101500073002000901088#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#91#87#article#121#<P><font face="Arial, 
Helvetica, sans-serif">The implications of this argument support the hypothesis 
of Arnold et al. (9) when reporting higher order occasion setting. By using tria
ls in which three stimuli were presented (A<font face="Symbol">&#174;</font>B1<f
ont face="Symbol">&#174;</font>L+; B1<font face="Symbol">&#174;</font>L-; A<font
 face="Symbol">&#174;</font>B2<font face="Symbol">&#174;</font>L-; B2<font face=
"Symbol">&#174;</font>L+), they observed third-order relations between events. T
his means that L signaled the moment of reinforcement, but the excitatory or inh
ibitory properties of this target would be set by B1 or B2 presentations, which 
were first signaled by A. According to these investigators, the temporal gaps in
serted between stimuli could have favored the establishment of such relations, i
nstead of less complex, configurational relations (the importance of temporal fa
ctors in providing more complex conditioning is also discussed by the authors me
ntioned above). </font>      ^cY#6947.htm##
00897000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704066900073002000900742#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#92#88#article#121#<P><font face="Arial, 
Helvetica, sans-serif">Although a configurational hypothesis seems to account fo
r the results of the present study, the performance of subjects does not suggest
 a simple configuration, but third-order relations, in which the composite featu
re would inform the reinforcement schedule (W - NMTS; P - MTS) and the respectiv
e response topography (light bars) for the occasion of reinforcement (as suggest
ed by the data, the configurational stimulus temporal gap/target). Such relation
s seem to have occurred only for the reinforced right-bar response in NMTS trial
s, considering the properties of this arrangement as discussed above. </font>   
   ^cY#6947.htm##
01452000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704122400073002000901297#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#93#89#article#121#<P><font face="Arial, 
Helvetica, sans-serif">However, if representations of both topographies occurred
 for this arrangement, allowing the occurrence of acquisition, even more complex
 representations might have been made. Such representations would concern not on
ly the relation between the stimuli, but the representation of the two operant r
esponses. Consequently, data must be discussed in terms of a more complex model.
 Schmajuk et al. (6), mostly based on Pavlovian procedure data, proposed a neura
l network approach, unifying both the configurational and occasion setting hypot
heses. Short-term memory traces would be responsible for activating output units
 of conditioned-unconditioned configurational stimuli (which refer to unitary re
presentations of the events altogether), along with simple representations of ea
ch stimulus separately. As training occurs, excitatory and inhibitory associatio
ns would be set and discriminated, strengthening or weakening a certain CR-outpu
t unit. The strength of associations among input entries of conditioned configur
ational stimuli and output units of CR would account for the properties that a s
timulus would acquire (simple conditioning or occasion setting). </font>      ^c
Y#6947.htm##
01086000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704085800073002000900931#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#94#90#article#121#<P><font face="Arial, 
Helvetica, sans-serif"> According to this model, it is possible that the strengt
h of the associations of the composite feature W-LB with the reinforcement allow
ed a configurational stimulus temporal-gap/T to acquire a strong excitatory comp
onent due to the temporal arrangement and the salience of the stimuli used in th
is trial. Since such relations occurred only for right-bar responding, the compl
exity of the procedure might have not allowed complete learning, favoring a gene
ralization of right-bar responding in order to optimize performance during a com
plex task. So, even with an incomplete acquisition of response-topography discri
mination, the performance suggests complex, third-order relations among the even
ts and the simultaneous use of configurational strategies, supporting the neural
 network approach. </font>      ^cY#6947.htm##
00647000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704041900073002000900492#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#95#91#article#121#<P><font face="Arial, 
Helvetica, sans-serif">Also, the possibility of a primary association between fe
ature and operant response cannot be ruled out, considering the tendency to incr
easing responding during the course of the trial. Nevertheless, it is relatively
 difficult to evaluate the relative contributions of the complex feature and the
 other elements of the compound trials to response control. </font>      ^cY#694
7.htm##
00312000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704008400073002000900157#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#96#92#article#121#<P><font face="Arial, 
Helvetica, sans-serif"><B>Transfer tests</B> </font>      ^cY#6947.htm##
01015000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704078700073002000900860#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#97#93#article#121#<P><font face="Arial, 
Helvetica, sans-serif">In order to evaluate the nature of the representations ac
quired during training, responding during the transfer tests must be discussed. 
During tests 1 and 4, features of NMTS preceded targets used in MTS training. Re
sponding to H preceded by W-LB and W-RB suggests that the composite features kep
t their associations with T at a certain level, although an effect of extinction
 seems to have masked any possible transfer, which indeed did not occur. No diff
erential, statistically significant responding was observed, not even between re
sponding during target in composite and single trials. This result contrasts wit
h data observed during conditional discrimination training, where this different
ial responding was observed.</font>      ^cY#6947.htm##
00933000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704070500073002000900778#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#98#94#article#121#<P><font face="Arial, 
Helvetica, sans-serif">In addition, unexpected high right-bar responding was obs
erved during W-RB<font face="Symbol">&#174;</font>H- trials, suggesting generali
zation of responding in this topography as a strategy to optimize performance in
 a too complex procedure. Thus, the incomplete acquisition of prior training mig
ht have been affected by the occurrence of different trials, favoring less compl
ex associations, in this case, excitatory associations with right-bar responding
 during composite trials. On the other hand, the lack of transfer observed suppo
rts the hypothesis of the acquisition of complex representations of the stimuli 
during previous training. </font>      ^cY#6947.htm##
01742000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000400069704151400073002000901587#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#99#95#article#121#<P><font face="Arial, 
Helvetica, sans-serif">Similar comments can be made for the data obtained in tes
ts 2 and 3. In these tests, MTS features preceded the targets used in NMTS trial
s. Although no statistically significant differential responding was found, high
 right-bar responding was observed during target presentation in all composite f
eatures, including P-LB<font face="Symbol">&#174;</font>H- and P-RB<font face="S
ymbol">&#174;</font>T- trials, where such data were not expected. On the one han
d, a certain level of transfer of P-RB to T can be suggested; however, the data 
of tests 1 and 4 support the hypothesis of effects of both extinction and genera
lization of right-bar responding. So, the separate excitatory components of both
 PRB and T (or a configurational stimulus temporal gap/T) might have strengthene
d the right-bar CR output since the complexity of the procedure might have favor
ed simpler strategies. It must also be noted that incomplete topography acquisit
ion was observed for MTS in prior training. Excitatory components of feature rep
resentations might have not acquired specific associations with H. The sum of th
e excitatory components of the composite features and T (during which better per
formance, and thus, more complex representations were observed) can explain the 
data obtained in tests 2 and 3. Thus, the effects of extinction reached the repr
esentations that were less established, that is, NMTS third-order relations and 
the incomplete acquisition of MTS. </font>      ^cY#6947.htm##
00908000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704067900074002000900753#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#100#96#article#121#<P><font face="Arial,
 Helvetica, sans-serif">The lack of transfer between NMTS and MTS supports the d
ata reported by Bueno and Croisfelts (12), who also did not observe transfer bet
ween feature-positive conditional discriminations. However, statements based on 
these data should be considered with caution given the number of subjects and in
complete acquisition observed both in the study by Bueno and Croisfelts (12) and
 in the present study. Nevertheless, the data observed contrast with the neural 
network approach proposed by Schmajuk et al. (6), which postulates that transfer
 between occasion setters occurs more easily than in response to a new stimulus.
 </font>      ^cY#6947.htm##
01052000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704082300074002000900897#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#101#97#article#121#<P><font face="Arial,
 Helvetica, sans-serif">The implications of this argument must also consider the
 data of test 5, in which a new auditory stimulus was presented after the compos
ite features. An overview of the data shows no transfer of the original properti
es of the composite features to C. In addition, there was unexpected higher righ
t-bar responding during trials in which left-bar responding was more likely to o
ccur. Right-bar responding during C in W-RB<font face="Symbol">&#174;</font>C- a
nd P-LB<font face="Symbol">&#174;</font>C- trials was differential for topograph
y in the former and when compared with T- and H- presentations for both composit
e trials. It should be observed that extinction seriously affected left-bar resp
onding, indicating a right-bar responding optimization strategy. </font>      ^c
Y#6947.htm##
00636000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704040700074002000900481#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#102#98#article#121#<P><font face="Arial,
 Helvetica, sans-serif">The procedure adopted was very complex, but allowed a ce
rtain acquisition. The data suggest that rats can acquire complex tasks if conti
ngencies are handled better in order to allow increasingly complex information p
rocessing. Thus, other experiments should be designed in order to test previous 
preparation that could facilitate such training. </font>      ^cY#6947.htm##
01903000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000400070704167400074002000901748#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#103#99#article#121#<P><font face="Arial,
 Helvetica, sans-serif">The lack of transfer for stimuli that were part of other
 conditional discriminations contrasts with the neural network approach (6), as 
pointed out above. The lack of transfer to a new stimulus, however, supports thi
s model, in contrast to the study by Caserta-Gon (11), who observed transfer to 
a new stimulus using both feature-positive and -negative discriminations. Bueno 
and Croisfelts (12) observed a similar effect of transfer, although more diffuse
 in terms of topography responding. The hypothesis that arises from the data of 
the present study indicates some questions which could not have been well discus
sed due to the data obtained. Would different modalities of stimuli have favored
 NMTS over MTS acquisition? How accurate was responding during the transfer test
s? The use of more subjects, counterbalancing groups and better prior training t
o the conditional discrimination should be considered in order to test the hypot
hesis proposed in the present study. Both Caserta-Gon (11) and Bueno and Croisfe
lts (12) have used procedures involving different topography operant responses; 
however, the use of a similar, although more complex procedure is relatively new
 in the literature (compare with Ref. 9). Thus, the complexity of this procedure
 can be a way to test variables that could soften the theories about conditional
 discrimination learning, especially the neural network approach, which does not
 offer a discussion about other schedules presented at the same time as in the c
lassical conditional discrimination design (in the present study, NMTS and MTS).
 </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6947.htm##
00546000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704031600075002000900391#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#104#100#article#121#<P><font face="Arial
, Helvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><
B>References</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif
"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM 
BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6947.htm##
00541000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704029700077002000900374#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#p#105#101#article#121#1#<P><fo
nt face="Arial, Helvetica, sans-serif">1. Jenkins HM, Sainsbury RS. The developm
ent of stimulus control through differential reinforcement. In: Mackintosh NJ, H
onig WK (Editors), <I>Fundamental issues in associative learning</I>. Hallifax: 
Dalhousie University Press; 1969. </font>      ^cY#6947.htm##
00489000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704024500077002000900322#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#p#106#102#article#121#2#<P><fo
nt face="Arial, Helvetica, sans-serif">2. Rescorla RA. Inhibition and facilitati
on. In: Miller RR, Spear NE (Editors), <I>Information processing in animals: Con
ditioned inhibition</I>. Hillsdale: Erlbaum; 1985. p 299-326. </font>      ^cY#6
947.htm##
00489000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704024500077002000900322#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#p#107#103#article#121#3#<P><fo
nt face="Arial, Helvetica, sans-serif">3. Holland PC. Occasion setting in Pavlov
ian conditioning. In: Medin DL (Editor), <I>The psychology of learning and motiv
ation</I>. Vol. 28. New York: Academic Press; 1992. p 69-125. </font>      ^cY#6
947.htm##
00446000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704020200077002000900279#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#p#108#104#article#121#4#<P><fo
nt face="Arial, Helvetica, sans-serif">4. Ross RT, Holland PC. Conditioning of s
imultaneous and serial feature positive discriminations. <I>Anim Learn Behav</I>
 1981; 9: 139-303. </font>      ^cY#6947.htm##
00436000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704019200077002000900269#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#p#109#105#article#121#5#<P><fo
nt face="Arial, Helvetica, sans-serif">5. Pearce JM. Similarity and discriminati
on: a selective review and a connectionist model. <I>Psychol Rev</I> 1994; 101: 
587-607. </font>      ^cY#6947.htm##
00429000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704018500077002000900262#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#p#110#106#article#121#6#<P><fo
nt face="Arial, Helvetica, sans-serif">6. Schmajuk NA, Lamoureux JA, Holland PC.
 Occasion setting: a neural network approach. <I>Psychol Rev</I> 1998; 105: 3-32
. </font>      ^cY#6947.htm##
00441000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704019700077002000900274#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#p#111#107#article#121#7#<P><fo
nt face="Arial, Helvetica, sans-serif">7. Colwill RM, Rescorla RA. Evidence for 
the hierarchical structure of instrumental learning. <I>Anim Learn Behav</I> 199
0; 18: 71-82. </font>      ^cY#6947.htm##
00469000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704022500077002000900302#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#p#112#108#article#121#8#<P><fo
nt face="Arial, Helvetica, sans-serif">8. Holland PC. Transfer of occasion setti
ng across stimulus and response in operant serial feature-positive discriminatio
ns. <I>Learn Motiv</I> 1995; 26: 239-263. </font>      ^cY#6947.htm##
00415000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000200075704017100077002000900248#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#p#113#109#article#121#9#<P><fo
nt face="Arial, Helvetica, sans-serif">9. Arnold HM, Grahame NJ, Miller RR. High
er order occasion setting. <I>Anim Learn Behav</I> 1991; 19: 58-64. </font>     
 ^cY#6947.htm##
00463000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704021800078002000900296#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#p#114#110#article#121#10#<P><f
ont face="Arial, Helvetica, sans-serif">10. Goddard MJ, Holland PC. Type of feat
ure affects transfer in operant serial feature-positive discriminations. <I>Anim
 Learn Behav</I> 1996; 24: 266-276. </font>      ^cY#6947.htm##
00575000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704033000078002000900408#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#p#115#111#article#121#11#<P><f
ont face="Arial, Helvetica, sans-serif">11. Caserta-Gon MC. Respostas de rota&cc
edil;&atilde;o como &iacute;ndice de associa&ccedil;&otilde;es em procedimentos 
de discrimina&ccedil;&atilde;o condicional. [Master's thesis]: Faculdade de Filo
sofia, Ci&ecirc;ncias e Letras de Ribeir&atilde;o Preto, USP; 1994. </font>     
 ^cY#6947.htm##
00570000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704032500078002000900403#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#p#116#112#article#121#12#<P><f
ont face="Arial, Helvetica, sans-serif">12. Bueno JLO, Croisfelts H. Efeito de d
iferentes modalidades de est&iacute;mulos em procedimentos de discrimina&ccedil;
&atilde;o condicional. <I>V Congresso Interno do N&uacute;cleo de Pesquisa em Ne
uroci&ecirc;ncias e Comportamento</I>. 1995. p 120 (Abstract). </font>      ^cY#
6947.htm##
00527000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704028200078002000900360#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#p#117#113#article#121#13#<P><f
ont face="Arial, Helvetica, sans-serif">13. Homem AJM. Interface para controles 
externos de caixas de experimentos de ratos via computador. <I>V Congresso Inter
no do N&uacute;cleo de Pesquisa em Neuroci&ecirc;ncias e Comportamento</I>. 1995
. p 128 (Abstract). </font>      ^cY#6947.htm##
00477000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704023200078002000900310#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#p#118#114#article#121#14#<P><f
ont face="Arial, Helvetica, sans-serif">14. Donzelli CAF, Croisfelts H, Bueno JL
O. Programa CONTEXP para controle experimental de pesquisa em comportamento anim
al. <I>Psicol Teoria Pesq</I> 1998; 14: 267-269. </font>       ^cY#6947.htm##
00439000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704019400078002000900272#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#p#119#115#article#121#15#<P><f
ont face="Arial, Helvetica, sans-serif">15. Holland PC, Reeve CE. Acquisition   
 and transfer of control by an ambiguous cue. <I>Anim Learn Behav</I> 1991; 19: 
   113-124. </font>      ^cY#6947.htm##
00432000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704018700078002000900265#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#p#120#116#article#121#16#<P><f
ont face="Arial, Helvetica, sans-serif">16. Bueno JLO, Moreira RCM. Conditional 
discrimination: the role of CS-alone trials. <I>Behav Processes</I> 1998; 42: 33
-45. </font>      ^cY#6947.htm##
00436000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704019100078002000900269#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#p#121#117#article#121#17#<P><f
ont face="Arial, Helvetica, sans-serif">17. Holland PC. Occasion setting with si
multaneous compounds in rats. <I>J Exp Psychol Anim Behav Process</I> 1989; 15: 
183-193. </font>      ^cY#6947.htm##
00512000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071888000300075704026700078002000900345#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#p#122#118#article#121#18#<P><f
ont face="Arial, Helvetica, sans-serif">18. Holland PC, Hamlin PA, Parsons JP. T
emporal specificity in serial feature-positive discrimination learning. <I>J Exp
 Psychol Anim Behav Process</I> 1997; 23: 95-109.</font>   <HR ALIGN=LEFT WIDTH=
100% SIZE=2>      ^cY#6947.htm##
00566000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704033600075002000900411#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#123#119#article#121#<P><FONT SIZE=4 face
="Arial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F
><B>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, H
elvetica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6947
.htm##
00635000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704040500075002000900480#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#124#120#article#121#<p><font face="Arial
, Helvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v41n2/
recor.gif" border="0"></a> Address for correspondence:</b>  J.L.O. Bueno, Setor 
de Psicobiologia, Departamento de Psicologia e Educa&ccedil;&atilde;o, FFCLRP, U
SP, 14049-900 Ribeir&atilde;o Preto, SP, Brasil. E-mail: <a href="mailto:jldobue
n@ffclrp.usp.br">jldobuen@ffclrp.usp.br</a></font> </p>      ^cY#6947.htm##
00488000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000400059709000800063708000400071704025800075002000900333#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6947.htm#S#p#125#121#article#121#<P><font face="Arial
, Helvetica, sans-serif">J.L.O. Bueno was the recipient of a CNPq Productivity S
cholarship (#304988/2005-7). Research supported by a CNPq research grant (#47549
0/2006-1). Received June 21, 2007. Accepted December 4, 2007.</font>      ^cY#69
47.htm##
00617000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100020000920120
07500112016002100187016001600208018004700224066000900271062002700280065000900307
064000500316865000900321002000900330#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
947.htm#S#c#126#1#article#18#1#^rND^sJenkins^nHM#^rND^sSainsbury^nRS#The develop
ment of stimulus control through differential reinforcement^len#^rND^sMackintosh
^nNJ#^rND^sHonig^nWK#Fundamental issues in associative learning^len#Hallifax#Dal
housie University Press#19690000#1969#20080200#6947.htm##
00556000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740120032000930160
01700125016001600142018006200158066001000220062000800230065000900238064000500247
014000800252865000900260002000900269#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
947.htm#S#c#127#2#article#18#2#^rND^sRescorla^nRA#Inhibition and facilitation^le
n#^rND^sMiller^nRR#^rND^sSpear^nNE#Information processing in animals: Conditione
d inhibition^len#Hillsdale#Erlbaum#19850000#1985#299-326#20080200#6947.htm##
00545000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740120047000920160
01600139018004600155031000300201066000900204062001500213065000900228064000500237
014000700242865000900249002000900258#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
947.htm#S#c#128#3#article#18#3#^rND^sHolland^nPC#Occasion setting in Pavlovian c
onditioning^len#^rND^sMedin^nDL#The psychology of learning and motivation^len#28
#New York#Academic Press#19920000#1992#69-125#20080200#6947.htm##
00548000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100015000740100018000890120
07700107030001700184065000900201064000500210031000200215014000800217865000900225
002000900234035001000243801001700253#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
947.htm#S#c#129#4#article#18#4#^rND^sRoss^nRT#^rND^sHolland^nPC#Conditioning of 
simultaneous and serial feature positive discriminations^len#Anim Learn Behav#19
810000#1981#9#139-303#20080200#6947.htm#0090-4996#Anim Learn Behav##
00515000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740120080000910300
01200171065000900183064000500192031000400197014000800201865000900209002000900218
035001000227801001200237#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#c#
130#5#article#18#5#^rND^sPearce^nJM#Similarity and discrimination: a selective r
eview and a connectionist model^len#Psychol Rev#19940000#1994#101#587-607#200802
00#6947.htm#0033-295X#Psychol Rev##
00544000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100019000740100020000930100
01800113012004800131030001200179065000900191064000500200031000400205014000500209
865000900214002000900223035001000232801001200242#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6947.htm#S#c#131#6#article#18#6#^rND^sSchmajuk^nNA#^rND^sLamoureux^nJ
A#^rND^sHolland^nPC#Occasion setting: a neural network approach^len#Psychol Rev#
19980000#1998#105#3-32#20080200#6947.htm#0033-295X#Psychol Rev##
00543000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100019000920120
06900111030001700180065000900197064000500206031000300211014000600214865000900220
002000900229035001000238801001700248#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
947.htm#S#c#132#7#article#18#7#^rND^sColwill^nRM#^rND^sRescorla^nRA#Evidence for
 the hierarchical structure of instrumental learning^len#Anim Learn Behav#199000
00#1990#18#71-82#20080200#6947.htm#0090-4996#Anim Learn Behav##
00548000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740120113000920300
01200205065000900217064000500226031000300231014000800234865000900242002000900251
035001000260801001200270#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#c#
133#8#article#18#8#^rND^sHolland^nPC#Transfer of occasion setting across stimulu
s and response in operant serial feature-positive discriminations^len#Learn Moti
v#19950000#1995#26#239-263#20080200#6947.htm#0023-9690#Learn Motiv##
00535000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100018000910100
01700109012003400126030001700160065000900177064000500186031000300191014000600194
865000900200002000900209035001000218801001700228#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6947.htm#S#c#134#9#article#18#9#^rND^sArnold^nHM#^rND^sGrahame^nNJ#^r
ND^sMiller^nRR#Higher order occasion setting^len#Anim Learn Behav#19910000#1991#
19#58-64#20080200#6947.htm#0090-4996#Anim Learn Behav##
00565000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100018000940120
08800112030001700200065000900217064000500226031000300231014000800234865000900242
002000900251035001000260801001700270#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
947.htm#S#c#135#10#article#18#10#^rND^sGoddard^nMJ#^rND^sHolland^nPC#Type of fea
ture affects transfer in operant serial feature-positive discriminations^len#Ani
m Learn Behav#19960000#1996#24#266-276#20080200#6947.htm#0090-4996#Anim Learn Be
hav##
00539000000000229000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730160022000760180098000980510
01600196050006500212045000900277044000500286865000900291002000900300#v41n2#v:\sc
ielo\serial\bjmbr\v41n2\markup\6947.htm#S#c#136#11#article#18#11#^rND^sCaserta-G
on^nMC#Respostas de rotação como índice de associações em procedimentos de discr
iminação condicional^lpt#Master's thesis#USP^dFaculdade de Filosofia, Ciências e
 Letras de Ribeirão Preto#19940000#1994#20080200#6947.htm##
00597000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100020000930120
09600113030007500209710000200284065000900286064000500295014000400300061000900304
865000900313002000900322#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#c#
137#12#article#18#12#^rND^sBueno^nJLO#^rND^sCroisfelts^nH#Efeito de diferentes m
odalidades de estímulos em procedimentos de discriminação condicional^lpt#V Cong
resso Interno do Núcleo de Pesquisa em Neurociências e Comportamento#2#19950000#
1995#120#Abstract#20080200#6947.htm##
00557000000000253000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760120088000930300
07500181710000200256065000900258064000500267014000400272061000900276865000900285
002000900294#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#c#138#13#artic
le#18#13#^rND^sHomem^nAJM#Interface para controles externos de caixas de experim
entos de ratos via computador^lpt#V Congresso Interno do Núcleo de Pesquisa em N
eurociências e Comportamento#2#19950000#1995#128#Abstract#20080200#6947.htm##
00559000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100020000960100
01700116012008400133030001900217710000200236065000900238064000500247031000300252
014000800255865000900263002000900272#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
947.htm#S#c#139#14#article#18#14#^rND^sDonzelli^nCAF#^rND^sCroisfelts^nH#^rND^sB
ueno^nJLO#Programa CONTEXP para controle experimental de pesquisa em comportamen
to animal^lpt#Psicol Teoria Pesq#2#19980000#1998#14#267-269#20080200#6947.htm##
00535000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940120
06000110030001700170065000900187064000500196031000300201014000800204865000900212
002000900221035001000230801001700240#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
947.htm#S#c#140#15#article#18#15#^rND^sHolland^nPC#^rND^sReeve^nCE#Acquisition a
nd transfer of control by an ambiguous cue^len#Anim Learn Behav#19910000#1991#19
#113-124#20080200#6947.htm#0090-4996#Anim Learn Behav##
00533000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100019000930120
06000112030001600172065000900188064000500197031000300202014000600205865000900211
002000900220035001000229801001600239#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
947.htm#S#c#141#16#article#18#16#^rND^sBueno^nJLO#^rND^sMoreira^nRCM#Conditional
 discrimination: the role of CS-alone trials^len#Behav Processes#19980000#1998#4
2#33-45#20080200#6947.htm#0376-6357#Behav Processes##
00536000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120057000940300
03300151065000900184064000500193031000300198014000800201865000900209002000900218
035001000227801003300237#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6947.htm#S#c#
142#17#article#18#17#^rND^sHolland^nPC#Occasion setting with simultaneous compou
nds in rats^len#J Exp Psychol Anim Behav Process#19890000#1989#15#183-193#200802
00#6947.htm#0097-7403#J Exp Psychol Anim Behav Process##
00613000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01800111012007600129030003300205065000900238064000500247031000300252014000700255
865000900262002000900271035001000280801003300290#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6947.htm#S#c#143#18#article#18#18#^rND^sHolland^nPC#^rND^sHamlin^nPA#
^rND^sParsons^nJP#Temporal specificity in serial feature-positive discrimination
 learning^len#J Exp Psychol Anim Behav Process#19970000#1997#23#95-109#20080200#
6947.htm#0097-7403#J Exp Psychol Anim Behav Process##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#o#1#1#article#1#20
080402#165808#6954.htm#124##
03107000000000601000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000400087121000300091049000900094158000300103030002000106
03100030012603200020012906500090013101400090014003500100014901201250015901000260
02840100025003100100022003350100027003570100028003840700154004120700062005660700
14800628083147800776085000802254085002902262085002502291085004802316085002602364
08500290239011700060241907200030242505800050242806000140243311200090244711100140
2456114000902470113001702479002000902496#v41n2#v:\scielo\serial\bjmbr\v41n2\mark
up\6954.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#TAB#02#BJMBR010#nd#Braz J Med Bi
ol Res#41#2#20080200#^f89^l94#0100-879X#Association of ApoE polymorphisms with p
revalent hypertension in 1406 older adults: the Bambuí Health Aging Study (BHAS)
^len#^rND^1A01^nA.K.^sFuzikawa#^rND^1A01^nS.V.^sPeixoto#^rND^1A02^nM.^sTaufer#^r
ND^1A03^nE.H.^sMoriguchi#^rND^1A01^nM.F.^sLima-Costa#Universidade Federal de Min
as Gerais^iA01^1Núcleo de Estudos em Saúde Pública e Envelhecimento (NESPE), Fun
dação Oswaldo Cruz^cBelo Horizonte^sMG^pBrasil#CMIC Brasil Pesquisas Clínicas^iA
02^cPorto Alegre^sRS^pBrasil#Hospital Moinhos de Vento de Porto Alegre^iA03^1Uni
versidade do Vale dos Sinos^2Universidade Federal do Rio Grande do Sul^cPorto Al
egre^sRS^pBrasil#^len^aApolipoprotein E (ApoE) polymorphism influences lipid met
abolism, but its association with arterial hypertension is controversial. The ob
jective of this study was to examine the association between ApoE polymorphism a
nd prevalent hypertension in a large unselected population of older adults. Part
icipants from the baseline of the Bambuí Health Aging Study whose ApoE genes had
 been genotyped were selected for this study (N = 1406, aged 60-95 years). These
 subjects represented 80.7% of the total elderly residents in Bambuí city, MG, B
razil. Hypertension was defined as a systolic blood pressure ³140 mmHg and/or a 
diastolic blood pressure ³90 mmHg, or the use of anti-hypertensive medication. T
he exposure variable was the ApoE genotype as follows: e3 carriers, e3e3; e2 car
riers, e2e2 or e2e3, and e4 carriers, e3e4 or e4e4. Potential confounding variab
les were age, gender, traditional cardiovascular risk factors, uric acid, and cr
eatinine levels. The prevalence of hypertension was 61.3%. Compared with the e3 
homozygotes, neither the e2 nor the e4 carrier status was associated with hypert
ension (adjusted prevalence ratios = 0.94, 95%CI = 0.83-1.07 and 0.98, 0.89-1.07
, respectively). On the other hand, the e2 allele carriers had lower LDL cholest
erol levels (P < 0.001) and the e4 carriers had higher LDL cholesterol levels (P
 = 0.036). This study provides epidemiologic evidence that the ApoE genotype is 
not associated with prevalent hypertension in old age.#^dnd^i1#^tm^len^kApolipop
rotein E^i1#^tm^len^kHypertension^i1#^tm^len^kLow-density lipoprotein cholestero
l^i1#^tm^len^kTriglycerides^i1#^tm^len^kLipid metabolism^i1#other#32#CNPq#470841
/2004-4#20070629#June 29, 2007#20071108#November 8, 2007#6954.htm##
03166000000000601000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000400087121000300091049000900094158000300103030002000106
03100030012603200020012906500090013101400090014003500100014901201460015901000260
03050100025003310100022003560100027003780100028004050700154004330700062005870700
14800649083151600797085000802313085002902321085002502350085004802375085002602423
08500290244911700060247807200030248405800050248706000140249211200090250611100140
2515114000902529113001702538002000902555#v41n2#v:\scielo\serial\bjmbr\v41n2\mark
up\6954.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#TAB#02#BJMBR010#nd#Braz J Med Bi
ol Res#41#2#20080200#^f89^l94#0100-879X#<b>Association of <i>ApoE</i> polymorphi
sms with prevalent hypertension in 1406 older adults</b>: <b>the Bambuí Health A
ging Study (BHAS)</b>^len#^rND^1A01^nA.K.^sFuzikawa#^rND^1A01^nS.V.^sPeixoto#^rN
D^1A02^nM.^sTaufer#^rND^1A03^nE.H.^sMoriguchi#^rND^1A01^nM.F.^sLima-Costa#Univer
sidade Federal de Minas Gerais^iA01^1Núcleo de Estudos em Saúde Pública e Envelh
ecimento (NESPE), Fundação Oswaldo Cruz^cBelo Horizonte^sMG^pBrasil#CMIC Brasil 
Pesquisas Clínicas^iA02^cPorto Alegre^sRS^pBrasil#Hospital Moinhos de Vento de P
orto Alegre^iA03^1Universidade do Vale dos Sinos^2Universidade Federal do Rio Gr
ande do Sul^cPorto Alegre^sRS^pBrasil#^len^aApolipoprotein E (<i>ApoE</i>) polym
orphism influences lipid metabolism, but its association with arterial hypertens
ion is controversial. The objective of this study was to examine the association
 between <i>ApoE</i> polymorphism and prevalent hypertension in a large unselect
ed population of older adults. Participants from the baseline of the Bambuí Heal
th Aging Study whose <i>ApoE </i>genes had been genotyped were selected for this
 study (N = 1406, aged 60-95 years). These subjects represented 80.7% of the tot
al elderly residents in Bambuí city, MG, Brazil. Hypertension was defined as a s
ystolic blood pressure ³140 mmHg and/or a diastolic blood pressure ³90 mmHg, or 
the use of anti-hypertensive medication. The exposure variable was the <i>ApoE</
i> genotype as follows: e3 carriers, e3e3; e2 carriers, e2e2 or e2e3, and e4 car
riers, e3e4 or e4e4. Potential confounding variables were age, gender, tradition
al cardiovascular risk factors, uric acid, and creatinine levels. The prevalence
 of hypertension was 61.3%. Compared with the e3 homozygotes, neither the e2 nor
 the e4 carrier status was associated with hypertension (adjusted prevalence rat
ios = 0.94, 95%CI = 0.83-1.07 and 0.98, 0.89-1.07, respectively). On the other h
and, the e2 allele carriers had lower LDL cholesterol levels (P &lt; 0.001) and 
the e4 carriers had higher LDL cholesterol levels (P = 0.036). This study provid
es epidemiologic evidence that the <i>ApoE</i> genotype is not associated with p
revalent hypertension in old age.#^dnd^i1#^tm^len^kApolipoprotein E^i1#^tm^len^k
Hypertension^i1#^tm^len^kLow-density lipoprotein cholesterol^i1#^tm^len^kTriglyc
erides^i1#^tm^len^kLipid metabolism^i1#other#32#CNPq#470841/2004-4#20070629#June
 29, 2007#20071108#November 8, 2007#6954.htm##
03263000000000625000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000400100121000300104049000900107158000300116
03000240011903100030014303200020014606500090014801400090015703500100016601201250
01760100026003010100025003270100021003520100027003730100028004000700156004280700
06400584070015000648083149900798085000802297085002902305085002502334085004802359
08500260240708500290243311700060246207200030246805800050247106000140247611200090
2490111001402499114000902513113001702522002000902539008008902548#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#l#4#1#article#1#^mFeb.^a2008#oa#en#bjmbr#1
#3.1#tab#02#BJMBR010#nd#Braz. j. med. biol. res#41#2#20080200#^f89^l94#0100-879X
#Association of ApoE polymorphisms with prevalent hypertension in 1406 older adu
lts: the Bambuí Health Aging Study (BHAS)^len#^rND^1A01^nA. K^sFuzikawa#^rND^1A0
1^nS. V^sPeixoto#^rND^1A02^nM^sTaufer#^rND^1A03^nE. H^sMoriguchi#^rND^1A01^nM. F
^sLima-Costa#^iA01^1Universidade Federal de Minas Gerais^2Núcleo de Estudos em S
aúde Pública e Envelhecimento (NESPE), Fundação Oswaldo Cruz^cBelo Horizonte^sMG
^pBrasil#^iA02^1CMIC Brasil Pesquisas Clínicas^cPorto Alegre^sRS^pBrasil#^iA03^1
Hospital Moinhos de Vento de Porto Alegre^2Universidade do Vale dos Sinos^3Unive
rsidade Federal do Rio Grande do Sul^cPorto Alegre^sRS^pBrasil#^len^aApolipoprot
ein E (ApoE) polymorphism influences lipid metabolism, but its association with 
arterial hypertension is controversial. The objective of this study was to exami
ne the association between ApoE polymorphism and prevalent hypertension in a lar
ge unselected population of older adults. Participants from the baseline of the 
Bambuí Health Aging Study whose ApoE genes had been genotyped were selected for 
this study (N = 1406, aged 60-95 years). These subjects represented 80.7 percent
 of the total elderly residents in Bambuí city, MG, Brazil. Hypertension was def
ined as a systolic blood pressure ³140 mmHg and/or a diastolic blood pressure ³9
0 mmHg, or the use of anti-hypertensive medication. The exposure variable was th
e ApoE genotype as follows: e3 carriers, e3e3; e2 carriers, e2e2 or e2e3, and e4
 carriers, e3e4 or e4e4. Potential confounding variables were age, gender, tradi
tional cardiovascular risk factors, uric acid, and creatinine levels. The preval
ence of hypertension was 61.3 percent. Compared with the e3 homozygotes, neither
 the e2 nor the e4 carrier status was associated with hypertension (adjusted pre
valence ratios = 0.94, 95 percentCI = 0.83-1.07 and 0.98, 0.89-1.07, respectivel
y). On the other hand, the e2 allele carriers had lower LDL cholesterol levels (
P < 0.001) and the e4 carriers had higher LDL cholesterol levels (P = 0.036). Th
is study provides epidemiologic evidence that the ApoE genotype is not associate
d with prevalent hypertension in old age.#^dnd^i1#^tm^len^kApolipoprotein E^i1#^
tm^len^kHypertension^i1#^tm^len^kLow-density lipoprotein cholesterol^i1#^tm^len^
kTriglycerides^i1#^tm^len^kLipid metabolism^i1#other#32#CNPq#470841/2004-4#20070
629#June 29, 2007#20071108#November 8, 2007#6954.htm#Internet^ihttp://www.scielo
.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000200002##
00373000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704014800070002000900218#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#5#1#article#88#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, February 2008, V
olume 41(2) 89-94</B> </font></P>      ^cY#6954.htm##
00438000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704021300070002000900283#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#6#2#article#88#<P><font size="5" face="A
rial, Helvetica, sans-serif"><B>Association of <I>ApoE</I> polymorphisms with pr
evalent hypertension in 1406 older adults: the Bambu&iacute; Health Aging Study 
(BHAS)</B> </font>      ^cY#6954.htm##
00679000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704045400070002000900524#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#7#3#article#88#<P><font face="Arial, Hel
vetica, sans-serif">A.K. Fuzikawa<SUP>1</SUP>, S.V. Peixoto<SUP>1</SUP>, M. Tauf
er<SUP>2</SUP>, E.H. Moriguchi<SUP>3</SUP> and <b><a href="#Correspondence"><img
 src="/img/revistas/bjmbr/v41n2/recor.gif" border="0"></a></b> <a href="mailto:l
ima-costa@cpqrr.fiocruz.br"><img src="/img/revistas/bjmbr/v41n2/email-ca.gif" bo
rder="0"></a> </font> <font face="Arial, Helvetica, sans-serif">M.F. Lima-Costa<
SUP>1</SUP> </font>      ^cY#6954.htm##
00474000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704024900070002000900319#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#8#4#article#88#<P><font face="Arial, Hel
vetica, sans-serif"><SUP>1</SUP>N&uacute;cleo de Estudos em Sa&uacute;de P&uacut
e;blica e Envelhecimento (NESPE), Funda&ccedil;&atilde;o Oswaldo Cruz, Universid
ade Federal de Minas Gerais, Belo Horizonte, MG, Brasil     ^cY#6954.htm##
00321000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704009600070002000900166#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#9#5#article#88#<br>        <SUP>2</SUP>C
MIC Brasil Pesquisas Cl&iacute;nicas, Porto Alegre, RS, Brasil     ^cY#6954.htm#
#
00410000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018400071002000900255#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#10#6#article#88#<br>        <SUP>3</SUP>
Universidade Federal do Rio Grande do Sul, Universidade do Vale dos Sinos, Hospi
tal Moinhos de Vento de Porto Alegre, Porto Alegre, RS, Brasil</font>       ^cY#
6954.htm##
00416000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704019000071002000900261#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#11#7#article#88#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n2/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>  
  ^cY#6954.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#12#8#article#88#<BR>   <A HREF="#Introdu
ction"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#6954.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#13#9#article#88#<BR>   <A HREF="#Materia
l"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    ^
cY#6954.htm##
00399000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704017200072002000900244#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#14#10#article#88#<BR>   <A HREF="#Result
s"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#6954.htm##
00408000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704018100072002000900253#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#15#11#article#88#<BR>   <A HREF="#Discus
sion"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#69
54.htm##
00395000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704016800072002000900240#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#16#12#article#88#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#6954.htm##
00461000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704023400072002000900306#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#17#13#article#88#<br>   </strong></A>   
<A HREF="#Correspondence"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspon
dence and Footnotes</strong></A>  </font>      ^cY#6954.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004800072002000900120#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#18#14#article#88#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>      ^cY#6954.htm##
00546000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031900072002000900391#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#19#15#article#88#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  <font
 face="Arial, Helvetica, sans-serif">  </font>      ^cY#6954.htm##
02409000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704218200072002000902254#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#20#16#article#88#<P><font face="Arial, H
elvetica, sans-serif">Apolipoprotein E (<I>ApoE</I>) polymorphism influences lip
id metabolism, but its association with arterial hypertension is controversial. 
The objective of this study was to examine the association between <I>ApoE</I> p
olymorphism and prevalent hypertension in a large unselected population of older
 adults. Participants from the baseline of the Bambu&iacute; Health Aging Study 
whose <I>ApoE </I>genes had been genotyped were selected for this study (N = 140
6, aged 60-95 years). These subjects represented 80.7% of the total elderly resi
dents in Bambu&iacute; city, MG, Brazil. Hypertension was defined as a systolic 
blood pressure <font face="Symbol">&#179;</font>140 mmHg and/or a diastolic bloo
d pressure <font face="Symbol">&#179;</font>90 mmHg, or the use of anti-hyperten
sive medication. The exposure variable was the <I>ApoE</I> genotype as follows: 
<font face="Symbol">e</font>3 carriers, <font face="Symbol">e</font>3<font face=
"Symbol">e</font>3; <font face="Symbol">e</font>2 carriers, <font face="Symbol">
e</font>2<font face="Symbol">e</font>2 or <font face="Symbol">e</font>2<font fac
e="Symbol">e</font>3, and <font face="Symbol">e</font>4 carriers, <font face="Sy
mbol">e</font>3<font face="Symbol">e</font>4 or <font face="Symbol">e</font>4<fo
nt face="Symbol">e</font>4. Potential confounding variables were age, gender, tr
aditional cardiovascular risk factors, uric acid, and creatinine levels. The pre
valence of hypertension was 61.3%. Compared with the <font face="Symbol">e</font
>3 homozygotes, neither the <font face="Symbol">e</font>2 nor the <font face="Sy
mbol">e</font>4 carrier status was associated with hypertension (adjusted preval
ence ratios = 0.94, 95%CI = 0.83-1.07 and 0.98, 0.89-1.07, respectively). On the
 other hand, the <font face="Symbol">e</font>2 allele carriers had lower LDL cho
lesterol levels (P &lt; 0.001) and the <font face="Symbol">e</font>4 carriers ha
d higher LDL cholesterol levels (P = 0.036). This study provides epidemiologic e
vidence that the <I>ApoE</I> genotype is not associated with prevalent hypertens
ion in old age.  </font>   <font face="Arial, Helvetica, sans-serif">      ^cY#6
954.htm##
00396000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704016900072002000900241#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#21#17#article#88#<P>Key words: Apolipopr
otein E; Hypertension; Low-density lipoprotein cholesterol; Triglycerides; Lipid
 metabolism   </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6954.htm##
00602000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704037500072002000900447#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#22#18#article#88#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>    <font face="Arial, Helvetica,
 sans-serif">  </font>      ^cY#6954.htm##
01228000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704100100072002000901073#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#23#19#article#88#<P><font face="Arial, H
elvetica, sans-serif">There has been an increasing interest in apolipoprotein E 
(<I>ApoE</I>) polymorphisms as predictors of hypertension. <I>ApoE </I>plays a f
undamental role in lipid metabolism, participating in the clearance of chylomicr
on remmants and very low-density lipoproteins (VLDL) by serving as a ligand for 
low-density lipoprotein (LDL) receptors (1). It is also an important determinant
 of intestinal cholesterol absorption (2) and plasma lipid levels (3). The <I>Ap
oE</I> gene is located on chromosome 19 (4,5) with three common alleles, termed 
<font face="Symbol">e</font>2, <font face="Symbol">e</font>3 and <font face="Sym
bol">e</font>4. The <font face="Symbol">e</font>4 allele has consistently been l
inked to increases in LDL cholesterol levels (6,7). The <font face="Symbol">e</f
ont>2 allele has been reported to be linked with higher triglyceride levels in s
ome (6,8), but not all studies (7). </font>   <font face="Arial, Helvetica, sans
-serif">      ^cY#6954.htm##
00830000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704060300072002000900675#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#24#20#article#88#<P>Although <I>ApoE</I>
 genotype is involved in lipid metabolism, its association with arterial hyperte
nsion is controversial. Nevertheless, only two previous studies (9,10) involved 
populations of more than 1000 subjects, few studies have been carried out in rep
resentative community-based samples, and few studies have considered traditional
 risk factors as potential confounders for the association between <I>ApoE</I> a
nd hypertension or blood pressure level (9-21). Aditionally, few studies focused
 on the influence of <I>ApoE</I> genotype on hypertension in older individuals (
9,12-14).       ^cY#6954.htm##
00766000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704053900072002000900611#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#25#21#article#88#<P>The primary objectiv
e of this study was to investigate the effect of the <I>ApoE</I> polymorphisms o
n the prevalence of hypertension in a population of 1406 community-dwelling olde
r adults, considering several potential confounding factors in the analysis. A s
econdary objective was to examine the association between <I>ApoE</I> polymorphi
sm and systolic blood pressure, diastolic blood pressure, high-density lipoprote
in (HDL) cholesterol, LDL cholesterol and triglyceride levels.  </font>  <HR ALI
GN=LEFT WIDTH=100% SIZE=2>      ^cY#6954.htm##
00595000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036800072002000900440#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#26#22#article#88#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Mat
erial and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>  <font face="Arial, Helvetic
a, sans-serif">      ^cY#6954.htm##
00301000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704007400072002000900146#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#27#23#article#88#<P><b>The Bambu&iacute;
 Health Ageing Study (BHAS) </b>  </font>      ^cY#6954.htm##
01262000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704103500072002000901107#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#28#24#article#88#<P><font face="Arial, H
elvetica, sans-serif">The BHAS is a population-based cohort of older adults, whi
ch has been carried out in Bambu&iacute; city (~15,000 inhabitants), which is si
tuated in Minas Gerais State, Southeastern Brazil. The cohort baseline was estab
lished in 1997. From November to December 1996, a complete census was carried ou
t by the research team for identification of participants. Of the 1742 inhabitan
ts aged 60 years or older by January 1, 1997, 1606 (92.0%) participated. The mea
n age of the cohort participants was 69.3 years (range: 60-95 years), and 60.0% 
were women. White skin color was predominant (60.4%), followed by light brown (&
quot;moreno&quot;, 33.3%), dark brown (&quot;mulato&quot;, 3.6%), and black (2.7
%) (22). The prevalence of hypertension (61.5%) was close to that described for 
the North American elderly (~60%) (23), as well as the prevalence of some tradit
ional risk factors (24). A detailed description of the study design and methods 
has been published elsewhere (25). </font>      ^cY#6954.htm##
00315000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704008800072002000900160#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#29#25#article#88#<P><font face="Arial, H
elvetica, sans-serif"><B>Study participants</B> </font>      ^cY#6954.htm##
00567000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704034000072002000900412#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#30#26#article#88#<P><font face="Arial, H
elvetica, sans-serif">All of the 1406 cohort members who had their blood pressur
e (BP) measured at baseline and whose <I>ApoE</I> was genotyped were selected fo
r the present study. The participants in this study were similar to non-particip
ants in relation to age (P = 0.999) and gender (P = 0.365). </font>      ^cY#695
4.htm##
00309000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704008200072002000900154#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#31#27#article#88#<P><font face="Arial, H
elvetica, sans-serif"><B>Measurements</B> </font>      ^cY#6954.htm##
01135000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704090800072002000900980#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#32#28#article#88#<P><font face="Arial, H
elvetica, sans-serif">Three measurements of systolic (SBP) and diastolic (DBP) w
ere taken on the right arm with an appropriately sized cuff using a mercury sphy
gmomanometer. BP measurements were taken early in the morning, after a 5-min ini
tial rest and subsequently at 2-min intervals between each measurement, and afte
r 30 or more min of the last caffeine intake or cigarette smoked. BP was conside
red as the arithmetic mean of the second and third measurements. According to th
e Seventh Joint National Committee criteria (26), hypertension was defined as SB
P <font face="Symbol">&#179;</font>140 mmHg and/or DBP <font face="Symbol">&#179
;</font>90 mmHg or the use of anti-hypertensive medication. Current use of anti-
hypertensive medication was ascertained by reviewing medication containers or pr
escription, and coding the medication as previously described (27). </font>     
 ^cY#6954.htm##
01427000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704120000072002000901272#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#33#29#article#88#<P><font face="Arial, H
elvetica, sans-serif">Genomic DNA for <I>ApoE</I> genotyping was extracted from 
blood samples using the Wizard<SUP>&#174;</SUP> Genomic DNA Purification System 
(Promega, Madison, WI, USA). DNA samples were then amplified by polymerase chain
 reaction (PCR), followed by digestion with <I>Hha</I>I, and restriction fragmen
t length polymorphism analysis, as previously described (28). The DNA samples we
re subjected to PCR with the following primers: forward 5' TAA GCT TGG CAC GGC T
GT CCA AGG A 3' and reverse 5' ACA GAA TTC GCC CCG GCC TGG TAC AC 3'. The PCR co
nditions were denaturation at 95&#176;C for 5 min, followed by 35 cycles of 95&#
176;C for 1 min, 60&#176;C for 1 min, and 70&#176;C for 2 min, and a final exten
sion at 72&#176;C for 10 min. Restriction fragment length polymorphism analysis 
yielded the following patterns: <font face="Symbol">e</font>2<font face="Symbol"
>e</font>2, 91 and 83 bp; <font face="Symbol">e</font>3<font face="Symbol">e</fo
nt>3, 91, 48 and 35 bp; <font face="Symbol">e</font>4<font face="Symbol">e</font
>4, 72, 48 and 35 bp. Each of the heterozygote genotypes contained both sets of 
fragments from each <I>ApoE </I>allele. </font>      ^cY#6954.htm##
01822000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704159500072002000901667#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#34#30#article#88#<P><font face="Arial, H
elvetica, sans-serif">Other variables considered included baseline age, gender, 
smoking, alcohol consumption, physical activity, family history of cardiovascula
r diseases, diabetes, traditional risk factors for cardiovascular diseases such 
as SBP, DBP, body mass index (BMI), and levels of LDL cholesterol, HDL cholester
ol, triglycerides, creatinine (29), and uric acid (30). Current smokers were def
ined as those who had smoked at least 100 cigarettes during their lifetime and w
ere still smoking. For alcohol consumption estimates, the subjects were shown ca
rds with a representation of the amount of liquid corresponding to one drink for
 liquor, beer or wine. The alcohol consumption was calculated by multiplying the
 number of drinks by the frequency of imbibing in a week during the previous 12 
months. Physical activity was defined as any exercise for 20-30 min at least thr
ee times a week, during leisure time in the previous 90 days. Diabetes was defin
ed by a fasting blood glucose level <font face="Symbol">&#179;</font>126 mg/dL a
nd/or current use of insulin or oral antidiabetic drug treatment, as defined by 
the 2003 American Diabetes Association updated criteria (31). BMI (weight/height
<SUP>2</SUP>) was calculated from height and weight measurements. Levels of LDL 
cholesterol, HDL cholesterol, triglycerides, creatinine, and uric acid were dete
rmined after a 12-h recommended overnight fast, using commercial kits (Boehringe
r Mannhein, Germany) and an automated analyzer (Eclipse Vitalab, Merck, Netherla
nds), as described elsewhere (25). </font>      ^cY#6954.htm##
00682000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704045500072002000900527#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#35#31#article#88#<P><font face="Arial, H
elvetica, sans-serif">All of the observers of the BHAS were trained and certifie
d before each examination. The BHAS was approved by the Ethics Committee of the 
Oswaldo Cruz Foundation in Rio de Janeiro, RJ, Brazil, in 1996, and the present 
investigation was approved by the Ethics Committee of the Oswaldo Cruz Foundatio
n in Belo Horizonte, MG, Brazil, in 2006. All participants gave full informed wr
itten consent. </font>      ^cY#6954.htm##
00317000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704009000072002000900162#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#36#32#article#88#<P><font face="Arial, H
elvetica, sans-serif"><B>Statistical analysis</B> </font>      ^cY#6954.htm##
02433000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704220600072002000902278#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#37#33#article#88#<P><font face="Arial, H
elvetica, sans-serif">The statistical analysis was performed by using the Stata 
version 9.1 software (Stata Corporation, College Station, TX, USA). Allele frequ
encies were estimated by gene counting. Hardy-Weinberg equilibrium expectations 
were tested by using a chi-square (<font face="Symbol">c</font><SUP>2</SUP>)good
ness-of-fit test. Non-adjusted analysis of the association between <I>ApoE</I> g
enotypes and alleles with prevalent hypertension was based on Person's chi-squar
e test. Age-gender adjusted means and standard errors of the mean by <I>ApoE</I>
 genotype were calculated for baseline SBP, DBP, LDL cholesterol, HDL cholestero
l, and triglyceride levels. Multiple linear regression was used to assess the as
sociation between <I>ApoE</I> genotype and the above mentioned parameters, after
 adjustments for age and gender. Poisson regression models (32) were used to est
imate the prevalence ratio for hypertension. The models included age and gender 
in model 1, and age, gender, smoking, alcohol consumption, physical activity, fa
mily history, diabetes, LDL cholesterol, HDL cholesterol, uric acid, creatinine,
 and BMI in model 2. In the adjusted analysis, <I>ApoE</I> genotypes were classi
fied into three groups: <font face="Symbol">e</font>3 carriers (<font face="Symb
ol">e</font>3<font face="Symbol">e</font>3), <font face="Symbol">e</font>2 carri
ers (<font face="Symbol">e</font>2<font face="Symbol">e</font>2, <font face="Sym
bol">e</font>2<font face="Symbol">e</font>3) and <font face="Symbol">e</font>4 c
arriers (<font face="Symbol">e</font>4<font face="Symbol">e</font>4, <font face=
"Symbol">e</font>3<font face="Symbol">e</font>4). In each model, the homozygous 
<font face="Symbol">e</font>3<font face="Symbol">e</font>3 genotype was the refe
rence group. Twenty subjects (1.4%) with the e2e4 genotype were excluded from th
e analysis because of the opposite effects of these two alleles on LDL cholester
ol levels. Since no effect modification by gender was noted, all analyses were f
or both sexes. Statistical significance in the models was assessed using Wald <f
ont face="Symbol">c</font><SUP>2 </SUP>statistics. </font>  <HR ALIGN=LEFT WIDTH
=100% SIZE=2>      ^cY#6954.htm##
00537000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031000072002000900382#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#38#34#article#88#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF
="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0 
VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6954.htm##
01069000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704084200072002000900914#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#39#35#article#88#<P><font face="Arial, H
elvetica, sans-serif">The prevalence of hypertension was 61.3% for the 1406 part
icipants in the BHAS baseline. As found in most western populations, the <font f
ace="Symbol">e</font>3<font face="Symbol">e</font>3 genotype was the most common
 (63.4%), followed by <font face="Symbol">e</font>3<font face="Symbol">e</font>4
 (21.9%), <font face="Symbol">e</font>2<font face="Symbol">e</font>3 (11.5%), <f
ont face="Symbol">e</font>4<font face="Symbol">e</font>4 (1.8%), <font face="Sym
bol">e</font>2<font face="Symbol">e</font>4 (1.4%), and <font face="Symbol">e</f
ont>2<font face="Symbol">e</font>2 (0.1%). Allele frequencies were within the Ha
rdy-Weinberg equilibrium expectations (P &gt; 0.05). Additional baseline charact
eristics of the study participants are shown in <a href="#Tab1">Table 1</a>. </f
ont> </P>      ^cY#6954.htm##
00964000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704073700072002000900809#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#40#36#article#88#<P><font face="Arial, H
elvetica, sans-serif">Selected baseline characteristics of the BHAS population b
y <I>ApoE</I> genotypes, adjusted for age and gender are shown in <a href="#Tab2
">Table 2</a>. The mean LDL cholesterol was significantly greater among the <fon
t face="Symbol">e</font>4 carriers (P = 0.036) and lower among the <font face="S
ymbol">e</font>2 carriers (P &lt; 0.001), in comparison to the homozygous <font 
face="Symbol">e</font>3<font face="Symbol">e</font>3 carriers. The mean triglyce
ride level was significantly greater among those with the <font face="Symbol">e<
/font>2 allele (P = 0.022). No significant associations were found between <I>Ap
oE</I> genotype and SBP, DBP and HDL cholesterol levels. </font>      ^cY#6954.h
tm##
00550000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704032300072002000900395#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#41#37#article#88#<P><font face="Arial, H
elvetica, sans-serif">The <I>ApoE</I> genotype and allele frequencies for the pr
evalence of hypertension are shown in <a href="#Tab3">Table 3</a>. Both the <I>A
poE</I> genotype and the allele frequencies showed similar distributions among p
revalent hypertension cases and non-cases. </font>      ^cY#6954.htm##
00920000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704069300072002000900765#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#42#38#article#88#<P><font face="Arial, H
elvetica, sans-serif">The results of the adjusted analysis for the association b
etween <I>ApoE</I> genotype and hypertension are shown in <a href="#Tab4">Table 
4</a>. Hypertension was not associated with the presence of either <font face="S
ymbol">e</font>2 or <font face="Symbol">e</font>4 alleles in the model adjusted 
by age and gender or in the model adjusted for several confounders.</font>   <HR
 ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr align="l
eft" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/v41n2/html/
6954t01.htm"><img src="/img/revistas/bjmbr/v41n2/table.jpg" border="2"></a></td>
      <td width="86%">    ^cY#6954.htm##
00460000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704023300072002000900305#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#43#39#article#88#<P><font face="Arial, H
elvetica, sans-serif"><a name="Tab1"></a>Table 1. Selected baseline characterist
ics of the 1406 participants from the Bambu&iacute; Health and Aging Study (BHAS
). </font>      </td>    </tr>  </table>      ^cY#6954.htm##
00610000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038300072002000900455#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#44#40#article#88#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (206 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/v
41n2/html/6954t02.htm"><img src="/img/revistas/bjmbr/v41n2/table.jpg" border="2"
></a></td>      <td width="86%">    ^cY#6954.htm##
00522000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704029500072002000900367#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#45#41#article#88#<P><font face="Arial, H
elvetica, sans-serif"><a name="Tab2"></a>Table 2. Age-sex adjusted analysis of t
he association between selected baseline characteristics of the Bambu&iacute; He
alth and Aging Study (BHAS) population and <I>ApoE</I> genotype. </font>      </
td>    </tr>  </table>      ^cY#6954.htm##
00610000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038300072002000900455#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#46#42#article#88#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (119 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/v
41n2/html/6954t03.htm"><img src="/img/revistas/bjmbr/v41n2/table.jpg" border="2"
></a></td>      <td width="86%">    ^cY#6954.htm##
00501000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704027400072002000900346#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#47#43#article#88#<P><font face="Arial, H
elvetica, sans-serif"><a name="Tab3"></a>Table 3. Non-adjusted analysis of the a
ssociation between <I>ApoE</I> polymorphism and hypertension in the Bambu&iacute
; Health and Aging Study (BHAS) population. </font>      </td>    </tr>  </table
>      ^cY#6954.htm##
00865000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704063800072002000900710#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#48#44#article#88#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (167 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="14%"><a href="/img/revistas/bjmbr/v
41n2/html/6954t04.htm"><img src="/img/revistas/bjmbr/v41n2/table.jpg" border="2"
></a></td>      <td width="86%"><font face="Arial, Helvetica, sans-serif"><a nam
e="Tab4"></a>Table 4. Poisson regression models and prevalence ratio for hyperte
nsion in the Bambu&iacute; Health and Aging Study (BHAS) population, by <I>ApoE<
/I> genotype. </font></td>    </tr>  </table>      ^cY#6954.htm##
00345000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704011800072002000900190#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#49#45#article#88#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (178 K JPG file)]</font
></P>      ^cY#6954.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004800072002000900120#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#50#46#article#88#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>      ^cY#6954.htm##
00497000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704027000072002000900342#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#51#47#article#88#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#6954.htm##
00766000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704053900072002000900611#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#52#48#article#88#<P><font face="Arial, H
elvetica, sans-serif">In this study, prevalent hypertension was not associated w
ith <I>ApoE</I> polymorphisms in a large sample of Brazilian older adults. This 
lack of association was observed in the age-gender adjusted analysis and in the 
analysis adjusted for factors <I>a priori</I> believed to be potential confounde
rs for the association between <I>ApoE</I> genotype and hypertension. Secondary 
analysis indicated that such associations were absent for both males and females
 (data not shown). </font>      ^cY#6954.htm##
01698000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704147100072002000901543#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#53#49#article#88#<P><font face="Arial, H
elvetica, sans-serif">An association was observed between greater LDL cholestero
l levels and the presence of the <font face="Symbol">e</font>4 allele, as well a
s between lower LDL cholesterol levels and the presence of the <font face="Symbo
l">e</font>2 allele. This observation is in agreement with other studies reporti
ng a consistent relationship between the <font face="Symbol">e</font>4 allele an
d greater levels of LDL cholesterol (6,7), as well as between the <font face="Sy
mbol">e</font>2 allele and lower LDL cholesterol levels (6). Higher triglyceride
 levels were found in <font face="Symbol">e</font>2 carriers. This association w
as reported in some (6,8), but not all previous investigations (7). The associat
ion of the <I>ApoE</I> alleles with plasma lipid levels is a direct consequence 
of the role of ApoE protein in lipid metabolism. ApoE2 is metabolically impaired
 when compared to ApoE3 and ApoE4, due to its reduced interaction with cellular 
receptors, resulting in delayed clearance and accumulation of chylomicrons and V
LDL remnants in the plasma. ApoE-mediated LDL conversion from VLDL remnants is a
lso reduced. The net effect is an up-regulation of LDL receptors, higher plasma 
concentrations of triglyceride- and cholesterol-containing remnant particles, an
d lower plasma levels of cholesterol-rich LDL particles (1). <I>ApoE4</I> allele
s have an opposite net effect compared to those of <I>ApoE2</I> (1,3). </font>  
    ^cY#6954.htm##
02099000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704187200072002000901944#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#54#50#article#88#<P><font face="Arial, H
elvetica, sans-serif">There have been several studies of the association between
 the <I>ApoE</I> genotypes and prevalent hypertension, with inconsistent finding
s. Results from small prevalent case control studies have consistently described
 a positive relationship between the presence of the <font face="Symbol">e</font
>4 allele and hypertension or with greater BP levels (15-19). The results from c
ross-sectional studies have been more inconsistent. Four investigations carried 
out in an mixed population of younger and older adults reported i) lack of assoc
iation between the <I>ApoE</I> genotype and hypertension in the USA (10) and in 
Tunisia (11), ii) a positive association between the <font face="Symbol">e</font
>2 allele and prevalent hypertension among male, but not female, Japanese immigr
ants living in Los Angeles or Hawaii (20), and iii) a negative association betwe
en the presence of the <font face="Symbol">e</font>4 allele and prevalent hypert
ension in young, but not older, Japanese (9). Three other cross-sectional studie
s included very old subjects. Two were carried out in Finland (12) and in Spain 
(14), and did not find significant association between <I>ApoE</I> genotype, pre
valent hypertension (14), or mean SBP and mean DBP (12). The third study include
d Italian descendents living in the south of Brazil and reported a significantly
 lower DBP among the <font face="Symbol">e</font>4 carriers, compared to the hom
ozygous <font face="Symbol">e</font>3<font face="Symbol">e</font>3, but the mean
 SBP was similar in both groups (13). In addition, two cohort studies carried ou
t with Japanese Americans (20) and North American males (21) reported contradict
ory results. In the present study, the mean baseline SBP and DBP, as well as pre
valent hypertension, were not associated with the <I>ApoE</I> genotype. </font> 
     ^cY#6954.htm##
00763000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704053600072002000900608#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#55#51#article#88#<P><font face="Arial, H
elvetica, sans-serif">This investigation benefits from a large number of subject
s, the use of an unselected community-based population, and the use of double-bl
ind data collection, as the technicians were unaware of the participants' <I>Apo
E</I> or hypertension status. Selection and information bias are therefore unlik
ely, but prevalence bias is a potential limitation. The population investigated 
here consisted of older adults; therefore, the results may not be relevant to yo
unger subjects. </font>      ^cY#6954.htm##
00741000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704051400072002000900586#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#56#52#article#88#<P><font face="Arial, H
elvetica, sans-serif">In conclusion, this study confirms that the presence of th
e <font face="Symbol">e</font>4 allele is associated with greater LDL cholestero
l levels and the presence of the <font face="Symbol">e</font>2 allele is associa
ted with lower LDL levels and greater triglyceride levels. This investigation al
so provides epidemiologic evidence that <I>ApoE</I> genotype is not associated w
ith prevalent hypertension in old age. </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2
>      ^cY#6954.htm##
00543000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031600072002000900388#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#57#53#article#88#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6954.htm##
00459000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704021800074002000900292#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#58#54#article#88#1#<P><font 
face="Arial, Helvetica, sans-serif">1. Mahley RW, Innerarity TL, Rall SC Jr, Wei
sgraber KH. Plasma lipoproteins: apolipoprotein structure and function. <I>J Lip
id Res</I> 1984; 25: 1277-1294. </font>      ^cY#6954.htm##
00475000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704023400074002000900308#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#59#55#article#88#2#<P><font 
face="Arial, Helvetica, sans-serif">2. Kesaniemi YA, Ehnholm C, Miettinen TA. In
testinal cholesterol absorption efficiency in man is related to apoprotein E phe
notype. <I>J Clin Invest</I> 1987; 80: 578-581. </font>      ^cY#6954.htm##
00427000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704018600074002000900260#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#60#56#article#88#3#<P><font 
face="Arial, Helvetica, sans-serif">3. Davignon J, Gregg RE, Sing CF. Apolipopro
tein E polymorphism and atherosclerosis. <I>Arteriosclerosis</I> 1988; 8: 1-21. 
</font>      ^cY#6954.htm##
00501000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704026000074002000900334#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#61#57#article#88#4#<P><font 
face="Arial, Helvetica, sans-serif">4. Das HK, McPherson J, Bruns GA, Karathanas
is SK, Breslow JL. Isolation, characterization, and mapping to chromosome 19 of 
the human apolipoprotein E gene. <I>J Biol Chem</I> 1985; 260: 6240-6247. </font
>      ^cY#6954.htm##
00493000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704025200074002000900326#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#62#58#article#88#5#<P><font 
face="Arial, Helvetica, sans-serif">5. Paik YK, Chang DJ, Reardon CA, Davies GE,
 Mahley RW, Taylor JM. Nucleotide sequence and structure of the human apolipopro
tein E gene. <I>Proc Natl Acad Sci U S A</I> 1985; 82: 3445-3449. </font>      ^
cY#6954.htm##
00557000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704031600074002000900390#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#63#59#article#88#6#<P><font 
face="Arial, Helvetica, sans-serif">6. Howard BV, Gidding SS, Liu K. Association
 of apolipoprotein E phenotype with plasma lipoproteins in African-American and 
white young adults. The CARDIA Study. Coronary artery risk development in young 
adults. <I>Am J Epidemiol</I> 1998; 148: 859-868. </font>      ^cY#6954.htm##
00617000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704037600074002000900450#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#64#60#article#88#7#<P><font 
face="Arial, Helvetica, sans-serif">7. Volcik KA, Barkley RA, Hutchinson RG, Mos
ley TH, Heiss G, Sharrett AR, et al. Apolipoprotein E polymorphisms predict low-
density lipoprotein cholesterol levels and carotid artery wall thickness but not
 incident coronary heart disease in 12,491 ARIC study participants. <I>Am J Epid
emiol</I> 2006; 164: 342-348. </font>      ^cY#6954.htm##
00474000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704023300074002000900307#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#65#61#article#88#8#<P><font 
face="Arial, Helvetica, sans-serif">8. Dallongeville J, Lussier-Cacan S, Davigno
n J. Modulation of plasma triglyceride levels by <I>ApoE</I> phenotype: a meta-a
nalysis. <I>J Lipid Res</I> 1992; 33: 447-454. </font>      ^cY#6954.htm##
00536000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704029500074002000900369#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#66#62#article#88#9#<P><font 
face="Arial, Helvetica, sans-serif">9. Katsuya T, Baba S, Ishikawa K, Mannami T,
 Fu Y, Inamoto N, et al. Epsilon 4 allele of apolipoprotein E gene associates wi
th lower blood pressure in young Japanese subjects: the Suita Study. <I>J Hypert
ens</I> 2002; 20: 2017-2021. </font>      ^cY#6954.htm##
00508000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026600075002000900341#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#67#63#article#88#10#<P><font
 face="Arial, Helvetica, sans-serif">10. Wilson PW, Myers RH, Larson MG, Ordovas
 JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary 
heart disease. The Framingham Offspring Study. <I>JAMA</I> 1994; 272: 1666-1671.
 </font>      ^cY#6954.htm##
00513000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027100075002000900346#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#68#64#article#88#11#<P><font
 face="Arial, Helvetica, sans-serif">11. Jemaa R, Elasmi M, Naouali C, Feki M, K
allel A, Souissi M, et al. Apolipoprotein E polymorphism in the Tunisian populat
ion: frequency and effect on lipid parameters. <I>Clin Biochem</I> 2006; 39: 816
-820. </font>      ^cY#6954.htm##
00541000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704029900075002000900374#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#69#65#article#88#12#<P><font
 face="Arial, Helvetica, sans-serif">12. Rastas S, Mattila K, Verkkoniemi A, Nii
nisto L, Juva K, Sulkava R, et al. Association of apolipoprotein E genotypes, bl
ood pressure, blood lipids and ECG abnormalities in a general population aged 85
+. <I>BMC Geriatr</I> 2004; 4: 1. </font>      ^cY#6954.htm##
00561000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704031900075002000900394#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#70#66#article#88#13#<P><font
 face="Arial, Helvetica, sans-serif">13. Schwanke CH, da Cruz I, Leal NF, Scheib
e R, Moriguchi Y, Moriguchi EH. Analysis of the association between apolipoprote
in E polymorphism and cardiovascular risk factors in an elderly population with 
longevity. <I>Arq Bras Cardiol</I> 2002; 78: 561-579. </font>      ^cY#6954.htm#
#
00438000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019600075002000900271#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#71#67#article#88#14#<P><font
 face="Arial, Helvetica, sans-serif">14. Formiga F, Alia P, Navarro MA, Pujol R.
 Apolipoprotein e genotypes in nonagenarians. <I>J Am Geriatr Soc</I> 2006; 54: 
1471-1473. </font>      ^cY#6954.htm##
00466000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022400075002000900299#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#72#68#article#88#15#<P><font
 face="Arial, Helvetica, sans-serif">15. Bhavani AB, Sastry KB, Reddy NK, Padma 
T. Lipid profile and apolipoprotein E polymorphism in essential hypertension. <I
>Indian Heart J</I> 2005; 57: 151-157. </font>      ^cY#6954.htm##
00459000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021700075002000900292#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#73#69#article#88#16#<P><font
 face="Arial, Helvetica, sans-serif">16. Isbir T, Yilmaz H, Bihorac A, Akoglu E.
 Mild-to-moderate hypertension and apolipoprotein E gene polymorphism. <I>Am J H
ypertens</I> 1997; 10: 827-828. </font>      ^cY#6954.htm##
00474000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023200075002000900307#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#74#70#article#88#17#<P><font
 face="Arial, Helvetica, sans-serif">17. Li X, Du Y, Du Y, Huang X. Association 
of apolipoprotein E gene polymorphism with essential hypertension and its compli
cations. <I>Clin Exp Med</I> 2003; 2: 175-179. </font>      ^cY#6954.htm##
00502000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026000075002000900335#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#75#71#article#88#18#<P><font
 face="Arial, Helvetica, sans-serif">18. Niu W, Guo X, Su Y, Qiu C. Apolipoprote
in E and low-density lipoprotein receptor gene polymorphisms in dyslipidemias-as
sociated essential hypertension. <I>J Hum Hypertens</I> 2007; 21: 337-339. </fon
t>      ^cY#6954.htm##
00503000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026100075002000900336#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#76#72#article#88#19#<P><font
 face="Arial, Helvetica, sans-serif">19. Yilmaz H, Isbir T, Agachan B, Aydin M. 
Is epsilon4 allele of apolipoprotein E associated with more severe end-organ dam
age in essential hypertension? <I>Cell Biochem Funct</I> 2001; 19: 191-195. </fo
nt>      ^cY#6954.htm##
00551000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704030900075002000900384#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#77#73#article#88#20#<P><font
 face="Arial, Helvetica, sans-serif">20. Imazu M, Yamamoto H, Toyofuku M, Watana
be T, Okubo M, Egusa G, et al. Association of apolipoprotein E phenotype with hy
pertension in Japanese-Americans: data from the Hawaii-Los Angeles-Hiroshima Stu
dy. <I>Hypertens Res</I> 2001; 24: 523-529. </font>      ^cY#6954.htm##
00518000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027600075002000900351#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#78#74#article#88#21#<P><font
 face="Arial, Helvetica, sans-serif">21. Scuteri A, Najjar SS, Muller D, Andres 
R, Morrell CH, Zonderman AB, et al. <I>ApoE</I>4 allele and the natural history 
of cardiovascular risk factors. <I>Am J Physiol Endocrinol Metab</I> 2005; 289: 
E322-E327. </font>      ^cY#6954.htm##
00541000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704029900075002000900374#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#79#75#article#88#22#<P><font
 face="Arial, Helvetica, sans-serif">22. Fuzikawa AK, Peixoto SV, Taufer M, Mori
guchi EH, Lima-Costa MF. Apolipoprotein E polymorphism distribution in an elderl
y Brazilian population: the Bambu&iacute; Health and Aging Study. <I>Braz J Med 
Biol Res</I> 2007; 40: 1429-1434. </font>      ^cY#6954.htm##
00561000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704031900075002000900394#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#80#76#article#88#23#<P><font
 face="Arial, Helvetica, sans-serif">23. Barreto SM, Passos VM, Firmo JO, Guerra
 HL, Vidigal PG, Lima-Costa MF. Hypertension and clustering of cardiovascular ri
sk factors in a community in Southeast Brazil - The Bambu&iacute; Health and Age
ing Study. <I>Arq Bras Cardiol</I> 2001; 77: 576-581. </font>      ^cY#6954.htm#
#
00546000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704030400075002000900379#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#81#77#article#88#24#<P><font
 face="Arial, Helvetica, sans-serif">24. Lima-Costa MF, Barreto SM, Uchoa E, Fir
mo JO, Vidigal PG, Guerra HL. The Bambu&iacute; Health and Aging Study (BHAS): p
revalence of risk factors and use of preventive health care services. <I>Rev Pan
am Salud Publica</I> 2001; 9: 219-227. </font>      ^cY#6954.htm##
00589000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704034700075002000900422#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#82#78#article#88#25#<P><font
 face="Arial, Helvetica, sans-serif">25. Costa MF, Uchoa E, Guerra HL, Firmo JO,
 Vidigal PG, Barreto SM. The Bambu&iacute; health and ageing study (BHAS): metho
dological approach and preliminary results of a population-based cohort study of
 the elderly in Brazil. <I>Rev Sa&uacute;de P&uacute;blica</I> 2000; 34: 126-135
. </font>      ^cY#6954.htm##
00564000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704032200075002000900397#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#83#79#article#88#26#<P><font
 face="Arial, Helvetica, sans-serif">26. Chobanian AV, Bakris GL, Black HR, Cush
man WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Co
mmittee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressu
re: the JNC 7 report. <I>JAMA</I> 2003; 289: 2560-2572. </font>       ^cY#6954.h
tm##
00579000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704033700075002000900412#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#84#80#article#88#27#<P><font
 face="Arial, Helvetica, sans-serif">27. World Health Organization. Anatomical  
  Therapeutical Chemical (ATC) classification index with Defined Daily Doses (DD
Ds).    <a href="http://www.whocc.no/atcddd/indexdatabase" target="_blank">http:
//www.whocc.no/atcddd/indexdatabase</a>.    Accessed February 10, 2005. </font> 
     ^cY#6954.htm##
00470000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022800075002000900303#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#85#81#article#88#28#<P><font
 face="Arial, Helvetica, sans-serif">28. Hixson JE, Vernier DT. Restriction isot
yping of human apolipoprotein E by gene amplification and cleavage with <I>Hha</
I>I. <I>J Lipid Res</I> 1990; 31: 545-548. </font>      ^cY#6954.htm##
00501000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025900075002000900334#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#86#82#article#88#29#<P><font
 face="Arial, Helvetica, sans-serif">29. Wattanakit K, Folsom AR, Chambless LE, 
Nieto FJ. Risk factors for cardiovascular event recurrence in the Atherosclerosi
s Risk in Communities (ARIC) study. <I>Am Heart J</I> 2005; 149: 606-612. </font
>      ^cY#6954.htm##
00511000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026900075002000900344#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#87#83#article#88#30#<P><font
 face="Arial, Helvetica, sans-serif">30. Sundstrom J, Sullivan L, D'Agostino RB,
 Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood
 pressure tracking and hypertension incidence. <I>Hypertension</I> 2005; 45: 28-
33. </font>      ^cY#6954.htm##
00474000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023200075002000900307#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#88#84#article#88#31#<P><font
 face="Arial, Helvetica, sans-serif">31. Genuth S, Alberti KG, Bennett P, Buse J
, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes melli
tus. <I>Diabetes Care</I> 2003; 26: 3160-3167. </font>      ^cY#6954.htm##
00472000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023000075002000900305#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#p#89#85#article#88#32#<P><font
 face="Arial, Helvetica, sans-serif">32. Zou G. A modified poisson regression ap
proach to prospective studies with binary data. <I>Am J Epidemiol</I> 2004; 159:
 702-706.</font>   <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6954.htm##
00564000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033700072002000900409#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#90#86#article#88#<P><FONT SIZE=4 face="A
rial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F><B
>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, Helv
etica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.g
if" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>       ^cY#6954.h
tm##
00742000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704051500072002000900587#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#91#87#article#88#<p><font face="Arial, H
elvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v41n2/rec
or.gif" border="0"></a>    Address for correspondence:</b> M.F. Lima-Costa, Labo
rat&oacute;rio de Epidemiologia    e Antropologia M&eacute;dica, Instituto Ren&e
acute; Rachou, Funda&ccedil;&atilde;o    Oswaldo Cruz, Av. Augusto de Lima, 1715
, 30190-002 Belo Horizonte, MG, Brasil.    Fax: +55-31-3295-3115. E-mail: <a hre
f="mailto:lima-costa@cpqrr.fiocruz.br">limacosta@cpqrr.fiocruz.br</a></font>  </
p>      ^cY#6954.htm##
00387000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704016000072002000900232#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6954.htm#S#p#92#88#article#88#<P><font face="Arial, H
elvetica, sans-serif">Research supported by CNPq (No. 470841/2004-4). Received J
une 29, 2007. Accepted November 8, 2007.</font>      ^cY#6954.htm##
00594000000000301000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100021000900100
01800111010002100129012006300150030001200213065000900225064000500234031000300239
014001000242865000900252002000900261035001000270801001200280#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6954.htm#S#c#93#1#article#32#1#^rND^sMahley^nRW#^rND^sInn
erarity^nTL#^rND^sRall^nSC Jr#^rND^sWeisgraber^nKH#Plasma lipoproteins: apolipop
rotein structure and function^len#J Lipid Res#19840000#1984#25#1277-1294#2008020
0#6954.htm#0022-2275#J Lipid Res##
00594000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100020000730100017000930100
02000110012009300130030001400223065000900237064000500246031000300251014000800254
865000900262002000900271035001000280801001400290#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6954.htm#S#c#94#2#article#32#2#^rND^sKesaniemi^nYA#^rND^sEhnholm^nC#^
rND^sMiettinen^nTA#Intestinal cholesterol absorption efficiency in man is relate
d to apoprotein E phenotype^len#J Clin Invest#19870000#1987#80#578-581#20080200#
6954.htm#0021-9738#J Clin Invest##
00549000000000289000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100018000730100016000910100
01500107012005400122030001700176065000900193064000500202031000200207014000500209
865000900214002000900223035001000232801001700242#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6954.htm#S#c#95#3#article#32#3#^rND^sDavignon^nJ#^rND^sGregg^nRE#^rND
^sSing^nCF#Apolipoprotein E polymorphism and atherosclerosis^len#Arteriosclerosi
s#19880000#1988#8#1-21#20080200#6954.htm#0276-5047#Arteriosclerosis##
00654000000000313000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100014000730100019000870100
01600106010002300122010001800145012009700163030001200260065000900272064000500281
031000400286014001000290865000900300002000900309035001000318801001200328#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#c#96#4#article#32#4#^rND^sDas^nHK#
^rND^sMcPherson^nJ#^rND^sBruns^nGA#^rND^sKarathanasis^nSK#^rND^sBreslow^nJL#Isol
ation, characterization, and mapping to chromosome 19 of the human apolipoprotei
n E gene^len#J Biol Chem#19850000#1985#260#6240-6247#20080200#6954.htm#0021-9258
#J Biol Chem##
00677000000000325000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100015000730100016000880100
01800104010001700122010001700139010001700156012007300173030002500246065000900271
06400050028003100030028501400100028886500090029800200090030703500100031680100250
0326#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#c#97#5#article#32#5#^r
ND^sPaik^nYK#^rND^sChang^nDJ#^rND^sReardon^nCA#^rND^sDavies^nGE#^rND^sMahley^nRW
#^rND^sTaylor^nJM#Nucleotide sequence and structure of the human apolipoprotein 
E gene^len#Proc Natl Acad Sci U S A#19850000#1985#82#3445-3449#20080200#6954.htm
#0027-8424#Proc Natl Acad Sci U S A##
00642000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100018000900100
01300108012013200121030006500253710000200318065000900320064000500329031000400334
014000800338865000900346002000900355#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
954.htm#S#c#98#6#article#32#6#^rND^sHoward^nBV#^rND^sGidding^nSS#^rND^sLiu^nK#As
sociation of apolipoprotein E phenotype with plasma lipoproteins in African-Amer
ican and white young adults: The CARDIA Study^len#Coronary artery risk developme
nt in young adults. Am J Epidemiol#2#19980000#1998#148#859-868#20080200#6954.htm
##
00802000000000337000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100017000730100018000900100
02100108010001700129010001500146010001900161810000600180012019400186030001500380
06500090039506400050040403100040040901400080041386500090042100200090043003500100
0439801001500449#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#c#99#7#art
icle#32#7#^rND^sVolcik^nKA#^rND^sBarkley^nRA#^rND^sHutchinson^nRG#^rND^sMosley^n
TH#^rND^sHeiss^nG#^rND^sSharrett^nAR#et al#Apolipoprotein E polymorphisms predic
t low-density lipoprotein cholesterol levels and carotid artery wall thickness b
ut not incident coronary heart disease in 12,491 ARIC study participants^len#Am 
J Epidemiol#20060000#2006#164#342-348#20080200#6954.htm#0002-9262#Am J Epidemiol
##
00585000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100023000740100023000970100
01800120012008000138030001200218065000900230064000500239031000300244014000800247
865000900255002000900264035001000273801001200283#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6954.htm#S#c#100#8#article#32#8#^rND^sDallongeville^nJ#^rND^sLussier-
Cacan^nS#^rND^sDavignon^nJ#Modulation of plasma triglyceride levels by ApoE phen
otype: a meta-analysis^len#J Lipid Res#19920000#1992#33#447-454#20080200#6954.ht
m#0022-2275#J Lipid Res##
00719000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100014000910100
01800105010001700123010001200140010001700152810000600169012012700175030001200302
06500090031406400050032303100030032801400100033186500090034100200090035003500100
0359801001200369#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#c#101#9#ar
ticle#32#9#^rND^sKatsuya^nT#^rND^sBaba^nS#^rND^sIshikawa^nK#^rND^sMannami^nT#^rN
D^sFu^nY#^rND^sInamoto^nN#et al#Epsilon 4 allele of apolipoprotein E gene associ
ates with lower blood pressure in young Japanese subjects: the Suita Study^len#J
 Hypertens#20020000#2002#20#2017-2021#20080200#6954.htm#0263-6352#J Hypertens##
00673000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01700109010001800126010001500144010001900159012010300178030000500281065000900286
06400050029503100040030001400100030486500090031400200090032303500100033280100050
0342#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#c#102#10#article#32#10
#^rND^sWilson^nPW#^rND^sMyers^nRH#^rND^sLarson^nMG#^rND^sOrdovas^nJM#^rND^sWolf^
nPA#^rND^sSchaefer^nEJ#Apolipoprotein E alleles, dyslipidemia, and coronary hear
t disease: The Framingham Offspring Study^len#JAMA#19940000#1994#272#1666-1671#2
0080200#6954.htm#0098-7484#JAMA##
00697000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910100
01700107010001400124010001600138010001700154810000600171012010300177030001300280
06500090029306400050030203100030030701400080031086500090031800200090032703500100
0336801001300346#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#c#103#11#a
rticle#32#11#^rND^sJemaa^nR#^rND^sElasmi^nM#^rND^sNaouali^nC#^rND^sFeki^nM#^rND^
sKallel^nA#^rND^sSouissi^nM#et al#Apolipoprotein E polymorphism in the Tunisian 
population: frequency and effect on lipid parameters^len#Clin Biochem#20060000#2
006#39#816-820#20080200#6954.htm#0009-9120#Clin Biochem##
00692000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
02100109010001800130010001400148010001700162810000600179012013100185030001200316
71000020032806500090033006400050033903100020034401400020034686500090034800200090
0357#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#c#104#12#article#32#12
#^rND^sRastas^nS#^rND^sMattila^nK#^rND^sVerkkoniemi^nA#^rND^sNiinisto^nL#^rND^sJ
uva^nK#^rND^sSulkava^nR#et al#Association of apolipoprotein E genotypes, blood p
ressure, blood lipids and ECG abnormalities in a general population aged 85+^len
#BMC Geriatr#2#20040000#2004#4#1#20080200#6954.htm##
00738000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100017000950100
01500112010001700127010001900144010002000163012014200183030001700325065000900342
06400050035103100030035601400080035986500090036700200090037603500100038580100170
0395#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#c#105#13#article#32#13
#^rND^sSchwanke^nCH#^rND^sda^nCruz I#^rND^sLeal^nNF#^rND^sScheibe^nR#^rND^sMorig
uchi^nY#^rND^sMoriguchi^nEH#Analysis of the association between apolipoprotein E
 polymorphism and cardiovascular risk factors in an elderly population with long
evity^len#Arq Bras Cardiol#20020000#2002#78#561-579#20080200#6954.htm#0066-782X#
Arq Bras Cardiol##
00579000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100014000930100
01800107010001500125012004800140030001700188065000900205064000500214031000300219
014001000222865000900232002000900241035001000250801001700260#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6954.htm#S#c#106#14#article#32#14#^rND^sFormiga^nF#^rND^s
Alia^nP#^rND^sNavarro^nMA#^rND^sPujol^nR#Apolipoprotein e genotypes in nonagenar
ians^len#J Am Geriatr Soc#20060000#2006#54#1471-1473#20080200#6954.htm#0002-8614
#J Am Geriatr Soc##
00605000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01600111010001500127012007800142030001500220065000900235064000500244031000300249
014000800252865000900260002000900269035001000278801001500288#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6954.htm#S#c#107#15#article#32#15#^rND^sBhavani^nAB#^rND^
sSastry^nKB#^rND^sReddy^nNK#^rND^sPadma^nT#Lipid profile and apolipoprotein E po
lymorphism in essential hypertension^len#Indian Heart J#20050000#2005#57#151-157
#20080200#6954.htm#0019-4832#Indian heart j##
00598000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910100
01700107010001600124012007300140030001500213065000900228064000500237031000300242
014000800245865000900253002000900262035001000271801001500281#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6954.htm#S#c#108#16#article#32#16#^rND^sIsbir^nT#^rND^sYi
lmaz^nH#^rND^sBihorac^nA#^rND^sAkoglu^nE#Mild-to-moderate hypertension and apoli
poprotein E gene polymorphism^len#Am J Hypertens#19970000#1997#10#827-828#200802
00#6954.htm#0895-7061#Am J Hypertens##
00578000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100012000760100012000880100
01200100010001500112012010400127030001300231710000200244065000900246064000500255
031000200260014000800262865000900270002000900279#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6954.htm#S#c#109#17#article#32#17#^rND^sLi^nX#^rND^sDu^nY#^rND^sDu^nY
#^rND^sHuang^nX#Association of apolipoprotein E gene polymorphism with essential
 hypertension and its complications^len#Clin Exp Med#2#20030000#2003#2#175-179#2
0080200#6954.htm##
00642000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100013000890100
01200102010001300114012012800127030001600255065000900271064000500280031000300285
014000800288865000900296002000900305035001000314801001600324#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6954.htm#S#c#110#18#article#32#18#^rND^sNiu^nW#^rND^sGuo^
nX#^rND^sSu^nY#^rND^sQiu^nC#Apolipoprotein E and low-density lipoprotein recepto
r gene polymorphisms in dyslipidemias-associated essential hypertension^len#J Hu
m Hypertens#20070000#2007#21#337-339#20080200#6954.htm#0950-9240#J Hum Hypertens
##
00647000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100015000920100
01700107010001500124012011500139030001900254065000900273064000500282031000300287
014000800290865000900298002000900307035001000316801001900326#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6954.htm#S#c#111#19#article#32#19#^rND^sYilmaz^nH#^rND^sI
sbir^nT#^rND^sAgachan^nB#^rND^sAydin^nM#Is epsilon4 allele of apolipoprotein E a
ssociated with more severe end-organ damage in essential hypertension?^len#Cell 
Biochem Funct#20010000#2001#19#191-195#20080200#6954.htm#0263-6484#Cell Biochem 
Funct##
00736000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100018000910100
01800109010001800127010001500145010001500160810000600175012013600181030001400317
06500090033106400050034003100030034501400080034886500090035600200090036503500100
0374801001400384#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#c#112#20#a
rticle#32#20#^rND^sImazu^nM#^rND^sYamamoto^nH#^rND^sToyofuku^nM#^rND^sWatanabe^n
T#^rND^sOkubo^nM#^rND^sEgusa^nG#et al#Association of apolipoprotein E phenotype 
with hypertension in Japanese-Americans: data from the Hawaii-Los Angeles-Hirosh
ima Study^len#Hypertens Res#20010000#2001#24#523-529#20080200#6954.htm#0916-9636
#Hypertens Res##
00662000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930100
01600110010001600126010001800142010002000160810000600180012007200186030003000258
71000020028806500090029006400050029903100040030401400100030886500090031800200090
0327#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#c#113#21#article#32#21
#^rND^sScuteri^nA#^rND^sNajjar^nSS#^rND^sMuller^nD#^rND^sAndres^nR#^rND^sMorrell
^nCH#^rND^sZonderman^nAB#et al#ApoE4 allele and the natural history of cardiovas
cular risk factors^len#Am J Physiol Endocrinol Metab#2#20050000#2005#289#E322-E3
27#20080200#6954.htm##
00696000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100018000950100
01600113010002000129010002100149012011700170030002000287065000900307064000500316
031000300321014001000324865000900334002000900343035001000352801002000362#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#c#114#22#article#32#22#^rND^sFuzik
awa^nAK#^rND^sPeixoto^nSV#^rND^sTaufer^nM#^rND^sMoriguchi^nEH#^rND^sLima-Costa^n
MF#Apolipoprotein E polymorphism distribution in an elderly Brazilian population
: the Bambuí Health and Aging Study^len#Braz J Med Biol Res#20070000#2007#40#142
9-1434#20080200#6954.htm#0100-879X#Braz J Med Biol Res##
00731000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01600111010001700127010001800144010002100162012013500183030001700318065000900335
06400050034403100030034901400080035286500090036000200090036903500100037880100170
0388#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#c#115#23#article#32#23
#^rND^sBarreto^nSM#^rND^sPassos^nVM#^rND^sFirmo^nJO#^rND^sGuerra^nHL#^rND^sVidig
al^nPG#^rND^sLima-Costa^nMF#Hypertension and clustering of cardiovascular risk f
actors in a community in Southeast Brazil - The Bambuí Health and Ageing Study^l
en#Arq Bras Cardiol#20010000#2001#77#576-581#20080200#6954.htm#0066-782X#Arq Bra
s Cardiol##
00723000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760100018000970100
01500115010001600130010001800146010001700164012011600181030002400297065000900321
06400050033003100020033501400080033786500090034500200090035403500100036380100240
0373#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#c#116#24#article#32#24
#^rND^sLima-Costa^nMF#^rND^sBarreto^nSM#^rND^sUchoa^nE#^rND^sFirmo^nJO#^rND^sVid
igal^nPG#^rND^sGuerra^nHL#The Bambuí Health and Aging Study (BHAS): prevalence o
f risk factors and use of preventive health care services^len#Rev Panam Salud Pu
blica#20010000#2001#9#219-227#20080200#6954.htm#1020-4989#Rev Panam Salud Public
a##
00708000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100015000920100
01700107010001600124010001800140010001800158012015500176030001800331710000200349
065000900351064000500360031000300365014000800368865000900376002000900385#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#c#117#25#article#32#25#^rND^sCosta
^nMF#^rND^sUchoa^nE#^rND^sGuerra^nHL#^rND^sFirmo^nJO#^rND^sVidigal^nPG#^rND^sBar
reto^nSM#The Bambuí health and ageing study (BHAS): methodological approach and 
preliminary results of a population-based cohort study of the elderly in Brazil^
len#Rev Saúde Pública#2#20000000#2000#34#126-135#20080200#6954.htm##
00739000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100017000960100
01600113010001800129010001600147010001800163810000600181012014800187030000500335
06500090034006400050034903100040035401400100035886500090036800200090037703500100
0386801000500396#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#c#118#26#a
rticle#32#26#^rND^sChobanian^nAV#^rND^sBakris^nGL#^rND^sBlack^nHR#^rND^sCushman^
nWC#^rND^sGreen^nLA#^rND^sIzzo^nJL Jr#et al#The Seventh Report of the Joint Nati
onal Committee on Prevention, Detection, Evaluation, and Treatment of High Blood
 Pressure: the JNC 7 report^len#JAMA#20030000#2003#289#2560-2572#20080200#6954.h
tm#0098-7484#JAMA##
00491000000000205000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730170026000760180097001020620
04100199061002700240865000900267002000900276#v41n2#v:\scielo\serial\bjmbr\v41n2\
markup\6954.htm#S#c#119#27#article#32#27#World Health Organization#Anatomical Th
erapeutical Chemical (ATC) classification index with Defined Daily Doses (DDDs)^
len#http://www.whocc.no/atcddd/indexdatabase#Accessed February 10, 2005#20080200
#6954.htm##
00563000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930120
09700111030001200208065000900220064000500229031000300234014000800237865000900245
002000900254035001000263801001200273#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
954.htm#S#c#120#28#article#32#28#^rND^sHixson^nJE#^rND^sVernier^nDT#Restriction 
isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI
^len#J Lipid Res#19900000#1990#31#545-548#20080200#6954.htm#0022-2275#J Lipid Re
s##
00636000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100017000960100
02000113010001600133012010900149030001100258065000900269064000500278031000400283
014000800287865000900295002000900304035001000313801001100323#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6954.htm#S#c#121#29#article#32#29#^rND^sWattanakit^nK#^rN
D^sFolsom^nAR#^rND^sChambless^nLE#^rND^sNieto^nFJ#Risk factors for cardiovascula
r event recurrence in the Atherosclerosis Risk in Communities (ARIC) study^len#A
m Heart J#20050000#2005#149#606-612#20080200#6954.htm#0002-8703#Am Heart J##
00684000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100018000950100
02100113010001400134010001700148010001600165012010000181030001300281065000900294
06400050030303100030030801400060031186500090031700200090032603500100033580100130
0345#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#c#122#30#article#32#30
#^rND^sSundstrom^nJ#^rND^sSullivan^nL#^rND^sD'Agostino^nRB#^rND^sLevy^nD#^rND^sK
annel^nWB#^rND^sVasan^nRS#Relations of serum uric acid to longitudinal blood pre
ssure tracking and hypertension incidence^len#Hypertension#20050000#2005#45#28-3
3#20080200#6954.htm#0194-911X#Hypertension##
00659000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01700110010001400127010001800141010001400159810000600173012005900179030001400238
06500090025206400050026103100030026601400100026986500090027900200090028803500100
0297801001400307#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#c#123#31#a
rticle#32#31#^rND^sGenuth^nS#^rND^sAlberti^nKG#^rND^sBennett^nP#^rND^sBuse^nJ#^r
ND^sDefronzo^nR#^rND^sKahn^nR#et al#Follow-up report on the diagnosis of diabete
s mellitus^len#Diabetes Care#20030000#2003#26#3160-3167#20080200#6954.htm#0149-5
992#Diabetes Care##
00522000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760120083000890300
01500172065000900187064000500196031000400201014000800205865000900213002000900222
035001000231801001500241#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6954.htm#S#c#
124#32#article#32#32#^rND^sZou^nG#A modified poisson regression approach to pros
pective studies with binary data^len#Am J Epidemiol#20040000#2004#159#702-706#20
080200#6954.htm#0002-9262#Am J Epidemiol##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#o#1#1#article#1#20
080402#165812#7057.htm#162##
02240000000000625000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400090014103500100015022300090016001200730
01690100023002420100023002650100024002880100024003120700098003360830779004340850
00801213085002001221085002401241085004101265085002301306085002301329117000601352
07200030135805300870136105500120144805400190146005800410147906000070152011200090
1527111001901536114000901555113001701564881002401581002000901605#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#h#2#1#article#1#ra#en#bjmbr#1#3.1#ILUS#01#
BJMBR090#nd#Braz J Med Biol Res#41#2#20080200#^f82^l88#0100-879X#20080111#Vitami
n B1 and B6 in the malaria parasite: requisite or dispensable?^len#^rND^1A01^nC.
^sWrenger#^rND^1A01^nJ.^sKnöckel#^rND^1A01^nR.D.^sWalter#^rND^1A01^nI.B.^sMüller
#Bernhard Nocht Institute for Tropical Medicine^iA01^1Department of Biochemistry
^cHamburg^pGermany#^len^aVitamins are essential compounds mainly involved in act
ing as enzyme co-factors or in response to oxidative stress. In the last two yea
rs it became apparent that apicomplexan parasites are able to generate B vitamer
s such as vitamin B1 and B6 de novo. The biosynthesis pathways responsible for v
itamin generation are considered as drug targets, since both provide a high degr
ee of selectivity due to their absence in the human host. This report updates th
e current knowledge about vitamin B1 and B6 biosynthesis in malaria and other ap
icomplexan parasites. Owing to the urgent need for novel antimalarials, the sign
ificance of the biosynthesis and salvage of these vitamins is critically discuss
ed in terms of parasite survival and their exploitation for drug development.#^d
nd^i1#^tm^len^kMalaria^i1#^tm^len^kApicomplexa^i1#^tm^len^kPyridoxal phosphate s
ynthase^i1#^tm^len^kVitamin B6^i1#^tm^len^kVitamin B1^i1#other#59#XXXVI Annual M
eeting of the Sociedade Brasileira de Bioquímica e Biologia Molecular^i1#2007052
1^i1#May 21-25, 2007^i1#Deutsche Forschungsgemeinschaft Grant WA#395/15#20070918
#September 18, 2007#20071206#December 6, 2007#S0100-879X2008005000006#7057.htm##
02278000000000637000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087121000300092049000900095158000300104030002000107
03100030012703200020013006500090013201400090014103500100015022300090016001200870
01690100023002560100023002790100024003020100024003260700098003500830786004480850
00801234085002001242085002401262085004101286085002301327085002301350117000601373
07200030137905300870138205600190146905700100148805500120149805400190151005800410
1529060000701570112000901577111001901586114000901605113001701614002000901631#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#f#3#1#article#1#ra#en#bjmbr#1#
3.1#ILUS#01#BJMBR090#nd#Braz J Med Biol Res#41#2#20080200#^f82^l88#0100-879X#200
80111#<b>Vitamin B1 and B6 in the malaria parasite</b>: <b>requisite or dispensa
ble?</b>^len#^rND^1A01^nC.^sWrenger#^rND^1A01^nJ.^sKnöckel#^rND^1A01^nR.D.^sWalt
er#^rND^1A01^nI.B.^sMüller#Bernhard Nocht Institute for Tropical Medicine^iA01^1
Department of Biochemistry^cHamburg^pGermany#^len^aVitamins are essential compou
nds mainly involved in acting as enzyme co-factors or in response to oxidative s
tress. In the last two years it became apparent that apicomplexan parasites are 
able to generate B vitamers such as vitamin B1 and B6 <i>de novo</i>. The biosyn
thesis pathways responsible for vitamin generation are considered as drug target
s, since both provide a high degree of selectivity due to their absence in the h
uman host. This report updates the current knowledge about vitamin B1 and B6 bio
synthesis in malaria and other apicomplexan parasites. Owing to the urgent need 
for novel antimalarials, the significance of the biosynthesis and salvage of the
se vitamins is critically discussed in terms of parasite survival and their expl
oitation for drug development.#^dnd^i1#^tm^len^kMalaria^i1#^tm^len^kApicomplexa^
i1#^tm^len^kPyridoxal phosphate synthase^i1#^tm^len^kVitamin B6^i1#^tm^len^kVita
min B1^i1#other#59#XXXVI Annual Meeting of the Sociedade Brasileira de Bioquímic
a e Biologia Molecular^i1#Salvador^i1^eBA^i1#Brazil^i1#20070521^i1#May 21-25, 20
07^i1#Deutsche Forschungsgemeinschaft Grant WA#395/15#20070918#September 18, 200
7#20071206#December 6, 2007#7057.htm##
02387000000000661000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100121000300105049000900108158000300117
03000240012003100030014403200020014706500090014901400090015803500100016722300090
01770120073001860100022002590100022002810100024003030100024003270700100003510830
77900451085000801230085002001238085002401258085004101282085002301323085002301346
11700060136907200030137505300870137805600190146505700100148405500120149405400190
15060580041015250600007015661120009015731110019015821140009016011130017016100020
00901627008008901636#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#l#4#1#
article#1#^mFeb.^a2008#ra#en#bjmbr#1#3.1#ilus#01#BJMBR090#nd#Braz. j. med. biol.
 res#41#2#20080200#^f82^l88#0100-879X#20080111#Vitamin B1 and B6 in the malaria 
parasite: requisite or dispensable?^len#^rND^1A01^nC^sWrenger#^rND^1A01^nJ^sKnöc
kel#^rND^1A01^nR. D^sWalter#^rND^1A01^nI. B^sMüller#^iA01^1Bernhard Nocht Instit
ute for Tropical Medicine^2Department of Biochemistry^cHamburg^pGermany#^len^aVi
tamins are essential compounds mainly involved in acting as enzyme co-factors or
 in response to oxidative stress. In the last two years it became apparent that 
apicomplexan parasites are able to generate B vitamers such as vitamin B1 and B6
 de novo. The biosynthesis pathways responsible for vitamin generation are consi
dered as drug targets, since both provide a high degree of selectivity due to th
eir absence in the human host. This report updates the current knowledge about v
itamin B1 and B6 biosynthesis in malaria and other apicomplexan parasites. Owing
 to the urgent need for novel antimalarials, the significance of the biosynthesi
s and salvage of these vitamins is critically discussed in terms of parasite sur
vival and their exploitation for drug development.#^dnd^i1#^tm^len^kMalaria^i1#^
tm^len^kApicomplexa^i1#^tm^len^kPyridoxal phosphate synthase^i1#^tm^len^kVitamin
 B6^i1#^tm^len^kVitamin B1^i1#other#59#XXXVI Annual Meeting of the Sociedade Bra
sileira de Bioquímica e Biologia Molecular^i1#Salvador^i1^eBA^i1#Brazil^i1#20070
521^i1#May 21-25, 2007^i1#Deutsche Forschungsgemeinschaft Grant WA#395/15#200709
18#September 18, 2007#20071206#December 6, 2007#7057.htm#Internet^ihttp://www.sc
ielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000200001##
00395000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704017000070002000900240#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#5#1#article#99#<P class="style4"> <A NAM
E="Home"></A><B>Braz J Med Biol Res, <font face="Arial, Helvetica, sans-serif">F
ebruary 2008, Volume 41(2) 82-88</font> (Review)</B></P>     ^cY#7057.htm##
00371000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704014600070002000900216#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#6#2#article#99#<P><font size="5" face="A
rial, Helvetica, sans-serif"><B>Vitamin B1 and B6 in the malaria parasite: requi
site or dispensable?</B> </font>     ^cY#7057.htm##
00599000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704037400070002000900444#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#7#3#article#99#<P><font face="Arial, Hel
vetica, sans-serif"><span class="style2"><span class="style4"><a href="#Correspo
ndence"><img src="/img/revistas/bjmbr/v41n2/recor.gif" border="0"></a> <a href="
mailto:wrenger@bni-hamburg.de"><img src="/img/revistas/bjmbr/v41n2/email-ca.gif"
 border="0"></a></span></span> C. Wrenger, J. Kn&ouml;ckel, R.D. Walter and I.B.
 M&uuml;ller </font>     ^cY#7057.htm##
00378000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704015300070002000900223#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#8#4#article#99#<P><font face="Arial, Hel
vetica, sans-serif">Department of Biochemistry, Bernhard Nocht Institute for Tro
pical Medicine, Hamburg, Germany</font>     ^cY#7057.htm##
00464000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704023900070002000900309#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#9#5#article#99#<P class="style4"> <A HRE
F="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=
0 VSPACE=0 HSPACE=0></A>    <A HREF="#Abstract"><strong><font face="Arial, Helve
tica, sans-serif">Abstract</font></strong></A>    ^cY#7057.htm##
00441000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704021500071002000900286#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#10#6#article#99#<BR>   <A HREF="#Text"><
IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0></A>    <A HREF="#Text"><strong><font face="Arial, Helvetica, sans-serif">T
ext</font></strong></A>    ^cY#7057.htm##
00446000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704022000071002000900291#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#11#7#article#99#<BR>   <A HREF="#Referen
ces"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=
0 HSPACE=0></A>    <A HREF="#References"><strong><font face="Arial, Helvetica, s
ans-serif">References</font>    ^cY#7057.htm##
00538000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704031200071002000900383#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#12#8#article#99#<br>   </strong></A> <A 
HREF="#Correspondence"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTO
M BORDER=0 VSPACE=0 HSPACE=0></A>    <A HREF="#Correspondence"><strong><font fac
e="Arial, Helvetica, sans-serif">Correspondence    and Footnotes</font></strong>
</a>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#7057.htm##
00616000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704039000071002000900461#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#13#9#article#99#<P class="style4"> <A NA
ME="Abstract"></A><span class="style3"><font color="#00007F" face="Arial, Helvet
ica, sans-serif" size="4"><b>Abstract</b></font><FONT COLOR=#00007F>    </FONT><
/span><A HREF="#Home"><FONT SIZE=4><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.g
if" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A>  </P> <font
 face="Arial, Helvetica, sans-serif">     ^cY#7057.htm##
01018000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704079100072002000900863#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#14#10#article#99#<P>Vitamins are essenti
al compounds mainly involved in acting as enzyme co-factors or in response to ox
idative stress. In the last two years it became apparent that apicomplexan paras
ites are able to generate B vitamers such as vitamin B1 and B6 <I>de novo</I>. T
he biosynthesis pathways responsible for vitamin generation are considered as dr
ug targets, since both provide a high degree of selectivity due to their absence
 in the human host. This report updates the current knowledge about vitamin B1 a
nd B6 biosynthesis in malaria and other apicomplexan parasites. Owing to the urg
ent need for novel antimalarials, the significance of the biosynthesis and salva
ge of these vitamins is critically discussed in terms of parasite survival and t
heir exploitation for drug development.     ^cY#7057.htm##
00365000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704013800072002000900210#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#15#11#article#99#<P>Key words: Malaria; 
Apicomplexa; Pyridoxal phosphate synthase; Vitamin B6; Vitamin B1</font> <HR ALI
GN=LEFT WIDTH=100% SIZE=2>     ^cY#7057.htm##
00566000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033900072002000900411#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#16#12#article#99#<P class="style4"><A NA
ME="Text"></A><FONT SIZE=4><B> <span class="style3"><font color="#00007F" face="
Arial, Helvetica, sans-serif">Text</font></span>    <a href="#Home"><IMG SRC="/i
mg/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0 LOOP="
0"></a></B></FONT>  </P> <font face="Arial, Helvetica, sans-serif">     ^cY#7057
.htm##
00268000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004100072002000900113#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#17#13#article#99#<P><strong>Introduction
</strong>     ^cY#7057.htm##
00880000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704065300072002000900725#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#18#14#article#99#<P>Apicomplexan parasit
es have a significant impact on human and livestock health, and chemotherapy rem
ains a problem. The most important apicomplexan parasite is <I>Plasmodium</I>, t
he pathogenic agent of malaria. Malaria is a devastating and quite often a deadl
y parasitic disease which causes important public health problems in the tropics
. However, coccidiosis caused by <I>Cryptosporidia</I> and <I>Toxoplasma</I> inf
ections also pose a serious threat especially to immunocompromised people such a
s HIV patients all over the world and first infection with <I>Toxoplasma</I> dur
ing pregnancy can lead to developmental damage to the fetus.      ^cY#7057.htm##
00816000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704058900072002000900661#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#19#15#article#99#<P>Due to the high muta
tional rate of <I>Plasmodium falciparum</I> and its resulting rapid adaptation t
o environmental changes, drug resistance to the standard medication with chloroq
uine and antifolates is increasing. Therefore, continuous discovery of novel dru
g targets and development of new chemotherapeutic agents are inevitable. It has 
been claimed that antiparasitic compounds should preferably be created to target
 only the parasite without harming the human host. In this respect, the biosynth
esis of parasite-specific vitamin B1 and B6 represents an ideal drug target.    
  ^cY#7057.htm##
00304000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704007700072002000900149#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#20#16#article#99#<P><strong>Alternative 
pathways of vitamin B6 biosynthesis </strong>     ^cY#7057.htm##
01884000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704165700072002000901729#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#21#17#article#99#<P>Two different pathwa
ys for the synthesis of vitamin B6 are currently known. While 4-phosphohydroxy-L
-threonine and 1-deoxyxylulose 5'-phosphate (DOXP) are substrates in the <I>Esch
erichia coli</I> (DOXP-dependent) pathway (1,2), vitamin B6 is synthesized from 
ribose 5'-phosphate, glyceraldehyde 3'-phosphate and glutamine in a DOXP-indepen
dent or fungus-like pathway (3-8). The DOXP-independent pathway has been identif
ied in fungi, plants and some bacteria and was originally considered to be invol
ved in the detoxification of singlet oxygen (<SUP>1</SUP>O<SUB>2</SUB>) (3,9). H
owever, the analysis of fungal mutants deficient in singlet oxygen resistance (S
OR1), and therefore sensitive to singlet oxygen, demonstrated that the product o
f this gene also participates in pyridoxine biosynthesis (3,4,9). The SOR1 enzym
e (also named Pdx1) belongs to the highly conserved enzyme family SNZ in <I>Sacc
haromyces cerevisiae</I>. The SNZ1 protein has been shown to interact with the S
NO1 protein (5), also named Pdx2, which is a member of another preserved family 
in yeast consisting of three SNO enzymes (10). The involvement of Pdx2 in <I>de 
novo</I> vitamin B6 synthesis was confirmed by complementation assays of mutants
 deficient in pyridoxine biosynthesis (11). This pathway for vitamin B6 biosynth
esis has been demonstrated in various other organisms such as <I>Bacillus subtil
is</I> and <I>Arabidopsis thaliana</I> (6,9,12-14). In contrast to the <I>E. col
i</I>-like formation of vitamin B6 leading to pyridoxine 5'-phosphate, the synth
esis of the latter pathway results directly in pyridoxal phosphate (PLP), the ac
tive form of vitamin B6.      ^cY#7057.htm##
01446000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704121900072002000901291#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#22#18#article#99#<P>A few years ago Cass
era et al. (15), using labeling experiments, suggested the presence of a vitamin
 B6 metabolite in <I>P. falciparum</I> which we later reported to be produced vi
a the DOXP-independent pathway (16) (<strong><a href="#Fig1">Figure 1</a></stron
g>). Moreover, we demonstrated a homologous pathway in the other apicomplexan pa
rasite <I>Toxoplasma gondii</I>, where PLP synthesis also is a product of the si
ngle copy genes Pdx1 and Pdx2 (17). The two proteins need to act together for en
zyme activity, similar to the homologous yeast proteins SNZ1 and SNO1 (6). The f
unctionality of the two proteins of the apicomplexan parasites was verified by c
omplementation of vitamin B6-deficient yeast strains (16). As is the case for ye
ast, in apicomplexa vitamin B6 is directly synthesized in its active form PLP (7
,8,17,18). The Pdx1 protein is responsible for the creation of PLP by utilizing 
pentose, triose as well as ammonia. The ammonia is provided by the Pdx2 protein,
 which possesses glutaminase activity. Interestingly, the activity of Pdx1 is no
t dependent on the presence of Pdx2 if glutamine is replaced by ammonia, whereas
 the activity of Pdx2 relies on its interaction with Pdx1 (16,17).      ^cY#7057
.htm##
01964000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704173700072002000901809#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#23#19#article#99#<P>The crystal structur
es of the <I>B. subtilis</I> and <I>Geobacillus stearothermophilus</I> Pdx1 and 
Pdx2 homologues have already been solved (19,20). The structures of the entire P
dx1/Pdx2 complex from <I>B. subtilis</I> and <I>Thermotoga maritima</I> have bee
n analyzed only recently, with the identification of PLP synthase as a multimeri
c protein complex consisting of 12 Pdx1 proteins decorated by 12 Pdx2 proteins (
21,22). These data suggest a channel between the individual Pdx1 and Pdx2 protei
ns for the transfer of the ammonia produced from Pdx2 towards the active site of
 Pdx1. Amino acid residues involved in the enzyme activity of Pdx1 proteins (21,
23) are also present in the Pdx1 enzymes of the apicomplexan parasites <I>P. fal
ciparum</I> and <I>T. gondii</I>. Interestingly, analyses of the genome data ava
ilable for <I>Eimeria</I> or <I>Cryptosporidia</I> and for other protozoan paras
ites such as <I>Trypanosoma</I> and <I>Leishmania</I> did not reveal any indices
 for genes involved in <I>de novo</I> vitamin B6 synthesis. This clearly indicat
es that PLP biosynthesis is not a general event in protozoan parasites. Parasite
s which are dependent on external sources of vitamin B6 need to take up this nut
rient like the human host. After import, B6 vitamers are immediately phosphoryla
ted and thereby trapped within the cell. This catalysis is carried out by pyrido
xine kinase (PdxK) (24-27). In addition to performing <I>de novo</I> synthesis, 
the malaria parasite also holds a PdxK which enables <I>P. falciparum</I> to sal
vage B6 vitamers (16) (<strong><a href="#Fig1">Figure 1</a></strong>). However, 
the value of the dual PLP provision in <I>Plasmodium</I> is not known and needs 
to be further analyzed.       ^cY#7057.htm##
00303000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704007600072002000900148#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#24#20#article#99#<P><b>Suitability of vi
tamin B6 biosynthesis for chemotherapy </b>      ^cY#7057.htm##
01249000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704102200072002000901094#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#25#21#article#99#<P>The question arises 
whether vitamin B6 metabolism can be exploited to develop novel antimalarials. I
n general, there are two options to interfere with the biosynthesis of plasmodia
l vitamin B6. i) Since the crystal structure of PLP synthase was solved for <I>T
. maritima</I> and <I>B. subtilis</I>, the design of inhibitors targeting this e
nzyme complex in order to block biosynthesis was facilitated (21,22). Neverthele
ss, rational drug design will benefit from structural analyses of the plasmodial
 PLP synthase crystal to detect parasite-specific targets. ii) On the other hand
, emphasis should also be placed on unphosphorylated B6 vitamers, which after up
take are phosphorylated by PdxK and trapped within the parasite (16). Derivative
s of these vitamers offer the strategy of channeling inactive co-factors into th
e depot of PLP, thereby poisoning PLP-dependent enzymes. Both strategies have a 
high potential for the design of novel drugs in order to interfere with the para
site's vitamin B6 metabolism.      ^cY#7057.htm##
00288000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704006100072002000900133#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#26#22#article#99#<P><strong>Vitamin B1 a
nd its biosynthesis </strong>     ^cY#7057.htm##
02292000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704206500072002000902137#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#27#23#article#99#<P>Until recently only 
prokaryotes, fungi and plants were reported to synthesize vitamin B1. Mammals en
tirely depend on the salvage of vitamin B1 from their diet. The active form of v
itamin B1 is thiamine pyrophosphate (TPP) which is a co-factor for various enzym
es mainly involved in carbohydrate metabolism such as 2-oxoglutarate dehydrogena
se, pyruvate dehydrogenase or transketolase (28,29). The biosynthesis of thiamin
e occurs by the combination of two different branches. The pyrimidine branch pro
vides 4-amino-5-hydroxymethyl-2-methylpyrimidine (HMP), which has to be phosphor
ylated to HMP diphosphate (HMP-PP) in two consecutive steps by HMP/HMP-P kinase 
(ThiD; <strong><a href="#Fig2">Figure 2</a></strong>) (30-33). In bacteria HMP i
tself is formed from precursors of the purine biosynthesis by the HMP synthesis 
enzyme ThiC (34), whereas in yeast the Thi5 protein is suggested to link pyridox
ine 5'-phosphate and histidine to form HMP-P (35-37). The product of the other b
ranch is 5-(2-hydroxyethyl)-4-methylthiazole phosphate (THZ-P), which can also b
e provided by the salvage of THZ upon phosphorylation by THZ kinase (ThiM) (38,3
9). Subsequently, the respective phosphorylated pyrimidine and thiazole moieties
, HMP-PP and THZ-P, are amalgamated by thiamine phosphate synthase (ThiE) to for
m thiamine phosphate (TMP) (40). An additional phosphorylation step by TMP kinas
e (ThiL) would be necessary for this to become the active diphosphorylated form 
(32). However, in yeast as well as in some bacteria ThiL is absent. Therefore, i
t has been suggested that TMP is first dephosphorylated by a phosphatase before 
it is pyrophosphorylated by thiamine pyrophosphokinase (TPK) (41,42). The malari
a parasite contains the genes encoding for the vitamin B1 synthesis enzymes ThiM
, ThiD, and ThiE and their expression and functionality was confirmed (33,43) (<
strong><a href="#Fig2">Figure 2</a></strong>). Consistent with the situation in 
other organisms, an open-reading frame encoding for ThiL is not found in the pla
smodial genome database.  </font>     ^cY#7057.htm##
00381000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704015400072002000900226#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#28#24#article#99#<P> <font face="Arial, 
Helvetica, sans-serif"><strong>Creation of a &quot;thiamine pool&quot; in <em>Pl
asmodium falciparum</em></strong> </font>      ^cY#7057.htm##
00931000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704070400072002000900776#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#29#25#article#99#<P><font face="Arial, H
elvetica, sans-serif">Instead of ThiL, a gene with homology to TPK has been iden
tified (43,44) and analyzed for its kinetic parameters (45) (<strong><a href="#F
ig2">Figure 2</a></strong>). The plasmodial TPK does not accept the <I>de novo</
I> synthesized TMP as substrate, which means that TMP must first be dephosphoryl
ated to thiamine before it is pyrophosphorylated to TPP by <I>Pf</I>TPK (45). Th
e dephosphorylation of TMP is thought to be carried out by a non-specific phosph
atase (46). Recently, such a phosphatase was characterized and its substrate spe
cificity for PLP and TMP shown (Kn&ouml;ckel J, M&uuml;ller IB, Walter RD, Wreng
er C, unpublished data). </font>     ^cY#7057.htm##
01175000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704094800072002000901020#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#30#26#article#99#<P><font face="Arial, H
elvetica, sans-serif">Pyrophosphorylation of thiamine to TPP takes place solely 
in the cytosol of the parasite, as demonstrated by immunofluorescence assays of 
<I>Pf</I>TPK (45). However, TPP- dependent enzymes are located not only in the c
ytosol but also in different compartments, a fact that raises the question of TP
P transport in these plasmodial organelles (<strong><a href="#Fig2">Figure 2</a>
</strong>). For instance, the TPP-dependent pyruvate dehydrogenase complex is ta
rgeted to the apicoplast, whereas the 2-oxoglutarate dehydrogenase complex has b
een reported to be mitochondrial (47,48). Assuming that thiamine is pyrophosphor
ylated exclusively in the cytosol, <I>P. falciparum</I> must hold specific trans
porters to fulfill the need for TPP of both organelle-specific dehydrogenase com
plexes. The relocation of TPP into the yeast mitochondrion by a specific transpo
rter has been reported (49). </font>     ^cY#7057.htm##
00381000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704015400072002000900226#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#31#27#article#99#<P><strong><font face="
Arial, Helvetica, sans-serif">Does plasmodial vitamin B1 biosynthesis serve as a
 target for chemotherapy? </font></strong>     ^cY#7057.htm##
00913000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704068600072002000900758#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#32#28#article#99#<P><font face="Arial, H
elvetica, sans-serif">Promising attempts to exploit vitamin B1 biosynthesis for 
chemotherapy have been made in bacteria by using the naturally occurring HMP ana
logue bacimethrin (MeO-HMP) or the synthetic CF<SUB>3</SUB>-HMP compound (50,51)
. Although the former compound was successfully tested as a substrate for the pl
asmodial ThiD protein, bacimethrin did not affect the proliferation rate of the 
parasite, a fact that could be explained by an inefficient salvage of this analo
gue (33). Nevertheless, HMP derivatives as such should be considered as promisin
g drug candidates against the malaria parasite, as already shown for bacteria (3
3,51). </font>     ^cY#7057.htm##
02055000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704182800072002000901900#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#33#29#article#99#<P><font face="Arial, H
elvetica, sans-serif">Culturing <I>P. falciparum</I> in thiamine-free medium for
 a few days showed no adverse effect on parasite growth behavior (52); however, 
extending the period of culture in vitamin B1-deficient medium to ten days revea
led a significant need for the externally supplied thiamine precursor HMP or thi
amine itself for growth (33). The necessity of HMP in the medium clearly indicat
es that the parasite is able to create thiamine but depends on added HMP. Consis
tent with these results a homologue of the yeast-like Thi5 enzyme was not found 
in the plasmodial genome database, indicating the absence of a linkage of the vi
tamin B6 and B1 biosynthesis pathways (36,53-55). Furthermore, there is no plasm
odial homologue coding for the bacterial ThiC protein, the enzyme that catalyzes
 the formation of HMP from aminoimidazole ribonucleotide, an intermediate of pur
ine synthesis (32). The latter is not surprising since purine biosynthesis is ab
sent in the malaria parasite (56). Considering that <I>Plasmodium</I> can either
 salvage HMP - as mentioned above - or thiamine for the formation of TPP offers 
novel chemotherapeutic strategies to import pro-drugs in the form of HMP or thia
mine derivatives. Indeed, pyrithiamine and thiochrome, both thiamine derivatives
, were tested as substrates for plasmodial TPK. While pyrithiamine is accepted e
quivalently to thiamine as substrate, thiochrome is not phosphorylated by <I>Pf<
/I>TPK (45). However, testing pyrithiamine on cultured parasites did not reveal 
any anti-proliferative effect even at a concentration of 0.5 mM, implying an ins
ufficient uptake of this analogue by the parasite or poor targeting of vitamin B
1-dependent enzymes by its pyrophosphorylated form (M&uuml;ller IB, Walter RD, W
renger C, unpublished data). </font>     ^cY#7057.htm##
00935000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704070800072002000900780#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#34#30#article#99#<P><font face="Arial, H
elvetica, sans-serif">Interestingly, cultivation of the parasite in THZ-deficien
t medium led to normal growth, suggesting that <I>P. falciparum</I> might be abl
e to generate THZ <I>de novo</I>. Despite the use of bioinformatic tools, genes 
coding for THZ biosynthesis enzymes could not be identified in the plasmodial ge
nome database (57). The synthesis of either the pyrimidine or the thiazole moiet
y was discussed for various other organisms, requiring the other part to be salv
aged (28,58,59). This might be also the case for the malaria parasite; however, 
we cannot exclude a THZ biosynthesis pathway different from the prokaryotic path
way in <I>P. falciparum</I>. </font>     ^cY#7057.htm##
00374000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704014700072002000900219#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#35#31#article#99#<P><font face="Arial, H
elvetica, sans-serif"><strong>Does vitamin B1 biosynthesis occur in other apicom
plexan parasites? </strong></font>      ^cY#7057.htm##
01712000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704148500072002000901557#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#36#32#article#99#<P><font face="Arial, H
elvetica, sans-serif">Enzymes involved in vitamin B1 synthesis    as shown for <
I>P. falciparum </I>are apparently absent in the genome of the    apicomplexan r
elatives <I>E. tenella</I> (<strong><a href="http://www.sanger.ac.uk/Projects/E_
tenella/" target="_blank">http://www.sanger.ac.uk/Projects/E_tenella/</a></stron
g>),    and <I>T. gondii</I> (<strong><a href="http://www.toxodb.org/toxo/home.j
sp" target="_blank">http://www.toxodb.org/toxo/home.jsp</a></strong>)    (17). T
his major difference poses questions about evolutionary adaptation of    these p
arasites to their hosts. Assuming that the ancestor of apicomplexa had    the po
tential to synthesize vitamin B1 <I>de novo</I> or at least to salvage    the TH
Z- and HMP-moieties, apicomplexan parasites like <I>T. gondii</I> have    lost t
heir ability to synthesize vitamin B1<I> de novo</I> during evolution.    Theref
ore, these parasites entirely depend on thiamine uptake to satisfy their    need
s, a fact that might be explained by their perfect accommodation to their    hos
t cells. The malaria parasite, however, still expresses a rudimentary set    of 
vitamin B1 synthesis enzymes pointing out an insufficient vitamin B1 supply    f
rom its host. This distinct adaptation of apicomplexan parasites may result    f
rom life cycle and host cell specificity. Further analyses are required to    so
lve the riddle concerning <I>de novo</I> co-factor synthesis, uptake and salvage
.    </font>      ^cY#7057.htm##
00933000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704070600072002000900778#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#37#33#article#99#<P><font face="Arial, H
elvetica, sans-serif">In summary, vitamins B1 and B6 are essential co-factors an
d their biosyntheses offer a powerful potential as drug targets, since these pat
hways are absent in the human host. Ongoing studies on the structures of the enz
ymes involved in vitamin B1 and B6 synthesis will allow the design of specific i
nhibitors blocking these crucial pathways and thereby impairing parasite growth.
 </font> <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <t
r align="left" valign="top">     <td width="12%"><a href="/img/revistas/bjmbr/v4
1n2/html/7057i01.htm"><img src="/img/revistas/bjmbr/v41n2/7057i01peq.jpg" border
="2"></a></td>     <td width="88%">    ^cY#7057.htm##
00448000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704022100072002000900293#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#38#34#article#99#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig1"></a>Figure 1. Vitamin B6 biosynthesis in <I
>Plasmodium falciparum. </I>For explanation of the abbreviations see text. </fon
t>     </td>   </tr> </table>     ^cY#7057.htm##
00887000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704066000072002000900732#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#39#35#article#99#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (79 K JPG file)]</font>
 <HR ALIGN=LEFT WIDTH=100% SIZE=2> <table width="100%"  border="0">   <tr align=
"left" valign="top">     <td width="12%"><a href="/img/revistas/bjmbr/v41n2/html
/7057i02.htm"><img src="/img/revistas/bjmbr/v41n2/7057i02peq.jpg" border="2"></a
></td>     <td width="88%"><font face="Arial, Helvetica, sans-serif"><a name="Fi
g2"></a>Figure 2. Generation of thiamine pyrophosphate and its trafficking withi
n <i>Plasmodium falciparum</i>. Transport mechanisms are indicated by . For expl
anation of the abbreviations see text.</font> </td>   </tr> </table>     ^cY#705
7.htm##
00374000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704014700072002000900219#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#40#36#article#99#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (238 K JPG file)]</font
> <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#7057.htm##
00534000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704030700072002000900379#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#41#37#article#99#<P class="style4"> <A N
AME="References"></A><FONT color="#00007F" SIZE=4><B><font face="Arial, Helvetic
a, sans-serif">References</font></B></FONT>    <A HREF="#Home"><FONT SIZE=4><B><
IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPA
CE=0 LOOP="0"></B></FONT></A>  </P>     ^cY#7057.htm##
00484000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704024300074002000900317#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#42#38#article#99#1#<P><font 
face="Arial, Helvetica, sans-serif">1. Roa BB, Connolly DM, Winkler ME. Overlap 
between pdxA and ksgA in the complex pdxA-ksgA-apaG-apaH operon of <I>Escherichi
a coli</I> K-12. <I>J Bacteriol</I> 1989; 171: 4767-4777. </font>     ^cY#7057.h
tm##
00502000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704026100074002000900335#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#43#39#article#99#2#<P><font 
face="Arial, Helvetica, sans-serif">2. Lam HM, Tancula E, Dempsey WB, Winkler ME
. Suppression of insertions in the complex pdxJ operon of <I>Escherichia coli</I
> K-12 by lon and other mutations. <I>J Bacteriol</I> 1992; 174: 1554-1567. </fo
nt>     ^cY#7057.htm##
00533000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704029200074002000900366#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#44#40#article#99#3#<P><font 
face="Arial, Helvetica, sans-serif">3. Ehrenshaft M, Jenns AE, Chung KR, Daub ME
. SOR1, a gene required for photosensitizer and singlet oxygen resistance in <I>
Cercospora</I> <I>fungi</I>, is highly conserved in divergent organisms. <I>Mol 
Cell</I> 1998; 1: 603-609. </font>     ^cY#7057.htm##
00544000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704030300074002000900377#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#45#41#article#99#4#<P><font 
face="Arial, Helvetica, sans-serif">4. Osmani AH, May GS, Osmani SA. The extreme
ly conserved pyroA gene of <I>Aspergillus nidulans</I> is required for pyridoxin
e synthesis and is required indirectly for resistance to photosensitizers. <I>J 
Biol Chem</I> 1999; 274: 23565-23569. </font>     ^cY#7057.htm##
00537000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704029600074002000900370#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#46#42#article#99#5#<P><font 
face="Arial, Helvetica, sans-serif">5. Padilla PA, Fuge EK, Crawford ME, Errett 
A, Werner-Washburne M. The highly conserved, coregulated SNO and SNZ gene famili
es in <I>Saccharomyces cerevisiae</I> respond to nutrient limitation. <I>J Bacte
riol</I> 1998; 180: 5718-5726. </font>     ^cY#7057.htm##
00512000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704027100074002000900345#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#47#43#article#99#6#<P><font 
face="Arial, Helvetica, sans-serif">6. Dong YX, Sueda S, Nikawa J, Kondo H. Char
acterization of the products of the genes SNO1 and SNZ1 involved in pyridoxine s
ynthesis in <I>Saccharomyces cerevisiae</I>. <I>Eur J Biochem</I> 2004; 271: 745
-752. </font>     ^cY#7057.htm##
00508000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704026700074002000900341#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#48#44#article#99#7#<P><font 
face="Arial, Helvetica, sans-serif">7. Burns KE, Xiang Y, Kinsland CL, McLaffert
y FW, Begley TP. Reconstitution and biochemical characterization of a new pyrido
xal-5'-phosphate biosynthetic pathway. <I>J Am Chem Soc</I> 2005; 127: 3682-3683
. </font>     ^cY#7057.htm##
00474000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704023300074002000900307#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#49#45#article#99#8#<P><font 
face="Arial, Helvetica, sans-serif">8. Raschle T, Amrhein N, Fitzpatrick TB. On 
the two components of pyridoxal 5'-phosphate synthase from <I>Bacillus subtilis<
/I>. <I>J Biol Chem</I> 2005; 280: 32291-32300. </font>     ^cY#7057.htm##
00507000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704026600074002000900340#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#50#46#article#99#9#<P><font 
face="Arial, Helvetica, sans-serif">9. Ehrenshaft M, Bilski P, Li MY, Chignell C
F, Daub ME. A highly conserved sequence is a novel gene involved in <I>de novo</
I> vitamin B6 biosynthesis. <I>Proc Natl Acad Sci U S A</I> 1999; 96: 9374-9378.
 </font>     ^cY#7057.htm##
00525000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028300075002000900358#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#51#47#article#99#10#<P><font
 face="Arial, Helvetica, sans-serif">10. Rodriguez-Navarro S, Llorente B, Rodrig
uez-Manzaneque MT, Ramne A, Uber G, Marchesan D, et al. Functional analysis of y
east gene families involved in metabolism of vitamins B1 and B6. <I>Yeast</I> 20
02; 19: 1261-1276. </font>     ^cY#7057.htm##
00508000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026600075002000900341#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#52#48#article#99#11#<P><font
 face="Arial, Helvetica, sans-serif">11. Ehrenshaft M, Daub ME. Isolation of PDX
2, a second novel gene in the pyridoxine biosynthesis pathway of eukaryotes, arc
haebacteria, and a subset of eubacteria. <I>J Bacteriol</I> 2001; 183: 3383-3390
. </font>     ^cY#7057.htm##
00492000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025000075002000900325#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#53#49#article#99#12#<P><font
 face="Arial, Helvetica, sans-serif">12. Mittenhuber G. Phylogenetic analyses an
d comparative genomics of vitamin B6 (pyridoxine) and pyridoxal phosphate biosyn
thesis pathways. <I>J Mol Microbiol Biotechnol</I> 2001; 3: 1-20. </font>     ^c
Y#7057.htm##
00502000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026000075002000900335#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#54#50#article#99#13#<P><font
 face="Arial, Helvetica, sans-serif">13. Belitsky BR. Physical and enzymological
 interaction of <I>Bacillus subtilis</I> proteins required for <I>de novo</I> py
ridoxal 5'-phosphate biosynthesis. <I>J Bacteriol</I> 2004; 186: 1191-1196. </fo
nt>     ^cY#7057.htm##
00483000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024100075002000900316#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#55#51#article#99#14#<P><font
 face="Arial, Helvetica, sans-serif">14. Tambasco-Studart M, Titiz O, Raschle T,
 Forster G, Amrhein N, Fitzpatrick TB. Vitamin B6 biosynthesis in higher plants.
 <I>Proc Natl Acad Sci U S A</I> 2005; 102: 13687-13692. </font>     ^cY#7057.ht
m##
00560000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704031800075002000900393#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#56#52#article#99#15#<P><font
 face="Arial, Helvetica, sans-serif">15. Cassera MB, Gozzo FC, D'Alexandri FL, M
erino EF, del Portillo HA, Peres VJ, et al. The methylerythritol phosphate pathw
ay is functionally active in all intraerythrocytic stages of <I>Plasmodium falci
parum</I>. <I>J Biol Chem</I> 2004; 279: 51749-51759. </font>     ^cY#7057.htm##
00514000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027200075002000900347#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#57#53#article#99#16#<P><font
 face="Arial, Helvetica, sans-serif">16. Wrenger C, Eschbach ML, Muller IB, Warn
ecke D, Walter RD. Analysis of the vitamin B6 biosynthesis pathway in the human 
malaria parasite <I>Plasmodium falciparum</I>. <I>J Biol Chem</I> 2005; 280: 524
2-5248. </font>     ^cY#7057.htm##
00509000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026700075002000900342#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#58#54#article#99#17#<P><font
 face="Arial, Helvetica, sans-serif">17. Knockel J, Muller IB, Bergmann B, Walte
r RD, Wrenger C. The apicomplexan parasite <I>Toxoplasma gondii</I> generates py
ridoxal phosphate <I>de novo</I>. <I>Mol Biochem Parasitol</I> 2007; 152: 108-11
1. </font>     ^cY#7057.htm##
00545000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704030300075002000900378#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#59#55#article#99#18#<P><font
 face="Arial, Helvetica, sans-serif">18. Gengenbacher M, Fitzpatrick TB, Raschle
 T, Flicker K, Sinning I, Muller S, et al. Vitamin B6 biosynthesis by the malari
a parasite <I>Plasmodium falciparum</I>: biochemical and structural insights. <I
>J Biol Chem</I> 2006; 281: 3633-3641. </font>     ^cY#7057.htm##
00524000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028200075002000900357#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#60#56#article#99#19#<P><font
 face="Arial, Helvetica, sans-serif">19. Bauer JA, Bennett EM, Begley TP, Ealick
 SE. Three-dimensional structure of YaaE from <I>Bacillus subtilis</I>, a glutam
inase implicated in pyridoxal-5'-phosphate biosynthesis. <I>J Biol Chem</I> 2004
; 279: 2704-2711. </font>     ^cY#7057.htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024300075002000900318#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#61#57#article#99#20#<P><font
 face="Arial, Helvetica, sans-serif">20. Zhu J, Burgner JW, Harms E, Belitsky BR
, Smith JL. A new arrangement of (beta/alpha)8 barrels in the synthase subunit o
f PLP synthase. <I>J Biol Chem</I> 2005; 280: 27914-27923. </font>     ^cY#7057.
htm##
00510000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026800075002000900343#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#62#58#article#99#21#<P><font
 face="Arial, Helvetica, sans-serif">21. Zein F, Zhang Y, Kang YN, Burns K, Begl
ey TP, Ealick SE. Structural insights into the mechanism of the PLP synthase hol
oenzyme from <I>Thermotoga maritima</I>. <I>Biochemistry</I> 2006; 45: 14609-146
20. </font>     ^cY#7057.htm##
00513000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027100075002000900346#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#63#59#article#99#22#<P><font
 face="Arial, Helvetica, sans-serif">22. Strohmeier M, Raschle T, Mazurkiewicz J
, Rippe K, Sinning I, Fitzpatrick TB, et al. Structure of a bacterial pyridoxal 
5'-phosphate synthase complex. <I>Proc Natl Acad Sci U S A</I> 2006; 103: 19284-
19289. </font>     ^cY#7057.htm##
00537000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704029500075002000900370#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#64#60#article#99#23#<P><font
 face="Arial, Helvetica, sans-serif">23. Raschle T, Arigoni D, Brunisholz R, Rec
hsteiner H, Amrhein N, Fitzpatrick TB. Reaction mechanism of pyridoxal 5'-phosph
ate synthase. Detection of an enzyme-bound chromophoric intermediate. <I>J Biol 
Chem</I> 2007; 282: 6098-6105. </font>     ^cY#7057.htm##
00434000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704019200075002000900267#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#65#61#article#99#24#<P><font
 face="Arial, Helvetica, sans-serif">24. Kerry JA, Rohde M, Kwok F. Brain pyrido
xal kinase. Purification and characterization. <I>Eur J Biochem</I> 1986; 158: 5
81-585. </font>     ^cY#7057.htm##
00489000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024700075002000900322#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#66#62#article#99#25#<P><font
 face="Arial, Helvetica, sans-serif">25. Yang Y, Zhao G, Winkler ME. Identificat
ion of the pdxK gene that encodes pyridoxine (vitamin B6) kinase in <I>Escherich
ia coli </I>K-12. <I>FEMS Microbiol Lett</I> 1996; 141: 89-95. </font>     ^cY#7
057.htm##
00511000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026900075002000900344#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#67#63#article#99#26#<P><font
 face="Arial, Helvetica, sans-serif">26. Scott TC, Phillips MA. Characterization
 of <I>Trypanosoma brucei</I> pyridoxal kinase: purification, gene isolation and
 expression in <I>Escherichia coli</I>. <I>Mol Biochem Parasitol</I> 1997; 88: 1
-11. </font>     ^cY#7057.htm##
00593000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704035100075002000900426#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#68#64#article#99#27#<P><font
 face="Arial, Helvetica, sans-serif">27. Park JH, Burns K, Kinsland C, Begley TP
. Characterization of two kinases involved in thiamine pyrophosphate and pyridox
al phosphate biosynthesis in <I>Bacillus subtilis</I>: 4-amino-5-hydroxymethyl-2
methylpyrimidine kinase and pyridoxal kinase. <I>J Bacteriol</I> 2004; 186: 1571
-1573. </font>     ^cY#7057.htm##
00370000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704012800075002000900203#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#69#65#article#99#28#<P><font
 face="Arial, Helvetica, sans-serif">28. Friedrich W. <I>Vitamins</I>. Berlin: W
alter de Gruyter; 1988. </font>     ^cY#7057.htm##
00426000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704018400075002000900259#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#70#66#article#99#29#<P><font
 face="Arial, Helvetica, sans-serif">29. Pohl M, Sprenger GA, Muller M. A new pe
rspective on thiamine catalysis. <I>Curr Opin Biotechnol</I> 2004; 15: 335-342. 
</font>     ^cY#7057.htm##
00600000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704035800075002000900433#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#71#67#article#99#30#<P><font
 face="Arial, Helvetica, sans-serif">30. Mizote T, Tsuda M, Smith DD, Nakayama H
, Nakazawa T. Cloning and characterization of the thiD/J gene of <I>Escherichia 
coli </I>encoding a thiamin-synthesizing bifunctional enzyme, hydroxymethylpyrim
idine kinase/phosphomethylpyrimidine kinase. <I>Microbiology</I> 1999; 145 (Part
 2): 495-501. </font>     ^cY#7057.htm##
00662000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704042000075002000900495#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#72#68#article#99#31#<P><font
 face="Arial, Helvetica, sans-serif">31. Reddick JJ, Kinsland C, Nicewonger R, C
hristian T, Downs DM, Winkler ME, et al. Overexpression, purification and charac
terization of two pyrimidine kinases involved in the biosynthesis of thiamine: 4
-amino-5-hydroxymethyl-2-methylpyrimidine kinase and 4-amino-5-hydroxymethyl-2-m
ethylpyrimidine phosphate kinase. <I>Tetrahedron</I> 1998; 54: 15983-15991. </fo
nt>     ^cY#7057.htm##
00463000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022100075002000900296#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#73#69#article#99#32#<P><font
 face="Arial, Helvetica, sans-serif">32. Begley TP, Downs DM, Ealick SE, McLaffe
rty FW, Van Loon AP, Taylor S, et al. Thiamin biosynthesis in prokaryotes. <I>Ar
ch Microbiol</I> 1999; 171: 293-300. </font>     ^cY#7057.htm##
00580000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704033800075002000900413#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#74#70#article#99#33#<P><font
 face="Arial, Helvetica, sans-serif">33. Wrenger C, Eschbach ML, Muller IB, Laun
 NP, Begley TP, Walter RD. Vitamin B1 <I>de novo</I> synthesis in the human mala
ria parasite <I>Plasmodium falciparum</I> depends on external provision of 4-ami
no-5-hydroxymethyl-2-methylpyrimidine. <I>Biol Chem</I> 2006; 387: 41-51. </font
>     ^cY#7057.htm##
00484000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024200075002000900317#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#75#71#article#99#34#<P><font
 face="Arial, Helvetica, sans-serif">34. Zhang Y, Taylor SV, Chiu HJ, Begley TP.
 Characterization of the <I>Bacillus subtilis</I> thiC operon involved in thiami
ne biosynthesis. <I>J Bacteriol</I> 1997; 179: 3030-3035. </font>     ^cY#7057.h
tm##
00506000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026400075002000900339#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#76#72#article#99#35#<P><font
 face="Arial, Helvetica, sans-serif">35. Hohmann S, Meacock PA. Thiamin metaboli
sm and thiamin diphosphate-dependent enzymes in the yeast <I>Saccharomyces cerev
isiae</I>: genetic regulation. <I>Biochim Biophys Acta</I> 1998; 1385: 201-219. 
</font>     ^cY#7057.htm##
00565000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704032300075002000900398#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#77#73#article#99#36#<P><font
 face="Arial, Helvetica, sans-serif">36. Wightman R, Meacock PA. The THI5 gene f
amily of <I>Saccharomyces cerevisiae</I>: distribution of homologues among the h
emiascomycetes and functional redundancy in the aerobic biosynthesis of thiamin 
from pyridoxine. <I>Microbiology</I> 2003; 149: 1447-1460. </font>     ^cY#7057.
htm##
00487000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024500075002000900320#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#78#74#article#99#37#<P><font
 face="Arial, Helvetica, sans-serif">37. Morett E, Korbel JO, Rajan E, Saab-Rinc
on G, Olvera L, Olvera M, et al. Systematic discovery of analogous enzymes in th
iamin biosynthesis. <I>Nat Biotechnol</I> 2003; 21: 790-795. </font>     ^cY#705
7.htm##
00473000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023100075002000900306#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#79#75#article#99#38#<P><font
 face="Arial, Helvetica, sans-serif">38. Mizote T, Nakayama H. The thiM locus an
d its relation to phosphorylation of hydroxyethylthiazole in <I>Escherichia coli
</I>. <I>J Bacteriol</I> 1989; 171: 3228-3232. </font>     ^cY#7057.htm##
00551000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704030900075002000900384#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#80#76#article#99#39#<P><font
 face="Arial, Helvetica, sans-serif">39. Settembre EC, Dorrestein PC, Zhai H, Ch
atterjee A, McLafferty FW, Begley TP, et al. Thiamin biosynthesis in <I>Bacillus
 subtilis</I>: structure of the thiazole synthase/sulfur carrier protein complex
. <I>Biochemistry</I> 2004; 43: 11647-11657. </font>     ^cY#7057.htm##
00552000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704031000075002000900385#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#81#77#article#99#40#<P><font
 face="Arial, Helvetica, sans-serif">40. Peapus DH, Chiu HJ, Campobasso N, Reddi
ck JJ, Begley TP, Ealick SE. Structural characterization of the enzyme-substrate
, enzyme-intermediate, and enzyme-product complexes of thiamin phosphate synthas
e. <I>Biochemistry</I> 2001; 40: 10103-10114. </font>     ^cY#7057.htm##
00508000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026600075002000900341#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#82#78#article#99#41#<P><font
 face="Arial, Helvetica, sans-serif">41. Nosaka K, Kaneko Y, Nishimura H, Iwashi
ma A. Isolation and characterization of a thiamin pyrophosphokinase gene, THI80,
 from <I>Saccharomyces cerevisiae</I>. <I>J Biol Chem</I> 1993; 268: 17440-17447
. </font>     ^cY#7057.htm##
00442000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020000075002000900275#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#83#79#article#99#42#<P><font
 face="Arial, Helvetica, sans-serif">42. Baker LJ, Dorocke JA, Harris RA, Timm D
E. The crystal structure of yeast thiamin pyrophosphokinase. <I>Structure</I> 20
01; 9: 539-546. </font>     ^cY#7057.htm##
00479000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704023700075002000900312#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#84#80#article#99#43#<P><font
 face="Arial, Helvetica, sans-serif">43. Bozdech Z, Ginsburg H. Data mining of t
he transcriptome of <I>Plasmodium falciparum</I>: the pentose phosphate pathway 
and ancillary processes. <I>Malar J</I> 2005; 4: 17. </font>     ^cY#7057.htm##
00536000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704029400075002000900369#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#85#81#article#99#44#<P><font
 face="Arial, Helvetica, sans-serif">44. Ralph SA, van Dooren GG, Waller RF, Cra
wford MJ, Fraunholz MJ, Foth BJ, et al. Tropical infectious diseases: metabolic 
maps and functions of the <I>Plasmodium falciparum</I> apicoplast. <I>Nat Rev Mi
crobiol</I> 2004; 2: 203-216. </font>     ^cY#7057.htm##
00555000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704031300075002000900388#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#86#82#article#99#45#<P><font
 face="Arial, Helvetica, sans-serif">45. Eschbach ML, Muller IB, Gilberger TW, W
alter RD, Wrenger C. The human malaria parasite <I>Plasmodium falciparum</I> exp
resses an atypical N-terminally extended pyrophosphokinase with specificity for 
thiamine. <I>Biol Chem</I> 2006; 387: 1583-1591. </font>     ^cY#7057.htm##
00468000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704022600075002000900301#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#87#83#article#99#46#<P><font
 face="Arial, Helvetica, sans-serif">46. Muller S, Kappes B. Vitamin and cofacto
r biosynthesis pathways in <I>Plasmodium</I> and other apicomplexan parasites. <
I>Trends Parasitol</I> 2007; 23: 112-121. </font>     ^cY#7057.htm##
00543000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704030100075002000900376#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#88#84#article#99#47#<P><font
 face="Arial, Helvetica, sans-serif">47. Foth BJ, Stimmler LM, Handman E, Crabb 
BS, Hodder AN, McFadden GI. The malaria parasite <I>Plasmodium falciparum</I> ha
s only one pyruvate dehydrogenase complex, which is located in the apicoplast. <
I>Mol Microbiol</I> 2005; 55: 39-53. </font>     ^cY#7057.htm##
00515000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027300075002000900348#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#89#85#article#99#48#<P><font
 face="Arial, Helvetica, sans-serif">48. McMillan PJ, Stimmler LM, Foth BJ, McFa
dden GI, Muller S. The human malaria parasite <I>Plasmodium falciparum</I> posse
sses two distinct dihydrolipoamide dehydrogenases. <I>Mol Microbiol</I> 2005; 55
: 27-38. </font>     ^cY#7057.htm##
00511000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704026900075002000900344#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#90#86#article#99#49#<P><font
 face="Arial, Helvetica, sans-serif">49. Marobbio CM, Vozza A, Harding M, Bisacc
ia F, Palmieri F, Walker JE. Identification and reconstitution of the yeast mito
chondrial transporter for thiamine pyrophosphate. <I>EMBO J</I> 2002; 21: 5653-5
661. </font>     ^cY#7057.htm##
00451000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020900075002000900284#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#91#87#article#99#50#<P><font
 face="Arial, Helvetica, sans-serif">50. Zilles JL, Croal LR, Downs DM. Action o
f the thiamine antagonist bacimethrin on thiamine biosynthesis. <I>J Bacteriol</
I> 2000; 182: 5606-5610. </font>     ^cY#7057.htm##
00452000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021000075002000900285#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#92#88#article#99#51#<P><font
 face="Arial, Helvetica, sans-serif">51. Lawhorn BG, Gerdes SY, Begley TP. A gen
etic screen for the identification of thiamin metabolic genes. <I>J Biol Chem</I
> 2004; 279: 43555-43559. </font>     ^cY#7057.htm##
00531000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028900075002000900364#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#93#89#article#99#52#<P><font
 face="Arial, Helvetica, sans-serif">52. Divo AA, Geary TG, Davis NL, Jensen JB.
 Nutritional requirements of <I>Plasmodium falciparum</I> in culture. I. Exogeno
usly supplied dialyzable components necessary for continuous growth. <I>J Protoz
ool</I> 1985; 32: 59-64. </font>     ^cY#7057.htm##
00485000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024300075002000900318#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#94#90#article#99#53#<P><font
 face="Arial, Helvetica, sans-serif">53. Tazuya K, Adachi Y, Masuda K, Yamada K,
 Kumaoka H. Origin of the nitrogen atom of pyridoxine in <I>Saccharomyces cerevi
siae</I>. <I>Biochim Biophys Acta</I> 1995; 1244: 113-116. </font>     ^cY#7057.
htm##
00497000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704025500075002000900330#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#95#91#article#99#54#<P><font
 face="Arial, Helvetica, sans-serif">54. Zeidler J, Ullah N, Gupta RN, Pauloski 
RM, Sayer BG, Spenser ID. 2'-Hydroxypyridoxol, a biosynthetic precursor of vitam
ins B(6) and B(1) in yeast. <I>J Am Chem Soc</I> 2002; 124: 4542-4543. </font>  
   ^cY#7057.htm##
00518000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027600075002000900351#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#96#92#article#99#55#<P><font
 face="Arial, Helvetica, sans-serif">55. Zeidler J, Sayer BG, Spenser ID. Biosyn
thesis of vitamin B1 in yeast. Derivation of the pyrimidine unit from pyridoxine
 and histidine. Intermediacy of urocanic acid. <I>J Am Chem Soc</I> 2003; 125: 1
3094-13105. </font>     ^cY#7057.htm##
00415000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704017300075002000900248#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#97#93#article#99#56#<P><font
 face="Arial, Helvetica, sans-serif">56. Sherman IW. Biochemistry of <I>Plasmodi
um</I> (malarial parasites). <I>Microbiol Rev</I> 1979; 43: 453-495. </font>    
 ^cY#7057.htm##
00483000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024100075002000900316#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#98#94#article#99#57#<P><font
 face="Arial, Helvetica, sans-serif">57. Gardner MJ, Hall N, Fung E, White O, Be
rriman M, Hyman RW, et al. Genome sequence of the human malaria parasite <I>Plas
modium falciparum</I>. <I>Nature</I> 2002; 419: 498-511. </font>     ^cY#7057.ht
m##
00390000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704014800075002000900223#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#99#95#article#99#58#<P><font
 face="Arial, Helvetica, sans-serif">58. Schopfer WH. <I>Plants and vitamins</I>
. Waltham: Chronica Botanica Company; 1949. </font>     ^cY#7057.htm##
00534000000000157000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000300070888000300073704029100076002000900367#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#p#100#96#article#99#59#<P><fon
t face="Arial, Helvetica, sans-serif">59. Rodionov DA, Vitreschak AG, Mironov AA
, Gelfand MS. Comparative genomics of thiamin biosynthesis in procaryotes. New g
enes and regulatory mechanisms. <I>J Biol Chem</I> 2002; 277: 48949-48959.</font
> <HR ALIGN=LEFT WIDTH=100% SIZE=2>     ^cY#7057.htm##
00554000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000300070704032600073002000900399#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#101#97#article#99#<P class="style4"><A N
AME="Correspondence"></A><FONT color="#00007F" SIZE=4><B><font face="Arial, Helv
etica, sans-serif">Correspondence    and Footnotes</font></B></FONT> <A HREF="#H
ome"><FONT SIZE=4><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM 
BORDER=0 VSPACE=0 HSPACE=0 LOOP="0"></B></FONT></A></P>     ^cY#7057.htm##
00677000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000300070704044900073002000900522#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#102#98#article#99#<P class="style4"><B><
a href="#Home"><img src="/img/revistas/bjmbr/v41n2/recor.gif" border="0"></a> Ad
dress for correspondence: </B><font face="Arial, Helvetica, sans-serif">C. Wreng
er, Department of Biochemistry, Bernhard Nocht Institute for Tropical Medicine, 
Bernhard Nocht Strasse 74, D-20359 Hamburg, Germany. Fax: +49-40-4281-8418. E-ma
il: <strong><a href="mailto:wrenger@bni-hamburg.de">wrenger@bni-hamburg.de</a></
strong></font></P>     ^cY#7057.htm##
00563000000000145000450000400060000070200450000670500020005170600020005370000040
0055701000300059709000800062708000300070704033500073002000900408#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\7057.htm#S#p#103#99#article#99#<P><font face="Arial, 
Helvetica, sans-serif">Presented at the XXXVI Annual Meeting of the Sociedade Br
asileira de Bioqu&iacute;mica e Biologia Molecular, Salvador, BA, Brazil, May 21
-25, 2007. Research supported by Deutsche Forschungsgemeinschaft Grant WA 395/15
. Received September 18, 2007. Accepted December 6, 2007.</font>     ^cY#7057.ht
m##
00596000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100014000740100019000880100
01800107012010100125030001200226065000900238064000500247031000400252014001000256
865000900266002000900275035001000284801001200294#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\7057.htm#S#c#104#1#article#59#1#^rND^sRoa^nBB#^rND^sConnolly^nDM#^rND
^sWinkler^nME#Overlap between pdxA and ksgA in the complex pdxA-ksgA-apaG-apaH o
peron of Escherichia coli K-12^len#J Bacteriol#19890000#1989#171#4767-4777#20080
200#7057.htm#0021-9193#J Bacteriol##
00632000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100014000740100017000880100
01800105010001800123012010900141030001200250065000900262064000500271031000400276
014001000280865000900290002000900299035001000308801001200318#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\7057.htm#S#c#105#2#article#59#2#^rND^sLam^nHM#^rND^sTancu
la^nE#^rND^sDempsey^nWB#^rND^sWinkler^nME#Suppression of insertions in the compl
ex pdxJ operon of Escherichia coli K-12 by lon and other mutations^len#J Bacteri
ol#19920000#1992#174#1554-1567#20080200#7057.htm#0021-9193#J Bacteriol##
00653000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100020000740100016000940100
01600110010001500126012014000141030000900281065000900290064000500299031000200304
014000800306865000900314002000900323035001000332801000900342#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\7057.htm#S#c#106#3#article#59#3#^rND^sEhrenshaft^nM#^rND^
sJenns^nAE#^rND^sChung^nKR#^rND^sDaub^nME#SOR1, a gene required for photosensiti
zer and singlet oxygen resistance in Cercospora fungi, is highly conserved in di
vergent organisms^len#Mol Cell#19980000#1998#1#603-609#20080200#7057.htm#1097-27
65#Mol Cell##
00656000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100014000910100
01700105012016200122030001200284065000900296064000500305031000400310014001200314
865000900326002000900335035001000344801001200354#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\7057.htm#S#c#107#4#article#59#4#^rND^sOsmani^nAH#^rND^sMay^nGS#^rND^s
Osmani^nSA#The extremely conserved pyroA gene of Aspergillus nidulans is require
d for pyridoxine synthesis and is required indirectly for resistance to photosen
sitizers^len#J Biol Chem#19990000#1999#274#23565-23569#20080200#7057.htm#0021-92
58#J Biol Chem##
00685000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100015000920100
01900107010001600126010002600142012012300168030001200291065000900303064000500312
031000400317014001000321865000900331002000900340035001000349801001200359#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#108#5#article#59#5#^rND^sPadilla
^nPA#^rND^sFuge^nEK#^rND^sCrawford^nME#^rND^sErrett^nA#^rND^sWerner-Washburne^nM
#The highly conserved, coregulated SNO and SNZ gene families in Saccharomyces ce
revisiae respond to nutrient limitation^len#J Bacteriol#19980000#1998#180#5718-5
726#20080200#7057.htm#0021-9193#J Bacteriol##
00644000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100015000740100015000890100
01600104010001500120012012500135030001400260065000900274064000500283031000400288
014000800292865000900300002000900309035001000318801001400328#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\7057.htm#S#c#109#6#article#59#6#^rND^sDong^nYX#^rND^sSued
a^nS#^rND^sNikawa^nJ#^rND^sKondo^nH#Characterization of the products of the gene
s SNO1 and SNZ1 involved in pyridoxine synthesis in Saccharomyces cerevisiae^len
#Eur J Biochem#20040000#2004#271#745-752#20080200#7057.htm#0014-2956#Eur J Bioch
em##
00665000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100015000900100
01900105010002100124010001700145012010500162030001400267065000900281064000500290
031000400295014001000299865000900309002000900318035001000327801001400337#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#110#7#article#59#7#^rND^sBurns^n
KE#^rND^sXiang^nY#^rND^sKinsland^nCL#^rND^sMcLafferty^nFW#^rND^sBegley^nTP#Recon
stitution and biochemical characterization of a new pyridoxal-5'-phosphate biosy
nthetic pathway^len#J Am Chem Soc#20050000#2005#127#3682-3683#20080200#7057.htm#
0002-7863#J Am Chem Soc##
00586000000000289000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100017000910100
02200108012008400130030001200214065000900226064000500235031000400240014001200244
865000900256002000900265035001000274801001200284#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\7057.htm#S#c#111#8#article#59#8#^rND^sRaschle^nT#^rND^sAmrhein^nN#^rN
D^sFitzpatrick^nTB#On the two components of pyridoxal 5'-phosphate synthase from
 Bacillus subtilis^len#J Biol Chem#20050000#2005#280#32291-32300#20080200#7057.h
tm#0021-9258#J Biol Chem##
00668000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100020000740100016000940100
01300110010001900123010001500142012009200157030002500249065000900274064000500283
031000300288014001000291865000900301002000900310035001000319801002500329#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#112#9#article#59#9#^rND^sEhrensh
aft^nM#^rND^sBilski^nP#^rND^sLi^nMY#^rND^sChignell^nCF#^rND^sDaub^nME#A highly c
onserved sequence is a novel gene involved in de novo vitamin B6 biosynthesis^le
n#Proc Natl Acad Sci U S A#19990000#1999#96#9374-9378#20080200#7057.htm#0027-842
4#Proc Natl Acad Sci U S A##
00703000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100027000760100018001030100
03100121010001500152010001400167010001900181810000600200012009200206030000600298
06500090030406400050031303100030031801400100032186500090033100200090034003500100
0349801000600359#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#113#10#a
rticle#59#10#^rND^sRodriguez-Navarro^nS#^rND^sLlorente^nB#^rND^sRodriguez-Manzan
eque^nMT#^rND^sRamne^nA#^rND^sUber^nG#^rND^sMarchesan^nD#et al#Functional analys
is of yeast gene families involved in metabolism of vitamins B1 and B6^len#Yeast
#20020000#2002#19#1261-1276#20080200#7057.htm#0749-503X#Yeast##
00609000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100015000960120
14000111030001200251065000900263064000500272031000400277014001000281865000900291
002000900300035001000309801001200319#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7
057.htm#S#c#114#11#article#59#11#^rND^sEhrenshaft^nM#^rND^sDaub^nME#Isolation of
 PDX2, a second novel gene in the pyridoxine biosynthesis pathway of eukaryotes,
 archaebacteria, and a subset of eubacteria^len#J Bacteriol#20010000#2001#183#33
83-3390#20080200#7057.htm#0021-9193#J Bacteriol##
00543000000000253000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100021000760120124000970300
02700221710000200248065000900250064000500259031000200264014000500266865000900271
002000900280#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#115#12#artic
le#59#12#^rND^sMittenhuber^nG#Phylogenetic analyses and comparative genomics of 
vitamin B6 (pyridoxine) and pyridoxal phosphate biosynthesis pathways^len#J Mol 
Microbiol Biotechnol#2#20010000#2001#3#1-20#20080200#7057.htm##
00571000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760120130000950300
01200225065000900237064000500246031000400251014001000255865000900265002000900274
035001000283801001200293#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#
116#13#article#59#13#^rND^sBelitsky^nBR#Physical and enzymological interaction o
f Bacillus subtilis proteins required for de novo pyridoxal 5'-phosphate biosynt
hesis^len#J Bacteriol#20040000#2004#186#1191-1196#20080200#7057.htm#0021-9193#J 
Bacteriol##
00669000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100026000760100015001020100
01700117010001700134010001700151010002200168012004500190030002500235065000900260
06400050026903100040027401400120027886500090029000200090029903500100030880100250
0318#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#117#14#article#59#14
#^rND^sTambasco-Studart^nM#^rND^sTitiz^nO#^rND^sRaschle^nT#^rND^sForster^nG#^rND
^sAmrhein^nN#^rND^sFitzpatrick^nTB#Vitamin B6 biosynthesis in higher plants^len#
Proc Natl Acad Sci U S A#20050000#2005#102#13687-13692#20080200#7057.htm#0027-84
24#Proc Natl Acad Sci U S A##
00737000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100016000940100
02200110010001700132010002300149010001600172810000600188012012300194030001200317
06500090032906400050033803100040034301400120034786500090035900200090036803500100
0377801001200387#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#118#15#a
rticle#59#15#^rND^sCassera^nMB#^rND^sGozzo^nFC#^rND^sD'Alexandri^nFL#^rND^sMerin
o^nEF#^rND^sdel^nPortillo HA#^rND^sPeres^nVJ#et al#The methylerythritol phosphat
e pathway is functionally active in all intraerythrocytic stages of Plasmodium f
alciparum^len#J Biol Chem#20040000#2004#279#51749-51759#20080200#7057.htm#0021-9
258#J Biol Chem##
00662000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100019000930100
01700112010001800129010001700147012010400164030001200268065000900280064000500289
031000400294014001000298865000900308002000900317035001000326801001200336#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#119#16#article#59#16#^rND^sWreng
er^nC#^rND^sEschbach^nML#^rND^sMuller^nIB#^rND^sWarnecke^nD#^rND^sWalter^nRD#Ana
lysis of the vitamin B6 biosynthesis pathway in the human malaria parasite Plasm
odium falciparum^len#J Biol Chem#20050000#2005#280#5242-5248#20080200#7057.htm#0
021-9258#J Biol Chem##
00660000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930100
01800110010001700128010001700145012008600162030002200248065000900270064000500279
031000400284014000800288865000900296002000900305035001000314801002200324#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#120#17#article#59#17#^rND^sKnock
el^nJ#^rND^sMuller^nIB#^rND^sBergmann^nB#^rND^sWalter^nRD#^rND^sWrenger^nC#The a
picomplexan parasite Toxoplasma gondii generates pyridoxal phosphate de novo^len
#Mol Biochem Parasitol#20070000#2007#152#108-111#20080200#7057.htm#0166-6851#Mol
 Biochem Parasitol##
00722000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100022000760100022000980100
01700120010001700137010001700154010001600171810000600187012011100193030001200304
06500090031606400050032503100040033001400100033486500090034400200090035303500100
0362801001200372#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#121#18#a
rticle#59#18#^rND^sGengenbacher^nM#^rND^sFitzpatrick^nTB#^rND^sRaschle^nT#^rND^s
Flicker^nK#^rND^sSinning^nI#^rND^sMuller^nS#et al#Vitamin B6 biosynthesis by the
 malaria parasite Plasmodium falciparum: biochemical and structural insights^len
#J Biol Chem#20060000#2006#281#3633-3641#20080200#7057.htm#0021-9258#J Biol Chem
##
00654000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01700110010001700127012012800144030001200272065000900284064000500293031000400298
014001000302865000900312002000900321035001000330801001200340#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\7057.htm#S#c#122#19#article#59#19#^rND^sBauer^nJA#^rND^sB
ennett^nEM#^rND^sBegley^nTP#^rND^sEalick^nSE#Three-dimensional structure of YaaE
 from Bacillus subtilis, a glutaminase implicated in pyridoxal-5'-phosphate bios
ynthesis^len#J Biol Chem#20040000#2004#279#2704-2711#20080200#7057.htm#0021-9258
#J Biol Chem##
00640000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100018000890100
01500107010001900122010001600141012008700157030001200244065000900256064000500265
031000400270014001200274865000900286002000900295035001000304801001200314#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#123#20#article#59#20#^rND^sZhu^n
J#^rND^sBurgner^nJW#^rND^sHarms^nE#^rND^sBelitsky^nBR#^rND^sSmith^nJL#A new arra
ngement of (beta/alpha)8 barrels in the synthase subunit of PLP synthase^len#J B
iol Chem#20050000#2005#280#27914-27923#20080200#7057.htm#0021-9258#J Biol Chem##
00677000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100015000900100
01500105010001500120010001700135010001700152012009900169030001300268065000900281
06400050029003100030029501400120029886500090031000200090031903500100032880100130
0338#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#124#21#article#59#21
#^rND^sZein^nF#^rND^sZhang^nY#^rND^sKang^nYN#^rND^sBurns^nK#^rND^sBegley^nTP#^rN
D^sEalick^nSE#Structural insights into the mechanism of the PLP synthase holoenz
yme from Thermotoga maritima^len#Biochemistry#20060000#2006#45#14609-14620#20080
200#7057.htm#0006-2960#Biochemistry##
00710000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100017000960100
02200113010001500135010001700150010002200167810000600189012006900195030002500264
06500090028906400050029803100040030301400120030786500090031900200090032803500100
0337801002500347#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#125#22#a
rticle#59#22#^rND^sStrohmeier^nM#^rND^sRaschle^nT#^rND^sMazurkiewicz^nJ#^rND^sRi
ppe^nK#^rND^sSinning^nI#^rND^sFitzpatrick^nTB#et al#Structure of a bacterial pyr
idoxal 5'-phosphate synthase complex^len#Proc Natl Acad Sci U S A#20060000#2006#
103#19284-19289#20080200#7057.htm#0027-8424#Proc Natl Acad Sci U S A##
00710000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930100
02000110010002100130010001700151010002200168012011400190030001200304065000900316
06400050032503100040033001400100033486500090034400200090035303500100036280100120
0372#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#126#23#article#59#23
#^rND^sRaschle^nT#^rND^sArigoni^nD#^rND^sBrunisholz^nR#^rND^sRechsteiner^nH#^rND
^sAmrhein^nN#^rND^sFitzpatrick^nTB#Reaction mechanism of pyridoxal 5'-phosphate 
synthase: Detection of an enzyme-bound chromophoric intermediate^len#J Biol Chem
#20070000#2007#282#6098-6105#20080200#7057.htm#0021-9258#J Biol Chem##
00555000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100015000920100
01400107012006200121030001400183065000900197064000500206031000400211014000800215
865000900223002000900232035001000241801001400251#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\7057.htm#S#c#127#24#article#59#24#^rND^sKerry^nJA#^rND^sRohde^nM#^rND
^sKwok^nF#Brain pyridoxal kinase: Purification and characterization^len#Eur J Bi
ochem#19860000#1986#158#581-585#20080200#7057.htm#0014-2956#Eur J Biochem##
00609000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100014000900100
01800104012010500122030002000227065000900247064000500256031000400261014000600265
865000900271002000900280035001000289801002000299#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\7057.htm#S#c#128#25#article#59#25#^rND^sYang^nY#^rND^sZhao^nG#^rND^sW
inkler^nME#Identification of the pdxK gene that encodes pyridoxine (vitamin B6) 
kinase in Escherichia coli K-12^len#FEMS Microbiol Lett#19960000#1996#141#89-95#
20080200#7057.htm#0378-1097#FEMS Microbiol Lett##
00608000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100019000920120
12500111030002200236065000900258064000500267031000300272014000500275865000900280
002000900289035001000298801002200308#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7
057.htm#S#c#129#26#article#59#26#^rND^sScott^nTC#^rND^sPhillips^nMA#Characteriza
tion of Trypanosoma brucei pyridoxal kinase: purification, gene isolation and ex
pression in Escherichia coli^len#Mol Biochem Parasitol#19970000#1997#88#1-11#200
80200#7057.htm#0166-6851#Mol Biochem Parasitol##
00723000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100015000910100
01800106010001700124012020000141030001200341065000900353064000500362031000400367
014001000371865000900381002000900390035001000399801001200409#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\7057.htm#S#c#130#27#article#59#27#^rND^sPark^nJH#^rND^sBu
rns^nK#^rND^sKinsland^nC#^rND^sBegley^nTP#Characterization of two kinases involv
ed in thiamine pyrophosphate and pyridoxal phosphate biosynthesis in Bacillus su
btilis: 4-amino-5-hydroxymethyl-2methylpyrimidine kinase and pyridoxal kinase^le
n#J Bacteriol#20040000#2004#186#1571-1573#20080200#7057.htm#0021-9193#J Bacterio
l##
00395000000000229000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730160019000760180013000950660
00700108062001800115065000900133064000500142865000900147002000900156#v41n2#v:\sc
ielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#131#28#article#59#28#^rND^sFriedrich
^nW#Vitamins^len#Berlin#Walter de Gruyter#19880000#1988#20080200#7057.htm##
00554000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100019000900100
01600109012004400125030002100169065000900190064000500199031000300204014000800207
865000900215002000900224035001000233801002100243#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\7057.htm#S#c#132#29#article#59#29#^rND^sPohl^nM#^rND^sSprenger^nGA#^r
ND^sMuller^nM#A new perspective on thiamine catalysis^len#Curr Opin Biotechnol#2
0040000#2004#15#335-342#20080200#7057.htm#0958-1669#Curr Opin Biotechnol##
00759000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100015000920100
01600107010001800123010001800141012018700159030001300346065000900359064000500368
03100040037306100070037701400080038486500090039200200090040103500100041080100130
0420#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#133#30#article#59#30
#^rND^sMizote^nT#^rND^sTsuda^nM#^rND^sSmith^nDD#^rND^sNakayama^nH#^rND^sNakazawa
^nT#Cloning and characterization of the thiD/J gene of Escherichia coli encoding
 a thiamin-synthesizing bifunctional enzyme, hydroxymethylpyrimidine kinase/phos
phomethylpyrimidine kinase^len#Microbiology#19990000#1999#145#Part 2#495-501#200
80200#7057.htm#0026-2617#MICROBIOLOGY##
00846000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100018000940100
02000112010001900132010001600151010001800167810000600185012023600191030001200427
06500090043906400050044803100030045301400120045686500090046800200090047703500100
0486801001200496#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#134#31#a
rticle#59#31#^rND^sReddick^nJJ#^rND^sKinsland^nC#^rND^sNicewonger^nR#^rND^sChris
tian^nT#^rND^sDowns^nDM#^rND^sWinkler^nME#et al#Overexpression, purification and
 characterization of two pyrimidine kinases involved in the biosynthesis of thia
mine: 4-amino-5-hydroxymethyl-2-methylpyrimidine kinase and 4-amino-5-hydroxymet
hyl-2-methylpyrimidine phosphate kinase^len#Tetrahedron#19980000#1998#54#15983-1
5991#20080200#7057.htm#0040-4020#TETRAHEDRON##
00650000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01700109010002100126010001900147010001600166810000600182012004000188030001500228
06500090024306400050025203100040025701400080026186500090026900200090027803500100
0287801001500297#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#135#32#a
rticle#59#32#^rND^sBegley^nTP#^rND^sDowns^nDM#^rND^sEalick^nSE#^rND^sMcLafferty^
nFW#^rND^sVan^nLoon AP#^rND^sTaylor^nS#et al#Thiamin biosynthesis in prokaryotes
^len#Arch Microbiol#19990000#1999#171#293-300#20080200#7057.htm#0302-8933#Arch M
icrobiol##
00737000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100019000930100
01700112010001500129010001700144010001700161012016100178030001000339065000900349
06400050035803100040036301400060036786500090037300200090038203500100039180100100
0401#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#136#33#article#59#33
#^rND^sWrenger^nC#^rND^sEschbach^nML#^rND^sMuller^nIB#^rND^sLaun^nNP#^rND^sBegle
y^nTP#^rND^sWalter^nRD#Vitamin B1 de novo synthesis in the human malaria parasit
e Plasmodium falciparum depends on external provision of 4-amino-5-hydroxymethyl
-2-methylpyrimidine^len#Biol Chem#20060000#2006#387#41-51#20080200#7057.htm#1431
-6730#Biol Chem##
00614000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100017000910100
01500108010001700123012009200140030001200232065000900244064000500253031000400258
014001000262865000900272002000900281035001000290801001200300#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\7057.htm#S#c#137#34#article#59#34#^rND^sZhang^nY#^rND^sTa
ylor^nSV#^rND^sChiu^nHJ#^rND^sBegley^nTP#Characterization of the Bacillus subtil
is thiC operon involved in thiamine biosynthesis^len#J Bacteriol#19970000#1997#1
79#3030-3035#20080200#7057.htm#0021-9193#J Bacteriol##
00609000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930120
12300111030002100234065000900255064000500264031000500269014000800274865000900282
002000900291035001000300801002100310#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7
057.htm#S#c#138#35#article#59#35#^rND^sHohmann^nS#^rND^sMeacock^nPA#Thiamin meta
bolism and thiamin diphosphate-dependent enzymes in the yeast Saccharomyces cere
visiae: genetic regulation^len#Biochim Biophys Acta#19980000#1998#1385#201-219#2
0080200#7057.htm#0006-3002#Biochim Biophys Acta##
00660000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100018000940120
18800112030001300300065000900313064000500322031000400327014001000331865000900341
002000900350035001000359801001300369#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7
057.htm#S#c#139#36#article#59#36#^rND^sWightman^nR#^rND^sMeacock^nPA#The THI5 ge
ne family of Saccharomyces cerevisiae: distribution of homologues among the hemi
ascomycetes and functional redundancy in the aerobic biosynthesis of thiamin fro
m pyridoxine^len#Microbiology#20030000#2003#149#1447-1460#20080200#7057.htm#0026
-2617#MICROBIOLOGY##
00674000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100017000920100
01500109010002100124010001600145010001600161810000600177012007000183030001500253
06500090026806400050027703100030028201400080028586500090029300200090030203500100
0311801001500321#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#140#37#a
rticle#59#37#^rND^sMorett^nE#^rND^sKorbel^nJO#^rND^sRajan^nE#^rND^sSaab-Rincon^n
G#^rND^sOlvera^nL#^rND^sOlvera^nM#et al#Systematic discovery of analogous enzyme
s in thiamin biosynthesis^len#Nat Biotechnol#20030000#2003#21#790-795#20080200#7
057.htm#1087-0156#Nat Biotechnol##
00567000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920120
09900110030001200209065000900221064000500230031000400235014001000239865000900249
002000900258035001000267801001200277#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7
057.htm#S#c#141#38#article#59#38#^rND^sMizote^nT#^rND^sNakayama^nH#The thiM locu
s and its relation to phosphorylation of hydroxyethylthiazole in Escherichia col
i^len#J Bacteriol#19890000#1989#171#3228-3232#20080200#7057.htm#0021-9193#J Bact
eriol##
00729000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100021000960100
01400117010002000131010002100151010001700172810000600189012011300195030001300308
06500090032106400050033003100030033501400120033886500090035000200090035903500100
0368801001300378#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#142#39#a
rticle#59#39#^rND^sSettembre^nEC#^rND^sDorrestein^nPC#^rND^sZhai^nH#^rND^sChatte
rjee^nA#^rND^sMcLafferty^nFW#^rND^sBegley^nTP#et al#Thiamin biosynthesis in Baci
llus subtilis: structure of the thiazole synthase/sulfur carrier protein complex
^len#Biochemistry#20040000#2004#43#11647-11657#20080200#7057.htm#0006-2960#Bioch
emistry##
00726000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100015000930100
02000108010001800128010001700146010001700163012013700180030001300317065000900330
06400050033903100030034401400120034786500090035900200090036803500100037780100130
0387#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#143#40#article#59#40
#^rND^sPeapus^nDH#^rND^sChiu^nHJ#^rND^sCampobasso^nN#^rND^sReddick^nJJ#^rND^sBeg
ley^nTP#^rND^sEalick^nSE#Structural characterization of the enzyme-substrate, en
zyme-intermediate, and enzyme-product complexes of thiamin phosphate synthase^le
n#Biochemistry#20010000#2001#40#10103-10114#20080200#7057.htm#0006-2960#Biochemi
stry##
00638000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920100
01900108010001800127012010900145030001200254065000900266064000500275031000400280
014001200284865000900296002000900305035001000314801001200324#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\7057.htm#S#c#144#41#article#59#41#^rND^sNosaka^nK#^rND^sK
aneko^nY#^rND^sNishimura^nH#^rND^sIwashima^nA#Isolation and characterization of 
a thiamin pyrophosphokinase gene, THI80, from Saccharomyces cerevisiae^len#J Bio
l Chem#19930000#1993#268#17440-17447#20080200#7057.htm#0021-9258#J Biol Chem##
00577000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100018000920100
01700110010001500127012006100142030001000203065000900213064000500222031000200227
014000800229865000900237002000900246035001000255801001000265#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\7057.htm#S#c#145#42#article#59#42#^rND^sBaker^nLJ#^rND^sD
orocke^nJA#^rND^sHarris^nRA#^rND^sTimm^nDE#The crystal structure of yeast thiami
n pyrophosphokinase^len#Structure#20010000#2001#9#539-546#20080200#7057.htm#0969
-2126#STRUCTURE##
00541000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100018000930120
11700111030000800228710000200236065000900238064000500247031000200252014000300254
865000900257002000900266#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#
146#43#article#59#43#^rND^sBozdech^nZ#^rND^sGinsburg^nH#Data mining of the trans
criptome of Plasmodium falciparum: the pentose phosphate pathway and ancillary p
rocesses^len#Malar J#2#20050000#2005#4#17#20080200#7057.htm##
00681000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100021000920100
01700113010001900130010002000149010001500169810000600184012010300190030001800293
71000020031106500090031306400050032203100020032701400080032986500090033700200090
0346#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#147#44#article#59#44
#^rND^sRalph^nSA#^rND^svan^nDooren GG#^rND^sWaller^nRF#^rND^sCrawford^nMJ#^rND^s
Fraunholz^nMJ#^rND^sFoth^nBJ#et al#Tropical infectious diseases: metabolic maps 
and functions of the Plasmodium falciparum apicoplast^len#Nat Rev Microbiol#2#20
040000#2004#2#203-216#20080200#7057.htm##
00701000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100017000950100
02000112010001700132010001700149012014500166030001000311065000900321064000500330
031000400335014001000339865000900349002000900358035001000367801001000377#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#148#45#article#59#45#^rND^sEschb
ach^nML#^rND^sMuller^nIB#^rND^sGilberger^nTW#^rND^sWalter^nRD#^rND^sWrenger^nC#T
he human malaria parasite Plasmodium falciparum expresses an atypical N-terminal
ly extended pyrophosphokinase with specificity for thiamine^len#Biol Chem#200600
00#2006#387#1583-1591#20080200#7057.htm#1431-6730#Biol Chem##
00530000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920120
09400108030001700202710000200219065000900221064000500230031000300235014000800238
865000900246002000900255#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#
149#46#article#59#46#^rND^sMuller^nS#^rND^sKappes^nB#Vitamin and cofactor biosyn
thesis pathways in Plasmodium and other apicomplexan parasites^len#Trends Parasi
tol#2#20070000#2007#23#112-121#20080200#7057.htm##
00711000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100019000910100
01700110010001600127010001700143010001900160012012700179030001400306065000900320
06400050032903100030033401400060033786500090034300200090035203500100036180100140
0371#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#150#47#article#59#47
#^rND^sFoth^nBJ#^rND^sStimmler^nLM#^rND^sHandman^nE#^rND^sCrabb^nBS#^rND^sHodder
^nAN#^rND^sMcFadden^nGI#The malaria parasite Plasmodium falciparum has only one 
pyruvate dehydrogenase complex, which is located in the apicoplast^len#Mol Micro
biol#20050000#2005#55#39-53#20080200#7057.htm#0950-382X#Mol Microbiol##
00665000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100019000950100
01500114010001900129010001600148012010800164030001400272065000900286064000500295
031000300300014000600303865000900309002000900318035001000327801001400337#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#151#48#article#59#48#^rND^sMcMil
lan^nPJ#^rND^sStimmler^nLM#^rND^sFoth^nBJ#^rND^sMcFadden^nGI#^rND^sMuller^nS#The
 human malaria parasite Plasmodium falciparum possesses two distinct dihydrolipo
amide dehydrogenases^len#Mol Microbiol#20050000#2005#55#27-38#20080200#7057.htm#
0950-382X#Mol Microbiol##
00679000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100015000950100
01700110010001800127010001800145010001700163012010400180030000700284065000900291
06400050030003100030030501400100030886500090031800200090032703500100033680100070
0346#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#152#49#article#59#49
#^rND^sMarobbio^nCM#^rND^sVozza^nA#^rND^sHarding^nM#^rND^sBisaccia^nF#^rND^sPalm
ieri^nF#^rND^sWalker^nJE#Identification and reconstitution of the yeast mitochon
drial transporter for thiamine pyrophosphate^len#EMBO J#20020000#2002#21#5653-56
61#20080200#7057.htm#0261-4189#Embo J##
00570000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01600109012007500125030001200200065000900212064000500221031000400226014001000230
865000900240002000900249035001000258801001200268#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\7057.htm#S#c#153#50#article#59#50#^rND^sZilles^nJL#^rND^sCroal^nLR#^r
ND^sDowns^nDM#Action of the thiamine antagonist bacimethrin on thiamine biosynth
esis^len#J Bacteriol#20000000#2000#182#5606-5610#20080200#7057.htm#0021-9193#J B
acteriol##
00571000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100017000940100
01700111012007100128030001200199065000900211064000500220031000400225014001200229
865000900241002000900250035001000259801001200269#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\7057.htm#S#c#154#51#article#59#51#^rND^sLawhorn^nBG#^rND^sGerdes^nSY#
^rND^sBegley^nTP#A genetic screen for the identification of thiamin metabolic ge
nes^len#J Biol Chem#20040000#2004#279#43555-43559#20080200#7057.htm#0021-9258#J 
Biol Chem##
00629000000000289000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100016000910100
01600107010001700123012006800140030008800208710000200296065000900298064000500307
031000300312014000600315865000900321002000900330#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\7057.htm#S#c#155#52#article#59#52#^rND^sDivo^nAA#^rND^sGeary^nTG#^rND
^sDavis^nNL#^rND^sJensen^nJB#Nutritional requirements of Plasmodium falciparum i
n culture: I^len#Exogenously supplied dialyzable components necessary for contin
uous growth. J Protozool#2#19850000#1985#32#59-64#20080200#7057.htm##
00642000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100016000920100
01600108010001600124010001700140012007400157030002100231065000900252064000500261
031000500266014000800271865000900279002000900288035001000297801002100307#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#156#53#article#59#53#^rND^sTazuy
a^nK#^rND^sAdachi^nY#^rND^sMasuda^nK#^rND^sYamada^nK#^rND^sKumaoka^nH#Origin of 
the nitrogen atom of pyridoxine in Saccharomyces cerevisiae^len#Biochim Biophys 
Acta#19950000#1995#1244#113-116#20080200#7057.htm#0006-3002#Biochim Biophys Acta
##
00672000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100015000930100
01600108010001900124010001600143010001800159012008500177030001400262065000900276
06400050028503100040029001400100029486500090030400200090031303500100032280100140
0332#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#157#54#article#59#54
#^rND^sZeidler^nJ#^rND^sUllah^nN#^rND^sGupta^nRN#^rND^sPauloski^nRM#^rND^sSayer^
nBG#^rND^sSpenser^nID#2'-Hydroxypyridoxol, a biosynthetic precursor of vitamins 
B(6) and B(1) in yeast^len#J Am Chem Soc#20020000#2002#124#4542-4543#20080200#70
57.htm#0002-7863#J Am Chem Soc##
00605000000000277000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01800109012010500127030004500232710000200277065000900279064000500288031000400293
014001200297865000900309002000900318#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7
057.htm#S#c#158#55#article#59#55#^rND^sZeidler^nJ#^rND^sSayer^nBG#^rND^sSpenser^
nID#Biosynthesis of vitamin B1 in yeast: Derivation of the pyrimidine unit from 
pyridoxine and histidine^len#Intermediacy of urocanic acid. J Am Chem Soc#2#2003
0000#2003#125#13094-13105#20080200#7057.htm##
00493000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760120052000940300
01400146065000900160064000500169031000300174014000800177865000900185002000900194
035001000203801001400213#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#
159#56#article#59#56#^rND^sSherman^nIW#Biochemistry of Plasmodium (malarial para
sites)^len#Microbiol Rev#19790000#1979#43#453-495#20080200#7057.htm#0146-0749#Mi
crobiol Rev##
00655000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100014000940100
01400108010001500122010001800137010001600155810000600171012007200177030000700249
06500090025606400050026503100040027001400080027486500090028200200090029103500100
0300801000700310#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#160#57#a
rticle#59#57#^rND^sGardner^nMJ#^rND^sHall^nN#^rND^sFung^nE#^rND^sWhite^nO#^rND^s
Berriman^nM#^rND^sHyman^nRW#et al#Genome sequence of the human malaria parasite 
Plasmodium falciparum^len#Nature#20020000#2002#419#498-511#20080200#7057.htm#002
8-0836#Nature##
00415000000000229000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730160019000760180024000950660
00800119062002600127065000900153064000500162865000900167002000900176#v41n2#v:\sc
ielo\serial\bjmbr\v41n2\markup\7057.htm#S#c#161#58#article#59#58#^rND^sSchopfer^
nWH#Plants and vitamins^len#Waltham#Chronica Botanica Company#19490000#1949#2008
0200#7057.htm##
00637000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100019000760100021000950100
01800116010001800134012010100152030001200253065000900265064000500274031000400279
014001200283865000900295002000900304035001000313801001200323#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\7057.htm#S#c#162#59#article#59#59#^rND^sRodionov^nDA#^rND
^sVitreschak^nAG#^rND^sMironov^nAA#^rND^sGelfand^nMS#Comparative genomics of thi
amin biosynthesis in procaryotes: New genes and regulatory mechanisms^len#J Biol
 Chem#20020000#2002#277#48949-48959#20080200#7057.htm#0021-9258#J Biol Chem##
00268000000000169000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670910009000690920007000780020009000857030
00400094#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#o#1#1#article#1#20
080402#165805#6953.htm#123##
03304000000000769000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000300108
03000200011103100030013103200020013406500090013601400110014503500100015601201090
01660100022002750100020002970100019003170100020003360100022003560100022003780100
02100400010002200421010002200443010002000465010002000485010002000505010002000525
07001060054508314390065108500080209008500300209808500200212808500310214808500380
21790850027022171170006022440720003022500580036022530600013022890600013023020580
03702315060000902352058003802361060001202399058005302411060001102464112000902475
111001402484114000902498113001802507002000902525#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6953.htm#S#h#2#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#06#BJMBR010#nd#
Braz J Med Biol Res#41#2#20080200#^f110^l116#0100-879X#Genetic variations of EBV
-LMP1 from nasopharyngeal carcinoma biopsies: potential loss of T cell epitopes^
len#^rND^1A01^nY.L.^sTang#^rND^1A01^nJ.H.^sLu#^rND^1A01^nL.^sCao#^rND^1A01^nM.H.
^sWu#^rND^1A01^nS.P.^sPeng#^rND^1A01^nH.D.^sZhou#^rND^1A01^nC.^sHuang#^rND^1A01^
nY.X.^sYang#^rND^1A01^nY.H.^sZhou#^rND^1A01^nQ.^sChen#^rND^1A01^nX.L.^sLi#^rND^1
A01^nM.^sZhou#^rND^1A01^nG.Y.^sLi#Central South University^iA01^1Cancer Research
 Institute^cChangsha^sHunan^pthe People's Republic of China#^len^aTo find Epstei
n-Barr virus (EBV) strains with genetic variations of EBV latent membrane protei
n 1 (EBV-LMP1) from nasopharyngeal carcinoma (NPC), the full-length DNA of LMP1 
genes from 21 NPC biopsies obtained in Hunan province in southern China was ampl
ified and sequenced. Our sequences were compared to those previously reported by
 the Clustal V method. Results showed that all 21 sequences displayed two amino 
acid changes most frequently in LMP1 of CD4+ T cell epitopes at codons 144 (F®I,
 21/21) and 212 (G®S, 19/21) or (G®N, 2/21). We also show that type A EBV strain
 is prevalent in the cases of NPC from Hunan province with a 30-bp 18/21 deletio
n, and we highlight that this deletion resulted in loss of one of the CD4+ T cel
l-restricted epitopes. The other 3 sequences without this deletion all had a cha
nge at codon 344 (G®D). Furthermore, in the major epitope sequence of CD8+ T cel
ls restricted by HLA-A2, all 21 sequences showed changes at codons 126 (L®F) and
 129 (M®I). Our study discovered that one of the 21 sequence variations harbored
 a new change at codon 131 (W®C), and 5/21 specimens showed another novel change
 at codon 115 (G®A) in the major epitope sequence of CD8+ T cells restricted by 
HLA-A2. Our study suggests that these sequence variations of NPC-derived LMP1 ma
y lead to a potential escape from host cell immune recognition, protecting laten
t EBV infection and causing an increase in tumorigenicity.#^dnd^i1#^tm^len^kGene
tic variation^i1#^tm^len^kEpitope^i1#^tm^len^kImmune recognition^i1#^tm^len^kLat
ent membrane protein 1^i1#^tm^len^kTumorigenicity^i1#other#26#Key National Resea
rch Plan of China#2006CB910502#2006CB910504#National Science Foundation of China
#30330560#China Postdoctoral Science Foundation#20060390264#Hunan Province Natur
al Sciences Foundations of China#05JJ300064#20070627#June 27, 2007#20071218#Dece
mber 18, 2007#6953.htm##
03369000000000769000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670710003000690400003000720010006000750420
00200081120000400083038000500087038000400092121000300096049000900099158000300108
03000200011103100030013103200020013406500090013601400110014503500100015601201160
01660100022002820100020003040100019003240100020003430100022003630100022003850100
02100407010002200428010002200450010002000472010002000492010002000512010002000532
07001060055208314830065808500080214108500300214908500200217908500310219908500380
22300850027022681170006022950720003023010580036023040600013023400600013023530580
03702366060000902403058003802412060001202450058005302462060001102515112000902526
111002102535114000902556113002502565002000902590#v41n2#v:\scielo\serial\bjmbr\v4
1n2\markup\6953.htm#S#f#3#1#article#1#oa#en#bjmbr#1#3.1#ILUS#TAB#06#BJMBR010#nd#
Braz J Med Biol Res#41#2#20080200#^f110^l116#0100-879X#<b>Genetic variations of 
EBV-LMP1 from nasopharyngeal carcinoma biopsies: potential loss of T cell epitop
es</b>^len#^rND^1A01^nY.L.^sTang#^rND^1A01^nJ.H.^sLu#^rND^1A01^nL.^sCao#^rND^1A0
1^nM.H.^sWu#^rND^1A01^nS.P.^sPeng#^rND^1A01^nH.D.^sZhou#^rND^1A01^nC.^sHuang#^rN
D^1A01^nY.X.^sYang#^rND^1A01^nY.H.^sZhou#^rND^1A01^nQ.^sChen#^rND^1A01^nX.L.^sLi
#^rND^1A01^nM.^sZhou#^rND^1A01^nG.Y.^sLi#Central South University^iA01^1Cancer R
esearch Institute^cChangsha^sHunan^pthe People's Republic of China#^len^aTo find
 Epstein-Barr virus (EBV) strains with genetic variations of EBV latent membrane
 protein 1 (EBV-LMP1) from nasopharyngeal carcinoma (NPC), the full-length DNA o
f LMP1 genes from 21 NPC biopsies obtained in Hunan province in southern China w
as amplified and sequenced. Our sequences were compared to those previously repo
rted by the Clustal V method. Results showed that all 21 sequences displayed two
 amino acid changes most frequently in LMP1 of CD4<sup>+ </sup>T cell epitopes a
t codons 144 (F®I, 21/21) and 212 (G®S, 19/21) or (G®N, 2/21). We also show that
 type A EBV strain is prevalent in the cases of NPC from Hunan province with a 3
0-bp 18/21 deletion, and we highlight that this deletion resulted in loss of one
 of the CD4<sup>+ </sup>T cell-restricted epitopes. The other 3 sequences withou
t this deletion all had a change at codon 344 (G®D). Furthermore, in the major e
pitope sequence of CD8<sup>+ </sup>T cells restricted by HLA-A2, all 21 sequence
s showed changes at codons 126 (L®F) and 129 (M®I). Our study discovered that on
e of the 21 sequence variations harbored a new change at codon 131 (W®C), and 5/
21 specimens showed another novel change at codon 115 (G®A) in the major epitope
 sequence of CD8<sup>+</sup> T cells restricted by HLA-A2. Our study suggests th
at these sequence variations of NPC-derived LMP1 may lead to a potential escape 
from host cell immune recognition, protecting latent EBV infection and causing a
n increase in tumorigenicity.#^dnd^i1#^tm^len^kGenetic variation^i1#^tm^len^kEpi
tope^i1#^tm^len^kImmune recognition^i1#^tm^len^kLatent membrane protein 1^i1#^tm
^len^kTumorigenicity^i1#other#26#Key National Research Plan of China#2006CB91050
2#2006CB910504#National Science Foundation of China#30330560#China Postdoctoral 
Science Foundation#20060390264#Hunan Province Natural Sciences Foundations of Ch
ina#05JJ300064#20070627#<i>June 27, 2007</i>#20071218#<i>December 18, 2007</i>#6
953.htm##
03432000000000793000450000400060000070200450000670500020005170600020005370000020
00557010002000577090008000597080002000670640013000690710003000820400003000850010
00600088042000200094120000400096038000500100038000400105121000300109049000900112
15800030012103000240012403100030014803200020015106500090015301400110016203500100
01730120109001830100022002920100020003140100018003340100020003520100022003720100
02200394010002000416010002200436010002200458010001900480010002000499010001900519
01000200053807001080055808314390066608500080210508500300211308500200214308500310
21630850038021940850027022321170006022590720003022650580036022680600013023040600
01302317058003702330060000902367058003802376060001202414058005302426060001102479
112000902490111001402499114000902513113001802522002000902540008008902549#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#l#4#1#article#1#^mFeb.^a2008#oa#en
#bjmbr#1#3.1#ilus#tab#06#BJMBR010#nd#Braz. j. med. biol. res#41#2#20080200#^f110
^l116#0100-879X#Genetic variations of EBV-LMP1 from nasopharyngeal carcinoma bio
psies: potential loss of T cell epitopes^len#^rND^1A01^nY. L^sTang#^rND^1A01^nJ.
 H^sLu#^rND^1A01^nL^sCao#^rND^1A01^nM. H^sWu#^rND^1A01^nS. P^sPeng#^rND^1A01^nH.
 D^sZhou#^rND^1A01^nC^sHuang#^rND^1A01^nY. X^sYang#^rND^1A01^nY. H^sZhou#^rND^1A
01^nQ^sChen#^rND^1A01^nX. L^sLi#^rND^1A01^nM^sZhou#^rND^1A01^nG. Y^sLi#^iA01^1Ce
ntral South University^2Cancer Research Institute^cChangsha^sHunan^pthe People's
 Republic of China#^len^aTo find Epstein-Barr virus (EBV) strains with genetic v
ariations of EBV latent membrane protein 1 (EBV-LMP1) from nasopharyngeal carcin
oma (NPC), the full-length DNA of LMP1 genes from 21 NPC biopsies obtained in Hu
nan province in southern China was amplified and sequenced. Our sequences were c
ompared to those previously reported by the Clustal V method. Results showed tha
t all 21 sequences displayed two amino acid changes most frequently in LMP1 of C
D4+ T cell epitopes at codons 144 (F®I, 21/21) and 212 (G®S, 19/21) or (G®N, 2/2
1). We also show that type A EBV strain is prevalent in the cases of NPC from Hu
nan province with a 30-bp 18/21 deletion, and we highlight that this deletion re
sulted in loss of one of the CD4+ T cell-restricted epitopes. The other 3 sequen
ces without this deletion all had a change at codon 344 (G®D). Furthermore, in t
he major epitope sequence of CD8+ T cells restricted by HLA-A2, all 21 sequences
 showed changes at codons 126 (L®F) and 129 (M®I). Our study discovered that one
 of the 21 sequence variations harbored a new change at codon 131 (W®C), and 5/2
1 specimens showed another novel change at codon 115 (G®A) in the major epitope 
sequence of CD8+ T cells restricted by HLA-A2. Our study suggests that these seq
uence variations of NPC-derived LMP1 may lead to a potential escape from host ce
ll immune recognition, protecting latent EBV infection and causing an increase i
n tumorigenicity.#^dnd^i1#^tm^len^kGenetic variation^i1#^tm^len^kEpitope^i1#^tm^
len^kImmune recognition^i1#^tm^len^kLatent membrane protein 1^i1#^tm^len^kTumori
genicity^i1#other#26#Key National Research Plan of China#2006CB910502#2006CB9105
04#National Science Foundation of China#30330560#China Postdoctoral Science Foun
dation#20060390264#Hunan Province Natural Sciences Foundations of China#05JJ3000
64#20070627#June 27, 2007#20071218#December 18, 2007#6953.htm#Internet^ihttp://w
ww.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2008000200006##
00375000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704015000070002000900220#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#5#1#article#93#<P> <font face="Arial, He
lvetica, sans-serif"><A NAME="Home"></A><B>Braz J Med Biol Res, February 2008, V
olume 41(2) 110-116</B> </font></P>      ^cY#6953.htm##
00407000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704018200070002000900252#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#6#2#article#93#<P><B><font size="5" face
="Arial, Helvetica, sans-serif">Genetic variations of EBV-LMP1 from nasopharynge
al carcinoma biopsies: potential loss of T cell epitopes</font></B>      ^cY#695
3.htm##
00611000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704038600070002000900456#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#7#3#article#93#<P><font face="Arial, Hel
vetica, sans-serif">Y.L. Tang*, J.H. Lu*, L. Cao, M.H. Wu, S.P. Peng, H.D. Zhou,
 C. Huang, Y.X. Yang, Y.H. Zhou, Q. Chen, X.L. Li, M. Zhou and <b><a href="#Corr
espondence"><img src="/img/revistas/bjmbr/v41n2/recor.gif" border="0"></a></b> <
a href="mailto:ligy@xysm.net"><img src="/img/revistas/bjmbr/v41n2/email-ca.gif" 
border="0"></a> G.Y. Li </font>      ^cY#6953.htm##
00389000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704016400070002000900234#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#8#4#article#93#<P><font face="Arial, Hel
vetica, sans-serif">Cancer Research Institute, Central South University, Changsh
a, Hunan, the People's Republic of China</font>        ^cY#6953.htm##
00337000000000145000450000400060000070200450000670500020005170600020005370000020
0055701000200057709000800059708000300067704011200070002000900182#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#9#5#article#93#<P><font face="Arial, Hel
vetica, sans-serif">*These authors contributed equally to this study.</font>    
   ^cY#6953.htm##
00416000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704019000071002000900261#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#10#6#article#93#<P> <font face="Arial, H
elvetica, sans-serif"><A HREF="#Abstract"><IMG SRC="/img/revistas/bjmbr/v41n2/do
wn.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0> <strong>Abstract</strong></A>  
  ^cY#6953.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#11#7#article#93#<BR>   <A HREF="#Introdu
ction"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPAC
E=0 HSPACE=0></A> <A HREF="#Introduction"><strong>Introduction</strong></A>    ^
cY#6953.htm##
00413000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704018700071002000900258#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#12#8#article#93#<BR>   <A HREF="#Materia
l"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 
HSPACE=0></A> <A HREF="#Material"><strong>Material and Methods</strong></A>    ^
cY#6953.htm##
00398000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000200058709000800060708000300068704017200071002000900243#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#13#9#article#93#<BR>   <A HREF="#Results
"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 H
SPACE=0></A> <A HREF="#Results"><strong>Results</strong></A>    ^cY#6953.htm##
00408000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704018100072002000900253#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#14#10#article#93#<BR>   <A HREF="#Discus
sion"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#Discussion"><strong>Discussion</strong></A>    ^cY#69
53.htm##
00395000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704016800072002000900240#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#15#11#article#93#<BR>   <A HREF="#Refere
nces"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BOTTOM BORDER=0 VSPACE
=0 HSPACE=0></A> <A HREF="#References"><strong>References    ^cY#6953.htm##
00461000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704023400072002000900306#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#16#12#article#93#<br>   </strong></A>   
<A HREF="#Correspondence"><IMG SRC="/img/revistas/bjmbr/v41n2/down.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></A> <A HREF="#Correspondence"><strong>Correspon
dence and Footnotes</strong></A>  </font>      ^cY#6953.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004800072002000900120#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#17#13#article#93#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>      ^cY#6953.htm##
00546000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031900072002000900391#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#18#14#article#93#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Abstract"></A><FONT SIZE=4><FONT COLOR=#00007F><
B>Abstract </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/bac
k.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>  <font
 face="Arial, Helvetica, sans-serif">  </font>      ^cY#6953.htm##
02068000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704184100072002000901913#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#19#15#article#93#<P><font face="Arial, H
elvetica, sans-serif">To find Epstein-Barr virus (EBV) strains with genetic vari
ations of EBV latent membrane protein 1 (EBV-LMP1) from nasopharyngeal carcinoma
 (NPC), the full-length DNA of LMP1 genes from 21 NPC biopsies obtained in Hunan
 province in southern China was amplified and sequenced. Our sequences were comp
ared to those previously reported by the Clustal V method. Results showed that a
ll 21 sequences displayed two amino acid changes most frequently in LMP1 of CD4<
SUP>+ </SUP>T cell epitopes at codons 144 (F<font face="Symbol">&#174;</font>I, 
21/21) and 212 (G<font face="Symbol">&#174;</font>S, 19/21) or (G<font face="Sym
bol">&#174;</font>N, 2/21). We also show that type A EBV strain is prevalent in 
the cases of NPC from Hunan province with a 30-bp 18/21 deletion, and we highlig
ht that this deletion resulted in loss of one of the CD4<SUP>+ </SUP>T cell-rest
ricted epitopes. The other 3 sequences without this deletion all had a change at
 codon 344 (G<font face="Symbol">&#174;</font>D). Furthermore, in the major epit
ope sequence of CD8<SUP>+ </SUP>T cells restricted by HLA-A2, all 21 sequences s
howed changes at codons 126 (L<font face="Symbol">&#174;</font>F) and 129 (M<fon
t face="Symbol">&#174;</font>I). Our study discovered that one of the 21 sequenc
e variations harbored a new change at codon 131 (W<font face="Symbol">&#174;</fo
nt>C), and 5/21 specimens showed another novel change at codon 115 (G<font face=
"Symbol">&#174;</font>A) in the major epitope sequence of CD8<SUP>+</SUP> T cell
s restricted by HLA-A2. Our study suggests that these sequence variations of NPC
-derived LMP1 may lead to a potential escape from host cell immune recognition, 
protecting latent EBV infection and causing an increase in tumorigenicity.  </fo
nt>   <font face="Arial, Helvetica, sans-serif">      ^cY#6953.htm##
00384000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704015700072002000900229#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#20#16#article#93#<P>Key words: Genetic v
ariation; Epitope; Immune recognition; Latent membrane protein 1; Tumorigenicity
  </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6953.htm##
00593000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036600072002000900438#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#21#17#article#93#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Introduction"></A><FONT color="#00007F" SIZE=4><B
>Introduction</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-seri
f"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM
 BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>    <font face="Arial, Helvetica,
 sans-serif">      ^cY#6953.htm##
01202000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704097500072002000901047#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#22#18#article#93#<P>It is now known that
 Epstein-Barr virus (EBV) infects more than 90% of the world's adult population.
 Upon infection, the individual remains a lifelong carrier of the virus. EBV is 
strongly associated with the development of several cancers, particularly with B
urkitt's lymphoma, Hodgkin's disease, lymphoproliferative disorders, and nasopha
ryngeal carcinoma (NPC) (1). The clonal EBV genome is consistently detected in i
nvasive carcinomas and high-grade dysplastic lesions (2,3). Such observations im
ply that latent viral infection may have taken place before the expansion of the
 malignant cell clone. A current hypothesis proposes that EBV plays a critical r
ole in transforming nasopharyngeal epithelial cells into invasive cancer (4). La
tent membrane protein 1 (LMP1) is of special interest since it is generally cons
idered to be the main EBV oncogene (5,6). EBV, in conjunction with environmental
 and genetic factors, plays a role in the development of NPC.       ^cY#6953.htm
##
01187000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704096000072002000901032#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#23#19#article#93#<P>Recent studies have 
suggested that some of the sequence variations in the LMP1 gene such as a 30-bp 
deletion and multiple base substitutions and amino acid changes in HLA-A2-restri
cted cytotoxic T lymphocyte (CTL) epitopes are associated with an increase in tu
morigenicity and with a decrease in immune recognition (7,8). HLA-A2-restricted 
CD8<SUP>+</SUP> epitopes in LMP1 that are recognized by CTLs from healthy, EBV-s
eropositive individuals have been identified (9). Data indicate that EBV strains
 with specific variants of LMP1 are more likely to be found in NPC (10). Further
more, although previous studies on LMP1 have indicated the existence of NPC-spec
ific strains and variation of the LMP1 gene in some regions in southern China (6
,11), this information is not known for Hunan, a province in southern China. Thu
s, it is critically important to study variations of the LMP1 gene since Hunan i
s also one of the high-risk areas for NPC (12).      ^cY#6953.htm##
00739000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704051200072002000900584#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#24#20#article#93#<P>Thus, in the present
 study, DNA and amino acid sequence analyses were conducted by the Clustal V met
hod to detect EBV strains with genetic variations of EBV-LMP1 integrated in the 
NPC genome, to evaluate specific sequence variations within HLA-A2-restricted ep
itopes and to find EBV strains with specific variants of LMP1 in NPC biopsy spec
imens obtained from patients from Hunan province. Twenty-one full-length LMP1 ge
nes were amplified and sequenced.    </font>  <HR ALIGN=LEFT WIDTH=100% SIZE=2> 
     ^cY#6953.htm##
00595000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704036800072002000900440#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#25#21#article#93#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Material"></A><FONT color="#00007F" SIZE=4><B>Mat
erial and Methods</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-
serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BO
TTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>  <font face="Arial, Helvetic
a, sans-serif">      ^cY#6953.htm##
00273000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004600072002000900118#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#26#22#article#93#<P><b>Biopsy specimens 
</b>  </font>      ^cY#6953.htm##
00744000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704051700072002000900589#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#27#23#article#93#<P><font face="Arial, H
elvetica, sans-serif">A total of 21 NPC biopsy specimens were collected from pat
ients in Hunan province in southern China, ranging in age from 31 to 64 years. F
our were females and 17 were males. A part of each specimen was submitted to his
topathological diagnosis of NPC in the Pathology Department of the First Affilia
ted Hospital of Xiangya Medical School, Central South University, and the remain
der was snap-frozen and kept in liquid nitrogen for subsequent DNA analysis. </f
ont>      ^cY#6953.htm##
00313000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704008600072002000900158#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#28#24#article#93#<P><font face="Arial, H
elvetica, sans-serif"><B>Isolation of DNA</B> </font>      ^cY#6953.htm##
00804000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704057700072002000900649#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#29#25#article#93#<P><font face="Arial, H
elvetica, sans-serif">Genomic DNA was prepared from 21 NPC biopsy samples as des
cribed previously (6). NPC tissues were digested for 16 h at 55&#176;C in a buff
er that contained 10 mM Tris-HCl, pH 8.0, 100 mM NaCl, 25 mM EDTA, and proteinas
e K (0.1 mg/mL). Samples were extracted twice with an equal volume of phenol/chl
oroform and dialyzed against 10 mM Tris-HCl, pH 8.0, and 1 mM EDTA. RNase A (100
 &#181;g/mL) was added to the dialyzed sample and incubated at 37&#176;C for 2 h
, followed by phenol/chloroform extraction and dialysis. </font>      ^cY#6953.h
tm##
00355000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704012800072002000900200#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#30#26#article#93#<P><font face="Arial, H
elvetica, sans-serif"><B>Polymerase chain reaction amplification and DNA sequenc
ing</B> </font>      ^cY#6953.htm##
01094000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704086700072002000900939#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#31#27#article#93#<P><font face="Arial, H
elvetica, sans-serif">The full-length DNA of the LMP1 gene was amplified by poly
merase chain reaction (PCR) using primers P-L-F: 5'-TCAGGCAAGCCTATGACATG-3' nucl
eotide coordination relative to B95-8, 168116-168135 and P-L-R: 5'-TCAGTT GCCTTG
CTCCTGCC-3' nucleotide coordination relative to B95-8, 169508-169489. Each PCR e
xperiment included a positive control of DNA from the B95-8 strain and a negativ
e control of ddH<SUB>2</SUB>O instead of DNA. Reactions were carried out in a th
ermal cycle (Gene Amp<SUP>R</SUP> PCR System 9700, Applied Biosystems, Foster ci
ty, CA, USA). Fifty microliters of reaction mixtures of 1.4-kb fragments was pur
ified with the Gel Extraction Mini Kit (Watson Biotechnologies, Inc., Shanghai, 
China)<B>. </B>Purified PCR products were sent to the Invitrogen Company (Shangh
ai, China) for sequencing. </font>      ^cY#6953.htm##
00318000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704009100072002000900163#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#32#28#article#93#<P><font face="Arial, H
elvetica, sans-serif"><B>Phylogenetic analysis</B> </font>      ^cY#6953.htm##
00565000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033800072002000900410#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#33#29#article#93#<P><font face="Arial, H
elvetica, sans-serif">Nucleotide sequences of LMP1 were translated into amino ac
id ones corresponding to that of the prototype B95-8 and were aligned by the Clu
stal V method using the Megalign software (DNA Star, Inc., Madison, WI, USA). Ge
netic distance and the phylogenetic tree were determined. </font>      ^cY#6953.
htm##
00334000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704010700072002000900179#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#34#30#article#93#<P><font face="Arial, H
elvetica, sans-serif"><B>Nucleotide sequence accession numbers</B> </font>      
^cY#6953.htm##
00449000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704022200072002000900294#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#35#31#article#93#<P><font face="Arial, H
elvetica, sans-serif">The nucleotide sequence data of LMP1 from 21 NPC reported 
in the present paper are available in the GenBank database under accession numbe
rs EF419184-EF419204. </font>      ^cY#6953.htm##
00326000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704009900072002000900171#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#36#32#article#93#<P><font face="Arial, H
elvetica, sans-serif"><B>Epstein-Barr virus genotyping</B> </font>      ^cY#6953
.htm##
00777000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704055000072002000900622#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#37#33#article#93#<P><font face="Arial, H
elvetica, sans-serif">The primers selected to amplify strain-specific variations
 in the EBNA-3C gene loci have been previously reported (11,13). Conditions and 
parameters for PCR amplification of the EBV DNA sequence corresponding to the EB
NA-3C gene were as described by Cheung et al. (11). The sizes of the PCR product
s were analyzed by agarose gel electrophoresis. DNA from B95-8 and Jijoye cells 
was used for control of the type A strain and type B strain, respectively. </fon
t>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6953.htm##
00537000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031000072002000900382#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#38#34#article#93#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="Results"></A><FONT color="#00007F" SIZE=4><B>Resu
lts</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><A HREF
="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BORDER=0 
VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6953.htm##
00345000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704011800072002000900190#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#39#35#article#93#<P><b><font face="Arial
, Helvetica, sans-serif">General sequence characteristics of the LMP1 gene</font
></b>      ^cY#6953.htm##
01361000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704113400072002000901206#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#40#36#article#93#<P><font face="Arial, H
elvetica, sans-serif">The full-length LMP1 gene from biopsies was amplified by P
CR and determined by and compared with the sequences of the prototype B95-8, NPC
-CAO strain (GenBank accession No. AF304432), and NPC strains (China1, China2, A
Y601307 (NPC1-Lin)), respectively. Sequence analysis revealed that the LMP1 gene
s from NPC samples were 82.6-91.7 and 89.8-99.7% similar at the amino acid level
 to those of the B95-8 strain, AY601307 (6), respectively. Pattern 1 reported by
 Lin et al. (6) is prevalent among the cases of NPC found in Hunan Province of S
outhern China. The full LMP1 sequences from NPC8 and NPC15 were fully identified
 (100%) and were found to be the same as the sequence of AY601307, except that t
he latter has one more copy of an 11-amino acid repeat. The phylogram tree is sh
own in <a href="#Fig1">Figure 1</a>. Loss of an <I>Xho</I>I cut site occurred at
 the N-terminus (21/21). A high frequency of deletions or mutations or multiple 
base substitutions leading to amino acid changes in LMP1 from NPC tissues was fo
und in Hunan Province (<a href="#Fig2">Figure 2</a>). </font>      ^cY#6953.htm#
#
00326000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704009900072002000900171#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#41#37#article#93#<P><font face="Arial, H
elvetica, sans-serif"><B>Epstein-Barr virus genotyping</B> </font>      ^cY#6953
.htm##
00808000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704058100072002000900653#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#42#38#article#93#<P><font face="Arial, H
elvetica, sans-serif">The primers chosen to amplify the EBNA-3C genes encompass 
strain-specific deletions (13). A representative result was shown in <a href="#F
ig3">Figure 3</a>. It showed 153-bp fragments from B95-8 and 21 NPC cases, as sh
own by NPC1-11. The expected size of the PCR product of the type A strain was 15
3 bp, as demonstrated by the B95-8 control, and the expected size of the type B 
strain was 246 bp, as shown by Jijoye cells. All EBV genotypes isolated from 21 
NPC cases from Hunan province were type A of the EBV strain. </font>      ^cY#69
53.htm##
00340000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704011300072002000900185#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#43#39#article#93#<P><font face="Arial, H
elvetica, sans-serif"><B>Sequence variations in CD4+ T cell epitopes</B> </font>
      ^cY#6953.htm##
01015000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704078800072002000900860#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#44#40#article#93#<P><font face="Arial, H
elvetica, sans-serif">Leen et al. (14) showed that three peptides in LMP1 were C
D4+ T cell epitopes. In the present study, 85.7% (18/21) of the NPC-LMP1 sequenc
es displayed the 30-bp deletion, which resulted in loss of the third CD4+ T cell
 epitope. The three sequences without this deletion all had a change at 344 (G<f
ont face="Symbol">&#174;</font>D). Furthermore, the most frequent amino acid cha
nges in the DNA sequences occurred at two positions: at amino acids 144 (F<font 
face="Symbol">&#174;</font>I, 21/21) and 212 (G<font face="Symbol">&#174;</font>
S, 19/21) or (G<font face="Symbol">&#174;</font>N, 2/21), and some sporadic muta
tions also occurred at other amino acids in the LMP1 of CD4+ T cell epitopes (<a
 href="#Tab1">Table 1</a>). </font>      ^cY#6953.htm##
00335000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704010800072002000900180#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#45#41#article#93#<P><font face="Arial, H
elvetica, sans-serif"><B>Analysis of HLA-A2-restricted epitopes</B> </font>     
 ^cY#6953.htm##
01505000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704127800072002000901350#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#46#42#article#93#<P><font face="Arial, H
elvetica, sans-serif">The DNA sequences of 12 potential HLA-A2-binding peptides 
(amino acids 32-181) within LMP1 were analyzed (6). DNA sequence changes that re
sulted in amino acid changes were detected in peptides 1, 2, 5, 8, 10, and 11 (<
a href="#Tab2">Table 2</a>). Of particular interest was peptide 1, which was ide
ntified previously as the major HLA-A2-restricted CTL epitope in LMP1 (9). The D
NA sequence of peptide 1 displayed amino acid changes at the following three pos
itions: 126, 129 and 131. At amino acid 126, Leu was substituted by Phe in 100% 
(21/21) of EBV isolates from NPC specimens. At amino acid 129, a consistent chan
ge from ATG to ATT resulting in an amino acid change from Met to Ile was detecte
d in 100% (21/21) of EBV isolates from NPC samples, and NPC4 had a point mutatio
n at residue 131 where TGG (Trp) was simultaneously changed to TGC (Cys). This p
atient was a 56-year-old man with poorly differentiated nasopharyngeal squamous 
cell carcinoma. Peptide 10 had an amino acid substituted at residue 115 where GG
G (Gly) was changed to GCC (Ala) in 23.8% (5/21) of NPC samples. It was the firs
t time that these variations were reported in the EBV-LMP1 gene from NPC compare
d with that from the prototype B95-8. </font>      ^cY#6953.htm##
00358000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704013100072002000900203#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#47#43#article#93#<P><font face="Arial, H
elvetica, sans-serif"><B>Copy numbers of the 33-bp repeat in latent membrane pro
tein 1</B> </font>      ^cY#6953.htm##
00973000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704074600072002000900818#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#48#44#article#93#<P><font face="Arial, H
elvetica, sans-serif">Previous reports have shown the presence of a varying copy
 of an 11-amino acid repeat between amino acids 250 and 308 in the carboxy-termi
nal domain of LMP1. Examination of the 21 DNA sequences revealed that 14 of them
 had four copies of this repeat, 5 of them had five copies, and 2 had a maximum 
of seven copies. There was no correlation between copy numbers of repeat element
s and disease status (P &gt; 0.05).</font>   <HR ALIGN=LEFT WIDTH=100% SIZE=2>  
<table width="100%"  border="0">    <tr align="left" valign="top">      <td widt
h="13%"><a href="/img/revistas/bjmbr/v41n2/html/6953i01.htm"><img src="/img/revi
stas/bjmbr/v41n2/6953i01peq.jpg" border="2"></a></td>      <td width="87%">    ^
cY#6953.htm##
00545000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031800072002000900390#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#49#45#article#93#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig1"></a>Figure 1. The phylogram tree of the LMP
1 gene at the amino acid level from 21 cases of nasopharyngeal carcinoma (NPC; c
ompared with the sequence from the prototype B95-8, NPC-CAO, China1, China2, NPC
1-Lin). </font>      </td>    </tr>  </table>      ^cY#6953.htm##
00615000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038800072002000900460#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#50#46#article#93#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (163 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v
41n2/html/6953i02.htm"><img src="/img/revistas/bjmbr/v41n2/6953i02peq.jpg" borde
r="2"></a></td>      <td width="87%">    ^cY#6953.htm##
00549000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704032200072002000900394#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#51#47#article#93#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig2"></a>Figure 2. Main variations of full-lengt
h amino acid sequences of LMP1 from NPC1-21, B95-8, and 4 previously described. 
The deletions are indicated by asterisks at codons 343-352. NPC = nasopharyngeal
 carcinoma. </font>      </td>    </tr>  </table>      ^cY#6953.htm##
00615000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038800072002000900460#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#52#48#article#93#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (155 K JPG file)]</font
></P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <t
r align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v
41n2/html/6953i03.htm"><img src="/img/revistas/bjmbr/v41n2/6953i03peq.jpg" borde
r="2"></a></td>      <td width="87%">    ^cY#6953.htm##
00448000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704022100072002000900293#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#53#49#article#93#<P><font face="Arial, H
elvetica, sans-serif"><a name="Fig3"></a>Figure 3. Epstein-Barr virus typing by 
the EBNA-3C region in primary nasopharyngeal carcinoma (NPC) specimens.</font>  
    </td>    </tr>  </table>      ^cY#6953.htm##
00609000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038200072002000900454#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#54#50#article#93#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this image (61 K JPG file)]</font>
</P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr
 align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v4
1n2/html/6953t01.htm"><img src="/img/revistas/bjmbr/v41n2/table.jpg" border="2">
</a></td>      <td width="87%">    ^cY#6953.htm##
00471000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704024400072002000900316#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#55#51#article#93#<P><font face="Arial, H
elvetica, sans-serif"><a name="Tab1"></a>Table 1. Sequence variation in CD4+ T c
ell epitopes of latent membrane protein 1 (LMP1) from patients with nasopharynge
al carcinoma. </font>      </td>    </tr>  </table>      ^cY#6953.htm##
00616000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704038900072002000900461#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#56#52#article#93#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (82 K JPG file)]</font>
</P>  <HR ALIGN=LEFT WIDTH=100% SIZE=2>  <table width="100%"  border="0">    <tr
 align="left" valign="top">      <td width="13%"><a href="/img/revistas/bjmbr/v4
1n2/html/6953t02.htm"><img src="/img/revistas/bjmbr/v41n2/table.jpg" border="2">
</a></td>      <td width="87%">           ^cY#6953.htm##
00502000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704027500072002000900347#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#57#53#article#93#<p><font face="Arial, H
elvetica, sans-serif"><a name="Tab2"></a>Table 2.          Sequence variation in
 the HLA-A2-restricted peptides of latent membrane          protein 1 (LMP1) fro
m patients with nasopharyngeal carcinoma. </font></p>     </td>    </tr>  </tabl
e>      ^cY#6953.htm##
00344000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704011700072002000900189#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#58#54#article#93#<P><font face="Arial, H
elvetica, sans-serif">[View larger version of this table (89 K JPG file)]</font>
</P>      ^cY#6953.htm##
00275000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704004800072002000900120#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#59#55#article#93#<P>  <HR ALIGN=LEFT WID
TH=100% SIZE=2>      ^cY#6953.htm##
00497000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704027000072002000900342#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#60#56#article#93#<P> <font face="Arial, 
Helvetica, sans-serif"><A NAME="Discussion"></A><FONT SIZE=4><FONT COLOR=#00007F
><B>Discussion </B></FONT><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2
/back.gif" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></FONT></font></P>   
   ^cY#6953.htm##
01792000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704156500072002000901637#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#61#57#article#93#<P><font face="Arial, H
elvetica, sans-serif">In contrast to the expression of nearly 100 viral genes du
ring replication, EBV-targeted cells express at most 12 latent genes. These gene
s are usually activated and proliferate to express 6 nuclear antigens, including
 EBNA-1, -2, -3 (3A), -4 (3B), -5 (LP), and -6 (3C), and 3 latent membrane prote
ins, LMP1, LMP2A, and LMP2B. Along with three kinds of untranslated RNAs, EBV en
codes mRNA 1 and mRNA 2, and a family of <I>Bam</I>H1A transcripts (15). The lim
ited numbers of viral genes expressed reduce the possibility of recognition of i
nfected cells by CTLs. During the development of NPC, LMP1 is expressed in the a
bsence of the EBNAs, the major viral CTL targets. Malignant cells that express L
MP1 are not recognized due to the persistence of epitope changes in LMP1, and ce
lls whose LMP1 epitopes are recognized would be eliminated. Our results showed t
hat the pattern 1 reported by Lin et al. (6) is prevalent in NPC cases from Huna
n, southern China. High frequencies of deletion and mutation in EBV-LMP1 from NP
C tissues were found in Hunan, which is also one of the high-risk areas for NPC 
(12). The data also indicated that LMP1 sequences from NPC tissues carry mutatio
ns which are likely to affect critical functions of the LMP1 gene. LMP1 sequence
s from NPC isolates significantly increased tumorigenicity when compared to LMP1
 sequences from the prototype B95-8 strain or EBV isolates from normal B cells (
16), but the exact role of these mutations in enhancing tumorigenicity is not cl
ear. </font>      ^cY#6953.htm##
01672000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704144500072002000901517#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#62#58#article#93#<P><font face="Arial, H
elvetica, sans-serif">CD4+ T cells are primarily known as helper immune cells, w
hile a role for CD4+ T cells as direct mediators of effector function was detect
ed in a recent report about the mouse <font face="Symbol">g</font>-herpesvirus m
odel (14,17,18). Bickham et al. (19) also revealed the polarized Th1 phenotype (
IFN-<font face="Symbol">g</font>) of EBNA-1-specific CD4+ T cells, and reported 
initial evidence that Th1 CD4+ T cells play several critical roles in host defen
se against viral infection and tumors. In the present study, 85.7% (18/21) of th
e NPC-LMP1 sequences displayed the 30-bp deletion, which resulted in loss of one
 of the CD4+ T cell-restricted epitopes. In previous reports, the 30-bp deletion
 was regarded as a biomarker in NPC-LMP1 (7,8,20,21). Interestingly, NPC4 harbor
ed a new change at 131 (W<font face="Symbol">&#174;</font>C), which was involved
 in CD4+ and CD8+ T cell-restricted epitopes. Antigen presentation to CD4+ T hel
per cells was reduced owing to the potentiation of regulatory T cell function by
 NPC-LMP1 transfectants, which produce increased levels of interleukin-10, rende
ring CD4+ T cells hyporesponsive (22). After primary EBV infection, T cells may 
not recognize activation by NPC-LMP1. These observations have important implicat
ions for the establishment of EBV-associated malignancy in the context of infect
ion with tumor-associated EBV-LMP1 variants. </font>      ^cY#6953.htm##
01947000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704172000072002000901792#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#63#59#article#93#<P><font face="Arial, H
elvetica, sans-serif">Recent reports have also indicated that variant sequences 
of CD8+ CTL responses can result in poor recognitions by specific T cells (10,23
). Polyclonal CD8+ CTLs that recognized the peptide epitopes YLLEMLWRL and YLQQN
WWTL from LMP1 in association with HLA-A2 were isolated from seropositive donors
 (9). Most of the sequence variations in LMP1 detected in our study are consiste
nt with those reported by Lin et al. (6) and Edwards et al. (10) for different E
BV strains while the variation in peptide 10 was first reported here (residue 11
5 (G<font face="Symbol">&#174;</font>A)). This variation was not associated with
 clinical stage, patient age or gender (P &gt; 0.05) in the limited samples. Fur
thermore, the results also demonstrated that the LMP1 sequence in EBV strains pr
esent in NPC patients from Hunan differed from that of B95-8, and that the main 
A2-restricted T cell epitope (amino acids 125-133: YLLEMLWRL) showed variations 
which were also present in patients from other regions (6). This variant sequenc
e is not recognized by epitope-specific T cells; this correlates with reduced bi
nding of the variant peptide sequence to HLA-A2 molecules (24). The prevalence o
f an HLA-A2-restricted `epitope loss variant' of LMP1 in a southern Chinese popu
lation with a high A2 prevalence may therefore contribute to immune escape by ma
lignant cells that express LMP1. Functional assays of the CD8+ epitope variant s
howed that EBV isolates from NPC were dominated by an HLA-A2-restricted `epitope
-loss variant' of LMP1, which would allow the virus to resist immune recognition
 and may contribute in part to the prevalence of NPC in these populations (25). 
</font>      ^cY#6953.htm##
01554000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704132700072002000901399#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#64#60#article#93#<P><font face="Arial, H
elvetica, sans-serif">We have obtained a panel of data about full-length LMP1 fr
om the NPC high-risk area of Hunan province, and found some novel variations in 
this study. Although these novel variations were found in the limited number of 
samples, they are involved in changes of several potential T cell epitopes. Thes
e variations may help some EBV strains to obtain stronger immune resistance in t
heir evolution. The striking consistent sequence variations of LMP1, especially 
in CD4+ T cell epitopes and HLA-A2-restricted CD8+ CTL epitopes, may contribute 
to the transformation of epithelial cells in NPC by reducing immune recognition 
and inducing tumorigenic activities and also by molecular differences and biolog
ical properties still to be elucidated. Of course, at present, strain identifica
tion based on the data from a limited region in LMP1 and these preferential infe
ctions cannot be solely attributed to this difference. Functional analysis of LM
P1 is underway and biological assays such as transfection experiments are furthe
r required to clarify the roles of each LMP1 variant in cell proliferative disea
ses. We have described a new technology of infectious cloning for the study of g
ene function in the Epstein-Barr virus genome (26). </font>  <HR ALIGN=LEFT WIDT
H=100% SIZE=2>      ^cY#6953.htm##
00543000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704031600072002000900388#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#65#61#article#93#<P><font face="Arial, H
elvetica, sans-serif"><A NAME="References"></A><FONT color="#00007F" SIZE=4><B>R
eferences</B></FONT></font> <font size="4" face="Arial, Helvetica, sans-serif"><
A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.gif" ALIGN=BOTTOM BOR
DER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6953.htm##
00404000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704016300074002000900237#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#66#62#article#93#1#<P><font 
face="Arial, Helvetica, sans-serif">1. Thompson MP, Kurzrock R. Epstein-Barr vir
us and cancer. <I>Clin Cancer Res</I> 2004; 10: 803-821. </font>      ^cY#6953.h
tm##
00461000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704022000074002000900294#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#67#63#article#93#2#<P><font 
face="Arial, Helvetica, sans-serif">2. Raab-Traub N, Flynn K. The structure of t
he termini of the Epstein-Barr virus as a marker of clonal cellular proliferatio
n. <I>Cell</I> 1986; 47: 883-889. </font>      ^cY#6953.htm##
00411000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704017000074002000900244#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#68#64#article#93#3#<P><font 
face="Arial, Helvetica, sans-serif">3. Raab-Traub N. Epstein-Barr virus in the p
athogenesis of NPC. <I>Semin Cancer Biol</I> 2002; 12: 431-441. </font>      ^cY
#6953.htm##
00402000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704016100074002000900235#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#69#65#article#93#4#<P><font 
face="Arial, Helvetica, sans-serif">4. Lo KW, To KF, Huang DP. Focus on nasophar
yngeal carcinoma. <I>Cancer Cell</I> 2004; 5: 423-428. </font>      ^cY#6953.htm
##
00532000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704029100074002000900365#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#70#66#article#93#5#<P><font 
face="Arial, Helvetica, sans-serif">5. Hu LF, Zabarovsky ER, Chen F, Cao SL, Ern
berg I, Klein G, et al. Isolation and sequencing of the Epstein-Barr virus BNLF-
1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. <I>J Gen Virol</I> 1991; 
72 (Part 10): 2399-2409. </font>      ^cY#6953.htm##
00608000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704036700074002000900441#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#71#67#article#93#6#<P><font 
face="Arial, Helvetica, sans-serif">6. Lin JC, Cherng JM, Lin HJ, Tsang CW, Liu 
YX, Lee SP. Amino acid changes in functional domains of latent membrane protein 
1 of Epstein-Barr virus in nasopharyngeal carcinoma of southern China and Taiwan
: prevalence of an HLA-A2-restricted `epitope-loss variant'. <I>J Gen Virol</I> 
2004; 85: 2023-2034. </font>      ^cY#6953.htm##
00494000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704025300074002000900327#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#72#68#article#93#7#<P><font 
face="Arial, Helvetica, sans-serif">7. Nagamine M, Takahara M, Kishibe K, Nagato
 T, Ishii H, Bandoh N, et al. Sequence variations of Epstein-Barr virus LMP1 gen
e in nasal NK/T-cell lymphoma. <I>Virus Genes</I> 2007; 34: 47-54. </font>      
^cY#6953.htm##
00528000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704028700074002000900361#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#73#69#article#93#8#<P><font 
face="Arial, Helvetica, sans-serif">8. Saechan V, Mori A, Mitarnun W, Settheetha
m-Ishida W, Ishida T. Analysis of LMP1 variants of EBV in Southern Thailand: evi
dence for strain-associated T-cell tropism and pathogenicity. <I>J Clin Virol</I
> 2006; 36: 119-125. </font>      ^cY#6953.htm##
00635000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000200072704039400074002000900468#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#74#70#article#93#9#<P><font 
face="Arial, Helvetica, sans-serif">9. Khanna R, Burrows SR, Nicholls J, Poulsen
 LM. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV)
 oncogene latent membrane protein 1 (LMP1): evidence for HLA-A2 supertype-restri
cted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymph
ocytes. <I>Eur J Immunol</I> 1998; 28: 451-458. </font>      ^cY#6953.htm##
00459000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704021700075002000900292#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#75#71#article#93#10#<P><font
 face="Arial, Helvetica, sans-serif">10. Edwards RH, Sitki-Green D, Moore DT, Ra
ab-Traub N. Potential selection of LMP1 variants in nasopharyngeal carcinoma. <I
>J Virol</I> 2004; 78: 868-881. </font>      ^cY#6953.htm##
00541000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704029900075002000900374#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#76#72#article#93#11#<P><font
 face="Arial, Helvetica, sans-serif">11. Cheung ST, Leung SF, Lo KW, Chiu KW, Ta
m JS, Fok TF, et al. Specific latent membrane protein 1 gene sequences in type 1
 and type 2 Epstein-Barr virus from nasopharyngeal carcinoma in Hong Kong. <I>In
t J Cancer</I> 1998; 76: 399-406. </font>      ^cY#6953.htm##
00490000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704024800075002000900323#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#77#73#article#93#12#<P><font
 face="Arial, Helvetica, sans-serif">12. Xiong W, Zeng ZY, Xia JH, Xia K, Shen S
R, Li XL, et al. A susceptibility locus at chromosome 3p21 linked to familial na
sopharyngeal carcinoma. <I>Cancer Res</I> 2004; 64: 1972-1974. </font>      ^cY#
6953.htm##
00583000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704034100075002000900416#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#78#74#article#93#13#<P><font
 face="Arial, Helvetica, sans-serif">13. Lin JC, Lin SC, De BK, Chan WP, Evatt B
L, Chan WC. Precision of genotyping of Epstein-Barr virus by polymerase chain re
action using three gene loci (EBNA-2, EBNA-3C, and EBER): predominance of type A
 virus associated with Hodgkin's disease. <I>Blood</I> 1993; 81: 3372-3381. </fo
nt>      ^cY#6953.htm##
00530000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028800075002000900363#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#79#75#article#93#14#<P><font
 face="Arial, Helvetica, sans-serif">14. Leen A, Meij P, Redchenko I, Middeldorp
 J, Bloemena E, Rickinson A, et al. Differential immunogenicity of Epstein-Barr 
virus latent-cycle proteins for human CD4(+) T-helper 1 responses. <I>J Virol</I
> 2001; 75: 8649-8659. </font>      ^cY#6953.htm##
00448000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020600075002000900281#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#80#76#article#93#15#<P><font
 face="Arial, Helvetica, sans-serif">15. Ohga S, Nomura A, Takada H, Hara T. Imm
unological aspects of Epstein-Barr virus infection. <I>Crit Rev Oncol Hematol</I
> 2002; 44: 203-215. </font>      ^cY#6953.htm##
00517000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704027500075002000900350#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#81#77#article#93#16#<P><font
 face="Arial, Helvetica, sans-serif">16. Hu LF, Chen F, Zheng X, Ernberg I, Cao 
SL, Christensson B, et al. Clonability and tumorigenicity of human epithelial ce
lls expressing the EBV encoded membrane protein LMP1. <I>Oncogene</I> 1993; 8: 1
575-1583. </font>      ^cY#6953.htm##
00528000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028600075002000900361#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#82#78#article#93#17#<P><font
 face="Arial, Helvetica, sans-serif">17. Liu H, Andreansky S, Diaz G, Hogg T, Do
herty PC. Reduced functional capacity of CD8+ T cells expanded by post-exposure 
vaccination of gamma-herpesvirus-infected CD4-deficient mice. <I>J Immunol</I> 2
002; 168: 3477-3483. </font>      ^cY#6953.htm##
00447000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704020500075002000900280#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#83#79#article#93#18#<P><font
 face="Arial, Helvetica, sans-serif">18. Thomas PG, Keating R, Hulse-Post DJ, Do
herty PC. Cell-mediated protection in influenza infection. <I>Emerg Infect Dis</
I> 2006; 12: 48-54. </font>      ^cY#6953.htm##
00523000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028100075002000900356#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#84#80#article#93#19#<P><font
 face="Arial, Helvetica, sans-serif">19. Bickham K, Munz C, Tsang ML, Larsson M,
 Fonteneau JF, Bhardwaj N, et al. EBNA1-specific CD4+ T cells in healthy carrier
s of Epstein-Barr virus are primarily Th1 in function. <I>J Clin Invest</I> 2001
; 107: 121-130. </font>      ^cY#6953.htm##
00531000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704028900075002000900364#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#85#81#article#93#20#<P><font
 face="Arial, Helvetica, sans-serif">20. Cheung ST, Lo KW, Leung SF, Chan WY, Ch
oi PH, Johnson PJ, et al. Prevalence of LMP1 deletion variant of Epstein-Barr vi
rus in nasopharyngeal carcinoma and gastric tumors in Hong Kong. <I>Int J Cancer
</I> 1996; 66: 711-712. </font>      ^cY#6953.htm##
00618000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704037600075002000900451#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#86#82#article#93#21#<P><font
 face="Arial, Helvetica, sans-serif">21. Leung SY, Yuen ST, Chung LP, Chan AS, W
ong MP. Prevalence of mutations and 30-bp deletion in the C-terminal region of E
pstein-Barr virus latent membrane protein-1 oncogene in reactive lymphoid tissue
 and non-nasopharyngeal EBV-associated carcinomas in Hong Kong Chinese. <I>Int J
 Cancer</I> 1997; 72: 225-230. </font>      ^cY#6953.htm##
00564000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704032200075002000900397#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#87#83#article#93#22#<P><font
 face="Arial, Helvetica, sans-serif">22. Pai S, O'Sullivan B, Abdul-Jabbar I, Pe
ng J, Connolly G, Khanna R, et al. Nasopharyngeal carcinoma-associated Epstein-B
arr virus-encoded oncogene latent membrane protein 1 potentiates regulatory T-ce
ll function. <I>Immunol Cell Biol</I> 2007; 85: 370-377. </font>      ^cY#6953.h
tm##
00405000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704016300075002000900238#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#88#84#article#93#23#<P><font
 face="Arial, Helvetica, sans-serif">23. Stevenson PG. Immune evasion by gamma-h
erpesviruses. <I>Curr Opin Immunol</I> 2004; 16: 456-462. </font>      ^cY#6953.
htm##
00630000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704038800075002000900463#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#89#85#article#93#24#<P><font
 face="Arial, Helvetica, sans-serif">24. Duraiswamy J, Burrows JM, Bharadwaj M, 
Burrows SR, Cooper L, Pimtanothai N, et al. <I>Ex vivo</I> analysis of T-cell re
sponses to Epstein-Barr virus-encoded oncogene latent membrane protein 1 reveals
 highly conserved epitope sequences in virus isolates from diverse geographic re
gions. <I>J Virol</I> 2003; 77: 7401-7410. </font>      ^cY#6953.htm##
00565000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704032300075002000900398#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#90#86#article#93#25#<P><font
 face="Arial, Helvetica, sans-serif">25. Lin HJ, Cherng JM, Hung MS, Sayion Y, L
in JC. Functional assays of HLA-A2-restricted epitope variant of latent membrane
 protein 1 (LMP-1) of Epstein-Barr virus in nasopharyngeal carcinoma of Southern
 China and Taiwan. <I>J Biomed Sci</I> 2005; 12: 925-936. </font>      ^cY#6953.
htm##
00538000000000157000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069888000300072704029600075002000900371#v41
n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#p#91#87#article#93#26#<P><font
 face="Arial, Helvetica, sans-serif">26. Tang YL, Lu JH, Wu MH, Huang C, Cao L, 
Peng SP, et al. Lytic replication and induction to production visualization reco
mbinant Epstein Barr virus. <I>Progr Biochem Biophys</I> 2007; 34: 418-424.</fon
t>   <HR ALIGN=LEFT WIDTH=100% SIZE=2>      ^cY#6953.htm##
00563000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704033600072002000900408#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#92#88#article#93#<P><FONT SIZE=4 face="A
rial, Helvetica, sans-serif"><a name="Correspondence"></a><FONT COLOR=#00007F><B
>Correspondence and Footnotes</B></FONT></FONT> <font size="4" face="Arial, Helv
etica, sans-serif"><A HREF="#Home"><B><IMG SRC="/img/revistas/bjmbr/v41n2/back.g
if" ALIGN=BOTTOM BORDER=0 VSPACE=0 HSPACE=0></B></A></font></P>      ^cY#6953.ht
m##
00645000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704041800072002000900490#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#93#89#article#93#<p><font face="Arial, H
elvetica, sans-serif"><b><a href="#Home"><img src="/img/revistas/bjmbr/v41n2/rec
or.gif" border="0"></a> Address for correspondence:</b> Correspondence to: G.Y. 
Li, Cancer Research Institute, Central South University, 110# Xiang-Ya Road, Cha
ngsha, Hunan 410078, the People's Republic of China. Fax: +86-731-480-5383. E-ma
il: <a href="mailto:ligy@xysm.net">ligy@xysm.net</a></font> </p>       ^cY#6953.
htm##
00641000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704041400072002000900486#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#94#90#article#93#<P><font face="Arial, H
elvetica, sans-serif"> Research supported by the Key National    Research Plan o
f China (2006CB910502, 2006CB910504), the National Science Foundation    of Chin
a (No. 30330560), China Postdoctoral Science Foundation (No. 20060390264),    an
d Hunan Province Natural Sciences Foundations of China (No. 05JJ300064). <I>Rece
ived    June 27, 2007. Accepted December 18, 2007</I>. </font>     ^cY#6953.htm#
#
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#95#91#article#93#<P>&nbsp;     ^cY#6953.
htm##
00245000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704001800072002000900090#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#96#92#article#93#<P>&nbsp;     ^cY#6953.
htm##
00392000000000145000450000400060000070200450000670500020005170600020005370000030
0055701000300058709000800061708000300069704016500072002000900237#v41n2#v:\scielo
\serial\bjmbr\v41n2\markup\6953.htm#S#p#97#93#article#93#<P><font face="Arial, H
elvetica, sans-serif">This article has received corrections    in agreement with
 the ERRATUM published in Volume 41 Number 4.</font>      ^cY#6953.htm##
00507000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100019000730100018000920120
03400110030001600144065000900160064000500169031000300174014000800177865000900185
002000900194035001000203801001600213#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
953.htm#S#c#98#1#article#26#1#^rND^sThompson^nMP#^rND^sKurzrock^nR#Epstein-Barr 
virus and cancer^len#Clin Cancer Res#20040000#2004#10#803-821#20080200#6953.htm#
1078-0432#Clin Cancer Res##
00553000000000277000450000400060000070200450000670500020005170600020005370000030
00557010002000587090008000607080003000681180002000710100020000730100015000930120
10400108030000500212065000900217064000500226031000300231014000800234865000900242
002000900251035001000260801000500270#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
953.htm#S#c#99#2#article#26#2#^rND^sRaab-Traub^nN#^rND^sFlynn^nK#The structure o
f the termini of the Epstein-Barr virus as a marker of clonal cellular prolifera
tion^len#Cell#19860000#1986#47#883-889#20080200#6953.htm#0092-8674#Cell##
00499000000000265000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100020000740120050000940300
01800144065000900162064000500171031000300176014000800179865000900187002000900196
035001000205801001800215#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#c#
100#3#article#26#3#^rND^sRaab-Traub^nN#Epstein-Barr virus in the pathogenesis of
 NPC^len#Semin Cancer Biol#20020000#2002#12#431-441#20080200#6953.htm#1044-579X#
Semin Cancer Biol##
00488000000000277000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100013000740100013000870100
01600100012003800116030001200154710000200166065000900168064000500177031000200182
014000800184865000900192002000900201#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6
953.htm#S#c#101#4#article#26#4#^rND^sLo^nKW#^rND^sTo^nKF#^rND^sHuang^nDP#Focus o
n nasopharyngeal carcinoma^len#Cancer Cell#2#20040000#2004#5#423-428#20080200#69
53.htm##
00725000000000349000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100013000740100021000870100
01400108010001400122010001700136010001500153810000600168012011400174030001200288
06500090030006400050030903100030031406100080031701400100032586500090033500200090
0344035001000353801001200363#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#
S#c#102#5#article#26#5#^rND^sHu^nLF#^rND^sZabarovsky^nER#^rND^sChen^nF#^rND^sCao
^nSL#^rND^sErnberg^nI#^rND^sKlein^nG#et al#Isolation and sequencing of the Epste
in-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma^len#J G
en Virol#19910000#1991#72#Part 10#2399-2409#20080200#6953.htm#0022-1317#J Gen Vi
rol##
00780000000000325000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100014000740100017000880100
01400105010001600119010001400135010001400149012021200163030001200375065000900387
06400050039603100030040101400100040486500090041400200090042303500100043280100120
0442#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#c#103#6#article#26#6#^
rND^sLin^nJC#^rND^sCherng^nJM#^rND^sLin^nHJ#^rND^sTsang^nCW#^rND^sLiu^nYX#^rND^s
Lee^nSP#Amino acid changes in functional domains of latent membrane protein 1 of
 Epstein-Barr virus in nasopharyngeal carcinoma of southern China and Taiwan: pr
evalence of an HLA-A2-restricted `epitope-loss variant'^len#J Gen Virol#20040000
#2004#85#2023-2034#20080200#6953.htm#0022-1317#J Gen Virol##
00684000000000337000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100018000740100018000920100
01700110010001600127010001500143010001600158010001300174012008400187030001200271
06500090028306400050029203100030029701400060030086500090030600200090031503500100
0324801001200334#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#c#104#7#ar
ticle#26#7#^rND^sNagamine^nM#^rND^sTakahara^nM#^rND^sKishibe^nK#^rND^sNagato^nT#
^rND^sIshii^nH#^rND^sBandoh^nN#^rND^set^nal#Sequence variations of Epstein-Barr 
virus LMP1 gene in nasal NK/T-cell lymphoma^len#Virus Genes#20070000#2007#34#47-
54#20080200#6953.htm#0920-8569#VIRUS GENES##
00683000000000313000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100017000740100014000910100
01800105010002800123010001600151012012300167030001300290065000900303064000500312
031000300317014000800320865000900328002000900337035001000346801001300356#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#c#105#8#article#26#8#^rND^sSaechan
^nV#^rND^sMori^nA#^rND^sMitarnun^nW#^rND^sSettheetham-Ishida^nW#^rND^sIshida^nT#
Analysis of LMP1 variants of EBV in Southern Thailand: evidence for strain-assoc
iated T-cell tropism and pathogenicity^len#J Clin Virol#20060000#2006#36#119-125
#20080200#6953.htm#0928-0197#J Clin Virol##
00773000000000301000450000400060000070200450000670500020005170600020005370000040
00557010002000597090008000617080003000691180002000720100016000740100018000900100
01800108010001800126012024600144030001400390065000900404064000500413031000300418
014000800421865000900429002000900438035001000447801001400457#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6953.htm#S#c#106#9#article#26#9#^rND^sKhanna^nR#^rND^sBur
rows^nSR#^rND^sNicholls^nJ#^rND^sPoulsen^nLM#Identification of cytotoxic T cell 
epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP
1): evidence for HLA-A2 supertype-restricted immune recognition of EBV-infected 
cells by LMP1-specific cytotoxic T lymphocytes^len#Eur J Immunol#19980000#1998#2
8#451-458#20080200#6953.htm#0014-2980#Eur J Immunol##
00591000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100018000760100021000940100
01600115010002000131012006900151030000800220065000900228064000500237031000300242
014000800245865000900253002000900262035001000271801000800281#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6953.htm#S#c#107#10#article#26#10#^rND^sEdwards^nRH#^rND^
sSitki-Green^nD#^rND^sMoore^nDT#^rND^sRaab-Traub^nN#Potential selection of LMP1 
variants in nasopharyngeal carcinoma^len#J Virol#20040000#2004#78#868-881#200802
00#6953.htm#0022-538X#J Virol##
00725000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100016000930100
01300109010001500122010001400137010001400151810000600165012013700171030001300308
06500090032106400050033003100030033501400080033886500090034600200090035503500100
0364801001300374#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#c#108#11#a
rticle#26#11#^rND^sCheung^nST#^rND^sLeung^nSF#^rND^sLo^nKW#^rND^sChiu^nKW#^rND^s
Tam^nJS#^rND^sFok^nTF#et al#Specific latent membrane protein 1 gene sequences in
 type 1 and type 2 Epstein-Barr virus from nasopharyngeal carcinoma in Hong Kong
^len#Int J Cancer#19980000#1998#76#399-406#20080200#6953.htm#0020-7136#Int J Can
cer##
00672000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100015000910100
01400106010001300120010001500133010001300148810000600161012009000167030001100257
06500090026806400050027703100030028201400100028586500090029500200090030403500100
0313801001100323#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#c#109#12#a
rticle#26#12#^rND^sXiong^nW#^rND^sZeng^nZY#^rND^sXia^nJH#^rND^sXia^nK#^rND^sShen
^nSR#^rND^sLi^nXL#et al#A susceptibility locus at chromosome 3p21 linked to fami
lial nasopharyngeal carcinoma^len#Cancer Res#20040000#2004#64#1972-1974#20080200
#6953.htm#0008-5472#Cancer res##
00749000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100014000900100
01300104010001500117010001600132010001500148012019300163030000600356065000900362
06400050037103100030037601400100037986500090038900200090039803500100040780100060
0417#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#c#110#13#article#26#13
#^rND^sLin^nJC#^rND^sLin^nSC#^rND^sDe^nBK#^rND^sChan^nWP#^rND^sEvatt^nBL#^rND^sC
han^nWC#Precision of genotyping of Epstein-Barr virus by polymerase chain reacti
on using three gene loci (EBNA-2, EBNA-3C, and EBER): predominance of type A vir
us associated with Hodgkin's disease^len#Blood#19930000#1993#81#3372-3381#200802
00#6953.htm#0006-4971#Blood##
00716000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100014000900100
01900104010002000123010001800143010001900161010001300180012011400193030000800307
06500090031506400050032403100030032901400100033286500090034200200090035103500100
0360801000800370#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#c#111#14#a
rticle#26#14#^rND^sLeen^nA#^rND^sMeij^nP#^rND^sRedchenko^nI#^rND^sMiddeldorp^nJ#
^rND^sBloemena^nE#^rND^sRickinson^nA#^rND^set^nal#Differential immunogenicity of
 Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses^
len#J Virol#20010000#2001#75#8649-8659#20080200#6953.htm#0022-538X#J Virol##
00595000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100016000900100
01600106010001400122012005800136030002300194065000900217064000500226031000300231
014000800234865000900242002000900251035001000260801002300270#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6953.htm#S#c#112#15#article#26#15#^rND^sOhga^nS#^rND^sNom
ura^nA#^rND^sTakada^nH#^rND^sHara^nT#Immunological aspects of Epstein-Barr virus
 infection^len#Crit Rev Oncol Hematol#20020000#2002#44#203-215#20080200#6953.htm
#1040-8428#Crit Rev Oncol Hematol##
00697000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100014000890100
01500103010001700118010001400135010002200149810000600171012011000177030000900287
06500090029606400050030503100020031001400100031286500090032200200090033103500100
0340801000900350#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#c#113#16#a
rticle#26#16#^rND^sHu^nLF#^rND^sChen^nF#^rND^sZheng^nX#^rND^sErnberg^nI#^rND^sCa
o^nSL#^rND^sChristensson^nB#et al#Clonability and tumorigenicity of human epithe
lial cells expressing the EBV encoded membrane protein LMP1^len#Oncogene#1993000
0#1993#8#1575-1583#20080200#6953.htm#0950-9232#Oncogene##
00680000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100020000890100
01400109010001400123010001800137012013500155030001000290065000900300064000500309
031000400314014001000318865000900328002000900337035001000346801001000356#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#c#114#17#article#26#17#^rND^sLiu^n
H#^rND^sAndreansky^nS#^rND^sDiaz^nG#^rND^sHogg^nT#^rND^sDoherty^nPC#Reduced func
tional capacity of CD8+ T cells expanded by post-exposure vaccination of gamma-h
erpesvirus-infected CD4-deficient mice^len#J Immunol#20020000#2002#168#3477-3483
#20080200#6953.htm#0022-1767#J Immunol##
00588000000000301000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100017000930100
02100110010001800131012005200149030001700201065000900218064000500227031000300232
014000600235865000900241002000900250035001000259801001700269#v41n2#v:\scielo\ser
ial\bjmbr\v41n2\markup\6953.htm#S#c#115#18#article#26#18#^rND^sThomas^nPG#^rND^s
Keating^nR#^rND^sHulse-Post^nDJ#^rND^sDoherty^nPC#Cell-mediated protection in in
fluenza infection^len#Emerg Infect Dis#20060000#2006#12#48-54#20080200#6953.htm#
1080-6040#Emerg Infect Dis##
00715000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100014000930100
01600107010001700123010002000140010001800160010001300178012010400191030001400295
06500090030906400050031803100040032301400080032786500090033500200090034403500100
0353801001400363#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#c#116#19#a
rticle#26#19#^rND^sBickham^nK#^rND^sMunz^nC#^rND^sTsang^nML#^rND^sLarsson^nM#^rN
D^sFonteneau^nJF#^rND^sBhardwaj^nN#^rND^set^nal#EBNA1-specific CD4+ T cells in h
ealthy carriers of Epstein-Barr virus are primarily Th1 in function^len#J Clin I
nvest#20010000#2001#107#121-130#20080200#6953.htm#0021-9738#J Clin Invest##
00715000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100017000760100013000930100
01600106010001500122010001500137010001800152810000600170012012200176030001300298
06500090031106400050032003100030032501400080032886500090033600200090034503500100
0354801001300364#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#c#117#20#a
rticle#26#20#^rND^sCheung^nST#^rND^sLo^nKW#^rND^sLeung^nSF#^rND^sChan^nWY#^rND^s
Choi^nPH#^rND^sJohnson^nPJ#et al#Prevalence of LMP1 deletion variant of Epstein-
Barr virus in nasopharyngeal carcinoma and gastric tumors in Hong Kong^len#Int J
 Cancer#19960000#1996#66#711-712#20080200#6953.htm#0020-7136#Int J Cancer##
00773000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100016000760100015000920100
01600107010001500123010001500138012022700153030001300380065000900393064000500402
031000300407014000800410865000900418002000900427035001000436801001300446#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#c#118#21#article#26#21#^rND^sLeung
^nSY#^rND^sYuen^nST#^rND^sChung^nLP#^rND^sChan^nAS#^rND^sWong^nMP#Prevalence of 
mutations and 30-bp deletion in the C-terminal region of Epstein-Barr virus late
nt membrane protein-1 oncogene in reactive lymphoid tissue and non-nasopharyngea
l EBV-associated carcinomas in Hong Kong Chinese^len#Int J Cancer#19970000#1997#
72#225-230#20080200#6953.htm#0020-7136#Int J Cancer##
00753000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100013000760100020000890100
02200109010001400131010001800145010001600163810000600179012014100185030001800326
06500090034406400050035303100030035801400080036186500090036900200090037803500100
0387801001800397#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#c#119#22#a
rticle#26#22#^rND^sPai^nS#^rND^sO'Sullivan^nB#^rND^sAbdul-Jabbar^nI#^rND^sPeng^n
J#^rND^sConnolly^nG#^rND^sKhanna^nR#et al#Nasopharyngeal carcinoma-associated Ep
stein-Barr virus-encoded oncogene latent membrane protein 1 potentiates regulato
ry T-cell function^len#Immunol Cell Biol#20070000#2007#85#370-377#20080200#6953.
htm#0818-9641#Immunol Cell Biol##
00493000000000265000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760120042000960300
01800138065000900156064000500165031000300170014000800173865000900181002000900190
035001000199801001800209#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#c#
120#23#article#26#23#^rND^sStevenson^nPG#Immune evasion by gamma-herpesviruses^l
en#Curr Opin Immunol#20040000#2004#16#456-462#20080200#6953.htm#0952-7915#Curr O
pin Immunol##
00802000000000337000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100020000760100018000960100
01900114010001800133010001600151010002100167810000600188012019900194030000800393
06500090040106400050041003100030041501400100041886500090042800200090043703500100
0446801000800456#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#c#121#24#a
rticle#26#24#^rND^sDuraiswamy^nJ#^rND^sBurrows^nJM#^rND^sBharadwaj^nM#^rND^sBurr
ows^nSR#^rND^sCooper^nL#^rND^sPimtanothai^nN#et al#Ex vivo analysis of T-cell re
sponses to Epstein-Barr virus-encoded oncogene latent membrane protein 1 reveals
 highly conserved epitope sequences in virus isolates from diverse geographic re
gions^len#J Virol#20030000#2003#77#7401-7410#20080200#6953.htm#0022-538X#J Virol
##
00720000000000313000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100014000760100017000900100
01500107010001600122010001400138012017500152030001300327065000900340064000500349
031000300354014000800357865000900365002000900374035001000383801001300393#v41n2#v
:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#c#122#25#article#26#25#^rND^sLin^n
HJ#^rND^sCherng^nJM#^rND^sHung^nMS#^rND^sSayion^nY#^rND^sLin^nJC#Functional assa
ys of HLA-A2-restricted epitope variant of latent membrane protein 1 (LMP-1) of 
Epstein-Barr virus in nasopharyngeal carcinoma of Southern China and Taiwan^len#
J Biomed Sci#20050000#2005#12#925-936#20080200#6953.htm#1021-7770#J Biomed Sci##
00654000000000325000450000400060000070200450000670500020005170600020005370000040
00557010003000597090008000627080003000701180003000730100015000760100013000910100
01300104010001500117010001300132010001500145810000600160012009500166030002200261
71000020028306500090028506400050029403100030029901400080030286500090031000200090
0319#v41n2#v:\scielo\serial\bjmbr\v41n2\markup\6953.htm#S#c#123#26#article#26#26
#^rND^sTang^nYL#^rND^sLu^nJH#^rND^sWu^nMH#^rND^sHuang^nC#^rND^sCao^nL#^rND^sPeng
^nSP#et al#Lytic replication and induction to production visualization recombina
nt Epstein Barr virus^len#Progr Biochem Biophys#2#20070000#2007#34#418-424#20080
200#6953.htm##
